assay_id,relationship_type,variant_id,cell_id,assay_strain,description,curated_by,src_assay_id,assay_cell_type,assay_category,tissue_id,tid,bao_format,assay_type,assay_subcellular_fraction,doc_id,assay_tissue,confidence_score,src_id,chembl_id
1,H,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,Autocuration,,,,,12052,BAO_0000019,B,,11087,,8,1,CHEMBL615117
2,U,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,Autocuration,,,,,22226,BAO_0000219,F,,684,,0,1,CHEMBL615118
3,U,,,,,Autocuration,,,,,22226,BAO_0000019,B,,15453,,0,1,CHEMBL615119
4,H,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Autocuration,,,,,104729,BAO_0000249,B,,17841,,4,1,CHEMBL615120
5,N,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,1,1,CHEMBL615121
6,N,,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,1,1,CHEMBL615122
7,N,,163.0,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Intermediate,,143B,,,80001,BAO_0000219,F,,13799,,1,1,CHEMBL615123
8,N,,163.0,,In vitro cell cytotoxicity was determined against 143B cell line,Expert,,143B,,,80001,BAO_0000219,F,,17774,,1,1,CHEMBL615124
9,N,,163.0,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Intermediate,,143B,,,80001,BAO_0000219,F,,3801,,1,1,CHEMBL615125
10,N,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,1,1,CHEMBL615126
11,N,,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,143B,,,80001,BAO_0000219,F,,17430,,1,1,CHEMBL615127
12,N,,163.0,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Expert,,143B,,,80001,BAO_0000219,F,,17774,,1,1,CHEMBL615128
13,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,1,1,CHEMBL857900
14,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,1,1,CHEMBL615129
15,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,1,1,CHEMBL615130
16,N,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,,,50185,BAO_0000218,F,,11324,,1,1,CHEMBL615131
17,D,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Expert,,,,,100122,BAO_0000357,A,,11347,,9,1,CHEMBL884521
18,H,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615132
19,H,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,Autocuration,,,,,12054,BAO_0000019,B,,10091,,8,1,CHEMBL615133
20,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615134
21,H,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615135
22,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615136
23,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615137
24,H,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,12054,BAO_0000357,B,,16474,,8,1,CHEMBL615138
25,U,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",Autocuration,,,,,22226,BAO_0000219,B,,14352,,0,1,CHEMBL836324
26,H,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Autocuration,,,,,12054,BAO_0000357,B,,5646,,8,1,CHEMBL615139
27,H,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Autocuration,,,,,12054,BAO_0000357,B,,5646,,8,1,CHEMBL615140
28,H,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,12426,BAO_0000219,B,,10997,,8,1,CHEMBL615141
29,H,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,Autocuration,,,,,12054,BAO_0000357,B,,6309,,8,1,CHEMBL615142
30,H,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Autocuration,,,,,12054,BAO_0000357,B,,167,,8,1,CHEMBL615143
31,H,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Autocuration,,,,,12054,BAO_0000357,B,,167,,8,1,CHEMBL615144
32,H,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Autocuration,,,,,12054,BAO_0000357,B,,11087,,8,1,CHEMBL872867
33,H,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Autocuration,,,,,12054,BAO_0000357,B,,11087,,8,1,CHEMBL615145
34,H,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,,,12054,BAO_0000357,B,,13622,,8,1,CHEMBL615146
35,H,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,,,12054,BAO_0000357,B,,13622,,8,1,CHEMBL615147
36,U,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Autocuration,,,,,22226,BAO_0000019,A,,11347,,0,1,CHEMBL615148
37,U,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Autocuration,,,,,22226,BAO_0000019,B,,5926,,0,1,CHEMBL615149
38,U,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,Autocuration,,,,,22226,BAO_0000019,B,,4567,,0,1,CHEMBL615150
39,M,,,,Dissociation constant towards 16S rRNA construct A,Intermediate,,,,,22222,BAO_0000225,B,,3782,,3,1,CHEMBL615151
40,M,,,,Dissociation constant towards 16S rRNA construct B,Intermediate,,,,,22222,BAO_0000225,B,,3782,,3,1,CHEMBL615152
41,M,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Expert,,,,,100263,BAO_0000225,B,,4466,,3,1,CHEMBL615153
42,M,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Expert,,,,,100263,BAO_0000225,B,,6592,,3,1,CHEMBL615154
43,H,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,8,1,CHEMBL615155
44,H,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,8,1,CHEMBL615156
45,H,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,,,20001,BAO_0000019,B,,13163,,8,1,CHEMBL615157
46,H,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,,,20001,BAO_0000019,B,,13163,,8,1,CHEMBL615158
47,D,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,,,12971,BAO_0000019,B,,10691,,9,1,CHEMBL615159
48,D,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,,,12971,BAO_0000019,B,,10691,,9,1,CHEMBL615172
49,D,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,,,12971,BAO_0000019,B,,10691,,9,1,CHEMBL615173
50,D,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,,,12971,BAO_0000019,B,,10691,,9,1,CHEMBL615174
51,H,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,13053,BAO_0000019,B,,898,,8,1,CHEMBL884518
52,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),Autocuration,,,,,11512,BAO_0000357,B,,912,,8,1,CHEMBL615175
53,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,Autocuration,,,,,11512,BAO_0000357,B,,912,,8,1,CHEMBL615176
54,H,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,Autocuration,,,,,11512,BAO_0000357,B,,912,,8,1,CHEMBL615177
55,D,,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Autocuration,,,,,104740,BAO_0000249,B,Membranes,15103,,5,1,CHEMBL615178
56,N,,506.0,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Intermediate,,1A9,,,80002,BAO_0000219,F,,5116,,1,1,CHEMBL615179
57,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Autocuration,,Oocytes,,,104835,BAO_0000219,F,,14578,,7,1,CHEMBL615180
58,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Autocuration,,Oocytes,,,104821,BAO_0000219,F,,14578,,7,1,CHEMBL615181
59,D,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Autocuration,,Oocytes,,,104848,BAO_0000219,F,,14578,,7,1,CHEMBL615182
60,N,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Expert,,1A9,,,80002,BAO_0000219,F,,4787,,1,1,CHEMBL615183
61,N,,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Intermediate,,1A9,,,80002,BAO_0000219,F,,4787,,1,1,CHEMBL615184
62,N,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line,Intermediate,,1A9,,,80002,BAO_0000219,F,,3547,,1,1,CHEMBL615185
63,N,,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Intermediate,,1A9,,,80002,BAO_0000219,F,,3547,,1,1,CHEMBL615186
64,N,,506.0,,Effective dose of compound against replication of 1A9 cell line was evaluated,Intermediate,,1A9,,,80002,BAO_0000219,F,,6726,,1,1,CHEMBL615187
65,N,,506.0,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Expert,,1A9,,,80002,BAO_0000219,F,,3455,,1,1,CHEMBL885343
66,N,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,1,1,CHEMBL615188
67,N,,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,1,1,CHEMBL615189
68,N,,506.0,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,5726,,1,1,CHEMBL615190
69,N,,506.0,,Inhibitory activity against Taxol resistant 1A9 cell lines,Intermediate,,1A9,,,80002,BAO_0000219,F,,3395,,1,1,CHEMBL615191
70,N,,506.0,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Expert,,1A9,,,80002,BAO_0000219,F,,3415,,1,1,CHEMBL615192
71,N,,506.0,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Expert,,1A9,,,80002,BAO_0000219,F,,3415,,1,1,CHEMBL827083
72,N,,506.0,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Expert,,1A9,,,80002,BAO_0000219,F,,17099,,1,1,CHEMBL615193
73,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,1,1,CHEMBL615194
74,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,1,1,CHEMBL615195
75,N,,506.0,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Intermediate,,1A9,,,80002,BAO_0000219,F,,17099,,1,1,CHEMBL615196
76,N,,503.0,,Inhibitory concentration against Jurkat cells,Intermediate,,Jurkat,,,81072,BAO_0000219,F,,17721,,1,1,CHEMBL615197
77,U,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL615198
78,D,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Expert,,,,,100121,BAO_0000357,A,,11347,,9,1,CHEMBL615199
79,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,11231,BAO_0000357,B,,17117,,8,1,CHEMBL615200
80,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,11231,BAO_0000357,B,,17117,,8,1,CHEMBL615201
81,H,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",Expert,,,,,11231,BAO_0000357,B,,17117,,8,1,CHEMBL615202
82,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,8,1,CHEMBL615203
83,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,8,1,CHEMBL615204
84,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,8,1,CHEMBL615205
85,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,,,11231,BAO_0000251,B,Microsomes,11375,,8,1,CHEMBL615206
86,H,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,Liver,8,1,CHEMBL615207
87,H,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Autocuration,,,,,11231,BAO_0000019,B,,791,,8,1,CHEMBL827084
88,H,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Autocuration,,,,,11231,BAO_0000019,B,,791,,8,1,CHEMBL615208
89,H,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Autocuration,,,,,11231,BAO_0000019,B,,791,,8,1,CHEMBL615209
90,D,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,Liver,9,1,CHEMBL615210
91,D,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,11375,Liver,9,1,CHEMBL615211
92,D,,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,,2107.0,12083,BAO_0000251,B,Microsomes,153,Liver,9,1,CHEMBL615212
93,H,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),Expert,,,,,11377,BAO_0000357,B,,8269,,8,1,CHEMBL615213
94,H,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,Expert,,,,,11377,BAO_0000357,B,,8269,,8,1,CHEMBL615273
95,N,,726.0,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,HepG2,,,81020,BAO_0000219,F,,17653,,1,1,CHEMBL615274
96,N,,726.0,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14277,,1,1,CHEMBL615275
97,N,,726.0,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,1717,,1,1,CHEMBL615276
98,N,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14091,,1,1,CHEMBL615277
99,N,,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14091,,1,1,CHEMBL615326
100,N,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,,,,50606,BAO_0000218,F,,17653,,1,1,CHEMBL883130
101,N,,726.0,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13105,,1,1,CHEMBL884519
102,N,,726.0,,Concentration required to inhibit 50% of 2.2.15 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,1717,,1,1,CHEMBL615327
103,N,,726.0,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Intermediate,,HepG2,,,81020,BAO_0000219,A,,13105,,1,1,CHEMBL615328
104,N,,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13600,,1,1,CHEMBL615329
105,N,,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,1,1,CHEMBL615330
106,N,,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Expert,,2.2.15,,,50606,BAO_0000218,F,,17477,,1,1,CHEMBL615331
107,N,,,,In vitro anti-HBV activity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,1,1,CHEMBL615332
108,N,,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,1,1,CHEMBL615333
109,N,,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,15089,,1,1,CHEMBL615334
110,N,,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,15089,,1,1,CHEMBL615335
111,N,,,,Cytotoxicity in 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,1,1,CHEMBL615336
112,N,,,,Cytotoxicity in 2.2.15 cells; Not determined,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,1593,,1,1,CHEMBL615337
113,N,,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13600,,1,1,CHEMBL615338
114,N,,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,1,1,CHEMBL615339
115,N,,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Intermediate,,2.2.15,,,50587,BAO_0000218,F,,13467,,1,1,CHEMBL615340
116,N,,726.0,,Antiviral activity against HBV was determined in 2.215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,14764,,1,1,CHEMBL615341
117,U,,,,Inhibition of 20-HETE synthesis in human renal microsomes,Autocuration,,,,,22226,BAO_0000251,B,Microsomes,6531,,0,1,CHEMBL615342
118,U,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,Autocuration,,,,,22226,BAO_0000019,B,,17322,,0,1,CHEMBL615343
119,N,,388.0,,Inhibitory concentration against 2008 (ovarian) cells,Intermediate,,2008,,,80612,BAO_0000219,F,,17072,,1,1,CHEMBL615344
120,N,,388.0,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Intermediate,,2008,,,80612,BAO_0000219,F,,16936,,1,1,CHEMBL615345
121,N,,388.0,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Intermediate,,2008,,,80612,BAO_0000219,F,,16936,,1,1,CHEMBL615346
122,N,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Intermediate,,2008,,,80612,BAO_0000219,F,,17146,,1,1,CHEMBL615347
123,N,,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Intermediate,,2008,,,80612,BAO_0000219,F,,17146,,1,1,CHEMBL615348
124,N,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line,Intermediate,,2008/R,,,80613,BAO_0000219,F,,10797,,1,1,CHEMBL827085
125,N,,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Intermediate,,2008/R,,,80613,BAO_0000219,F,,10797,,1,1,CHEMBL615349
126,N,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line,Intermediate,,2008/S,,,80614,BAO_0000219,F,,10797,,1,1,CHEMBL615350
127,N,,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Intermediate,,2008/S,,,80614,BAO_0000219,F,,10797,,1,1,CHEMBL615351
128,S,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Expert,,,,,100256,BAO_0000220,B,,4823,,2,1,CHEMBL615352
129,S,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Intermediate,,,,,100256,BAO_0000220,B,,12912,,2,1,CHEMBL615353
130,S,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,Expert,,,,,100256,BAO_0000220,B,,2957,,2,1,CHEMBL615354
131,S,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,Expert,,,,,100256,BAO_0000220,B,,2957,,2,1,CHEMBL615355
132,S,,,,Inhibitory activity against 20S proteosome,Intermediate,,,,,100256,BAO_0000220,B,,3260,,2,1,CHEMBL615356
133,U,,,,Compound was tested for inhibitory activity against tryptase,Autocuration,,,,,22226,BAO_0000019,B,,3451,,0,1,CHEMBL615357
134,N,,726.0,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13885,,1,1,CHEMBL615358
135,N,,726.0,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,HepG2,,,81020,BAO_0000219,F,,13885,,1,1,CHEMBL827086
136,U,,,,Compound was tested for the inhibition of Alpha-glucosidase,Autocuration,,,,,22226,BAO_0000019,B,,3676,,0,1,CHEMBL615359
137,H,,,,Inhibitory concentration against human neutrophil elastase (HNE),Autocuration,,,,,235,BAO_0000357,B,,6043,,8,1,CHEMBL615360
138,U,,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Autocuration,,,,948.0,22226,BAO_0000218,F,,11140,Heart,0,1,CHEMBL615361
139,H,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,19640,BAO_0000019,F,,10543,,8,1,CHEMBL615362
140,H,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,19640,BAO_0000019,F,,10543,,8,1,CHEMBL615363
141,H,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,19640,BAO_0000357,B,,10543,,8,1,CHEMBL615364
142,H,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,19640,BAO_0000019,F,,10543,,8,1,CHEMBL615365
143,N,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Intermediate,,P338,,,80360,BAO_0000219,F,,11365,,1,1,CHEMBL615366
144,N,,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Intermediate,,P338,,,80360,BAO_0000219,F,,11365,,1,1,CHEMBL615367
145,N,,554.0,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Intermediate,,PBL,,,80384,BAO_0000219,F,,11803,,1,1,CHEMBL615368
146,U,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Autocuration,,,,,22226,BAO_0000019,F,,11803,,0,1,CHEMBL615369
147,U,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Autocuration,,,,,22226,BAO_0000019,F,,11803,,0,1,CHEMBL615370
148,H,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),Autocuration,,,,,191,BAO_0000357,B,,12278,,8,1,CHEMBL615673
149,U,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Autocuration,,,,,22226,BAO_0000019,F,,8249,,0,1,CHEMBL615674
150,U,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Autocuration,,,,,22226,BAO_0000019,F,,8249,,0,1,CHEMBL615675
151,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,0,1,CHEMBL615676
152,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,0,1,CHEMBL615677
153,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,0,1,CHEMBL615678
154,U,,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Autocuration,,CCRF-CEM,,,22226,BAO_0000219,F,,8249,,0,1,CHEMBL615679
155,U,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Autocuration,,,,,22226,BAO_0000019,F,,8249,,0,1,CHEMBL615680
156,U,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Autocuration,,,,,22226,BAO_0000019,F,,8249,,0,1,CHEMBL615681
157,H,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,Autocuration,,,,,104290,BAO_0000249,B,,16992,,6,1,CHEMBL857972
158,N,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Intermediate,,,,,50264,BAO_0000218,F,,10543,,1,1,CHEMBL857899
159,N,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Intermediate,,,,,50527,BAO_0000218,F,,17833,,1,1,CHEMBL615371
160,N,,468.0,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,Expert,,HEL,,,50527,BAO_0000218,F,,17290,,1,1,CHEMBL615372
161,N,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,Intermediate,,,,,50527,BAO_0000218,F,,17290,,1,1,CHEMBL615373
162,N,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,Intermediate,,,,,50527,BAO_0000218,F,,17290,,1,1,CHEMBL615374
163,N,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",Intermediate,,,,,50145,BAO_0000218,F,,10932,,1,1,CHEMBL615375
164,U,,,,Ratio of Ki at A2 to Ki at A1 receptors,Autocuration,,,,,22226,BAO_0000019,B,,9707,,0,1,CHEMBL615376
165,H,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Expert,,,,,11143,BAO_0000249,B,,2346,,8,1,CHEMBL615377
166,H,,,,"Inhibition of 1,3-beta-glucan synthase",Expert,,,,,18077,BAO_0000357,B,,2205,,8,1,CHEMBL615378
167,N,,832.0,,Inhibition of growth of 1-87 human tumor cell line,Intermediate,,1-87 tumor cell line,,,80609,BAO_0000219,F,,11900,,1,1,CHEMBL615379
168,D,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Expert,,,,,12166,BAO_0000219,B,,14864,,9,1,CHEMBL615380
169,D,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),Autocuration,,,,,100171,BAO_0000357,B,,16474,,9,1,CHEMBL615381
170,D,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Autocuration,,,,,100171,BAO_0000357,B,,16474,,9,1,CHEMBL615382
171,D,,,,% inhibition against soybean 1-lipoxygenase (SLO),Autocuration,,,,,100171,BAO_0000357,B,,16474,,9,1,CHEMBL615383
172,D,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Autocuration,,,,,100171,BAO_0000357,B,,16474,,9,1,CHEMBL615384
173,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615385
174,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615386
175,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615387
176,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615388
177,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615214
178,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL827087
179,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615215
180,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615216
181,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615217
182,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615218
183,D,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Autocuration,,,,,100171,BAO_0000357,B,,3094,,9,1,CHEMBL615219
184,U,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Autocuration,,,,,22226,BAO_0000019,B,,10413,,0,1,CHEMBL615220
185,N,,294.0,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Intermediate,,C3H 10T1/2,,,80049,BAO_0000219,F,,16929,,1,1,CHEMBL615221
186,U,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL615222
187,H,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,11489,BAO_0000357,B,,16587,,8,1,CHEMBL615223
188,H,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,11862,BAO_0000357,B,,16587,,8,1,CHEMBL615224
189,H,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,Autocuration,,,,,11862,BAO_0000357,B,,16587,,8,1,CHEMBL615225
190,H,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,Autocuration,,,,,11489,BAO_0000357,B,,16587,,8,1,CHEMBL615226
191,H,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,Autocuration,,,,,11862,BAO_0000357,B,,16587,,8,1,CHEMBL615227
192,D,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Expert,,,,,12347,BAO_0000019,F,,8058,,9,1,CHEMBL615228
193,D,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Expert,,,,,100120,BAO_0000357,B,,9065,,9,1,CHEMBL615229
194,D,,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Expert,,,,2369.0,100120,BAO_0000357,B,,8865,Adrenal gland,9,1,CHEMBL615230
195,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,,,100120,BAO_0000357,B,,9066,,9,1,CHEMBL615231
196,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,,,100120,BAO_0000357,B,,8394,,9,1,CHEMBL884520
197,D,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Expert,,,,,100120,BAO_0000357,B,,8394,,9,1,CHEMBL615232
198,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,Autocuration,,,,,10328,BAO_0000019,B,,6431,,8,1,CHEMBL615233
199,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,11490,BAO_0000357,B,,6431,,8,1,CHEMBL827088
200,H,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,11490,BAO_0000357,B,,6431,,8,1,CHEMBL615234
201,H,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,Autocuration,,,,,11134,BAO_0000019,F,,9295,,8,1,CHEMBL615235
202,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615236
203,H,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,11134,BAO_0000019,B,,13622,,8,1,CHEMBL615237
204,H,,,,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,F,,12079,,8,1,CHEMBL615238
205,H,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,11134,BAO_0000019,B,,13622,,8,1,CHEMBL615239
206,D,,,,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,F,,12079,,9,1,CHEMBL615240
207,H,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,Expert,,,,,11835,BAO_0000019,B,,13500,,8,1,CHEMBL615241
208,H,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,Expert,,,,,11601,BAO_0000357,B,,13723,,8,1,CHEMBL615242
209,H,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,11134,BAO_0000019,B,,16474,,8,1,CHEMBL615243
210,H,,,,Inhibitory activity against human platelet 12-lipoxygenase,Autocuration,,,,,11134,BAO_0000019,B,,1630,,8,1,CHEMBL615244
211,H,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,Autocuration,,,,,11134,BAO_0000019,B,,167,,8,1,CHEMBL615245
212,H,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,11134,BAO_0000019,B,,16474,,8,1,CHEMBL615246
213,H,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,Autocuration,,,,,11134,BAO_0000019,B,,167,,8,1,CHEMBL615247
214,H,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,Autocuration,,,,,11134,BAO_0000019,B,,16474,,8,1,CHEMBL615248
215,H,,,,Inhibitory activity towards porcine 12-lipoxygenase,Autocuration,,,,,11601,BAO_0000357,B,,10091,,8,1,CHEMBL615249
216,H,,,,Tested for inhibition against porcine 12-LO,Autocuration,,,,,11601,BAO_0000357,B,,11966,,8,1,CHEMBL615250
217,H,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,Autocuration,,,,,12052,BAO_0000019,B,,951,,8,1,CHEMBL615251
218,H,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,Autocuration,,,,,12052,BAO_0000019,B,,10997,,8,1,CHEMBL615252
219,H,,,,In vitro inhibition of rat platelet 12-lipoxygenase,Expert,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL828340
220,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615253
221,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615254
222,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615255
223,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615256
224,H,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,Autocuration,,,,,12052,BAO_0000019,B,,10193,,8,1,CHEMBL615257
225,H,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,Autocuration,,,,,12052,BAO_0000019,B,,11087,,8,1,CHEMBL615258
226,N,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Intermediate,,41M,,,80007,BAO_0000219,F,,15569,,1,1,CHEMBL615259
227,N,,621.0,,In vitro antitumor activity against 41M cell line.,Expert,,41M,,,80007,BAO_0000219,F,,12989,,1,1,CHEMBL615260
228,N,,621.0,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Intermediate,,41M,,,80007,BAO_0000219,F,,16745,,1,1,CHEMBL615261
229,N,,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Intermediate,,41M,,,80007,BAO_0000219,F,,15569,,1,1,CHEMBL615262
230,N,,621.0,,In vitro antitumor activity against 41McisR cell line.,Expert,,41M,,,80007,BAO_0000219,F,,12989,,1,1,CHEMBL615263
231,N,,621.0,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Expert,,41M,,,80007,BAO_0000219,F,,12989,,1,1,CHEMBL838393
232,N,,621.0,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Intermediate,,41M,,,80007,BAO_0000219,F,,16745,,1,1,CHEMBL615264
233,D,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Expert,,,,,84,BAO_0000357,B,,6210,,9,1,CHEMBL615265
234,D,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,,,68,BAO_0000357,B,,6210,,9,1,CHEMBL615266
235,H,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,,,68,BAO_0000357,B,,6226,,8,1,CHEMBL615267
236,H,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,10201,BAO_0000357,B,,17855,,8,1,CHEMBL615268
237,H,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,Expert,,,,,10201,BAO_0000357,B,,17855,,8,1,CHEMBL615269
238,H,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,10201,BAO_0000357,B,,17855,,8,1,CHEMBL615270
239,H,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,8,1,CHEMBL615271
240,H,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,8,1,CHEMBL615272
241,H,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,8,1,CHEMBL615103
242,H,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Autocuration,,,,,11303,BAO_0000357,B,,10413,,8,1,CHEMBL615104
243,H,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,8,1,CHEMBL615105
244,H,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,12220,BAO_0000357,B,,10413,,8,1,CHEMBL872866
245,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,8,1,CHEMBL615106
246,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615107
247,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,8,1,CHEMBL615108
248,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,8,1,CHEMBL615109
249,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,8,1,CHEMBL615110
250,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL840105
251,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615111
252,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615112
253,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615113
254,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615114
255,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000357,B,,7587,,8,1,CHEMBL615115
256,H,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,11303,BAO_0000019,B,,7587,,8,1,CHEMBL615116
257,H,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",Autocuration,,,,,11303,BAO_0000357,B,,7323,,8,1,CHEMBL615698
258,U,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,,,22226,BAO_0000019,B,,7587,,0,1,CHEMBL615699
259,U,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Autocuration,,,,,22226,BAO_0000019,B,,7587,,0,1,CHEMBL615700
260,H,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Expert,,,,,100249,BAO_0000357,B,,13750,,8,1,CHEMBL615701
261,U,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,,,22226,BAO_0000019,B,,7662,,0,1,CHEMBL615702
262,U,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,,,22226,BAO_0000019,B,,7662,,0,1,CHEMBL615703
263,U,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Autocuration,,,,,22226,BAO_0000019,B,,7662,,0,1,CHEMBL615704
264,H,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,104698,BAO_0000019,F,,12211,,6,1,CHEMBL615705
265,H,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,104698,BAO_0000019,F,,12211,,6,1,CHEMBL615706
266,D,,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12211,Ileum,9,1,CHEMBL615707
267,H,,,,Stimulatory activity of intragastric pressure was tested in the rat,Expert,,,,,10623,BAO_0000019,F,,12211,,8,1,CHEMBL615708
268,H,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,Autocuration,,,,,121,BAO_0000357,B,,15453,,8,1,CHEMBL615709
269,U,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Autocuration,,,,,22226,BAO_0000218,F,,11884,,0,1,CHEMBL615710
270,H,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,12688,BAO_0000019,F,,7185,,8,1,CHEMBL615711
271,D,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Expert,,,,,121,BAO_0000357,B,,6876,,9,1,CHEMBL615712
272,D,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Expert,,,,,121,BAO_0000357,B,,6876,,9,1,CHEMBL836325
273,H,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,Autocuration,,,,,12198,BAO_0000019,F,,11863,,8,1,CHEMBL615713
274,H,,,,Inhibition constant of high-affinity 5-HT uptake,Autocuration,,,,,12198,BAO_0000357,B,,11863,,8,1,CHEMBL615714
275,H,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,Autocuration,,,,,12198,BAO_0000019,F,,11863,,8,1,CHEMBL615715
276,H,,,,Maximum rate was determined for high affinity transport of 5-HT,Autocuration,,,,,12198,BAO_0000019,F,,11863,,8,1,CHEMBL615716
277,H,,,,Compound was tested for agonistic activity against 5-HT uptake,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL615717
278,H,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,Expert,,,,,10577,BAO_0000019,B,,15796,,8,1,CHEMBL881818
279,H,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Expert,,,,,105,BAO_0000357,B,,15796,,8,1,CHEMBL884540
280,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000224,B,,12801,,5,1,CHEMBL615718
281,H,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000224,B,,12801,,4,1,CHEMBL615719
282,H,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Autocuration,,,,,104744,BAO_0000249,B,Membranes,12120,,4,1,CHEMBL615720
283,H,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Autocuration,,,,,104744,BAO_0000249,B,Membranes,12120,,4,1,CHEMBL615721
284,H,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11963,,4,1,CHEMBL615722
285,H,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,Autocuration,,,,,51,BAO_0000019,F,,11701,,8,1,CHEMBL615723
286,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615724
287,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615725
288,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615726
289,H,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615727
290,D,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Intermediate,,,,,105570,BAO_0000019,F,,11574,,9,1,CHEMBL615728
291,H,,449.0,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,279,BAO_0000219,B,,15779,,8,1,CHEMBL857971
292,H,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,8,1,CHEMBL615729
293,D,,,,Efficacy against 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,F,,15363,,9,1,CHEMBL615730
294,H,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615731
295,H,,,,Relative potency towards 5-HT2A receptor of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615732
296,H,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615733
297,H,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615734
298,H,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,Autocuration,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615735
299,H,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL615736
300,D,,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL615737
301,D,,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL615738
302,D,,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL615739
303,H,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,Autocuration,,,,,10623,BAO_0000357,B,,12092,,8,1,CHEMBL615278
304,D,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Expert,,,,,10623,BAO_0000019,F,,1317,,9,1,CHEMBL615279
305,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,12409,,8,1,CHEMBL615280
306,U,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Autocuration,,,,,22226,BAO_0000019,B,,11126,,0,1,CHEMBL615281
307,U,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Autocuration,,,,,22226,BAO_0000019,F,,11126,,0,1,CHEMBL615282
308,U,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,,,22226,BAO_0000019,F,,11126,,0,1,CHEMBL615283
309,N,,649.0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Autocuration,,HL-60,,,80156,BAO_0000219,B,,11126,,1,1,CHEMBL615284
310,U,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Autocuration,,,,,22226,BAO_0000019,B,,11126,,0,1,CHEMBL615285
311,U,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,,,22226,BAO_0000019,B,,11126,,0,1,CHEMBL615286
312,D,,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Autocuration,,Oocytes,,,104703,BAO_0000219,B,,17807,,7,1,CHEMBL615287
313,S,,,,Chymotryptic inhibitory activity against 26S proteasome,Intermediate,,,,,100256,BAO_0000220,F,,16575,,2,1,CHEMBL615288
314,S,,,,Inhibitory activity against 26S proteasome degradation of IkB,Intermediate,,,,,100256,BAO_0000220,B,,15407,,2,1,CHEMBL615289
315,N,,478.0,,In vitro inhibition of 2780/DOX ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,10797,,1,1,CHEMBL615290
316,N,,478.0,,In vitro inhibition of 2780/S ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,10797,,1,1,CHEMBL884522
317,U,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Autocuration,,,,,22226,BAO_0000019,F,,3469,,0,1,CHEMBL615291
318,M,,,,Association constant for binding to AATT 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,3,1,CHEMBL615292
319,M,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,Intermediate,,,,,22222,BAO_0000225,B,,16037,,3,1,CHEMBL615293
320,M,,,,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,3,1,CHEMBL615294
321,M,,,,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,22222,BAO_0000225,B,,16037,,3,1,CHEMBL615295
322,U,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Autocuration,,,,,22226,BAO_0000019,F,,16524,,0,1,CHEMBL825021
323,U,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Autocuration,,,,,22226,BAO_0000019,F,,16524,,0,1,CHEMBL615296
324,U,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Autocuration,,,,,22226,BAO_0000019,F,,16524,,0,1,CHEMBL615297
325,U,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,0,1,CHEMBL615298
326,U,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,0,1,CHEMBL615299
327,U,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Autocuration,,,,,22226,BAO_0000019,F,,16758,,0,1,CHEMBL615300
328,H,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,Autocuration,,,,,241,BAO_0000357,B,,14360,,8,1,CHEMBL615301
329,D,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Expert,,,,,241,BAO_0000357,B,,14360,,9,1,CHEMBL615302
330,U,,,,Selectivity ratio of ID50 in liver and heart,Autocuration,,,,,22226,BAO_0000019,B,,9964,,0,1,CHEMBL615303
331,H,,,,"Selectivity, ratio of relative ID50 in liver and heart",Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615304
332,H,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615305
333,H,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,8,1,CHEMBL615306
334,H,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,8,1,CHEMBL615307
335,H,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,8,1,CHEMBL615308
336,H,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,F,,9964,,8,1,CHEMBL615309
337,U,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",Autocuration,,,,,22226,BAO_0000019,B,,9964,,0,1,CHEMBL615310
338,H,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615311
339,U,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Autocuration,,,,,22226,BAO_0000019,B,,9964,,0,1,CHEMBL615312
340,H,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615313
341,H,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,12132,BAO_0000019,F,,9964,,8,1,CHEMBL615314
342,H,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615315
343,U,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Autocuration,,,,,22226,BAO_0000218,B,,9964,,0,1,CHEMBL615316
344,H,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,Autocuration,,,,,12132,BAO_0000218,B,,9964,,8,1,CHEMBL615317
345,H,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000218,B,,9964,,8,1,CHEMBL615318
346,U,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Autocuration,,,,,22226,BAO_0000218,B,,9964,,0,1,CHEMBL615319
347,H,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,B,,9964,,8,1,CHEMBL615320
348,H,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,12132,BAO_0000019,F,,9964,,8,1,CHEMBL615321
349,U,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Autocuration,,,,,22226,BAO_0000019,B,,3796,,0,1,CHEMBL615322
350,H,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,8,1,CHEMBL615323
351,H,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,8,1,CHEMBL615407
352,H,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,8,1,CHEMBL857267
353,H,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,,,19690,BAO_0000357,B,,4251,,8,1,CHEMBL615408
354,H,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,Autocuration,,,,,19690,BAO_0000357,B,,166,,8,1,CHEMBL615409
355,H,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,17861,,8,1,CHEMBL615410
356,H,,,,Inhibition constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,8,1,CHEMBL615411
357,H,,,,Association rate constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,8,1,CHEMBL615412
358,H,,,,Rate constant against 3-dehydroquinate synthase,Autocuration,,,,,19690,BAO_0000357,B,,166,,8,1,CHEMBL615413
359,U,,,,Inhibitory activity against fuc-TVII,Autocuration,,,,,22226,BAO_0000019,B,,3548,,0,1,CHEMBL615414
360,D,,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615415
361,D,,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615416
362,D,,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615417
363,D,,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615418
364,D,,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615419
365,D,,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615420
366,D,,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615421
367,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615422
368,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615423
369,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL872868
370,D,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Autocuration,,,,2107.0,12236,BAO_0000251,B,Microsomes,9877,Liver,9,1,CHEMBL615424
371,H,,,,Inhibitory activity against 3-phosphoglycerate kinase.,Autocuration,,,,,104832,BAO_0000224,B,,3003,,4,1,CHEMBL825022
372,H,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,Autocuration,,,,,104832,BAO_0000224,B,,3003,,4,1,CHEMBL615425
373,H,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",Autocuration,,,,,104832,BAO_0000224,B,,3003,,4,1,CHEMBL615426
374,D,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Expert,,,,,10612,BAO_0000357,B,,17185,,9,1,CHEMBL615427
375,N,,844.0,,Cytotoxicity on 3677 melanoma cells,Intermediate,,3677 melanoma cell line,,,80616,BAO_0000219,F,,6072,,1,1,CHEMBL615428
376,N,,844.0,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Intermediate,,3677 melanoma cell line,,,80616,BAO_0000219,F,,6072,,1,1,CHEMBL615429
377,N,,700.0,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Intermediate,,MC-38,,,80617,BAO_0000219,F,,5018,,1,1,CHEMBL615430
378,U,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Intermediate,,,,,22226,BAO_0000019,F,,2852,,0,1,CHEMBL615431
379,U,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,Autocuration,,B16,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615432
380,U,,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Autocuration,,B16,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615433
381,D,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Expert,,,,,12464,BAO_0000019,F,,3245,,9,1,CHEMBL615434
382,N,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Intermediate,,,,,50085,BAO_0000218,F,,3245,,1,1,CHEMBL615435
383,N,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,Intermediate,,,,,50679,BAO_0000218,F,,3877,,1,1,CHEMBL615436
384,N,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,Intermediate,,,,,50679,BAO_0000218,F,,3877,,1,1,CHEMBL615437
385,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,9,1,CHEMBL615438
386,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,9,1,CHEMBL615439
387,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,,,12464,BAO_0000019,F,,5861,,9,1,CHEMBL615440
388,D,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Expert,,,,,12464,BAO_0000019,F,,5861,,9,1,CHEMBL615441
389,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,1,1,CHEMBL615641
390,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,1,1,CHEMBL872065
391,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,1,1,CHEMBL825023
392,N,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Intermediate,,,,,50665,BAO_0000218,F,,13748,,1,1,CHEMBL615642
393,H,,,,Inhibition of human rhinovirus 3C protease,Expert,,,,,12464,BAO_0000357,B,,13748,,8,1,CHEMBL615643
394,U,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Autocuration,,,,,22226,BAO_0000019,B,,17699,,0,1,CHEMBL615644
395,N,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615645
396,N,,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615646
397,N,,833.0,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615647
398,N,,833.0,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615648
399,N,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615649
400,N,,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Intermediate,,3EM 37,,,80619,BAO_0000218,F,,7145,,1,1,CHEMBL615650
401,N,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,3LL cell line,,,80620,BAO_0000218,F,,5325,,1,1,CHEMBL615651
402,N,,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,3LL cell line,,,80620,BAO_0000218,F,,5325,,1,1,CHEMBL615652
403,N,,847.0,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Expert,,3LL cell line,,,80620,BAO_0000218,F,,5325,,1,1,CHEMBL615653
404,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615654
405,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615655
406,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL825024
407,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615656
408,N,,847.0,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615657
409,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615658
410,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615659
411,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615660
412,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615661
413,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615662
414,N,,847.0,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615663
415,N,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615664
416,N,,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615665
417,N,,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615666
418,N,,847.0,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615667
419,N,,847.0,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615668
420,N,,847.0,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615669
421,N,,847.0,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615670
422,N,,847.0,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL836739
423,N,,847.0,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615671
424,N,,847.0,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615672
425,N,,847.0,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615791
426,N,,847.0,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615792
427,N,,847.0,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615793
428,N,,847.0,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615794
429,N,,847.0,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,3LL cell line,,,80620,BAO_0000219,F,,16169,,1,1,CHEMBL615795
430,N,,971.0,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Intermediate,,3LLD122,,,80621,BAO_0000219,F,,15547,,1,1,CHEMBL615590
431,U,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Autocuration,,,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615591
432,U,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,Autocuration,,,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615592
433,U,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,Autocuration,,,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615593
434,U,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,Autocuration,,,,,22226,BAO_0000218,F,,8663,,0,1,CHEMBL615594
435,N,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,4504,,1,1,CHEMBL615595
436,N,,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,4504,,1,1,CHEMBL615596
437,H,,723.0,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,Expert,,NIH3T3,,,11169,BAO_0000219,F,,12695,,8,1,CHEMBL615597
438,N,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,1,1,CHEMBL615598
439,N,,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,1,1,CHEMBL615599
440,N,,723.0,,Effective dose against murine 3T3 fibroblasts cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,17642,,1,1,CHEMBL615600
441,N,,723.0,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Expert,,NIH3T3,,,80951,BAO_0000219,F,,17642,,1,1,CHEMBL615601
442,N,,723.0,,Cytotoxic effect on 3T3 cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12340,,1,1,CHEMBL615602
443,N,,723.0,,Cytotoxic effect on 3T3 cells,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12340,,1,1,CHEMBL615603
444,N,,723.0,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12716,,1,1,CHEMBL615604
445,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615605
446,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615606
447,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL884526
448,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615607
449,N,,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615608
450,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615609
451,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615682
452,N,,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615683
453,N,,723.0,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Expert,,NIH3T3,,,80951,BAO_0000218,F,,17780,,1,1,CHEMBL615684
454,D,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Autocuration,,,,,104860,BAO_0000219,F,,12751,,7,1,CHEMBL615685
455,N,,723.0,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12380,,1,1,CHEMBL615686
456,N,,723.0,,Inhibitory activity against 3T3 cell line,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,14892,,1,1,CHEMBL615687
457,N,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,1,1,CHEMBL884523
458,H,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,Expert,,,,,11169,BAO_0000019,F,,12695,,8,1,CHEMBL615688
459,N,,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,1,1,CHEMBL615689
460,N,,723.0,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12695,,1,1,CHEMBL615690
461,H,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,Expert,,,,,11169,BAO_0000019,F,,12695,,8,1,CHEMBL615691
462,H,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,Expert,,,,,11169,BAO_0000019,F,,12695,,8,1,CHEMBL615692
463,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615693
464,N,,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Expert,,NIH3T3,,,80951,BAO_0000219,F,,6277,,1,1,CHEMBL615324
465,D,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Expert,,NIH3T3,,,9,BAO_0000219,F,,4959,,9,1,CHEMBL615325
466,D,,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Expert,,NIH3T3,,,9,BAO_0000219,F,,4959,,9,1,CHEMBL615490
467,D,,723.0,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Expert,,NIH3T3,,,188,BAO_0000219,F,,4959,,9,1,CHEMBL615491
468,D,,723.0,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Expert,,NIH3T3,,,188,BAO_0000219,F,,4959,,9,1,CHEMBL615492
469,N,,723.0,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,1,1,CHEMBL615493
470,N,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,1,1,CHEMBL615494
471,N,,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,1,1,CHEMBL615495
472,N,,723.0,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,12082,,1,1,CHEMBL615496
473,N,,723.0,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,2643,,1,1,CHEMBL615497
474,N,,723.0,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,11926,,1,1,CHEMBL615498
475,N,,723.0,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Intermediate,,NIH3T3,,,80951,BAO_0000219,A,,15204,,1,1,CHEMBL615499
476,N,,723.0,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Expert,,NIH3T3,,,80951,BAO_0000219,F,,15992,,1,1,CHEMBL835522
477,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615500
478,N,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615501
479,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615502
480,N,,723.0,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615503
481,N,,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615504
482,N,,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,16279,,1,1,CHEMBL615505
483,N,,723.0,,Inhibition of swiss 3T3 mouse fibroblast proliferation,Expert,,NIH3T3,,,80951,BAO_0000219,F,,12831,,1,1,CHEMBL615506
484,N,,723.0,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Intermediate,,NIH3T3,,,80951,BAO_0000219,F,,13497,,1,1,CHEMBL615507
485,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615508
486,N,,620.0,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13618,,1,1,CHEMBL615509
487,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,1,1,CHEMBL615510
488,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,1,1,CHEMBL615511
489,N,,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,11902,,1,1,CHEMBL615512
490,N,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,14840,,1,1,CHEMBL615513
491,N,,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,14840,,1,1,CHEMBL615514
492,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615515
493,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615516
494,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615517
495,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615518
496,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615519
497,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615520
498,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615521
499,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615522
500,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615523
501,N,,620.0,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615524
502,N,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615525
503,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615526
504,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615527
505,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615528
506,N,,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615529
507,N,,620.0,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615530
508,N,,620.0,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Expert,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615531
509,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615532
510,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615533
511,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,13715,,1,1,CHEMBL615534
512,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615535
513,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615536
514,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615537
515,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL615538
516,N,,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Intermediate,,3T3-L1,,,80006,BAO_0000218,F,,13715,,1,1,CHEMBL836166
517,H,,620.0,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,Expert,,3T3-L1,,,11214,BAO_0000219,F,,6411,,8,1,CHEMBL615539
518,N,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,6411,,1,1,CHEMBL615540
519,H,,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,Expert,,3T3-L1,,,11214,BAO_0000219,F,,6411,,8,1,CHEMBL615541
520,N,,620.0,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Expert,,3T3-L1,,,80006,BAO_0000219,F,,3966,,1,1,CHEMBL615542
521,N,,620.0,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Intermediate,,3T3-L1,,,80006,BAO_0000219,F,,3966,,1,1,CHEMBL615543
522,N,,620.0,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Expert,,3T3-L1,,,80006,BAO_0000219,F,,15556,,1,1,CHEMBL615544
523,N,,620.0,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,5845,,1,1,CHEMBL615545
524,N,,620.0,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14422,,1,1,CHEMBL615546
525,N,,620.0,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Expert,,3T3-L1,,,80006,BAO_0000219,F,,5845,,1,1,CHEMBL615547
526,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,1,1,CHEMBL615548
527,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,1,1,CHEMBL615549
528,N,,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Expert,,3T3-L1,,,80006,BAO_0000219,F,,14508,,1,1,CHEMBL615550
529,N,,1118.0,,Inhibitory activity against rat fibroblast (3Y1) cell line,Intermediate,,3Y1 cell line,,,80622,BAO_0000219,F,,6349,,1,1,CHEMBL615551
530,N,,1118.0,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,1,1,CHEMBL615552
531,N,,1118.0,,Cytotoxicity in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,1,1,CHEMBL615553
532,N,,1118.0,,Cytostatic effect in 3Y1 cells.,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,1,1,CHEMBL615554
533,N,,1118.0,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Intermediate,,3Y1 cell line,,,80622,BAO_0000219,F,,15899,,1,1,CHEMBL615555
534,N,,1118.0,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Expert,,3Y1 cell line,,,80622,BAO_0000219,F,,17038,,1,1,CHEMBL615556
535,U,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,Autocuration,,,,,22226,BAO_0000019,B,,12421,,0,1,CHEMBL615557
536,U,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,22226,BAO_0000019,B,,12947,,0,1,CHEMBL615558
537,U,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,22226,BAO_0000019,B,,12947,,0,1,CHEMBL872066
538,D,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Expert,,,,,11607,BAO_0000019,B,,4896,,9,1,CHEMBL615559
539,H,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,Autocuration,,,,,11607,BAO_0000019,B,,6148,,8,1,CHEMBL615560
540,H,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,Autocuration,,,,,11607,BAO_0000019,B,,16432,,8,1,CHEMBL615561
541,H,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,Expert,,,,,11607,BAO_0000019,B,,4978,,8,1,CHEMBL857062
542,H,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),Expert,,,,,11607,BAO_0000019,B,,4978,,8,1,CHEMBL615562
543,H,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,Autocuration,,,,,11607,BAO_0000019,B,,3723,,8,1,CHEMBL615563
544,H,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),Autocuration,,,,,11607,BAO_0000357,B,,3518,,8,1,CHEMBL615564
545,H,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,Autocuration,,,,,11607,BAO_0000019,B,,4164,,8,1,CHEMBL615565
546,H,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,Autocuration,,,,,11607,BAO_0000019,B,,3518,,8,1,CHEMBL615566
547,D,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Expert,,,,,11607,BAO_0000019,B,,4164,,9,1,CHEMBL615567
548,H,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,Autocuration,,,,,11607,BAO_0000019,B,,3518,,8,1,CHEMBL615568
549,H,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),Autocuration,,,,,11607,BAO_0000357,B,,3518,,8,1,CHEMBL615569
550,H,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,Autocuration,,,,,11607,BAO_0000019,B,,4978,,8,1,CHEMBL615570
551,H,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),Autocuration,,,,,11607,BAO_0000019,B,,4978,,8,1,CHEMBL615571
552,H,,,,Binding affinity against melatonin (MT1) receptor (pC1),Autocuration,,,,,104733,BAO_0000224,B,,6455,,4,1,CHEMBL615572
553,U,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,2222,,0,1,CHEMBL615573
554,U,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,Autocuration,,,,,22226,BAO_0000019,B,,13020,,0,1,CHEMBL615574
555,U,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,Autocuration,,,,,22226,BAO_0000019,B,,13021,,0,1,CHEMBL615575
556,H,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,Autocuration,,,,,10619,BAO_0000357,B,,14532,,8,1,CHEMBL615576
557,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,,,10619,BAO_0000357,B,,14118,,8,1,CHEMBL615577
558,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11884,Hippocampus,8,1,CHEMBL615578
559,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,13969,,8,1,CHEMBL615579
560,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13392,,8,1,CHEMBL615580
561,H,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Expert,,,,,51,BAO_0000019,B,,14430,,8,1,CHEMBL615581
562,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12248,Hippocampus,8,1,CHEMBL615582
563,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12249,Hippocampus,8,1,CHEMBL615583
564,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615584
565,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL833691
566,H,,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615585
567,H,,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615586
568,H,,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL884524
569,H,,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12249,Hippocampus,8,1,CHEMBL615587
570,H,,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Autocuration,,,,10000000.0,51,BAO_0000221,B,,11799,Hippocampus,8,1,CHEMBL615588
571,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,14331,,9,1,CHEMBL615589
572,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000221,B,,11884,Hippocampus,8,1,CHEMBL615442
573,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Autocuration,,,,10000000.0,51,BAO_0000221,B,,14331,Hippocampus,8,1,CHEMBL615443
574,H,,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11701,Hippocampus,8,1,CHEMBL615444
575,H,,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000221,B,,11701,Hippocampus,8,1,CHEMBL615445
576,H,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,12248,Hippocampus,8,1,CHEMBL615446
577,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12248,,8,1,CHEMBL615447
578,H,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,12248,Hippocampus,8,1,CHEMBL615448
579,H,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,12249,Hippocampus,8,1,CHEMBL615449
580,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12248,,8,1,CHEMBL615450
581,H,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Expert,,,,10000000.0,51,BAO_0000221,B,,11799,Hippocampus,8,1,CHEMBL615451
582,H,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,51,BAO_0000357,B,,634,,8,1,CHEMBL615452
583,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615453
584,H,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615454
585,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615455
586,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615456
587,H,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,9995,Hippocampus,8,1,CHEMBL615457
588,H,,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Expert,,,,10000000.0,51,BAO_0000218,B,,12210,Hippocampus,8,1,CHEMBL615458
589,H,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Expert,,,,10000000.0,51,BAO_0000221,B,,13311,Hippocampus,8,1,CHEMBL615459
590,D,,449.0,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Expert,,CHO,,,51,BAO_0000219,B,,2331,,9,1,CHEMBL615460
591,H,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Autocuration,,,,,51,BAO_0000019,F,,1375,,8,1,CHEMBL615461
592,H,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Autocuration,,,,,51,BAO_0000019,F,,1375,,8,1,CHEMBL615462
593,H,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Autocuration,,,,10000000.0,51,BAO_0000221,F,,11574,Hippocampus,8,1,CHEMBL615463
594,H,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615464
595,H,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615465
596,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615466
597,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615467
598,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615468
599,H,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Autocuration,,,,2116.0,51,BAO_0000221,B,,12867,Ileum,8,1,CHEMBL615469
600,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,11574,,8,1,CHEMBL615470
601,H,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13114,,8,1,CHEMBL615471
602,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13181,,8,1,CHEMBL615472
603,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,,10000000.0,106,BAO_0000221,B,,10639,Hippocampus,8,1,CHEMBL883242
604,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,,10000000.0,106,BAO_0000221,F,,10639,Hippocampus,8,1,CHEMBL615473
605,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,CHO,,,11863,BAO_0000218,B,,11883,,8,1,CHEMBL615474
606,H,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17785,,8,1,CHEMBL615475
607,H,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,Autocuration,,HeLa,,,51,BAO_0000219,F,,1558,,8,1,CHEMBL615476
608,H,,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,Autocuration,,HeLa,,,51,BAO_0000219,F,,1558,,8,1,CHEMBL615477
609,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15740,,8,1,CHEMBL615478
610,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615160
611,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Expert,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615161
612,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615162
613,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615163
614,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615164
615,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615165
616,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615166
617,H,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,Autocuration,,,,,51,BAO_0000219,F,,14256,,8,1,CHEMBL615167
618,D,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,9,1,CHEMBL615168
619,D,,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,9,1,CHEMBL615169
620,D,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Expert,,CHO,,,51,BAO_0000219,B,,17200,,9,1,CHEMBL615170
621,D,,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Expert,,CHO,,,51,BAO_0000219,B,,17200,,9,1,CHEMBL615171
622,H,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15180,,8,1,CHEMBL615694
623,H,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15180,,8,1,CHEMBL615695
624,H,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,8,1,CHEMBL615696
625,H,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL615697
626,D,,449.0,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,9,1,CHEMBL859410
627,H,,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL615841
628,D,,449.0,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,CHO,,,51,BAO_0000219,F,,2759,,9,1,CHEMBL615842
629,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL835003
630,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL615843
631,D,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,9,1,CHEMBL615979
632,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL615980
633,D,,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,CHO,,,51,BAO_0000219,F,,2759,,9,1,CHEMBL615981
634,D,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Expert,,,,,51,BAO_0000019,F,,3445,,9,1,CHEMBL615982
635,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL615983
636,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL615984
637,D,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL615985
638,H,,449.0,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615986
639,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615987
640,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615988
641,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Expert,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615989
642,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615990
643,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615991
644,H,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615992
645,H,,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615993
646,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Expert,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615994
647,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615995
648,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615996
649,H,,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615997
650,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615998
651,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615999
652,H,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL616000
653,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,8,1,CHEMBL616001
654,D,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Expert,,,,,51,BAO_0000019,F,,6876,,9,1,CHEMBL616002
655,H,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",Expert,,,,,51,BAO_0000019,F,,6876,,8,1,CHEMBL616003
656,D,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616004
657,D,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616005
658,H,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,8,1,CHEMBL616006
659,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",Expert,,,,,51,BAO_0000019,F,,5548,,8,1,CHEMBL616007
660,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,8,1,CHEMBL616008
661,H,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5548,,8,1,CHEMBL616009
662,H,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",Expert,,,,,51,BAO_0000019,F,,5929,,8,1,CHEMBL616010
663,D,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Expert,,,,,51,BAO_0000019,F,,5929,,9,1,CHEMBL616011
664,D,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Expert,,,,,51,BAO_0000019,F,,5929,,9,1,CHEMBL615740
665,H,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16245,,8,1,CHEMBL615741
666,H,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL615742
667,H,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL615743
668,H,,449.0,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,Autocuration,,CHO,,,51,BAO_0000219,F,,14509,,8,1,CHEMBL615744
669,H,,449.0,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,Expert,,CHO,,,51,BAO_0000219,F,,14509,,8,1,CHEMBL615745
670,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,51,BAO_0000357,B,,15331,,8,1,CHEMBL615746
671,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,51,BAO_0000357,B,,15331,,8,1,CHEMBL615747
672,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615748
673,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615749
674,H,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615750
675,D,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,F,,6563,,9,1,CHEMBL616259
676,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL616260
677,D,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616261
678,D,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616262
679,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616263
680,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616264
681,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616265
682,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616266
683,D,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616267
684,D,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Expert,,,,,51,BAO_0000019,F,,5272,,9,1,CHEMBL616268
685,D,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,16146,,9,1,CHEMBL616269
686,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL884528
687,D,,722.0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,Expert,,HEK293,,,105,BAO_0000219,B,,13706,,9,1,CHEMBL616270
688,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,15250,,8,1,CHEMBL616271
689,H,,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL616272
690,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,Expert,,,,,51,BAO_0000357,B,,6861,,8,1,CHEMBL616273
691,D,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17200,,9,1,CHEMBL616274
692,H,,449.0,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL616275
693,H,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL616276
694,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616277
695,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616278
696,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616279
697,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616280
698,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616281
699,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616282
700,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616283
701,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616284
702,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616285
703,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616286
704,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616287
705,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616288
706,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL616289
707,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615610
708,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615611
709,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615612
710,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615613
711,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615614
712,U,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,,,22226,BAO_0000218,F,,12058,,0,1,CHEMBL615615
713,H,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,Autocuration,,,,,105093,BAO_0000019,B,,11440,,4,1,CHEMBL615616
714,H,,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Autocuration,,,,1898.0,11923,BAO_0000249,B,,6238,Hypothalamus,8,1,CHEMBL615617
715,H,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,Autocuration,,,,,10577,BAO_0000019,B,,10046,,8,1,CHEMBL615618
716,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,Autocuration,,,,,10577,BAO_0000019,B,,10046,,8,1,CHEMBL615619
717,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Expert,,,,,10577,BAO_0000019,B,,10046,,8,1,CHEMBL615620
718,H,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,55,BAO_0000357,B,,167,,8,1,CHEMBL615621
719,H,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,55,BAO_0000357,B,,167,,8,1,CHEMBL615622
720,H,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),Autocuration,,,,,12166,BAO_0000019,F,,11520,,8,1,CHEMBL615623
721,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,8,1,CHEMBL615624
722,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,8,1,CHEMBL615625
723,H,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,12166,BAO_0000019,F,,11520,,8,1,CHEMBL767045
724,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Autocuration,,,,,55,BAO_0000019,F,,135,,8,1,CHEMBL615626
725,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Autocuration,,,,,55,BAO_0000019,F,,135,,8,1,CHEMBL615627
726,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Autocuration,,,,,55,BAO_0000019,B,,11311,,8,1,CHEMBL615628
727,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL615629
728,D,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,Expert,,,,,55,BAO_0000357,B,,12281,,9,1,CHEMBL615630
729,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,8,1,CHEMBL615631
730,H,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,17087,BAO_0000218,F,,12576,,8,1,CHEMBL615632
731,H,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,Autocuration,,,,,17087,BAO_0000357,B,,12281,,8,1,CHEMBL615633
732,H,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,17087,BAO_0000218,F,,12576,,8,1,CHEMBL615634
733,H,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Expert,,,,,55,BAO_0000019,B,,11089,,8,1,CHEMBL615635
734,H,,,,In vitro inhibition of rat 5-Lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11006,,8,1,CHEMBL615636
735,D,,,,Inhibitory activity against 5-Lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11481,,9,1,CHEMBL615637
736,H,,702.0,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10864,,8,1,CHEMBL615638
737,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL615639
738,H,,702.0,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL615640
739,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,Autocuration,,,,,12166,BAO_0000019,B,,11311,,8,1,CHEMBL615796
740,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL615845
741,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,12166,BAO_0000357,B,,11006,,8,1,CHEMBL615846
742,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL615847
743,H,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11311,,8,1,CHEMBL615848
744,U,,,,Ratio of IC50 against 5-LO and COX,Autocuration,,,,,22226,BAO_0000019,B,,11481,,0,1,CHEMBL615849
745,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,12166,BAO_0000357,B,,11006,,8,1,CHEMBL615850
746,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,Autocuration,,,,,12166,BAO_0000357,B,,11006,,8,1,CHEMBL615851
747,H,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL615852
748,H,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,Autocuration,,,,,12166,BAO_0000019,F,,11006,,8,1,CHEMBL615853
749,H,,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Autocuration,,,,2367.0,120,BAO_0000357,B,,4288,Prostate gland,8,1,CHEMBL884527
750,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Autocuration,,,,,22226,BAO_0000019,B,,7587,,0,1,CHEMBL872871
751,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Autocuration,,,,,22226,BAO_0000019,B,,7587,,0,1,CHEMBL615854
752,U,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Autocuration,,,,,22226,BAO_0000019,B,,7587,,0,1,CHEMBL767046
753,H,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,Autocuration,,,,,10732,BAO_0000357,B,,11249,,8,1,CHEMBL615855
754,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Expert,,,,,12198,BAO_0000019,F,,8003,,9,1,CHEMBL615856
755,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,,,12198,BAO_0000019,F,,8003,,9,1,CHEMBL615857
756,D,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,,,12198,BAO_0000019,F,,8003,,9,1,CHEMBL615858
757,H,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12416,Hippocampus,8,1,CHEMBL615859
758,H,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,Autocuration,,,,,51,BAO_0000357,B,,16293,,8,1,CHEMBL615860
759,U,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,0,1,CHEMBL615861
760,U,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,0,1,CHEMBL615862
761,U,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,0,1,CHEMBL615863
762,U,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,,,22226,BAO_0000019,B,,13047,,0,1,CHEMBL615864
763,H,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,Hippocampus,4,1,CHEMBL615865
764,H,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,Hippocampus,4,1,CHEMBL615866
765,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,10085,Hippocampus,4,1,CHEMBL615867
766,H,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104744,BAO_0000249,B,Membranes,9841,,4,1,CHEMBL615868
767,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Autocuration,,,,,104744,BAO_0000249,B,,8822,,5,1,CHEMBL615869
768,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Autocuration,,,,,104744,BAO_0000019,B,,9806,,5,1,CHEMBL615870
769,D,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Autocuration,,,,,104744,BAO_0000019,B,,9806,,5,1,CHEMBL615871
770,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Autocuration,,,,,104744,BAO_0000224,B,,8868,,4,1,CHEMBL615872
771,H,,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,9036,Hippocampus,4,1,CHEMBL833492
772,H,,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Autocuration,,,,10000000.0,104744,BAO_0000221,B,,11374,Hippocampus,4,1,CHEMBL615873
773,H,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,Autocuration,,,,,104744,BAO_0000224,B,,10881,,4,1,CHEMBL615479
774,H,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,Autocuration,,,,,104744,BAO_0000019,B,,8822,,4,1,CHEMBL615480
775,D,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Autocuration,,,,,104744,BAO_0000249,B,,9806,,5,1,CHEMBL615481
776,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,15463,,4,1,CHEMBL872869
777,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,15463,,4,1,CHEMBL615482
778,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,Brain,4,1,CHEMBL615483
779,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,Brain,4,1,CHEMBL615484
780,H,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,Autocuration,,,,,104744,BAO_0000019,B,,8569,,4,1,CHEMBL615485
781,D,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,5,1,CHEMBL615486
782,H,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,4771,,4,1,CHEMBL615487
783,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,4,1,CHEMBL615488
784,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,4,1,CHEMBL615489
785,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,104744,BAO_0000224,B,,10062,,4,1,CHEMBL615389
786,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000019,B,,15463,,4,1,CHEMBL615390
787,H,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,104744,BAO_0000019,B,,15463,,4,1,CHEMBL615391
788,H,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,Autocuration,,,,,104744,BAO_0000224,B,,9098,,4,1,CHEMBL615392
789,U,,,,Affinity for 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,3070,,0,1,CHEMBL615393
790,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,Brain,4,1,CHEMBL615394
791,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,955.0,104744,BAO_0000221,B,,14542,Brain,4,1,CHEMBL615395
792,H,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,Autocuration,,,,,104744,BAO_0000224,B,,6398,,4,1,CHEMBL615396
793,H,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Autocuration,,,,955.0,104744,BAO_0000221,B,,1344,Brain,4,1,CHEMBL615397
794,H,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11963,,4,1,CHEMBL615398
795,U,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Autocuration,,,,,22226,BAO_0000019,B,,8908,,0,1,CHEMBL615399
796,H,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,Autocuration,,,,,104744,BAO_0000019,B,,9098,,4,1,CHEMBL615400
797,D,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Autocuration,,,,,104744,BAO_0000019,B,,8841,,5,1,CHEMBL615401
798,U,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Autocuration,,,,,22226,BAO_0000019,B,,8814,,0,1,CHEMBL615402
799,H,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,Autocuration,,,,,104744,BAO_0000019,B,,11752,,4,1,CHEMBL615403
800,H,,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Autocuration,,,,955.0,104744,BAO_0000221,B,,11642,Brain,4,1,CHEMBL615404
801,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,Autocuration,,,,,104744,BAO_0000019,B,,11642,,4,1,CHEMBL615781
802,H,,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Autocuration,,,,955.0,104744,BAO_0000220,B,,9231,Brain,4,1,CHEMBL615782
803,H,,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Autocuration,,,,955.0,104744,BAO_0000221,B,,11351,Brain,4,1,CHEMBL615783
804,U,,,,Compound was tested for binding affinity against 5-HT1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,4639,,0,1,CHEMBL873481
805,U,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,22226,BAO_0000019,B,,1205,,0,1,CHEMBL615784
806,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,10576,BAO_0000357,B,,10025,,8,1,CHEMBL615785
807,H,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,10576,BAO_0000249,F,,13241,,8,1,CHEMBL615786
808,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,,8,1,CHEMBL615787
809,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,,8,1,CHEMBL615788
810,H,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,F,,12438,,8,1,CHEMBL767044
811,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,,8,1,CHEMBL615789
812,H,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,10576,BAO_0000218,F,,16245,,8,1,CHEMBL615790
813,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,Autocuration,,,,,10576,BAO_0000019,F,,15740,,8,1,CHEMBL615813
814,H,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,Autocuration,,,,,10576,BAO_0000219,F,,15535,,8,1,CHEMBL615814
815,H,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,Expert,,,,,51,BAO_0000219,F,,15535,,8,1,CHEMBL615815
816,H,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,Autocuration,,,,,10576,BAO_0000219,F,,15535,,8,1,CHEMBL615816
817,H,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,Expert,,,,,10576,BAO_0000249,B,,9888,,8,1,CHEMBL615817
818,H,,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10085,Hippocampus,8,1,CHEMBL615818
819,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10085,Hippocampus,8,1,CHEMBL615819
820,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,17331,,8,1,CHEMBL615820
821,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,Hippocampus,9,1,CHEMBL615821
822,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,Hippocampus,9,1,CHEMBL615822
823,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,Hippocampus,8,1,CHEMBL615823
824,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,Hippocampus,9,1,CHEMBL615824
825,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,,10000000.0,10576,BAO_0000221,B,,10845,Hippocampus,9,1,CHEMBL615825
826,H,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,13730,,8,1,CHEMBL615826
827,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000249,B,,13508,,8,1,CHEMBL615827
828,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000249,B,,13508,Hippocampus,8,1,CHEMBL615828
829,H,,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12073,Hippocampus,8,1,CHEMBL615829
830,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,4671,Hippocampus,8,1,CHEMBL615830
831,H,,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,13631,Hippocampus,8,1,CHEMBL615831
832,H,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12438,,8,1,CHEMBL615832
833,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,,10576,BAO_0000019,B,,10483,,8,1,CHEMBL615833
834,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10483,Hippocampus,8,1,CHEMBL615834
835,H,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,Intermediate,,,,,10576,BAO_0000249,B,,12352,,8,1,CHEMBL615835
836,H,,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,14732,Hippocampus,8,1,CHEMBL615836
837,D,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Expert,,,,,10576,BAO_0000019,B,,11049,,9,1,CHEMBL615837
838,D,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Expert,,,,,10576,BAO_0000019,B,,11049,,9,1,CHEMBL615838
839,H,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",Expert,,,,,10576,BAO_0000249,B,,13657,,8,1,CHEMBL615839
840,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000019,B,,11473,,8,1,CHEMBL884525
841,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Autocuration,,,,,10576,BAO_0000249,B,,2014,,8,1,CHEMBL615840
842,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,3086,Hippocampus,8,1,CHEMBL615405
843,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10576,BAO_0000019,B,,15854,,8,1,CHEMBL615406
844,H,,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Expert,,,,10000000.0,10576,BAO_0000221,B,,10922,Hippocampus,8,1,CHEMBL615900
845,H,,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Expert,,,,10000000.0,10576,BAO_0000221,B,,13346,Hippocampus,8,1,CHEMBL615901
846,H,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,Expert,,,,,10576,BAO_0000357,B,,15311,,8,1,CHEMBL615902
847,H,,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10922,Hippocampus,8,1,CHEMBL615903
848,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,Autocuration,,,,,10576,BAO_0000357,B,,10025,,8,1,CHEMBL615904
849,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,10576,BAO_0000357,B,,10025,,8,1,CHEMBL615905
850,H,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,B,,9742,,8,1,CHEMBL615906
851,H,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,F,,9742,,8,1,CHEMBL615907
852,H,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Expert,,,,,10576,BAO_0000019,B,,12304,,8,1,CHEMBL615908
853,H,,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15789,Hippocampus,8,1,CHEMBL615909
854,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",Autocuration,,,,,10576,BAO_0000019,B,,9912,,8,1,CHEMBL615910
855,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",Autocuration,,,,,10576,BAO_0000019,B,,9912,,8,1,CHEMBL615911
856,H,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",Autocuration,,,,,10576,BAO_0000019,B,,9912,,8,1,CHEMBL615912
857,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000019,B,,16693,,8,1,CHEMBL615913
858,H,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,13276,,8,1,CHEMBL615914
859,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12678,Hippocampus,8,1,CHEMBL615915
860,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,Autocuration,,,,,10576,BAO_0000357,B,,11825,,8,1,CHEMBL615916
861,H,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Expert,,,,,10576,BAO_0000357,B,,12443,,8,1,CHEMBL615917
862,H,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13830,,8,1,CHEMBL615918
863,H,,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Expert,,,,10000000.0,10576,BAO_0000249,B,,14286,Hippocampus,8,1,CHEMBL615919
864,D,,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,14356,Hippocampus,9,1,CHEMBL615920
865,H,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,15306,,8,1,CHEMBL615921
866,H,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),Expert,,,,,10576,BAO_0000357,B,,15306,,8,1,CHEMBL615922
867,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,,16616,,9,1,CHEMBL881290
868,H,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Autocuration,,,,10000000.0,10576,BAO_0000221,B,,3651,Hippocampus,8,1,CHEMBL615923
869,H,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,F,,14331,Hippocampus,8,1,CHEMBL615924
870,H,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,F,,14331,Hippocampus,8,1,CHEMBL615925
871,D,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,14178,,9,1,CHEMBL615926
872,D,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,10639,,9,1,CHEMBL615927
873,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,Hippocampus,8,1,CHEMBL615928
874,D,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,10576,BAO_0000357,B,,1348,,9,1,CHEMBL615929
875,H,,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13605,Hippocampus,8,1,CHEMBL615930
876,H,,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615931
877,H,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615932
878,H,,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,17624,,8,1,CHEMBL615933
879,H,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15267,,8,1,CHEMBL615934
880,H,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,Autocuration,,,,,51,BAO_0000357,B,,16532,,8,1,CHEMBL615935
881,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,51,BAO_0000019,F,,6563,,8,1,CHEMBL615936
882,H,,449.0,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,Autocuration,,CHO,,,51,BAO_0000219,B,,4751,,8,1,CHEMBL615937
883,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15463,,8,1,CHEMBL615938
884,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),Autocuration,,,,,51,BAO_0000357,B,,3805,,8,1,CHEMBL615797
885,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5640,,8,1,CHEMBL615798
886,H,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,Autocuration,,,,,51,BAO_0000357,B,,6563,,8,1,CHEMBL872870
887,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,Autocuration,,,,,51,BAO_0000357,B,,5548,,8,1,CHEMBL615799
888,H,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,6347,,8,1,CHEMBL615800
889,H,,722.0,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,8,1,CHEMBL615801
890,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,Autocuration,,,,,51,BAO_0000019,B,,13047,,8,1,CHEMBL615802
891,H,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,8,1,CHEMBL615803
892,H,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL835002
893,H,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL615804
894,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,Expert,,HeLa,,,51,BAO_0000219,B,,17211,,8,1,CHEMBL615805
895,H,,449.0,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,Autocuration,,CHO,,,51,BAO_0000219,B,,4751,,8,1,CHEMBL615806
896,D,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Expert,,,,,51,BAO_0000357,B,,6491,,9,1,CHEMBL615807
897,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,Autocuration,,,,,51,BAO_0000357,B,,4707,,8,1,CHEMBL615808
898,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13910,,9,1,CHEMBL615809
899,H,,308.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,Autocuration,,HeLa,,,51,BAO_0000219,B,,16190,,8,1,CHEMBL615810
900,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16633,,8,1,CHEMBL615811
901,H,,449.0,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,11898,,8,1,CHEMBL615812
902,H,,449.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,11898,,8,1,CHEMBL615751
903,H,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,14331,,8,1,CHEMBL615752
904,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,Expert,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615753
905,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,Autocuration,,CHO,,,51,BAO_0000219,B,,17624,,8,1,CHEMBL615754
906,H,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,3307,,8,1,CHEMBL615755
907,D,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,6563,,9,1,CHEMBL615756
908,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000019,B,,14165,,8,1,CHEMBL615757
909,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,5732,,8,1,CHEMBL615758
910,H,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,51,BAO_0000357,B,,13366,,8,1,CHEMBL615759
911,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17626,,8,1,CHEMBL615760
912,H,,308.0,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,6588,,8,1,CHEMBL615761
913,H,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16209,,8,1,CHEMBL872104
914,H,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,15463,,8,1,CHEMBL615762
915,H,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,15463,,8,1,CHEMBL615763
916,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,51,BAO_0000357,B,,14770,,8,1,CHEMBL615764
917,H,,1167.0,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Autocuration,,Cell line,,,51,BAO_0000219,B,,16245,,8,1,CHEMBL615765
918,H,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),Autocuration,,,,,51,BAO_0000019,B,,16245,,8,1,CHEMBL615766
919,H,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5548,,8,1,CHEMBL615767
920,H,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,5548,,8,1,CHEMBL615768
921,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,5548,,8,1,CHEMBL615769
922,H,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,6876,,8,1,CHEMBL615770
923,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,2598,,8,1,CHEMBL615771
924,H,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,Expert,,,,,51,BAO_0000357,B,,17785,,8,1,CHEMBL615772
925,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,6013,,8,1,CHEMBL615773
926,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,5929,,8,1,CHEMBL615774
927,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,16633,,8,1,CHEMBL615775
928,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,1558,,8,1,CHEMBL615776
929,H,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,16026,,8,1,CHEMBL615777
930,H,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,Autocuration,,,,,51,BAO_0000219,B,,12469,,8,1,CHEMBL615778
931,D,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,15874,,9,1,CHEMBL615779
932,H,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,51,BAO_0000357,B,,15874,,8,1,CHEMBL615780
933,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,3935,,8,1,CHEMBL616298
934,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15818,,8,1,CHEMBL616299
935,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,51,BAO_0000219,B,,13706,,8,1,CHEMBL616300
936,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,Expert,,CHO-K1,,,51,BAO_0000219,F,,13729,,8,1,CHEMBL616301
937,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,B,,15413,,8,1,CHEMBL616302
938,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),Autocuration,,,,,51,BAO_0000019,B,,15413,,8,1,CHEMBL616117
939,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),Autocuration,,,,,51,BAO_0000019,B,,15413,,8,1,CHEMBL616118
940,H,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,Autocuration,,,,,51,BAO_0000019,B,,15413,,8,1,CHEMBL616119
941,D,,308.0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,3445,,9,1,CHEMBL616120
942,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,8,1,CHEMBL616121
943,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,8,1,CHEMBL616122
944,H,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,17626,,8,1,CHEMBL616123
945,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,4234,,9,1,CHEMBL616124
946,H,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,51,BAO_0000357,B,,5640,,8,1,CHEMBL616125
947,H,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,5272,,8,1,CHEMBL616126
948,H,,449.0,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,Autocuration,,CHO,,,51,BAO_0000219,B,,4622,,8,1,CHEMBL616127
949,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,B,,17085,,8,1,CHEMBL616128
950,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,51,BAO_0000357,B,,3025,,8,1,CHEMBL616129
951,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,15315,,8,1,CHEMBL616130
952,H,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,Autocuration,,,,,51,BAO_0000357,B,,15267,,8,1,CHEMBL616131
953,H,,308.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,Autocuration,,HeLa,,,51,BAO_0000219,B,,17158,,8,1,CHEMBL616132
954,D,,308.0,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Expert,,HeLa,,,51,BAO_0000219,B,,14214,,9,1,CHEMBL616133
955,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,17133,,8,1,CHEMBL616134
956,H,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,Autocuration,,,,,51,BAO_0000357,B,,16532,,8,1,CHEMBL616135
957,D,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000357,B,,2391,,9,1,CHEMBL616136
958,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,Autocuration,,,,,51,BAO_0000019,B,,14447,,8,1,CHEMBL616137
959,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,Autocuration,,,,,51,BAO_0000019,B,,14447,,8,1,CHEMBL872105
960,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,51,BAO_0000357,B,,15086,,8,1,CHEMBL616138
961,D,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,13051,,9,1,CHEMBL616139
962,H,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",Autocuration,,,,,51,BAO_0000019,F,,16026,,8,1,CHEMBL616140
963,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,Expert,,,,,51,BAO_0000019,B,,17085,,8,1,CHEMBL616141
964,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,17133,,8,1,CHEMBL616142
965,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,Autocuration,,,,,51,BAO_0000357,B,,17133,,8,1,CHEMBL616143
966,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,8,1,CHEMBL616144
967,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,8,1,CHEMBL616145
968,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,8,1,CHEMBL616012
969,H,,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,HeLa,,,51,BAO_0000219,B,,17211,,8,1,CHEMBL616013
970,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,8,1,CHEMBL616014
971,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,8,1,CHEMBL616015
972,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,51,BAO_0000019,F,,16394,,8,1,CHEMBL616016
973,H,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,Autocuration,,,,,51,BAO_0000218,F,,16394,,8,1,CHEMBL616017
974,H,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,Autocuration,,,,,51,BAO_0000019,B,,16394,,8,1,CHEMBL616018
975,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,Autocuration,,,,,51,BAO_0000019,F,,15740,,8,1,CHEMBL616019
976,H,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,,51,BAO_0000019,F,,15740,,8,1,CHEMBL616020
977,H,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15740,,8,1,CHEMBL858018
978,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,8,1,CHEMBL616021
979,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",Expert,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL616022
980,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL616023
981,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL616024
982,H,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",Autocuration,,,,,51,BAO_0000019,F,,5640,,8,1,CHEMBL616025
983,H,,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL616026
984,H,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",Autocuration,,,,,51,BAO_0000019,F,,16394,,8,1,CHEMBL616027
985,D,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Expert,,,,,51,BAO_0000019,F,,16394,,9,1,CHEMBL616028
986,D,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Expert,,,,,51,BAO_0000019,F,,3445,,9,1,CHEMBL616029
987,H,,449.0,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,Expert,,CHO,,,51,BAO_0000219,B,,4316,,8,1,CHEMBL616030
988,H,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,Expert,,,,,51,BAO_0000019,B,,4316,,8,1,CHEMBL616031
989,D,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000019,F,,15180,,9,1,CHEMBL616032
990,D,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,,,51,BAO_0000019,F,,15180,,9,1,CHEMBL616033
991,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616034
992,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616035
993,H,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616036
994,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616037
995,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616038
996,H,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616039
997,H,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,15042,,8,1,CHEMBL616040
998,D,,308.0,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,9,1,CHEMBL616041
999,D,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,9,1,CHEMBL616042
1000,D,,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,HeLa,,,51,BAO_0000219,F,,15180,,9,1,CHEMBL616043
1001,H,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16245,,8,1,CHEMBL616044
1002,H,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,8,1,CHEMBL616045
1003,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,HEK293,,,51,BAO_0000219,F,,17296,,8,1,CHEMBL616046
1004,H,,449.0,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL616047
1005,H,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL616048
1006,D,,449.0,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Expert,,CHO,,,51,BAO_0000219,F,,2759,,9,1,CHEMBL616049
1007,H,,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,CHO,,,51,BAO_0000219,F,,2759,,8,1,CHEMBL616050
1008,H,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,Expert,,,,,51,BAO_0000219,F,,15419,,8,1,CHEMBL616051
1009,H,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,Autocuration,,,,,51,BAO_0000219,F,,15419,,8,1,CHEMBL616212
1010,H,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,51,BAO_0000019,F,,16026,,8,1,CHEMBL616213
1011,H,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,Expert,,,,,51,BAO_0000219,B,,1414,,8,1,CHEMBL616214
1012,H,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,Expert,,,,,51,BAO_0000219,B,,1414,,8,1,CHEMBL616215
1013,H,,,,Binding activity radioligand.,Autocuration,,,,,51,BAO_0000357,B,,12861,,8,1,CHEMBL616216
1014,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,51,BAO_0000019,B,,12861,,8,1,CHEMBL616217
1015,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5104,,8,1,CHEMBL616218
1016,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5105,,8,1,CHEMBL616219
1017,H,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,16312,,8,1,CHEMBL616220
1018,D,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,15180,,9,1,CHEMBL833493
1019,H,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5033,,8,1,CHEMBL616221
1020,D,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,CHO,,,51,BAO_0000219,B,,16909,,9,1,CHEMBL616222
1021,H,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000019,F,,2590,,8,1,CHEMBL616223
1022,H,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,Autocuration,,,,,51,BAO_0000019,F,,2590,,8,1,CHEMBL616224
1023,H,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,Expert,,,,,51,BAO_0000019,B,,16394,,8,1,CHEMBL616225
1024,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Expert,,HEK293,,,51,BAO_0000219,B,,4540,,9,1,CHEMBL616226
1025,H,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,Autocuration,,HEK293,,,51,BAO_0000219,B,,17296,,8,1,CHEMBL616227
1026,H,,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,17296,,8,1,CHEMBL616228
1027,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,8,1,CHEMBL616229
1028,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,8,1,CHEMBL616230
1029,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,8,1,CHEMBL616231
1030,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000357,B,,6166,,8,1,CHEMBL616232
1031,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,HEK293,,,51,BAO_0000219,B,,15779,,8,1,CHEMBL616233
1032,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,4199,,8,1,CHEMBL857973
1033,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,Autocuration,,,,,51,BAO_0000219,B,,15316,,8,1,CHEMBL616234
1034,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,14875,,8,1,CHEMBL616235
1035,H,,308.0,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,HeLa,,,51,BAO_0000219,B,,14727,,8,1,CHEMBL616236
1036,H,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,,,,51,BAO_0000019,B,,14727,,8,1,CHEMBL616237
1037,H,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,Autocuration,,HEK293,,,51,BAO_0000219,B,,15146,,8,1,CHEMBL616238
1038,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,Autocuration,,HEK293,,,51,BAO_0000219,B,,5213,,8,1,CHEMBL616239
1039,H,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,Autocuration,,,,,51,BAO_0000219,B,,16429,,8,1,CHEMBL616240
1040,D,,308.0,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Expert,,HeLa,,,51,BAO_0000219,B,,15042,,9,1,CHEMBL616241
1041,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,Autocuration,,HEK293,,,51,BAO_0000219,B,,14818,,8,1,CHEMBL616242
1042,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",Autocuration,,HEK293,,,51,BAO_0000219,B,,4829,,8,1,CHEMBL616243
1043,D,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17200,,9,1,CHEMBL616244
1044,D,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,13051,,9,1,CHEMBL616245
1045,H,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,106,BAO_0000357,B,,5486,,8,1,CHEMBL616246
1046,H,,,,Binding affinity against 5-HT1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5254,,8,1,CHEMBL616247
1047,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,105,BAO_0000357,B,,5254,,8,1,CHEMBL616248
1048,H,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,107,BAO_0000357,B,,15331,,8,1,CHEMBL616249
1049,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13506,,8,1,CHEMBL616250
1050,H,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,15267,,8,1,CHEMBL616251
1051,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,,8,1,CHEMBL616252
1052,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,,8,1,CHEMBL616253
1053,H,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,Autocuration,,,,,11863,BAO_0000218,F,,16616,,8,1,CHEMBL616254
1054,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL616255
1055,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL832872
1056,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL616256
1057,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL616257
1058,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL616258
1059,D,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Expert,,,,,11863,BAO_0000218,F,,16616,,9,1,CHEMBL616384
1060,H,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,8,1,CHEMBL616385
1061,H,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Expert,,,,,11863,BAO_0000357,B,,13704,,8,1,CHEMBL616386
1062,D,,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,9,1,CHEMBL616387
1063,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,8,1,CHEMBL616388
1064,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,9,1,CHEMBL616389
1065,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,8,1,CHEMBL616390
1066,H,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,11863,BAO_0000357,B,,217,,8,1,CHEMBL616391
1067,D,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Expert,,,,10000000.0,11863,BAO_0000221,B,,10297,Hippocampus,9,1,CHEMBL616392
1068,H,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4921,,8,1,CHEMBL616393
1069,H,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Autocuration,,,,,51,BAO_0000357,B,,4921,,8,1,CHEMBL616394
1070,H,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Autocuration,,,,,51,BAO_0000019,B,,4996,,8,1,CHEMBL616395
1071,H,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,Autocuration,,,,,51,BAO_0000357,B,,12918,,8,1,CHEMBL616396
1072,H,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,,,51,BAO_0000019,B,,5333,,8,1,CHEMBL872907
1073,H,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,,,51,BAO_0000019,B,,4437,,8,1,CHEMBL616397
1074,H,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Autocuration,,,,,51,BAO_0000019,B,,1742,,8,1,CHEMBL616398
1075,H,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,16688,,8,1,CHEMBL616399
1076,H,,,,Binding activity radioligand.,Autocuration,,,,,51,BAO_0000357,B,,12861,,8,1,CHEMBL857065
1077,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Expert,,,,,51,BAO_0000019,B,,12861,,8,1,CHEMBL616400
1078,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,,,51,BAO_0000019,B,,12861,,8,1,CHEMBL616401
1079,H,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,Expert,,,,,10624,BAO_0000019,B,,12490,,8,1,CHEMBL616402
1080,H,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000019,B,,11828,,8,1,CHEMBL616403
1081,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Autocuration,,,,10000000.0,51,BAO_0000221,B,,11866,Hippocampus,8,1,CHEMBL616404
1082,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Autocuration,,,,,51,BAO_0000249,B,,12827,,8,1,CHEMBL616405
1083,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Autocuration,,,,,51,BAO_0000019,B,,12918,,8,1,CHEMBL616406
1084,H,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Expert,,,,,51,BAO_0000019,F,,12919,,8,1,CHEMBL616407
1085,H,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Autocuration,,,,,51,BAO_0000019,B,,13047,,8,1,CHEMBL616408
1086,D,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Expert,,,,,10576,BAO_0000249,B,,15796,,9,1,CHEMBL616409
1087,D,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Expert,,,,10000000.0,10576,BAO_0000221,B,,3651,Hippocampus,9,1,CHEMBL616410
1088,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,Autocuration,,,,,10576,BAO_0000357,B,,188,,8,1,CHEMBL616411
1089,D,,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,9,1,CHEMBL616412
1090,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,,10000000.0,10576,BAO_0000249,F,Membranes,16616,Hippocampus,9,1,CHEMBL616413
1091,H,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,Hippocampus,8,1,CHEMBL616414
1092,D,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Expert,,,,10000000.0,10576,BAO_0000221,B,,17167,Hippocampus,9,1,CHEMBL616415
1093,H,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Autocuration,,,,,10576,BAO_0000019,B,,14776,,8,1,CHEMBL616416
1094,H,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,12158,,8,1,CHEMBL616417
1095,H,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13481,,8,1,CHEMBL616418
1096,H,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,10576,BAO_0000219,B,,13427,,8,1,CHEMBL616419
1097,H,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,10210,,8,1,CHEMBL616420
1098,H,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,,10576,BAO_0000249,B,Membranes,10205,,8,1,CHEMBL616421
1099,H,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,,10576,BAO_0000249,B,Membranes,10205,,8,1,CHEMBL616422
1100,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,Membranes,10205,,8,1,CHEMBL616423
1101,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Expert,,,,,10576,BAO_0000357,B,,12280,,9,1,CHEMBL616424
1102,H,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,17386,,8,1,CHEMBL616425
1103,H,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,Expert,,,,,10576,BAO_0000357,B,,13654,,8,1,CHEMBL616426
1104,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14423,Hippocampus,8,1,CHEMBL616427
1105,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15412,Hippocampus,8,1,CHEMBL616428
1106,H,,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12073,Hippocampus,8,1,CHEMBL616290
1107,D,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,4101,,9,1,CHEMBL616052
1108,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,10062,,8,1,CHEMBL616053
1109,H,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,6238,,8,1,CHEMBL616054
1110,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,16273,,8,1,CHEMBL616055
1111,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,Autocuration,,,,,10576,BAO_0000357,B,,11139,,8,1,CHEMBL616056
1112,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Expert,,,,,10576,BAO_0000019,B,,16796,,8,1,CHEMBL616057
1113,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,,955.0,10576,BAO_0000221,B,,9548,Brain,9,1,CHEMBL616058
1114,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Autocuration,,,,955.0,10576,BAO_0000221,B,,10381,Brain,8,1,CHEMBL616059
1115,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,13408,,8,1,CHEMBL616060
1116,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,13825,Hippocampus,9,1,CHEMBL616061
1117,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,11147,Hippocampus,8,1,CHEMBL616062
1118,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000249,B,,10552,,8,1,CHEMBL616063
1119,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,2435.0,10576,BAO_0000249,B,,10552,Striatum,8,1,CHEMBL616064
1120,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,17136,,9,1,CHEMBL616065
1121,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,5778,,9,1,CHEMBL616066
1122,H,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13481,Hippocampus,8,1,CHEMBL616067
1123,H,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13481,Hippocampus,8,1,CHEMBL616068
1124,H,,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Intermediate,,,,10000000.0,10576,BAO_0000221,B,,13630,Hippocampus,8,1,CHEMBL616069
1125,H,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,,16245,,8,1,CHEMBL616070
1126,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,Hippocampus,8,1,CHEMBL616071
1127,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Expert,,,,10000000.0,10576,BAO_0000221,B,,14509,Hippocampus,8,1,CHEMBL616072
1128,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,Hippocampus,8,1,CHEMBL616073
1129,H,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14509,Hippocampus,8,1,CHEMBL616074
1130,H,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,Expert,,,,,10576,BAO_0000019,B,,14256,,8,1,CHEMBL616075
1131,H,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,11139,,8,1,CHEMBL616076
1132,D,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Expert,,,,,10576,BAO_0000019,B,,11047,,9,1,CHEMBL616077
1133,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Expert,,,,,10576,BAO_0000019,B,,11047,,9,1,CHEMBL616078
1134,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Expert,,,,,10576,BAO_0000019,B,,11047,,9,1,CHEMBL616079
1135,D,,485.0,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,10576,BAO_0000219,B,,2395,,9,1,CHEMBL616080
1136,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,9699,,8,1,CHEMBL616081
1137,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Expert,,,,10000000.0,10576,BAO_0000221,B,,12028,Hippocampus,9,1,CHEMBL616082
1138,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12028,Hippocampus,8,1,CHEMBL616083
1139,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,5815,,8,1,CHEMBL616084
1140,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,Expert,,,,,10576,BAO_0000019,B,,16616,,8,1,CHEMBL616085
1141,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,Autocuration,,,,,10576,BAO_0000019,B,,5815,,8,1,CHEMBL616086
1142,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Autocuration,,,,10000000.0,10576,BAO_0000221,B,,2761,Hippocampus,8,1,CHEMBL616087
1143,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Expert,,,,,10576,BAO_0000357,B,,13133,,8,1,CHEMBL616088
1144,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,10576,BAO_0000019,B,,10444,,8,1,CHEMBL616089
1145,D,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Expert,,,,,10576,BAO_0000357,B,,13278,,9,1,CHEMBL616090
1146,H,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,15874,,8,1,CHEMBL616091
1147,H,,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,2435.0,10576,BAO_0000249,B,Membranes,10552,Striatum,8,1,CHEMBL616092
1148,H,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),Autocuration,,,,,10576,BAO_0000357,B,,11130,,8,1,CHEMBL616093
1149,H,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),Autocuration,,,,,10576,BAO_0000218,B,,11130,,8,1,CHEMBL616094
1150,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Autocuration,,,,955.0,10576,BAO_0000221,B,,14542,Brain,8,1,CHEMBL616095
1151,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13670,,9,1,CHEMBL616096
1152,H,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,,9888,,8,1,CHEMBL616097
1153,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,3678,,9,1,CHEMBL616098
1154,H,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11332,Hippocampus,8,1,CHEMBL616099
1155,H,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11332,Hippocampus,8,1,CHEMBL616100
1156,H,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,1185,,8,1,CHEMBL616101
1157,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,,2014,,8,1,CHEMBL616102
1158,H,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,1185,,8,1,CHEMBL616103
1159,H,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Expert,,,,,10576,BAO_0000019,B,,14429,,8,1,CHEMBL616104
1160,H,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,16288,,8,1,CHEMBL616105
1161,D,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,5432,,9,1,CHEMBL616106
1162,H,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,14429,,8,1,CHEMBL616107
1163,H,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,Expert,,,,,10576,BAO_0000357,B,,13672,,8,1,CHEMBL616108
1164,H,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11296,Hippocampus,8,1,CHEMBL616109
1165,H,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,Autocuration,,,,,10576,BAO_0000357,B,,11296,,8,1,CHEMBL616110
1166,H,,449.0,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,Expert,,CHO,,,10576,BAO_0000219,B,,14749,,8,1,CHEMBL616111
1167,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000019,B,,15086,,8,1,CHEMBL616112
1168,H,,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13462,Hippocampus,8,1,CHEMBL616113
1169,H,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,B,,15363,,8,1,CHEMBL616114
1170,H,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,B,,15363,,8,1,CHEMBL616115
1171,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,10796,,8,1,CHEMBL616116
1172,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,955.0,10576,BAO_0000221,B,,12816,Brain,8,1,CHEMBL615844
1173,H,,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,13542,Hippocampus,8,1,CHEMBL615939
1174,H,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,Expert,,,,,10576,BAO_0000019,B,,13308,,8,1,CHEMBL615940
1175,H,,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Expert,,,,10000000.0,10576,BAO_0000221,B,,13541,Hippocampus,8,1,CHEMBL615941
1176,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615942
1177,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615943
1178,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615944
1179,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615945
1180,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615946
1181,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615947
1182,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615948
1183,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615949
1184,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615950
1185,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615951
1186,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615952
1187,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615953
1188,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615954
1189,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,9,1,CHEMBL615955
1190,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615956
1191,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL615957
1192,H,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,Expert,,,,,10576,BAO_0000019,B,,12879,,8,1,CHEMBL615958
1193,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,Expert,,,,,10576,BAO_0000019,B,,11964,,8,1,CHEMBL615959
1194,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),Autocuration,,,,,10576,BAO_0000019,B,,11964,,8,1,CHEMBL615960
1195,H,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),Autocuration,,,,,10576,BAO_0000019,B,,11964,,8,1,CHEMBL615961
1196,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,,955.0,10576,BAO_0000221,B,,9548,Brain,8,1,CHEMBL615962
1197,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,Expert,,,,,10576,BAO_0000019,B,,9098,,8,1,CHEMBL615963
1198,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,Autocuration,,,,,10576,BAO_0000019,B,,9098,,8,1,CHEMBL615964
1199,H,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,Autocuration,,,,,10576,BAO_0000019,B,,9098,,8,1,CHEMBL615965
1200,H,,449.0,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,Expert,,CHO,,,10576,BAO_0000219,B,,13248,,8,1,CHEMBL615966
1201,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,Expert,,,,,10576,BAO_0000249,B,,3147,,8,1,CHEMBL615967
1202,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,B,,13949,,8,1,CHEMBL615968
1203,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,CHO,,,10576,BAO_0000218,B,,11883,,8,1,CHEMBL615969
1204,H,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),Autocuration,,,,,10576,BAO_0000218,B,,11883,,8,1,CHEMBL615970
1205,D,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,11883,,9,1,CHEMBL615971
1206,H,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,15535,,8,1,CHEMBL615972
1207,H,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,Autocuration,,,,,10576,BAO_0000249,B,,15535,,8,1,CHEMBL615973
1208,H,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,Autocuration,,,,,10576,BAO_0000249,B,,15535,,8,1,CHEMBL615974
1209,D,,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,CHO,,,51,BAO_0000219,B,,16372,,9,1,CHEMBL615975
1210,H,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,Expert,,,,,10576,BAO_0000249,B,,14608,,8,1,CHEMBL615976
1211,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,4795,Hippocampus,9,1,CHEMBL872106
1212,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL615977
1213,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL615978
1214,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616166
1215,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616167
1216,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616168
1217,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616169
1218,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616170
1219,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616171
1220,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616172
1221,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616173
1222,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616174
1223,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616175
1224,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616176
1225,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616177
1226,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616178
1227,H,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,10576,BAO_0000019,B,,9742,,8,1,CHEMBL616179
1228,H,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12073,,8,1,CHEMBL616180
1229,H,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,4101,,8,1,CHEMBL616181
1230,H,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,Autocuration,,,,,10576,BAO_0000019,B,,15360,,8,1,CHEMBL616182
1231,H,,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11576,Hippocampus,8,1,CHEMBL616183
1232,H,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,Expert,,,,,10576,BAO_0000019,B,,5834,,8,1,CHEMBL615874
1233,D,,485.0,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,10576,BAO_0000219,B,,2395,,9,1,CHEMBL615875
1234,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,Autocuration,,,,,10576,BAO_0000019,B,,1375,,8,1,CHEMBL615876
1235,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Autocuration,,,,,10576,BAO_0000019,B,,1375,,8,1,CHEMBL615877
1236,H,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),Autocuration,,,,,10576,BAO_0000357,B,,3967,,8,1,CHEMBL615878
1237,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,Expert,,,,,10576,BAO_0000357,B,,12884,,8,1,CHEMBL615879
1238,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,Expert,,,,,10576,BAO_0000357,B,,2343,,8,1,CHEMBL615880
1239,H,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Autocuration,,,,,10576,BAO_0000019,B,,11511,,8,1,CHEMBL615881
1240,D,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,11511,,9,1,CHEMBL615882
1241,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615883
1242,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615884
1243,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615885
1244,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615886
1245,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615887
1246,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615888
1247,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615889
1248,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615890
1249,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615891
1250,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615892
1251,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615893
1252,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615894
1253,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615895
1254,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615896
1255,H,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,Autocuration,,,,,10576,BAO_0000218,F,,16394,,8,1,CHEMBL615897
1256,D,,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,9,1,CHEMBL615898
1257,H,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,Autocuration,,,,,10576,BAO_0000019,B,,16796,,8,1,CHEMBL615899
1258,H,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Autocuration,,,,,10576,BAO_0000019,B,,16796,,8,1,CHEMBL616291
1259,H,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,Autocuration,,,,,10576,BAO_0000357,B,,15629,,8,1,CHEMBL616292
1260,H,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,10576,BAO_0000249,F,,13241,,8,1,CHEMBL616293
1261,H,,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,12073,Hippocampus,8,1,CHEMBL616294
1262,H,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,14286,Hippocampus,8,1,CHEMBL616295
1263,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Autocuration,,,,955.0,10576,BAO_0000221,B,,14542,Brain,8,1,CHEMBL616296
1264,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616297
1265,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616605
1266,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616606
1267,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616607
1268,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616608
1269,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616609
1270,D,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Expert,,,,,10576,BAO_0000019,F,,13630,,9,1,CHEMBL616610
1271,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616611
1272,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616612
1273,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616613
1274,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616614
1275,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616615
1276,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616616
1277,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616617
1278,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616618
1279,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616619
1280,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616620
1281,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616621
1282,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616622
1283,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,Expert,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616146
1284,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL832873
1285,H,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616147
1286,H,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL872872
1287,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616148
1288,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9783,Hippocampus,8,1,CHEMBL616149
1289,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Expert,,,,10000000.0,10576,BAO_0000221,B,,9783,Hippocampus,8,1,CHEMBL616150
1290,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Expert,,,,,10576,BAO_0000249,B,Membranes,14331,,9,1,CHEMBL616151
1291,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Expert,,,,10000000.0,10576,BAO_0000221,B,,15260,Hippocampus,8,1,CHEMBL872873
1292,H,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,Hippocampus,8,1,CHEMBL616670
1293,H,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,Hippocampus,8,1,CHEMBL616671
1294,D,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,,,10576,BAO_0000249,F,,16616,,9,1,CHEMBL884861
1295,H,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,15629,,8,1,CHEMBL616672
1296,H,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,10576,BAO_0000019,B,,15086,,8,1,CHEMBL616673
1297,H,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,F,,5717,,8,1,CHEMBL616674
1298,H,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,12652,,8,1,CHEMBL616675
1299,H,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14608,Hippocampus,8,1,CHEMBL616676
1300,H,,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,Hippocampus,8,1,CHEMBL616677
1301,H,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,Hippocampus,8,1,CHEMBL616678
1302,D,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,15247,,9,1,CHEMBL616679
1303,H,,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,17529,Hippocampus,8,1,CHEMBL616680
1304,H,,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14826,Hippocampus,8,1,CHEMBL616681
1305,H,,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14826,Hippocampus,8,1,CHEMBL616682
1306,H,,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13241,Hippocampus,8,1,CHEMBL616683
1307,H,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14093,Hippocampus,8,1,CHEMBL616684
1308,H,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14093,Hippocampus,8,1,CHEMBL616685
1309,H,,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Autocuration,,,,955.0,10576,BAO_0000221,B,,14442,Brain,8,1,CHEMBL616686
1310,H,,,,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,10576,BAO_0000357,B,,9919,,8,1,CHEMBL616687
1311,H,,,,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,10576,BAO_0000357,B,,9919,,8,1,CHEMBL616688
1312,H,,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11440,Hippocampus,8,1,CHEMBL616689
1313,H,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,11257,,8,1,CHEMBL616690
1314,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,10330,,8,1,CHEMBL616691
1315,D,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Expert,,,,10000000.0,10576,BAO_0000221,B,,17331,Hippocampus,9,1,CHEMBL616692
1316,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,Expert,,,,,10576,BAO_0000249,B,,16567,,8,1,CHEMBL616693
1317,D,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Expert,,,,,10576,BAO_0000019,B,,12058,,9,1,CHEMBL616694
1318,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9699,Hippocampus,8,1,CHEMBL616695
1319,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,Autocuration,,,,,10576,BAO_0000357,B,,9547,,8,1,CHEMBL616696
1320,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,Autocuration,,,,,10576,BAO_0000357,B,,10330,,8,1,CHEMBL616697
1321,H,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,14331,,8,1,CHEMBL616698
1322,D,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000019,B,,14060,,9,1,CHEMBL616949
1323,H,,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14744,Hippocampus,8,1,CHEMBL616950
1324,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,,,10576,BAO_0000357,B,,13506,,8,1,CHEMBL832875
1325,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,955.0,10576,BAO_0000221,B,,10862,Brain,8,1,CHEMBL616951
1326,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,955.0,10576,BAO_0000221,B,,10862,Brain,8,1,CHEMBL616952
1327,H,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,Expert,,,,,10576,BAO_0000357,B,,10062,,8,1,CHEMBL616953
1328,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,Autocuration,,,,,10576,BAO_0000357,B,,12073,,8,1,CHEMBL616954
1329,H,,,,GTPgammaS radioligand binding assay,Autocuration,,,,,106,BAO_0000357,B,,14875,,8,1,CHEMBL616955
1330,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,106,BAO_0000357,B,,2391,,8,1,CHEMBL616956
1331,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,8,1,CHEMBL616957
1332,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,8,1,CHEMBL616958
1333,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,2391,,8,1,CHEMBL616959
1334,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,106,BAO_0000357,B,,2391,,8,1,CHEMBL616960
1335,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,8,1,CHEMBL616961
1336,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,Expert,,HeLa,,,106,BAO_0000219,B,,17211,,8,1,CHEMBL616962
1337,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,8,1,CHEMBL616963
1338,D,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Expert,,,,,106,BAO_0000357,B,,6491,,9,1,CHEMBL616524
1339,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,16190,,8,1,CHEMBL616525
1340,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,106,BAO_0000019,B,,14165,,8,1,CHEMBL872908
1341,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,Autocuration,,,,,106,BAO_0000019,B,,14165,,8,1,CHEMBL616526
1342,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,4234,,9,1,CHEMBL616527
1343,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,106,BAO_0000219,B,,6328,,8,1,CHEMBL616528
1344,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,106,BAO_0000357,B,,14770,,8,1,CHEMBL616529
1345,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,2598,,8,1,CHEMBL616530
1346,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,6897,,8,1,CHEMBL616531
1347,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,6897,,8,1,CHEMBL616532
1348,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,6013,,8,1,CHEMBL616533
1349,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,5843,,8,1,CHEMBL616534
1350,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,106,BAO_0000357,B,,14454,,8,1,CHEMBL616535
1351,H,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,Autocuration,,,,,106,BAO_0000357,B,,16209,,8,1,CHEMBL616536
1352,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,3935,,8,1,CHEMBL616537
1353,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,Expert,,CHO-K1,,,106,BAO_0000219,F,,13729,,8,1,CHEMBL616538
1354,H,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000019,F,,14251,,8,1,CHEMBL616539
1355,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000019,B,,17085,,8,1,CHEMBL616540
1356,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,106,BAO_0000357,B,,3025,,8,1,CHEMBL616429
1357,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15315,,8,1,CHEMBL616430
1358,D,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Expert,,,,,106,BAO_0000219,B,,14214,,9,1,CHEMBL616431
1359,D,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,3804,,9,1,CHEMBL616432
1360,D,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,Expert,,,,,106,BAO_0000357,B,,2391,,9,1,CHEMBL616433
1361,D,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,4175,,9,1,CHEMBL616434
1362,H,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,8,1,CHEMBL616435
1363,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,Expert,,,,,106,BAO_0000019,B,,17085,,8,1,CHEMBL616436
1364,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,8,1,CHEMBL616437
1365,H,,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,8,1,CHEMBL616438
1366,H,,308.0,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,HeLa,,,106,BAO_0000219,B,,17211,,8,1,CHEMBL616439
1367,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Expert,,,,,106,BAO_0000357,B,,15926,,9,1,CHEMBL616440
1368,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,16312,,8,1,CHEMBL616441
1369,H,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,Expert,,,,,106,BAO_0000357,B,,5843,,8,1,CHEMBL616442
1370,H,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,106,BAO_0000357,B,,5843,,8,1,CHEMBL616443
1371,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,Expert,,CHO-K1,,,106,BAO_0000219,B,,16312,,8,1,CHEMBL616444
1372,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15926,,9,1,CHEMBL616445
1373,D,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,15926,,9,1,CHEMBL616446
1374,D,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Expert,,CHO,,,106,BAO_0000219,B,,4540,,9,1,CHEMBL616447
1375,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,6166,,8,1,CHEMBL616448
1376,H,,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,8,1,CHEMBL616449
1377,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,8,1,CHEMBL616450
1378,H,,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,17296,,8,1,CHEMBL857974
1379,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,8,1,CHEMBL616451
1380,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,8,1,CHEMBL616452
1381,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,CHO,,,106,BAO_0000219,B,,15779,,8,1,CHEMBL616453
1382,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,106,BAO_0000219,B,,4199,,8,1,CHEMBL616454
1383,D,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,14875,,9,1,CHEMBL616455
1384,H,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,15146,,8,1,CHEMBL616456
1385,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,106,BAO_0000357,B,,5213,,8,1,CHEMBL616457
1386,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,14818,,8,1,CHEMBL616458
1387,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,106,BAO_0000219,B,,4829,,8,1,CHEMBL616459
1388,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,Expert,,,,,106,BAO_0000019,F,,14454,,8,1,CHEMBL616460
1389,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,Expert,,,,,106,BAO_0000019,F,,14454,,8,1,CHEMBL616461
1390,H,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,CHO,,,106,BAO_0000219,F,,14875,,8,1,CHEMBL616462
1391,H,,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,CHO,,,106,BAO_0000219,F,,14875,,8,1,CHEMBL616463
1392,H,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",Autocuration,,,,,105,BAO_0000019,F,,15250,,8,1,CHEMBL616464
1393,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,Autocuration,,CHO,,,105,BAO_0000219,B,,15250,,8,1,CHEMBL616465
1394,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,17105,BAO_0000357,B,,15086,,8,1,CHEMBL832874
1395,H,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Autocuration,,,,,106,BAO_0000019,F,,3025,,8,1,CHEMBL616184
1396,H,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Autocuration,,,,,106,BAO_0000019,B,,14998,,8,1,CHEMBL616185
1397,H,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Intermediate,,,,,106,BAO_0000019,B,,14998,,8,1,CHEMBL616186
1398,H,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Autocuration,,,,,106,BAO_0000019,B,,14998,,8,1,CHEMBL616187
1399,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,Expert,,,,,10577,BAO_0000357,B,,13969,,8,1,CHEMBL616188
1400,D,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,Intermediate,,,,,10577,BAO_0000357,B,,13392,,9,1,CHEMBL873475
1401,D,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Expert,,,,2435.0,10577,BAO_0000019,B,,3651,Striatum,9,1,CHEMBL616189
1402,H,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Expert,,,,,10577,BAO_0000357,B,,10025,,8,1,CHEMBL616190
1403,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616191
1404,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616192
1405,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616193
1406,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616194
1407,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616195
1408,H,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,Autocuration,,,,,10576,BAO_0000357,B,,13863,,8,1,CHEMBL616196
1409,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Autocuration,,,,10000000.0,10576,BAO_0000249,B,,4622,Hippocampus,8,1,CHEMBL616197
1410,H,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Intermediate,,,,,10576,BAO_0000019,B,,14911,,8,1,CHEMBL616198
1411,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12678,Hippocampus,8,1,CHEMBL616199
1412,H,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Expert,,,,10000000.0,10576,BAO_0000221,B,,12678,Hippocampus,8,1,CHEMBL616200
1413,H,,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,14235,Hippocampus,8,1,CHEMBL616201
1414,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616202
1415,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616203
1416,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616204
1417,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616205
1418,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616206
1419,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Expert,,,,,10576,BAO_0000249,B,,16118,,8,1,CHEMBL616207
1420,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,Autocuration,,,,,10576,BAO_0000249,B,,3268,,8,1,CHEMBL616208
1421,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,Autocuration,,,,,10576,BAO_0000249,B,,3268,,8,1,CHEMBL616209
1422,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,16117,,8,1,CHEMBL616210
1423,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Expert,,,,10000000.0,10576,BAO_0000221,B,,9783,Hippocampus,8,1,CHEMBL616211
1424,H,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,9783,Hippocampus,8,1,CHEMBL616504
1425,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,14356,Hippocampus,9,1,CHEMBL616505
1426,H,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000019,F,,15740,,8,1,CHEMBL616506
1427,H,,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12306,Hippocampus,8,1,CHEMBL872107
1428,D,,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Expert,,,,10000000.0,10576,BAO_0000221,B,,13348,Hippocampus,9,1,CHEMBL616507
1429,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,10576,BAO_0000249,B,,10394,,8,1,CHEMBL616303
1430,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15260,Hippocampus,8,1,CHEMBL616304
1431,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Expert,,,,10000000.0,10576,BAO_0000221,B,,10046,Hippocampus,8,1,CHEMBL616305
1432,H,,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Intermediate,,,,10000000.0,10576,BAO_0000221,F,,15260,Hippocampus,8,1,CHEMBL616306
1433,H,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12851,,8,1,CHEMBL616307
1434,D,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,2148,Hippocampus,9,1,CHEMBL881829
1435,H,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Expert,,,,,10576,BAO_0000357,B,,13134,,8,1,CHEMBL616308
1436,H,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,Autocuration,,,,,10576,BAO_0000019,B,,12462,,8,1,CHEMBL616309
1437,H,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,Expert,,,,,10576,BAO_0000019,B,,12462,,8,1,CHEMBL616310
1438,H,,449.0,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,Autocuration,,CHO,,,10576,BAO_0000219,B,,12462,,8,1,CHEMBL616311
1439,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,Expert,,,,,10576,BAO_0000357,B,,11933,,8,1,CHEMBL616312
1440,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,Autocuration,,,,,10576,BAO_0000357,B,,11933,,8,1,CHEMBL616313
1441,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,10000000.0,10576,BAO_0000221,B,,403,Hippocampus,9,1,CHEMBL616314
1442,H,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,Hippocampus,8,1,CHEMBL616315
1443,H,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,Hippocampus,8,1,CHEMBL616567
1444,H,,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,15538,Hippocampus,8,1,CHEMBL616568
1445,H,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,Intermediate,,,,,10576,BAO_0000019,B,,12464,,8,1,CHEMBL616569
1446,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,Expert,,,,,10576,BAO_0000357,B,,1455,,8,1,CHEMBL616570
1447,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,10576,BAO_0000357,B,,12652,,8,1,CHEMBL616571
1448,H,,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12639,Hippocampus,8,1,CHEMBL616572
1449,H,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,Expert,,,,,10576,BAO_0000249,B,,13949,,8,1,CHEMBL616573
1450,D,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Expert,,,,,10576,BAO_0000357,B,,12463,,9,1,CHEMBL616574
1451,H,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Expert,,,,10000000.0,10576,BAO_0000221,B,,14829,Hippocampus,8,1,CHEMBL616575
1452,H,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14829,Hippocampus,8,1,CHEMBL872108
1453,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,Autocuration,,,,,10576,BAO_0000357,B,,12092,,8,1,CHEMBL616576
1454,H,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,Autocuration,,,,,10576,BAO_0000249,B,,403,,8,1,CHEMBL616577
1455,H,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,Autocuration,,,,,10576,BAO_0000249,B,,403,,8,1,CHEMBL616578
1456,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,Expert,,,,,10576,BAO_0000357,B,,3967,,8,1,CHEMBL616579
1457,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Expert,,,,,10576,BAO_0000019,B,,12771,,9,1,CHEMBL616580
1458,H,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,10576,BAO_0000019,B,,15086,,8,1,CHEMBL616581
1459,H,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,14909,Hippocampus,8,1,CHEMBL616582
1460,H,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,14949,Hippocampus,8,1,CHEMBL616583
1461,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,2309,Hippocampus,9,1,CHEMBL616584
1462,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,4170,,8,1,CHEMBL616585
1463,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11642,Hippocampus,9,1,CHEMBL616586
1464,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11642,Hippocampus,8,1,CHEMBL616587
1465,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12953,Hippocampus,8,1,CHEMBL616588
1466,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12953,Hippocampus,8,1,CHEMBL616589
1467,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Expert,,,,10000000.0,10576,BAO_0000221,B,,12953,Hippocampus,8,1,CHEMBL616590
1468,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",Expert,,CHO,,,10576,BAO_0000219,B,,12903,,8,1,CHEMBL616591
1469,H,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,12536,,8,1,CHEMBL616592
1470,H,,,,The inhibition activity of 5-HT1A at 1 uM,Autocuration,,,,,10576,BAO_0000357,B,,10058,,8,1,CHEMBL616593
1471,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",Expert,,CHO-K1,,,10576,BAO_0000219,B,,12902,,8,1,CHEMBL616594
1472,H,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,Expert,,,,,10576,BAO_0000249,B,,14057,,8,1,CHEMBL616595
1473,H,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,Autocuration,,,,,10576,BAO_0000357,B,,11296,,8,1,CHEMBL616596
1474,H,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,11296,Hippocampus,8,1,CHEMBL616597
1475,H,,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,10000000.0,10576,BAO_0000221,B,,11296,Hippocampus,8,1,CHEMBL616598
1476,D,,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Expert,,,,,10576,BAO_0000249,F,Membranes,16616,,9,1,CHEMBL616599
1477,D,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,,10000000.0,10576,BAO_0000249,F,Membranes,16616,Hippocampus,9,1,CHEMBL616600
1478,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,8,1,CHEMBL616601
1479,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,8,1,CHEMBL616602
1480,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,8,1,CHEMBL616603
1481,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,8,1,CHEMBL616604
1482,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,Autocuration,,,,,10576,BAO_0000249,B,,17136,,8,1,CHEMBL616316
1483,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,Autocuration,,,,,10576,BAO_0000249,B,,17136,,8,1,CHEMBL616317
1484,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Expert,,,,,10576,BAO_0000019,B,,16616,,9,1,CHEMBL616318
1485,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,17331,Hippocampus,8,1,CHEMBL616319
1486,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,17331,Hippocampus,8,1,CHEMBL616320
1487,D,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Expert,,,,10000000.0,10576,BAO_0000221,B,,17167,Hippocampus,9,1,CHEMBL616321
1488,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,8,1,CHEMBL616322
1489,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,8,1,CHEMBL616323
1490,H,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,Autocuration,,,,,10576,BAO_0000357,B,,4671,,8,1,CHEMBL616324
1491,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL616325
1492,H,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL616326
1493,H,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10058,Hippocampus,8,1,CHEMBL616327
1494,H,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,10576,BAO_0000357,B,,12073,,8,1,CHEMBL616328
1495,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,10576,BAO_0000249,B,,2759,,8,1,CHEMBL858110
1496,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,10576,BAO_0000249,F,,2759,,8,1,CHEMBL616329
1497,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,10576,BAO_0000249,B,,2759,,8,1,CHEMBL616330
1498,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,10576,BAO_0000249,F,,2759,,8,1,CHEMBL616331
1499,H,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,10576,BAO_0000249,F,,2759,,8,1,CHEMBL616332
1500,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10576,BAO_0000249,B,,9737,Brain,8,1,CHEMBL857063
1501,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,10576,BAO_0000019,B,,9737,,8,1,CHEMBL616333
1502,H,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000019,F,,5717,,8,1,CHEMBL616334
1503,H,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12253,Hippocampus,8,1,CHEMBL616335
1504,H,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,Autocuration,,,,,10576,BAO_0000019,B,,14025,,8,1,CHEMBL616336
1505,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000249,B,,10425,,8,1,CHEMBL616337
1506,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,Autocuration,,,,,10576,BAO_0000019,B,,14998,,8,1,CHEMBL616338
1507,H,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13694,Hippocampus,8,1,CHEMBL616339
1508,H,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13694,Hippocampus,8,1,CHEMBL616340
1509,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,10576,BAO_0000357,B,,4342,,8,1,CHEMBL616341
1510,D,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,12936,,9,1,CHEMBL616342
1511,D,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Expert,,,,,10576,BAO_0000019,B,,13144,,9,1,CHEMBL616343
1512,H,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Expert,,,,,10576,BAO_0000019,B,,13343,,8,1,CHEMBL616344
1513,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,10576,BAO_0000357,B,,12132,,8,1,CHEMBL616345
1514,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,Expert,,,,,10576,BAO_0000019,B,,15419,,8,1,CHEMBL616346
1515,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,1479,Hippocampus,8,1,CHEMBL616347
1516,H,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,Expert,,,,,10576,BAO_0000019,B,,14287,,8,1,CHEMBL616348
1517,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,Expert,,,,,10576,BAO_0000357,B,,13116,,8,1,CHEMBL616349
1518,D,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Expert,,,,,10576,BAO_0000249,B,Membranes,2759,,9,1,CHEMBL616152
1519,H,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,10576,BAO_0000249,B,,2759,,8,1,CHEMBL616153
1520,H,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",Expert,,,,,10576,BAO_0000019,B,,14748,,8,1,CHEMBL616154
1521,H,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,10576,BAO_0000019,B,,12304,,8,1,CHEMBL616155
1522,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,12409,Hippocampus,9,1,CHEMBL616156
1523,D,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Expert,,,,10000000.0,10576,BAO_0000221,B,,12409,Hippocampus,9,1,CHEMBL616157
1524,H,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,13267,Hippocampus,8,1,CHEMBL616158
1525,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,,10576,BAO_0000357,B,,15194,,8,1,CHEMBL616159
1526,H,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,Expert,,,,,10576,BAO_0000357,B,,14256,,8,1,CHEMBL616160
1527,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,Autocuration,,,,,10576,BAO_0000019,B,,16567,,8,1,CHEMBL616161
1528,H,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,10576,BAO_0000019,F,,15740,,8,1,CHEMBL616162
1529,D,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,,,12687,BAO_0000357,B,,13278,,9,1,CHEMBL616163
1530,H,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,10626,BAO_0000249,B,Membranes,1970,,8,1,CHEMBL616164
1531,H,,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Autocuration,,,,955.0,10576,BAO_0000221,B,,10034,Brain,8,1,CHEMBL616165
1532,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Autocuration,,,,,51,BAO_0000019,B,,13348,,8,1,CHEMBL616355
1533,H,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Autocuration,,,,,10576,BAO_0000019,F,,13630,,8,1,CHEMBL616356
1534,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Autocuration,,,,955.0,10576,BAO_0000221,B,,10862,Brain,8,1,CHEMBL616357
1535,H,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Autocuration,,,,,10576,BAO_0000019,B,,12058,,8,1,CHEMBL616358
1536,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4639,,8,1,CHEMBL616359
1537,H,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,Expert,,,,,51,BAO_0000357,B,,15453,,8,1,CHEMBL616360
1538,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,4820,,8,1,CHEMBL616361
1539,H,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,1089,,8,1,CHEMBL616362
1540,H,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Autocuration,,,,,51,BAO_0000249,B,Brain membranes,386,,8,1,CHEMBL616363
1541,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,Autocuration,,,,,51,BAO_0000357,B,,6011,,8,1,CHEMBL616364
1542,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5014,,8,1,CHEMBL616365
1543,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Expert,,,,,51,BAO_0000357,B,,4402,,8,1,CHEMBL616366
1544,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,51,BAO_0000357,B,,17066,,8,1,CHEMBL872906
1545,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,Autocuration,,,,,51,BAO_0000357,B,,17515,,8,1,CHEMBL616367
1546,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,2474,,8,1,CHEMBL616368
1547,H,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4775,,8,1,CHEMBL616369
1548,D,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Expert,,,,,51,BAO_0000357,B,,14294,,9,1,CHEMBL616370
1549,D,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Expert,,,,,51,BAO_0000357,B,,14294,,9,1,CHEMBL616371
1550,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,51,BAO_0000219,B,,12249,,8,1,CHEMBL616372
1551,H,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,Expert,,,,,51,BAO_0000219,B,,11376,,8,1,CHEMBL616373
1552,H,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,51,BAO_0000218,B,,2474,,8,1,CHEMBL616374
1553,H,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,10000000.0,51,BAO_0000221,B,,13311,Hippocampus,8,1,CHEMBL616375
1554,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4373,,8,1,CHEMBL616376
1555,H,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,Expert,,,,,51,BAO_0000357,B,,1633,,8,1,CHEMBL857064
1556,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,11866,,8,1,CHEMBL616377
1557,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,51,BAO_0000357,B,,4373,,8,1,CHEMBL616378
1558,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,51,BAO_0000357,B,,4687,,8,1,CHEMBL616379
1559,H,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,16946,,8,1,CHEMBL616380
1560,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,Autocuration,,,,,11863,BAO_0000357,B,,13291,,8,1,CHEMBL616381
1561,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,14159,,8,1,CHEMBL616382
1562,H,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,10812,,8,1,CHEMBL616383
1563,D,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Expert,,CHO,,,11863,BAO_0000219,B,,3032,,9,1,CHEMBL616350
1564,H,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,16655,,8,1,CHEMBL616351
1565,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,Autocuration,,,,,11863,BAO_0000357,B,,14532,,8,1,CHEMBL616352
1566,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,13944,,8,1,CHEMBL616353
1567,H,,,,Binding affinity against serotonergic 5-HT1a receptor,Autocuration,,,,,11863,BAO_0000357,B,,13033,,8,1,CHEMBL616354
1568,H,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,10321,,8,1,CHEMBL616508
1569,D,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,,,11863,BAO_0000357,B,,2968,,9,1,CHEMBL616559
1570,H,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,13964,,8,1,CHEMBL616560
1571,H,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,11863,BAO_0000357,B,,15527,,8,1,CHEMBL616561
1572,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,11863,BAO_0000219,B,,12248,,8,1,CHEMBL616562
1573,H,,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,CHO,,,11863,BAO_0000219,B,,12249,,8,1,CHEMBL616563
1574,H,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,15120,,8,1,CHEMBL616564
1575,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,11863,BAO_0000357,B,,13313,,8,1,CHEMBL616565
1576,H,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000218,B,,2613,,8,1,CHEMBL616566
1577,H,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,Autocuration,,,,,11863,BAO_0000357,B,,16700,,8,1,CHEMBL616989
1578,H,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,2201,,8,1,CHEMBL857975
1579,D,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,,,11863,BAO_0000357,B,,1274,,9,1,CHEMBL616990
1580,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,11863,BAO_0000357,B,,1317,,8,1,CHEMBL616991
1581,H,,,,Tested against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,12146,,8,1,CHEMBL616992
1582,H,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,11863,BAO_0000357,B,,14059,,8,1,CHEMBL616993
1583,H,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Expert,,,,,106,BAO_0000019,B,,14025,,8,1,CHEMBL616994
1584,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Autocuration,,,,,106,BAO_0000019,B,,14025,,8,1,CHEMBL616995
1585,D,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Intermediate,,HEK293,,,105571,BAO_0000219,B,,14447,,9,1,CHEMBL616996
1586,H,,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,,,106,BAO_0000218,F,,3025,,8,1,CHEMBL616997
1587,H,,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,,,106,BAO_0000218,F,,3025,,8,1,CHEMBL616998
1588,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Autocuration,,,,,106,BAO_0000019,F,,15329,,8,1,CHEMBL616999
1589,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Autocuration,,,,,106,BAO_0000019,F,,15329,,8,1,CHEMBL617000
1590,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Autocuration,,,,,106,BAO_0000019,F,,15847,,8,1,CHEMBL617001
1591,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Autocuration,,,,,106,BAO_0000019,F,,15847,,8,1,CHEMBL858111
1592,H,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,Autocuration,,,,,106,BAO_0000019,F,,14165,,8,1,CHEMBL617002
1593,H,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),Autocuration,,,,,106,BAO_0000019,F,,14214,,8,1,CHEMBL617003
1594,H,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),Autocuration,,,,,106,BAO_0000019,F,,14214,,8,1,CHEMBL617004
1595,D,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Expert,,,,,106,BAO_0000019,F,,14214,,9,1,CHEMBL617005
1596,D,,485.0,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,106,BAO_0000219,F,,13729,,9,1,CHEMBL616623
1597,H,,449.0,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,Autocuration,,CHO,,,106,BAO_0000219,F,,3025,,8,1,CHEMBL616624
1598,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,2391,,8,1,CHEMBL883243
1599,H,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,Autocuration,,,,,106,BAO_0000019,F,,2391,,8,1,CHEMBL616625
1600,H,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",Expert,,CHO,,,106,BAO_0000219,F,,14956,,8,1,CHEMBL616626
1601,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,8,1,CHEMBL616627
1602,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,8,1,CHEMBL616628
1603,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,8,1,CHEMBL616629
1604,H,,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,Autocuration,,CHO,,,106,BAO_0000219,F,,2598,,8,1,CHEMBL616630
1605,H,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,106,BAO_0000019,F,,14956,,8,1,CHEMBL616631
1606,H,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",Autocuration,,,,,106,BAO_0000019,F,,14956,,8,1,CHEMBL616632
1607,D,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,14214,,9,1,CHEMBL616633
1608,H,,449.0,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,Expert,,CHO,,,106,BAO_0000219,B,,3463,,8,1,CHEMBL616634
1609,H,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,Autocuration,,,,,106,BAO_0000357,B,,15331,,8,1,CHEMBL616635
1610,D,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,Expert,,,,,106,BAO_0000357,B,,16146,,9,1,CHEMBL885358
1611,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,14159,,9,1,CHEMBL616636
1612,H,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,Expert,,CHO,,,106,BAO_0000219,B,,14158,,8,1,CHEMBL616637
1613,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,14159,,8,1,CHEMBL616638
1614,H,,449.0,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,15250,,8,1,CHEMBL616639
1615,H,,449.0,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,106,BAO_0000219,B,,15250,,8,1,CHEMBL616640
1616,H,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,15331,,8,1,CHEMBL616641
1617,H,,449.0,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,Expert,,CHO,,,106,BAO_0000219,B,,15332,,8,1,CHEMBL616642
1618,H,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,CHO,,,106,BAO_0000219,B,,14956,,8,1,CHEMBL616643
1619,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),Autocuration,,,,,106,BAO_0000357,B,,3805,,8,1,CHEMBL616644
1620,H,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,Autocuration,,,,,106,BAO_0000357,B,,14875,,8,1,CHEMBL616645
1621,H,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,,,105,BAO_0000019,F,,14454,,8,1,CHEMBL616646
1622,H,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Expert,,,,,105,BAO_0000019,F,,14454,,8,1,CHEMBL616647
1623,H,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),Autocuration,,,,,105,BAO_0000357,B,,16288,,8,1,CHEMBL616509
1624,H,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),Autocuration,,,,,105,BAO_0000357,B,,16288,,8,1,CHEMBL616510
1625,H,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,16312,,8,1,CHEMBL616511
1626,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Expert,,,,,105,BAO_0000357,B,,1348,,8,1,CHEMBL616512
1627,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Autocuration,,,,,105,BAO_0000357,B,,5834,,8,1,CHEMBL616513
1628,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,,2435.0,105,BAO_0000019,B,,13366,Striatum,8,1,CHEMBL616514
1629,H,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Expert,,,,,105,BAO_0000357,B,,1414,,8,1,CHEMBL616515
1630,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Autocuration,,,,,105,BAO_0000019,B,,14998,,8,1,CHEMBL616516
1631,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11473,,8,1,CHEMBL616517
1632,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11473,,8,1,CHEMBL616518
1633,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,,,105,BAO_0000357,B,,10639,,8,1,CHEMBL616519
1634,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,,,105,BAO_0000357,B,,10639,,8,1,CHEMBL616520
1635,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Autocuration,,,,,105,BAO_0000357,B,,1375,,8,1,CHEMBL616521
1636,H,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Autocuration,,,,,105,BAO_0000357,B,,1375,,8,1,CHEMBL616522
1637,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,,,105,BAO_0000357,B,,16532,,8,1,CHEMBL884531
1638,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,11147,,8,1,CHEMBL616523
1639,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,,2435.0,105,BAO_0000019,B,,13366,Striatum,8,1,CHEMBL616731
1640,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Autocuration,,,,,105,BAO_0000019,B,,10444,,8,1,CHEMBL616732
1641,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Autocuration,,,,,105,BAO_0000357,B,,16532,,8,1,CHEMBL616733
1642,H,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,,,105,BAO_0000357,B,,16532,,8,1,CHEMBL616734
1643,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Autocuration,,,,,105,BAO_0000249,B,,12827,,8,1,CHEMBL616735
1644,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Autocuration,,,,,105,BAO_0000249,B,,12827,,8,1,CHEMBL616736
1645,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,8,1,CHEMBL616737
1646,H,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Autocuration,,,,,105,BAO_0000019,B,,14025,,8,1,CHEMBL616738
1647,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,8,1,CHEMBL616739
1648,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,8,1,CHEMBL616740
1649,H,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,,,105,BAO_0000019,F,,12919,,8,1,CHEMBL616741
1650,H,,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Autocuration,,HEK293,,,105,BAO_0000219,B,,14447,,8,1,CHEMBL616742
1651,D,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Intermediate,,,,,105570,BAO_0000019,B,,1375,,9,1,CHEMBL616743
1652,D,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Intermediate,,,,,105570,BAO_0000019,B,,1375,,9,1,CHEMBL616744
1653,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000019,F,,12409,,9,1,CHEMBL616745
1654,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000019,F,,12409,,9,1,CHEMBL616746
1655,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Intermediate,,,,,105570,BAO_0000019,F,,12409,,9,1,CHEMBL616747
1656,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Intermediate,,,,,105570,BAO_0000019,F,,12409,,9,1,CHEMBL616748
1657,D,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Intermediate,,,,,105570,BAO_0000019,F,,12409,,9,1,CHEMBL616648
1658,D,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Intermediate,,,,,105570,BAO_0000357,B,,11574,,9,1,CHEMBL616649
1659,D,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Intermediate,,,,,105570,BAO_0000357,B,,1558,,9,1,CHEMBL616650
1660,D,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,9,1,CHEMBL616651
1661,D,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,9,1,CHEMBL616652
1662,D,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,,,105570,BAO_0000218,F,,12409,,9,1,CHEMBL616653
1663,D,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Intermediate,,,,,105570,BAO_0000218,F,,12409,,9,1,CHEMBL616654
1664,D,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Intermediate,,,,,105570,BAO_0000019,B,,12253,,9,1,CHEMBL616655
1665,D,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Intermediate,,,,,105570,BAO_0000357,B,,12936,,9,1,CHEMBL616656
1666,H,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Autocuration,,,,,105,BAO_0000019,B,,13181,,8,1,CHEMBL616657
1667,D,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Intermediate,,,,2435.0,105570,BAO_0000357,B,,12409,Striatum,9,1,CHEMBL616658
1668,D,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Intermediate,,,,,105570,BAO_0000357,B,,10639,,9,1,CHEMBL616659
1669,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,51,BAO_0000357,B,,5254,,8,1,CHEMBL616660
1670,H,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,Autocuration,,,,,106,BAO_0000357,B,,13051,,8,1,CHEMBL616661
1671,H,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000019,F,,3463,,8,1,CHEMBL616662
1672,H,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,15315,,8,1,CHEMBL616663
1673,H,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,6011,,8,1,CHEMBL616664
1674,D,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,14159,,9,1,CHEMBL881820
1675,H,,449.0,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",Autocuration,,CHO,,,105,BAO_0000219,F,,14159,,8,1,CHEMBL616665
1676,H,,449.0,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,CHO,,,105,BAO_0000219,B,,15250,,8,1,CHEMBL616666
1677,H,,449.0,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,Autocuration,,CHO,,,105,BAO_0000219,B,,15250,,8,1,CHEMBL616667
1678,H,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,15331,,8,1,CHEMBL616668
1679,D,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,15332,,9,1,CHEMBL616669
1680,H,,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",Expert,,CHO,,,105,BAO_0000219,F,,15332,,8,1,CHEMBL617040
1681,H,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",Autocuration,,CHO,,,105,BAO_0000219,F,,3294,,8,1,CHEMBL617041
1682,H,,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",Expert,,CHO,,,105,BAO_0000219,F,,14158,,8,1,CHEMBL617042
1683,H,,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",Expert,,CHO,,,105,BAO_0000219,F,,14956,,8,1,CHEMBL617043
1684,H,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,12469,,8,1,CHEMBL617044
1685,H,,449.0,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,CHO,,,105,BAO_0000219,F,,3463,,8,1,CHEMBL617045
1686,D,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,CHO,,,105,BAO_0000219,F,,15250,,9,1,CHEMBL617046
1687,D,,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,CHO,,,105,BAO_0000219,F,,15250,,9,1,CHEMBL617047
1688,H,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,105,BAO_0000019,F,,14956,,8,1,CHEMBL617048
1689,H,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",Autocuration,,,,,105,BAO_0000019,F,,14159,,8,1,CHEMBL616897
1690,D,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Expert,,,,,105,BAO_0000019,F,,14159,,9,1,CHEMBL616898
1691,D,,449.0,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Expert,,CHO,,,105,BAO_0000219,F,,14499,,9,1,CHEMBL858201
1692,H,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,F,,15315,,8,1,CHEMBL616899
1693,H,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),Autocuration,,,,,105,BAO_0000219,B,,3294,,8,1,CHEMBL616900
1694,H,,449.0,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,Expert,,CHO,,,105,BAO_0000219,B,,3463,,8,1,CHEMBL616901
1695,H,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,Autocuration,,,,,105,BAO_0000357,B,,15331,,8,1,CHEMBL616902
1696,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14159,,9,1,CHEMBL616903
1697,H,,449.0,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,105,BAO_0000219,B,,14158,,8,1,CHEMBL616904
1698,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,14159,,8,1,CHEMBL616905
1699,H,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,CHO,,,105,BAO_0000219,B,,15250,,8,1,CHEMBL616906
1700,H,,449.0,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15250,,8,1,CHEMBL616907
1701,H,,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15331,,8,1,CHEMBL616908
1702,D,,449.0,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15332,,9,1,CHEMBL616909
1703,D,,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14499,,9,1,CHEMBL616910
1704,H,,449.0,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,15332,,8,1,CHEMBL616911
1705,H,,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,CHO,,,105,BAO_0000219,B,,14956,,8,1,CHEMBL616912
1706,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),Autocuration,,,,,105,BAO_0000357,B,,3805,,8,1,CHEMBL616913
1707,D,,449.0,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Expert,,CHO,,,105,BAO_0000219,B,,6011,,9,1,CHEMBL616914
1708,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,105,BAO_0000219,B,,16190,,8,1,CHEMBL616915
1709,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,105,BAO_0000019,B,,14165,,8,1,CHEMBL616916
1710,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4234,,9,1,CHEMBL616917
1711,H,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,105,BAO_0000357,B,,15527,,8,1,CHEMBL616918
1712,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,105,BAO_0000219,B,,6328,,8,1,CHEMBL616919
1713,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,16209,,8,1,CHEMBL616920
1714,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,Autocuration,,,,,105,BAO_0000357,B,,14770,,8,1,CHEMBL872914
1715,H,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,2598,,8,1,CHEMBL616921
1716,H,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,6897,,8,1,CHEMBL616922
1717,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,6013,,8,1,CHEMBL616923
1718,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,5843,,8,1,CHEMBL616924
1719,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,105,BAO_0000357,B,,14454,,8,1,CHEMBL875909
1720,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,Autocuration,,,,,105,BAO_0000357,B,,14454,,8,1,CHEMBL616925
1721,H,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,Autocuration,,,,,105,BAO_0000357,B,,14454,,8,1,CHEMBL616926
1722,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,15818,,8,1,CHEMBL616927
1723,H,,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,Expert,,CHO-K1,,,105,BAO_0000219,F,,13729,,8,1,CHEMBL616928
1724,D,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Expert,,,,,105,BAO_0000219,B,,6011,,9,1,CHEMBL616929
1725,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4234,,9,1,CHEMBL616930
1726,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000019,B,,17085,,8,1,CHEMBL616931
1727,H,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,105,BAO_0000357,B,,3025,,8,1,CHEMBL616932
1728,H,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,15315,,8,1,CHEMBL616933
1729,D,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Expert,,,,,105,BAO_0000219,B,,14214,,9,1,CHEMBL616934
1730,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,3804,,9,1,CHEMBL616935
1731,H,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,Autocuration,,,,,105,BAO_0000357,B,,16700,,8,1,CHEMBL616936
1732,D,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,Expert,,,,,105,BAO_0000357,B,,2391,,9,1,CHEMBL616937
1733,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,4175,,9,1,CHEMBL616938
1734,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000019,B,,17085,,8,1,CHEMBL616939
1735,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,Expert,,,,,105,BAO_0000019,B,,17085,,8,1,CHEMBL616940
1736,D,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Expert,,,,,105,BAO_0000357,B,,15926,,9,1,CHEMBL616941
1737,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,16312,,8,1,CHEMBL616942
1738,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,16312,,8,1,CHEMBL616943
1739,H,,449.0,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,Autocuration,,CHO,,,104802,BAO_0000219,B,,14956,,4,1,CHEMBL616944
1740,H,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",Autocuration,,,,,105,BAO_0000019,F,,3294,,8,1,CHEMBL616945
1741,H,,,,Binding activity radioligand.,Autocuration,,,,,105,BAO_0000357,B,,12861,,8,1,CHEMBL616946
1742,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,105,BAO_0000019,B,,12861,,8,1,CHEMBL616947
1743,H,,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,Expert,,CHO-K1,,,105,BAO_0000219,B,,16312,,8,1,CHEMBL616948
1744,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5104,,8,1,CHEMBL616851
1745,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5105,,8,1,CHEMBL616852
1746,H,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,14499,,8,1,CHEMBL616853
1747,D,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,15926,,9,1,CHEMBL616854
1748,D,,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Expert,,CHO,,,105,BAO_0000219,B,,4540,,9,1,CHEMBL616855
1749,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,8,1,CHEMBL616856
1750,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,8,1,CHEMBL616857
1751,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,6166,,8,1,CHEMBL616858
1752,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,8,1,CHEMBL616859
1753,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,Autocuration,,CHO,,,105,BAO_0000219,B,,15779,,8,1,CHEMBL616860
1754,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,8,1,CHEMBL616861
1755,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,8,1,CHEMBL616541
1756,H,,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,Autocuration,,HEK293,,,105,BAO_0000219,B,,17451,,8,1,CHEMBL616542
1757,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,105,BAO_0000219,B,,4199,,8,1,CHEMBL616543
1758,D,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,14875,,9,1,CHEMBL616544
1759,H,,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,Autocuration,,CHO,,,105,BAO_0000219,B,,15146,,8,1,CHEMBL616545
1760,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,105,BAO_0000357,B,,5213,,8,1,CHEMBL616546
1761,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,105,BAO_0000219,B,,14818,,8,1,CHEMBL616547
1762,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,105,BAO_0000219,B,,4829,,8,1,CHEMBL616548
1763,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,Expert,,,,,105,BAO_0000019,F,,14454,,8,1,CHEMBL616549
1764,H,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,Expert,,,,,105,BAO_0000019,F,,14454,,8,1,CHEMBL616550
1765,H,,,,Binding affinity against 5-HT2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,8,1,CHEMBL857066
1766,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,8,1,CHEMBL616551
1767,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,10577,BAO_0000357,B,,10639,,8,1,CHEMBL616552
1768,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,10577,BAO_0000019,F,,10639,,8,1,CHEMBL832876
1769,H,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",Expert,,,,,10577,BAO_0000019,B,,12352,,8,1,CHEMBL616553
1770,H,,,,Binding affinity towards 5-HT1B was determined,Autocuration,,,,,10577,BAO_0000357,B,,9098,,8,1,CHEMBL616554
1771,H,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Expert,,,,,10577,BAO_0000019,B,,14430,,8,1,CHEMBL616555
1772,H,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",Expert,,,,,10577,BAO_0000019,B,,13657,,8,1,CHEMBL616556
1773,H,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",Autocuration,,,,,10577,BAO_0000019,B,,13657,,8,1,CHEMBL616557
1774,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10577,BAO_0000019,B,,15854,,8,1,CHEMBL616558
1775,D,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Expert,,,,,10577,BAO_0000019,B,,10639,,9,1,CHEMBL616749
1776,H,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Autocuration,,,,,10577,BAO_0000357,B,,10025,,8,1,CHEMBL616750
1777,H,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",Autocuration,,,,,10577,BAO_0000357,B,,10025,,8,1,CHEMBL616751
1778,H,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,10577,BAO_0000249,B,,14286,,8,1,CHEMBL616752
1779,H,,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Autocuration,,,,2435.0,10577,BAO_0000019,B,,3651,Striatum,8,1,CHEMBL616753
1780,D,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,14178,,9,1,CHEMBL616754
1781,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,Autocuration,,,,,10577,BAO_0000019,B,,10639,,8,1,CHEMBL616755
1782,H,,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,13605,Striatum,8,1,CHEMBL616756
1783,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Autocuration,,,,2435.0,10577,BAO_0000019,B,,5834,Striatum,8,1,CHEMBL616757
1784,H,,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Autocuration,,,,2435.0,10577,BAO_0000357,B,,10922,Striatum,8,1,CHEMBL616758
1785,H,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,10577,BAO_0000249,B,,14286,,8,1,CHEMBL616759
1786,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,Autocuration,,,,,10577,BAO_0000357,B,,11825,,8,1,CHEMBL616760
1787,H,,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,14826,Striatum,8,1,CHEMBL616761
1788,H,,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Autocuration,,,,2435.0,10577,BAO_0000019,B,,9699,Striatum,8,1,CHEMBL616762
1789,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,Autocuration,,,,,10577,BAO_0000019,B,,14423,,8,1,CHEMBL616763
1790,H,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,Expert,,,,,10577,BAO_0000357,B,,10062,,8,1,CHEMBL872909
1791,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,10062,,8,1,CHEMBL616764
1792,D,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,12280,,9,1,CHEMBL616765
1793,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Autocuration,,,,2435.0,10577,BAO_0000357,B,,15412,Striatum,8,1,CHEMBL616766
1794,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Autocuration,,,,2435.0,10577,BAO_0000357,B,,15412,Striatum,8,1,CHEMBL616767
1795,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,10062,,8,1,CHEMBL616768
1796,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,11147,,8,1,CHEMBL616769
1797,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,Autocuration,,,,,10577,BAO_0000019,B,,9547,,8,1,CHEMBL616770
1798,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,10577,BAO_0000019,B,,10444,,8,1,CHEMBL616771
1799,H,,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Autocuration,,,,2435.0,10577,BAO_0000019,B,,12469,Striatum,8,1,CHEMBL616772
1800,H,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,Expert,,,,,10577,BAO_0000019,B,,9098,,8,1,CHEMBL616773
1801,H,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,Autocuration,,,,,10577,BAO_0000019,B,,9098,,8,1,CHEMBL616774
1802,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,9699,,8,1,CHEMBL616775
1803,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,10577,BAO_0000249,B,,10394,,8,1,CHEMBL616776
1804,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,12092,,8,1,CHEMBL616777
1805,H,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,Autocuration,,,,,10577,BAO_0000357,B,,16700,,8,1,CHEMBL616778
1806,D,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Expert,,,,,10577,BAO_0000249,B,,403,,9,1,CHEMBL616779
1807,D,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,12771,,9,1,CHEMBL616780
1808,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,Autocuration,,,,,10577,BAO_0000019,B,,11642,,8,1,CHEMBL616781
1809,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,12953,,8,1,CHEMBL616782
1810,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,12953,,8,1,CHEMBL616783
1811,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Expert,,,,2435.0,10577,BAO_0000019,B,,12953,Striatum,8,1,CHEMBL616784
1812,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,Autocuration,,,,,10577,BAO_0000357,B,,12953,,8,1,CHEMBL616785
1813,H,,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10577,BAO_0000249,B,,9737,Brain,8,1,CHEMBL857067
1814,H,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,Autocuration,,,,,10577,BAO_0000019,B,,9737,,8,1,CHEMBL616786
1815,H,,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,10577,BAO_0000249,B,,9737,Brain,8,1,CHEMBL616787
1816,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,Autocuration,,,,,10577,BAO_0000357,B,,12827,,8,1,CHEMBL616788
1817,H,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,5033,,8,1,CHEMBL616789
1818,D,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Expert,,,,,10577,BAO_0000019,B,,9786,,9,1,CHEMBL616790
1819,H,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,Expert,,,,,10577,BAO_0000357,B,,13116,,8,1,CHEMBL616791
1820,H,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,Autocuration,,,,,10577,BAO_0000019,B,,16429,,8,1,CHEMBL616792
1821,D,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Expert,,,,,10577,BAO_0000249,B,,12409,,9,1,CHEMBL616793
1822,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,10577,BAO_0000357,B,,15194,,8,1,CHEMBL616794
1823,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,10577,BAO_0000357,B,,15194,,8,1,CHEMBL616795
1824,H,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,5486,,4,1,CHEMBL616796
1825,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,4639,,8,1,CHEMBL616797
1826,H,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Autocuration,,,,,106,BAO_0000249,B,Brain membranes,386,,8,1,CHEMBL616798
1827,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,Autocuration,,,,,106,BAO_0000357,B,,2474,,8,1,CHEMBL616799
1828,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,Autocuration,,,,,106,BAO_0000357,B,,6011,,8,1,CHEMBL616800
1829,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,5014,,8,1,CHEMBL616801
1830,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,Autocuration,,,,,106,BAO_0000357,B,,17515,,8,1,CHEMBL616802
1831,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,4373,,8,1,CHEMBL616803
1832,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,Expert,,,,,106,BAO_0000357,B,,1633,,8,1,CHEMBL857068
1833,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,Autocuration,,,,,106,BAO_0000357,B,,1633,,8,1,CHEMBL616804
1834,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,106,BAO_0000357,B,,4373,,8,1,CHEMBL616805
1835,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,4687,,8,1,CHEMBL616806
1836,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,106,BAO_0000357,B,,11574,,8,1,CHEMBL616807
1837,H,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,10321,,8,1,CHEMBL616808
1838,H,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,106,BAO_0000357,B,,15527,,8,1,CHEMBL616809
1839,H,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,Autocuration,,,,,106,BAO_0000357,B,,17200,,8,1,CHEMBL616810
1840,H,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,104802,BAO_0000224,B,,14423,,4,1,CHEMBL616811
1841,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Autocuration,,,,,108,BAO_0000357,B,,5834,,8,1,CHEMBL616812
1842,H,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,11473,,8,1,CHEMBL616813
1843,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,11473,,8,1,CHEMBL616814
1844,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,10639,,8,1,CHEMBL616815
1845,H,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,10639,,8,1,CHEMBL616816
1846,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Autocuration,,,,,108,BAO_0000357,B,,14331,,8,1,CHEMBL616817
1847,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Autocuration,,,,,108,BAO_0000357,B,,10796,,8,1,CHEMBL616818
1848,H,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Expert,,,,,108,BAO_0000357,B,,9098,,8,1,CHEMBL616819
1849,H,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Expert,,,,,108,BAO_0000357,B,,14331,,8,1,CHEMBL616820
1850,H,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Expert,,,,,108,BAO_0000019,B,,11828,,8,1,CHEMBL616821
1851,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Autocuration,,,,,108,BAO_0000357,B,,11866,,8,1,CHEMBL616822
1852,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,,,108,BAO_0000019,B,,13047,,8,1,CHEMBL616823
1853,D,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Autocuration,,,,,12689,BAO_0000357,B,,188,,9,1,CHEMBL616824
1854,D,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,,,12689,BAO_0000357,B,,11825,,9,1,CHEMBL616825
1855,D,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,,,12689,BAO_0000357,B,,11825,,9,1,CHEMBL616826
1856,D,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000019,B,,11624,,9,1,CHEMBL616827
1857,D,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Autocuration,,,,,12689,BAO_0000357,B,,11139,,9,1,CHEMBL616828
1858,D,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,11147,,9,1,CHEMBL616829
1859,D,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,12689,BAO_0000019,B,,10444,,9,1,CHEMBL616830
1860,D,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Expert,,,,,12689,BAO_0000357,B,,11624,,9,1,CHEMBL616831
1861,D,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,9,1,CHEMBL616832
1862,D,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,9,1,CHEMBL616833
1863,D,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Expert,,,,,12689,BAO_0000019,B,,11662,,9,1,CHEMBL616834
1864,D,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,,,12689,BAO_0000019,B,,11662,,9,1,CHEMBL829595
1865,D,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,9098,,9,1,CHEMBL616835
1866,D,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Autocuration,,,,,12689,BAO_0000249,B,,10394,,9,1,CHEMBL872910
1867,H,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,11933,,8,1,CHEMBL616836
1868,D,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,12092,,9,1,CHEMBL616837
1869,D,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,,,12689,BAO_0000019,B,,12253,,9,1,CHEMBL616466
1870,D,,722.0,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Autocuration,,HEK293,,,12689,BAO_0000219,B,,12253,,9,1,CHEMBL616467
1871,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,108,BAO_0000357,B,,1558,,8,1,CHEMBL616468
1872,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,2474,,8,1,CHEMBL616469
1873,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,2474,,8,1,CHEMBL616470
1874,H,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,11574,,8,1,CHEMBL616471
1875,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,1558,,8,1,CHEMBL616472
1876,H,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,12689,BAO_0000357,B,,13944,,8,1,CHEMBL616473
1877,H,,,,Binding affinity against serotonergic 5-HT1c receptor,Autocuration,,,,,12689,BAO_0000357,B,,13033,,8,1,CHEMBL616474
1878,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,10321,,8,1,CHEMBL616475
1879,H,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,Autocuration,,,,,12689,BAO_0000357,B,,11866,,8,1,CHEMBL616476
1880,H,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,,,105,BAO_0000019,B,,14454,,8,1,CHEMBL616477
1881,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,11574,,4,1,CHEMBL616478
1882,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,11574,,4,1,CHEMBL616479
1883,H,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Autocuration,,,,,104686,BAO_0000019,B,,13631,,4,1,CHEMBL616480
1884,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Autocuration,,,,,104686,BAO_0000019,B,,9630,,5,1,CHEMBL616481
1885,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,,8822,,5,1,CHEMBL616482
1886,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,Brain,5,1,CHEMBL884713
1887,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,104686,BAO_0000224,B,,8868,,4,1,CHEMBL616483
1888,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,Autocuration,,,,,104686,BAO_0000224,B,,9064,,4,1,CHEMBL616484
1889,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,Autocuration,,,,,104686,BAO_0000019,B,,9806,,4,1,CHEMBL616485
1890,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104686,BAO_0000224,B,,9098,,4,1,CHEMBL616486
1891,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,104686,BAO_0000224,B,,8868,,4,1,CHEMBL616487
1892,H,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,12765,,4,1,CHEMBL616488
1893,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616489
1894,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616490
1895,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616491
1896,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616492
1897,H,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616493
1898,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11473,,4,1,CHEMBL616494
1899,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11473,,4,1,CHEMBL616495
1900,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,3086,,4,1,CHEMBL616496
1901,H,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616497
1902,H,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,11049,,4,1,CHEMBL616498
1903,H,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10639,,4,1,CHEMBL616499
1904,H,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Autocuration,,,,,104686,BAO_0000019,B,,10922,,4,1,CHEMBL616500
1905,D,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,Brain,5,1,CHEMBL616501
1906,H,,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Autocuration,,,,955.0,104686,BAO_0000221,B,,10748,Brain,4,1,CHEMBL616502
1907,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11614,,4,1,CHEMBL884529
1908,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11615,,4,1,CHEMBL616503
1909,H,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11615,,4,1,CHEMBL616964
1910,H,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11614,,4,1,CHEMBL616965
1911,H,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL616966
1912,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL616967
1913,D,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,5,1,CHEMBL616968
1914,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL616969
1915,H,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Autocuration,,,,,104686,BAO_0000019,B,,13346,,4,1,CHEMBL884530
1916,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10025,,4,1,CHEMBL616970
1917,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,104686,BAO_0000224,B,,10025,,4,1,CHEMBL616971
1918,H,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,104686,BAO_0000224,B,,10025,,4,1,CHEMBL616972
1919,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,Autocuration,,,,,104686,BAO_0000224,B,,9036,,4,1,CHEMBL616973
1920,H,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,Autocuration,,,,,104686,BAO_0000224,B,,9036,,4,1,CHEMBL616974
1921,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL616975
1922,H,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,12304,,4,1,CHEMBL616976
1923,H,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,13276,,4,1,CHEMBL616977
1924,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,104686,BAO_0000224,B,,11825,,4,1,CHEMBL616978
1925,H,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,12443,,4,1,CHEMBL616979
1926,H,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13830,,4,1,CHEMBL616980
1927,H,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9592,,4,1,CHEMBL616981
1928,H,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9592,,4,1,CHEMBL616982
1929,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,Autocuration,,,,,104686,BAO_0000224,B,,10881,,4,1,CHEMBL616983
1930,H,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,13605,,4,1,CHEMBL616984
1931,D,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,5,1,CHEMBL616985
1932,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,4,1,CHEMBL616986
1933,H,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,4,1,CHEMBL616987
1934,H,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,Autocuration,,,,,104686,BAO_0000019,B,,15360,,4,1,CHEMBL616988
1935,H,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,11576,,4,1,CHEMBL617243
1936,H,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,Autocuration,,,,,104686,BAO_0000019,B,,5834,,4,1,CHEMBL617244
1937,D,,485.0,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,5,1,CHEMBL617245
1938,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,11965,,4,1,CHEMBL617246
1939,H,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),Autocuration,,,,,104686,BAO_0000224,B,,3967,,4,1,CHEMBL617546
1940,H,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Autocuration,,,,,104686,BAO_0000249,B,Brain membranes,11130,,4,1,CHEMBL617547
1941,H,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,104686,BAO_0000219,B,,13427,,4,1,CHEMBL617548
1942,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9443,,4,1,CHEMBL617549
1943,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,104686,BAO_0000224,B,,9443,,4,1,CHEMBL617550
1944,H,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,104686,BAO_0000224,B,,11825,,4,1,CHEMBL617551
1945,H,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12120,,4,1,CHEMBL617552
1946,H,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12120,,4,1,CHEMBL617553
1947,H,,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Autocuration,,,,1515.0,104686,BAO_0000019,F,,11963,Thoracic aorta,4,1,CHEMBL617554
1948,H,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,9069,,4,1,CHEMBL617555
1949,H,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,104686,BAO_0000224,B,,8868,,4,1,CHEMBL617556
1950,H,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,10624,BAO_0000357,B,,17200,,8,1,CHEMBL617557
1951,H,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,10624,BAO_0000357,B,,17200,,8,1,CHEMBL617558
1952,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,Expert,,,,,17106,BAO_0000357,B,,13969,,8,1,CHEMBL617559
1953,D,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,Expert,,,,,17106,BAO_0000357,B,,13392,,9,1,CHEMBL617560
1954,H,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,1742,,8,1,CHEMBL617561
1955,H,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,1742,,8,1,CHEMBL617562
1956,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Autocuration,,,,2435.0,17106,BAO_0000357,B,,14331,Striatum,8,1,CHEMBL617563
1957,H,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,Autocuration,,,,,17106,BAO_0000019,F,,12861,,8,1,CHEMBL617564
1958,H,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,Expert,,,,,17106,BAO_0000019,B,,12861,,8,1,CHEMBL617565
1959,H,,,,Binding activity radioligand.,Autocuration,,,,,17106,BAO_0000357,B,,12861,,8,1,CHEMBL856076
1960,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,17106,BAO_0000019,B,,12861,,8,1,CHEMBL617566
1961,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Expert,,,,,17106,BAO_0000019,B,,12861,,8,1,CHEMBL875911
1962,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,17106,BAO_0000019,B,,12861,,8,1,CHEMBL617567
1963,H,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,17106,BAO_0000249,B,,675,,8,1,CHEMBL617568
1964,H,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,Expert,,,,,17106,BAO_0000019,B,,12490,,8,1,CHEMBL617569
1965,H,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,Expert,,,,,17106,BAO_0000249,B,,11828,,8,1,CHEMBL617570
1966,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,Autocuration,,,,,17106,BAO_0000357,B,,11866,,8,1,CHEMBL617571
1967,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Autocuration,,,,,105,BAO_0000357,B,,773,,8,1,CHEMBL617572
1968,H,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,Expert,,,,,105,BAO_0000357,B,,13047,,8,1,CHEMBL617573
1969,H,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,8,1,CHEMBL617574
1970,H,,,,The compound was tested for binding affinity against 5-HT1D receptor,Expert,,,,,105,BAO_0000357,B,,13047,,8,1,CHEMBL617575
1971,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,Autocuration,,,,,10578,BAO_0000357,B,,188,,8,1,CHEMBL617576
1972,H,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,Autocuration,,,,,10578,BAO_0000019,F,,10639,,8,1,CHEMBL617577
1973,H,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10578,BAO_0000019,F,,12438,,8,1,CHEMBL617578
1974,H,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10578,BAO_0000357,B,,12438,,8,1,CHEMBL617579
1975,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,10578,BAO_0000019,B,,15854,,8,1,CHEMBL617580
1976,H,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,10578,BAO_0000249,B,,10394,,8,1,CHEMBL617581
1977,H,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,10578,BAO_0000357,B,,12092,,8,1,CHEMBL617582
1978,H,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,Expert,,,,,10578,BAO_0000019,B,,3389,,8,1,CHEMBL617583
1979,H,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,Autocuration,,,,,105,BAO_0000357,B,,6011,,8,1,CHEMBL617584
1980,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,4639,,8,1,CHEMBL617585
1981,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,2474,,8,1,CHEMBL875912
1982,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,5014,,8,1,CHEMBL617586
1983,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,Autocuration,,,,,105,BAO_0000357,B,,17515,,8,1,CHEMBL617587
1984,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,Autocuration,,,,,105,BAO_0000357,B,,11866,,8,1,CHEMBL617588
1985,H,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,4687,,8,1,CHEMBL857980
1986,H,,,,Tested against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,105,BAO_0000357,B,,12146,,8,1,CHEMBL617589
1987,H,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,10321,,8,1,CHEMBL617590
1988,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,105,BAO_0000219,B,,13267,,8,1,CHEMBL617591
1989,D,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,Expert,,,,,105,BAO_0000357,B,,1274,,9,1,CHEMBL617592
1990,H,,,,,Autocuration,,,,,105,BAO_0000357,B,,15250,,8,1,CHEMBL617593
1991,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,8,1,CHEMBL617594
1992,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,13706,,8,1,CHEMBL617595
1993,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,HEK293,,,105,BAO_0000219,B,,13706,,8,1,CHEMBL617596
1994,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,HEK293,,,105,BAO_0000219,B,,13706,,8,1,CHEMBL617597
1995,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,8,1,CHEMBL617598
1996,H,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,Autocuration,,,,,105,BAO_0000357,B,,13366,,8,1,CHEMBL872916
1997,H,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,Expert,,,,,105,BAO_0000357,B,,13366,,8,1,CHEMBL617599
1998,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,Autocuration,,,,,105,BAO_0000357,B,,1558,,8,1,CHEMBL617091
1999,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",Expert,,CHO-K1,,,105,BAO_0000219,B,,12902,,8,1,CHEMBL617092
2000,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,105,BAO_0000219,B,,13706,,8,1,CHEMBL617093
2001,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,105,BAO_0000019,F,,13706,,8,1,CHEMBL617094
2002,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,105,BAO_0000019,F,,13706,,8,1,CHEMBL617095
2003,H,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,8,1,CHEMBL617096
2004,H,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,8,1,CHEMBL617097
2005,H,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,105,BAO_0000019,F,,14251,,8,1,CHEMBL617098
2006,H,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,8,1,CHEMBL617301
2007,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,8,1,CHEMBL617302
2008,H,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,13366,,8,1,CHEMBL617303
2009,H,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,105,BAO_0000357,B,,13051,,8,1,CHEMBL617304
2010,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,CHO,,,105,BAO_0000219,B,,12903,,8,1,CHEMBL617305
2011,D,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Autocuration,,,,,105,BAO_0000219,B,,12469,,9,1,CHEMBL617306
2012,H,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,Autocuration,,,,,17106,BAO_0000357,B,,5619,,8,1,CHEMBL617307
2013,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,,,105,BAO_0000019,B,,13047,,8,1,CHEMBL617308
2014,H,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,8,1,CHEMBL617309
2015,H,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,8,1,CHEMBL617310
2016,H,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,16633,,8,1,CHEMBL617311
2017,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,16633,,8,1,CHEMBL617312
2018,H,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,105,BAO_0000357,B,,3269,,8,1,CHEMBL617313
2019,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,105,BAO_0000357,B,,12409,,8,1,CHEMBL617314
2020,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,106,BAO_0000019,F,,13706,,8,1,CHEMBL617315
2021,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,HEK293,,,106,BAO_0000219,B,,13706,,8,1,CHEMBL617316
2022,H,,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,HEK293,,,106,BAO_0000219,B,,13706,,8,1,CHEMBL617317
2023,H,,449.0,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Autocuration,,CHO,,,106,BAO_0000219,B,,12903,,8,1,CHEMBL617318
2024,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,106,BAO_0000019,B,,13047,,8,1,CHEMBL617319
2025,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,9,1,CHEMBL617320
2026,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,9,1,CHEMBL617321
2027,D,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,106,BAO_0000357,B,,13366,,9,1,CHEMBL617322
2028,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,13366,,8,1,CHEMBL616862
2029,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,106,BAO_0000357,B,,13366,,8,1,CHEMBL616863
2030,H,,449.0,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,Autocuration,,CHO,,,106,BAO_0000219,B,,12469,,8,1,CHEMBL616864
2031,H,,485.0,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,8,1,CHEMBL616865
2032,H,,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,Autocuration,,CHO-K1,,,106,BAO_0000219,B,,13706,,8,1,CHEMBL616866
2033,H,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,106,BAO_0000019,F,,13706,,8,1,CHEMBL616867
2034,H,,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",Expert,,CHO-K1,,,106,BAO_0000219,B,,12902,,8,1,CHEMBL616868
2035,H,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,105,BAO_0000357,B,,13051,,8,1,CHEMBL616869
2036,H,,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,CHO,,,106,BAO_0000219,B,,12903,,8,1,CHEMBL616870
2037,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,8,1,CHEMBL616871
2038,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,8,1,CHEMBL616872
2039,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,8,1,CHEMBL616873
2040,H,,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,Autocuration,,CHO-K1,,,105,BAO_0000219,F,,1558,,8,1,CHEMBL616838
2041,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,Autocuration,,,,,105,BAO_0000357,B,,1558,,8,1,CHEMBL616839
2042,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Autocuration,,,,,106,BAO_0000019,B,,13047,,8,1,CHEMBL616840
2043,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,8,1,CHEMBL616841
2044,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,Autocuration,,,,,105,BAO_0000357,B,,13313,,8,1,CHEMBL616842
2045,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,Expert,,,,,105,BAO_0000357,B,,12409,,8,1,CHEMBL857976
2046,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,Autocuration,,CHO,,,10618,BAO_0000219,B,,15250,,8,1,CHEMBL616843
2047,D,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Expert,,,,,10618,BAO_0000357,B,,1348,,9,1,CHEMBL616844
2048,H,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,Autocuration,,,,,10618,BAO_0000357,B,,1348,,8,1,CHEMBL616845
2049,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Expert,,,,,10618,BAO_0000357,B,,4234,,9,1,CHEMBL616846
2050,H,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,10618,BAO_0000357,B,,16209,,8,1,CHEMBL616847
2051,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,Autocuration,,,,,10618,BAO_0000019,B,,10444,,8,1,CHEMBL616848
2052,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,3935,,8,1,CHEMBL616849
2053,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,15818,,8,1,CHEMBL872911
2054,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000019,B,,17085,,8,1,CHEMBL616850
2055,D,,449.0,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Expert,,CHO,,,10618,BAO_0000219,B,,12936,,9,1,CHEMBL616699
2056,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,6166,,8,1,CHEMBL616700
2057,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,8,1,CHEMBL616701
2058,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,8,1,CHEMBL616702
2059,H,,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,CHO,,,10618,BAO_0000219,B,,15779,,8,1,CHEMBL616703
2060,H,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,10618,BAO_0000357,B,,13181,,8,1,CHEMBL616704
2061,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,CHO,,,10618,BAO_0000219,B,,4199,,8,1,CHEMBL616705
2062,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,14875,,8,1,CHEMBL616706
2063,H,,449.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,Autocuration,,CHO,,,10618,BAO_0000219,B,,15146,,8,1,CHEMBL616707
2064,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,10618,BAO_0000357,B,,5213,,8,1,CHEMBL616708
2065,H,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,Autocuration,,,,,10618,BAO_0000357,B,,12146,,8,1,CHEMBL616709
2066,H,,449.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,Autocuration,,CHO,,,10618,BAO_0000219,B,,13267,,8,1,CHEMBL616710
2067,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,10618,BAO_0000219,B,,14818,,8,1,CHEMBL616711
2068,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,10618,BAO_0000219,B,,4829,,8,1,CHEMBL616712
2069,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,4373,,8,1,CHEMBL616713
2070,H,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,10618,BAO_0000357,B,,4373,,8,1,CHEMBL616714
2071,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,14159,,8,1,CHEMBL616715
2072,H,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,Autocuration,,,,,10618,BAO_0000357,B,,16633,,8,1,CHEMBL616716
2073,H,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",Autocuration,,,,,279,BAO_0000019,F,,17085,,8,1,CHEMBL616717
2074,H,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",Expert,,,,,279,BAO_0000019,F,,17085,,8,1,CHEMBL616718
2075,H,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000019,F,,16209,,8,1,CHEMBL875905
2076,H,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000019,F,,16209,,8,1,CHEMBL616719
2077,H,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",Expert,,,,,279,BAO_0000019,F,,17085,,8,1,CHEMBL616720
2078,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,14159,,8,1,CHEMBL616721
2079,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,Autocuration,,CHO,,,279,BAO_0000219,B,,15250,,8,1,CHEMBL616722
2080,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),Autocuration,,,,,279,BAO_0000357,B,,3805,,8,1,CHEMBL616723
2081,H,,449.0,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,Autocuration,,CHO,,,279,BAO_0000219,B,,16190,,8,1,CHEMBL616724
2082,H,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,Autocuration,,,,,279,BAO_0000357,B,,16190,,8,1,CHEMBL616725
2083,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,16209,,8,1,CHEMBL616726
2084,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,16209,,8,1,CHEMBL616727
2085,H,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,Autocuration,,,,,279,BAO_0000357,B,,16209,,8,1,CHEMBL616728
2086,H,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,6866,,8,1,CHEMBL616729
2087,H,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,Expert,,,,,279,BAO_0000019,B,,17085,,8,1,CHEMBL616730
2088,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,16312,,8,1,CHEMBL617125
2089,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,6166,,8,1,CHEMBL857977
2090,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,CHO,,,279,BAO_0000219,B,,15779,,8,1,CHEMBL617126
2091,H,,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,Autocuration,,CHO,,,279,BAO_0000219,B,,4199,,8,1,CHEMBL617127
2092,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,14875,,8,1,CHEMBL617128
2093,H,,449.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,CHO,,,279,BAO_0000219,B,,15146,,8,1,CHEMBL617129
2094,H,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,279,BAO_0000357,B,,5213,,8,1,CHEMBL617130
2095,H,,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,Autocuration,,CHO,,,279,BAO_0000219,B,,14818,,8,1,CHEMBL617131
2096,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,279,BAO_0000219,B,,4829,,8,1,CHEMBL617132
2097,H,,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,CHO,,,279,BAO_0000219,B,,4829,,8,1,CHEMBL617133
2098,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,4373,,8,1,CHEMBL617134
2099,H,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,279,BAO_0000357,B,,4373,,8,1,CHEMBL617135
2100,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,Autocuration,,,,,279,BAO_0000357,B,,5014,,8,1,CHEMBL617136
2101,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617137
2102,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617138
2103,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617139
2104,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,14093,,8,1,CHEMBL617140
2105,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,,4,1,CHEMBL617141
2106,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL858112
2107,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,Intermediate,,,,,17005,BAO_0000019,B,,12352,,8,1,CHEMBL617142
2108,U,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Autocuration,,,,,22226,BAO_0000019,B,,13657,,0,1,CHEMBL617143
2109,U,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Autocuration,,,,,22226,BAO_0000019,B,,14331,,0,1,CHEMBL617144
2110,U,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Autocuration,,,,,22226,BAO_0000019,B,,14331,,0,1,CHEMBL617145
2111,U,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,Autocuration,,,,,22226,BAO_0000019,B,,14331,,0,1,CHEMBL617146
2112,H,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Autocuration,,,,,104784,BAO_0000019,B,,12685,,4,1,CHEMBL617147
2113,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Autocuration,,,,,104784,BAO_0000019,B,,14389,,4,1,CHEMBL617148
2114,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Autocuration,,,,,104784,BAO_0000019,B,,14386,,4,1,CHEMBL617149
2115,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,5732,,4,1,CHEMBL617150
2116,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,16293,,4,1,CHEMBL617151
2117,H,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,2078,,4,1,CHEMBL617201
2118,H,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,10209,BAO_0000357,B,,5486,,8,1,CHEMBL617202
2119,H,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,104826,BAO_0000218,B,,11820,,4,1,CHEMBL617203
2120,H,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,4,1,CHEMBL617204
2121,H,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Autocuration,,,,,104826,BAO_0000224,B,,13704,,4,1,CHEMBL617205
2122,D,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,5,1,CHEMBL617206
2123,H,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,104826,BAO_0000218,B,,11820,,4,1,CHEMBL617207
2124,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,5,1,CHEMBL617208
2125,H,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104826,BAO_0000224,B,,11555,,4,1,CHEMBL617209
2126,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,Autocuration,,,,,104826,BAO_0000224,B,,11555,,4,1,CHEMBL617210
2127,H,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,Autocuration,,,,,104826,BAO_0000224,B,,11555,,4,1,CHEMBL617211
2128,D,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,,,104826,BAO_0000019,B,,10297,,5,1,CHEMBL617212
2129,H,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Autocuration,,,,,104784,BAO_0000224,B,,16688,,4,1,CHEMBL617213
2130,H,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Autocuration,,,,,104784,BAO_0000224,B,,16688,,4,1,CHEMBL617214
2131,U,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,22226,BAO_0000221,B,,5333,,0,1,CHEMBL617215
2132,U,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,22226,BAO_0000221,B,,4437,,0,1,CHEMBL617216
2133,H,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,5033,,8,1,CHEMBL617217
2134,H,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15267,,4,1,CHEMBL617218
2135,H,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15267,,4,1,CHEMBL872913
2136,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Autocuration,,,,,104826,BAO_0000019,B,,11820,,4,1,CHEMBL617219
2137,H,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9069,,4,1,CHEMBL873482
2138,D,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Autocuration,,,,,104686,BAO_0000019,B,,9162,,5,1,CHEMBL617220
2139,H,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,Autocuration,,,,,104686,BAO_0000019,B,,9162,,4,1,CHEMBL617221
2140,H,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,Autocuration,,,,,104686,BAO_0000019,B,,9162,,4,1,CHEMBL617222
2141,H,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,104686,BAO_0000019,F,,10428,,4,1,CHEMBL875906
2142,H,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,104686,BAO_0000019,B,,9628,,4,1,CHEMBL617223
2143,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12704,,4,1,CHEMBL617224
2144,D,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,15453,,5,1,CHEMBL617225
2145,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,Autocuration,,,,,104686,BAO_0000224,B,,188,,4,1,CHEMBL617226
2146,H,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,10349,,4,1,CHEMBL617227
2147,H,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,10349,,4,1,CHEMBL617228
2148,H,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,104686,BAO_0000224,B,,8868,,4,1,CHEMBL617229
2149,H,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,104686,BAO_0000224,B,,10025,,4,1,CHEMBL617230
2150,H,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,104686,BAO_0000224,B,,10025,,4,1,CHEMBL617231
2151,H,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL617232
2152,H,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL617233
2153,H,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,104686,BAO_0000224,B,,11702,,4,1,CHEMBL617234
2154,H,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,Autocuration,,,,,104686,BAO_0000019,F,,11702,,4,1,CHEMBL617235
2155,H,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,Autocuration,,,,,104686,BAO_0000019,F,,11702,,4,1,CHEMBL617236
2156,H,,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,10000000.0,104686,BAO_0000221,B,,10085,Hippocampus,4,1,CHEMBL617237
2157,H,,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,10000000.0,104686,BAO_0000221,B,,10085,Hippocampus,4,1,CHEMBL617238
2158,D,,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Autocuration,,,,955.0,104686,BAO_0000221,B,,9630,Brain,5,1,CHEMBL617239
2159,H,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,11070,,4,1,CHEMBL617240
2160,H,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9841,,4,1,CHEMBL617241
2161,H,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,9841,,4,1,CHEMBL875907
2162,H,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Autocuration,,,,,104686,BAO_0000019,B,,13291,,4,1,CHEMBL617242
2163,H,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,Autocuration,,,,,104686,BAO_0000019,F,,10590,,4,1,CHEMBL617152
2164,D,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,,955.0,104686,BAO_0000221,B,,9064,Brain,5,1,CHEMBL617153
2165,D,,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Autocuration,,,,,104686,BAO_0000249,B,Membranes,12268,,5,1,CHEMBL617154
2166,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Autocuration,,,,955.0,104686,BAO_0000221,B,,13508,Brain,4,1,CHEMBL617155
2167,H,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,104686,BAO_0000019,F,,11279,,4,1,CHEMBL617156
2168,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617157
2169,H,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617158
2170,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617159
2171,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617160
2172,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL858113
2173,H,,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Autocuration,,,,955.0,104686,BAO_0000220,B,,9231,Brain,4,1,CHEMBL617247
2174,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9737,,4,1,CHEMBL617248
2175,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,955.0,104686,BAO_0000249,B,,9737,Brain,4,1,CHEMBL617249
2176,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,9737,,4,1,CHEMBL617250
2177,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9737,,4,1,CHEMBL617251
2178,D,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,11828,,5,1,CHEMBL617252
2179,H,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,12253,,4,1,CHEMBL617006
2180,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,12253,,4,1,CHEMBL617007
2181,H,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",Autocuration,,,,,104686,BAO_0000019,F,,11279,,4,1,CHEMBL617008
2182,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,Autocuration,,,,,104686,BAO_0000019,B,,11866,,4,1,CHEMBL617009
2183,D,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Autocuration,,,,,104686,BAO_0000224,B,,14424,,5,1,CHEMBL617010
2184,D,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15180,,5,1,CHEMBL857978
2185,D,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15180,,5,1,CHEMBL617011
2186,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Autocuration,,,,,104686,BAO_0000019,B,,9786,,5,1,CHEMBL617012
2187,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,12132,,4,1,CHEMBL617013
2188,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,Autocuration,,,,,104686,BAO_0000249,B,,5486,,4,1,CHEMBL617014
2189,H,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,15316,,4,1,CHEMBL617015
2190,H,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,Autocuration,,,,,104686,BAO_0000019,B,,16429,,4,1,CHEMBL617016
2191,H,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,Autocuration,,,,,104686,BAO_0000224,B,,14617,,4,1,CHEMBL617017
2192,H,,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Autocuration,,,,955.0,104686,BAO_0000221,B,,11351,Brain,4,1,CHEMBL617018
2193,H,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,104686,BAO_0000019,F,,11279,,4,1,CHEMBL617019
2194,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617020
2195,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617021
2196,H,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617022
2197,H,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617023
2198,H,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617024
2199,H,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,105075,BAO_0000019,B,,9523,,4,1,CHEMBL617025
2200,H,,,,Hill coefficient of compound was determined,Autocuration,,,,,105075,BAO_0000224,B,,9523,,4,1,CHEMBL617026
2201,U,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,Autocuration,,,,,22226,BAO_0000019,B,,4771,,0,1,CHEMBL617027
2202,D,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Autocuration,,,,,104686,BAO_0000019,B,,5033,,5,1,CHEMBL617028
2203,H,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,Expert,,,,,12687,BAO_0000019,B,,10845,,8,1,CHEMBL617029
2204,H,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,Expert,,,,,12687,BAO_0000019,B,,10845,,8,1,CHEMBL875908
2205,H,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),Autocuration,,,,,12687,BAO_0000357,B,,16288,,8,1,CHEMBL617030
2206,H,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),Autocuration,,,,,12687,BAO_0000019,B,,16288,,8,1,CHEMBL617031
2207,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,Autocuration,,,,,12687,BAO_0000019,B,,16190,,8,1,CHEMBL617032
2208,D,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,12463,,5,1,CHEMBL617033
2209,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",Autocuration,,,,,104686,BAO_0000224,B,,9699,,4,1,CHEMBL617034
2210,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,9699,,4,1,CHEMBL617035
2211,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617036
2212,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1205,,4,1,CHEMBL617037
2213,U,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,Autocuration,,,,,22226,BAO_0000219,B,,11376,,0,1,CHEMBL617038
2214,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",Autocuration,,,,,104784,BAO_0000219,B,,11376,,4,1,CHEMBL617039
2215,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4639,,4,1,CHEMBL617161
2216,H,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,2222,,4,1,CHEMBL617162
2217,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1558,,4,1,CHEMBL617163
2218,H,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,1089,,4,1,CHEMBL617164
2219,H,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Autocuration,,,,,104784,BAO_0000249,B,Brain membranes,386,,4,1,CHEMBL617165
2220,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,Autocuration,,,,,104784,BAO_0000224,B,,2474,,4,1,CHEMBL617166
2221,H,,,,Binding affinity towards 5-HT2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,17066,,4,1,CHEMBL617167
2222,H,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,959,,4,1,CHEMBL872912
2223,H,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,Autocuration,,,,,104784,BAO_0000224,B,,6398,,4,1,CHEMBL617168
2224,H,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Autocuration,,,,,104686,BAO_0000224,B,,11889,,4,1,CHEMBL617169
2225,H,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4221,,4,1,CHEMBL617170
2226,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,Autocuration,,,,,104784,BAO_0000224,B,,11026,,4,1,CHEMBL617171
2227,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104784,BAO_0000224,B,,11866,,4,1,CHEMBL617172
2228,H,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4221,,4,1,CHEMBL617173
2229,U,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,22226,BAO_0000019,B,,13950,,0,1,CHEMBL617174
2230,H,,,,5-hydroxytryptamine 2 receptor binding affinity,Autocuration,,,,,104784,BAO_0000224,B,,1263,,4,1,CHEMBL617175
2231,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,Autocuration,,,,,17005,BAO_0000357,B,,13291,,8,1,CHEMBL617176
2232,H,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,10812,,8,1,CHEMBL617177
2233,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,104784,BAO_0000224,B,,13020,,4,1,CHEMBL617178
2234,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,Autocuration,,,,,104784,BAO_0000224,B,,13021,,4,1,CHEMBL617179
2235,H,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,104784,BAO_0000224,B,,13020,,4,1,CHEMBL617180
2236,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,Autocuration,,,,,17005,BAO_0000357,B,,14532,,8,1,CHEMBL617181
2237,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,13944,,8,1,CHEMBL617182
2238,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,14331,,8,1,CHEMBL617183
2239,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,14118,,8,1,CHEMBL617184
2240,H,,,,Binding affinity against serotonergic 5-HT2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,13033,,8,1,CHEMBL617185
2241,H,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,Autocuration,,,,,17005,BAO_0000357,B,,10321,,8,1,CHEMBL617186
2242,H,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,12918,,8,1,CHEMBL617187
2243,H,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,15120,,8,1,CHEMBL617188
2244,H,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000218,B,,2613,,8,1,CHEMBL617189
2245,D,,,,Inhibitory activity against cloned human 5-HT2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,13378,,5,1,CHEMBL617190
2246,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,5,1,CHEMBL617191
2247,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,5,1,CHEMBL617192
2248,D,,449.0,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,5,1,CHEMBL617193
2249,D,,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Autocuration,,CHO,,,104784,BAO_0000219,B,,2331,,5,1,CHEMBL617194
2250,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104784,BAO_0000224,B,,4170,,4,1,CHEMBL617195
2251,H,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,,,104784,BAO_0000224,B,,15453,,4,1,CHEMBL881830
2252,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,17005,BAO_0000357,B,,1479,,8,1,CHEMBL617196
2253,H,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,Autocuration,,,,,104686,BAO_0000224,B,,11139,,4,1,CHEMBL617197
2254,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,Expert,,,,,17005,BAO_0000357,B,,13969,,8,1,CHEMBL617198
2255,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,17005,BAO_0000357,B,,13392,,8,1,CHEMBL873476
2256,H,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Expert,,,,,17005,BAO_0000019,B,,14430,,8,1,CHEMBL617199
2257,H,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,13181,,8,1,CHEMBL617200
2258,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,51,BAO_0000357,B,,17200,,8,1,CHEMBL617484
2259,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,107,BAO_0000357,B,,17200,,8,1,CHEMBL617485
2260,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,51,BAO_0000357,B,,17200,,8,1,CHEMBL617486
2261,H,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,13463,,8,1,CHEMBL858022
2262,H,,449.0,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,8,1,CHEMBL617049
2263,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,107,BAO_0000219,F,,6857,,9,1,CHEMBL617050
2264,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,107,BAO_0000219,F,,4176,,8,1,CHEMBL617051
2265,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,Autocuration,,,,,107,BAO_0000219,F,,4176,,8,1,CHEMBL617052
2266,H,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,107,BAO_0000219,F,,4176,,8,1,CHEMBL617053
2267,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,8,1,CHEMBL617054
2268,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,8,1,CHEMBL617055
2269,H,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,Autocuration,,,,,107,BAO_0000357,B,,15331,,8,1,CHEMBL882924
2270,D,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16146,,9,1,CHEMBL617056
2271,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Autocuration,,CHO,,,107,BAO_0000219,B,,15250,,8,1,CHEMBL617057
2272,H,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Expert,,,,,107,BAO_0000219,B,,13631,,8,1,CHEMBL617058
2273,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),Autocuration,,,,,107,BAO_0000357,B,,3805,,8,1,CHEMBL617059
2274,H,,449.0,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,Autocuration,,CHO,,,107,BAO_0000219,B,,4011,,8,1,CHEMBL617060
2275,H,,449.0,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,Expert,,CHO,,,107,BAO_0000219,B,,4012,,8,1,CHEMBL617061
2276,H,,307.0,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,Expert,,L929,,,107,BAO_0000219,B,,6366,,8,1,CHEMBL617062
2277,H,,449.0,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,15949,,8,1,CHEMBL617063
2278,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,Autocuration,,,,,107,BAO_0000019,F,,14093,,8,1,CHEMBL617064
2279,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,107,BAO_0000019,F,,13481,,8,1,CHEMBL617065
2280,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,8,1,CHEMBL617066
2281,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,Autocuration,,CHO,,,107,BAO_0000219,B,,6347,,8,1,CHEMBL617067
2282,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,Autocuration,,,,,107,BAO_0000019,F,,14093,,8,1,CHEMBL617068
2283,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,Autocuration,,,,,107,BAO_0000019,F,,14093,,8,1,CHEMBL617069
2284,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000019,F,,13481,,8,1,CHEMBL617070
2285,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,Autocuration,,,,,107,BAO_0000357,B,,14442,,8,1,CHEMBL617071
2286,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,14442,,8,1,CHEMBL872915
2287,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,Autocuration,,,,,107,BAO_0000357,B,,14755,,8,1,CHEMBL617072
2288,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,Autocuration,,,,,107,BAO_0000357,B,,16441,,8,1,CHEMBL617073
2289,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,Autocuration,,,,,107,BAO_0000357,B,,14744,,8,1,CHEMBL617074
2290,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,16659,,8,1,CHEMBL617075
2291,H,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3307,,8,1,CHEMBL617076
2292,D,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Expert,,,,,107,BAO_0000019,B,,6857,,9,1,CHEMBL617077
2293,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,Expert,,,,,107,BAO_0000357,B,,5635,,8,1,CHEMBL617078
2294,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,4234,,9,1,CHEMBL617079
2295,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,107,BAO_0000357,B,,15527,,8,1,CHEMBL617080
2296,H,,449.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,6588,,8,1,CHEMBL617081
2297,H,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,Expert,,,,,107,BAO_0000219,B,,13631,,8,1,CHEMBL617082
2298,H,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,17723,,8,1,CHEMBL617083
2299,H,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,107,BAO_0000357,B,,14770,,8,1,CHEMBL617084
2300,D,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16293,,9,1,CHEMBL617085
2301,H,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,107,BAO_0000357,B,,16209,,8,1,CHEMBL617086
2302,H,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,Autocuration,,,,,107,BAO_0000219,B,,12469,,8,1,CHEMBL617087
2303,H,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,8,1,CHEMBL617088
2304,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,15363,,8,1,CHEMBL617089
2305,H,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",Expert,,,,,107,BAO_0000019,B,,16441,,8,1,CHEMBL617090
2306,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Autocuration,,,,,107,BAO_0000357,B,,8,,8,1,CHEMBL617513
2307,H,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,4176,,8,1,CHEMBL617514
2308,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000019,B,,17085,,8,1,CHEMBL617515
2309,H,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,107,BAO_0000357,B,,17200,,8,1,CHEMBL617516
2310,D,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Expert,,,,,107,BAO_0000357,B,,17200,,9,1,CHEMBL617517
2311,D,,449.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,4013,,9,1,CHEMBL617518
2312,H,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5088,,8,1,CHEMBL617519
2313,D,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5088,,9,1,CHEMBL617520
2314,H,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,Autocuration,,,,,107,BAO_0000357,B,,5088,,8,1,CHEMBL617521
2315,D,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5088,,9,1,CHEMBL617522
2316,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,Autocuration,,,,,107,BAO_0000357,B,,5088,,8,1,CHEMBL617523
2317,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,107,BAO_0000357,B,,5088,,8,1,CHEMBL617524
2318,H,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,Autocuration,,,,,104686,BAO_0000019,B,,9786,,4,1,CHEMBL617525
2319,D,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Autocuration,,,,,104686,BAO_0000019,B,,9205,,5,1,CHEMBL617526
2320,H,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,Autocuration,,,,,104686,BAO_0000224,B,,11257,,4,1,CHEMBL617527
2321,H,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,104686,BAO_0000019,B,,9362,,4,1,CHEMBL617528
2322,H,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,104686,BAO_0000019,B,,9362,,4,1,CHEMBL617529
2323,H,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,Autocuration,,,,,104686,BAO_0000224,B,,10590,,4,1,CHEMBL617530
2324,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10468,,4,1,CHEMBL617531
2325,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,13050,,4,1,CHEMBL617532
2326,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11624,,4,1,CHEMBL617533
2327,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,104686,BAO_0000019,B,,10468,,4,1,CHEMBL617534
2328,H,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,10330,,4,1,CHEMBL617535
2329,H,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,10062,,4,1,CHEMBL617536
2330,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11642,,4,1,CHEMBL617537
2331,H,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10062,,4,1,CHEMBL617538
2332,H,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,104686,BAO_0000219,B,,13427,,4,1,CHEMBL617539
2333,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12280,,5,1,CHEMBL617540
2334,D,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Autocuration,,,,,104686,BAO_0000224,B,,4101,,5,1,CHEMBL617541
2335,H,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10062,,4,1,CHEMBL617542
2336,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,Autocuration,,,,,104686,BAO_0000224,B,,11147,,4,1,CHEMBL617543
2337,D,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,5,1,CHEMBL617544
2338,D,,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,CHO-K1,,,104686,BAO_0000219,B,,2395,,5,1,CHEMBL617545
2339,D,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9098,,5,1,CHEMBL617413
2340,H,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617414
2341,D,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,5,1,CHEMBL617415
2342,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9443,,4,1,CHEMBL617416
2343,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,104686,BAO_0000224,B,,9443,,4,1,CHEMBL617417
2344,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",Autocuration,,,,,104686,BAO_0000019,B,,9699,,4,1,CHEMBL617418
2345,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,Autocuration,,,,,104686,BAO_0000019,B,,9699,,4,1,CHEMBL617419
2346,H,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,104686,BAO_0000224,B,,9098,,4,1,CHEMBL617420
2347,D,,,,Affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,3070,,5,1,CHEMBL617421
2348,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,Autocuration,,,,,104686,BAO_0000224,B,,9547,,4,1,CHEMBL617422
2349,H,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,Autocuration,,,,,104686,BAO_0000019,B,,10444,,4,1,CHEMBL617423
2350,H,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,Autocuration,,,,,104686,BAO_0000019,B,,14617,,4,1,CHEMBL617424
2351,H,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Autocuration,,,,,104686,BAO_0000019,B,,14617,,4,1,CHEMBL617425
2352,H,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),Autocuration,,,,,104686,BAO_0000224,B,,11130,,4,1,CHEMBL617426
2353,H,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),Autocuration,,,,,104686,BAO_0000218,B,,11130,,4,1,CHEMBL617427
2354,H,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Autocuration,,,,955.0,104686,BAO_0000221,B,,14542,Brain,4,1,CHEMBL617428
2355,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,Autocuration,,,,,104686,BAO_0000224,B,,2797,,4,1,CHEMBL617429
2356,H,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11332,,4,1,CHEMBL617430
2357,H,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,104686,BAO_0000019,B,,11332,,4,1,CHEMBL617431
2358,H,,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Autocuration,,,,1870.0,104686,BAO_0000019,B,,10752,Frontal cortex,4,1,CHEMBL617432
2359,H,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,1185,,4,1,CHEMBL617433
2360,H,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,1185,,4,1,CHEMBL617434
2361,D,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,5,1,CHEMBL617435
2362,H,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,Autocuration,,,,,104686,BAO_0000019,B,,1344,,4,1,CHEMBL617436
2363,D,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Autocuration,,,,2435.0,104686,BAO_0000019,B,,15453,Striatum,5,1,CHEMBL617437
2364,H,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617438
2365,H,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,104686,BAO_0000019,B,,11662,,4,1,CHEMBL617439
2366,H,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,10796,,4,1,CHEMBL617440
2367,H,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,9069,,4,1,CHEMBL617441
2368,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Autocuration,,,,,104686,BAO_0000019,B,,8814,,5,1,CHEMBL872918
2369,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,8908,,5,1,CHEMBL617442
2370,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617443
2371,H,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617444
2372,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617445
2373,H,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617446
2374,H,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,Autocuration,,,,,104686,BAO_0000249,B,,9098,,4,1,CHEMBL617447
2375,H,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617448
2376,H,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,Autocuration,,,,,104686,BAO_0000019,B,,9098,,4,1,CHEMBL617449
2377,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617450
2378,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617451
2379,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617452
2380,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617453
2381,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617660
2382,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617661
2383,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617662
2384,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL872919
2385,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617663
2386,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617664
2387,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617665
2388,H,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,Autocuration,,,,,104686,BAO_0000019,B,,9161,,4,1,CHEMBL617666
2389,H,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,Autocuration,,,,,104686,BAO_0000019,B,,12094,,4,1,CHEMBL617667
2390,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000249,B,,12018,,4,1,CHEMBL617668
2391,H,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Autocuration,,,,,104686,BAO_0000249,B,,10394,,4,1,CHEMBL617669
2392,H,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,15260,,4,1,CHEMBL617670
2393,D,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,11624,,5,1,CHEMBL617671
2394,H,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13654,,4,1,CHEMBL617672
2395,H,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,Autocuration,,,,,104686,BAO_0000019,B,,9541,,4,1,CHEMBL617673
2396,H,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,Autocuration,,,,,104686,BAO_0000224,B,,11933,,4,1,CHEMBL617674
2397,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,104686,BAO_0000019,B,,15538,,4,1,CHEMBL617675
2398,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,Autocuration,,,,,104686,BAO_0000019,B,,15538,,4,1,CHEMBL617676
2399,H,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,Autocuration,,,,,104686,BAO_0000019,B,,15538,,4,1,CHEMBL617677
2400,D,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000019,B,,8841,,5,1,CHEMBL617678
2401,H,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,Autocuration,,,,,104686,BAO_0000224,B,,1455,,4,1,CHEMBL617679
2402,H,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,Autocuration,,,,,104686,BAO_0000224,B,,1455,,4,1,CHEMBL617680
2403,H,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,Autocuration,,,,,104686,BAO_0000019,B,,11752,,4,1,CHEMBL617681
2404,H,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Autocuration,,,,955.0,104686,BAO_0000221,B,,11642,Brain,4,1,CHEMBL617682
2405,H,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,Autocuration,,,,,104686,BAO_0000224,B,,12092,,4,1,CHEMBL617683
2406,H,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,Autocuration,,,,,104686,BAO_0000224,B,,3967,,4,1,CHEMBL617684
2407,D,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,12771,,5,1,CHEMBL617685
2408,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,Autocuration,,,,,104686,BAO_0000019,B,,11642,,4,1,CHEMBL617686
2409,H,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,Autocuration,,,,,104686,BAO_0000224,B,,11628,,4,1,CHEMBL617687
2410,H,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,104686,BAO_0000224,B,,13654,,4,1,CHEMBL617688
2411,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617689
2412,H,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,104686,BAO_0000019,F,,11200,,4,1,CHEMBL617690
2413,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,,4,1,CHEMBL617691
2414,H,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,,4,1,CHEMBL617692
2415,H,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,,4,1,CHEMBL617693
2416,H,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,104686,BAO_0000218,F,,11200,,4,1,CHEMBL617694
2417,H,,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Expert,,,,955.0,12687,BAO_0000221,B,,15436,Brain,8,1,CHEMBL857985
2418,D,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,9,1,CHEMBL617695
2419,H,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,Autocuration,,,,,12687,BAO_0000019,B,,14025,,8,1,CHEMBL617696
2420,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,12687,BAO_0000357,B,,4342,,8,1,CHEMBL617697
2421,D,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Expert,,,,,12687,BAO_0000019,B,,13735,,9,1,CHEMBL617257
2422,D,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,,,12687,BAO_0000357,B,,5816,,9,1,CHEMBL617258
2423,H,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,Expert,,,,,12687,BAO_0000019,B,,14287,,8,1,CHEMBL617259
2424,H,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,Autocuration,,,,,12687,BAO_0000357,B,,15738,,8,1,CHEMBL617260
2425,D,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,15738,,9,1,CHEMBL617261
2426,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,15026,,8,1,CHEMBL617262
2427,H,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,16647,,8,1,CHEMBL617263
2428,H,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,Autocuration,,,,,12687,BAO_0000019,B,,16647,,8,1,CHEMBL617264
2429,D,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,13345,,9,1,CHEMBL617265
2430,H,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000249,B,Membranes,1543,,8,1,CHEMBL617266
2431,H,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Autocuration,,,,,12687,BAO_0000019,B,,12444,,8,1,CHEMBL617267
2432,H,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Expert,,,,,12687,BAO_0000019,B,,16404,,8,1,CHEMBL617268
2433,H,,449.0,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Autocuration,,CHO,,,12687,BAO_0000219,B,,16404,,8,1,CHEMBL617269
2434,H,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,Expert,,,,,12687,BAO_0000357,B,,15577,,8,1,CHEMBL617323
2435,H,,,,Serotonergic activity of the compound.,Autocuration,,,,,12687,BAO_0000357,B,,15577,,8,1,CHEMBL617324
2436,H,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Autocuration,,,,,12687,BAO_0000249,B,,2495,,8,1,CHEMBL617325
2437,D,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Expert,,,,,12687,BAO_0000019,B,,15042,,9,1,CHEMBL617326
2438,H,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Expert,,,,,12687,BAO_0000249,B,,15026,,8,1,CHEMBL617327
2439,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,9,1,CHEMBL617328
2440,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,9,1,CHEMBL617329
2441,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,9,1,CHEMBL617330
2442,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,15194,,8,1,CHEMBL617331
2443,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,15194,,8,1,CHEMBL617332
2444,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,4820,,8,1,CHEMBL617333
2445,H,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,Autocuration,,,,,107,BAO_0000357,B,,6736,,8,1,CHEMBL617334
2446,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,107,BAO_0000357,B,,5163,,8,1,CHEMBL617335
2447,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,107,BAO_0000357,B,,5163,,8,1,CHEMBL617336
2448,H,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,Autocuration,,,,,107,BAO_0000357,B,,6011,,8,1,CHEMBL617337
2449,D,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Expert,,,,,107,BAO_0000357,B,,14294,,9,1,CHEMBL617338
2450,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5014,,8,1,CHEMBL617339
2451,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,17066,,8,1,CHEMBL617340
2452,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,Autocuration,,,,,107,BAO_0000357,B,,17515,,8,1,CHEMBL617341
2453,H,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,6736,,8,1,CHEMBL617342
2454,H,,,,Affinity for 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,5163,,8,1,CHEMBL617343
2455,H,,723.0,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,Expert,,NIH3T3,,,107,BAO_0000219,B,,16911,,8,1,CHEMBL617344
2456,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,,,107,BAO_0000357,B,,6841,,8,1,CHEMBL617345
2457,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,Expert,,,,,107,BAO_0000357,B,,6119,,8,1,CHEMBL617346
2458,H,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3962,,8,1,CHEMBL617347
2459,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,8,1,CHEMBL617348
2460,H,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,8,1,CHEMBL617349
2461,H,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000019,F,,3962,,8,1,CHEMBL617350
2462,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,Expert,,,,,107,BAO_0000357,B,,1633,,8,1,CHEMBL872339
2463,H,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,4373,,8,1,CHEMBL617351
2464,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,6576,,8,1,CHEMBL617352
2465,H,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,4687,,8,1,CHEMBL617353
2466,H,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16946,,8,1,CHEMBL617354
2467,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,14159,,8,1,CHEMBL617355
2468,H,,449.0,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,3032,,8,1,CHEMBL617356
2469,H,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16655,,8,1,CHEMBL617357
2470,H,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,13964,,8,1,CHEMBL617358
2471,H,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,16989,,8,1,CHEMBL617359
2472,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,107,BAO_0000357,B,,16117,,8,1,CHEMBL617360
2473,H,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,Autocuration,,,,,107,BAO_0000357,B,,16700,,8,1,CHEMBL875913
2474,H,,,,Affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,3269,,8,1,CHEMBL617361
2475,D,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,1274,,9,1,CHEMBL617362
2476,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,107,BAO_0000357,B,,1317,,8,1,CHEMBL617363
2477,H,,,,Tested against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,12146,,8,1,CHEMBL617364
2478,H,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,4,1,CHEMBL617365
2479,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,4,1,CHEMBL617366
2480,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,Autocuration,,,,,105075,BAO_0000224,B,,12652,,4,1,CHEMBL617367
2481,H,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,105075,BAO_0000224,B,,12652,,4,1,CHEMBL617368
2482,H,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Autocuration,,,,,107,BAO_0000357,B,,16647,,8,1,CHEMBL617369
2483,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,9,1,CHEMBL617370
2484,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,227,BAO_0000219,F,,6857,,9,1,CHEMBL617371
2485,H,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),Autocuration,,,,,227,BAO_0000357,B,,3805,,8,1,CHEMBL617372
2486,D,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Expert,,,,,227,BAO_0000357,B,,6491,,9,1,CHEMBL617373
2487,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,8,1,CHEMBL617374
2488,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,Autocuration,,,,,227,BAO_0000019,F,,13481,,8,1,CHEMBL617375
2489,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,8,1,CHEMBL617376
2490,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,Autocuration,,,,,227,BAO_0000019,F,,14093,,8,1,CHEMBL617377
2491,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,Autocuration,,,,,227,BAO_0000019,F,,14093,,8,1,CHEMBL617378
2492,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000019,F,,13481,,8,1,CHEMBL617379
2493,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,8,1,CHEMBL617380
2494,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,8,1,CHEMBL617381
2495,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,227,BAO_0000357,B,,14442,,8,1,CHEMBL617382
2496,H,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,12369,,8,1,CHEMBL617383
2497,H,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,Expert,,,,,107,BAO_0000357,B,,12369,,8,1,CHEMBL617384
2498,H,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,Expert,,,,,107,BAO_0000357,B,,12369,,8,1,CHEMBL617385
2499,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,Autocuration,,,,,107,BAO_0000019,B,,14447,,8,1,CHEMBL617386
2500,H,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,Autocuration,,,,,107,BAO_0000019,B,,14447,,8,1,CHEMBL617387
2501,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,8,1,CHEMBL617388
2502,H,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Autocuration,,CHO,,,107,BAO_0000219,F,,6857,,8,1,CHEMBL617389
2503,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,107,BAO_0000219,F,,6857,,9,1,CHEMBL617390
2504,H,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,Autocuration,,,,,104817,BAO_0000224,B,,5635,,4,1,CHEMBL617391
2505,H,,,,Binding activity radioligand.,Autocuration,,,,,107,BAO_0000357,B,,12861,,8,1,CHEMBL617392
2506,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,107,BAO_0000019,B,,12861,,8,1,CHEMBL617393
2507,H,,307.0,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Autocuration,,L929,,,107,BAO_0000219,B,,5105,,8,1,CHEMBL617394
2508,H,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Expert,,L929,,,107,BAO_0000219,B,,5104,,8,1,CHEMBL617395
2509,H,,307.0,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,Expert,,L929,,,107,BAO_0000219,B,,5105,,8,1,CHEMBL617396
2510,H,,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,Autocuration,,L929,,,107,BAO_0000219,B,,5105,,8,1,CHEMBL617397
2511,H,,,,Binding affinity against 5-HT2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5254,,8,1,CHEMBL617398
2512,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,107,BAO_0000357,B,,5254,,8,1,CHEMBL617399
2513,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,13267,,8,1,CHEMBL617400
2514,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,13267,,8,1,CHEMBL617401
2515,D,,722.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Expert,,HEK293,,,107,BAO_0000219,B,,14157,,9,1,CHEMBL617402
2516,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,9,1,CHEMBL617403
2517,H,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,Expert,,,,,107,BAO_0000357,B,,14068,,8,1,CHEMBL617404
2518,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,9,1,CHEMBL857981
2519,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,9,1,CHEMBL617405
2520,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Expert,,HEK293,,,107,BAO_0000219,B,,4540,,9,1,CHEMBL617253
2521,H,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,Expert,,,,,107,BAO_0000357,B,,6166,,8,1,CHEMBL617254
2522,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,8,1,CHEMBL617255
2523,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,8,1,CHEMBL617256
2524,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,17296,,8,1,CHEMBL616874
2525,D,,722.0,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Expert,,HEK293,,,107,BAO_0000219,B,,15779,,9,1,CHEMBL616875
2526,H,,722.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,Expert,,HEK293,,,107,BAO_0000219,B,,14391,,8,1,CHEMBL616876
2527,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",Expert,,HEK293,,,107,BAO_0000219,B,,15851,,8,1,CHEMBL616877
2528,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Expert,,HEK293,,,107,BAO_0000219,B,,15851,,9,1,CHEMBL616878
2529,H,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,3832,,8,1,CHEMBL616879
2530,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,Expert,,HEK293,,,107,BAO_0000219,B,,3833,,8,1,CHEMBL616880
2531,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,HEK293,,,107,BAO_0000219,B,,12936,,9,1,CHEMBL616881
2532,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,8,1,CHEMBL616882
2533,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,8,1,CHEMBL616883
2534,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,107,BAO_0000219,B,,17451,,8,1,CHEMBL616884
2535,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,4199,,8,1,CHEMBL616885
2536,H,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,Autocuration,,CHO-K1,,,107,BAO_0000219,B,,1883,,8,1,CHEMBL616886
2537,H,,485.0,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,Expert,,CHO-K1,,,107,BAO_0000219,B,,1883,,8,1,CHEMBL616887
2538,D,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,,,107,BAO_0000357,B,,14875,,9,1,CHEMBL616888
2539,H,,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,Autocuration,,HEK293,,,107,BAO_0000219,B,,15146,,8,1,CHEMBL616889
2540,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,HEK293,,,107,BAO_0000219,B,,5213,,8,1,CHEMBL616890
2541,D,,449.0,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Expert,,CHO,,,107,BAO_0000219,B,,16404,,9,1,CHEMBL616891
2542,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,Autocuration,,HEK293,,,107,BAO_0000219,B,,14818,,8,1,CHEMBL616892
2543,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",Autocuration,,HEK293,,,107,BAO_0000219,B,,4829,,8,1,CHEMBL616893
2544,H,,723.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,Autocuration,,NIH3T3,,,10620,BAO_0000219,F,,12652,,8,1,CHEMBL616894
2545,H,,723.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Expert,,NIH3T3,,,107,BAO_0000219,B,,4682,,8,1,CHEMBL616895
2546,H,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,Autocuration,,,,,10620,BAO_0000019,F,,12652,,8,1,CHEMBL616896
2547,H,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,Autocuration,,,,,10621,BAO_0000357,B,,4921,,8,1,CHEMBL617099
2548,H,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Autocuration,,,,,10621,BAO_0000357,B,,4921,,8,1,CHEMBL617100
2549,H,,,,Binding affinity against rabbit aorta 5-HT2A receptor,Autocuration,,,,,107,BAO_0000357,B,,16312,,8,1,CHEMBL884532
2550,H,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Expert,,,,,107,BAO_0000357,B,,14998,,8,1,CHEMBL617101
2551,H,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Expert,,,,,107,BAO_0000357,B,,14025,,8,1,CHEMBL617102
2552,H,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,,,107,BAO_0000019,B,,13047,,8,1,CHEMBL617103
2553,H,,,,The compound was tested for binding affinity against 5-HT2A receptor,Expert,,,,,107,BAO_0000357,B,,13047,,8,1,CHEMBL617104
2554,H,,485.0,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,Autocuration,,CHO-K1,,,10576,BAO_0000219,B,,1883,,8,1,CHEMBL857979
2555,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,Autocuration,,,,,12687,BAO_0000019,B,,13463,,8,1,CHEMBL857502
2556,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,12687,BAO_0000019,B,,13463,,8,1,CHEMBL617105
2557,H,,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Autocuration,,,,945.0,12687,BAO_0000019,B,,13463,Stomach,8,1,CHEMBL858021
2558,D,,,,Binding affinity for 5-HT 2A in rat stomach fundus,Expert,,,,945.0,12687,BAO_0000019,B,,13463,Stomach,9,1,CHEMBL875910
2559,H,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,12687,BAO_0000019,B,,13463,,8,1,CHEMBL617106
2560,H,,723.0,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,16326,,8,1,CHEMBL617107
2561,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,14093,,8,1,CHEMBL617108
2562,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,14093,,8,1,CHEMBL617109
2563,H,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15740,,8,1,CHEMBL617110
2564,H,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,Autocuration,,,,,12687,BAO_0000357,B,,16633,,8,1,CHEMBL617111
2565,D,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Expert,,,,,12687,BAO_0000019,F,,17200,,9,1,CHEMBL617112
2566,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,8,1,CHEMBL617113
2567,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,8,1,CHEMBL617114
2568,H,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17133,,8,1,CHEMBL617115
2569,H,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,12687,BAO_0000219,F,,17200,,8,1,CHEMBL617116
2570,H,,,,Efficacy at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,F,,15363,,8,1,CHEMBL617117
2571,H,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Autocuration,,,,,12687,BAO_0000357,B,,17200,,8,1,CHEMBL617118
2572,D,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Expert,,,,,12687,BAO_0000357,B,,17200,,9,1,CHEMBL617119
2573,D,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Expert,,,,,12687,BAO_0000357,B,,17200,,9,1,CHEMBL617120
2574,D,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Expert,,,,,12687,BAO_0000219,F,,17200,,9,1,CHEMBL617121
2575,H,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,12687,BAO_0000219,F,,17200,,8,1,CHEMBL617122
2576,H,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,17211,,8,1,CHEMBL617123
2577,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,12687,BAO_0000019,B,,17331,,8,1,CHEMBL617124
2578,H,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,Expert,,,,,12687,BAO_0000249,B,,13565,,8,1,CHEMBL617600
2579,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,13730,,8,1,CHEMBL617601
2580,H,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Expert,,,,,12687,BAO_0000019,B,,12416,,8,1,CHEMBL882923
2581,H,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15295,,8,1,CHEMBL617602
2582,H,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,Autocuration,,,,,12687,BAO_0000019,B,,1742,,8,1,CHEMBL617603
2583,H,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15295,,8,1,CHEMBL617604
2584,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,14970,,8,1,CHEMBL617605
2585,H,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,16693,,8,1,CHEMBL617606
2586,D,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,14776,,9,1,CHEMBL617607
2587,H,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,14286,,8,1,CHEMBL617455
2588,D,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,,,12687,BAO_0000019,B,,17200,,9,1,CHEMBL617456
2589,H,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),Expert,,,,,12687,BAO_0000357,B,,15306,,8,1,CHEMBL617457
2590,D,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,14178,,9,1,CHEMBL617458
2591,D,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Expert,,,,,12687,BAO_0000019,B,,14229,,9,1,CHEMBL617459
2592,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,Expert,,,,,12687,BAO_0000357,B,,12884,,8,1,CHEMBL617460
2593,H,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Expert,,,,,12687,BAO_0000357,B,,13149,,8,1,CHEMBL617461
2594,D,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Expert,,,,,12687,BAO_0000019,B,,15295,,9,1,CHEMBL617462
2595,H,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,Autocuration,,,,,12687,BAO_0000357,B,,15740,,8,1,CHEMBL617463
2596,H,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",Autocuration,,,,,12687,BAO_0000019,B,,15185,,8,1,CHEMBL617464
2597,H,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",Autocuration,,,,,12687,BAO_0000019,B,,15185,,8,1,CHEMBL617465
2598,H,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,Expert,,,,,12687,BAO_0000019,B,,17529,,8,1,CHEMBL617466
2599,H,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,14826,,8,1,CHEMBL617467
2600,H,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,Expert,,,,,12687,BAO_0000019,B,,17211,,8,1,CHEMBL617468
2601,H,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,14826,,8,1,CHEMBL617469
2602,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000019,B,,14093,,8,1,CHEMBL617470
2603,H,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,Autocuration,,,,,12687,BAO_0000019,B,,14093,,8,1,CHEMBL617471
2604,H,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,Expert,,NIH3T3,,,12687,BAO_0000219,B,,13246,,8,1,CHEMBL617472
2605,H,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Expert,,,,,12687,BAO_0000357,B,,13246,,8,1,CHEMBL617473
2606,D,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,9,1,CHEMBL617474
2607,D,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,15436,,9,1,CHEMBL617475
2608,H,,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Autocuration,,,,955.0,12687,BAO_0000221,B,,14442,Brain,8,1,CHEMBL617476
2609,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,12457,,8,1,CHEMBL617477
2610,H,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,12457,,8,1,CHEMBL617478
2611,H,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",Autocuration,,,,,12687,BAO_0000221,F,,14755,,8,1,CHEMBL617479
2612,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,4707,,8,1,CHEMBL617480
2613,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,13297,,8,1,CHEMBL617481
2614,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,12687,BAO_0000019,B,,17331,,8,1,CHEMBL617482
2615,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,4664,,8,1,CHEMBL617483
2616,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,16633,,8,1,CHEMBL621528
2617,D,,723.0,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Expert,,NIH3T3,,,12687,BAO_0000219,B,,4664,,9,1,CHEMBL621529
2618,H,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,12687,BAO_0000357,B,,16133,,8,1,CHEMBL621530
2619,H,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,16133,,8,1,CHEMBL621531
2620,D,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,14060,,9,1,CHEMBL621532
2621,H,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,12687,BAO_0000357,B,,16326,,8,1,CHEMBL621533
2622,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,CHO,,,12687,BAO_0000219,B,,16659,,8,1,CHEMBL621534
2623,H,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Autocuration,,,,,12687,BAO_0000019,B,,14776,,8,1,CHEMBL621535
2624,H,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,12687,BAO_0000357,B,,13481,,8,1,CHEMBL621536
2625,H,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,17386,,8,1,CHEMBL621537
2626,D,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000357,B,,6611,,9,1,CHEMBL621538
2627,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,Autocuration,,,,,12687,BAO_0000019,B,,14423,,8,1,CHEMBL621539
2628,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,Autocuration,,,,,12687,BAO_0000019,B,,15412,,8,1,CHEMBL621540
2629,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,Autocuration,,,,,12687,BAO_0000019,B,,15412,,8,1,CHEMBL621541
2630,H,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000019,B,,6238,,8,1,CHEMBL621542
2631,H,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,Expert,,,,,12687,BAO_0000357,B,,6648,,8,1,CHEMBL621543
2632,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000357,B,,5667,,8,1,CHEMBL621544
2633,D,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Expert,,,,,12687,BAO_0000357,B,,6611,,9,1,CHEMBL621545
2634,H,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,13481,,8,1,CHEMBL621546
2635,H,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,Autocuration,,,,,12687,BAO_0000357,B,,13481,,8,1,CHEMBL621547
2636,H,,723.0,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,Expert,,NIH3T3,,,12687,BAO_0000219,B,,15558,,8,1,CHEMBL618692
2637,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618693
2638,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,16633,,8,1,CHEMBL872922
2639,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618694
2640,D,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Expert,,,,,12687,BAO_0000357,B,,6013,,9,1,CHEMBL618695
2641,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,Autocuration,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618696
2642,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,Expert,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618697
2643,H,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618892
2644,H,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,6013,,8,1,CHEMBL618893
2645,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,16293,,8,1,CHEMBL618894
2646,H,,723.0,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,Expert,,NIH3T3,,,12687,BAO_0000219,B,,17175,,8,1,CHEMBL618895
2647,D,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,,,12687,BAO_0000357,B,,13278,,9,1,CHEMBL618896
2648,H,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,5383.0,12687,BAO_0000019,B,,3682,Caudate-putamen,8,1,CHEMBL618897
2649,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,Autocuration,,,,,12687,BAO_0000357,B,,2014,,8,1,CHEMBL618898
2650,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,Autocuration,,,,,12687,BAO_0000357,B,,2014,,8,1,CHEMBL618899
2651,H,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,Autocuration,,,,,12687,BAO_0000357,B,,4932,,8,1,CHEMBL618900
2652,H,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,Autocuration,,,,,12687,BAO_0000019,B,,4932,,8,1,CHEMBL618901
2653,H,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,3935,,8,1,CHEMBL618902
2654,D,,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Expert,,,,10000000.0,12687,BAO_0000221,B,,5432,Hippocampus,9,1,CHEMBL618903
2655,H,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15818,,8,1,CHEMBL618904
2656,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,13672,,8,1,CHEMBL618905
2657,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,13672,,8,1,CHEMBL618906
2658,H,,723.0,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,Expert,,NIH3T3,,,12687,BAO_0000219,B,,14749,,8,1,CHEMBL618907
2659,H,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Autocuration,,,,,12687,BAO_0000019,B,,13462,,8,1,CHEMBL618908
2660,H,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15740,,8,1,CHEMBL617909
2661,H,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,16647,,8,1,CHEMBL617910
2662,H,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Autocuration,,,,955.0,12687,BAO_0000221,B,,13345,Brain,8,1,CHEMBL617911
2663,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,8,1,CHEMBL872923
2664,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,8,1,CHEMBL617912
2665,D,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Expert,,,,,12687,BAO_0000019,B,,15535,,9,1,CHEMBL617913
2666,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Expert,,,,,12687,BAO_0000249,B,,16740,,8,1,CHEMBL617914
2667,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,8,1,CHEMBL617915
2668,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,12687,BAO_0000249,B,,16740,,8,1,CHEMBL617916
2669,D,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Expert,,,,,12687,BAO_0000019,B,,4795,,9,1,CHEMBL617917
2670,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Expert,,,,,12687,BAO_0000019,B,,8,,8,1,CHEMBL617918
2671,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,Autocuration,,,,,12687,BAO_0000019,B,,8,,8,1,CHEMBL617919
2672,D,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,,,12687,BAO_0000019,B,,17200,,9,1,CHEMBL617920
2673,D,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Expert,,,,,12687,BAO_0000019,B,,2148,,9,1,CHEMBL617921
2674,D,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Expert,,,,,105102,BAO_0000224,B,,13345,,5,1,CHEMBL617922
2675,H,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,5088,,8,1,CHEMBL617923
2676,H,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,5088,,8,1,CHEMBL617924
2677,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,Autocuration,,,,,12687,BAO_0000357,B,,17133,,8,1,CHEMBL617925
2678,D,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Expert,,,,,12687,BAO_0000357,B,,17133,,9,1,CHEMBL617926
2679,H,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,Autocuration,,,,,12687,BAO_0000357,B,,16532,,8,1,CHEMBL617927
2680,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,12687,BAO_0000357,B,,15086,,8,1,CHEMBL617928
2681,D,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,,,12687,BAO_0000019,B,,2309,,9,1,CHEMBL617929
2682,H,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,Expert,,,,,12687,BAO_0000019,B,,12953,,8,1,CHEMBL617930
2683,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,Autocuration,,,,,12687,BAO_0000019,B,,12953,,8,1,CHEMBL617931
2684,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,Autocuration,,,,,12687,BAO_0000019,B,,12953,,8,1,CHEMBL617932
2685,H,,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,Autocuration,,CHO,,,12687,BAO_0000219,B,,16659,,8,1,CHEMBL617933
2686,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,12687,BAO_0000019,B,,16740,,8,1,CHEMBL617934
2687,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,12687,BAO_0000019,B,,16740,,8,1,CHEMBL617935
2688,H,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,Autocuration,,,,,12687,BAO_0000357,B,,17133,,8,1,CHEMBL617936
2689,H,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,Autocuration,,,,,12687,BAO_0000019,B,,17211,,8,1,CHEMBL617937
2690,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,Autocuration,,,,,12687,BAO_0000019,B,,17331,,8,1,CHEMBL617938
2691,H,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,Autocuration,,,,,12687,BAO_0000218,B,,16633,,8,1,CHEMBL617939
2692,H,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,Autocuration,,,,,12687,BAO_0000218,B,,16633,,8,1,CHEMBL617940
2693,H,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,Autocuration,,,,,12687,BAO_0000218,B,,16633,,8,1,CHEMBL617941
2694,H,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,Expert,,,,,12687,BAO_0000357,B,,15026,,8,1,CHEMBL617942
2695,H,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,Expert,,,,,12687,BAO_0000357,B,,15026,,8,1,CHEMBL617943
2696,H,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,105093,BAO_0000224,B,,16404,,4,1,CHEMBL617944
2697,H,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,105093,BAO_0000224,B,,16404,,4,1,CHEMBL617945
2698,H,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,Expert,,,,,105075,BAO_0000224,B,,16404,,4,1,CHEMBL617946
2699,H,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,Autocuration,,,,,12687,BAO_0000357,B,,16404,,8,1,CHEMBL617947
2700,H,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,Expert,,,,,12687,BAO_0000357,B,,16326,,8,1,CHEMBL617948
2701,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,Autocuration,,,,,12687,BAO_0000019,F,,15847,,8,1,CHEMBL858116
2702,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,Autocuration,,,,,12687,BAO_0000019,F,,15847,,8,1,CHEMBL617949
2703,H,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,Autocuration,,,,,12687,BAO_0000019,F,,15329,,8,1,CHEMBL617950
2704,H,,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Expert,,,,1515.0,12687,BAO_0000019,F,,16404,Thoracic aorta,8,1,CHEMBL617951
2705,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Expert,,,,1515.0,12687,BAO_0000019,F,,16404,Thoracic aorta,8,1,CHEMBL617952
2706,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Autocuration,,,,1515.0,12687,BAO_0000019,F,,16404,Thoracic aorta,8,1,CHEMBL617953
2707,H,,,,Binding activity radioligand.,Autocuration,,,,,12687,BAO_0000357,B,,12861,,8,1,CHEMBL617954
2708,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,12687,BAO_0000019,B,,12861,,8,1,CHEMBL617955
2709,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,12687,BAO_0000019,B,,12861,,8,1,CHEMBL857071
2710,H,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,Expert,,,,,12687,BAO_0000019,B,,12490,,8,1,CHEMBL617270
2711,H,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,Autocuration,,N1E-115,,,12687,BAO_0000219,B,,12827,,8,1,CHEMBL617271
2712,H,,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,Autocuration,,N1E-115,,,12687,BAO_0000219,B,,12827,,8,1,CHEMBL617272
2713,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,Autocuration,,,,,12687,BAO_0000019,B,,12918,,8,1,CHEMBL617273
2714,D,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Expert,,,,,12687,BAO_0000019,F,,12919,,9,1,CHEMBL617274
2715,H,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,17723,,8,1,CHEMBL617275
2716,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,6013,,8,1,CHEMBL617276
2717,H,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,16293,,8,1,CHEMBL617277
2718,H,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000019,B,,3857,,8,1,CHEMBL617278
2719,H,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,Expert,,,,,108,BAO_0000019,B,,3857,,8,1,CHEMBL617279
2720,H,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000019,B,,3857,,8,1,CHEMBL617280
2721,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15363,,8,1,CHEMBL617281
2722,H,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15363,,8,1,CHEMBL617282
2723,H,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,Expert,,,,,108,BAO_0000019,B,,16441,,8,1,CHEMBL617283
2724,H,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,Expert,,,,,108,BAO_0000019,B,,16441,,8,1,CHEMBL617284
2725,H,,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,4176,,8,1,CHEMBL617285
2726,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000019,B,,17085,,8,1,CHEMBL617286
2727,D,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Expert,,,,,108,BAO_0000357,B,,17200,,9,1,CHEMBL617287
2728,H,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,Expert,,,,,108,BAO_0000357,B,,5088,,8,1,CHEMBL617288
2729,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,8,1,CHEMBL617289
2730,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,8,1,CHEMBL872917
2731,H,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,108,BAO_0000357,B,,5088,,8,1,CHEMBL617290
2732,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Autocuration,,CHO,,,108,BAO_0000219,B,,16659,,8,1,CHEMBL617291
2733,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,Autocuration,,CHO,,,108,BAO_0000219,B,,16659,,8,1,CHEMBL617292
2734,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,NIH3T3,,,108,BAO_0000219,B,,17451,,8,1,CHEMBL617293
2735,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,108,BAO_0000219,F,,6857,,9,1,CHEMBL617294
2736,H,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Expert,,,,,108,BAO_0000019,B,,3857,,8,1,CHEMBL617295
2737,H,,,,Binding activity radioligand.,Autocuration,,,,,108,BAO_0000357,B,,12861,,8,1,CHEMBL617296
2738,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,108,BAO_0000019,B,,12861,,8,1,CHEMBL617297
2739,H,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,Expert,,CHO,,,108,BAO_0000219,B,,5104,,8,1,CHEMBL617298
2740,H,,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,Expert,,CHO,,,108,BAO_0000219,B,,5105,,8,1,CHEMBL617299
2741,H,,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,Autocuration,,CHO,,,108,BAO_0000219,B,,5105,,8,1,CHEMBL617300
2742,H,,,,Binding affinity against 5-HT2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5254,,8,1,CHEMBL617454
2743,H,,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,13267,,8,1,CHEMBL617505
2744,D,,722.0,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Expert,,HEK293,,,108,BAO_0000219,B,,14157,,9,1,CHEMBL617506
2745,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,12936,,9,1,CHEMBL617507
2746,H,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,Expert,,,,,108,BAO_0000357,B,,14068,,8,1,CHEMBL617508
2747,D,,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,12936,,9,1,CHEMBL857982
2748,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Expert,,HEK293,,,108,BAO_0000219,B,,4540,,9,1,CHEMBL617509
2749,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Expert,,HEK293,,,108,BAO_0000219,B,,4540,,9,1,CHEMBL617510
2750,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,6166,,8,1,CHEMBL617511
2751,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,17296,,8,1,CHEMBL617512
2752,H,,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,17296,,8,1,CHEMBL617749
2753,H,,722.0,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,8,1,CHEMBL617750
2754,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,8,1,CHEMBL617751
2755,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,Expert,,HEK293,,,108,BAO_0000219,B,,14391,,8,1,CHEMBL617752
2756,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,8,1,CHEMBL617753
2757,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",Expert,,HEK293,,,108,BAO_0000219,B,,15851,,8,1,CHEMBL617754
2758,D,,722.0,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Expert,,HEK293,,,108,BAO_0000219,B,,15851,,9,1,CHEMBL617755
2759,H,,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",Autocuration,,HEK293,,,108,BAO_0000219,B,,15779,,8,1,CHEMBL617756
2760,H,,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,Expert,,HEK293,,,108,BAO_0000219,B,,3832,,8,1,CHEMBL617757
2761,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,Expert,,HEK293,,,108,BAO_0000219,B,,3833,,8,1,CHEMBL617758
2762,H,,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,NIH3T3,,,108,BAO_0000219,B,,17451,,8,1,CHEMBL617759
2763,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,4199,,8,1,CHEMBL617760
2764,H,,485.0,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,108,BAO_0000219,B,,1883,,8,1,CHEMBL617761
2765,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4321,,9,1,CHEMBL617762
2766,H,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,14875,,8,1,CHEMBL617763
2767,H,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,Autocuration,,HEK293,,,108,BAO_0000219,B,,15146,,8,1,CHEMBL857983
2768,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,Autocuration,,HEK293,,,108,BAO_0000219,B,,5213,,8,1,CHEMBL617764
2769,H,,308.0,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,Autocuration,,HeLa,,,108,BAO_0000219,B,,16404,,8,1,CHEMBL617765
2770,H,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,108,BAO_0000019,F,,13267,,8,1,CHEMBL617766
2771,H,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Autocuration,,,,10000000.0,108,BAO_0000221,F,,13267,Hippocampus,8,1,CHEMBL617767
2772,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,Autocuration,,HEK293,,,108,BAO_0000219,B,,14818,,8,1,CHEMBL617768
2773,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",Autocuration,,HEK293,,,108,BAO_0000219,B,,4829,,8,1,CHEMBL617769
2774,H,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,Autocuration,,,,,11864,BAO_0000357,B,,13463,,8,1,CHEMBL858023
2775,H,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Autocuration,,,,945.0,11864,BAO_0000019,B,,13463,Stomach,8,1,CHEMBL617770
2776,H,,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Autocuration,,,,945.0,11864,BAO_0000019,B,,13463,Stomach,8,1,CHEMBL617771
2777,H,,625.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,Autocuration,,A9,,,11864,BAO_0000219,F,,12652,,8,1,CHEMBL617772
2778,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,8,1,CHEMBL617773
2779,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,8,1,CHEMBL617850
2780,H,,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,NIH3T3,,,11864,BAO_0000219,B,,4682,,8,1,CHEMBL617851
2781,H,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,Autocuration,,,,,11864,BAO_0000019,F,,12652,,8,1,CHEMBL617852
2782,H,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Autocuration,,,,945.0,12689,BAO_0000019,B,,13463,Stomach,8,1,CHEMBL858024
2783,D,,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Expert,,,,945.0,12689,BAO_0000019,B,,13463,Stomach,9,1,CHEMBL617853
2784,H,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,Expert,,,,,108,BAO_0000357,B,,13969,,8,1,CHEMBL617854
2785,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,8,1,CHEMBL873477
2786,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,8,1,CHEMBL617855
2787,H,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Expert,,,,,108,BAO_0000019,B,,14430,,8,1,CHEMBL617856
2788,H,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,Autocuration,,,,,108,BAO_0000019,B,,1742,,8,1,CHEMBL617857
2789,H,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,Autocuration,,,,,108,BAO_0000249,B,,14286,,8,1,CHEMBL617858
2790,H,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5619,,8,1,CHEMBL617859
2791,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,15086,,8,1,CHEMBL617860
2792,H,,,,Binding activity radioligand.,Autocuration,,,,,108,BAO_0000357,B,,12861,,8,1,CHEMBL617861
2793,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,108,BAO_0000019,B,,12861,,8,1,CHEMBL617862
2794,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,108,BAO_0000019,B,,12861,,8,1,CHEMBL617863
2795,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,Autocuration,,,,,108,BAO_0000249,B,,12827,,8,1,CHEMBL617864
2796,H,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,Autocuration,,,,,108,BAO_0000249,B,,12827,,8,1,CHEMBL617649
2797,H,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,,,108,BAO_0000019,F,,12919,,8,1,CHEMBL617650
2798,H,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,,,108,BAO_0000019,F,,12919,,8,1,CHEMBL617651
2799,H,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,16429,,8,1,CHEMBL617652
2800,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Autocuration,,,,,108,BAO_0000019,B,,773,,8,1,CHEMBL857072
2801,H,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5033,,8,1,CHEMBL617653
2802,H,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Autocuration,,,,,12687,BAO_0000019,B,,12861,,8,1,CHEMBL617654
2803,H,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000019,F,,14093,,8,1,CHEMBL617655
2804,H,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,14970,,8,1,CHEMBL617656
2805,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,14970,,8,1,CHEMBL617657
2806,H,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,Autocuration,,,,,12689,BAO_0000357,B,,14970,,8,1,CHEMBL617658
2807,D,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,14178,,9,1,CHEMBL617659
2808,D,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,14178,,9,1,CHEMBL617838
2809,D,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Expert,,,,,12689,BAO_0000249,B,Brain membranes,14229,,9,1,CHEMBL617839
2810,H,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,Autocuration,,,,,12689,BAO_0000357,B,,16532,,8,1,CHEMBL617840
2811,H,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,Autocuration,,,,,12689,BAO_0000019,B,,14826,,8,1,CHEMBL617841
2812,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,Autocuration,,,,,12689,BAO_0000019,B,,17211,,8,1,CHEMBL875915
2813,H,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,Expert,,,,,12689,BAO_0000219,B,,17211,,8,1,CHEMBL617842
2814,H,,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,Expert,,NIH3T3,,,12689,BAO_0000219,B,,13246,,8,1,CHEMBL617843
2815,H,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Expert,,,,,12689,BAO_0000357,B,,13246,,8,1,CHEMBL617844
2816,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,12457,,8,1,CHEMBL617845
2817,H,,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,Expert,,NIH3T3,,,12689,BAO_0000219,B,,12457,,8,1,CHEMBL617846
2818,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,4707,,8,1,CHEMBL617847
2819,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,13297,,8,1,CHEMBL617848
2820,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,16633,,8,1,CHEMBL617849
2821,H,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000357,B,,16133,,8,1,CHEMBL621507
2822,H,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,Expert,,,,,12689,BAO_0000357,B,,16326,,8,1,CHEMBL621508
2823,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,Autocuration,,,,,12689,BAO_0000019,B,,14423,,8,1,CHEMBL621509
2824,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,Autocuration,,,,,12689,BAO_0000019,B,,15412,,8,1,CHEMBL621510
2825,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,Autocuration,,,,,12689,BAO_0000019,B,,15412,,8,1,CHEMBL621511
2826,H,,625.0,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,Expert,,A9,,,12689,BAO_0000219,B,,15558,,8,1,CHEMBL621512
2827,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,16633,,8,1,CHEMBL621513
2828,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,Expert,,,,,12689,BAO_0000357,B,,6013,,8,1,CHEMBL621514
2829,H,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,Expert,,,,,12689,BAO_0000219,B,,17175,,8,1,CHEMBL621515
2830,H,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,Autocuration,,,,,12689,BAO_0000219,B,,12469,,8,1,CHEMBL621516
2831,H,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,5383.0,12689,BAO_0000019,B,,3682,Caudate-putamen,8,1,CHEMBL621517
2832,H,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,Autocuration,,,,,12689,BAO_0000357,B,,4932,,8,1,CHEMBL621518
2833,H,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,Autocuration,,,,,12689,BAO_0000019,B,,4932,,8,1,CHEMBL621519
2834,H,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,3935,,8,1,CHEMBL621520
2835,H,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15818,,8,1,CHEMBL621521
2836,H,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15818,,8,1,CHEMBL621522
2837,H,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,Expert,,,,,12689,BAO_0000219,B,,14749,,8,1,CHEMBL621523
2838,H,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,15740,,8,1,CHEMBL621524
2839,D,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Expert,,,,,12689,BAO_0000357,B,,17133,,9,1,CHEMBL621525
2840,H,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,Autocuration,,,,,12689,BAO_0000357,B,,16532,,8,1,CHEMBL872921
2841,H,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,12369,,8,1,CHEMBL621526
2842,H,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,Expert,,,,,12689,BAO_0000219,B,,12369,,8,1,CHEMBL621527
2843,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Expert,,,,,12689,BAO_0000019,B,,2309,,9,1,CHEMBL617865
2844,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000357,B,,12953,,8,1,CHEMBL617866
2845,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,Autocuration,,,,,12689,BAO_0000019,B,,12953,,8,1,CHEMBL617867
2846,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,Autocuration,,,,,12689,BAO_0000357,B,,12953,,8,1,CHEMBL617487
2847,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,12689,BAO_0000357,B,,12953,,8,1,CHEMBL617488
2848,H,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,Autocuration,,,,,12689,BAO_0000357,B,,17133,,8,1,CHEMBL617489
2849,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,Autocuration,,,,,12689,BAO_0000019,B,,17211,,8,1,CHEMBL617490
2850,H,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,Autocuration,,,,,12689,BAO_0000019,B,,17211,,8,1,CHEMBL617491
2851,H,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,Autocuration,,,,,12689,BAO_0000019,B,,14025,,8,1,CHEMBL617492
2852,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,Autocuration,,,,,12689,BAO_0000019,B,,14998,,8,1,CHEMBL617493
2853,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,12689,BAO_0000357,B,,4342,,8,1,CHEMBL617494
2854,D,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Expert,,,,,12689,BAO_0000019,B,,13735,,9,1,CHEMBL617495
2855,H,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,13181,,8,1,CHEMBL617496
2856,H,,485.0,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,Autocuration,,CHO-K1,,,12689,BAO_0000219,B,,1883,,8,1,CHEMBL617497
2857,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,12689,BAO_0000357,B,,15194,,8,1,CHEMBL617498
2858,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,Autocuration,,,,,12689,BAO_0000357,B,,15194,,8,1,CHEMBL617499
2859,H,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,12689,BAO_0000019,F,,14579,,8,1,CHEMBL617500
2860,H,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,4639,,8,1,CHEMBL617501
2861,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4820,,8,1,CHEMBL617502
2862,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,Autocuration,,,,,227,BAO_0000357,B,,14442,,8,1,CHEMBL617503
2863,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,227,BAO_0000357,B,,14755,,8,1,CHEMBL617504
2864,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,Autocuration,,,,,227,BAO_0000357,B,,14744,,8,1,CHEMBL617406
2865,D,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Expert,,,,,227,BAO_0000019,B,,6857,,9,1,CHEMBL617407
2866,H,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,Autocuration,,,,,227,BAO_0000357,B,,16209,,8,1,CHEMBL617408
2867,H,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,8,1,CHEMBL617409
2868,H,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,8,1,CHEMBL617410
2869,H,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,15363,,8,1,CHEMBL617411
2870,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000019,B,,17085,,8,1,CHEMBL617412
2871,D,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Expert,,,,,227,BAO_0000357,B,,17200,,9,1,CHEMBL617774
2872,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,9,1,CHEMBL617775
2873,D,,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,9,1,CHEMBL617776
2874,D,,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,227,BAO_0000219,F,,6857,,9,1,CHEMBL617777
2875,D,,449.0,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,CHO,,,227,BAO_0000219,F,,6857,,9,1,CHEMBL617778
2876,H,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,8,1,CHEMBL617779
2877,H,,722.0,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,8,1,CHEMBL617780
2878,H,,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,8,1,CHEMBL617781
2879,D,,722.0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Expert,,HEK293,,,227,BAO_0000219,B,,14157,,9,1,CHEMBL617782
2880,D,,722.0,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Expert,,HEK293,,,227,BAO_0000219,B,,4540,,9,1,CHEMBL617783
2881,H,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,6166,,8,1,CHEMBL617784
2882,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,Autocuration,,HEK293,,,227,BAO_0000219,B,,15779,,8,1,CHEMBL617785
2883,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,Expert,,HEK293,,,227,BAO_0000219,B,,14391,,8,1,CHEMBL857984
2884,H,,722.0,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,Expert,,HEK293,,,227,BAO_0000219,B,,3832,,8,1,CHEMBL617786
2885,H,,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,Expert,,HEK293,,,227,BAO_0000219,B,,3833,,8,1,CHEMBL617787
2886,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,9,1,CHEMBL617788
2887,D,,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Expert,,HEK293,,,227,BAO_0000219,B,,15851,,9,1,CHEMBL617789
2888,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,Autocuration,,HEK293,,,227,BAO_0000219,B,,4199,,8,1,CHEMBL617790
2889,H,,485.0,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,Expert,,CHO-K1,,,227,BAO_0000219,B,,1883,,8,1,CHEMBL617791
2890,H,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,Expert,,,,,227,BAO_0000357,B,,4321,,8,1,CHEMBL617608
2891,H,,722.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,Autocuration,,HEK293,,,227,BAO_0000219,B,,15146,,8,1,CHEMBL617609
2892,H,,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,HEK293,,,227,BAO_0000219,B,,5213,,8,1,CHEMBL617610
2893,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,Autocuration,,HEK293,,,227,BAO_0000219,B,,14818,,8,1,CHEMBL617611
2894,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,4829,,8,1,CHEMBL617612
2895,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,HEK293,,,227,BAO_0000219,B,,4829,,8,1,CHEMBL617613
2896,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Autocuration,,,,,227,BAO_0000019,B,,14025,,8,1,CHEMBL617614
2897,H,,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Expert,,,,945.0,12688,BAO_0000019,B,,13463,Stomach,8,1,CHEMBL617615
2898,H,,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Expert,,,,945.0,12688,BAO_0000357,B,,7259,Stomach,8,1,CHEMBL858114
2899,H,,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000357,B,,7259,Stomach,8,1,CHEMBL617616
2900,D,,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Expert,,,,945.0,12688,BAO_0000019,F,,7185,Stomach,9,1,CHEMBL617617
2901,D,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,Expert,,,,,12688,BAO_0000019,F,,7185,,9,1,CHEMBL875914
2902,H,,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,13267,Stomach,8,1,CHEMBL617618
2903,D,,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Expert,,,,945.0,12688,BAO_0000357,B,,13735,Stomach,9,1,CHEMBL617619
2904,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Autocuration,,,,,12688,BAO_0000019,F,,15738,,8,1,CHEMBL617620
2905,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,Autocuration,,,,,12688,BAO_0000019,F,,15738,,8,1,CHEMBL617621
2906,H,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,Autocuration,,,,,12688,BAO_0000019,F,,15738,,8,1,CHEMBL617622
2907,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,Stomach,9,1,CHEMBL617623
2908,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,Stomach,9,1,CHEMBL617624
2909,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,Stomach,9,1,CHEMBL617625
2910,D,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,,945.0,12688,BAO_0000357,B,,12936,Stomach,9,1,CHEMBL617626
2911,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,8,1,CHEMBL617627
2912,H,,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Expert,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,8,1,CHEMBL617628
2913,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,8,1,CHEMBL617629
2914,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,8,1,CHEMBL858115
2915,D,,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Expert,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,9,1,CHEMBL617630
2916,H,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Autocuration,,,,1515.0,12688,BAO_0000019,F,,16404,Thoracic aorta,8,1,CHEMBL617631
2917,H,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,8,1,CHEMBL617632
2918,H,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,Expert,,,,,12688,BAO_0000357,B,,7483,,8,1,CHEMBL617633
2919,H,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,8,1,CHEMBL617634
2920,H,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,12688,BAO_0000357,B,,7483,,8,1,CHEMBL617635
2922,D,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,,945.0,12688,BAO_0000019,F,,16404,Stomach,9,1,CHEMBL617637
2923,H,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,227,BAO_0000357,B,,6347,,8,1,CHEMBL617638
2924,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,4373,,8,1,CHEMBL617639
2925,H,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,227,BAO_0000357,B,,4373,,8,1,CHEMBL617640
2926,H,,,,Evaluated for the binding affinity to 5-HT 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,4687,,8,1,CHEMBL617641
2927,H,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16946,,8,1,CHEMBL617642
2928,H,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16633,,8,1,CHEMBL617643
2929,H,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,227,BAO_0000357,B,,16633,,8,1,CHEMBL617644
2930,H,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,Autocuration,,,,,227,BAO_0000357,B,,16633,,8,1,CHEMBL617645
2931,H,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,,,108,BAO_0000357,B,,15026,,8,1,CHEMBL617646
2932,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,,,108,BAO_0000357,B,,15738,,8,1,CHEMBL617647
2933,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,8,1,CHEMBL617648
2934,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,8,1,CHEMBL617875
2935,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Autocuration,,,,,108,BAO_0000357,B,,15738,,8,1,CHEMBL617876
2936,H,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Expert,,,,,108,BAO_0000357,B,,16404,,8,1,CHEMBL617877
2937,H,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,,,108,BAO_0000357,B,,15026,,8,1,CHEMBL617878
2938,H,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,,,108,BAO_0000357,B,,15738,,8,1,CHEMBL617879
2939,H,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Autocuration,,,,,108,BAO_0000019,B,,16312,,8,1,CHEMBL617880
2940,D,,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,5486,Striatum,9,1,CHEMBL617881
2941,H,,,,Binding affinity against 5-HT1A receptor,Autocuration,,,,,51,BAO_0000357,B,,5254,,8,1,CHEMBL857073
2942,H,,449.0,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,Expert,,CHO,,,108,BAO_0000219,F,,3857,,8,1,CHEMBL617882
2943,D,,449.0,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,CHO,,,108,BAO_0000219,F,,6857,,9,1,CHEMBL617883
2944,H,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,Autocuration,,,,,108,BAO_0000219,F,,4176,,8,1,CHEMBL617884
2945,H,,449.0,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,Autocuration,,CHO,,,108,BAO_0000219,B,,6347,,8,1,CHEMBL617885
2946,H,,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",Autocuration,,CHO,,,108,BAO_0000219,B,,6347,,8,1,CHEMBL617886
2947,D,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,16146,,9,1,CHEMBL617887
2948,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),Autocuration,,,,,108,BAO_0000357,B,,3805,,8,1,CHEMBL617888
2949,H,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Autocuration,,,,,108,BAO_0000019,B,,3857,,8,1,CHEMBL617889
2950,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5635,,8,1,CHEMBL617890
2951,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,108,BAO_0000357,B,,5635,,8,1,CHEMBL617891
2952,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,108,BAO_0000357,B,,5635,,8,1,CHEMBL617892
2953,H,,449.0,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,Expert,,CHO,,,108,BAO_0000219,B,,4012,,8,1,CHEMBL617893
2954,H,,449.0,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,6366,,8,1,CHEMBL617894
2955,H,,449.0,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,15949,,8,1,CHEMBL617895
2956,H,,449.0,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,Autocuration,,CHO,,,108,BAO_0000219,B,,17211,,8,1,CHEMBL617896
2957,D,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Expert,,,,,108,BAO_0000357,B,,6491,,9,1,CHEMBL617897
2958,H,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,Autocuration,,,,,108,BAO_0000019,F,,14093,,8,1,CHEMBL617898
2959,H,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,108,BAO_0000019,F,,13481,,8,1,CHEMBL617899
2960,H,,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Expert,,CHO,,,108,BAO_0000219,B,,6347,,8,1,CHEMBL617900
2961,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,Autocuration,,,,,108,BAO_0000019,F,,14093,,8,1,CHEMBL617901
2962,H,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,Autocuration,,,,,108,BAO_0000019,F,,14093,,8,1,CHEMBL617902
2963,H,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000019,F,,13481,,8,1,CHEMBL617903
2964,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,Autocuration,,,,,108,BAO_0000357,B,,14442,,8,1,CHEMBL617904
2965,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,14442,,8,1,CHEMBL617905
2966,H,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,Autocuration,,,,,108,BAO_0000357,B,,14442,,8,1,CHEMBL617906
2967,H,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,Autocuration,,,,,108,BAO_0000357,B,,14755,,8,1,CHEMBL617907
2968,H,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,Autocuration,,,,,108,BAO_0000357,B,,14744,,8,1,CHEMBL617908
2969,H,,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,CHO,,,108,BAO_0000219,B,,16659,,8,1,CHEMBL620617
2970,D,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Expert,,,,,108,BAO_0000019,B,,6857,,9,1,CHEMBL620618
2971,H,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,Expert,,,,,108,BAO_0000357,B,,5635,,8,1,CHEMBL620619
2972,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,4234,,9,1,CHEMBL620620
2973,H,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,108,BAO_0000357,B,,16209,,8,1,CHEMBL620621
2974,D,,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Autocuration,,,,,104698,BAO_0000249,B,Membranes,5778,,7,1,CHEMBL872920
2975,H,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,Autocuration,,,,,104698,BAO_0000223,B,,5094,,6,1,CHEMBL620622
2976,D,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,809,,7,1,CHEMBL620623
2977,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,1578,,6,1,CHEMBL620624
2978,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,Autocuration,,,,,104698,BAO_0000019,B,,809,,6,1,CHEMBL620625
2979,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,Autocuration,,,,,104698,BAO_0000219,B,,12469,,6,1,CHEMBL620626
2980,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,Autocuration,,,,,104698,BAO_0000019,B,,14290,,6,1,CHEMBL621307
2981,H,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,Autocuration,,,,,104698,BAO_0000019,B,,14290,,6,1,CHEMBL621308
2982,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Autocuration,,,,,104698,BAO_0000223,B,,10609,,6,1,CHEMBL621309
2983,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Autocuration,,,,,104698,BAO_0000223,B,,10609,,6,1,CHEMBL621310
2984,H,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Autocuration,,,,,104698,BAO_0000223,B,,10609,,6,1,CHEMBL621311
2985,H,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,104698,BAO_0000249,B,,15253,,6,1,CHEMBL621502
2986,H,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,104698,BAO_0000249,B,,15253,,6,1,CHEMBL621503
2987,H,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Autocuration,,,,,104698,BAO_0000249,B,Membranes,11683,,6,1,CHEMBL621504
2988,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12092,,6,1,CHEMBL621505
2989,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,1946,,6,1,CHEMBL621506
2990,H,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Autocuration,,,,,104698,BAO_0000223,B,,11623,,6,1,CHEMBL619781
2991,H,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,Autocuration,,,,,104698,BAO_0000223,B,,11623,,6,1,CHEMBL619782
2992,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,14788,,6,1,CHEMBL619783
2993,D,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,5432,,7,1,CHEMBL619784
2994,H,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,14826,,6,1,CHEMBL619785
2995,H,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,2222,,6,1,CHEMBL619786
2996,H,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,11963,,6,1,CHEMBL619787
2997,H,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Autocuration,,,,,104698,BAO_0000019,B,,14145,,6,1,CHEMBL872925
2998,H,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,Autocuration,,,,,104698,BAO_0000019,B,,17819,,6,1,CHEMBL619788
2999,H,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,104698,BAO_0000249,B,,10394,,6,1,CHEMBL619789
3000,H,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,104698,BAO_0000249,B,,10394,,6,1,CHEMBL619790
3001,H,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15034,,6,1,CHEMBL619791
3002,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,691,,6,1,CHEMBL619792
3003,H,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Autocuration,,,,,104698,BAO_0000249,B,Membranes,12092,,6,1,CHEMBL619793
3004,D,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,11752,,7,1,CHEMBL619794
3005,H,,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Autocuration,,,,955.0,104698,BAO_0000221,B,,11752,Brain,6,1,CHEMBL619795
3006,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,Autocuration,,,,,104698,BAO_0000019,B,,301,,6,1,CHEMBL619796
3007,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,Autocuration,,,,,104698,BAO_0000223,B,,16532,,6,1,CHEMBL620448
3008,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,104698,BAO_0000223,B,,16532,,6,1,CHEMBL620449
3009,H,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,12092,,6,1,CHEMBL620450
3010,H,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,Autocuration,,,,,104698,BAO_0000223,B,,11684,,6,1,CHEMBL620451
3011,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Autocuration,,,,,104698,BAO_0000223,B,,11684,,6,1,CHEMBL620631
3012,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,12953,,6,1,CHEMBL620632
3013,H,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,Autocuration,,,,,104698,BAO_0000019,B,,12953,,6,1,CHEMBL620633
3014,H,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,Autocuration,,,,,104698,BAO_0000223,B,,12953,,6,1,CHEMBL620634
3015,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,104698,BAO_0000019,B,,12861,,6,1,CHEMBL620635
3016,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620636
3017,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620637
3018,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620638
3019,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620639
3020,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620640
3021,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620641
3022,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620642
3023,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620643
3024,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620644
3025,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620645
3026,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620646
3027,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620647
3028,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620648
3029,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620649
3030,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620650
3031,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620651
3032,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL872875
3033,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL620652
3034,H,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Autocuration,,,,,104698,BAO_0000019,F,,10609,,6,1,CHEMBL620653
3035,H,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,Autocuration,,,,,104698,BAO_0000019,B,,12861,,6,1,CHEMBL857076
3036,D,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,12861,,7,1,CHEMBL620654
3037,H,,,,Binding activity radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,12861,,6,1,CHEMBL620655
3038,H,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,6,1,CHEMBL620656
3039,H,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,6,1,CHEMBL620657
3040,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,108,BAO_0000357,B,,5163,,8,1,CHEMBL620658
3041,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,108,BAO_0000357,B,,5163,,8,1,CHEMBL620659
3042,H,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,Autocuration,,,,,108,BAO_0000357,B,,6011,,8,1,CHEMBL620660
3043,H,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5014,,8,1,CHEMBL620661
3044,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,5635,,8,1,CHEMBL620662
3045,H,,,,Affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,5163,,8,1,CHEMBL620663
3046,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,108,BAO_0000357,B,,6841,,8,1,CHEMBL620664
3047,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,Expert,,,,,108,BAO_0000357,B,,6119,,8,1,CHEMBL620665
3048,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,4373,,8,1,CHEMBL620666
3049,H,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,Autocuration,,,,,108,BAO_0000357,B,,1633,,8,1,CHEMBL620667
3050,H,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,Expert,,,,,108,BAO_0000357,B,,1633,,8,1,CHEMBL620668
3051,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,108,BAO_0000357,B,,4373,,8,1,CHEMBL620669
3052,H,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,6576,,8,1,CHEMBL620670
3053,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,4687,,8,1,CHEMBL620671
3054,H,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,Autocuration,,,,,108,BAO_0000357,B,,12146,,8,1,CHEMBL620672
3055,H,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,Autocuration,,,,,108,BAO_0000357,B,,12146,,8,1,CHEMBL620673
3056,H,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,16946,,8,1,CHEMBL620674
3057,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,14159,,8,1,CHEMBL620675
3058,H,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,Autocuration,,,,,108,BAO_0000357,B,,16700,,8,1,CHEMBL620676
3059,H,,,,Affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,108,BAO_0000357,B,,3269,,8,1,CHEMBL621382
3060,D,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,1274,,9,1,CHEMBL621383
3061,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,Autocuration,,,,,108,BAO_0000357,B,,1317,,8,1,CHEMBL621384
3062,H,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Autocuration,,,,,144,BAO_0000357,B,,5834,,8,1,CHEMBL621385
3063,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Autocuration,,,,,144,BAO_0000357,B,,11147,,8,1,CHEMBL617989
3064,H,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Expert,,,,,104714,BAO_0000019,F,,14145,,4,1,CHEMBL617990
3065,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,10561,Ileum,4,1,CHEMBL875085
3066,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Autocuration,,,,,104714,BAO_0000019,F,,15847,,4,1,CHEMBL617991
3067,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Autocuration,,,,,104714,BAO_0000019,F,,15847,,4,1,CHEMBL617992
3068,H,,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,10561,Ileum,4,1,CHEMBL617993
3069,H,,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Autocuration,,,,2116.0,104714,BAO_0000221,B,,11454,Ileum,4,1,CHEMBL617994
3070,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL617995
3071,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL617996
3072,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL617997
3073,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL617998
3074,H,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL617999
3075,H,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618000
3076,H,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Autocuration,,,,2116.0,104714,BAO_0000221,F,,15253,Ileum,4,1,CHEMBL617815
3077,H,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Autocuration,,,,2116.0,104714,BAO_0000221,F,,15253,Ileum,4,1,CHEMBL617816
3078,H,,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,F,,11963,Ileum,4,1,CHEMBL617817
3079,H,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1946,Ileum,4,1,CHEMBL617818
3080,H,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1946,Ileum,4,1,CHEMBL617819
3081,H,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Autocuration,,,,,104714,BAO_0000223,B,,12045,,4,1,CHEMBL617820
3082,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,Ileum,4,1,CHEMBL617821
3083,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,Ileum,4,1,CHEMBL617822
3084,H,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,Ileum,4,1,CHEMBL617823
3085,H,,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Autocuration,,,,2116.0,104714,BAO_0000221,F,,188,Ileum,4,1,CHEMBL617824
3086,H,,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Autocuration,,,,2116.0,104714,BAO_0000221,F,,12919,Ileum,4,1,CHEMBL617825
3087,H,,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Autocuration,,,,2116.0,104714,BAO_0000221,F,,12918,Ileum,4,1,CHEMBL617826
3088,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,Ileum,4,1,CHEMBL617827
3089,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,Ileum,4,1,CHEMBL617828
3090,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,Ileum,4,1,CHEMBL617829
3091,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,Ileum,4,1,CHEMBL617830
3092,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Autocuration,,,,2116.0,104714,BAO_0000221,B,,1559,Ileum,4,1,CHEMBL617831
3093,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Autocuration,,,,2116.0,104714,BAO_0000221,B,,14424,Ileum,4,1,CHEMBL617832
3094,U,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,22226,BAO_0000019,B,,13181,,0,1,CHEMBL617833
3095,H,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,Autocuration,,,,,51,BAO_0000357,B,,5486,,8,1,CHEMBL617834
3096,D,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Expert,,,,,104714,BAO_0000223,B,,6491,,5,1,CHEMBL617835
3097,H,,,,Binding affinity towards 5-HT3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,6013,,4,1,CHEMBL617836
3098,H,,,,Binding activity radioligand.,Autocuration,,,,,104714,BAO_0000223,B,,12861,,4,1,CHEMBL617837
3099,H,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,,,104714,BAO_0000019,B,,12861,,4,1,CHEMBL620392
3100,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5104,,4,1,CHEMBL620393
3101,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5105,,4,1,CHEMBL620394
3102,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,Autocuration,,,,,104714,BAO_0000223,B,,5104,,4,1,CHEMBL620395
3103,U,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,Autocuration,,,,,22226,BAO_0000019,B,,3935,,0,1,CHEMBL620396
3104,H,,433.0,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,Expert,,NG108-15,,,105030,BAO_0000219,B,,13657,,4,1,CHEMBL620582
3105,H,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",Autocuration,,,,,105030,BAO_0000218,B,,10369,,4,1,CHEMBL620583
3106,H,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,105030,BAO_0000019,B,,10369,,4,1,CHEMBL620584
3107,H,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,Autocuration,,,,,105030,BAO_0000224,B,,12918,,4,1,CHEMBL620585
3108,H,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,Autocuration,,,,,105030,BAO_0000224,B,,12918,,4,1,CHEMBL620586
3109,H,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,105030,BAO_0000019,B,,10369,,4,1,CHEMBL620587
3110,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,105030,BAO_0000019,B,,773,,4,1,CHEMBL620588
3111,H,,,,5-hydroxytryptamine 3 receptor agonism in mouse,Autocuration,,,,,105030,BAO_0000218,F,,12918,,4,1,CHEMBL620589
3112,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Autocuration,,,,,105030,BAO_0000219,B,,10561,,4,1,CHEMBL620590
3113,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,105030,BAO_0000019,B,,12827,,4,1,CHEMBL617956
3114,H,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,105030,BAO_0000019,B,,12827,,4,1,CHEMBL617957
3115,H,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,Autocuration,,,,,105030,BAO_0000224,B,,12918,,4,1,CHEMBL617958
3116,H,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,105030,BAO_0000219,B,,273,,4,1,CHEMBL617959
3117,H,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,105030,BAO_0000219,B,,273,,4,1,CHEMBL617960
3118,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,,,105030,BAO_0000224,B,,10561,,4,1,CHEMBL617961
3119,H,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,Autocuration,,,,,105030,BAO_0000219,B,,5033,,4,1,CHEMBL617962
3120,H,,339.0,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,Autocuration,,N1E-115,,,105030,BAO_0000219,B,,16429,,4,1,CHEMBL617963
3121,H,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,11765,BAO_0000019,B,,10322,,8,1,CHEMBL617964
3122,H,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,Autocuration,,,,,11765,BAO_0000219,B,,14331,,8,1,CHEMBL617965
3123,D,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Autocuration,,,,,10630,BAO_0000357,B,,13462,,9,1,CHEMBL617966
3124,H,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,17106,BAO_0000019,B,,12861,,8,1,CHEMBL857074
3125,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15086,,8,1,CHEMBL617967
3126,H,,,,Binding activity radioligand.,Autocuration,,,,,144,BAO_0000357,B,,12861,,8,1,CHEMBL617968
3127,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Autocuration,,,,,104714,BAO_0000223,B,,10561,,4,1,CHEMBL617969
3128,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,,,104714,BAO_0000223,B,,10561,,4,1,CHEMBL617970
3129,H,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Autocuration,,,,,104714,BAO_0000223,B,,10561,,4,1,CHEMBL617971
3130,H,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,,,104714,BAO_0000019,B,,10561,,4,1,CHEMBL617972
3131,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617973
3132,H,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617974
3133,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,,2116.0,104714,BAO_0000221,F,,273,Ileum,4,1,CHEMBL617975
3134,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617976
3135,H,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617977
3136,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617978
3137,H,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,,,104714,BAO_0000019,F,,273,,4,1,CHEMBL617979
3138,H,,449.0,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,104714,BAO_0000219,B,,13047,,4,1,CHEMBL617980
3139,D,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,1650,,7,1,CHEMBL617981
3140,H,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),Autocuration,,,,,12020,BAO_0000019,B,,16288,,8,1,CHEMBL617982
3141,H,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),Autocuration,,,,,12020,BAO_0000357,B,,16288,,8,1,CHEMBL617983
3142,D,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Autocuration,,,,,104698,BAO_0000019,B,,10254,,7,1,CHEMBL617984
3143,H,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",Autocuration,,,,,104698,BAO_0000019,B,,14532,,6,1,CHEMBL617985
3144,H,,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000218,F,,13392,Heart,6,1,CHEMBL617986
3145,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,Heart,6,1,CHEMBL617987
3146,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,Heart,6,1,CHEMBL617988
3147,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,Heart,6,1,CHEMBL617792
3148,H,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,948.0,104698,BAO_0000019,F,,13392,Heart,6,1,CHEMBL617793
3149,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,6,1,CHEMBL617794
3150,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,6,1,CHEMBL617795
3151,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,6,1,CHEMBL617796
3152,H,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,104698,BAO_0000019,F,,13392,,6,1,CHEMBL617797
3153,D,,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,,,104698,BAO_0000218,F,,1089,,7,1,CHEMBL617798
3154,H,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),Autocuration,,,,,104698,BAO_0000218,F,,1089,,6,1,CHEMBL617799
3155,D,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,7,1,CHEMBL617800
3156,D,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Autocuration,,,,,104698,BAO_0000019,F,,11454,,7,1,CHEMBL617801
3157,D,,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Autocuration,,,,,104698,BAO_0000218,F,,12205,,7,1,CHEMBL617802
3158,D,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,,,104698,BAO_0000019,F,,1089,,7,1,CHEMBL617803
3159,H,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,104698,BAO_0000019,B,,5094,,6,1,CHEMBL617804
3160,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,2622,,7,1,CHEMBL617805
3161,H,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,245,,6,1,CHEMBL617806
3162,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,Autocuration,,,,,104698,BAO_0000019,B,,14788,,6,1,CHEMBL617807
3163,H,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,Autocuration,,,,,104698,BAO_0000019,B,,14788,,6,1,CHEMBL617808
3164,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,Autocuration,,,,,104698,BAO_0000249,B,,3020,,6,1,CHEMBL617809
3165,H,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,Autocuration,,,,,104698,BAO_0000019,B,,1742,,6,1,CHEMBL617810
3166,H,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Autocuration,,,,955.0,104698,BAO_0000249,B,,17394,Brain,6,1,CHEMBL617811
3167,H,,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Autocuration,,,,955.0,104698,BAO_0000221,B,,17394,Brain,6,1,CHEMBL617812
3168,H,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,17394,,6,1,CHEMBL617813
3169,H,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,104698,BAO_0000249,B,,14286,,6,1,CHEMBL617814
3170,H,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,Autocuration,,,,,104698,BAO_0000019,B,,14178,,6,1,CHEMBL617698
3171,D,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Autocuration,,,,,104698,BAO_0000019,B,,14178,,7,1,CHEMBL617699
3172,D,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Autocuration,,,,,104698,BAO_0000019,B,,14178,,7,1,CHEMBL617700
3173,D,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,14178,,7,1,CHEMBL617701
3174,H,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15034,,6,1,CHEMBL617702
3175,H,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Autocuration,,,,,104698,BAO_0000249,B,Membranes,1089,,6,1,CHEMBL617703
3176,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,1089,,7,1,CHEMBL617704
3177,H,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,104698,BAO_0000223,B,,16532,,6,1,CHEMBL617705
3178,D,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12801,,7,1,CHEMBL617706
3179,H,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),Autocuration,,NG108-15,,,104698,BAO_0000219,B,,15194,,6,1,CHEMBL617707
3180,H,,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,Autocuration,,NG108-15,,,104698,BAO_0000219,B,,15194,,6,1,CHEMBL617708
3181,H,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,15194,,6,1,CHEMBL617709
3182,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,6,1,CHEMBL617710
3183,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,6,1,CHEMBL882925
3184,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,Autocuration,,,,,104698,BAO_0000019,B,,15194,,6,1,CHEMBL617711
3185,H,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Autocuration,,,,,104698,BAO_0000019,F,,10610,,6,1,CHEMBL617712
3186,D,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Autocuration,,,,,104698,BAO_0000019,F,,10355,,7,1,CHEMBL617713
3187,H,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",Autocuration,,,,,104698,BAO_0000019,F,,691,,6,1,CHEMBL617714
3188,H,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,Autocuration,,,,,104698,BAO_0000218,F,,10611,,6,1,CHEMBL617715
3189,H,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,Autocuration,,,,,104698,BAO_0000218,F,,12801,,6,1,CHEMBL617716
3190,H,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,Autocuration,,,,,104698,BAO_0000218,F,,10609,,6,1,CHEMBL617717
3191,H,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617718
3192,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617719
3193,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617720
3194,D,,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,7,1,CHEMBL617721
3195,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617722
3196,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617723
3197,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617724
3198,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617725
3199,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617726
3200,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617727
3201,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617728
3202,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617729
3203,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617730
3204,H,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617731
3205,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617732
3206,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617733
3207,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617734
3208,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL872874
3209,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617735
3210,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617736
3211,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617737
3212,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617738
3213,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617739
3214,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617740
3215,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617741
3216,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617742
3217,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617743
3218,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617744
3219,H,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,104698,BAO_0000218,F,,11454,,6,1,CHEMBL617745
3220,H,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",Autocuration,,,,,104698,BAO_0000218,F,,670,,6,1,CHEMBL617746
3221,H,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",Autocuration,,,,,104698,BAO_0000218,F,,670,,6,1,CHEMBL617747
3222,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,,6,1,CHEMBL617748
3223,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,,6,1,CHEMBL618909
3224,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,,6,1,CHEMBL618910
3225,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,,6,1,CHEMBL618911
3226,H,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,Autocuration,,,,,104698,BAO_0000218,F,,10321,,6,1,CHEMBL618912
3227,H,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),Autocuration,,,,,104698,BAO_0000218,F,,10322,,6,1,CHEMBL618913
3228,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,6,1,CHEMBL618914
3229,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,6,1,CHEMBL618915
3230,D,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,15412,,7,1,CHEMBL618916
3231,H,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,Autocuration,,,,,104698,BAO_0000019,F,,15412,,6,1,CHEMBL618917
3232,D,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Intermediate,,,,10000000.0,104698,BAO_0000221,B,,15412,Hippocampus,7,1,CHEMBL618918
3233,D,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Autocuration,,,,,104698,BAO_0000019,B,,15412,,7,1,CHEMBL618919
3234,D,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,17394,,7,1,CHEMBL618920
3235,H,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12457,,6,1,CHEMBL618921
3236,H,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,12457,,6,1,CHEMBL618922
3237,H,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Autocuration,,,,,104698,BAO_0000019,B,,12205,,6,1,CHEMBL618923
3238,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Autocuration,,,,,104698,BAO_0000019,B,,14532,,6,1,CHEMBL618924
3239,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,1122,,6,1,CHEMBL618925
3240,H,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,104698,BAO_0000019,B,,5094,,6,1,CHEMBL618926
3241,D,,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL618927
3242,D,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL618928
3243,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL618929
3244,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL618930
3245,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL618931
3246,D,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619594
3247,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619595
3248,D,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL619596
3249,D,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL619755
3250,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL619756
3251,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL619757
3252,D,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL619758
3253,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619759
3254,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619760
3255,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619761
3256,D,,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619762
3257,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL619763
3258,D,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,,2116.0,20033,BAO_0000221,F,,14290,Ileum,9,1,CHEMBL617868
3259,D,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,,,20033,BAO_0000357,B,,15034,,9,1,CHEMBL617869
3260,D,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,Striatum,9,1,CHEMBL882926
3261,D,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,Striatum,9,1,CHEMBL617870
3262,D,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,5399,Striatum,9,1,CHEMBL617871
3263,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,Striatum,9,1,CHEMBL617872
3264,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,Striatum,9,1,CHEMBL617873
3265,D,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,Striatum,9,1,CHEMBL617874
3266,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL619067
3267,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL619068
3268,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL619069
3269,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Intermediate,,,,,20033,BAO_0000357,B,,16946,,9,1,CHEMBL619070
3270,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Intermediate,,,,,20033,BAO_0000357,B,,16946,,9,1,CHEMBL619071
3271,D,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,15034,,9,1,CHEMBL619072
3272,D,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Intermediate,,,,,20033,BAO_0000019,F,,15034,,9,1,CHEMBL619073
3273,D,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,12918,,9,1,CHEMBL619074
3274,D,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,16946,,9,1,CHEMBL619075
3275,D,,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,,2435.0,20033,BAO_0000357,B,,17394,Striatum,9,1,CHEMBL619076
3276,D,,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,15034,Striatum,9,1,CHEMBL619077
3277,D,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,Striatum,9,1,CHEMBL619078
3278,D,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,,2435.0,20033,BAO_0000249,B,,5094,Striatum,9,1,CHEMBL619079
3279,D,,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,Ileum,9,1,CHEMBL619080
3280,D,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Expert,,,,,20033,BAO_0000357,B,,12953,,9,1,CHEMBL619081
3281,D,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,,,20033,BAO_0000357,B,,12953,,9,1,CHEMBL619082
3282,D,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Intermediate,,,,,20033,BAO_0000357,B,,12953,,9,1,CHEMBL619083
3283,D,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,,,20033,BAO_0000357,B,,12953,,9,1,CHEMBL619084
3284,D,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL859397
3285,D,,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12918,Ileum,9,1,CHEMBL619085
3286,D,,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Intermediate,,,,2116.0,20033,BAO_0000221,F,,12919,Ileum,9,1,CHEMBL619086
3287,D,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL619087
3288,D,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,273,Ileum,9,1,CHEMBL619088
3289,D,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Intermediate,,,,,20033,BAO_0000357,B,,13181,,9,1,CHEMBL619089
3290,H,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,168,BAO_0000357,B,,13181,,8,1,CHEMBL619090
3291,D,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000019,F,,15034,,9,1,CHEMBL619091
3292,D,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,5033,,9,1,CHEMBL619092
3293,D,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Intermediate,,,,,20033,BAO_0000019,B,,1980,,9,1,CHEMBL619093
3294,H,,722.0,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Autocuration,,HEK293,,,168,BAO_0000219,B,,13181,,8,1,CHEMBL619094
3295,D,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Intermediate,,,,,20033,BAO_0000019,B,,14287,,9,1,CHEMBL619095
3296,D,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Intermediate,,,,,20033,BAO_0000357,B,,1317,,9,1,CHEMBL857988
3297,D,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Intermediate,,,,,20033,BAO_0000357,B,,15316,,9,1,CHEMBL619096
3298,D,,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Intermediate,,,,2435.0,20033,BAO_0000357,B,,16429,Striatum,9,1,CHEMBL619097
3299,D,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Intermediate,,,,10000000.0,20033,BAO_0000221,B,,14818,Hippocampus,9,1,CHEMBL619098
3300,D,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Intermediate,,,,,20033,BAO_0000357,B,,15194,,9,1,CHEMBL619751
3301,D,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Intermediate,,,,,20033,BAO_0000357,B,,15194,,9,1,CHEMBL619752
3302,D,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,,2116.0,20033,BAO_0000221,F,,13961,Ileum,9,1,CHEMBL875096
3303,H,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,Autocuration,,,,,108,BAO_0000357,B,,5486,,8,1,CHEMBL619004
3304,H,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,Autocuration,,,,,168,BAO_0000357,B,,16209,,8,1,CHEMBL619005
3305,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000019,B,,17085,,8,1,CHEMBL619006
3306,H,,308.0,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,Autocuration,,HeLa,,,168,BAO_0000219,B,,4199,,8,1,CHEMBL619007
3307,H,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,15146,,8,1,CHEMBL619008
3308,H,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,5213,,8,1,CHEMBL619009
3309,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",Autocuration,,HeLa,,,168,BAO_0000219,B,,4829,,8,1,CHEMBL619010
3310,H,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,Autocuration,,,,,10622,BAO_0000357,B,,17358,,8,1,CHEMBL619011
3311,H,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,Autocuration,,,,,10622,BAO_0000357,B,,17358,,8,1,CHEMBL619012
3312,H,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,Autocuration,,,,,10622,BAO_0000219,B,,16946,,8,1,CHEMBL619013
3313,H,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,Autocuration,,,,,10622,BAO_0000357,B,,17358,,8,1,CHEMBL619014
3314,H,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Autocuration,,,,2081.0,11249,BAO_0000019,F,,268,Cardiac atrium,8,1,CHEMBL857503
3315,H,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Autocuration,,,,2081.0,11249,BAO_0000019,F,,268,Cardiac atrium,8,1,CHEMBL619015
3316,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,11249,BAO_0000357,B,,15086,,8,1,CHEMBL619016
3317,H,,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Autocuration,,,,10000000.0,11249,BAO_0000221,B,,14875,Hippocampus,8,1,CHEMBL619017
3318,H,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Autocuration,,,,10000000.0,168,BAO_0000221,B,,13267,Hippocampus,8,1,CHEMBL619018
3319,H,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Autocuration,,,,,168,BAO_0000019,B,,13047,,8,1,CHEMBL619019
3320,D,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,1650,,9,1,CHEMBL619020
3321,H,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,567,,8,1,CHEMBL619021
3322,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,Autocuration,,,,,10623,BAO_0000357,B,,17358,,8,1,CHEMBL619022
3323,H,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,Autocuration,,,,,10623,BAO_0000357,B,,188,,8,1,CHEMBL619023
3324,H,,,,lntrinsic activity relative to 5-HT receptor,Autocuration,,,,,10623,BAO_0000019,F,,670,,8,1,CHEMBL619024
3325,H,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,Autocuration,,,,,10623,BAO_0000019,F,,204,,8,1,CHEMBL619025
3326,H,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,Expert,,,,,10623,BAO_0000019,F,,1946,,8,1,CHEMBL619026
3327,H,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,Autocuration,,,,,10623,BAO_0000019,F,,6398,,8,1,CHEMBL619027
3328,H,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,Autocuration,,,,,10623,BAO_0000019,F,,6398,,8,1,CHEMBL619028
3329,H,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,17358,,8,1,CHEMBL619029
3330,H,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,Autocuration,,,,,10623,BAO_0000019,F,,6398,,8,1,CHEMBL619030
3331,H,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,Expert,,,,,10623,BAO_0000357,B,,11752,,8,1,CHEMBL619031
3332,H,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,809,,8,1,CHEMBL619032
3333,D,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,14178,,9,1,CHEMBL619033
3334,H,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,10623,BAO_0000357,B,,567,,8,1,CHEMBL619034
3335,H,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,Autocuration,,,,,10623,BAO_0000357,B,,1946,,8,1,CHEMBL619035
3336,H,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,Autocuration,,,,,10623,BAO_0000357,B,,1946,,8,1,CHEMBL619036
3337,D,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Expert,,,,,10623,BAO_0000019,B,,13961,,9,1,CHEMBL619037
3338,H,,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Autocuration,,,,2435.0,10623,BAO_0000249,B,,6238,Striatum,8,1,CHEMBL619038
3339,H,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,Autocuration,,,,,10623,BAO_0000249,B,,14290,,8,1,CHEMBL619039
3340,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,Expert,,,,,10623,BAO_0000249,B,,14290,,8,1,CHEMBL619040
3341,D,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Expert,,,,2435.0,10623,BAO_0000019,B,,809,Striatum,9,1,CHEMBL619041
3342,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Autocuration,,,,2435.0,10623,BAO_0000019,B,,1578,Striatum,8,1,CHEMBL619042
3343,H,,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,16709,Striatum,8,1,CHEMBL619043
3344,H,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Expert,,,,2435.0,10623,BAO_0000019,B,,1946,Striatum,8,1,CHEMBL619044
3345,H,,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Expert,,,,2435.0,10623,BAO_0000249,B,,15253,Striatum,8,1,CHEMBL619045
3346,H,,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,4535,Striatum,8,1,CHEMBL619046
3347,H,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,Expert,,,,,10623,BAO_0000249,B,,13961,,8,1,CHEMBL619047
3348,H,,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Autocuration,,,,955.0,10623,BAO_0000221,F,,17358,Brain,8,1,CHEMBL619048
3349,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,Autocuration,,,,,10623,BAO_0000019,F,,15847,,8,1,CHEMBL859398
3350,H,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,Autocuration,,,,,10623,BAO_0000019,F,,15847,,8,1,CHEMBL619049
3351,H,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,670,,8,1,CHEMBL857886
3352,H,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,Autocuration,,,,,10623,BAO_0000019,F,,670,,8,1,CHEMBL619050
3353,H,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Autocuration,,,,,10623,BAO_0000019,F,,1317,,8,1,CHEMBL620591
3354,D,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Expert,,,,,10623,BAO_0000357,B,,12936,,9,1,CHEMBL620592
3355,H,,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,2435.0,10623,BAO_0000249,B,,4535,Striatum,8,1,CHEMBL620593
3356,D,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,9,1,CHEMBL620594
3357,H,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,8,1,CHEMBL875079
3358,H,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,8,1,CHEMBL620595
3359,D,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,9,1,CHEMBL620596
3360,H,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,Autocuration,,,,,10623,BAO_0000019,F,,14424,,8,1,CHEMBL620597
3361,H,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,Expert,,,,,10623,BAO_0000019,F,,14424,,8,1,CHEMBL620598
3362,H,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),Expert,,,,,10623,BAO_0000218,F,,14424,,8,1,CHEMBL620599
3363,H,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Autocuration,,,,,10623,BAO_0000019,F,,14424,,8,1,CHEMBL620600
3364,H,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Autocuration,,,,,168,BAO_0000019,F,,1980,,8,1,CHEMBL620601
3365,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,Autocuration,,,,,168,BAO_0000019,F,,4639,,8,1,CHEMBL620602
3366,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620603
3367,H,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620604
3368,H,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620605
3369,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,1558,,8,1,CHEMBL620606
3370,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,8,1,CHEMBL620607
3371,H,,,,In vitro binding affinity towards 5-HT4 receptor was determined,Autocuration,,,,,168,BAO_0000357,B,,16117,,8,1,CHEMBL620608
3372,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,8,1,CHEMBL620609
3373,H,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000019,F,,17358,,8,1,CHEMBL620610
3374,H,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620611
3375,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620612
3376,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620613
3377,H,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,Autocuration,,,,,168,BAO_0000357,B,,17358,,8,1,CHEMBL620614
3378,H,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,1274,,8,1,CHEMBL620615
3379,H,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,10728,,6,1,CHEMBL857075
3380,H,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,11695,,6,1,CHEMBL620616
3381,H,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Autocuration,,,,,104698,BAO_0000249,B,Brain membranes,11695,,6,1,CHEMBL619411
3382,H,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,Autocuration,,,,,104698,BAO_0000019,B,,12490,,6,1,CHEMBL619412
3383,D,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000019,B,,11828,,7,1,CHEMBL619413
3384,H,,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Autocuration,,,,10000000.0,104698,BAO_0000221,B,,12253,Hippocampus,6,1,CHEMBL619414
3385,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,10561,,6,1,CHEMBL619415
3386,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,10561,,6,1,CHEMBL619416
3387,H,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,Autocuration,,,,,104698,BAO_0000019,F,,14432,,6,1,CHEMBL619417
3388,D,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,12936,,7,1,CHEMBL619418
3389,D,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,1274,,7,1,CHEMBL619419
3390,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,1980,,6,1,CHEMBL619420
3391,H,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,Autocuration,,,,,104698,BAO_0000249,B,,670,,6,1,CHEMBL619421
3392,D,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,968,,7,1,CHEMBL619422
3393,H,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Autocuration,,,,,104698,BAO_0000019,B,,14287,,6,1,CHEMBL619423
3394,H,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,Autocuration,,,,,104698,BAO_0000019,B,,567,,6,1,CHEMBL875080
3395,H,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,104698,BAO_0000019,B,,13267,,6,1,CHEMBL619424
3396,H,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,Autocuration,,,,,104698,BAO_0000249,B,,14826,,6,1,CHEMBL619425
3397,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,Autocuration,,,,,104698,BAO_0000223,B,,15194,,6,1,CHEMBL619426
3398,H,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,Autocuration,,,,,104698,BAO_0000223,B,,15194,,6,1,CHEMBL619427
3399,D,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,10394,,7,1,CHEMBL619645
3400,D,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",Expert,,,,,10576,BAO_0000249,B,,13657,,9,1,CHEMBL619646
3401,H,,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Autocuration,,,,955.0,12020,BAO_0000221,F,,1879,Brain,8,1,CHEMBL619647
3402,H,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000019,F,,1879,,8,1,CHEMBL619648
3403,H,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,Autocuration,,,,,12020,BAO_0000019,F,,1879,,8,1,CHEMBL619165
3404,H,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000218,F,,204,,8,1,CHEMBL620719
3405,H,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,8,1,CHEMBL872924
3406,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,12020,BAO_0000357,B,,1879,,8,1,CHEMBL620720
3407,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,8,1,CHEMBL620721
3408,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,Autocuration,,,,,12020,BAO_0000019,B,,1879,,8,1,CHEMBL620722
3409,H,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",Autocuration,,,,,104698,BAO_0000019,B,,10641,,6,1,CHEMBL620723
3410,H,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,12020,BAO_0000019,B,,773,,8,1,CHEMBL620724
3411,H,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Autocuration,,,,,104698,BAO_0000249,B,,11952,,6,1,CHEMBL620725
3412,D,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Autocuration,,,,,12020,BAO_0000019,F,,14145,,9,1,CHEMBL620726
3413,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Expert,,,,,144,BAO_0000357,B,,17066,,8,1,CHEMBL620727
3414,H,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,Autocuration,,,,,104714,BAO_0000223,B,,6398,,4,1,CHEMBL620728
3415,U,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,22226,BAO_0000019,B,,10321,,0,1,CHEMBL620729
3416,H,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,Autocuration,,,,,104714,BAO_0000019,F,,511,,4,1,CHEMBL858288
3417,H,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,4639,,4,1,CHEMBL620730
3418,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,4639,,4,1,CHEMBL620731
3419,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL620732
3420,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618042
3421,H,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618043
3422,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,1558,,4,1,CHEMBL618044
3423,H,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Autocuration,,,,,104714,BAO_0000019,F,,268,,4,1,CHEMBL618045
3424,H,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,Autocuration,,,,,104714,BAO_0000223,B,,2474,,4,1,CHEMBL618046
3425,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL618047
3426,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL875084
3427,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL618048
3428,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL618049
3429,H,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL619764
3430,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL619765
3431,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL619766
3432,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL619767
3433,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL619768
3434,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,Autocuration,,,,,104714,BAO_0000019,F,,5067,,4,1,CHEMBL619769
3435,H,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL619770
3436,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL619771
3437,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,Autocuration,,,,,104714,BAO_0000219,B,,14331,,4,1,CHEMBL619772
3438,H,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,Autocuration,,,,,104714,BAO_0000223,B,,5067,,4,1,CHEMBL619773
3439,H,,433.0,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,Autocuration,,NG108-15,,,104714,BAO_0000219,B,,6179,,4,1,CHEMBL619774
3440,H,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,Autocuration,,,,,104714,BAO_0000019,B,,4265,,4,1,CHEMBL875083
3441,H,,433.0,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,Autocuration,,NG108-15,,,104714,BAO_0000219,B,,4265,,4,1,CHEMBL620718
3442,H,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,104714,BAO_0000223,B,,17358,,4,1,CHEMBL618127
3443,H,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,104714,BAO_0000223,B,,17358,,4,1,CHEMBL618128
3444,H,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,Autocuration,,,,,104714,BAO_0000219,B,,13628,,4,1,CHEMBL618129
3445,H,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,104714,BAO_0000223,B,,4612,,4,1,CHEMBL618130
3446,H,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,Autocuration,,,,,104714,BAO_0000019,F,,17358,,4,1,CHEMBL618131
3447,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618132
3448,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618133
3449,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618134
3450,H,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618135
3451,H,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,Autocuration,,,,,104714,BAO_0000223,B,,511,,4,1,CHEMBL618136
3452,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,1479,,4,1,CHEMBL618137
3453,H,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,Autocuration,,,,,104714,BAO_0000223,B,,1317,,4,1,CHEMBL618138
3454,H,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,Autocuration,,,,,104714,BAO_0000223,B,,12146,,4,1,CHEMBL618139
3455,H,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,Autocuration,,,,,104714,BAO_0000223,B,,12146,,4,1,CHEMBL618140
3456,H,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,Autocuration,,,,,104714,BAO_0000223,B,,13969,,4,1,CHEMBL618141
3457,H,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,108,BAO_0000357,B,,13392,,8,1,CHEMBL873478
3458,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104698,BAO_0000223,B,,13392,,6,1,CHEMBL618142
3459,H,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,14159,,8,1,CHEMBL618143
3460,H,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,1558,,8,1,CHEMBL618144
3461,H,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,16655,,8,1,CHEMBL618145
3462,H,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,104714,BAO_0000223,B,,13020,,4,1,CHEMBL618146
3463,H,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,Autocuration,,,,,104714,BAO_0000223,B,,13021,,4,1,CHEMBL618147
3464,H,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,104714,BAO_0000223,B,,13020,,4,1,CHEMBL618148
3465,H,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,144,BAO_0000019,B,,10321,,8,1,CHEMBL618149
3466,H,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15818,,8,1,CHEMBL872927
3467,H,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,15818,,8,1,CHEMBL618150
3468,H,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,144,BAO_0000357,B,,17358,,8,1,CHEMBL618151
3469,H,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,144,BAO_0000357,B,,2222,,8,1,CHEMBL875094
3470,H,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,144,BAO_0000019,B,,10322,,8,1,CHEMBL618152
3471,H,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,144,BAO_0000357,B,,16117,,8,1,CHEMBL618153
3472,H,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,Autocuration,,,,,144,BAO_0000357,B,,17200,,8,1,CHEMBL618888
3473,H,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,Autocuration,,,,,144,BAO_0000019,F,,17358,,8,1,CHEMBL618889
3474,H,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,Autocuration,,,,,144,BAO_0000357,B,,16700,,8,1,CHEMBL618890
3475,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,Autocuration,,,,,144,BAO_0000019,B,,1980,,8,1,CHEMBL618891
3476,H,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,Autocuration,,,,,144,BAO_0000019,B,,1980,,8,1,CHEMBL619054
3477,H,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,104714,BAO_0000223,B,,12409,,4,1,CHEMBL619055
3478,H,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000357,B,,4365,,8,1,CHEMBL619056
3479,H,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000019,F,,4365,,8,1,CHEMBL619057
3480,H,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,144,BAO_0000357,B,,4365,,8,1,CHEMBL619058
3481,D,,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,9,1,CHEMBL619059
3482,D,,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,9,1,CHEMBL619060
3483,D,,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Expert,,Oocytes,,,12020,BAO_0000219,F,,6769,,9,1,CHEMBL875095
3484,D,,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL619061
3485,D,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,F,,809,Ileum,9,1,CHEMBL619062
3486,D,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Intermediate,,,,,20033,BAO_0000019,F,,14290,,9,1,CHEMBL619063
3487,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,Ileum,9,1,CHEMBL619064
3488,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Intermediate,,,,,20033,BAO_0000357,B,,17358,,9,1,CHEMBL619065
3489,D,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Intermediate,,,,2116.0,20033,BAO_0000221,B,,17358,Ileum,9,1,CHEMBL619066
3490,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,2116.0,10209,BAO_0000221,B,,17386,Ileum,8,1,CHEMBL619775
3491,H,,,,Affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,3269,,8,1,CHEMBL619776
3492,H,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,,,104841,BAO_0000224,B,,7721,,4,1,CHEMBL619777
3493,H,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,,,104841,BAO_0000224,B,,7721,,4,1,CHEMBL619778
3494,H,,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Autocuration,,,,2116.0,104841,BAO_0000221,B,,9117,Ileum,4,1,CHEMBL619779
3495,H,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,,,104841,BAO_0000224,B,,7721,,4,1,CHEMBL619780
3496,H,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,,,104841,BAO_0000224,B,,7721,,4,1,CHEMBL619166
3497,H,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,,,104841,BAO_0000019,F,,15796,,4,1,CHEMBL619167
3498,H,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,,,104841,BAO_0000019,F,,15796,,4,1,CHEMBL619168
3499,D,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Expert,,,,2081.0,168,BAO_0000219,B,,15650,Cardiac atrium,9,1,CHEMBL619169
3500,D,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Expert,,,,2081.0,168,BAO_0000219,B,,15650,Cardiac atrium,9,1,CHEMBL619170
3501,D,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Autocuration,,,,,104841,BAO_0000019,F,,6866,,5,1,CHEMBL619171
3502,D,,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Expert,,,,2081.0,168,BAO_0000219,F,,15650,Cardiac atrium,9,1,CHEMBL619172
3503,U,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Autocuration,,,,,22226,BAO_0000019,B,,10063,,0,1,CHEMBL619173
3504,U,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Autocuration,,,,,22226,BAO_0000019,B,,12665,,0,1,CHEMBL619174
3505,H,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,Autocuration,,,,,104705,BAO_0000019,B,,7504,,4,1,CHEMBL619175
3506,H,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,Autocuration,,,,,104705,BAO_0000224,B,,7504,,4,1,CHEMBL619176
3507,H,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,Autocuration,,,,,104705,BAO_0000019,B,,7038,,4,1,CHEMBL619177
3508,H,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,Autocuration,,,,,104705,BAO_0000224,B,,7626,,4,1,CHEMBL619178
3509,H,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,Autocuration,,,,,104705,BAO_0000224,B,,7626,,4,1,CHEMBL619179
3510,H,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Autocuration,,,,945.0,104705,BAO_0000019,F,,7185,Stomach,4,1,CHEMBL619180
3511,H,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Autocuration,,,,945.0,104705,BAO_0000019,F,,7185,Stomach,4,1,CHEMBL619181
3512,H,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,104705,BAO_0000019,F,,7185,,4,1,CHEMBL619182
3513,H,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,Autocuration,,,,,104705,BAO_0000224,B,,6960,,4,1,CHEMBL619183
3514,H,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",Autocuration,,,,,104705,BAO_0000224,B,,6960,,4,1,CHEMBL619184
3515,H,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,12416,Hippocampus,8,1,CHEMBL619185
3516,H,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,Expert,,,,,12198,BAO_0000357,B,,15753,,8,1,CHEMBL619186
3517,H,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,Autocuration,,,,,104705,BAO_0000019,B,,8062,,4,1,CHEMBL619187
3518,D,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Autocuration,,,,,104705,BAO_0000019,B,,9036,,5,1,CHEMBL619188
3519,D,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Autocuration,,,,,104705,BAO_0000224,B,,15067,,5,1,CHEMBL619189
3520,D,,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Expert,,,,955.0,12198,BAO_0000019,F,,15753,Brain,9,1,CHEMBL619190
3521,D,,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Expert,,,,2037.0,12198,BAO_0000221,F,,15753,Cerebellum,9,1,CHEMBL619191
3522,D,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Autocuration,,,,,104705,BAO_0000019,B,,15295,,5,1,CHEMBL619192
3523,D,,,,Percent binding affinity against 5-hydroxytryptamine receptor,Autocuration,,,,,104705,BAO_0000224,B,,6347,,5,1,CHEMBL619193
3524,U,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,Autocuration,,,,,22226,BAO_0000019,B,,6763,,0,1,CHEMBL619194
3525,D,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Autocuration,,,,,104705,BAO_0000224,B,,12092,,5,1,CHEMBL619195
3526,D,,,,Affinity against 5-hydroxytryptamine receptor was determined,Autocuration,,,,,104705,BAO_0000224,B,,1579,,5,1,CHEMBL619196
3527,D,,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Autocuration,,,,945.0,104705,BAO_0000019,B,,1579,Stomach,5,1,CHEMBL619197
3528,D,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,,,121,BAO_0000219,B,,5963,,9,1,CHEMBL619198
3529,D,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,,,121,BAO_0000219,B,,5963,,9,1,CHEMBL875081
3530,H,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,Autocuration,,,,,18065,BAO_0000357,B,,5030,,8,1,CHEMBL884712
3531,H,,,,Inhibition of 5-hydroxytryptamine reuptake,Expert,,,,,121,BAO_0000357,B,,15796,,8,1,CHEMBL884710
3532,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",Autocuration,,,,,18065,BAO_0000019,F,,15413,,8,1,CHEMBL619199
3533,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",Autocuration,,,,,18065,BAO_0000019,F,,15413,,8,1,CHEMBL619200
3534,H,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",Autocuration,,,,,18065,BAO_0000019,F,,15413,,8,1,CHEMBL619201
3535,H,,,,Tested for 5-hydroxytryptamine receptor uptake,Autocuration,,,,,18065,BAO_0000019,F,,12409,,8,1,CHEMBL619202
3536,D,,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,CHO,,,51,BAO_0000219,B,,16909,,9,1,CHEMBL619203
3537,D,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Expert,,,,,51,BAO_0000019,F,,16909,,9,1,CHEMBL619204
3538,H,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Autocuration,,,,,10576,BAO_0000249,B,,15629,,8,1,CHEMBL619205
3539,H,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,Autocuration,,,,,10576,BAO_0000357,B,,15629,,8,1,CHEMBL619206
3540,H,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,10576,BAO_0000249,B,,15629,,8,1,CHEMBL619207
3541,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL619208
3542,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL619209
3543,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL619210
3544,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL619211
3545,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL619212
3546,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620681
3547,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620682
3548,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620683
3549,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620684
3550,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620685
3551,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,2435.0,10825,BAO_0000019,F,,10034,Striatum,8,1,CHEMBL620686
3552,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620687
3553,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620688
3554,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620689
3555,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620690
3556,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620691
3557,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620692
3558,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL620693
3559,H,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,1274,,8,1,CHEMBL620694
3560,H,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,168,BAO_0000019,F,,17358,,8,1,CHEMBL857986
3561,H,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,Autocuration,,,,,168,BAO_0000357,B,,14532,,8,1,CHEMBL620695
3562,H,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,Expert,,,,,168,BAO_0000357,B,,16989,,8,1,CHEMBL620696
3563,H,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,Autocuration,,,,,168,BAO_0000357,B,,17200,,8,1,CHEMBL620697
3564,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,168,BAO_0000357,B,,15779,,8,1,CHEMBL620698
3565,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,168,BAO_0000357,B,,15779,,8,1,CHEMBL620699
3566,H,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,168,BAO_0000357,B,,15779,,8,1,CHEMBL620700
3567,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,8,1,CHEMBL620701
3568,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,8,1,CHEMBL875082
3569,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,8,1,CHEMBL620702
3570,H,,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,Autocuration,,COS-7,,,168,BAO_0000219,B,,15650,,8,1,CHEMBL620703
3571,H,,673.0,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Autocuration,,C6,,,168,BAO_0000219,B,,17046,,8,1,CHEMBL620704
3572,H,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Expert,,C6,,,168,BAO_0000219,B,,17046,,8,1,CHEMBL620705
3573,H,,673.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,Expert,,C6,,,168,BAO_0000219,B,,15650,,8,1,CHEMBL620706
3574,H,,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,Expert,,C6,,,168,BAO_0000219,B,,17046,,8,1,CHEMBL620707
3575,H,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,8,1,CHEMBL620708
3576,H,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,Autocuration,,,,,105,BAO_0000357,B,,17200,,8,1,CHEMBL620709
3577,D,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,16146,,9,1,CHEMBL620710
3578,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,Autocuration,,CHO,,,10624,BAO_0000219,B,,15250,,8,1,CHEMBL620711
3579,D,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Expert,,,,,10624,BAO_0000357,B,,6491,,9,1,CHEMBL620712
3580,D,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,9,1,CHEMBL620713
3581,D,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Expert,,,,,10624,BAO_0000357,B,,17066,,9,1,CHEMBL620714
3582,D,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,4234,,9,1,CHEMBL620715
3583,H,,,,Binding affinity towards 5-HT5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,6013,,8,1,CHEMBL620716
3584,H,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,10624,BAO_0000357,B,,17175,,8,1,CHEMBL620717
3585,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,15818,,8,1,CHEMBL618072
3586,H,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,Autocuration,,,,,10624,BAO_0000357,B,,6166,,8,1,CHEMBL857987
3587,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,10624,BAO_0000219,B,,15779,,8,1,CHEMBL618073
3588,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,HEK293,,,10624,BAO_0000219,B,,15779,,8,1,CHEMBL618074
3589,H,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),Autocuration,,HEK293,,,10624,BAO_0000219,B,,5213,,8,1,CHEMBL618075
3590,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Expert,,,,,10625,BAO_0000357,B,,17066,,9,1,CHEMBL618076
3591,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,9,1,CHEMBL618077
3592,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,9,1,CHEMBL618078
3593,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17066,,9,1,CHEMBL881821
3594,D,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Expert,,,,,10625,BAO_0000357,B,,17066,,9,1,CHEMBL618079
3595,H,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,10625,BAO_0000357,B,,17175,,8,1,CHEMBL618080
3596,H,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,HEK293,,,10576,BAO_0000219,B,,16190,,8,1,CHEMBL618081
3597,H,,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,HEK293,,,10626,BAO_0000219,B,,16190,,8,1,CHEMBL618082
3598,H,,,,Binding affinity towards 5-HT5a receptor,Expert,,,,,10624,BAO_0000357,B,,4820,,8,1,CHEMBL618083
3599,D,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,9,1,CHEMBL618084
3600,H,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,Expert,,,,,10624,BAO_0000357,B,,17066,,8,1,CHEMBL618085
3601,H,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,Expert,,,,,10624,BAO_0000357,B,,17175,,8,1,CHEMBL618086
3602,H,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,16633,,8,1,CHEMBL875092
3603,H,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,Autocuration,,,,,10624,BAO_0000357,B,,16633,,8,1,CHEMBL618087
3604,H,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,Autocuration,,,,,10624,BAO_0000357,B,,16700,,8,1,CHEMBL872926
3605,H,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,,,104714,BAO_0000019,F,,4639,,4,1,CHEMBL618088
3606,H,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,Autocuration,,,,,104714,BAO_0000223,B,,5486,,4,1,CHEMBL618089
3607,D,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,16146,,9,1,CHEMBL618090
3608,D,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17273,,9,1,CHEMBL618091
3609,H,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,17687,,8,1,CHEMBL618092
3610,D,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Expert,,,,,10627,BAO_0000357,B,,6491,,9,1,CHEMBL618093
3611,H,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,Expert,,HeLa,,,10627,BAO_0000219,B,,16190,,8,1,CHEMBL618094
3612,D,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,9,1,CHEMBL618095
3613,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,9,1,CHEMBL875093
3614,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17066,,9,1,CHEMBL618096
3615,D,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Expert,,,,,10627,BAO_0000357,B,,17066,,9,1,CHEMBL618118
3616,D,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,3555,,9,1,CHEMBL618119
3617,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,5808,,8,1,CHEMBL618120
3618,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,6013,,8,1,CHEMBL618121
3619,H,,722.0,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",Expert,,HEK293,,,10627,BAO_0000219,B,,15818,,8,1,CHEMBL618122
3620,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,Autocuration,,,,,10627,BAO_0000357,B,,16209,,8,1,CHEMBL618123
3621,H,,722.0,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Expert,,HEK293,,,10627,BAO_0000219,B,,3935,,8,1,CHEMBL618124
3622,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,15818,,8,1,CHEMBL618125
3623,D,,722.0,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Expert,,HEK293,,,10627,BAO_0000219,B,,3805,,9,1,CHEMBL618126
3624,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,Expert,,,,,10627,BAO_0000019,B,,16441,,8,1,CHEMBL618236
3625,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,10627,BAO_0000019,B,,16441,,8,1,CHEMBL618237
3626,H,,643.0,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,Expert,,COS-7,,,10627,BAO_0000219,B,,6786,,8,1,CHEMBL618238
3627,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4234,,9,1,CHEMBL618239
3628,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000019,B,,17085,,8,1,CHEMBL618240
3629,H,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,Autocuration,,,,,10627,BAO_0000357,B,,17200,,8,1,CHEMBL618241
3630,H,,722.0,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Autocuration,,HEK293,,,10627,BAO_0000219,B,,17451,,8,1,CHEMBL859399
3631,H,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,Autocuration,,,,,10627,BAO_0000019,F,,3935,,8,1,CHEMBL618242
3632,H,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,5033,,8,1,CHEMBL857991
3633,H,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4540,,8,1,CHEMBL619951
3634,D,,308.0,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,HeLa,,,10627,BAO_0000219,B,,4540,,9,1,CHEMBL619952
3635,D,,308.0,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,HeLa,,,10627,BAO_0000219,B,,4540,,9,1,CHEMBL619953
3636,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,8,1,CHEMBL619954
3637,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,8,1,CHEMBL619955
3638,H,,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17296,,8,1,CHEMBL619956
3639,H,,449.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,CHO,,,10627,BAO_0000219,B,,15779,,8,1,CHEMBL619957
3640,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,8,1,CHEMBL619958
3641,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,8,1,CHEMBL620627
3642,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,HEK293,,,10627,BAO_0000219,B,,15779,,8,1,CHEMBL620628
3643,H,,308.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,Autocuration,,HeLa,,,10627,BAO_0000219,B,,15779,,8,1,CHEMBL620629
3644,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,6166,,8,1,CHEMBL620630
3645,H,,308.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,Autocuration,,HeLa,,,10627,BAO_0000219,B,,17451,,8,1,CHEMBL620782
3646,H,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,15316,,8,1,CHEMBL620783
3647,H,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4199,,8,1,CHEMBL620784
3648,H,,308.0,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,Expert,,HeLa,,,10627,BAO_0000219,B,,15146,,8,1,CHEMBL620785
3649,H,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),Autocuration,,,,,10627,BAO_0000357,B,,5213,,8,1,CHEMBL857992
3650,H,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,Autocuration,,,,,10627,BAO_0000219,B,,16429,,8,1,CHEMBL620786
3651,H,,308.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,Autocuration,,HeLa,,,10627,BAO_0000219,B,,14818,,8,1,CHEMBL620787
3652,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,8,1,CHEMBL620788
3653,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,8,1,CHEMBL620789
3654,H,,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",Autocuration,,HeLa,,,10627,BAO_0000219,B,,4829,,8,1,CHEMBL620790
3655,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,Autocuration,,CHO,,,10628,BAO_0000219,B,,15250,,8,1,CHEMBL620791
3656,H,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,Autocuration,,,,,10628,BAO_0000019,B,,14423,,8,1,CHEMBL620792
3657,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10628,BAO_0000357,B,,15086,,8,1,CHEMBL620793
3658,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10628,BAO_0000357,B,,4342,,8,1,CHEMBL620794
3659,D,,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Autocuration,,HeLa,,,10627,BAO_0000219,B,,16190,,9,1,CHEMBL620795
3660,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,4820,,8,1,CHEMBL620796
3661,H,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,Autocuration,,,,,10627,BAO_0000357,B,,4639,,8,1,CHEMBL620797
3662,D,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,,,10627,BAO_0000019,F,,17066,,9,1,CHEMBL620798
3663,H,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,Autocuration,,,,,10627,BAO_0000357,B,,6011,,8,1,CHEMBL620799
3664,H,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,8,1,CHEMBL620800
3665,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,Autocuration,,,,,10627,BAO_0000357,B,,17515,,8,1,CHEMBL620801
3666,H,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,5014,,8,1,CHEMBL875100
3667,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10627,BAO_0000357,B,,4373,,8,1,CHEMBL620802
3668,H,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000019,F,,17066,,8,1,CHEMBL620803
3669,H,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,,,10627,BAO_0000019,F,,17066,,8,1,CHEMBL620804
3670,H,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,10627,BAO_0000357,B,,4373,,8,1,CHEMBL620805
3671,H,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,4687,,8,1,CHEMBL620806
3672,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,Autocuration,,,,,10627,BAO_0000357,B,,16946,,8,1,CHEMBL620807
3673,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,Autocuration,,,,,10627,BAO_0000357,B,,16946,,8,1,CHEMBL620808
3674,H,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,16633,,8,1,CHEMBL620809
3675,H,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,16633,,8,1,CHEMBL620810
3676,D,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,Expert,,,,,10627,BAO_0000357,B,,17066,,9,1,CHEMBL620811
3677,H,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,Autocuration,,,,,10627,BAO_0000357,B,,16700,,8,1,CHEMBL620812
3678,H,,,,Affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,10627,BAO_0000357,B,,3269,,8,1,CHEMBL620813
3679,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],Autocuration,,,,,10627,BAO_0000357,B,,5486,,8,1,CHEMBL620814
3680,D,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,16146,,9,1,CHEMBL620815
3681,H,,722.0,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,Autocuration,,HEK293,,,10209,BAO_0000219,B,,5014,,8,1,CHEMBL620816
3682,H,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,15463,,8,1,CHEMBL620817
3683,H,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),Autocuration,,,,,10209,BAO_0000357,B,,3805,,8,1,CHEMBL620818
3684,H,,722.0,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,Expert,,HEK293,,,10209,BAO_0000219,B,,5014,,8,1,CHEMBL620819
3685,D,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Expert,,,,,10209,BAO_0000357,B,,6491,,9,1,CHEMBL620820
3686,H,,449.0,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,CHO,,,10209,BAO_0000219,B,,16190,,8,1,CHEMBL620821
3687,D,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,9,1,CHEMBL620822
3688,D,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,9,1,CHEMBL620823
3689,D,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,3555,,9,1,CHEMBL620824
3690,H,,449.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,Expert,,CHO,,,10209,BAO_0000219,B,,6588,,8,1,CHEMBL620825
3691,H,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,Autocuration,,,,,10209,BAO_0000357,B,,15463,,8,1,CHEMBL872930
3692,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,6013,,8,1,CHEMBL620826
3693,H,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,10209,BAO_0000357,B,,16209,,8,1,CHEMBL620827
3694,H,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,3935,,8,1,CHEMBL620828
3695,H,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,15818,,8,1,CHEMBL620829
3696,H,,722.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,Expert,,HEK293,,,10209,BAO_0000219,B,,5014,,8,1,CHEMBL620830
3697,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,Expert,,,,,10209,BAO_0000019,B,,16441,,8,1,CHEMBL620831
3698,H,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,10209,BAO_0000019,B,,16441,,8,1,CHEMBL620832
3699,D,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,4234,,9,1,CHEMBL621548
3700,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000019,B,,17085,,8,1,CHEMBL621549
3701,H,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,Autocuration,,,,,10209,BAO_0000357,B,,17200,,8,1,CHEMBL621550
3702,H,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,Autocuration,,CHO,,,10209,BAO_0000219,B,,17451,,8,1,CHEMBL621551
3703,H,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,Autocuration,,,,,10209,BAO_0000019,B,,17085,,8,1,CHEMBL621552
3704,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,5104,,8,1,CHEMBL857077
3705,H,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,Autocuration,,,,,10209,BAO_0000357,B,,5104,,8,1,CHEMBL618158
3706,D,,643.0,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Expert,,COS-7,,,10209,BAO_0000219,B,,5033,,9,1,CHEMBL618159
3707,H,,643.0,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Autocuration,,COS-7,,,10209,BAO_0000219,B,,5486,,8,1,CHEMBL875101
3708,D,,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,4540,,9,1,CHEMBL618160
3709,H,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,Expert,,,,,10209,BAO_0000357,B,,6166,,8,1,CHEMBL618161
3710,H,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,17342,,8,1,CHEMBL618162
3711,H,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,Expert,,,,,10209,BAO_0000357,B,,17342,,8,1,CHEMBL618163
3712,H,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,Autocuration,,,,,10209,BAO_0000357,B,,17296,,8,1,CHEMBL618164
3713,H,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,Expert,,,,,10209,BAO_0000219,B,,16429,,8,1,CHEMBL618165
3714,H,,722.0,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,8,1,CHEMBL618166
3715,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,8,1,CHEMBL857989
3716,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,8,1,CHEMBL619888
3717,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,8,1,CHEMBL619889
3718,H,,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15779,,8,1,CHEMBL619890
3719,H,,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,Autocuration,,CHO,,,10209,BAO_0000219,B,,17451,,8,1,CHEMBL619891
3720,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),Autocuration,,HEK293,,,10209,BAO_0000219,B,,4199,,8,1,CHEMBL619892
3721,D,,722.0,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,Expert,,HEK293,,,10209,BAO_0000219,B,,4199,,9,1,CHEMBL619893
3722,H,,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),Autocuration,,HEK293,,,10209,BAO_0000219,B,,4199,,8,1,CHEMBL619894
3723,D,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,Intermediate,,HEK293,,,10209,BAO_0000219,B,,3680,,9,1,CHEMBL619895
3724,D,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,Intermediate,,,,,10209,BAO_0000357,B,,3680,,9,1,CHEMBL619896
3725,H,,643.0,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,Autocuration,,COS-7,,,10209,BAO_0000219,B,,15316,,8,1,CHEMBL619897
3726,H,,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,Autocuration,,HEK293,,,10209,BAO_0000219,B,,15146,,8,1,CHEMBL619898
3727,H,,722.0,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,Expert,,HEK293,,,10209,BAO_0000219,B,,5213,,8,1,CHEMBL619899
3728,H,,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),Autocuration,,HEK293,,,10209,BAO_0000219,B,,5213,,8,1,CHEMBL619900
3729,D,,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Expert,,HEK293,,,10209,BAO_0000219,B,,14818,,9,1,CHEMBL619901
3730,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,Autocuration,,HEK293,,,10209,BAO_0000219,B,,14818,,8,1,CHEMBL620580
3731,H,,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,Autocuration,,HEK293,,,10209,BAO_0000219,B,,14818,,8,1,CHEMBL620581
3732,H,,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",Autocuration,,HEK293,,,10209,BAO_0000219,B,,4829,,8,1,CHEMBL620733
3733,D,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Autocuration,,,,,10209,BAO_0000357,B,,17200,,9,1,CHEMBL620734
3734,D,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,,,10022,BAO_0000357,B,,17066,,9,1,CHEMBL620735
3735,H,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Autocuration,,,,,10209,BAO_0000019,B,,14025,,8,1,CHEMBL620736
3736,H,,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,Autocuration,,CHO,,,11923,BAO_0000219,B,,15250,,8,1,CHEMBL620737
3737,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620738
3738,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620739
3739,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620740
3740,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620741
3741,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620742
3742,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620743
3743,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620744
3744,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620745
3745,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620746
3746,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620747
3747,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620748
3748,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620749
3749,H,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,17066,,8,1,CHEMBL620750
3750,D,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,,,11923,BAO_0000357,B,,17066,,9,1,CHEMBL620751
3751,H,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,17386,,8,1,CHEMBL620752
3752,H,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,Autocuration,,,,,11923,BAO_0000019,B,,14423,,8,1,CHEMBL872929
3753,D,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Expert,,,,,11923,BAO_0000357,B,,15874,,9,1,CHEMBL620753
3754,D,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,15874,,9,1,CHEMBL620754
3755,D,,449.0,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Expert,,CHO,,,11923,BAO_0000219,B,,16372,,9,1,CHEMBL620755
3756,H,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,11923,BAO_0000357,B,,4622,,8,1,CHEMBL620756
3757,H,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,11923,BAO_0000357,B,,15086,,8,1,CHEMBL620757
3758,H,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620758
3759,H,,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620759
3760,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620760
3761,H,,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,Autocuration,,CHO,,,11923,BAO_0000219,B,,16372,,8,1,CHEMBL620761
3762,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,Ileum,8,1,CHEMBL620762
3763,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,Ileum,8,1,CHEMBL620763
3764,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Autocuration,,,,2116.0,11923,BAO_0000221,F,,17386,Ileum,8,1,CHEMBL620764
3765,D,,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Expert,,,,,11923,BAO_0000249,B,Membranes,5831,,9,1,CHEMBL857990
3766,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,11923,BAO_0000357,B,,4342,,8,1,CHEMBL620765
3767,H,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,Expert,,,,,11923,BAO_0000357,B,,17319,,8,1,CHEMBL620766
3768,H,,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Expert,,,,1898.0,11923,BAO_0000019,B,,17342,Hypothalamus,8,1,CHEMBL620767
3769,H,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,11923,BAO_0000357,B,,17342,,8,1,CHEMBL620768
3770,H,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Expert,,,,1898.0,11923,BAO_0000249,B,,3680,Hypothalamus,8,1,CHEMBL619051
3771,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,11923,BAO_0000357,B,,3680,,8,1,CHEMBL619052
3772,D,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Expert,,HEK293,,,11923,BAO_0000219,F,,17319,,9,1,CHEMBL619053
3773,D,,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Expert,,HEK293,,,11923,BAO_0000219,F,,17319,,9,1,CHEMBL619703
3774,D,,722.0,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Autocuration,,HEK293,,,11923,BAO_0000219,F,,17319,,9,1,CHEMBL619704
3775,H,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,4820,,8,1,CHEMBL619851
3776,H,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,Autocuration,,,,,10209,BAO_0000357,B,,4639,,8,1,CHEMBL619852
3777,H,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,Autocuration,,,,,10209,BAO_0000357,B,,6011,,8,1,CHEMBL619853
3778,D,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,9,1,CHEMBL619854
3779,H,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,8,1,CHEMBL619855
3780,H,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,Autocuration,,,,,10209,BAO_0000357,B,,17515,,8,1,CHEMBL619856
3781,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,8,1,CHEMBL619857
3782,H,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,Expert,,,,,10209,BAO_0000019,F,,17066,,8,1,CHEMBL619858
3783,H,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,8,1,CHEMBL619859
3784,H,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,10209,BAO_0000357,B,,4373,,8,1,CHEMBL619860
3785,H,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,4687,,8,1,CHEMBL619861
3786,H,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17342,,8,1,CHEMBL619862
3787,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,Autocuration,,,,,10209,BAO_0000357,B,,16946,,8,1,CHEMBL619863
3788,H,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,Autocuration,,,,,10209,BAO_0000357,B,,16946,,8,1,CHEMBL619864
3789,H,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,16633,,8,1,CHEMBL872928
3790,H,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,10209,BAO_0000357,B,,16633,,8,1,CHEMBL619865
3791,H,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,10209,BAO_0000357,B,,17066,,8,1,CHEMBL619866
3792,H,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,Autocuration,,,,,10209,BAO_0000357,B,,16700,,8,1,CHEMBL619867
3793,H,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,2116.0,10209,BAO_0000221,B,,17386,Ileum,8,1,CHEMBL619868
3794,H,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,Autocuration,,,,,55,BAO_0000019,F,,14080,,8,1,CHEMBL619869
3795,D,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Expert,,,,,55,BAO_0000019,F,,14080,,9,1,CHEMBL619870
3796,H,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,Autocuration,,,,,55,BAO_0000357,B,,409,,8,1,CHEMBL619871
3797,H,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,Autocuration,,,,,55,BAO_0000357,B,,409,,8,1,CHEMBL619872
3798,H,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,409,,8,1,CHEMBL619873
3799,H,,,,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,178.0,55,BAO_0000357,B,,11090,Blood,8,1,CHEMBL619874
3800,H,,,,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,178.0,55,BAO_0000357,B,,11090,Blood,8,1,CHEMBL619875
3801,H,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,Autocuration,,,,,55,BAO_0000357,B,,948,,8,1,CHEMBL619876
3802,H,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),Autocuration,,,,,55,BAO_0000357,B,,948,,8,1,CHEMBL619877
3803,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,Expert,,,,,55,BAO_0000219,F,,13622,,8,1,CHEMBL619878
3804,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,13622,Blood,8,1,CHEMBL619879
3805,H,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,Autocuration,,,,,55,BAO_0000357,B,,9637,,8,1,CHEMBL619880
3806,H,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),Autocuration,,,,,55,BAO_0000357,B,,11320,,8,1,CHEMBL619881
3807,H,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,11320,,8,1,CHEMBL619882
3808,H,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,Autocuration,,,,,55,BAO_0000357,B,,6838,,8,1,CHEMBL619883
3809,D,,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Expert,,,,178.0,55,BAO_0000357,B,,17667,Blood,9,1,CHEMBL619884
3810,H,,,,In vitro potency against human 5-Lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12703,,8,1,CHEMBL619885
3811,D,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Expert,,,,,55,BAO_0000019,F,,14312,,9,1,CHEMBL619886
3812,H,,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Autocuration,,,,178.0,55,BAO_0000019,F,,14312,Blood,8,1,CHEMBL619887
3813,H,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,55,BAO_0000019,F,,5364,,8,1,CHEMBL875097
3814,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618001
3815,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618002
3816,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618003
3817,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618004
3818,H,,,,Inhibition of human 5-lipoxygenase in human cells,Autocuration,,,,,55,BAO_0000219,B,,12365,,8,1,CHEMBL618005
3819,H,,,,Inhibition of human neutrophil 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,10603,,8,1,CHEMBL618006
3820,H,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,Autocuration,,,,,55,BAO_0000019,B,,10501,,8,1,CHEMBL875086
3821,H,,,,Inhibition of 5-lipoxygenase from human whole blood,Expert,,,,178.0,55,BAO_0000357,B,,12281,Blood,8,1,CHEMBL618007
3822,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,2567,,8,1,CHEMBL618008
3823,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,Autocuration,,,,,55,BAO_0000219,B,,2567,,8,1,CHEMBL618009
3824,H,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618010
3825,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618011
3826,H,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,13623,,8,1,CHEMBL618012
3827,H,,,,Tested against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12780,,8,1,CHEMBL882927
3828,H,,,,Tested for activity against 5-Lipoxygenase (5-LO),Autocuration,,,,,55,BAO_0000357,B,,12780,,8,1,CHEMBL618013
3829,H,,,,Tested for activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,12780,,8,1,CHEMBL618014
3830,H,,,,Tested for inhibition of 5-HPETE production by human 5-LO,Autocuration,,,,,55,BAO_0000357,B,,11966,,8,1,CHEMBL618015
3831,H,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,55,BAO_0000019,F,,5364,,8,1,CHEMBL618016
3832,H,,,,Inhibition of Human 5-lipoxygenase,Expert,,,,,55,BAO_0000357,B,,13165,,8,1,CHEMBL618017
3833,H,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,Autocuration,,,,,55,BAO_0000019,B,,5364,,8,1,CHEMBL618018
3834,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,8,1,CHEMBL875087
3835,H,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,55,BAO_0000219,B,,11311,,8,1,CHEMBL618019
3836,H,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,Autocuration,,,,,55,BAO_0000019,B,,14863,,8,1,CHEMBL618020
3837,H,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,Autocuration,,,,,55,BAO_0000019,B,,14863,,8,1,CHEMBL618021
3838,H,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Autocuration,,,,178.0,55,BAO_0000357,B,,11087,Blood,8,1,CHEMBL618022
3839,H,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,455,,8,1,CHEMBL618023
3840,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,8,1,CHEMBL618024
3841,H,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,Expert,,,,,55,BAO_0000019,B,,10319,,8,1,CHEMBL873950
3842,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618025
3843,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618026
3844,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618027
3845,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618028
3846,H,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,Autocuration,,,,,55,BAO_0000219,B,,951,,8,1,CHEMBL618029
3847,H,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Expert,,,,,55,BAO_0000357,B,,9859,,8,1,CHEMBL618030
3848,H,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,Expert,,,,,55,BAO_0000357,B,,9859,,8,1,CHEMBL618031
3849,H,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,Autocuration,,,,,55,BAO_0000357,B,,9859,,8,1,CHEMBL618032
3850,H,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,55,BAO_0000357,B,,2567,,8,1,CHEMBL618033
3851,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618034
3852,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL875088
3853,H,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,Autocuration,,,,,55,BAO_0000019,B,,949,,8,1,CHEMBL618035
3854,H,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,Autocuration,,,,,55,BAO_0000019,B,,949,,8,1,CHEMBL618036
3855,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,8,1,CHEMBL618037
3856,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,8,1,CHEMBL618038
3857,H,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Autocuration,,,,,55,BAO_0000019,F,,10603,,8,1,CHEMBL618761
3858,H,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,8,1,CHEMBL618762
3859,H,,,,Inhibition of lipoxygenase at the concentration of 1 uM,Expert,,,,,55,BAO_0000357,B,,10603,,8,1,CHEMBL618763
3860,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618764
3861,D,,,,Inhibition of 5-Lipoxygenase (5-LOX),Expert,,,,,55,BAO_0000357,B,,14580,,9,1,CHEMBL618765
3862,H,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,17087,BAO_0000357,B,,11090,,8,1,CHEMBL618766
3863,H,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,17087,BAO_0000357,B,,11090,,8,1,CHEMBL618767
3864,H,,,,Inhibitory activity against lipoxygenase-2 in mice,Autocuration,,,,,17087,BAO_0000357,B,,6339,,8,1,CHEMBL619380
3865,H,,,,Inhibitory activity against murine lipoxygenase-2.,Expert,,,,,17087,BAO_0000357,B,,6339,,8,1,CHEMBL619381
3866,D,,,,Inhibition of 5-lipoxygenase from mouse macrophage,Expert,,,,,17087,BAO_0000357,B,,12281,,9,1,CHEMBL619382
3867,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,Autocuration,,,,,17087,BAO_0000357,B,,11311,,8,1,CHEMBL619383
3868,H,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Autocuration,,,,,55,BAO_0000019,B,,11089,,8,1,CHEMBL619384
3869,H,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Autocuration,,,,,55,BAO_0000019,B,,10091,,8,1,CHEMBL619385
3870,H,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Autocuration,,,,,55,BAO_0000019,B,,14352,,8,1,CHEMBL882928
3871,D,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Expert,,,,,12166,BAO_0000019,B,,13329,,9,1,CHEMBL619386
3872,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619387
3873,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619388
3874,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619389
3875,H,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),Expert,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619390
3876,H,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",Expert,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619391
3877,H,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619392
3878,H,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),Autocuration,,,,,12166,BAO_0000019,B,,11311,,8,1,CHEMBL619393
3879,H,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,Autocuration,,,,,12166,BAO_0000019,B,,11311,,8,1,CHEMBL619394
3880,H,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,RBL-1,,,12166,BAO_0000219,B,,105,,8,1,CHEMBL619395
3881,H,,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,RBL-1,,,12166,BAO_0000219,B,,105,,8,1,CHEMBL619396
3882,H,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),Autocuration,,,,,12166,BAO_0000357,B,,9138,,8,1,CHEMBL619397
3883,H,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",Autocuration,,,,,12166,BAO_0000357,B,,9138,,8,1,CHEMBL619398
3884,H,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",Autocuration,,,,,12166,BAO_0000357,B,,9138,,8,1,CHEMBL619399
3885,H,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,14427,,8,1,CHEMBL619400
3886,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619401
3887,H,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",Autocuration,,,,,12166,BAO_0000019,B,,13329,,8,1,CHEMBL619402
3888,D,,663.0,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Expert,,RBL-2H3,,,12166,BAO_0000219,B,,14427,,9,1,CHEMBL619403
3889,H,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,14427,,8,1,CHEMBL619404
3890,H,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,Autocuration,,,,,12166,BAO_0000357,B,,14427,,8,1,CHEMBL619405
3891,H,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,Expert,,RBL-1,,,12166,BAO_0000219,B,,10293,,8,1,CHEMBL619406
3892,D,,702.0,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,338,,9,1,CHEMBL619407
3893,H,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),Autocuration,,,,,12166,BAO_0000357,B,,303,,8,1,CHEMBL619408
3894,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,8,1,CHEMBL619409
3895,H,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,Expert,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL619410
3896,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL619753
3897,H,,702.0,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,137,,8,1,CHEMBL619754
3898,H,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,11481,,8,1,CHEMBL619903
3899,H,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",Expert,,,,,12166,BAO_0000357,B,,11481,,8,1,CHEMBL619904
3900,H,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,Expert,,,,,12166,BAO_0000357,B,,9029,,8,1,CHEMBL619905
3901,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,1701,,8,1,CHEMBL619906
3902,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,Autocuration,,,,,12166,BAO_0000019,B,,1701,,8,1,CHEMBL619907
3903,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,Autocuration,,,,,12166,BAO_0000019,B,,1701,,8,1,CHEMBL619908
3904,H,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,Autocuration,,,,,12166,BAO_0000019,B,,1701,,8,1,CHEMBL619909
3905,H,,702.0,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,Expert,,RBL-1,,,12166,BAO_0000219,F,,13358,,8,1,CHEMBL619910
3906,H,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,1175,,8,1,CHEMBL882929
3907,H,,702.0,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,8797,,8,1,CHEMBL619911
3908,H,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,Autocuration,,,,,12166,BAO_0000019,B,,8797,,8,1,CHEMBL619912
3909,D,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,577,,9,1,CHEMBL619913
3910,H,,702.0,,In vitro inhibitory activity against RBL-1 5-LO,Expert,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL619914
3911,H,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL619915
3912,H,,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL619916
3913,H,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,Autocuration,,,,,12166,BAO_0000218,B,,9295,,8,1,CHEMBL619917
3914,H,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,Autocuration,,,,,12166,BAO_0000357,B,,9295,,8,1,CHEMBL619918
3915,H,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,Autocuration,,,,,12166,BAO_0000218,B,,216,,8,1,CHEMBL619919
3916,H,,702.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11090,,8,1,CHEMBL883710
3917,H,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Autocuration,,,,178.0,12166,BAO_0000019,B,,11090,Blood,8,1,CHEMBL619920
3918,H,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,10091,,8,1,CHEMBL619921
3919,H,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,Autocuration,,,,,12166,BAO_0000019,F,,10274,,8,1,CHEMBL619922
3920,H,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,Autocuration,,,,,12166,BAO_0000219,F,,13622,,8,1,CHEMBL619923
3921,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Expert,,RBL-1,,,12166,BAO_0000219,B,,12118,,8,1,CHEMBL619924
3922,H,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,Expert,,,,,12166,BAO_0000357,B,,12576,,8,1,CHEMBL619925
3923,H,,702.0,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,9546,,8,1,CHEMBL619926
3924,H,,702.0,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9521,,8,1,CHEMBL619927
3925,H,,702.0,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10626,,8,1,CHEMBL619928
3926,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619929
3927,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL875089
3928,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619930
3929,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619931
3930,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619932
3931,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619933
3932,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619934
3933,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619935
3934,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619936
3935,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619937
3936,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619938
3937,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619939
3938,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619940
3939,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL875090
3940,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619941
3941,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619942
3942,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL883711
3943,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619943
3944,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619944
3945,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619945
3946,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619946
3947,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619947
3948,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619948
3949,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL619949
3950,H,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,Expert,,,,,12166,BAO_0000019,B,,9401,,8,1,CHEMBL619950
3951,H,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,Autocuration,,,,,12166,BAO_0000019,B,,10325,,8,1,CHEMBL618050
3952,H,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,Expert,,RBL-2H3,,,12166,BAO_0000219,F,,1556,,8,1,CHEMBL875091
3953,H,,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,Expert,,RBL-2H3,,,12166,BAO_0000219,F,,1556,,8,1,CHEMBL618051
3954,D,,702.0,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,961,,9,1,CHEMBL618052
3955,H,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,Autocuration,,,,,12166,BAO_0000019,B,,6838,,8,1,CHEMBL618053
3956,H,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),Expert,,,,,12166,BAO_0000019,B,,10325,,8,1,CHEMBL618054
3957,D,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,9209,,9,1,CHEMBL618055
3958,H,,702.0,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,Expert,,RBL-1,,,12166,BAO_0000219,B,,11520,,8,1,CHEMBL618056
3959,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,Autocuration,,,,,12166,BAO_0000357,B,,137,,8,1,CHEMBL618057
3960,H,,702.0,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,8,1,CHEMBL618058
3961,H,,702.0,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Expert,,RBL-1,,,12166,BAO_0000219,B,,10636,,8,1,CHEMBL618059
3962,D,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Expert,,,,,12166,BAO_0000019,F,,14312,,9,1,CHEMBL618060
3963,H,,702.0,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,1203,,8,1,CHEMBL618061
3964,H,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,Autocuration,,,,,12166,BAO_0000019,B,,1203,,8,1,CHEMBL618062
3965,H,,702.0,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,Expert,,RBL-1,,,12166,BAO_0000219,B,,13622,,8,1,CHEMBL618063
3966,H,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,Autocuration,,,,,12166,BAO_0000357,B,,9793,,8,1,CHEMBL618064
3967,D,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Expert,,RBL-1,,,12166,BAO_0000219,B,,1143,,9,1,CHEMBL618065
3968,D,,702.0,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,11854,,9,1,CHEMBL618066
3969,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL618067
3970,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL618068
3971,D,,702.0,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Expert,,RBL-1,,,12166,BAO_0000219,B,,10501,,9,1,CHEMBL618069
3972,H,,702.0,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Expert,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL618070
3973,H,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL618071
3974,H,,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,349.0,10825,BAO_0000019,F,,10034,Limbic system,8,1,CHEMBL619247
3975,H,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,Autocuration,,,,,10825,BAO_0000019,F,,10034,,8,1,CHEMBL619248
3976,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10046,Hippocampus,8,1,CHEMBL619249
3977,H,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,10000000.0,10576,BAO_0000221,B,,10046,Hippocampus,8,1,CHEMBL619250
3978,H,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Autocuration,,,,,10577,BAO_0000019,B,,10046,,8,1,CHEMBL619251
3979,H,,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,12079,Blood,8,1,CHEMBL619252
3980,H,,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Autocuration,,,,178.0,55,BAO_0000019,F,,12079,Blood,8,1,CHEMBL619253
3981,H,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL619254
3982,H,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,Expert,,,,,17140,BAO_0000219,B,,12338,,8,1,CHEMBL619255
3983,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,Expert,,,,,17140,BAO_0000219,B,,12143,,8,1,CHEMBL619256
3984,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),Autocuration,,,,,17140,BAO_0000219,B,,12143,,8,1,CHEMBL875418
3985,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Expert,,,,,17140,BAO_0000219,B,,12143,,8,1,CHEMBL619257
3986,H,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Autocuration,,,,,17140,BAO_0000219,B,,12143,,8,1,CHEMBL619258
3987,H,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,Expert,,,,,17140,BAO_0000357,B,,12365,,8,1,CHEMBL619259
3988,H,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,Expert,,,,,17140,BAO_0000357,B,,13500,,8,1,CHEMBL619260
3989,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619261
3990,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619263
3991,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619264
3992,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619265
3993,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619266
3994,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619902
3995,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620058
3996,H,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620059
3997,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620060
3998,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620061
3999,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620062
4000,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620063
4001,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620064
4002,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620065
4003,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620066
4004,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620067
4005,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620068
4006,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620069
4007,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620070
4008,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620071
4009,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620072
4010,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620036
4011,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL857702
4012,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620037
4013,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620038
4014,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620039
4015,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620040
4016,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620041
4017,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620042
4018,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620043
4019,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620044
4020,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620045
4021,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620046
4022,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620047
4023,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620048
4024,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL857703
4025,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620049
4026,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620050
4027,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL620051
4028,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619213
4029,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619214
4030,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619804
4031,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619805
4032,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619806
4033,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619807
4034,H,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,F,,12832,Blood,8,1,CHEMBL619808
4035,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL619809
4036,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL619810
4037,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL619811
4038,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL620769
4039,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL620770
4040,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL620771
4041,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL620772
4042,H,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Autocuration,,,,,55,BAO_0000218,B,,3595,,8,1,CHEMBL620773
4043,H,,,,Ability to inhibit 5-lipoxygenase in guinea pig,Autocuration,,,,,55,BAO_0000357,B,,9203,,8,1,CHEMBL620774
4044,H,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Expert,,,,,55,BAO_0000357,B,,82,,8,1,CHEMBL620775
4045,H,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Autocuration,,,,,55,BAO_0000357,B,,11090,,8,1,CHEMBL620776
4046,H,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,,178.0,55,BAO_0000218,B,,12832,Blood,8,1,CHEMBL620777
4047,H,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Autocuration,,,,,55,BAO_0000357,B,,1065,,8,1,CHEMBL620778
4048,H,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Autocuration,,,,,55,BAO_0000357,B,,1065,,8,1,CHEMBL620779
4049,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,,,55,BAO_0000019,B,,12832,,8,1,CHEMBL621500
4050,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,,,55,BAO_0000019,B,,12832,,8,1,CHEMBL621501
4051,H,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Autocuration,,,,,55,BAO_0000019,B,,12832,,8,1,CHEMBL618098
4052,H,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,,,55,BAO_0000019,B,,10504,,8,1,CHEMBL618099
4053,H,,,,Inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,7788,,8,1,CHEMBL618100
4054,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Autocuration,,,,,55,BAO_0000357,B,,10001,,8,1,CHEMBL618101
4055,H,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618102
4056,H,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,13243,,8,1,CHEMBL618103
4057,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,8,1,CHEMBL618104
4058,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Autocuration,,,,,55,BAO_0000219,B,,969,,8,1,CHEMBL883712
4059,H,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10001,,8,1,CHEMBL618105
4060,H,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,,,55,BAO_0000357,B,,7788,,8,1,CHEMBL618106
4061,H,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Autocuration,,,,,55,BAO_0000357,B,,10001,,8,1,CHEMBL618107
4062,H,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,10193,,8,1,CHEMBL618108
4063,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,8,1,CHEMBL618109
4064,H,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Autocuration,,,,,55,BAO_0000357,B,,13243,,8,1,CHEMBL618110
4065,H,,,,Inhibitory activity uM,Expert,,,,,55,BAO_0000357,B,,13243,,8,1,CHEMBL618111
4066,H,,,,Inhibitory activity uM,Autocuration,,,,,55,BAO_0000019,F,,13243,,8,1,CHEMBL618112
4067,H,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,,,55,BAO_0000019,B,,10504,,8,1,CHEMBL618113
4068,H,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,,,55,BAO_0000357,B,,7788,,8,1,CHEMBL618114
4069,H,,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Expert,,,,2116.0,55,BAO_0000221,F,,10546,Ileum,8,1,CHEMBL620871
4070,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,8,1,CHEMBL620872
4071,H,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,55,BAO_0000357,B,,13183,,8,1,CHEMBL620873
4072,H,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),Autocuration,,,,,55,BAO_0000357,B,,2578,,8,1,CHEMBL620874
4073,H,,,,In vitro inhibition of human 5-Lipoxygenase.,Expert,,,,,55,BAO_0000357,B,,12780,,8,1,CHEMBL620875
4074,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620876
4075,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620877
4076,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL857854
4077,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620878
4078,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620879
4079,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620880
4080,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620881
4081,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620882
4082,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620883
4083,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620884
4084,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620885
4085,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620886
4086,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620887
4087,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618039
4088,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618040
4089,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618041
4090,U,,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618216
4091,U,,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618217
4092,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618218
4093,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618219
4094,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618220
4095,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618221
4096,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618222
4097,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618223
4098,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618224
4099,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618225
4100,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618226
4101,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618227
4102,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618228
4103,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618229
4104,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618230
4105,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618231
4106,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618232
4107,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618233
4108,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618234
4109,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618235
4110,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618115
4111,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618116
4112,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL618117
4113,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619968
4114,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619969
4115,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619970
4116,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619971
4117,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619972
4118,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619973
4119,U,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619974
4120,U,,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619975
4121,U,,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,,,22226,BAO_0000251,B,Microsomes,7411,,0,1,CHEMBL619976
4122,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619977
4123,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619978
4124,U,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619979
4125,U,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619980
4126,U,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619981
4127,N,,741.0,,In vitro inhibition of 7226/S myeloma cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,10797,,1,1,CHEMBL619982
4128,N,,993.0,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Intermediate,,BEL-7404 tumor cell line,,,80698,BAO_0000219,F,,6881,,1,1,CHEMBL619983
4129,N,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,3838,,1,1,CHEMBL620031
4130,N,,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,3838,,1,1,CHEMBL620032
4131,N,,505.0,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Expert,,V79,,,81264,BAO_0000219,F,,12981,,1,1,CHEMBL620033
4132,N,,505.0,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Expert,,V79,,,81264,BAO_0000219,F,,12981,,1,1,CHEMBL620034
4133,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL620035
4134,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL618318
4135,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL618319
4136,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL618320
4137,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL618321
4138,N,,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Intermediate,,7800C1 cell line,,,80635,BAO_0000219,F,,7653,,1,1,CHEMBL883118
4139,N,,391.0,,In vitro antitumor activity against renal 786-0 tumor cell lines,Intermediate,,786-0,,,80640,BAO_0000219,F,,17229,,1,1,CHEMBL883795
4140,N,,391.0,,Cytotoxic activity against 786-0 Renal cancer cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12858,,1,1,CHEMBL618322
4141,N,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,1,1,CHEMBL618323
4142,N,,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,1,1,CHEMBL618324
4143,N,,391.0,,In vitro antitumor activity against human renal 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,5858,,1,1,CHEMBL618325
4144,N,,391.0,,Inhibition of Renal cancer in 786-0 cancer cell lines,Intermediate,,786-0,,,80640,BAO_0000219,F,,16325,,1,1,CHEMBL875416
4145,N,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,1,1,CHEMBL618326
4146,N,,391.0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Intermediate,,786-0,,,80640,BAO_0000219,F,,3786,,1,1,CHEMBL618327
4147,N,,391.0,,inhibition of the growth of renal cancer(786-0) cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,1,1,CHEMBL619215
4148,N,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,786-0,,,80640,BAO_0000219,F,,14769,,1,1,CHEMBL619216
4149,N,,391.0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,15354,,1,1,CHEMBL619217
4150,N,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,1,1,CHEMBL619218
4151,N,,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,1,1,CHEMBL619219
4152,N,,391.0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,Intermediate,,786-0,,,80640,BAO_0000219,F,,14255,,1,1,CHEMBL619220
4153,N,,391.0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Intermediate,,786-0,,,80640,BAO_0000219,F,,14696,,1,1,CHEMBL619221
4154,N,,391.0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12016,,1,1,CHEMBL619222
4155,N,,391.0,,Compound was tested for growth inhibitory activity against 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,2597,,1,1,CHEMBL857454
4156,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL619223
4157,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL619224
4158,H,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,14799,,8,1,CHEMBL619225
4159,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL619226
4160,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL619227
4161,H,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,12767,,8,1,CHEMBL619228
4162,H,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,12166,BAO_0000219,B,,10997,,8,1,CHEMBL619229
4163,H,,702.0,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11388,,8,1,CHEMBL619230
4164,H,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,Autocuration,,,,,12166,BAO_0000357,B,,167,,8,1,CHEMBL619231
4165,H,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,12166,BAO_0000357,B,,167,,8,1,CHEMBL619232
4166,H,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,Expert,,,,,12166,BAO_0000357,B,,13744,,8,1,CHEMBL619233
4167,H,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,1630,,8,1,CHEMBL619234
4168,H,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),Autocuration,,,,,12166,BAO_0000357,B,,1630,,8,1,CHEMBL619235
4169,D,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Expert,,,,,12166,BAO_0000019,B,,969,,9,1,CHEMBL619236
4170,H,,702.0,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,13621,,8,1,CHEMBL619237
4171,H,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,Autocuration,,,,,12166,BAO_0000357,B,,10089,,8,1,CHEMBL619238
4172,H,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,Expert,,,,,12166,BAO_0000357,B,,10193,,8,1,CHEMBL619239
4173,H,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,Autocuration,,,,,12166,BAO_0000357,B,,11966,,8,1,CHEMBL619240
4174,H,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,12251,,8,1,CHEMBL875417
4175,H,,702.0,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Autocuration,,RBL-1,,,12166,BAO_0000219,B,,211,,8,1,CHEMBL619241
4176,H,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Expert,,,,,12166,BAO_0000019,F,,12251,,8,1,CHEMBL619242
4177,H,,702.0,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12495,,8,1,CHEMBL883796
4178,H,,,,Tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,414,,8,1,CHEMBL619243
4179,H,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,Autocuration,,,,,12166,BAO_0000357,B,,414,,8,1,CHEMBL619244
4180,H,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",Expert,,,,,12166,BAO_0000019,B,,10325,,8,1,CHEMBL619245
4181,H,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Expert,,,,,12166,BAO_0000019,B,,11966,,8,1,CHEMBL619246
4182,H,,702.0,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL619984
4183,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL619985
4184,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL619986
4185,H,,702.0,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL619987
4186,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,Autocuration,,,,,12166,BAO_0000218,B,,11311,,8,1,CHEMBL619988
4187,H,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL619989
4188,H,,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL619990
4189,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL619991
4190,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL619992
4191,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),Autocuration,,,,,12166,BAO_0000218,B,,11311,,8,1,CHEMBL619993
4192,H,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,8,1,CHEMBL619994
4193,H,,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,8,1,CHEMBL619995
4194,H,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,12166,BAO_0000019,B,,11311,,8,1,CHEMBL619996
4195,H,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000019,B,,11732,,8,1,CHEMBL619997
4196,H,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,Expert,,,,,12166,BAO_0000019,B,,11732,,8,1,CHEMBL619998
4197,H,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,Expert,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL619999
4198,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL620000
4199,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11087,,8,1,CHEMBL620001
4200,D,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Expert,,,,,12166,BAO_0000357,B,,11087,,9,1,CHEMBL620002
4201,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,8,1,CHEMBL620003
4202,H,,702.0,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,Expert,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620004
4203,H,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11520,,8,1,CHEMBL874063
4204,H,,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10293,,8,1,CHEMBL620005
4205,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,8,1,CHEMBL620006
4206,H,,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,303,,8,1,CHEMBL620007
4207,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620008
4208,D,,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,9247,,9,1,CHEMBL620009
4209,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620010
4210,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620011
4211,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620677
4212,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620678
4213,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620679
4214,H,,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9247,,8,1,CHEMBL620680
4215,D,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,Expert,,,,,12166,BAO_0000357,B,,11481,,9,1,CHEMBL620838
4216,H,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,Autocuration,,,,,12166,BAO_0000357,B,,105,,8,1,CHEMBL620839
4217,H,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,Expert,,,,,12166,BAO_0000357,B,,9029,,8,1,CHEMBL620840
4218,H,,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,1175,,8,1,CHEMBL620841
4219,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,8,1,CHEMBL620842
4220,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,8,1,CHEMBL620843
4221,H,,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12118,,8,1,CHEMBL620844
4222,H,,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9225,,8,1,CHEMBL620845
4223,H,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,9401,,8,1,CHEMBL620846
4224,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,12166,BAO_0000357,B,,137,,8,1,CHEMBL873951
4225,H,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,12166,BAO_0000357,B,,137,,8,1,CHEMBL620847
4226,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,8,1,CHEMBL620848
4227,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL620849
4228,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,8,1,CHEMBL620850
4229,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,8,1,CHEMBL620851
4230,H,,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,10501,,8,1,CHEMBL620852
4231,H,,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL875098
4232,D,,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,14799,,9,1,CHEMBL620853
4233,H,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Autocuration,,,,,12166,BAO_0000019,B,,14799,,8,1,CHEMBL620854
4234,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL620855
4235,H,,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Expert,,RBL-1,,,12166,BAO_0000219,B,,3595,,8,1,CHEMBL839884
4236,H,,702.0,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL620856
4237,H,,702.0,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,12526,,8,1,CHEMBL620857
4238,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,8,1,CHEMBL620858
4239,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,8,1,CHEMBL620859
4240,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,8,1,CHEMBL620860
4241,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,8,1,CHEMBL620861
4242,H,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),Expert,,,,,12166,BAO_0000357,B,,9138,,8,1,CHEMBL620862
4243,H,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,Autocuration,,,,,12166,BAO_0000357,B,,9138,,8,1,CHEMBL620863
4244,H,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Autocuration,,,,,12166,BAO_0000019,B,,11966,,8,1,CHEMBL620864
4245,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL620865
4246,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL620866
4247,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL620867
4248,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL620868
4249,H,,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,8,1,CHEMBL620869
4250,H,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000019,F,,11311,,8,1,CHEMBL873952
4251,H,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,11311,,8,1,CHEMBL875099
4252,H,,663.0,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,Autocuration,,RBL-2H3,,,12166,BAO_0000219,F,,11311,,8,1,CHEMBL620870
4253,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL618261
4254,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL618262
4255,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL619428
4256,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL619429
4257,H,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,12166,BAO_0000019,B,,11087,,8,1,CHEMBL619430
4258,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,8,1,CHEMBL620017
4259,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,496,,8,1,CHEMBL620018
4260,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620019
4261,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620020
4262,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620021
4263,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620022
4264,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620023
4265,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620024
4266,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620025
4267,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620026
4268,H,,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,F,,13986,,8,1,CHEMBL620027
4269,D,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Expert,,,,,12166,BAO_0000019,F,,13986,,9,1,CHEMBL620028
4270,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,Autocuration,,,,,12166,BAO_0000357,B,,10193,,8,1,CHEMBL620029
4271,H,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,Autocuration,,,,,12166,BAO_0000357,B,,9295,,8,1,CHEMBL620030
4272,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,8,1,CHEMBL875415
4273,H,,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,4717,,8,1,CHEMBL618256
4274,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,8,1,CHEMBL618257
4275,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,8,1,CHEMBL618258
4276,H,,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,11854,,8,1,CHEMBL618259
4277,H,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,12166,BAO_0000019,B,,10193,,8,1,CHEMBL618260
4278,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL618215
4279,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL618390
4280,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL618391
4281,H,,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,9295,,8,1,CHEMBL618392
4282,H,,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,165,,8,1,CHEMBL618393
4283,H,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,Autocuration,,,,,12166,BAO_0000219,B,,11311,,8,1,CHEMBL618394
4284,H,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,8,1,CHEMBL618395
4285,D,,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,9,1,CHEMBL618396
4286,D,,702.0,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Expert,,RBL-1,,,12166,BAO_0000219,B,,10489,,9,1,CHEMBL858253
4287,D,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,,,12166,BAO_0000019,B,,14799,,9,1,CHEMBL618397
4288,H,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Autocuration,,,,,12054,BAO_0000357,B,,9295,,8,1,CHEMBL618398
4289,U,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",Autocuration,,,,,22226,BAO_0000019,B,,16811,,0,1,CHEMBL618399
4290,H,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,Expert,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618400
4291,H,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,6309,,8,1,CHEMBL618401
4292,H,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,Autocuration,,,,,55,BAO_0000357,B,,6309,,8,1,CHEMBL618402
4293,H,,702.0,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,Autocuration,,RBL-1,,,55,BAO_0000219,B,,3092,,8,1,CHEMBL876400
4294,H,,,,Inhibitory activity against 5-lipoxygenase.,Expert,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618403
4295,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,Autocuration,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618404
4296,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,Autocuration,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618405
4297,H,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,Autocuration,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618406
4298,H,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,Expert,,,,,55,BAO_0000019,F,,12338,,8,1,CHEMBL618407
4299,H,,,,Tested for the inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,4501,,8,1,CHEMBL618408
4300,H,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,55,BAO_0000357,B,,1132,,8,1,CHEMBL618409
4301,H,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,Autocuration,,,,,55,BAO_0000357,B,,2117,,8,1,CHEMBL618410
4302,H,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,Autocuration,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618411
4303,H,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,Autocuration,,,,,55,BAO_0000357,B,,168,,8,1,CHEMBL618412
4304,H,,702.0,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,Autocuration,,RBL-1,,,12166,BAO_0000219,B,,13575,,8,1,CHEMBL618413
4305,H,,,,,Autocuration,,,,,12166,BAO_0000357,B,,11089,,8,1,CHEMBL618414
4306,H,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),Autocuration,,,,,10102,BAO_0000357,B,,216,,8,1,CHEMBL618415
4307,H,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,Autocuration,,,,,10102,BAO_0000019,B,,13165,,8,1,CHEMBL618416
4308,H,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,Autocuration,,,,,10102,BAO_0000357,B,,3278,,8,1,CHEMBL876401
4309,H,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,Expert,,,,,10102,BAO_0000357,B,,3278,,8,1,CHEMBL618417
4310,H,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,Autocuration,,,,,10102,BAO_0000357,B,,11966,,8,1,CHEMBL618418
4311,H,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",Autocuration,,,,,10102,BAO_0000357,B,,175,,8,1,CHEMBL618419
4312,H,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",Autocuration,,,,,10102,BAO_0000357,B,,175,,8,1,CHEMBL618420
4313,H,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,Autocuration,,,,,10102,BAO_0000357,B,,13449,,8,1,CHEMBL618421
4314,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,Autocuration,,,,,11238,BAO_0000019,B,,12014,,8,1,CHEMBL618422
4315,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),Autocuration,,,,,11238,BAO_0000019,B,,12014,,8,1,CHEMBL618423
4316,H,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),Autocuration,,,,,11238,BAO_0000019,B,,12014,,8,1,CHEMBL618424
4317,S,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,Intermediate,,,,,100284,BAO_0000220,B,,99,,2,1,CHEMBL618425
4318,U,,,,The dark toxicity against 543 human galactophore carcinoma cells,Autocuration,,,,,22226,BAO_0000019,F,,4349,,0,1,CHEMBL618426
4319,N,,390.0,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Expert,,Panel (56 tumour cell lines),,,80623,BAO_0000219,F,,4071,,1,1,CHEMBL618427
4320,N,,345.0,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Expert,,5637,,,80008,BAO_0000219,F,,17589,,1,1,CHEMBL618428
4321,N,,345.0,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Intermediate,,5637,,,80008,BAO_0000219,F,,15002,,1,1,CHEMBL618429
4322,N,,345.0,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Intermediate,,5637,,,80008,BAO_0000219,F,,13958,,1,1,CHEMBL618430
4323,N,,345.0,,Growth inhibition against human 5637 cell lines,Expert,,5637,,,80008,BAO_0000219,F,,17589,,1,1,CHEMBL618431
4324,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells.,Expert,,5637,,,80008,BAO_0000219,F,,16748,,1,1,CHEMBL883799
4325,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,5637,,,80008,BAO_0000219,F,,16747,,1,1,CHEMBL618432
4326,N,,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,5637,,,80008,BAO_0000219,F,,16747,,1,1,CHEMBL618433
4327,D,,,,In vitro inhibition of bovine trypsin(Trp).,Expert,,,,,10443,BAO_0000357,B,,15285,,9,1,CHEMBL618434
4328,H,,407.0,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Expert,,CV-1,,,240,BAO_0000219,B,,3726,,8,1,CHEMBL618435
4329,H,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,Autocuration,,,,,10577,BAO_0000357,B,,5033,,8,1,CHEMBL876402
4330,H,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,Autocuration,,,,,104698,BAO_0000019,F,,11756,,6,1,CHEMBL618436
4331,U,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,Autocuration,,,,,22226,BAO_0000218,F,,11953,,0,1,CHEMBL618437
4332,D,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Intermediate,,,,,20033,BAO_0000357,B,,5033,,9,1,CHEMBL618438
4333,H,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,,,17045,BAO_0000251,A,Microsomes,11347,,8,1,CHEMBL883800
4334,H,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,,,17045,BAO_0000251,A,Microsomes,11347,,8,1,CHEMBL618439
4335,U,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL618440
4336,U,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL618441
4337,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Expert,,,,,11938,BAO_0000019,B,,17588,,8,1,CHEMBL618442
4338,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Autocuration,,,,,11938,BAO_0000019,B,,17588,,8,1,CHEMBL618443
4339,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Expert,,,,,11938,BAO_0000019,B,,17588,,8,1,CHEMBL619158
4340,H,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Autocuration,,,,,11938,BAO_0000019,B,,17588,,8,1,CHEMBL620974
4341,H,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,Autocuration,,,,,11938,BAO_0000357,B,,16485,,8,1,CHEMBL620975
4342,U,,,,Average inhibitory concentration against 60 human cell lines was reported,Intermediate,,,,,22226,BAO_0000019,F,,4337,,0,1,CHEMBL620976
4343,U,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Expert,,,,,22226,BAO_0000019,F,,4112,,0,1,CHEMBL620977
4344,N,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,16160,,1,1,CHEMBL620978
4345,N,,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,16160,,1,1,CHEMBL620979
4346,N,,542.0,,In vitro mean growth inhibitory activity against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,1,1,CHEMBL620980
4347,N,,542.0,,In vitro mean growth lethal concentration against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,1,1,CHEMBL620981
4348,N,,542.0,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,1,1,CHEMBL620982
4349,N,,542.0,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,80315,BAO_0000219,F,,17376,,1,1,CHEMBL620983
4350,H,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,104775,BAO_0000019,F,,3241,,4,1,CHEMBL620984
4351,H,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,104775,BAO_0000019,F,,3241,,4,1,CHEMBL620985
4352,H,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,Expert,,,,,275,BAO_0000357,B,,3725,,8,1,CHEMBL620986
4353,N,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Expert,,,,,50425,BAO_0000218,F,,10805,,1,1,CHEMBL620987
4354,N,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Expert,,,,,50425,BAO_0000218,F,,10805,,1,1,CHEMBL620988
4355,N,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Expert,,,,,50425,BAO_0000218,F,,10805,,1,1,CHEMBL620989
4356,N,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Expert,,,,,50425,BAO_0000218,F,,10805,,1,1,CHEMBL620990
4357,N,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Intermediate,,,,,50425,BAO_0000218,F,,10805,,1,1,CHEMBL620991
4358,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL620992
4359,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL620993
4360,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL620994
4361,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL620995
4362,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL620996
4363,N,,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10144,,1,1,CHEMBL875581
4364,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL620997
4365,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL620998
4366,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL620999
4367,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621000
4368,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621001
4369,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621002
4370,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621003
4371,U,,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621004
4372,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621005
4373,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621006
4374,U,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL621007
4375,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,0,1,CHEMBL621008
4376,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,0,1,CHEMBL621009
4377,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,0,1,CHEMBL857705
4378,U,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Autocuration,,,,,22224,BAO_0000218,F,,10144,,0,1,CHEMBL619828
4379,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL619829
4380,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL619830
4381,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL619831
4382,U,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,,,22224,BAO_0000218,F,,10685,,0,1,CHEMBL619832
4383,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,0,1,CHEMBL619833
4384,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,0,1,CHEMBL619834
4385,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,0,1,CHEMBL619835
4386,U,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Autocuration,,,,,22224,BAO_0000218,A,,10685,,0,1,CHEMBL619836
4387,N,,850.0,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Intermediate,,6C3HED,,,80628,BAO_0000218,F,,8831,,1,1,CHEMBL619837
4388,U,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,Autocuration,,,,,22224,BAO_0000218,F,,11704,,0,1,CHEMBL619838
4389,N,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Intermediate,,,,,50594,BAO_0000218,A,,11704,,1,1,CHEMBL619839
4390,N,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10685,,1,1,CHEMBL619840
4391,N,,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Intermediate,,6C3HED,,,80628,BAO_0000218,F,,10685,,1,1,CHEMBL619841
4392,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Expert,,6C3HED,,,80628,BAO_0000218,F,,11368,,1,1,CHEMBL857704
4393,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Intermediate,,6C3HED,,,80628,BAO_0000218,F,,11368,,1,1,CHEMBL619842
4394,N,,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Expert,,6C3HED,,,80628,BAO_0000218,F,,11368,,1,1,CHEMBL619843
4395,U,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Autocuration,,,,,22226,BAO_0000019,B,,17763,,0,1,CHEMBL619844
4396,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL857855
4397,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619845
4398,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619846
4399,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619847
4400,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL619848
4401,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620893
4402,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620894
4403,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620895
4404,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620896
4405,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620897
4406,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620898
4407,U,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,,2107.0,22226,BAO_0000251,B,Microsomes,7411,Liver,0,1,CHEMBL620899
4408,U,,,,The apparent total plasma clearance in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,347,Plasma,0,1,CHEMBL620900
4409,U,,,,Compound was evaluated for Hepatic clearance in monkey,Autocuration,,,,,22224,BAO_0000218,A,,3341,,0,1,CHEMBL620901
4410,U,,,,Lower clearance in monkey (i.v.) at 0.5 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,,0,1,CHEMBL620902
4411,U,,,,Plasma clearance in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4514,,0,1,CHEMBL620903
4412,U,,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,0,1,CHEMBL620904
4413,U,,,,Plasma clearance of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,,0,1,CHEMBL620905
4414,U,,,,Plasma clearance was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,,0,1,CHEMBL620906
4415,U,,,,Plasma clearance in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,,0,1,CHEMBL875420
4416,U,,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,,0,1,CHEMBL620907
4417,U,,,,Plasma clearance was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5472,,0,1,CHEMBL620908
4418,U,,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL620909
4419,U,,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,,0,1,CHEMBL620910
4420,U,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL620911
4421,U,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL620912
4422,U,,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,0,1,CHEMBL620913
4423,U,,,,Cmax in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,,0,1,CHEMBL620914
4424,U,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,,0,1,CHEMBL620915
4425,U,,,,Cmax in cynomolgus monkey by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5922,,0,1,CHEMBL620916
4426,U,,,,Cmax in cynomolgus monkey by po administration,Autocuration,,,,,22224,BAO_0000218,A,,5922,,0,1,CHEMBL620917
4427,U,,,,Cmax value evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,0,1,CHEMBL620918
4428,U,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL620919
4429,U,,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3249,Plasma,0,1,CHEMBL620920
4430,U,,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3249,Plasma,0,1,CHEMBL620921
4431,U,,,,Maximal plasma concentration in squirrel monkeys,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5553,Plasma,0,1,CHEMBL620922
4432,U,,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL620923
4433,U,,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6227,Plasma,0,1,CHEMBL620924
4434,U,,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL620925
4435,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620926
4436,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620927
4437,U,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620928
4438,U,,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620929
4439,U,,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6221,Plasma,0,1,CHEMBL620930
4440,U,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Autocuration,,,,,22224,BAO_0000218,A,,167,,0,1,CHEMBL620931
4441,U,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Autocuration,,,,,22224,BAO_0000218,A,,167,,0,1,CHEMBL620932
4442,U,,,,Absolute bioavailability was evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL620933
4443,U,,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,,0,1,CHEMBL620934
4444,U,,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,,0,1,CHEMBL620935
4445,U,,,,Bioavailability of compound was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,17267,,0,1,CHEMBL620936
4446,U,,,,Bioavailability determined after oral administration in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL620937
4447,U,,,,Oral bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL620938
4448,U,,,,Bioavailability in monkey (p.o.) at 2.0 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,,0,1,CHEMBL620939
4449,U,,,,Bioavailability was evaluated after oral administration in monkey,Autocuration,,,,,22224,BAO_0000218,A,,16365,,0,1,CHEMBL620940
4450,U,,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL620941
4451,U,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL620942
4452,U,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL620943
4453,U,,,,Bioavailability of the compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,,0,1,CHEMBL620944
4454,U,,,,Bioavailability in squirrel monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,1399,,0,1,CHEMBL620945
4455,U,,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL620946
4456,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,3341,,0,1,CHEMBL620947
4457,U,,,,Compound was tested for bioavailability in squirrel monkey,Autocuration,,,,,22224,BAO_0000218,A,,64,,0,1,CHEMBL620948
4458,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL620949
4459,U,,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL620950
4460,U,,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Autocuration,,,,,22224,BAO_0000218,A,,5237,,0,1,CHEMBL620951
4461,U,,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Autocuration,,,,,22224,BAO_0000218,A,,5237,,0,1,CHEMBL620952
4462,U,,,,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,5302,,0,1,CHEMBL875421
4463,U,,,,Oral bioavailability of compound at 5 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17667,,0,1,CHEMBL620953
4464,N,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,,1,1,CHEMBL873491
4465,N,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,,1,1,CHEMBL620954
4466,N,,,,Plasma half life determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3854,Plasma,1,1,CHEMBL620955
4467,N,,,,Plasma half life in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,993,Plasma,1,1,CHEMBL618097
4468,N,,,,Plasma half-life in Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4514,Plasma,1,1,CHEMBL618268
4469,N,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL618269
4470,N,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL618270
4471,N,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL618271
4472,N,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL873493
4473,N,,,,Tested for the half life period in dog,Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL621031
4474,N,,,,Tested for the half life period in dog at dosage of 10 mpk,Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL621032
4475,N,,,,The compound was tested for half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,,1,1,CHEMBL621033
4476,N,,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Intermediate,,,,1969.0,50588,BAO_0000218,A,,3639,Plasma,1,1,CHEMBL621034
4477,N,,,,The half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3880,,1,1,CHEMBL621035
4478,N,,,,The plasma half-life in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3918,Plasma,1,1,CHEMBL621036
4479,N,,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16452,Plasma,1,1,CHEMBL621037
4480,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,,1,1,CHEMBL619812
4481,N,,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL619813
4482,N,,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL873335
4483,N,,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,,1,1,CHEMBL619814
4484,N,,,,Cmax in ferrets after 30 mg/kg oral dose,Expert,,,,,50506,BAO_0000218,A,,6113,,1,1,CHEMBL619815
4485,N,,,,Emesis in ferrets at 30 mg/kg oral dose,Expert,,,,,50506,BAO_0000218,F,,6113,,1,1,CHEMBL619816
4486,U,,,,Bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,17796,,0,1,CHEMBL619817
4487,N,,,,Volume of distribution in cynomolgus,Intermediate,,,,,100710,BAO_0000218,A,,17796,,1,1,CHEMBL619818
4488,U,,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5308,Plasma,0,1,CHEMBL619819
4489,U,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4877,,0,1,CHEMBL619820
4490,U,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Autocuration,,,,,22224,BAO_0000218,A,,4876,,0,1,CHEMBL875419
4491,U,,,,AUC in guinea pig after 3mg/kg oral dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4878,Plasma,0,1,CHEMBL619821
4492,U,,,,Bioavailability in guinea pig was tested,Autocuration,,,,,22224,BAO_0000218,A,,5308,,0,1,CHEMBL619822
4493,U,,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4877,,0,1,CHEMBL619823
4494,U,,,,Tested for the oral bioavailability of the compound,Autocuration,,,,,22224,BAO_0000218,A,,4876,,0,1,CHEMBL619824
4495,U,,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Autocuration,,,,,22224,BAO_0000218,A,,4876,,0,1,CHEMBL619825
4496,U,,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,,,22224,BAO_0000218,A,,5308,,0,1,CHEMBL619826
4497,U,,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,,2048.0,22224,BAO_0000218,A,,4877,Lung,0,1,CHEMBL619827
4498,U,,,,Cmax in guinea pig after 3mg/kg oral dose,Autocuration,,,,,22224,BAO_0000218,A,,4878,,0,1,CHEMBL618167
4499,U,,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,178.0,22224,BAO_0000019,A,,5689,Blood,0,1,CHEMBL618168
4500,U,,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,955.0,22224,BAO_0000019,A,,5689,Brain,0,1,CHEMBL618169
4501,U,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,,22224,BAO_0000019,A,,5689,,0,1,CHEMBL618170
4502,U,,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,160.0,22224,BAO_0000019,A,,5689,Intestine,0,1,CHEMBL618171
4503,U,,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2113.0,22224,BAO_0000019,A,,5689,Kidney,0,1,CHEMBL618172
4504,U,,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2107.0,22224,BAO_0000019,A,,5689,Liver,0,1,CHEMBL618173
4505,U,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,,22224,BAO_0000019,A,,5689,,0,1,CHEMBL618174
4506,U,,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,,2106.0,22224,BAO_0000019,A,,5689,Spleen,0,1,CHEMBL875408
4507,U,,,,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14465,,0,1,CHEMBL839827
4508,U,,,,Partition coefficient was measured as -log (counts per min ),Autocuration,,,,,22224,BAO_0000019,A,,5689,,0,1,CHEMBL618175
4509,U,,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,,,22224,BAO_0000218,A,,611,,0,1,CHEMBL618176
4510,U,,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,,,22224,BAO_0000218,A,,611,,0,1,CHEMBL618177
4511,U,,,,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14465,,0,1,CHEMBL618178
4512,U,,,,"Tested for the half life period of the compound, intravenously",Autocuration,,,,,22224,BAO_0000218,A,,4876,,0,1,CHEMBL618179
4513,U,,,,Half-life was measured,Autocuration,,,,,22224,BAO_0000019,A,,5689,,0,1,CHEMBL873489
4514,U,,,,The time required for onset of inotropy after addition of a single dose of delta F75,Autocuration,,,,,22224,BAO_0000019,A,,7515,,0,1,CHEMBL618180
4515,U,,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,,0,1,CHEMBL618181
4516,U,,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,17667,,0,1,CHEMBL618182
4517,U,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL618183
4518,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618184
4519,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618185
4520,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618186
4521,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618187
4522,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618188
4523,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL875409
4524,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,,50594,BAO_0000218,A,,10107,,1,1,CHEMBL618189
4525,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,Blood,1,1,CHEMBL618190
4526,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,Blood,1,1,CHEMBL618191
4527,N,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,3655,Blood,1,1,CHEMBL618192
4528,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,Bone,1,1,CHEMBL618193
4529,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,Bone,1,1,CHEMBL618194
4530,N,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,3655,Bone,1,1,CHEMBL618195
4531,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,Brain,1,1,CHEMBL618196
4532,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,Brain,1,1,CHEMBL618197
4533,N,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Intermediate,,,,955.0,50594,BAO_0000218,A,,3655,Brain,1,1,CHEMBL618198
4534,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,Heart,1,1,CHEMBL618199
4535,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,Heart,1,1,CHEMBL618200
4536,N,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,3655,Heart,1,1,CHEMBL618201
4537,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,Intestine,1,1,CHEMBL618202
4538,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,Intestine,1,1,CHEMBL618203
4539,N,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intermediate,,,,160.0,50594,BAO_0000218,A,,3655,Intestine,1,1,CHEMBL618204
4540,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,Kidney,1,1,CHEMBL618205
4541,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,Kidney,1,1,CHEMBL618206
4542,N,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,3655,Kidney,1,1,CHEMBL618207
4543,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,Liver,1,1,CHEMBL618208
4544,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,Liver,1,1,CHEMBL618932
4545,N,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,3655,Liver,1,1,CHEMBL618933
4546,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,Lung,1,1,CHEMBL618934
4547,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,Lung,1,1,CHEMBL618935
4548,N,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,3655,Lung,1,1,CHEMBL618936
4549,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,Muscle tissue,1,1,CHEMBL618937
4550,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,Muscle tissue,1,1,CHEMBL618938
4551,N,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,3655,Muscle tissue,1,1,CHEMBL619104
4552,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,Spleen,1,1,CHEMBL619105
4553,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,Spleen,1,1,CHEMBL619106
4554,N,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,3655,Spleen,1,1,CHEMBL619107
4555,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,Stomach,1,1,CHEMBL875410
4556,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,Stomach,1,1,CHEMBL619108
4557,N,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,3655,Stomach,1,1,CHEMBL619109
4558,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL619110
4559,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,,,50594,BAO_0000218,F,,16597,,1,1,CHEMBL619111
4560,N,,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL619112
4561,N,,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL619113
4562,N,,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL619114
4563,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL619115
4564,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3830,,1,1,CHEMBL619116
4565,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3829,,1,1,CHEMBL619117
4566,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,1,1,CHEMBL619118
4567,N,,478.0,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619119
4568,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619120
4569,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619121
4570,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619122
4571,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619123
4572,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619124
4573,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2859,,1,1,CHEMBL619125
4574,N,,478.0,,In vitro inhibitory activity against human tumor cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,5618,,1,1,CHEMBL875411
4575,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619126
4576,N,,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619127
4577,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619128
4578,N,,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619129
4579,N,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,1,1,CHEMBL619130
4580,N,,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,1,1,CHEMBL619131
4581,N,,478.0,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16745,,1,1,CHEMBL619132
4582,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,1,1,CHEMBL619133
4583,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619134
4584,N,,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15684,,1,1,CHEMBL619135
4585,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,1,1,CHEMBL619136
4586,N,,478.0,,Relative resistance factor in A2780 cisplatin-resistant line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2040,,1,1,CHEMBL619137
4587,N,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Intermediate,,A2780,,,81034,BAO_0000219,F,,16165,,1,1,CHEMBL883713
4588,N,,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16165,,1,1,CHEMBL875412
4589,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,1,1,CHEMBL619138
4590,N,,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,A2780,,,81034,BAO_0000218,F,,16597,,1,1,CHEMBL619262
4591,N,,478.0,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Intermediate,,A2780,,,81034,BAO_0000219,F,,3992,,1,1,CHEMBL619139
4592,N,,478.0,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Intermediate,,A2780,,,81034,BAO_0000219,F,,10553,,1,1,CHEMBL619140
4593,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619141
4594,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619142
4595,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619143
4596,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619144
4597,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619145
4598,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL619146
4599,N,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Intermediate,,A2780,,,81034,BAO_0000219,F,,15569,,1,1,CHEMBL619147
4600,N,,478.0,,Antiproliferative effect of compound on A2780/DX cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17420,,1,1,CHEMBL619148
4601,N,,478.0,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Intermediate,,A2780,,,81034,BAO_0000219,F,,17420,,1,1,CHEMBL619149
4602,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,1,1,CHEMBL619150
4603,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,1,1,CHEMBL619151
4604,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,1,1,CHEMBL883794
4605,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,1,1,CHEMBL619152
4606,N,,478.0,,In vitro cytotoxicity against A2780ADR cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,1,1,CHEMBL619153
4607,N,,478.0,,In vitro cytotoxicity against A2780CIS cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,1,1,CHEMBL619154
4608,N,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Intermediate,,A2780,,,81034,BAO_0000219,F,,5574,,1,1,CHEMBL619155
4609,N,,478.0,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,2113,,1,1,CHEMBL619156
4610,N,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL619157
4611,N,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL619797
4612,U,,,,Oral bioavailability of compound in rhesus macaques,Autocuration,,,,,22224,BAO_0000218,A,,17839,,0,1,CHEMBL619798
4613,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,,0,1,CHEMBL619799
4614,U,,,,Oral bioavailability evaluated in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,0,1,CHEMBL619800
4615,U,,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,6535,,0,1,CHEMBL619801
4616,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4449,,0,1,CHEMBL619802
4617,U,,,,Oral bioavailability was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,,0,1,CHEMBL619803
4618,U,,,,Oral bioavailability in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,,0,1,CHEMBL619965
4619,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,,0,1,CHEMBL619966
4620,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6265,,0,1,CHEMBL619967
4621,U,,,,Oral bioavailability in monkey (dose 1 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,6265,,0,1,CHEMBL620073
4622,U,,,,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,6265,,0,1,CHEMBL620074
4623,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,,0,1,CHEMBL620075
4624,U,,,,Oral bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,5940,,0,1,CHEMBL620076
4625,U,,,,Oral bioavailability in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4514,,0,1,CHEMBL620077
4626,U,,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,,0,1,CHEMBL620078
4627,U,,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5553,,0,1,CHEMBL620079
4628,U,,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,,0,1,CHEMBL620080
4629,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5472,,0,1,CHEMBL620081
4630,U,,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,5668,,0,1,CHEMBL620082
4631,U,,,,Oral bioavailability in monkey at 10 mg/kg of the compound,Autocuration,,,,,22224,BAO_0000218,A,,5711,,0,1,CHEMBL620083
4632,U,,,,Bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,,0,1,CHEMBL620084
4633,U,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL620085
4634,U,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL874595
4635,U,,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3249,,0,1,CHEMBL873352
4636,U,,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3249,,0,1,CHEMBL620086
4637,U,,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620087
4638,U,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620088
4639,U,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL620089
4640,U,,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL620090
4641,U,,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL620091
4642,U,,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620092
4643,U,,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620093
4644,U,,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620094
4645,U,,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620095
4646,U,,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL620096
4647,U,,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL620097
4648,U,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL620098
4649,U,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL620099
4650,U,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL620100
4651,U,,,,Elimination Half-life of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000019,A,,6821,,0,1,CHEMBL620101
4652,U,,,,Half life of compound was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,17267,,0,1,CHEMBL620102
4653,U,,,,Half life in monkey plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,Plasma,0,1,CHEMBL620103
4654,U,,,,Half life in monkey plasma; Not detected,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,Plasma,0,1,CHEMBL620104
4655,U,,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL874596
4656,U,,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,0,1,CHEMBL873490
4657,U,,,,Terminal half life of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,1399,,0,1,CHEMBL620105
4658,U,,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL620780
4659,U,,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL620781
4660,U,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,,0,1,CHEMBL620956
4661,U,,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1088.0,22224,BAO_0000218,A,,3443,Urine,0,1,CHEMBL620957
4662,U,,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1088.0,22224,BAO_0000218,A,,3443,Urine,0,1,CHEMBL620958
4663,U,,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL620959
4664,U,,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,,0,1,CHEMBL620960
4665,U,,,,Volume of distribution was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5472,,0,1,CHEMBL620961
4666,U,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL620962
4667,U,,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL620963
4668,U,,,,Bioavailability in hamster was determined,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL620964
4669,U,,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL620965
4670,U,,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Autocuration,,,,,22224,BAO_0000218,A,,4727,,0,1,CHEMBL620966
4671,U,,,,Half life of compound was determined in hamster blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,4727,Blood,0,1,CHEMBL620967
4672,U,,,,Michaelis-Menten constant of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,0,1,CHEMBL620968
4673,U,,,,Vmax value was measured at 0 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,0,1,CHEMBL874597
4674,U,,,,Vmax value was measured at 10 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,0,1,CHEMBL620969
4675,U,,,,Vmax value was measured at 5 uM concentration of silyl ether.,Autocuration,,,,,22224,BAO_0000019,A,,1452,,0,1,CHEMBL620970
4676,D,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Expert,,,,,235,BAO_0000357,B,,11706,,9,1,CHEMBL620971
4677,U,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL620972
4678,U,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,17791,,0,1,CHEMBL620973
4679,U,,,,Active metabolite of ifosfamide determined in humans; A-Active,Autocuration,,,,,22224,BAO_0000019,A,,7766,,0,1,CHEMBL618243
4680,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Autocuration,,,,,22224,BAO_0000019,A,,6567,,0,1,CHEMBL618244
4681,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Autocuration,,,,,22224,BAO_0000019,A,,6567,,0,1,CHEMBL618245
4682,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Autocuration,,,,,22224,BAO_0000019,A,,6567,,0,1,CHEMBL618246
4683,U,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Autocuration,,,,,22224,BAO_0000019,A,,6567,,0,1,CHEMBL618247
4684,U,,,,Compound was evaluated for oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,17791,,0,1,CHEMBL618248
4685,U,,,,Metabolite of ifosfamide determined in urine; NF-Not found,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618249
4686,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618250
4687,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL874598
4688,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618251
4689,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618252
4690,U,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618253
4691,U,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618254
4692,U,,,,Percent of compound in healthy individuals (Group D),Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL618255
4693,U,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,4397,Liver,0,1,CHEMBL618983
4694,U,,,,Binding towards human plasma protein at 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,0,1,CHEMBL618984
4695,U,,,,Binding towards human plasma protein at 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,0,1,CHEMBL618985
4696,U,,,,Human plasma protein binding activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,17176,,0,1,CHEMBL618986
4697,U,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,,,22224,BAO_0000019,A,,15444,,0,1,CHEMBL618987
4698,U,,,,Percent binding of compound towards human plasma protein was determined,Autocuration,,,,,22224,BAO_0000019,A,,17267,,0,1,CHEMBL618988
4699,U,,,,Plasma clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5944,Liver,0,1,CHEMBL618989
4700,U,,,,In vitro intrinsic clearance in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5668,Liver,0,1,CHEMBL618990
4701,U,,,,In vitro intrinsic clearance in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5669,Liver,0,1,CHEMBL618991
4702,U,,,,In vitro microsome metabolism clearance in human was determined,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,,0,1,CHEMBL876725
4703,U,,,,In vitro microsome metabolism clearance in human was determined; High,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,,0,1,CHEMBL618992
4704,U,,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5041,,0,1,CHEMBL618993
4705,U,,,,Pharmacokinetic property (clearance) in human liver microsome,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5676,Liver,0,1,CHEMBL618994
4706,U,,,,Plasma clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5944,Liver,0,1,CHEMBL618995
4707,U,,,,In vitro clearance in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,17538,Liver,0,1,CHEMBL618996
4708,U,,,,Intrinsic clearance in human liver microsomes was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6331,Liver,0,1,CHEMBL618997
4709,U,,,,Intrinsic clearance in human liver microsomes was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5948,Liver,0,1,CHEMBL618998
4710,U,,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,,,22224,BAO_0000218,A,,5965,,0,1,CHEMBL618999
4711,U,,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL620223
4712,U,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,,,22224,BAO_0000218,A,,5965,,0,1,CHEMBL620224
4713,U,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,Autocuration,,,,,22224,BAO_0000019,A,,1299,,0,1,CHEMBL620225
4714,U,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,Autocuration,,,,,22224,BAO_0000019,A,,1299,,0,1,CHEMBL620226
4715,U,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL620227
4716,U,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL876726
4717,U,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL620228
4718,U,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL620229
4719,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620230
4720,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620231
4721,N,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620232
4722,N,,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620233
4723,N,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,1,1,CHEMBL620234
4724,N,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,1,1,CHEMBL620235
4725,N,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50594,BAO_0000218,A,,14294,,1,1,CHEMBL620236
4726,N,,,,In vitro metabolic potential in mouse liver microsomes,Intermediate,,,,2107.0,50594,BAO_0000218,A,,6251,Liver,1,1,CHEMBL620237
4727,N,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,Intermediate,,,,,50594,BAO_0000218,A,,17582,,1,1,CHEMBL620238
4728,N,,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Intermediate,,,,2369.0,50594,BAO_0000218,A,,17811,Adrenal gland,1,1,CHEMBL620239
4729,N,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,17811,Brain,1,1,CHEMBL620240
4730,N,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,17811,Brain,1,1,CHEMBL620241
4731,N,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Intermediate,,,,,50594,BAO_0000218,A,,17811,,1,1,CHEMBL876727
4732,N,,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17811,Kidney,1,1,CHEMBL620242
4733,N,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Intermediate,,,,,50594,BAO_0000218,A,,17811,,1,1,CHEMBL620243
4734,N,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,5288,,1,1,CHEMBL620244
4735,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,Serum,1,1,CHEMBL620245
4736,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,Serum,1,1,CHEMBL620246
4737,N,,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Intermediate,,,,1977.0,50594,BAO_0000218,A,,2717,Serum,1,1,CHEMBL620247
4738,N,,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,Plasma,1,1,CHEMBL620248
4739,N,,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,Plasma,1,1,CHEMBL873497
4740,N,,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17753,Plasma,1,1,CHEMBL620249
4741,N,,,,Half life after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620250
4742,N,,,,Half life after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620251
4743,N,,,,Half life after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620252
4744,N,,,,Half life after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620253
4745,N,,,,Half life after intravenous administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL620254
4746,N,,,,Half life after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL620255
4747,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL620256
4748,N,,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL876728
4749,N,,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL620257
4750,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL620258
4751,N,,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Intermediate,,,,,50594,BAO_0000218,A,,4890,,1,1,CHEMBL620259
4752,N,,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL620260
4753,N,,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,178.0,50594,BAO_0000218,A,,17837,Blood,1,1,CHEMBL620261
4754,N,,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL620262
4755,N,,,,Half life at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL620263
4756,N,,,,Half life in ob/ob mice,Intermediate,,,,,50594,BAO_0000218,A,,6619,,1,1,CHEMBL620264
4757,N,,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,,1,1,CHEMBL620265
4758,N,,,,Half-life was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,,1,1,CHEMBL620266
4759,N,,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL620267
4760,N,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Intermediate,,,,,50594,BAO_0000218,A,,8999,,1,1,CHEMBL619364
4761,N,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Intermediate,,,,,50594,BAO_0000218,A,,8999,,1,1,CHEMBL619365
4762,N,,,,T2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,Brain,1,1,CHEMBL619366
4763,N,,,,T2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,Kidney,1,1,CHEMBL619367
4764,N,,,,T2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,Liver,1,1,CHEMBL619368
4765,N,,,,T2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,Lung,1,1,CHEMBL619369
4766,N,,,,T2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,Spleen,1,1,CHEMBL876729
4767,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL619370
4768,N,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Intermediate,,,,,50594,BAO_0000218,A,,4890,,1,1,CHEMBL619371
4769,N,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL619372
4770,N,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL620012
4771,N,,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL620013
4772,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL620014
4773,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL620015
4774,N,,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL621010
4775,N,,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL621011
4776,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL621012
4777,N,,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,A2780,,,81034,BAO_0000219,F,,16913,,1,1,CHEMBL621013
4778,N,,478.0,,In vitro cytotoxicity against A2780TAX cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,1,1,CHEMBL621014
4779,N,,481.0,,In vitro inhibitory activity against human tumor cell line A2780cis,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,5618,,1,1,CHEMBL618154
4780,N,,478.0,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,17777,,1,1,CHEMBL618155
4781,N,,481.0,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,16112,,1,1,CHEMBL618156
4782,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,1,1,CHEMBL618157
4783,N,,478.0,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,1,1,CHEMBL618328
4784,N,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Intermediate,,A2780,,,81034,BAO_0000219,F,,16930,,1,1,CHEMBL618329
4785,N,,478.0,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17496,,1,1,CHEMBL618330
4786,N,,478.0,,In vitro antitumor activity against A2780cisR cell line.,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,1,1,CHEMBL618331
4787,N,,478.0,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Intermediate,,A2780,,,81034,BAO_0000219,F,,4840,,1,1,CHEMBL618332
4788,N,,478.0,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,1,1,CHEMBL618333
4789,N,,481.0,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,16745,,1,1,CHEMBL618334
4790,N,,478.0,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,1,1,CHEMBL618335
4791,D,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Expert,,,,,11736,BAO_0000019,B,,16547,,9,1,CHEMBL618336
4792,H,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,,,11736,BAO_0000019,F,,16547,,8,1,CHEMBL618337
4793,D,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,,,11736,BAO_0000019,F,,16547,,9,1,CHEMBL618338
4794,D,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Expert,,HEK293,,,278,BAO_0000219,F,,15856,,9,1,CHEMBL618339
4795,D,,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Expert,,HEK293,,,278,BAO_0000219,F,,15856,,9,1,CHEMBL618340
4796,D,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Expert,,,,,11831,BAO_0000019,B,,16547,,9,1,CHEMBL618341
4797,H,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,,,11831,BAO_0000019,F,,16547,,8,1,CHEMBL618342
4798,D,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,,,11831,BAO_0000019,F,,16547,,9,1,CHEMBL618343
4799,H,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,Expert,,,,,280,BAO_0000357,B,,17402,,8,1,CHEMBL621038
4800,U,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Autocuration,,T-cells,,,22226,BAO_0000219,F,,11746,,0,1,CHEMBL621039
4801,U,,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Autocuration,,T-cells,,,22226,BAO_0000219,F,,11746,,0,1,CHEMBL621040
4802,N,,455.0,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,5455,,1,1,CHEMBL621041
4803,N,,455.0,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Intermediate,,A-375,,,80018,BAO_0000219,F,,2068,,1,1,CHEMBL621042
4804,N,,455.0,,In vitro antitumor activity against A375cell line extracted form melanoma,Intermediate,,A-375,,,80018,BAO_0000219,F,,2683,,1,1,CHEMBL621043
4805,N,,455.0,,Inhibition of cell growth in (A375) melan cell line,Expert,,A-375,,,80018,BAO_0000219,F,,15313,,1,1,CHEMBL621044
4806,N,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,13739,,1,1,CHEMBL621045
4807,N,,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Intermediate,,A-375,,,80018,BAO_0000219,F,,13739,,1,1,CHEMBL621046
4808,N,,455.0,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Intermediate,,A-375,,,80018,BAO_0000219,F,,14750,,1,1,CHEMBL621047
4809,N,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,A-427,,,80019,BAO_0000219,F,,14777,,1,1,CHEMBL621048
4810,N,,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,A-427,,,80019,BAO_0000219,F,,14777,,1,1,CHEMBL883798
4811,N,,797.0,,Cytotoxicity against lung carcinoma A427 tumor cell lines,Intermediate,,A-427,,,80019,BAO_0000219,F,,17672,,1,1,CHEMBL621049
4812,N,,797.0,,Inhibition of large cell lung carcinoma (A427),Intermediate,,A-427,,,80019,BAO_0000219,F,,14368,,1,1,CHEMBL621050
4813,N,,797.0,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Intermediate,,A-427,,,80019,BAO_0000219,F,,14368,,1,1,CHEMBL621051
4814,N,,797.0,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,A-427,,,80019,BAO_0000219,F,,13866,,1,1,CHEMBL621052
4815,N,,797.0,,Inhibitory concentration in human lung carcinoma A427 cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,2545,,1,1,CHEMBL621053
4816,N,,797.0,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,2545,,1,1,CHEMBL621054
4817,U,,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,0,1,CHEMBL621055
4818,U,,,,Tested for volume of distribution upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,,0,1,CHEMBL876398
4819,U,,,,Volume of distribution in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,,0,1,CHEMBL621056
4820,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL621057
4821,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Autocuration,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL621058
4822,U,,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,,0,1,CHEMBL621059
4823,U,,,,The distribution volume after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL621060
4824,U,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL621061
4825,U,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL621062
4826,U,,,,Volume displacement was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,6057,,0,1,CHEMBL621063
4827,U,,,,Volume of distribution in steady state was determined in rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5145,,0,1,CHEMBL621064
4828,U,,,,Volume of distribution of compound was determined in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6821,,0,1,CHEMBL621065
4829,U,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL621066
4830,U,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL621067
4831,U,,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,,0,1,CHEMBL621068
4832,U,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL876399
4833,U,,,,Volume distribution in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,,0,1,CHEMBL621069
4834,U,,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL621070
4835,U,,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,0,1,CHEMBL621071
4836,U,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL621072
4837,U,,,,Oral systemic bioavailability upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,,0,1,CHEMBL618209
4838,U,,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL618210
4839,U,,,,Baboon plasma free fraction. ,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL618211
4840,U,,,,Area under the curve was calculated in rhesus monkey after iv administration,Autocuration,,,,,22224,BAO_0000218,A,,6057,,0,1,CHEMBL618212
4841,U,,,,Area under the curve was calculated in rhesus monkey after peroral administration,Autocuration,,,,,22224,BAO_0000019,A,,6057,,0,1,CHEMBL618213
4842,U,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Autocuration,,,,,22224,BAO_0000019,A,,17853,,0,1,CHEMBL618214
4843,U,,,,Half life period in monkey after 5 mg/kg dose,Autocuration,,,,,22224,BAO_0000218,A,,5302,,0,1,CHEMBL873492
4844,U,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL618272
4845,U,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL618273
4846,U,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13501,Plasma,0,1,CHEMBL618274
4847,U,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,,0,1,CHEMBL618275
4848,U,,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL618276
4849,U,,,,Compound was evaluated for terminal half life in monkey,Autocuration,,,,,22224,BAO_0000019,A,,3341,,0,1,CHEMBL618277
4850,U,,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,3045,,0,1,CHEMBL618278
4851,U,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL618279
4852,U,,,,Half life of compound was determined in squirrel monkey,Autocuration,,,,,22224,BAO_0000019,A,,4847,,0,1,CHEMBL618280
4853,U,,,,Half life after iv administration in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL618281
4854,U,,,,Half life in monkey plasma after administration of 1 mg/kg iv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6535,Plasma,0,1,CHEMBL618282
4855,U,,,,Half life was calculated in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,6057,,0,1,CHEMBL618283
4856,U,,,,Half life in monkey,Autocuration,,,,,22224,BAO_0000019,A,,17592,,0,1,CHEMBL618284
4857,U,,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,,,22224,BAO_0000218,A,,6641,,0,1,CHEMBL618285
4858,U,,,,Half life was evaluated in rhesus,Autocuration,,,,,22224,BAO_0000019,A,,5472,,0,1,CHEMBL618286
4859,U,,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,,0,1,CHEMBL618287
4860,U,,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,,0,1,CHEMBL618288
4861,U,,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,,,22224,BAO_0000218,A,,4809,,0,1,CHEMBL876393
4862,U,,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,,,22224,BAO_0000218,A,,5546,,0,1,CHEMBL618289
4863,U,,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5553,,0,1,CHEMBL618290
4864,U,,,,Half-life was calculated in monkey,Autocuration,,,,,22224,BAO_0000019,A,,6078,,0,1,CHEMBL618291
4865,U,,,,Half-life in Squirrel monkey,Autocuration,,,,,22224,BAO_0000019,A,,5147,,0,1,CHEMBL618292
4866,U,,,,Half-life in rhesus monkey,Autocuration,,,,,22224,BAO_0000019,A,,5145,,0,1,CHEMBL618293
4867,U,,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,0,1,CHEMBL618294
4868,U,,,,Half-life period after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL618295
4869,U,,,,Half-life period after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL618296
4870,U,,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL618297
4871,U,,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618298
4872,U,,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618299
4873,U,,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618300
4874,U,,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618301
4875,U,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618302
4876,U,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL876394
4877,U,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618303
4878,U,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618304
4879,U,,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL618305
4880,U,,,,Oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,16643,,0,1,CHEMBL618306
4881,U,,,,Compound was tested for human plasma protein binding,Autocuration,,,,,22224,BAO_0000019,A,,17248,,0,1,CHEMBL618307
4882,U,,,,Compound was tested for human plasma protein binding; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,17248,,0,1,CHEMBL618308
4883,U,,,,Protein binding activity of compound in human plasma; % Free,Autocuration,,,,,22224,BAO_0000019,A,,6241,,0,1,CHEMBL618309
4884,U,,,,Unbound fraction (plasma),Autocuration,,,,,22224,BAO_0000019,A,,17716,,0,1,CHEMBL618310
4885,U,,,,Half life for the hydrolysis of compound in human blood serum,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17605,Plasma,0,1,CHEMBL873353
4886,U,,,,Half life period in human plasma using phosphate buffer (0.08 M),Autocuration,,,,1969.0,22224,BAO_0000366,A,,17625,Plasma,0,1,CHEMBL618311
4887,U,,,,Half life period in human plasma using phosphate buffer (0.1 M),Autocuration,,,,1969.0,22224,BAO_0000366,A,,17625,Plasma,0,1,CHEMBL618312
4888,U,,,,Half-life in human plasma was determined,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17747,Plasma,0,1,CHEMBL618313
4889,U,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Autocuration,,,,,22224,BAO_0000019,A,,15613,,0,1,CHEMBL618314
4890,U,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Autocuration,,,,,22224,BAO_0000019,A,,354,,0,1,CHEMBL618315
4891,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,,,22224,BAO_0000019,A,,3741,,0,1,CHEMBL618316
4892,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,,,22224,BAO_0000019,A,,3741,,0,1,CHEMBL618317
4893,U,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,,,22224,BAO_0000019,A,,3741,,0,1,CHEMBL620138
4894,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,17599,,0,1,CHEMBL858280
4895,U,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Autocuration,,,,,22224,BAO_0000019,A,,5486,,0,1,CHEMBL620139
4896,U,,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5600,,0,1,CHEMBL620140
4897,U,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,0,1,CHEMBL620141
4898,U,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,0,1,CHEMBL620142
4899,U,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000019,A,,14294,,0,1,CHEMBL620143
4900,U,,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620144
4901,U,,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620145
4902,U,,,,Metabolism of compound in human microsomes; Trace,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL620146
4903,U,,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6260,Liver,0,1,CHEMBL620147
4904,U,,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,6187,,0,1,CHEMBL620148
4905,U,,,,In vitro metabolic potential in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6251,Liver,0,1,CHEMBL620149
4906,U,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3246,,0,1,CHEMBL876412
4907,U,,,,Tested for human plasma protein binding of the compound; Not tested,Autocuration,,,,,22224,BAO_0000019,A,,17313,,0,1,CHEMBL619352
4908,U,,,,Compound was tested for percent protein binding (PB) in human,Autocuration,,,,,22224,BAO_0000019,A,,6227,,0,1,CHEMBL619353
4909,U,,,,Protein binding in human plasma,Autocuration,,,,1969.0,22224,BAO_0000019,A,,5530,Plasma,0,1,CHEMBL619354
4910,U,,,,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL619355
4911,U,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL619356
4912,U,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Autocuration,,,,,22224,BAO_0000019,A,,2774,,0,1,CHEMBL619357
4913,U,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,Autocuration,,,,,22224,BAO_0000019,A,,16643,,0,1,CHEMBL619358
4914,U,,495.0,,Cellular permeability of compound was determined in Caco-2 cells; High,Autocuration,,Caco-2,,,22224,BAO_0000219,A,,17582,,0,1,CHEMBL619359
4915,U,,495.0,,Permeability in Caco-2 cells of compound,Autocuration,,Caco-2,,,22224,BAO_0000219,A,,6838,,0,1,CHEMBL619360
4916,U,,,,Permeability coefficient (A to B) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL619361
4917,U,,,,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL619362
4918,U,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL619363
4919,U,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Autocuration,,,,,22224,BAO_0000019,A,,2146,,0,1,CHEMBL618942
4920,U,,,,Compound was tested for protein binding in human plasma,Autocuration,,,,,22224,BAO_0000019,A,,4514,,0,1,CHEMBL618943
4921,U,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Autocuration,,,,,22224,BAO_0000019,A,,6108,,0,1,CHEMBL618944
4922,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL618945
4923,N,,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL618946
4924,N,,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,,1,1,CHEMBL876413
4925,N,,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3802,,1,1,CHEMBL618947
4926,N,,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2862,Plasma,1,1,CHEMBL618948
4927,N,,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,6348,Plasma,1,1,CHEMBL618949
4928,N,,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL618950
4929,N,,,,Tmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,,50594,BAO_0000218,A,,5781,,1,1,CHEMBL618951
4930,N,,,,Tmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL618952
4931,N,,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,,1,1,CHEMBL618953
4932,N,,,,Tmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,Brain,1,1,CHEMBL618954
4933,N,,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,Kidney,1,1,CHEMBL618955
4934,N,,,,Tmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,Liver,1,1,CHEMBL618956
4935,N,,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,Lung,1,1,CHEMBL618957
4936,N,,,,Tmax in mice at 18 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL618958
4937,N,,,,Tmax in mice at 23 uM/kg i.v. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL618959
4938,N,,,,Tmax in mice at 25 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL618960
4939,N,,,,Tmax in mice at 26 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL876723
4940,N,,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,Spleen,1,1,CHEMBL618961
4941,N,,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL618962
4942,N,,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL618963
4943,N,,,,Tmax value in IRC mice,Intermediate,,,,,50594,BAO_0000218,A,,5951,,1,1,CHEMBL618964
4944,N,,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL618965
4945,N,,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL618966
4946,N,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Intermediate,,,,1088.0,50594,BAO_0000218,A,,429,Urine,1,1,CHEMBL618967
4947,N,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Intermediate,,,,1088.0,50594,BAO_0000218,A,,429,Urine,1,1,CHEMBL618968
4948,N,,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Intermediate,,,,1088.0,50594,BAO_0000218,A,,4066,Urine,1,1,CHEMBL618969
4949,N,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL618970
4950,N,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL618971
4951,N,,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,1,1,CHEMBL618972
4952,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL618973
4953,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL618974
4954,N,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL618975
4955,N,,,,Vd in mice,Intermediate,,,,,50594,BAO_0000218,A,,5980,,1,1,CHEMBL618976
4956,N,,,,Volume of distribution in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,,1,1,CHEMBL618977
4957,N,,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,,1,1,CHEMBL876724
4958,N,,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL618978
4959,N,,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL618979
4960,N,,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL618980
4961,N,,,,Pharmacokinetic property (vdss) was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,,1,1,CHEMBL618981
4962,N,,,,Value distribution upon iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL618982
4963,N,,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL620150
4964,N,,,,Volume of distribution was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL620151
4965,N,,,,Volume of distribution was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL620152
4966,N,,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,1,1,CHEMBL620153
4967,N,,,,Steady state volume of distribution was determined in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,,1,1,CHEMBL876395
4968,N,,,,Volume distribution (steady state) of compound was determined in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,,1,1,CHEMBL620154
4969,N,,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL620155
4970,N,,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL620156
4971,N,,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,1,1,CHEMBL620157
4972,N,,,,Biodistribution of compound (oxidized form) in in kidney tissue,Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL620158
4973,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL620159
4974,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL620160
4975,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL620161
4976,N,,797.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,A-427,,,80019,BAO_0000219,F,,10708,,1,1,CHEMBL620162
4977,N,,500.0,,Inhibition of A431 human squamous cell carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,16597,,1,1,CHEMBL620163
4978,N,,500.0,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Expert,,A-431,,,80852,BAO_0000219,F,,16062,,1,1,CHEMBL620833
4979,N,,500.0,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Expert,,A-431,,,80852,BAO_0000219,F,,16062,,1,1,CHEMBL876396
4980,N,,500.0,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Expert,,A-431,,,80852,BAO_0000219,F,,16958,,1,1,CHEMBL620834
4981,N,,500.0,,Inhibition of A431 human carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,6700,,1,1,CHEMBL620835
4982,N,,500.0,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Expert,,A-431,,,80852,BAO_0000219,F,,17226,,1,1,CHEMBL620836
4983,N,,500.0,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Intermediate,,A-431,,,80852,BAO_0000219,F,,6828,,1,1,CHEMBL620837
4984,N,,500.0,,In vitro cytotoxicity against epidermoid carcinoma cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,12314,,1,1,CHEMBL621017
4985,D,,500.0,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Expert,,A-431,,,9,BAO_0000218,F,,13412,,9,1,CHEMBL621018
4986,N,,500.0,,Antiproliferative activity of compound was measured on human tumor cell line A431.,Intermediate,,A-431,,,80852,BAO_0000219,F,,13299,,1,1,CHEMBL621019
4987,N,,500.0,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Intermediate,,A-431,,,80852,BAO_0000219,F,,17420,,1,1,CHEMBL621020
4988,N,,500.0,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Intermediate,,A-431,,,80852,BAO_0000219,F,,13678,,1,1,CHEMBL621021
4989,H,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Expert,,A-431,,,9,BAO_0000219,F,,14171,,8,1,CHEMBL621022
4990,N,,500.0,,Tested for antiproliferative activity against human A431 cells,Expert,,A-431,,,80852,BAO_0000219,F,,6333,,1,1,CHEMBL621023
4991,D,,500.0,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,2356,,9,1,CHEMBL621024
4992,N,,500.0,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Expert,,A-431,,,80852,BAO_0000219,F,,15578,,1,1,CHEMBL621025
4993,N,,500.0,,Inhibition of A431 cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,5126,,1,1,CHEMBL621026
4994,N,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells,Expert,,A-431,,,80852,BAO_0000219,F,,6844,,1,1,CHEMBL621027
4995,N,,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Expert,,A-431,,,80852,BAO_0000219,F,,6844,,1,1,CHEMBL876397
4996,N,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,4925,,1,1,CHEMBL883797
4997,N,,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Intermediate,,A-431,,,80852,BAO_0000219,F,,4925,,1,1,CHEMBL621028
4998,N,,500.0,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Intermediate,,A-431,,,80852,BAO_0000219,F,,13978,,1,1,CHEMBL621029
4999,N,,500.0,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Intermediate,,A-431,,,80852,BAO_0000219,F,,16786,,1,1,CHEMBL621030
5000,H,,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,13412,,8,1,CHEMBL621147
5001,N,,500.0,,In vivo antiproliferative activity against A431 cell line,Intermediate,,A-431,,,80852,BAO_0000218,F,,17824,,1,1,CHEMBL621148
5002,D,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,12751,,9,1,CHEMBL621149
5003,N,,500.0,,Inhibition of A431 human epidermoid carcinoma cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,12380,,1,1,CHEMBL621150
5004,D,,500.0,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,4959,,9,1,CHEMBL621151
5005,N,,500.0,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,1,1,CHEMBL621152
5006,N,,500.0,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,1,1,CHEMBL621153
5007,N,,500.0,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Intermediate,,A-431,,,80852,BAO_0000219,F,,6333,,1,1,CHEMBL884000
5008,D,,,,Inhibition of EGFR overexpressing A431 cell proliferation,Expert,,,,,9,BAO_0000019,F,,5296,,9,1,CHEMBL621154
5009,N,,500.0,,Inhibition of A431 cell proliferation,Expert,,A-431,,,80852,BAO_0000219,F,,12624,,1,1,CHEMBL621155
5010,D,,500.0,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Expert,,A-431,,,9,BAO_0000219,F,,14926,,9,1,CHEMBL621156
5011,D,,500.0,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Expert,,A-431,,,9,BAO_0000219,F,,14926,,9,1,CHEMBL621157
5012,H,,500.0,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),Expert,,A-431,,,9,BAO_0000219,F,,14926,,8,1,CHEMBL621158
5013,N,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,15144,,1,1,CHEMBL621159
5014,N,,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,15144,,1,1,CHEMBL621160
5015,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621161
5016,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621162
5017,N,,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621163
5018,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621164
5019,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621165
5020,U,,,,Half-life period in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000019,A,,5922,,0,1,CHEMBL619159
5021,U,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,1116,Plasma,0,1,CHEMBL619160
5022,U,,,,Longer half-life in monkey (i.v.) at 0.5 mpk,Autocuration,,,,,22224,BAO_0000218,A,,17853,,0,1,CHEMBL619161
5023,U,,,,Plasma half life in monkey,Autocuration,,,,1969.0,22224,BAO_0000366,A,,993,Plasma,0,1,CHEMBL619162
5024,U,,,,Plasma half-life in rhesus monkey,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4514,Plasma,0,1,CHEMBL619163
5025,U,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,Plasma,0,1,CHEMBL619164
5026,U,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,Plasma,0,1,CHEMBL619320
5027,U,,,,Tested for half life upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,,0,1,CHEMBL619321
5028,U,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL873336
5029,U,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL619322
5030,U,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL619323
5031,U,,,,The time for peak concentration value after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL619324
5032,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619325
5033,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL876411
5034,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619326
5035,U,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619327
5036,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619328
5037,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619329
5038,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619330
5039,U,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619331
5040,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619332
5041,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619333
5042,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619334
5043,U,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619335
5044,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619336
5045,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619337
5046,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619338
5047,U,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11271,,0,1,CHEMBL619339
5048,N,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5809,,1,1,CHEMBL619340
5049,N,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,Plasma,1,1,CHEMBL873496
5050,N,,,,AUC value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3546,Plasma,1,1,CHEMBL619341
5051,N,,,,AUC value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3546,Plasma,1,1,CHEMBL619342
5052,N,,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,1,1,CHEMBL619343
5053,N,,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,1,1,CHEMBL619344
5054,N,,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,1,1,CHEMBL619345
5055,N,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,1,1,CHEMBL619346
5056,N,,,,Half life period in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3546,,1,1,CHEMBL619347
5057,U,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL619348
5058,U,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL619349
5059,U,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL619350
5060,U,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL619351
5061,U,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL875953
5062,U,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL621716
5063,U,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL621717
5064,U,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,,,22224,BAO_0000019,A,,10625,,0,1,CHEMBL621718
5065,U,,,,Area under curve after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000019,A,,3510,,0,1,CHEMBL621719
5066,U,,,,Area under curve after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000019,A,,3510,,0,1,CHEMBL621720
5067,U,,,,Cmax value after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,,0,1,CHEMBL621721
5068,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL621722
5069,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL621723
5070,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL621724
5071,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL623443
5072,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL623444
5073,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL623445
5074,U,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Autocuration,,,,1088.0,22224,BAO_0000019,A,,7766,Urine,0,1,CHEMBL623446
5075,U,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,16643,Liver,0,1,CHEMBL623447
5076,U,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL623448
5077,U,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL623449
5078,U,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Autocuration,,,,,22224,BAO_0000019,A,,6852,,0,1,CHEMBL623450
5079,U,,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6567,Liver,0,1,CHEMBL623451
5080,U,,,,Metabolic stability (% remaining at 30 mins) in human S9.,Autocuration,,,,,22224,BAO_0000019,A,,6570,,0,1,CHEMBL623452
5081,U,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Autocuration,,,,,22224,BAO_0000019,A,,6570,,0,1,CHEMBL623453
5082,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,Liver,0,1,CHEMBL623454
5083,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,Liver,0,1,CHEMBL623455
5084,U,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5237,Liver,0,1,CHEMBL624371
5085,U,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Autocuration,,,,,22224,BAO_0000218,A,,5202,,0,1,CHEMBL624372
5086,U,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,,,22224,BAO_0000019,A,,5481,,0,1,CHEMBL624373
5087,U,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,,,22224,BAO_0000019,A,,5481,,0,1,CHEMBL624374
5088,U,,,,The percent remaining in human plasma after 30 min was determined,Autocuration,,,,,22224,BAO_0000019,A,,3956,,0,1,CHEMBL624556
5089,U,,,,Conversion rate of the prodrug in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5074,Plasma,0,1,CHEMBL624557
5090,U,,,,Conversion rate of the prodrug in human plasma; ND means no data,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5074,Plasma,0,1,CHEMBL624558
5091,U,,,,Half life of compound was determined in human blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,4727,Blood,0,1,CHEMBL624559
5092,U,,,,Half life of compound was determined in man with once daily dosing,Autocuration,,,,,22224,BAO_0000019,A,,5965,,0,1,CHEMBL624560
5093,U,,,,Half life in human microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5732,,0,1,CHEMBL624561
5094,U,,,,Half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,Plasma,0,1,CHEMBL624562
5095,U,,,,Half life in human plasma; Not detected,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5819,Plasma,0,1,CHEMBL624563
5096,U,,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL624564
5097,U,,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6597,Liver,0,1,CHEMBL624565
5098,U,,,,Half-life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5229,Plasma,0,1,CHEMBL875152
5099,U,,,,Half-life of the parent prodrug in plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,5229,Plasma,0,1,CHEMBL624566
5100,U,,,,In vitro half life in human plasma was determined,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2192,Plasma,0,1,CHEMBL873805
5101,U,,,,The compound was tested In Vitro for half life in human liver microsomes.,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,3032,Liver,0,1,CHEMBL624567
5102,U,,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL624568
5103,U,,,,Observed volume of distribution,Autocuration,,,,,22224,BAO_0000218,A,,17716,,0,1,CHEMBL624569
5104,U,,,,Oral bioavailability in human,Autocuration,,,,,22224,BAO_0000218,A,,15778,,0,1,CHEMBL624570
5105,U,,,,Tested for human plasma protein binding of the compound,Autocuration,,,,,22224,BAO_0000019,A,,17313,,0,1,CHEMBL624571
5106,U,,,,"First order rate constant, k was determined in human plasma",Autocuration,,,,,22224,BAO_0000019,A,,4231,,0,1,CHEMBL624572
5107,U,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4755,,0,1,CHEMBL624573
5108,U,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4755,,0,1,CHEMBL875153
5109,U,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,16907,Liver,0,1,CHEMBL624574
5110,U,,,,The compound was tested for the plasma binding in human,Autocuration,,,,,22224,BAO_0000019,A,,10839,,0,1,CHEMBL624575
5111,U,,,,Plasma protein binding (human),Autocuration,,,,,22224,BAO_0000019,A,,10839,,0,1,CHEMBL624576
5112,U,,,,Compound was evaluated for half-life in human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,3199,Liver,0,1,CHEMBL624577
5113,U,,,,Half life measured in vitro for its stability in human blood,Autocuration,,,,178.0,22224,BAO_0000221,A,,1345,Blood,0,1,CHEMBL624578
5114,U,,,,Half life in human serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,4297,Serum,0,1,CHEMBL622796
5115,U,,,,Half life in human serum; ND=not determined,Autocuration,,,,1977.0,22224,BAO_0000019,A,,4297,Serum,0,1,CHEMBL622797
5116,U,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,Autocuration,,,,,22224,BAO_0000019,A,,4297,,0,1,CHEMBL622798
5117,U,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,Autocuration,,,,,22224,BAO_0000019,A,,4297,,0,1,CHEMBL622799
5118,U,,,,Half life of the in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4231,Plasma,0,1,CHEMBL622800
5119,U,,,,Half life period in human hepatic S9 fraction was determined,Autocuration,,,,,22224,BAO_0000220,A,S9,5633,,0,1,CHEMBL622801
5120,U,,,,Half life period in human liver microsome was determined,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,5633,Liver,0,1,CHEMBL622802
5121,U,,,,Half life period was determined; 6-7,Autocuration,,,,,22224,BAO_0000019,A,,17791,,0,1,CHEMBL622803
5122,U,,,,Half life period was evaluated in human,Autocuration,,,,,22224,BAO_0000019,A,,17791,,0,1,CHEMBL875154
5123,U,,,,Half life time in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,3160,Plasma,0,1,CHEMBL622804
5124,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622805
5125,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622611
5126,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622612
5127,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL875160
5128,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL622613
5129,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL622614
5130,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL622615
5131,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL622616
5132,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL622617
5133,N,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL622618
5134,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL622619
5135,N,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL622620
5136,N,,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622621
5137,N,,,,Biodistribution of compound (oxidized form) in blood tissue,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622622
5138,N,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622623
5139,N,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622624
5140,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622625
5141,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622626
5142,N,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622627
5143,N,,,,Biodistribution of compound (oxidized form) in brain tissue of mice,Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622628
5144,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622629
5145,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622630
5146,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622631
5147,N,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622632
5148,N,,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622633
5149,N,,,,Biodistribution of compound (oxidized form) in heart tissue of mice,Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622634
5150,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622635
5151,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL875161
5152,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622636
5153,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL623335
5154,N,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL623336
5155,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL623337
5156,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL623338
5157,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL623339
5158,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL623524
5159,N,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL623525
5160,N,,,,Biodistribution of compound (oxidized form) in liver tissue,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL623526
5161,N,,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL623527
5162,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL623528
5163,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL624615
5164,N,,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,A-431,,,80852,BAO_0000219,F,,5245,,1,1,CHEMBL621672
5165,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL621673
5166,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL621674
5167,D,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,16093,,9,1,CHEMBL884002
5168,N,,500.0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Intermediate,,A-431,,,80852,BAO_0000219,F,,16825,,1,1,CHEMBL621850
5169,N,,500.0,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Intermediate,,A-431,,,80852,BAO_0000219,F,,4848,,1,1,CHEMBL621851
5170,D,,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Expert,,A-431,,,9,BAO_0000219,F,,14827,,9,1,CHEMBL621852
5171,D,,500.0,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Expert,,A-431,,,9,BAO_0000219,F,,14827,,9,1,CHEMBL621853
5172,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL621854
5173,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL621855
5174,N,,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623724
5175,N,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623725
5176,N,,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623726
5177,D,,500.0,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Expert,,A-431,,,9,BAO_0000219,F,,16289,,9,1,CHEMBL623727
5178,H,,500.0,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,Expert,,A-431,,,9,BAO_0000219,F,,16289,,8,1,CHEMBL623728
5179,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623729
5180,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623730
5181,N,,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,A-431,,,80852,BAO_0000218,F,,16289,,1,1,CHEMBL623731
5182,N,,500.0,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,1,1,CHEMBL623732
5183,N,,500.0,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,1,1,CHEMBL623733
5184,N,,500.0,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,1,1,CHEMBL623734
5185,N,,500.0,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,A-431,,,80852,BAO_0000218,F,,14555,,1,1,CHEMBL623735
5186,N,,500.0,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Expert,,A-431,,,80852,BAO_0000219,F,,1937,,1,1,CHEMBL623736
5187,N,,500.0,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Intermediate,,A-431,,,80852,BAO_0000219,F,,13739,,1,1,CHEMBL623737
5188,N,,500.0,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Intermediate,,A-431,,,80852,BAO_0000219,F,,3558,,1,1,CHEMBL623738
5189,N,,500.0,,Dose giving a 50% decrease in the living cell number (A437 cells),Intermediate,,A-431,,,80852,BAO_0000219,F,,3558,,1,1,CHEMBL875168
5190,N,,646.0,,In vitro inhibitory concentration against proliferation of A459 cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17686,,1,1,CHEMBL623739
5191,N,,646.0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5305,,1,1,CHEMBL623740
5192,N,,646.0,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,3614,,1,1,CHEMBL624424
5193,N,,624.0,,In vitro antitumor activity against renal A498 tumor cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,17229,,1,1,CHEMBL624425
5194,N,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Intermediate,,A498,,,80021,BAO_0000219,F,,15935,,1,1,CHEMBL624426
5195,N,,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Intermediate,,A498,,,80021,BAO_0000219,F,,15935,,1,1,CHEMBL624427
5196,N,,624.0,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Intermediate,,A498,,,80021,BAO_0000219,F,,15560,,1,1,CHEMBL624428
5197,N,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,13891,,1,1,CHEMBL624429
5198,N,,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Intermediate,,A498,,,80021,BAO_0000219,F,,13891,,1,1,CHEMBL624620
5199,N,,624.0,,Cytotoxicity on kidney carcinoma (A-498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,13788,,1,1,CHEMBL624621
5200,N,,624.0,,Compound was evaluated against Human cell line renal A498,Intermediate,,A498,,,80021,BAO_0000219,F,,15403,,1,1,CHEMBL624622
5201,N,,624.0,,Compound was tested for inhibition of A498 human renal cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1009,,1,1,CHEMBL624623
5202,N,,624.0,,Growth inhibitory activity against A498 human cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1043,,1,1,CHEMBL874365
5203,N,,624.0,,In vitro antitumor activity against human renal A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5858,,1,1,CHEMBL624624
5204,N,,624.0,,In vitro cytotoxic activity against renal (A498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5958,,1,1,CHEMBL624625
5205,N,,624.0,,In vitro cytotoxic activity against human renal cancer (A498) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,5506,,1,1,CHEMBL624626
5206,N,,624.0,,Tested for cytostatic activity against renal A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,12781,,1,1,CHEMBL624627
5207,N,,624.0,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Intermediate,,A498,,,80021,BAO_0000219,F,,14399,,1,1,CHEMBL883157
5208,N,,624.0,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Expert,,A498,,,80021,BAO_0000219,F,,5958,,1,1,CHEMBL624628
5209,U,,,,Cmax value after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,,0,1,CHEMBL624629
5210,U,,,beagle,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,3510,,0,1,CHEMBL623551
5211,U,,,beagle,Bioavailability after 1 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,,0,1,CHEMBL623552
5212,U,,,beagle,Bioavailability after 2 mpk peroral administration to beagles,Autocuration,,,,,22224,BAO_0000218,A,,3510,,0,1,CHEMBL623553
5213,U,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL623554
5214,U,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL623555
5215,U,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL623556
5216,U,,,,Solubility against bovine alpha-chymotrypsin,Autocuration,,,,,22224,BAO_0000019,A,,9372,,0,1,CHEMBL623557
5217,U,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL623558
5218,U,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL623559
5219,U,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Autocuration,,,,2106.0,22224,BAO_0000221,A,,1469,Spleen,0,1,CHEMBL623560
5220,U,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Autocuration,,,,,22224,BAO_0000019,A,,4297,,0,1,CHEMBL623561
5221,U,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Autocuration,,,,,22224,BAO_0000019,A,,4297,,0,1,CHEMBL623562
5222,U,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Autocuration,,,,,22224,BAO_0000019,A,,17585,,0,1,CHEMBL623563
5223,U,,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Autocuration,,,,2106.0,22224,BAO_0000221,A,,1336,Spleen,0,1,CHEMBL623564
5224,U,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,Autocuration,,,,,22224,BAO_0000019,A,,3085,,0,1,CHEMBL873806
5225,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Autocuration,,,,,22224,BAO_0000019,A,,2857,,0,1,CHEMBL623565
5226,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Autocuration,,,,,22224,BAO_0000019,A,,2857,,0,1,CHEMBL623566
5227,U,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2857,,0,1,CHEMBL623567
5228,U,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Autocuration,,,,,22224,BAO_0000019,A,,1540,,0,1,CHEMBL623568
5229,N,,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6316,Plasma,1,1,CHEMBL623569
5230,N,,,,AUC after administration at 100 mg/kg/day in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17594,Plasma,1,1,CHEMBL623570
5231,N,,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4953,Plasma,1,1,CHEMBL624254
5232,N,,,,AUC value after 15 mg/kg iv dose in Dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,Plasma,1,1,CHEMBL624255
5233,N,,,,AUC value after 30 mg/kg po dose in Dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,Plasma,1,1,CHEMBL624256
5234,N,,,,AUC value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,2959,Plasma,1,1,CHEMBL624257
5235,N,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17594,Plasma,1,1,CHEMBL624258
5236,N,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Intermediate,,,,,50588,BAO_0000218,A,,5356,,1,1,CHEMBL875277
5237,N,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Intermediate,,,,,50588,BAO_0000218,A,,16807,,1,1,CHEMBL622667
5238,N,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL622668
5239,N,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL622669
5240,N,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL622670
5241,N,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL622671
5242,N,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,,1,1,CHEMBL622672
5243,N,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,1,1,CHEMBL622673
5244,N,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,1,1,CHEMBL622674
5245,N,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL622675
5246,N,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL622676
5247,N,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL622677
5248,N,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL622678
5249,N,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,,1,1,CHEMBL622679
5250,N,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,,1,1,CHEMBL622680
5251,N,,,,Area under curve was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL622681
5252,N,,,,Area under curve was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL875278
5253,N,,,,Area under curve was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL622682
5254,N,,,,Area under curve in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL622683
5255,N,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,Intermediate,,,,,50588,BAO_0000218,A,,3771,,1,1,CHEMBL622684
5256,N,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Intermediate,,,,,50588,BAO_0000218,A,,3771,,1,1,CHEMBL622685
5257,N,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,3771,,1,1,CHEMBL622686
5258,N,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,1,1,CHEMBL618344
5259,N,,,,Area under curve value in dog at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5302,,1,1,CHEMBL875582
5260,N,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL618345
5261,N,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL618346
5262,N,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL618347
5263,N,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,1,1,CHEMBL618348
5264,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,0,1,CHEMBL618349
5265,U,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,0,1,CHEMBL618350
5266,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,0,1,CHEMBL618351
5267,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,0,1,CHEMBL618352
5268,U,,,,Time taken to reduce 50% of the concentration of compound in blood plasma,Autocuration,,,,178.0,22224,BAO_0000221,A,,14518,Blood,0,1,CHEMBL873494
5269,U,,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,Plasma,0,1,CHEMBL618353
5270,U,,,,Half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6787,Plasma,0,1,CHEMBL618354
5271,U,,,,Half life in human plasma was reported,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4898,Plasma,0,1,CHEMBL875583
5272,U,,,,Half life in human serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,6072,Serum,0,1,CHEMBL618355
5273,U,,,,Half life upon exposure to human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,16907,Plasma,0,1,CHEMBL618356
5274,U,,,,t1/2 in human microsomes,Autocuration,,,,,22224,BAO_0000251,A,Microsomes,5656,,0,1,CHEMBL618357
5275,U,,,,Half life period in 80% human plasma at 37 degree Centigrade,Autocuration,,,,1969.0,22224,BAO_0000366,A,,4755,Plasma,0,1,CHEMBL618358
5276,U,,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Autocuration,,,,14.0,22224,BAO_0000221,A,,17503,Zone of skin,0,1,CHEMBL618359
5277,U,,,,Half-life measured in in vitro Cathepsin B assay in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,12357,Plasma,0,1,CHEMBL618360
5278,U,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Autocuration,,,,,22224,BAO_0000019,A,,3076,,0,1,CHEMBL618361
5279,U,,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,6410,Liver,0,1,CHEMBL618362
5280,U,,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,Plasma,0,1,CHEMBL618363
5281,U,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,Plasma,0,1,CHEMBL618364
5282,U,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,,1969.0,22224,BAO_0000366,A,,3741,Plasma,0,1,CHEMBL875584
5283,U,,,,Half-life in the CEM cell extracts,Autocuration,,,,,22224,BAO_0000019,A,,1540,,0,1,CHEMBL618365
5284,U,,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2905,Plasma,0,1,CHEMBL873495
5285,U,,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2905,Plasma,0,1,CHEMBL618366
5286,U,,,,Half-life was determined,Autocuration,,,,,22224,BAO_0000019,A,,5523,,0,1,CHEMBL618367
5287,U,,,,Half-life (human blood stability),Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,Blood,0,1,CHEMBL618368
5288,U,,,,Half-life (human blood stability); no data,Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,Blood,0,1,CHEMBL618369
5289,U,,,,Half-life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,17065,Plasma,0,1,CHEMBL618370
5290,U,,,,CYP3A4 metabolism half-life (t1/2),Autocuration,,,,,22224,BAO_0000019,A,,6861,,0,1,CHEMBL618371
5291,U,,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Autocuration,,,,178.0,22224,BAO_0000221,A,,1499,Blood,0,1,CHEMBL618372
5292,U,,,,In vitro half life in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,530,Plasma,0,1,CHEMBL618373
5293,U,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Autocuration,,,,1969.0,22224,BAO_0000366,A,,1116,Plasma,0,1,CHEMBL618374
5294,U,,,,In vitro hydrolysis in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6695,Plasma,0,1,CHEMBL618375
5295,U,,,,In vitro hydrolysis in human plasma; no data,Autocuration,,,,1969.0,22224,BAO_0000366,A,,6695,Plasma,0,1,CHEMBL618376
5296,U,,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,10,Liver,0,1,CHEMBL618377
5297,U,,,,Plasma half life in human,Autocuration,,,,1969.0,22224,BAO_0000366,A,,993,Plasma,0,1,CHEMBL618378
5298,U,,,,Stability after incubation with human plasma (at 37 degree C),Autocuration,,,,1969.0,22224,BAO_0000366,A,,15429,Plasma,0,1,CHEMBL618379
5299,U,,,,T1/2 was evaluated in human plasma,Autocuration,,,,1969.0,22224,BAO_0000366,A,,1675,Plasma,0,1,CHEMBL618380
5300,U,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,Plasma,0,1,CHEMBL618381
5301,U,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Autocuration,,,,1969.0,22224,BAO_0000366,A,,2209,Plasma,0,1,CHEMBL618382
5302,U,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,,,22224,BAO_0000019,A,,5318,,0,1,CHEMBL618383
5303,U,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Autocuration,,,,,22224,BAO_0000019,A,,2412,,0,1,CHEMBL618384
5304,U,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2412,,0,1,CHEMBL618385
5305,U,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2906,Plasma,0,1,CHEMBL619099
5306,U,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Autocuration,,,,1969.0,22224,BAO_0000366,A,,2906,Plasma,0,1,CHEMBL619100
5307,U,,,,Time taken for 50% to be consumed by serum PON1 was determined,Autocuration,,,,,22224,BAO_0000019,A,,5495,,0,1,CHEMBL619101
5308,U,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Autocuration,,,,,22224,BAO_0000019,A,,5495,,0,1,CHEMBL619102
5309,U,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,4397,Liver,0,1,CHEMBL619103
5310,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL619268
5311,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL619269
5312,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL619270
5313,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL619271
5314,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL875585
5315,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL619272
5316,N,,391.0,,Compound tested for growth inhibition of renal cancer cell line 786-0,Intermediate,,786-0,,,80640,BAO_0000219,F,,6058,,1,1,CHEMBL619273
5317,N,,391.0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,17708,,1,1,CHEMBL619274
5318,N,,391.0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Expert,,786-0,,,80640,BAO_0000219,F,,14017,,1,1,CHEMBL619275
5319,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,1,1,CHEMBL619276
5320,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,1,1,CHEMBL619277
5321,N,,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Intermediate,,786-0,,,80640,BAO_0000219,F,,16818,,1,1,CHEMBL619278
5322,N,,391.0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,11970,,1,1,CHEMBL619279
5323,N,,391.0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Intermediate,,786-0,,,80640,BAO_0000219,F,,12400,,1,1,CHEMBL858458
5324,N,,391.0,,Cytotoxic effect on renal cancer line 786-0,Expert,,786-0,,,80640,BAO_0000219,F,,12888,,1,1,CHEMBL619280
5325,N,,391.0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Intermediate,,786-0,,,80640,BAO_0000219,F,,15300,,1,1,CHEMBL619281
5326,N,,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,786-0,,,80640,BAO_0000219,F,,14769,,1,1,CHEMBL619282
5327,N,,391.0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Intermediate,,786-0,,,80640,BAO_0000219,F,,15895,,1,1,CHEMBL619283
5328,N,,391.0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,17376,,1,1,CHEMBL619284
5329,N,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,786-0,,,80640,BAO_0000219,F,,14882,,1,1,CHEMBL619285
5330,N,,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Intermediate,,786-0,,,80640,BAO_0000219,F,,14882,,1,1,CHEMBL619286
5331,N,,391.0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Intermediate,,786-0,,,80640,BAO_0000219,F,,15176,,1,1,CHEMBL619287
5332,N,,391.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,786-0,,,80640,BAO_0000219,F,,12696,,1,1,CHEMBL857455
5333,N,,391.0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Intermediate,,786-0,,,80640,BAO_0000219,F,,2496,,1,1,CHEMBL883801
5334,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619288
5335,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619289
5336,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619290
5337,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619291
5338,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619292
5339,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619293
5340,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619294
5341,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619295
5342,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619296
5343,N,,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,791T cell line,,,80641,BAO_0000219,F,,11831,,1,1,CHEMBL619297
5344,N,,391.0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Intermediate,,786-0,,,80640,BAO_0000219,F,,12782,,1,1,CHEMBL619298
5345,U,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL619299
5346,N,,741.0,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,15313,,1,1,CHEMBL619300
5347,N,,741.0,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,15313,,1,1,CHEMBL619301
5348,N,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,11544,,1,1,CHEMBL619302
5349,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619303
5350,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619304
5351,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL857706
5352,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619305
5353,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619306
5354,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619307
5355,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619308
5356,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619309
5357,N,,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL619310
5358,N,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,A498,,,80021,BAO_0000219,F,,14769,,1,1,CHEMBL619311
5359,N,,624.0,,Compound was tested for the growth inhibition of A498 renal tumor cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,15354,,1,1,CHEMBL619312
5360,N,,624.0,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Intermediate,,A498,,,80021,BAO_0000219,F,,17445,,1,1,CHEMBL619313
5361,N,,624.0,,In vitro inhibitory concentration against renal cancer cell line A498,Intermediate,,A498,,,80021,BAO_0000219,F,,4337,,1,1,CHEMBL619314
5362,N,,624.0,,Cytotoxicity against A 498 tumor cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,15277,,1,1,CHEMBL619959
5363,N,,624.0,,In vitro antitumor activity against A498 human cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,4812,,1,1,CHEMBL619960
5364,N,,624.0,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Intermediate,,A498,,,80021,BAO_0000219,F,,4812,,1,1,CHEMBL619961
5365,N,,624.0,,Inhibitory dose required against A498 human tumor cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,4995,,1,1,CHEMBL619962
5366,N,,624.0,,Anticancer activity against one renal cancer (A498 cell line),Intermediate,,A498,,,80021,BAO_0000219,F,,5847,,1,1,CHEMBL875586
5367,N,,624.0,,In vitro cytotoxicity against melanoma A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,6557,,1,1,CHEMBL619963
5368,N,,624.0,,Compound was tested for growth inhibitory activity against A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2597,,1,1,CHEMBL619964
5369,N,,624.0,,Compound tested for growth inhibition of renal cancer cell line A498,Intermediate,,A498,,,80021,BAO_0000219,F,,6058,,1,1,CHEMBL620108
5370,N,,624.0,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,17708,,1,1,CHEMBL620109
5371,N,,624.0,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Intermediate,,A498,,,80021,BAO_0000219,F,,15176,,1,1,CHEMBL620110
5372,N,,624.0,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Intermediate,,A498,,,80021,BAO_0000219,F,,15300,,1,1,CHEMBL620111
5373,N,,624.0,,Tested for cytotoxicity against A498 cell lines in renal cancer,Intermediate,,A498,,,80021,BAO_0000219,F,,11970,,1,1,CHEMBL620112
5374,N,,624.0,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Intermediate,,A498,,,80021,BAO_0000219,F,,12400,,1,1,CHEMBL620113
5375,N,,624.0,,Cytotoxic effect on renal cancer lines A498,Expert,,A498,,,80021,BAO_0000219,F,,12888,,1,1,CHEMBL620114
5376,N,,624.0,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Intermediate,,A498,,,80021,BAO_0000219,F,,3030,,1,1,CHEMBL620115
5377,N,,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,A498,,,80021,BAO_0000219,F,,14769,,1,1,CHEMBL620116
5378,N,,624.0,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,17376,,1,1,CHEMBL620117
5379,N,,624.0,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Intermediate,,A498,,,80021,BAO_0000219,F,,16558,,1,1,CHEMBL620118
5380,N,,624.0,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Intermediate,,A498,,,80021,BAO_0000219,F,,5194,,1,1,CHEMBL620119
5381,N,,624.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,A498,,,80021,BAO_0000219,F,,10708,,1,1,CHEMBL620120
5382,N,,646.0,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,16880,,1,1,CHEMBL620121
5383,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,1,1,CHEMBL620122
5384,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,1,1,CHEMBL620123
5385,N,,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Intermediate,,A549,,,80682,BAO_0000219,F,,10196,,1,1,CHEMBL620124
5386,N,,646.0,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Intermediate,,A549,,,80682,BAO_0000219,F,,12083,,1,1,CHEMBL620125
5387,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Expert,,A549,,,80682,BAO_0000219,F,,16464,,1,1,CHEMBL620126
5388,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A549,,,80682,BAO_0000219,F,,16464,,1,1,CHEMBL883027
5389,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,16470,,1,1,CHEMBL620127
5390,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,1,1,CHEMBL620128
5391,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line),Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,1,1,CHEMBL620129
5392,N,,646.0,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Intermediate,,A549,,,80682,BAO_0000219,F,,16470,,1,1,CHEMBL620130
5393,N,,646.0,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Expert,,A549,,,80682,BAO_0000219,F,,16582,,1,1,CHEMBL620131
5394,N,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Intermediate,,A549,,,80682,BAO_0000219,F,,15935,,1,1,CHEMBL620132
5395,N,,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Intermediate,,A549,,,80682,BAO_0000219,F,,15935,,1,1,CHEMBL620133
5396,N,,646.0,,Inhibition of A549 human lung carcinoma cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,16597,,1,1,CHEMBL620134
5397,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,1,1,CHEMBL620135
5398,N,,646.0,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,16496,,1,1,CHEMBL620136
5399,N,,646.0,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16152,,1,1,CHEMBL620137
5400,N,,646.0,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16152,,1,1,CHEMBL620268
5401,N,,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A549,,,80682,BAO_0000219,F,,16464,,1,1,CHEMBL620269
5402,N,,646.0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,2288,,1,1,CHEMBL620270
5403,N,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,17350,,1,1,CHEMBL620271
5404,N,,646.0,,Inhibition of A549 cancer cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,4090,,1,1,CHEMBL620272
5405,N,,646.0,,Inhibition of A549 cancer cell proliferation (Not tested),Expert,,A549,,,80682,BAO_0000219,F,,4090,,1,1,CHEMBL620273
5406,N,,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,17350,,1,1,CHEMBL620274
5407,N,,646.0,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Intermediate,,A549,,,80682,BAO_0000219,F,,4197,,1,1,CHEMBL620275
5408,N,,646.0,,Antiproliferative potency determined as inhibitory concentration against A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17072,,1,1,CHEMBL620276
5409,N,,646.0,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Intermediate,,A549,,,80682,BAO_0000219,F,,17072,,1,1,CHEMBL620277
5410,N,,646.0,,Cytotoxicity against Renal cell lines A549 was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5194,,1,1,CHEMBL620278
5411,N,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,,1,1,CHEMBL620279
5412,N,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,,1,1,CHEMBL620280
5413,N,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,,50588,BAO_0000218,A,,1337,,1,1,CHEMBL620281
5414,N,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,,50588,BAO_0000218,A,,1337,,1,1,CHEMBL620282
5415,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,1,1,CHEMBL621134
5416,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,1,1,CHEMBL621135
5417,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,1,1,CHEMBL621136
5418,N,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Intermediate,,,,,50588,BAO_0000218,A,,8833,,1,1,CHEMBL621137
5419,N,,,,Area under plasma concentration time curve in dog upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17657,Plasma,1,1,CHEMBL621138
5420,N,,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,Plasma,1,1,CHEMBL875587
5421,N,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Intermediate,,,,,50588,BAO_0000218,A,,1977,,1,1,CHEMBL621139
5422,N,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Intermediate,,,,,50588,BAO_0000218,A,,1977,,1,1,CHEMBL621140
5423,N,,,,Area under the curve for the compound was obtained when tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,,1,1,CHEMBL621141
5424,N,,,,Area under the curve at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5473,,1,1,CHEMBL621142
5425,N,,,,Area under the curve at a dose of 1 mg/kg (oral),Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL621143
5426,N,,,,Area under the curve at i.v. dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL621144
5427,N,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,1,1,CHEMBL621145
5428,N,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL621146
5429,N,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL622567
5430,N,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL622568
5431,N,,,,Compound was evaluated for area under the curve in dog blood.,Intermediate,,,,,50588,BAO_0000218,A,,2877,,1,1,CHEMBL622569
5432,N,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL622570
5433,N,,,,AUC in dog after oral dose (1 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5130,Plasma,1,1,CHEMBL622571
5434,N,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,,1,1,CHEMBL622572
5435,N,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Intermediate,,,,,50588,BAO_0000218,A,,4657,,1,1,CHEMBL622573
5436,N,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL622574
5437,N,,,,Pharmacokinetic parameter AUC after oral administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL622575
5438,N,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL622576
5439,N,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL622577
5440,N,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL622578
5441,N,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,,1,1,CHEMBL622579
5442,N,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL622580
5443,N,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL622581
5444,N,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL622582
5445,N,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL622583
5446,N,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,,,50588,BAO_0000218,A,,6641,,1,1,CHEMBL622584
5447,N,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL622585
5448,N,,,,Compound was evaluated for oral bioavailability in dog; 90-100,Intermediate,,,,,50588,BAO_0000218,A,,17791,,1,1,CHEMBL622586
5449,N,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Intermediate,,,,,50588,BAO_0000218,A,,17655,,1,1,CHEMBL623281
5450,N,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17655,,1,1,CHEMBL623282
5451,N,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,Intermediate,,,,,50588,BAO_0000218,A,,6596,,1,1,CHEMBL623283
5452,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,,1,1,CHEMBL623284
5453,N,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL623285
5454,N,,,,Plasma protein binding towards dog plasma at 10 uM,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17409,Plasma,1,1,CHEMBL623463
5455,N,,,,Plasma protein binding towards dog plasma at 100 uM,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17409,Plasma,1,1,CHEMBL875952
5456,N,,,,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,2959,,1,1,CHEMBL621705
5457,N,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13501,,1,1,CHEMBL621706
5458,N,,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL621707
5459,N,,,,Bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,15145,,1,1,CHEMBL621708
5460,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,4219,,1,1,CHEMBL621709
5461,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,17538,,1,1,CHEMBL621710
5462,N,,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50588,BAO_0000218,A,,17538,,1,1,CHEMBL621711
5463,N,,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL621712
5464,N,,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17650,,1,1,CHEMBL621713
5465,N,,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,,1,1,CHEMBL621714
5466,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL621715
5467,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,Liver,0,1,CHEMBL623717
5468,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,Liver,0,1,CHEMBL623718
5469,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2107.0,22224,BAO_0000218,A,,2413,Liver,0,1,CHEMBL623719
5470,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL623720
5471,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL623721
5472,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,Muscle tissue,0,1,CHEMBL623722
5473,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,Muscle tissue,0,1,CHEMBL623723
5474,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2385.0,22224,BAO_0000218,A,,2413,Muscle tissue,0,1,CHEMBL618543
5475,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,2106.0,22224,BAO_0000218,A,,2413,Spleen,0,1,CHEMBL618544
5476,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,2106.0,22224,BAO_0000218,A,,2413,Spleen,0,1,CHEMBL875155
5477,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL618545
5478,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL618546
5479,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL623529
5480,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL623530
5481,U,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,,,22224,BAO_0000218,A,,2413,,0,1,CHEMBL621764
5482,U,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,0,1,CHEMBL621765
5483,U,,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2037.0,22224,BAO_0000019,A,,17827,Cerebellum,0,1,CHEMBL621766
5484,U,,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,,1870.0,22224,BAO_0000019,A,,17827,Frontal cortex,0,1,CHEMBL621767
5485,U,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,0,1,CHEMBL621768
5486,U,,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Autocuration,,,,2435.0,22224,BAO_0000019,A,,17827,Striatum,0,1,CHEMBL621769
5487,U,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,0,1,CHEMBL621770
5488,U,,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2037.0,22224,BAO_0000019,A,,17827,Cerebellum,0,1,CHEMBL621771
5489,U,,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,,1870.0,22224,BAO_0000019,A,,17827,Frontal cortex,0,1,CHEMBL621772
5490,U,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Autocuration,,,,,22224,BAO_0000019,A,,17827,,0,1,CHEMBL621773
5491,U,,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Autocuration,,,,2435.0,22224,BAO_0000019,A,,17827,Striatum,0,1,CHEMBL621774
5492,U,,,,Compound was evaluated for oral bioavailability in rats,Autocuration,,,,,22224,BAO_0000218,A,,17791,,0,1,CHEMBL621775
5493,U,,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17667,Plasma,0,1,CHEMBL621776
5494,U,,,,Half life period was evaluated in monkey,Autocuration,,,,,22224,BAO_0000019,A,,17791,,0,1,CHEMBL621777
5495,U,,,,Half-life in rhesus monkeys by intravenous administration of dose,Autocuration,,,,,22224,BAO_0000218,A,,110,,0,1,CHEMBL875162
5496,N,,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,5781,Plasma,1,1,CHEMBL621778
5497,N,,,,AUC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17734,Plasma,1,1,CHEMBL621779
5498,N,,,,AUC value was determined after oral administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17718,Plasma,1,1,CHEMBL622479
5499,N,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,,1,1,CHEMBL622480
5500,N,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,,1,1,CHEMBL622481
5501,N,,,,Area under curve by ioral administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL622482
5502,N,,,,Area under curve by iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL622483
5503,N,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,Intermediate,,,,,50594,BAO_0000218,A,,5951,,1,1,CHEMBL622484
5504,N,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL622641
5505,N,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL622642
5506,N,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL622643
5507,N,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL622644
5508,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL622645
5509,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL622646
5510,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL621238
5511,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL621239
5512,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL621240
5513,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL621241
5514,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL621242
5515,N,,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620350
5516,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620351
5517,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620352
5518,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620353
5519,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620354
5520,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620355
5521,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620356
5522,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620357
5523,N,,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620358
5524,N,,741.0,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Expert,,RPMI-8226,,,80433,BAO_0000219,F,,9424,,1,1,CHEMBL620359
5525,N,,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,11544,,1,1,CHEMBL620360
5526,N,,741.0,,Cytotoxicity of compound against 8226/DOX1V cells,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17378,,1,1,CHEMBL620361
5527,N,,741.0,,Cytotoxicity of compound against 8226/S cells,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17378,,1,1,CHEMBL620362
5528,N,,741.0,,Inhibitory concentration against 8226 myeloma cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17079,,1,1,CHEMBL620363
5529,N,,741.0,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Intermediate,,RPMI-8226,,,80433,BAO_0000219,F,,17079,,1,1,CHEMBL620364
5530,N,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Intermediate,,833K,,,80647,BAO_0000219,F,,13466,,1,1,CHEMBL620365
5531,N,,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Intermediate,,833K,,,80647,BAO_0000219,F,,13466,,1,1,CHEMBL620366
5532,N,,854.0,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Expert,,833K,,,80647,BAO_0000219,F,,2392,,1,1,CHEMBL620367
5533,N,,854.0,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Intermediate,,833K,,,80647,BAO_0000219,F,,2392,,1,1,CHEMBL620368
5534,U,,,,Inhibitory activity against caspase-1,Autocuration,,,,,22226,BAO_0000019,B,,6608,,0,1,CHEMBL620369
5535,H,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Autocuration,,,,,45,BAO_0000357,B,,10199,,8,1,CHEMBL620370
5536,N,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Intermediate,,8701-BC,,,80648,BAO_0000219,F,,17749,,1,1,CHEMBL620371
5537,N,,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Intermediate,,8701-BC,,,80648,BAO_0000219,F,,17749,,1,1,CHEMBL620372
5538,U,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL876492
5539,U,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL620373
5540,U,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,Intermediate,,,,,22226,BAO_0000019,F,,1229,,0,1,CHEMBL620374
5541,U,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,Autocuration,,,,,22226,BAO_0000019,B,,6390,,0,1,CHEMBL620375
5542,U,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL857902
5543,U,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL620376
5544,H,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,Autocuration,,,,,11922,BAO_0000357,B,,17043,,8,1,CHEMBL620377
5545,N,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,KB ,,,81115,BAO_0000219,F,,6929,,1,1,CHEMBL620378
5546,N,,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,KB ,,,81115,BAO_0000219,A,,6929,,1,1,CHEMBL620379
5547,U,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,Autocuration,,,,,22226,BAO_0000219,F,,7083,,0,1,CHEMBL620380
5548,N,,392.0,,Cytotoxic concentration against 9L cells was determined on day 3,Intermediate,,9L,,,80653,BAO_0000219,F,,12446,,1,1,CHEMBL884006
5549,N,,392.0,,Tested in vitro for anticancer activity against 9L cells,Expert,,9L,,,80653,BAO_0000219,F,,15345,,1,1,CHEMBL620381
5550,N,,392.0,,Tested in vitro for anticancer activity against 9L cells; Not determined,Expert,,9L,,,80653,BAO_0000219,F,,15345,,1,1,CHEMBL620382
5551,N,,646.0,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Intermediate,,A549,,,80682,BAO_0000219,F,,6301,,1,1,CHEMBL620383
5552,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,1,1,CHEMBL876493
5553,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,1,1,CHEMBL620384
5554,N,,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,1,1,CHEMBL620385
5555,N,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,13330,,1,1,CHEMBL620386
5556,D,,646.0,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Expert,,A549,,,25,BAO_0000219,F,,17517,,9,1,CHEMBL620387
5557,D,,646.0,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Expert,,A549,,,25,BAO_0000219,F,,17517,,9,1,CHEMBL621404
5558,N,,646.0,,"In vitro growth inhibition of A549, lung carcinoma",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL621405
5559,N,,646.0,,"In vitro growth inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL621406
5560,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,5228,,1,1,CHEMBL621407
5561,N,,646.0,,Cytotoxic activity against human lung cancer A549 cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5351,,1,1,CHEMBL621408
5562,N,,646.0,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,12198,,1,1,CHEMBL885345
5563,N,,646.0,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,13891,,1,1,CHEMBL621409
5564,N,,646.0,,Cytotoxicity in A549 (human carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,5677,,1,1,CHEMBL876034
5565,N,,646.0,,Cytotoxicity on lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,13788,,1,1,CHEMBL621410
5566,N,,646.0,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Expert,,A549,,,80682,BAO_0000219,F,,13384,,1,1,CHEMBL621411
5567,N,,646.0,,Effective dose of compound against replication of A549 cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,6726,,1,1,CHEMBL621412
5568,N,,646.0,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,3455,,1,1,CHEMBL621413
5569,N,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,1,1,CHEMBL621414
5570,N,,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,1,1,CHEMBL621415
5571,N,,646.0,,The compound was evaluated for antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3936,,1,1,CHEMBL621416
5572,N,,646.0,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,14991,,1,1,CHEMBL621417
5573,N,,646.0,,Concentration required for growth inhibition of human lung carcinoma cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,5243,,1,1,CHEMBL621418
5574,N,,646.0,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12858,,1,1,CHEMBL621419
5575,N,,646.0,,Growth inhibition against A549 cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,6776,,1,1,CHEMBL621420
5576,N,,646.0,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,16558,,1,1,CHEMBL875823
5577,N,,646.0,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Expert,,A549,,,80682,BAO_0000219,F,,4583,,1,1,CHEMBL621421
5578,N,,646.0,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Intermediate,,A549,,,80682,BAO_0000219,F,,13514,,1,1,CHEMBL621422
5579,N,,646.0,,Chemosensitivity against DT-diaphorase rich A549 cell lines,Expert,,A549,,,80682,BAO_0000219,F,,15166,,1,1,CHEMBL884014
5580,N,,646.0,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,1,1,CHEMBL621423
5581,N,,646.0,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,6447,,1,1,CHEMBL621424
5582,N,,646.0,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,2068,,1,1,CHEMBL621425
5583,N,,646.0,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,1863,,1,1,CHEMBL621426
5584,N,,646.0,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,1,1,CHEMBL621427
5585,N,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,1,1,CHEMBL621428
5586,N,,646.0,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Expert,,A549,,,80682,BAO_0000219,F,,13873,,1,1,CHEMBL621429
5587,N,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Intermediate,,A549,,,80682,BAO_0000219,F,,579,,1,1,CHEMBL621430
5588,N,,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Intermediate,,A549,,,80682,BAO_0000219,F,,579,,1,1,CHEMBL621431
5589,N,,646.0,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,4584,,1,1,CHEMBL621432
5590,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Expert,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621433
5591,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL875824
5592,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621434
5593,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621435
5594,N,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,14188,,1,1,CHEMBL621436
5595,N,,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Intermediate,,A549,,,80682,BAO_0000219,F,,14188,,1,1,CHEMBL621437
5596,N,,646.0,,Compound was tested for the growth inhibition of A549 lung tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15354,,1,1,CHEMBL621438
5597,N,,646.0,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,14253,,1,1,CHEMBL621439
5598,N,,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,13873,,1,1,CHEMBL621440
5599,N,,,,Oral bioavailability in dog (conscious),Intermediate,,,,,50588,BAO_0000218,A,,3043,,1,1,CHEMBL621441
5600,N,,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,Intermediate,,,,,50588,BAO_0000218,A,,3045,,1,1,CHEMBL621442
5601,N,,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3022,,1,1,CHEMBL621443
5602,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4453,,1,1,CHEMBL621444
5603,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,,1,1,CHEMBL625133
5604,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5045,,1,1,CHEMBL625134
5605,N,,,,Oral bioavailability in dog (fasted),Intermediate,,,,,50588,BAO_0000218,A,,5356,,1,1,CHEMBL625135
5606,N,,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL625136
5607,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL625137
5608,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,1475,,1,1,CHEMBL625138
5609,N,,,,Percent bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3788,,1,1,CHEMBL625139
5610,N,,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL872264
5611,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,13397,,1,1,CHEMBL625140
5612,N,,,,The compound was evaluated for bioavailability in dogs; 34-44,Intermediate,,,,,50588,BAO_0000218,A,,2137,,1,1,CHEMBL624436
5613,N,,,,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,2959,,1,1,CHEMBL624437
5614,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL872261
5615,N,,,,8 hour trough Blood level in dog was measured after administration of compound,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL624438
5616,N,,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3639,Plasma,1,1,CHEMBL624439
5617,N,,,,C24 after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,,1,1,CHEMBL624440
5618,N,,,,Clearance after oral and iv dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5238,,1,1,CHEMBL624441
5619,N,,,,Clearance of the drug was measured in the plasma of dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17796,Plasma,1,1,CHEMBL624442
5620,N,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL624443
5621,N,,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,,1,1,CHEMBL624444
5622,N,,,,Clearance of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6621,,1,1,CHEMBL624445
5623,N,,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,,1,1,CHEMBL624446
5624,N,,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,,1,1,CHEMBL624447
5625,N,,,,Plasma clearance in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,17267,,1,1,CHEMBL624448
5626,N,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL624449
5627,N,,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL624450
5628,N,,,,Plasma clearance in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL875942
5629,N,,,,Plasma clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL624451
5630,N,,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL624452
5631,N,,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50588,BAO_0000218,A,,5199,,1,1,CHEMBL624453
5632,N,,,,Plasma clearance after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL624454
5633,N,,,,Plasma clearance after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL624455
5634,N,,,,Plasma administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL624456
5635,N,,,,Plasma clearance was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,,1,1,CHEMBL624457
5636,N,,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,,1,1,CHEMBL624458
5637,N,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL624459
5638,S,,,,Intrinsic clearance in human liver microsomes,Intermediate,,,,2107.0,102164,BAO_0000251,A,Microsomes,5007,Liver,2,1,CHEMBL624460
5639,S,,,,Intrinsic clearance in human liver microsomes,Intermediate,,,,2107.0,102164,BAO_0000251,A,Microsomes,5007,Liver,2,1,CHEMBL624461
5640,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL875943
5641,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL624462
5642,N,,,,Clearance in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL624463
5643,N,,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,,1,1,CHEMBL624464
5644,N,,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,,1,1,CHEMBL624465
5645,N,,,,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL624466
5646,N,,,,Plasma clearance after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL624467
5647,N,,,,Plasma clearance after peroral administration at 5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL624468
5648,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL624469
5649,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL624470
5650,N,,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL624471
5651,N,,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL624472
5652,N,,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL622775
5653,N,,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL622776
5654,N,,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL622777
5655,N,,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL622778
5656,N,,,,Clearance by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,1,1,CHEMBL622779
5657,N,,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,4305,,1,1,CHEMBL622780
5658,N,,,,Clearance value was evaluated in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1918,Plasma,1,1,CHEMBL622781
5659,N,,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,,1,1,CHEMBL622782
5660,N,,,,Compound was tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4839,Plasma,1,1,CHEMBL622783
5661,N,,,,Pharmacokinetic property (Plasma clearance) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,,1,1,CHEMBL622784
5662,N,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL622785
5663,N,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL622786
5664,N,,,,Area under curve value in mouse at a dose of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5302,,1,1,CHEMBL622787
5665,N,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL875949
5666,N,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL622788
5667,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622789
5668,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622790
5669,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622791
5670,N,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622792
5671,N,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL622793
5672,N,,,,Area under curve was determined for the compound at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL622794
5673,N,,,,Area under curve was determined for the compound at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL622795
5674,N,,,,Area under curve was determined for the compound at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL621803
5675,N,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL621804
5676,N,,,,Area under the curve for the compound was obtained when tested in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL621805
5677,N,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,1,1,CHEMBL621806
5678,N,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,1,1,CHEMBL621807
5679,N,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,1,1,CHEMBL621808
5680,N,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,,1,1,CHEMBL621809
5681,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL621810
5682,N,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,1,1,CHEMBL875164
5683,N,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,1,1,CHEMBL621811
5684,N,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Intermediate,,,,,50594,BAO_0000218,A,,4890,,1,1,CHEMBL621812
5685,N,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL621813
5686,N,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL621814
5687,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL621815
5688,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL621816
5689,N,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL621817
5690,N,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL621818
5691,N,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL621819
5692,N,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL621820
5693,N,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL621821
5694,N,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,1,1,CHEMBL621822
5695,N,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,1,1,CHEMBL619474
5696,N,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50594,BAO_0000218,A,,6619,,1,1,CHEMBL619475
5697,N,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50594,BAO_0000218,A,,6619,,1,1,CHEMBL619476
5698,N,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL619477
5699,N,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL619478
5700,N,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL619479
5701,N,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL619480
5702,N,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Intermediate,,,,,50594,BAO_0000218,A,,3192,,1,1,CHEMBL619481
5703,N,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Intermediate,,,,,50594,BAO_0000218,A,,3192,,1,1,CHEMBL619482
5704,N,,,,Area under the curve was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL619483
5705,N,,,,Area under the curve was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL619484
5706,N,,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,16597,Plasma,1,1,CHEMBL619485
5707,N,,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,16597,Plasma,1,1,CHEMBL619486
5708,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL619487
5709,N,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL619488
5710,N,,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,Blood,1,1,CHEMBL620106
5711,N,,392.0,,The compound was tested in vitro for anticancer activity against 9L cells,Intermediate,,9L,,,80653,BAO_0000219,F,,15345,,1,1,CHEMBL620107
5712,U,,,,Anti proliferation activity determined; Weak effect,Autocuration,,,,,22226,BAO_0000019,F,,2181,,0,1,CHEMBL620283
5713,U,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,,,22226,BAO_0000219,F,,2181,,0,1,CHEMBL875176
5714,U,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Autocuration,,,,,22226,BAO_0000219,F,,2181,,0,1,CHEMBL620284
5715,U,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,,,22226,BAO_0000219,F,,2181,,0,1,CHEMBL623515
5716,U,,,,The cytotoxic activity was in vitro tested by 9PS assay method,Autocuration,,,,,22226,BAO_0000019,F,,10486,,0,1,CHEMBL623516
5717,U,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,Autocuration,,,,,22226,BAO_0000019,F,,10486,,0,1,CHEMBL623517
5718,U,,,,Partition coefficient (logD6.5),Autocuration,,,,,22224,BAO_0000019,A,,15508,,0,1,CHEMBL857878
5719,N,,478.0,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Expert,,A2780,,,81034,BAO_0000219,F,,5242,,1,1,CHEMBL623518
5720,N,,455.0,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Intermediate,,A-375,,,80018,BAO_0000219,F,,16167,,1,1,CHEMBL624195
5721,N,,500.0,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Expert,,A-431,,,80852,BAO_0000219,F,,4782,,1,1,CHEMBL624196
5722,D,,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,A-431,,,9,BAO_0000219,F,,16093,,9,1,CHEMBL624197
5723,N,,624.0,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2596,,1,1,CHEMBL624198
5724,N,,624.0,,in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,2596,,1,1,CHEMBL621287
5725,N,,624.0,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Intermediate,,A498,,,80021,BAO_0000219,F,,3239,,1,1,CHEMBL621288
5726,N,,624.0,,Cytotoxic activity against A 498 renal cancer cell lines.,Intermediate,,A498,,,80021,BAO_0000219,F,,1847,,1,1,CHEMBL876496
5727,N,,624.0,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Intermediate,,A498,,,80021,BAO_0000219,F,,10553,,1,1,CHEMBL621289
5728,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL621290
5729,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL621291
5730,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL621292
5731,U,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,,,22226,BAO_0000019,F,,16219,,0,1,CHEMBL621293
5732,N,,646.0,,Inhibitory concentration required against A 549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4782,,1,1,CHEMBL621294
5733,N,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Intermediate,,A549,,,80682,BAO_0000219,F,,11805,,1,1,CHEMBL621295
5734,N,,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Intermediate,,A549,,,80682,BAO_0000219,F,,11805,,1,1,CHEMBL884007
5735,N,,646.0,,In vitro cytotoxicity against lung cancer A 549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,2007,,1,1,CHEMBL621296
5736,N,,646.0,,Compound was tested for its cytotoxicity against A 549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4594,,1,1,CHEMBL621297
5737,N,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Expert,,A549,,,80682,BAO_0000219,F,,6018,,1,1,CHEMBL839828
5738,N,,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Intermediate,,A549,,,80682,BAO_0000219,F,,6018,,1,1,CHEMBL620397
5739,N,,646.0,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Expert,,A549,,,80682,BAO_0000219,F,,3599,,1,1,CHEMBL620398
5740,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Intermediate,,A549,,,80682,BAO_0000219,F,,2551,,1,1,CHEMBL620399
5741,N,,646.0,,In vitro inhibition of A549 (human lung cancer) cell growth.,Expert,,A549,,,80682,BAO_0000219,F,,16132,,1,1,CHEMBL620400
5742,N,,646.0,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Intermediate,,A549,,,80682,BAO_0000219,F,,16132,,1,1,CHEMBL620401
5743,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Expert,,A549,,,80682,BAO_0000219,F,,2551,,1,1,CHEMBL620402
5744,N,,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Expert,,A549,,,80682,BAO_0000219,F,,2551,,1,1,CHEMBL620403
5745,U,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,Autocuration,,,,,22226,BAO_0000218,F,,11913,,0,1,CHEMBL620404
5746,H,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,Autocuration,,,,,104694,BAO_0000218,F,,12621,,4,1,CHEMBL620405
5747,H,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,104694,BAO_0000218,F,,12621,,4,1,CHEMBL620406
5748,H,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,Autocuration,,,,,104694,BAO_0000218,F,,12621,,4,1,CHEMBL620407
5749,H,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,104694,BAO_0000218,F,,12621,,4,1,CHEMBL620408
5750,H,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,Autocuration,,,,,104694,BAO_0000218,F,,12621,,4,1,CHEMBL620409
5751,N,,624.0,,Inhibition of A-498 human Renal cell proliferation,Expert,,A498,,,80021,BAO_0000219,F,,3600,,1,1,CHEMBL620410
5752,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,0,1,CHEMBL620411
5753,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,0,1,CHEMBL620412
5754,U,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Autocuration,,,,,22226,BAO_0000019,F,,1796,,0,1,CHEMBL876596
5755,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Expert,,A 172,,,80012,BAO_0000219,F,,16464,,1,1,CHEMBL620413
5756,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A 172,,,80012,BAO_0000219,F,,16464,,1,1,CHEMBL620414
5757,N,,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A 172,,,80012,BAO_0000219,F,,16464,,1,1,CHEMBL620415
5758,N,,646.0,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,13617,,1,1,CHEMBL620416
5759,N,,646.0,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,4584,,1,1,CHEMBL620417
5760,N,,646.0,,Cytotoxic activity evaluated against A549 tumor cells,Expert,,A549,,,80682,BAO_0000219,F,,13799,,1,1,CHEMBL620418
5761,N,,646.0,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,1,1,CHEMBL620419
5762,N,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Intermediate,,A549,,,80682,BAO_0000219,F,,16109,,1,1,CHEMBL620420
5763,N,,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Intermediate,,A549,,,80682,BAO_0000219,F,,16109,,1,1,CHEMBL620421
5764,N,,646.0,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Intermediate,,A549,,,80682,BAO_0000219,F,,15474,,1,1,CHEMBL620422
5765,N,,646.0,,Cytotoxicity of compound against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6851,,1,1,CHEMBL620423
5766,N,,646.0,,Cytotoxicity against human lung cell carcinoma A549 cell line,Expert,,A549,,,80682,BAO_0000219,F,,17534,,1,1,CHEMBL620424
5767,N,,646.0,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,2621,,1,1,CHEMBL620425
5768,N,,646.0,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,830,,1,1,CHEMBL620426
5769,N,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Intermediate,,A549,,,80682,BAO_0000219,F,,14255,,1,1,CHEMBL620427
5770,N,,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,14255,,1,1,CHEMBL620428
5771,N,,646.0,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Intermediate,,A549,,,80682,BAO_0000219,F,,1590,,1,1,CHEMBL620429
5772,N,,646.0,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Expert,,A549,,,80682,BAO_0000219,F,,6146,,1,1,CHEMBL620430
5773,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17427,,1,1,CHEMBL839887
5774,N,,646.0,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Intermediate,,A549,,,80682,BAO_0000219,F,,5280,,1,1,CHEMBL620431
5775,N,,646.0,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,16786,,1,1,CHEMBL884010
5776,N,,646.0,,In vitro cytotoxicity against A549 (human lung cancer),Intermediate,,A549,,,80682,BAO_0000219,F,,5895,,1,1,CHEMBL620538
5777,N,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,14297,,1,1,CHEMBL620539
5778,N,,646.0,,In vivo antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL623373
5779,N,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549),Intermediate,,A549,,,80682,BAO_0000219,F,,14368,,1,1,CHEMBL623374
5780,N,,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Intermediate,,A549,,,80682,BAO_0000219,F,,14368,,1,1,CHEMBL623375
5781,N,,646.0,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Intermediate,,A549,,,80682,BAO_0000219,F,,14254,,1,1,CHEMBL623376
5782,N,,646.0,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Intermediate,,A549,,,80682,BAO_0000219,F,,15897,,1,1,CHEMBL623377
5783,N,,646.0,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,A549,,,80682,BAO_0000219,F,,13866,,1,1,CHEMBL623378
5784,N,,646.0,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,13370,,1,1,CHEMBL623379
5785,N,,646.0,,Inhibitory activity against A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,1,1,CHEMBL623380
5786,N,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,1,1,CHEMBL623381
5787,N,,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4862,,1,1,CHEMBL623382
5788,N,,646.0,,Inhibitory concentration against A549 (lung cancer) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15970,,1,1,CHEMBL623383
5789,N,,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17713,,1,1,CHEMBL623384
5790,N,,646.0,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4833,,1,1,CHEMBL623385
5791,N,,646.0,,Activity against A549 cancer cell line.,Expert,,A549,,,80682,BAO_0000219,F,,13736,,1,1,CHEMBL623386
5792,N,,646.0,,The compound was evaluated for cytotoxicity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,1,1,CHEMBL884105
5793,N,,646.0,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL623387
5794,N,,646.0,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621568
5795,N,,646.0,,Growth inhibitory activity was measured for human A549 tumor cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,14717,,1,1,CHEMBL621569
5796,N,,646.0,,Inhibitory activity against A549 lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4634,,1,1,CHEMBL621570
5797,N,,646.0,,Inhibitory activity against A549 cell line; inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,1149,,1,1,CHEMBL621571
5798,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621572
5799,N,,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621573
5800,N,,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,5421,,1,1,CHEMBL621574
5801,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,1,1,CHEMBL621575
5802,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,1,1,CHEMBL621576
5803,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,1,1,CHEMBL621577
5804,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,1,1,CHEMBL621578
5805,N,,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Intermediate,,A549,,,80682,BAO_0000219,F,,3320,,1,1,CHEMBL621579
5806,N,,646.0,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,5726,,1,1,CHEMBL621580
5807,N,,,,Plasma clearance (in vivo) in mongrel dogs was determined,Intermediate,,,,,50588,BAO_0000218,A,,17800,,1,1,CHEMBL621581
5808,N,,,,Plasma clearance was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,,1,1,CHEMBL621582
5809,N,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621583
5810,N,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621584
5811,N,,,,Tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4839,Plasma,1,1,CHEMBL621585
5812,N,,,,The compound was tested for clearance in dog plasma.,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL621586
5813,N,,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Intermediate,,,,,50588,BAO_0000218,A,,4838,,1,1,CHEMBL875835
5814,N,,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,,1,1,CHEMBL621587
5815,N,,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5017,Plasma,1,1,CHEMBL621588
5816,N,,,,In vitro clearance in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,Microsomes,17538,Liver,1,1,CHEMBL621589
5817,N,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,,1,1,CHEMBL621590
5818,N,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,6161,,1,1,CHEMBL621591
5819,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,,1,1,CHEMBL621592
5820,N,,,,Clearance rate in dog,Intermediate,,,,,50588,BAO_0000218,A,,6762,,1,1,CHEMBL621593
5821,N,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL621594
5822,N,,,,Clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,,1,1,CHEMBL621595
5823,N,,,,Plasma clearance in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4942,,1,1,CHEMBL621596
5824,N,,,,Plasma clearance was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,,1,1,CHEMBL621597
5825,N,,,,Lower clearance in dog (i.v.) at 0.5 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,,1,1,CHEMBL621598
5826,N,,,,Plasma clearance in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,4514,,1,1,CHEMBL621599
5827,N,,,,Plasma clearance (Clp) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL875836
5828,N,,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL621600
5829,N,,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL621601
5830,N,,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,1,1,CHEMBL618474
5831,N,,,,Plasma clearance of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,,1,1,CHEMBL618475
5832,N,,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL624524
5833,N,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL624525
5834,N,,,,Plasma clearance in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,5374,,1,1,CHEMBL624526
5835,N,,,,Plasma clearance was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL624527
5836,N,,,,Plasma clearance at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,,1,1,CHEMBL624528
5837,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,,1,1,CHEMBL624529
5838,N,,,,Plasma clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,17657,,1,1,CHEMBL624530
5839,N,,,,Plasma clearance in dog; Unable to calculate,Intermediate,,,,,50588,BAO_0000218,A,,17657,,1,1,CHEMBL624531
5840,N,,,,Plasma clearance in rhesus monkey,Intermediate,,,,,50588,BAO_0000218,A,,5145,,1,1,CHEMBL624532
5841,N,,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL624533
5842,N,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,,1,1,CHEMBL624534
5843,N,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL624535
5844,N,,,,Plasma clearance was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL624536
5845,N,,,,Plasma clearance was evaluated in dog; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL624537
5846,N,,,,Plasma clearance was evaluated in rhesus,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL624538
5847,N,,,,Plasma clearance was evaluated in rhesus; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL624539
5848,N,,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,,1,1,CHEMBL624540
5849,N,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,,1,1,CHEMBL624541
5850,N,,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,,1,1,CHEMBL624542
5851,N,,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,,1,1,CHEMBL624543
5852,N,,,,Clearance value at a dose of 0.2 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL624544
5853,N,,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6316,Plasma,1,1,CHEMBL624545
5854,N,,,,Cmax after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,,1,1,CHEMBL624546
5855,N,,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,,1,1,CHEMBL875957
5856,N,,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,,1,1,CHEMBL624547
5857,N,,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL624548
5858,N,,,,Cmax in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL624549
5859,N,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1466,Plasma,1,1,CHEMBL624550
5860,N,,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,,1,1,CHEMBL621613
5861,N,,,,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL621614
5862,N,,,,Cmax was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL623431
5863,N,,,,Cmax was determine after peroral administration at 5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL623432
5864,N,,,,Cmax after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL623433
5865,N,,,,Cmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL623434
5866,N,,,,Cmax in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,,1,1,CHEMBL623435
5867,N,,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Intermediate,,,,,50588,BAO_0000218,A,,6123,,1,1,CHEMBL623436
5868,N,,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6757,,1,1,CHEMBL875958
5869,N,,,,Cmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL623437
5870,N,,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,Blood,1,1,CHEMBL623438
5871,N,,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,178.0,50594,BAO_0000218,A,,7767,Blood,1,1,CHEMBL623439
5872,N,,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,Bone,1,1,CHEMBL623440
5873,N,,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,Bone,1,1,CHEMBL623441
5874,N,,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,7767,Bone,1,1,CHEMBL623442
5875,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL623469
5876,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL623470
5877,N,,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL623471
5878,N,,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,Heart,1,1,CHEMBL623472
5879,N,,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,Heart,1,1,CHEMBL623473
5880,N,,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,948.0,50594,BAO_0000218,A,,7767,Heart,1,1,CHEMBL623474
5881,N,,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,Kidney,1,1,CHEMBL623475
5882,N,,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,Kidney,1,1,CHEMBL623476
5883,N,,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2113.0,50594,BAO_0000218,A,,7767,Kidney,1,1,CHEMBL623477
5884,N,,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL621896
5885,N,,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL621897
5886,N,,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL621898
5887,N,,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,Liver,1,1,CHEMBL621899
5888,N,,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,Liver,1,1,CHEMBL621900
5889,N,,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2107.0,50594,BAO_0000218,A,,7767,Liver,1,1,CHEMBL621901
5890,N,,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,Lung,1,1,CHEMBL621902
5891,N,,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,Lung,1,1,CHEMBL621903
5892,N,,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2048.0,50594,BAO_0000218,A,,7767,Lung,1,1,CHEMBL622587
5893,N,,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,Muscle tissue,1,1,CHEMBL620285
5894,N,,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,Muscle tissue,1,1,CHEMBL875285
5895,N,,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2385.0,50594,BAO_0000218,A,,7767,Muscle tissue,1,1,CHEMBL620286
5896,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL620287
5897,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL620288
5898,N,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,,50594,BAO_0000218,A,,7767,,1,1,CHEMBL620289
5899,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL620290
5900,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL620291
5901,N,,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,160.0,50594,BAO_0000218,A,,7767,Intestine,1,1,CHEMBL620292
5902,N,,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,Spleen,1,1,CHEMBL620293
5903,N,,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,Spleen,1,1,CHEMBL620294
5904,N,,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,2106.0,50594,BAO_0000218,A,,7767,Spleen,1,1,CHEMBL618614
5905,N,,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,Stomach,1,1,CHEMBL618615
5906,N,,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,Stomach,1,1,CHEMBL618616
5907,N,,622.0,,Cytotoxicity against A-172 human tumor cell lines,Expert,,A 172,,,80012,BAO_0000219,F,,2036,,1,1,CHEMBL618617
5908,N,,622.0,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2357,,1,1,CHEMBL618618
5909,N,,623.0,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Intermediate,,A204,,,80014,BAO_0000219,F,,1457,,1,1,CHEMBL618619
5910,N,,478.0,,Tested for antiproliferative activity against A-2780 tumoral cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4379,,1,1,CHEMBL618620
5911,N,,455.0,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Intermediate,,A-375,,,80018,BAO_0000219,F,,1093,,1,1,CHEMBL618621
5912,N,,455.0,,Tested in vitro against A-375 cell line human melanoma,Intermediate,,A-375,,,80018,BAO_0000219,F,,12152,,1,1,CHEMBL618622
5913,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Expert,,A-427,,,80019,BAO_0000219,F,,16464,,1,1,CHEMBL618623
5914,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A-427,,,80019,BAO_0000219,F,,16464,,1,1,CHEMBL618624
5915,N,,797.0,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Expert,,A-427,,,80019,BAO_0000219,F,,16582,,1,1,CHEMBL618625
5916,N,,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,A-427,,,80019,BAO_0000219,F,,16464,,1,1,CHEMBL618626
5917,N,,797.0,,Antitumor activity on A-427 lung carcinoma cell lines,Intermediate,,A-427,,,80019,BAO_0000219,F,,10413,,1,1,CHEMBL618627
5918,N,,797.0,,Cytotoxic activity against human A-427 lung tumor cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,6418,,1,1,CHEMBL618628
5919,N,,797.0,,In vitro antitumor effects against human A-427 cell lines.,Expert,,A-427,,,80019,BAO_0000219,F,,17134,,1,1,CHEMBL618629
5920,N,,797.0,,In vitro inhibition of A-427 (human lung cancer) cell growth.,Expert,,A-427,,,80019,BAO_0000219,F,,16132,,1,1,CHEMBL618630
5921,N,,797.0,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Intermediate,,A-427,,,80019,BAO_0000219,F,,16132,,1,1,CHEMBL618631
5922,N,,797.0,,Cytotoxic activity of compound against A-427 lung human tumor cell line,Intermediate,,A-427,,,80019,BAO_0000219,F,,16780,,1,1,CHEMBL618632
5923,N,,500.0,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Expert,,A-431,,,80852,BAO_0000219,F,,4085,,1,1,CHEMBL618633
5924,N,,624.0,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,1276,,1,1,CHEMBL619315
5925,N,,624.0,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Expert,,A498,,,80021,BAO_0000219,F,,3498,,1,1,CHEMBL619316
5926,N,,624.0,,Cytotoxicity against human kidney carcinoma A-498cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,1169,,1,1,CHEMBL619317
5927,N,,624.0,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Intermediate,,A498,,,80021,BAO_0000219,F,,4450,,1,1,CHEMBL619318
5928,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,1,1,CHEMBL619319
5929,N,,624.0,,Antitumor cytotoxic activity against A-498 cell line was determined,Intermediate,,A498,,,80021,BAO_0000219,F,,4461,,1,1,CHEMBL619739
5930,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,1,1,CHEMBL619740
5931,N,,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Intermediate,,A498,,,80021,BAO_0000219,F,,3311,,1,1,CHEMBL883158
5932,N,,624.0,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Intermediate,,A498,,,80021,BAO_0000219,F,,1457,,1,1,CHEMBL884012
5933,N,,624.0,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Intermediate,,A498,,,80021,BAO_0000219,F,,3664,,1,1,CHEMBL619741
5934,N,,624.0,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Intermediate,,A498,,,80021,BAO_0000219,F,,15895,,1,1,CHEMBL619742
5935,N,,646.0,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,11843,,1,1,CHEMBL876610
5936,N,,646.0,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,11843,,1,1,CHEMBL619743
5937,N,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17705,,1,1,CHEMBL619744
5938,N,,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Intermediate,,A549,,,80682,BAO_0000219,F,,17705,,1,1,CHEMBL619745
5939,N,,646.0,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL619746
5940,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL619747
5941,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL619748
5942,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL619749
5943,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL619750
5944,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL624014
5945,N,,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4369,,1,1,CHEMBL624015
5946,N,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Expert,,A549,,,80682,BAO_0000219,F,,4787,,1,1,CHEMBL885344
5947,N,,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Intermediate,,A549,,,80682,BAO_0000219,F,,4787,,1,1,CHEMBL623224
5948,N,,646.0,,Cytotoxic activity against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6513,,1,1,CHEMBL623225
5949,N,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Intermediate,,A549,,,80682,BAO_0000219,F,,6690,,1,1,CHEMBL622698
5950,N,,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Intermediate,,A549,,,80682,BAO_0000219,F,,6690,,1,1,CHEMBL622699
5951,N,,646.0,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Expert,,A549,,,80682,BAO_0000219,F,,12263,,1,1,CHEMBL622700
5952,N,,646.0,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Intermediate,,A549,,,80682,BAO_0000219,F,,1054,,1,1,CHEMBL622701
5953,N,,646.0,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Intermediate,,A549,,,80682,BAO_0000219,F,,1359,,1,1,CHEMBL622702
5954,N,,646.0,,Cytotoxic activity against human lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3547,,1,1,CHEMBL622703
5955,N,,646.0,,Cytotoxic activity towards A-549 cells,Expert,,A549,,,80682,BAO_0000219,F,,5771,,1,1,CHEMBL622704
5956,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL622705
5957,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL622706
5958,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL622707
5959,N,,646.0,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Intermediate,,A549,,,80682,BAO_0000219,F,,14425,,1,1,CHEMBL622708
5960,N,,646.0,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,5280,,1,1,CHEMBL622709
5961,N,,646.0,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Intermediate,,A549,,,80682,BAO_0000219,F,,15176,,1,1,CHEMBL622710
5962,N,,646.0,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Intermediate,,A549,,,80682,BAO_0000219,F,,15300,,1,1,CHEMBL622711
5963,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL622712
5964,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL622713
5965,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL622714
5966,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL622715
5967,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,A549,,,80682,BAO_0000218,F,,17824,,1,1,CHEMBL622716
5968,N,,646.0,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Intermediate,,A549,,,80682,BAO_0000219,F,,17824,,1,1,CHEMBL622717
5969,N,,646.0,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Intermediate,,A549,,,80682,BAO_0000218,F,,17528,,1,1,CHEMBL622718
5970,N,,646.0,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Expert,,A549,,,80682,BAO_0000219,F,,6870,,1,1,CHEMBL622719
5971,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,1,1,CHEMBL622720
5972,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,1,1,CHEMBL622721
5973,N,,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,6870,,1,1,CHEMBL622722
5974,N,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,1,1,CHEMBL876030
5975,N,,646.0,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Intermediate,,A549,,,80682,BAO_0000219,F,,6170,,1,1,CHEMBL620206
5976,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,1,1,CHEMBL620207
5977,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,1,1,CHEMBL620208
5978,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,1,1,CHEMBL620209
5979,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,1,1,CHEMBL620210
5980,N,,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6583,,1,1,CHEMBL621639
5981,N,,646.0,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17321,,1,1,CHEMBL621640
5982,N,,646.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,A549,,,80682,BAO_0000219,F,,17528,,1,1,CHEMBL621641
5983,N,,646.0,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Expert,,A549,,,80682,BAO_0000219,F,,12888,,1,1,CHEMBL621642
5984,N,,646.0,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,1,1,CHEMBL621643
5985,N,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,1,1,CHEMBL621644
5986,N,,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Intermediate,,A549,,,80682,BAO_0000219,F,,4312,,1,1,CHEMBL621645
5987,N,,646.0,,In vitro antiproliferative activity against A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17737,,1,1,CHEMBL621646
5988,N,,646.0,,Synergism with indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621647
5989,N,,646.0,,Synergism with tolmetin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621648
5990,N,,646.0,,Synergism with sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621649
5991,N,,646.0,,Antagonism of indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621650
5992,N,,646.0,,Antagonism of sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621651
5993,N,,646.0,,Antagonism of tolmetin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621652
5994,N,,646.0,,Synergism with indomethacin in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621653
5995,N,,646.0,,Synergism with sulindac in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621654
5996,N,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL621655
5997,N,,,,Cmax value after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL621656
5998,N,,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL621657
5999,N,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL621658
6000,N,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL621659
6001,N,,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,,,50588,BAO_0000218,A,,5944,,1,1,CHEMBL621660
6002,N,,,,Cmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,,1,1,CHEMBL621661
6003,N,,,,Cmax value in dog,Intermediate,,,,,50588,BAO_0000218,A,,6241,,1,1,CHEMBL621662
6004,N,,,,Cmax value in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,,1,1,CHEMBL621663
6005,N,,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL621664
6006,N,,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1806,Plasma,1,1,CHEMBL621665
6007,N,,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1806,Plasma,1,1,CHEMBL621666
6008,N,,,,Concentration maxima after oral dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1021,,1,1,CHEMBL621667
6009,N,,,,Concentration maxima after oral dosing in dogs; not available,Intermediate,,,,,50588,BAO_0000218,A,,1021,,1,1,CHEMBL876738
6010,N,,,,Concentration maxima after oral dosing in dogs; not available,Intermediate,,,,,50588,BAO_0000218,A,,1021,,1,1,CHEMBL621668
6011,N,,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL621669
6012,N,,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL621670
6013,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL621671
6014,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL622360
6015,N,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL622361
6016,N,,,,Cmax in dog plasma after oral dose (1 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5130,Plasma,1,1,CHEMBL622362
6017,N,,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3249,Plasma,1,1,CHEMBL622363
6018,N,,,,Maximal plasma concentration at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5473,Plasma,1,1,CHEMBL622364
6019,N,,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5474,Plasma,1,1,CHEMBL622365
6020,N,,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4657,Plasma,1,1,CHEMBL622533
6021,N,,,,Maximum concentration of compound in dog was evaluated.,Intermediate,,,,,50588,BAO_0000218,A,,3031,,1,1,CHEMBL622534
6022,N,,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL622535
6023,N,,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,,1,1,CHEMBL876739
6024,N,,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,,1,1,CHEMBL622536
6025,N,,,,Maximum concentration obtained in dog plasma was determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL622537
6026,N,,,,Maximum concentration was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL622538
6027,N,,,,Maximum concentration at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,,1,1,CHEMBL627867
6028,N,,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,1,1,CHEMBL627868
6029,N,,,,Maximum concentration was evaluated in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1918,Plasma,1,1,CHEMBL627869
6030,N,,,,Maximum concentration was evaluated after 75 min after administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,3045,,1,1,CHEMBL627870
6031,N,,,,Maximum plasma concentration determined in dog after oral administration of 17b,Intermediate,,,,1969.0,50588,BAO_0000218,A,,9579,Plasma,1,1,CHEMBL627871
6032,N,,,,Maximum plasma concentration determined in dog after oral administration of 2b,Intermediate,,,,1969.0,50588,BAO_0000218,A,,9579,Plasma,1,1,CHEMBL627872
6033,N,,,,Maximum plasma concentration in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,933,Plasma,1,1,CHEMBL627873
6034,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,Plasma,1,1,CHEMBL627874
6035,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,Plasma,1,1,CHEMBL627875
6036,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,Plasma,1,1,CHEMBL627876
6037,N,,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17839,Plasma,1,1,CHEMBL627877
6038,N,,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6348,Plasma,1,1,CHEMBL627878
6039,N,,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16367,Plasma,1,1,CHEMBL627879
6040,N,,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1337,Plasma,1,1,CHEMBL875355
6041,N,,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1337,Plasma,1,1,CHEMBL627880
6042,N,,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL627881
6043,N,,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,Plasma,1,1,CHEMBL627882
6044,N,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6679,Plasma,1,1,CHEMBL627883
6045,N,,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5356,Plasma,1,1,CHEMBL628526
6046,N,,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5356,Plasma,1,1,CHEMBL628527
6047,N,,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,Plasma,1,1,CHEMBL628528
6048,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,Plasma,1,1,CHEMBL628529
6049,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,Plasma,1,1,CHEMBL628530
6050,N,,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6227,Plasma,1,1,CHEMBL625243
6051,N,,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,1969.0,50588,BAO_0000218,A,,3598,Plasma,1,1,CHEMBL625244
6052,N,,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,1,1,CHEMBL625245
6053,N,,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,,1,1,CHEMBL625246
6054,N,,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,,945.0,50594,BAO_0000218,A,,7767,Stomach,1,1,CHEMBL625247
6055,N,,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,Urine,1,1,CHEMBL625248
6056,N,,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,Urine,1,1,CHEMBL625249
6057,N,,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,,1088.0,50594,BAO_0000218,A,,7767,Urine,1,1,CHEMBL625250
6058,N,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Intermediate,,,,,50594,BAO_0000218,A,,17811,,1,1,CHEMBL625251
6059,N,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Intermediate,,,,,50594,BAO_0000218,A,,17811,,1,1,CHEMBL875356
6060,N,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625252
6061,N,,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,Blood,1,1,CHEMBL625253
6062,N,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625254
6063,N,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625255
6064,N,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625256
6065,N,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,Blood,1,1,CHEMBL625257
6066,N,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Intermediate,,,,178.0,50594,BAO_0000218,A,,17827,Blood,1,1,CHEMBL625258
6067,N,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625259
6068,N,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625260
6069,N,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625261
6070,N,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL625262
6071,N,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL622639
6072,N,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Intermediate,,,,,50594,BAO_0000218,A,,17257,,1,1,CHEMBL622640
6073,N,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Intermediate,,,,,50594,BAO_0000218,A,,17257,,1,1,CHEMBL622812
6074,N,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Intermediate,,,,,50594,BAO_0000218,A,,17257,,1,1,CHEMBL622813
6075,N,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Intermediate,,,,,50594,BAO_0000218,A,,17257,,1,1,CHEMBL622814
6076,N,,,,Time at maximum activity in mice (Radiolabeled compound),Intermediate,,,,,50594,BAO_0000218,A,,17827,,1,1,CHEMBL622815
6077,N,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL625342
6078,N,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL625343
6079,N,,,,Binding towards mouse plasma protein at 10 uM,Intermediate,,,,,50594,BAO_0000218,A,,17409,,1,1,CHEMBL877591
6080,N,,,,Binding towards mouse plasma protein at 100 uM,Intermediate,,,,,50594,BAO_0000218,A,,17409,,1,1,CHEMBL625344
6081,N,,,,Bioavailability was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL625345
6082,N,,,,Bioavailability was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL625346
6083,N,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL625347
6084,N,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL625348
6085,N,,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL625349
6086,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL625350
6087,N,,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL882952
6088,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL625351
6089,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL625352
6090,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL877592
6091,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL625353
6092,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL625354
6093,N,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,955.0,50594,BAO_0000218,A,,846,Brain,1,1,CHEMBL626019
6094,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL626020
6095,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL626021
6096,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL626022
6097,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL626192
6098,N,,646.0,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Intermediate,,A549,,,80682,BAO_0000219,F,,1276,,1,1,CHEMBL626193
6099,N,,646.0,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Expert,,A549,,,80682,BAO_0000219,F,,3498,,1,1,CHEMBL626194
6100,N,,646.0,,Cytotoxicity against human lung carcinoma A-549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,1169,,1,1,CHEMBL626195
6101,N,,646.0,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4450,,1,1,CHEMBL626196
6102,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626197
6103,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626198
6104,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626199
6105,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626200
6106,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626201
6107,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626202
6108,N,,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Intermediate,,A549,,,80682,BAO_0000219,F,,358,,1,1,CHEMBL626203
6109,N,,646.0,,In vitro cytotoxicity against A-549 human lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,15167,,1,1,CHEMBL626204
6110,N,,646.0,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4139,,1,1,CHEMBL624701
6111,N,,646.0,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,833,,1,1,CHEMBL624702
6112,N,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,15718,,1,1,CHEMBL624703
6113,N,,646.0,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,12373,,1,1,CHEMBL624704
6114,N,,646.0,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Intermediate,,A549,,,80682,BAO_0000219,F,,637,,1,1,CHEMBL624705
6115,N,,646.0,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Expert,,A549,,,80682,BAO_0000219,F,,14867,,1,1,CHEMBL624706
6116,N,,646.0,,Antitumor cytotoxic activity against A-549 cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4461,,1,1,CHEMBL624707
6117,N,,646.0,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Intermediate,,A549,,,80682,BAO_0000219,F,,5406,,1,1,CHEMBL624708
6118,N,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4457,,1,1,CHEMBL624709
6119,N,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,1386,,1,1,CHEMBL884107
6120,N,,646.0,,Antitumoral activity was assayed against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3265,,1,1,CHEMBL624710
6121,N,,646.0,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Intermediate,,A549,,,80682,BAO_0000219,F,,2359,,1,1,CHEMBL624711
6122,N,,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4457,,1,1,CHEMBL624712
6123,N,,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,12454,,1,1,CHEMBL624713
6124,N,,646.0,,Compound was tested for inhibition of cell growth of A-549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,1481,,1,1,CHEMBL624714
6125,N,,646.0,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Intermediate,,A549,,,80682,BAO_0000219,F,,1750,,1,1,CHEMBL624715
6126,N,,646.0,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,5065,,1,1,CHEMBL624716
6127,N,,646.0,,In vitro cytotoxicity against A549-human lung carcinoma cells.,Expert,,A549,,,80682,BAO_0000219,F,,808,,1,1,CHEMBL619505
6128,N,,646.0,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Expert,,A549,,,80682,BAO_0000219,F,,16364,,1,1,CHEMBL619506
6129,N,,646.0,,Cytotoxic activity against A-549 cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,1847,,1,1,CHEMBL619507
6130,N,,646.0,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Expert,,A549,,,80682,BAO_0000219,F,,1747,,1,1,CHEMBL619508
6131,N,,646.0,,Cytotoxicity against human A549 non small cell lung cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,1003,,1,1,CHEMBL619509
6132,N,,646.0,,Inhibition of cell growth in (A-549) lung cell line,Expert,,A549,,,80682,BAO_0000219,F,,15313,,1,1,CHEMBL619510
6133,N,,646.0,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3122,,1,1,CHEMBL619511
6134,N,,646.0,,In vitro antitumor activity against A-549 tumor cells.,Intermediate,,A549,,,80682,BAO_0000219,F,,16049,,1,1,CHEMBL619512
6135,N,,646.0,,In vitro antitumor effects against human A-549 cell lines.,Expert,,A549,,,80682,BAO_0000219,F,,17134,,1,1,CHEMBL619513
6136,N,,646.0,,In vitro cytotoxic activity of compound against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6406,,1,1,CHEMBL619514
6137,N,,646.0,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,627,,1,1,CHEMBL619515
6138,N,,646.0,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Intermediate,,A549,,,80682,BAO_0000219,F,,12307,,1,1,CHEMBL619516
6139,N,,646.0,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Intermediate,,A549,,,80682,BAO_0000219,F,,17861,,1,1,CHEMBL884005
6140,N,,646.0,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Expert,,A549,,,80682,BAO_0000219,F,,6682,,1,1,CHEMBL619517
6141,N,,646.0,,Inhibitory concentration of compound against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL619518
6142,N,,646.0,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Intermediate,,A549,,,80682,BAO_0000219,F,,2454,,1,1,CHEMBL619519
6143,N,,646.0,,cytotoxic activity against leukemia (A-549) cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14709,,1,1,CHEMBL876489
6144,N,,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,A549,,,80682,BAO_0000219,F,,15718,,1,1,CHEMBL619520
6145,N,,646.0,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,15718,,1,1,CHEMBL619521
6146,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL619522
6147,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL619523
6148,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL619524
6149,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL619525
6150,N,,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,Intermediate,,A549,,,80682,BAO_0000219,F,,6630,,1,1,CHEMBL619526
6151,N,,646.0,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,1,1,CHEMBL619527
6152,N,,646.0,,Cytotoxicity against A549 cells; No cytotoxicity,Intermediate,,A549,,,80682,BAO_0000219,F,,17846,,1,1,CHEMBL619528
6153,N,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines,Expert,,A549,,,80682,BAO_0000219,F,,3415,,1,1,CHEMBL619529
6154,N,,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Expert,,A549,,,80682,BAO_0000219,F,,3415,,1,1,CHEMBL619530
6155,N,,646.0,,In vitro anticancer activity against human lung (A549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5609,,1,1,CHEMBL876490
6156,N,,646.0,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619531
6157,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619532
6158,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619533
6159,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619534
6160,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL620164
6161,N,,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL620165
6162,N,,646.0,,Inhibition of A549 human lung tumor cell proliferation,Expert,,A549,,,80682,BAO_0000219,F,,16295,,1,1,CHEMBL620166
6163,N,,646.0,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Intermediate,,A549,,,80682,BAO_0000219,F,,16825,,1,1,CHEMBL620167
6164,N,,646.0,,In vitro cytotoxicity against human tumor cell line A549,Expert,,A549,,,80682,BAO_0000219,F,,3439,,1,1,CHEMBL620168
6165,N,,646.0,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Intermediate,,A549,,,80682,BAO_0000219,F,,10870,,1,1,CHEMBL620338
6166,N,,646.0,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,4845,,1,1,CHEMBL620339
6167,N,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,1,1,CHEMBL620340
6168,N,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,1,1,CHEMBL620341
6169,N,,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,1,1,CHEMBL876491
6170,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL620342
6171,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL620343
6172,N,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL620344
6173,N,,646.0,,In vitro anticancer activity against human lung (A549) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,5609,,1,1,CHEMBL620345
6174,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,1,1,CHEMBL620346
6175,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,1,1,CHEMBL620347
6176,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,1,1,CHEMBL620348
6177,N,,646.0,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,1,1,CHEMBL620349
6178,N,,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,5822,,1,1,CHEMBL618667
6179,N,,646.0,,Percentage inhibition of human lung carcinoma (A549) cell lines,Expert,,A549,,,80682,BAO_0000219,F,,3415,,1,1,CHEMBL618668
6180,N,,646.0,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,1,1,CHEMBL876031
6181,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL618759
6182,N,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL618760
6183,N,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619000
6184,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619001
6185,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619002
6186,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619003
6187,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619597
6188,N,,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619598
6189,N,,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619599
6190,N,,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619600
6191,N,,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,A549,,,80682,BAO_0000219,F,,16726,,1,1,CHEMBL619601
6192,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619602
6193,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619603
6194,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619604
6195,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619605
6196,N,,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL619606
6197,N,,,,Pharmacokinetic activity (Cmax) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL876032
6198,N,,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL619607
6199,N,,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL619608
6200,N,,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6251,,1,1,CHEMBL619609
6201,N,,,,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL619610
6202,N,,,,Tested for the peak blood level in dog,Intermediate,,,,178.0,50588,BAO_0000218,A,,4273,Blood,1,1,CHEMBL619611
6203,N,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL619612
6204,N,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL619613
6205,N,,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Intermediate,,,,178.0,50588,BAO_0000218,A,,6221,Blood,1,1,CHEMBL619614
6206,N,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL619615
6207,N,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Intermediate,,,,,50588,BAO_0000218,A,,167,,1,1,CHEMBL619616
6208,N,,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6241,Plasma,1,1,CHEMBL619617
6209,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,1,1,CHEMBL619618
6210,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,1,1,CHEMBL876033
6211,N,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Intermediate,,,,,50588,BAO_0000218,A,,344,,1,1,CHEMBL619619
6212,N,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Intermediate,,,,,50588,BAO_0000218,A,,2189,,1,1,CHEMBL619620
6213,N,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,Urine,1,1,CHEMBL619621
6214,N,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,Urine,1,1,CHEMBL619622
6215,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50588,BAO_0000218,A,,2189,Urine,1,1,CHEMBL618874
6216,N,,,,Absolute bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,4257,,1,1,CHEMBL618875
6217,N,,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,,1,1,CHEMBL618876
6218,N,,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,,1,1,CHEMBL618877
6219,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17267,,1,1,CHEMBL618878
6220,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6621,,1,1,CHEMBL618879
6221,N,,,,Bioavailability after intravenous administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3854,,1,1,CHEMBL618880
6222,N,,,,Bioavailability after peroral administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3854,,1,1,CHEMBL618881
6223,N,,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5007,,1,1,CHEMBL618882
6224,N,,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Intermediate,,,,,50588,BAO_0000218,A,,4333,,1,1,CHEMBL624226
6225,N,,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,4333,Plasma,1,1,CHEMBL624227
6226,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL624228
6227,N,,,,Bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,5199,,1,1,CHEMBL624229
6228,N,,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,1,1,CHEMBL624230
6229,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3771,,1,1,CHEMBL624231
6230,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4953,,1,1,CHEMBL624232
6231,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5064,,1,1,CHEMBL625127
6232,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17657,,1,1,CHEMBL625128
6233,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,,1,1,CHEMBL621675
6234,N,,,,Bioavailability in dog (p.o.) at 2.0 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,,1,1,CHEMBL621676
6235,N,,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL621677
6236,N,,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL621678
6237,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL621679
6238,N,,,,Bioavailability was evaluated after oral administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,16365,,1,1,CHEMBL621680
6239,N,,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,1,1,CHEMBL621681
6240,N,,,,Bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1918,,1,1,CHEMBL876740
6241,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,,1,1,CHEMBL621682
6242,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,,1,1,CHEMBL621683
6243,N,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,,1,1,CHEMBL621684
6244,N,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,,1,1,CHEMBL621685
6245,N,,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL621686
6246,N,,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,,1,1,CHEMBL621687
6247,N,,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,,1,1,CHEMBL621688
6248,N,,,,Bioavailability of compound in dog was determined after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,17804,,1,1,CHEMBL621689
6249,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,,1,1,CHEMBL621690
6250,N,,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1806,,1,1,CHEMBL621691
6251,N,,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,,,50588,BAO_0000218,A,,1806,,1,1,CHEMBL875941
6252,N,,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Intermediate,,,,,50588,BAO_0000218,A,,1806,,1,1,CHEMBL621692
6253,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,,1,1,CHEMBL621693
6254,N,,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5017,,1,1,CHEMBL621694
6255,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL621695
6256,N,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,948.0,50594,BAO_0000218,A,,846,Heart,1,1,CHEMBL621696
6257,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL621697
6258,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL621698
6259,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL623420
6260,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL623421
6261,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL623422
6262,N,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2113.0,50594,BAO_0000218,A,,846,Kidney,1,1,CHEMBL623423
6263,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL623424
6264,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL623425
6265,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL623426
6266,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL623427
6267,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL623428
6268,N,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2107.0,50594,BAO_0000218,A,,846,Liver,1,1,CHEMBL875947
6269,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL623429
6270,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL623430
6271,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL622588
6272,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL622589
6273,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL622751
6274,N,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,,2048.0,50594,BAO_0000218,A,,846,Lung,1,1,CHEMBL622752
6275,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL622753
6276,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL622647
6277,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL875163
6278,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL622648
6279,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL622649
6280,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,Brain,1,1,CHEMBL622650
6281,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,Brain,1,1,CHEMBL622651
6282,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,Brain,1,1,CHEMBL622652
6283,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,Brain,1,1,CHEMBL622653
6284,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,955.0,50594,BAO_0000218,A,,6599,Brain,1,1,CHEMBL622654
6285,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL622655
6286,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL622656
6287,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL622657
6288,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL622658
6289,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL622659
6290,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,Kidney,1,1,CHEMBL624630
6291,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,Kidney,1,1,CHEMBL624631
6292,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,Kidney,1,1,CHEMBL624632
6293,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL624633
6294,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL624634
6295,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL624635
6296,N,,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Intermediate,,A549,,,80682,BAO_0000219,F,,17130,,1,1,CHEMBL624636
6297,N,,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,3263,,1,1,CHEMBL857055
6298,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624637
6299,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624638
6300,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL874366
6301,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624639
6302,N,,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Expert,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624640
6303,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624641
6304,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624642
6305,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624643
6306,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624644
6307,N,,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,6663,,1,1,CHEMBL624645
6308,N,,646.0,,The compound was evaluated for its cytotoxic potency against A-549 cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,3983,,1,1,CHEMBL619445
6309,N,,646.0,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Expert,,A549,,,80682,BAO_0000219,F,,11141,,1,1,CHEMBL839886
6310,N,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,5076,,1,1,CHEMBL619446
6311,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,1,1,CHEMBL619447
6312,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,1,1,CHEMBL619448
6313,N,,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Intermediate,,A549,,,80682,BAO_0000219,F,,3311,,1,1,CHEMBL619449
6314,N,,646.0,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,5076,,1,1,CHEMBL619450
6315,N,,646.0,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Intermediate,,A549,,,80682,BAO_0000219,F,,4150,,1,1,CHEMBL619451
6316,N,,646.0,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Expert,,A549,,,80682,BAO_0000219,F,,2150,,1,1,CHEMBL619452
6317,N,,646.0,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Intermediate,,A549,,,80682,BAO_0000219,F,,4644,,1,1,CHEMBL619453
6318,N,,646.0,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Intermediate,,A549,,,80682,BAO_0000219,F,,263,,1,1,CHEMBL874367
6319,N,,646.0,,Cytotoxic concentration against A-549 tumor cells.,Intermediate,,A549,,,80682,BAO_0000219,F,,11333,,1,1,CHEMBL619454
6320,N,,646.0,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Intermediate,,A549,,,80682,BAO_0000219,F,,11333,,1,1,CHEMBL619455
6321,N,,646.0,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Intermediate,,A549,,,80682,BAO_0000219,F,,15895,,1,1,CHEMBL619456
6322,N,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Expert,,,,,50191,BAO_0000218,F,,16677,,1,1,CHEMBL619457
6323,N,,,,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,,,50192,BAO_0000218,F,,10624,,1,1,CHEMBL619458
6324,N,,,,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,,,50274,BAO_0000218,F,,16717,,1,1,CHEMBL619459
6325,N,,,,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,,,50274,BAO_0000218,F,,16717,,1,1,CHEMBL619460
6326,N,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Intermediate,,,,,50416,BAO_0000218,F,,5513,,1,1,CHEMBL619461
6327,N,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,1,1,CHEMBL619462
6328,N,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,1,1,CHEMBL620388
6329,N,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,1,1,CHEMBL620389
6330,N,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,,,50416,BAO_0000218,F,,15962,,1,1,CHEMBL620390
6331,N,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,,,50416,BAO_0000218,F,,16717,,1,1,CHEMBL620391
6332,N,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,,,50416,BAO_0000218,F,,16717,,1,1,CHEMBL621073
6333,N,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,8117,,1,1,CHEMBL621074
6334,N,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Intermediate,,,,,50366,BAO_0000218,F,,8117,,1,1,CHEMBL621075
6335,N,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,,,50535,BAO_0000218,F,,15472,,1,1,CHEMBL619554
6336,N,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,,,50535,BAO_0000218,F,,15472,,1,1,CHEMBL619555
6337,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Intermediate,,,,,50169,BAO_0000218,F,,16443,,1,1,CHEMBL619556
6338,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Intermediate,,,,,50169,BAO_0000218,F,,16443,,1,1,CHEMBL619557
6339,N,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Intermediate,,,,,50169,BAO_0000218,F,,16443,,1,1,CHEMBL619558
6340,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619559
6341,N,,646.0,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619560
6342,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL619561
6343,N,,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL619562
6344,N,,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL619563
6345,N,,646.0,,GI values against A549 cells (lung cancer),Intermediate,,A549,,,80682,BAO_0000219,F,,16381,,1,1,CHEMBL857457
6346,N,,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17206,,1,1,CHEMBL619564
6347,N,,646.0,,Inhibitory activity against A549 human adenocarcinoma,Intermediate,,A549,,,80682,BAO_0000219,F,,16325,,1,1,CHEMBL619565
6348,N,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Intermediate,,A549,,,80682,BAO_0000218,F,,10708,,1,1,CHEMBL619566
6349,N,,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Intermediate,,A549,,,80682,BAO_0000218,F,,10708,,1,1,CHEMBL619567
6350,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,1,1,CHEMBL619568
6351,N,,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,1,1,CHEMBL619569
6352,N,,646.0,,Cytotoxicity against human A549 lung cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17488,,1,1,CHEMBL619570
6353,N,,646.0,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Intermediate,,A549,,,80682,BAO_0000218,F,,17404,,1,1,CHEMBL619571
6354,N,,646.0,,Growth inhibition of A549 (human lung carcinoma) cell line.,Expert,,A549,,,80682,BAO_0000219,F,,10958,,1,1,CHEMBL619572
6355,N,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line.,Expert,,A549,,,80682,BAO_0000219,F,,17099,,1,1,CHEMBL619573
6356,N,,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Intermediate,,A549,,,80682,BAO_0000219,F,,17099,,1,1,CHEMBL619574
6357,N,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,4096,,1,1,CHEMBL619575
6358,N,,646.0,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Expert,,A549,,,80682,BAO_0000219,F,,4096,,1,1,CHEMBL619576
6359,N,,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Intermediate,,A549,,,80682,BAO_0000219,F,,4096,,1,1,CHEMBL619577
6360,N,,646.0,,In vitro inhibitory activity against A549 tumor cell culture,Intermediate,,A549,,,80682,BAO_0000219,F,,2525,,1,1,CHEMBL619578
6361,N,,646.0,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Intermediate,,A549,,,80682,BAO_0000219,F,,2525,,1,1,CHEMBL884009
6362,N,,646.0,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Intermediate,,A549,,,80682,BAO_0000219,F,,5302,,1,1,CHEMBL619579
6363,N,,646.0,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,16325,,1,1,CHEMBL619580
6364,N,,646.0,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,16939,,1,1,CHEMBL619581
6365,N,,646.0,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,17229,,1,1,CHEMBL619582
6366,N,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Intermediate,,A549,,,80682,BAO_0000219,F,,17380,,1,1,CHEMBL619583
6367,N,,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Intermediate,,A549,,,80682,BAO_0000219,F,,17380,,1,1,CHEMBL876502
6368,N,,646.0,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Intermediate,,A549,,,80682,BAO_0000219,F,,1903,,1,1,CHEMBL619584
6369,N,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,3838,,1,1,CHEMBL619585
6370,N,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,1,1,CHEMBL619586
6371,N,,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,3838,,1,1,CHEMBL619587
6372,N,,646.0,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Intermediate,,A549,,,80682,BAO_0000219,F,,1522,,1,1,CHEMBL619588
6373,N,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,12400,,1,1,CHEMBL619589
6374,N,,646.0,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,1,1,CHEMBL619590
6375,N,,646.0,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Intermediate,,A549,,,80682,BAO_0000219,F,,14769,,1,1,CHEMBL619591
6376,N,,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Intermediate,,A549,,,80682,BAO_0000219,F,,14696,,1,1,CHEMBL619592
6377,N,,646.0,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Intermediate,,A549,,,80682,BAO_0000219,F,,1888,,1,1,CHEMBL619593
6378,N,,646.0,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12016,,1,1,CHEMBL620217
6379,N,,646.0,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Intermediate,,A549,,,80682,BAO_0000219,F,,6058,,1,1,CHEMBL620218
6380,N,,646.0,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17708,,1,1,CHEMBL620219
6381,N,,646.0,,Antitumor activity against A549/ATCC cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,12301,,1,1,CHEMBL620220
6382,N,,646.0,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,11970,,1,1,CHEMBL625141
6383,N,,646.0,,In vitro cytotoxicity against A549/ATCC cell line.,Expert,,A549,,,80682,BAO_0000219,F,,11818,,1,1,CHEMBL625142
6384,N,,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Intermediate,,A549,,,80682,BAO_0000219,F,,12400,,1,1,CHEMBL625143
6385,N,,646.0,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Intermediate,,A549,,,80682,BAO_0000219,F,,3381,,1,1,CHEMBL625144
6386,N,,646.0,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Intermediate,,A549,,,80682,BAO_0000219,F,,17376,,1,1,CHEMBL622474
6387,N,,646.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,A549,,,80682,BAO_0000219,F,,10708,,1,1,CHEMBL884104
6388,U,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Autocuration,,,,,22226,BAO_0000219,F,,2964,,0,1,CHEMBL622475
6389,U,,,,Compound was tested for oral bioavailability in dogs,Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL622476
6390,N,,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Intermediate,,,,,50588,BAO_0000218,A,,6229,,1,1,CHEMBL875831
6391,N,,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Intermediate,,,,,50588,BAO_0000218,A,,6229,,1,1,CHEMBL622477
6392,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5374,,1,1,CHEMBL622478
6393,N,,,,Compound was tested for the oral bioavailability in dog; No availability,Intermediate,,,,,50588,BAO_0000218,A,,5374,,1,1,CHEMBL623172
6394,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6265,,1,1,CHEMBL623173
6395,N,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,,,50588,BAO_0000218,A,,5654,,1,1,CHEMBL623174
6396,N,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,,,50588,BAO_0000218,A,,5654,,1,1,CHEMBL623175
6397,N,,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,16456,,1,1,CHEMBL623340
6398,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5302,,1,1,CHEMBL623341
6399,N,,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Intermediate,,,,,50588,BAO_0000218,A,,3624,,1,1,CHEMBL623342
6400,N,,,,Oral bioavailability of active FTIs in dogs,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL623343
6401,N,,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5802,,1,1,CHEMBL623344
6402,N,,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,1,1,CHEMBL623345
6403,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL875832
6404,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6762,,1,1,CHEMBL623346
6405,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,,1,1,CHEMBL623347
6406,N,,,,Oral bioavailability of compound was determined in dog; Not tested,Intermediate,,,,,50588,BAO_0000218,A,,6821,,1,1,CHEMBL623348
6407,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,,1,1,CHEMBL623349
6408,N,,,,Oral bioavailability (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL623350
6409,N,,,,Oral bioavailability,Intermediate,,,,,50588,BAO_0000218,A,,761,,1,1,CHEMBL623351
6410,N,,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Intermediate,,,,,50588,BAO_0000218,A,,761,,1,1,CHEMBL623352
6411,N,,,,Oral bioavailability administered in solution in rats,Intermediate,,,,,50588,BAO_0000218,A,,761,,1,1,CHEMBL623353
6412,N,,,,Oral bioavailability after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL875833
6413,N,,,,Oral bioavailability at a dose of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL623354
6414,N,,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL623355
6415,N,,,,Oral bioavailability in Dog; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL623356
6416,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3352,,1,1,CHEMBL623357
6417,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6168,,1,1,CHEMBL623358
6418,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5988,,1,1,CHEMBL623359
6419,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4942,,1,1,CHEMBL623360
6420,N,,,,Oral bioavailability in dogs; No data,Intermediate,,,,,50588,BAO_0000218,A,,4942,,1,1,CHEMBL623361
6421,N,,,,Oral bioavailability measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14541,,1,1,CHEMBL623362
6422,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4449,,1,1,CHEMBL623363
6423,N,,,,Oral bioavailability was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL623364
6424,N,,,,Oral bioavailability after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL875834
6425,N,,,,Oral bioavailability in dog (i.v. dosing),Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL623365
6426,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL623366
6427,N,,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,,1,1,CHEMBL623367
6428,N,,,,Oral bioavailability in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,4514,,1,1,CHEMBL623368
6429,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3624,,1,1,CHEMBL623369
6430,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3854,,1,1,CHEMBL623370
6431,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5836,,1,1,CHEMBL623371
6432,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5940,,1,1,CHEMBL623372
6433,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6168,,1,1,CHEMBL621351
6434,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL621352
6435,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6251,,1,1,CHEMBL621353
6436,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL621354
6437,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6647,,1,1,CHEMBL621355
6438,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5940,,1,1,CHEMBL621356
6439,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,933,,1,1,CHEMBL621357
6440,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,,1,1,CHEMBL621358
6441,N,,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL621359
6442,N,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6641,,1,1,CHEMBL621360
6443,N,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL621361
6444,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL621362
6445,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,,1,1,CHEMBL621363
6446,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL621364
6447,N,,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621166
6448,N,,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621167
6449,N,,,,Oral bioavailability (F) in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,,1,1,CHEMBL621168
6450,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5210,,1,1,CHEMBL621169
6451,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5238,,1,1,CHEMBL875950
6452,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL621170
6453,N,,,,Oral bioavailability after peroral administration at 5 mpk in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL621171
6454,N,,,,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL621172
6455,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL621173
6456,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,Kidney,1,1,CHEMBL621174
6457,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2113.0,50594,BAO_0000218,A,,6599,Kidney,1,1,CHEMBL621175
6458,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621176
6459,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621177
6460,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621178
6461,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621179
6462,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621180
6463,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL875951
6464,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL621181
6465,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL621182
6466,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL621183
6467,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL621184
6468,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621185
6469,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621186
6470,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621187
6471,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621188
6472,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621189
6473,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,Spleen,1,1,CHEMBL621190
6474,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,Spleen,1,1,CHEMBL618520
6475,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,Spleen,1,1,CHEMBL621739
6476,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,Spleen,1,1,CHEMBL621740
6477,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2106.0,50594,BAO_0000218,A,,6599,Spleen,1,1,CHEMBL621741
6478,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621742
6479,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621743
6480,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621744
6481,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621745
6482,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621746
6483,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621747
6484,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621748
6485,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621749
6486,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621750
6487,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL621751
6488,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL621752
6489,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL621753
6490,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL875955
6491,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL621754
6492,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,948.0,50594,BAO_0000218,A,,6599,Heart,1,1,CHEMBL621755
6493,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL621756
6494,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL624199
6495,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL624200
6496,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL624375
6497,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2107.0,50594,BAO_0000218,A,,6599,Liver,1,1,CHEMBL624376
6498,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL624377
6499,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL624378
6500,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,1,1,CHEMBL857901
6501,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,1,1,CHEMBL875274
6502,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,1,1,CHEMBL624379
6503,N,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,,,50067,BAO_0000218,F,,12269,,1,1,CHEMBL624380
6504,N,,,,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,,,50192,BAO_0000218,F,,10624,,1,1,CHEMBL624381
6505,N,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Intermediate,,,,,50714,BAO_0000218,F,,17216,,1,1,CHEMBL624382
6506,N,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Intermediate,,,,,50714,BAO_0000218,F,,17216,,1,1,CHEMBL624383
6507,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624384
6508,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624385
6509,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624386
6510,N,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624387
6511,N,,,,Plaque bactericidal index against Actinomyces naeslundii 631,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624388
6512,N,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624389
6513,N,,,,Plaque bactericidal index against Actinomyces naeslundii B74,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL624390
6514,N,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,Intermediate,,,,,50296,BAO_0000218,F,,9560,,1,1,CHEMBL875275
6515,N,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Intermediate,,,,,50056,BAO_0000218,F,,114,,1,1,CHEMBL624391
6516,N,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Intermediate,,,,,50056,BAO_0000218,F,,114,,1,1,CHEMBL623636
6517,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623637
6518,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623638
6519,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623639
6520,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623640
6521,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623641
6522,N,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623642
6523,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623643
6524,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623644
6525,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623645
6526,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623646
6527,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623647
6528,N,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Intermediate,,,,,50532,BAO_0000218,F,,10841,,1,1,CHEMBL623648
6529,N,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,,,50366,BAO_0000218,F,,8117,,1,1,CHEMBL623649
6530,N,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,,,50366,BAO_0000218,F,,8117,,1,1,CHEMBL623650
6531,N,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623651
6532,N,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,Expert,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623652
6533,N,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623653
6534,N,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623654
6535,N,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623655
6536,N,,,,Plaque bactericidal index against Actinomyces viscosus M-100,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623656
6537,N,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Expert,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623657
6538,N,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623658
6539,N,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623659
6540,N,,,,Plaque bactericidal index against Actinomyces viscosus 626,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623660
6541,N,,,,Plaque bactericidal index against Actinomyces viscosus T14V,Intermediate,,,,,50366,BAO_0000218,F,,9560,,1,1,CHEMBL623661
6542,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL875281
6543,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL623662
6544,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL623663
6545,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL623664
6546,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL623665
6547,N,,165.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Intermediate,,A673,,,80023,BAO_0000219,F,,10708,,1,1,CHEMBL621856
6548,N,,645.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,A704,,,80661,BAO_0000219,F,,10708,,1,1,CHEMBL620432
6549,U,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Autocuration,,,,,22226,BAO_0000219,F,,416,,0,1,CHEMBL620433
6550,N,,625.0,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,A9,,,80024,BAO_0000219,F,,14354,,1,1,CHEMBL620434
6551,N,,625.0,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,A9,,,80024,BAO_0000219,F,,14354,,1,1,CHEMBL620435
6552,N,,625.0,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Intermediate,,A9,,,80024,BAO_0000219,F,,5116,,1,1,CHEMBL620436
6553,N,,625.0,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Intermediate,,A9,,,80024,BAO_0000219,F,,5116,,1,1,CHEMBL876597
6554,N,,874.0,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Expert,,Human ovarian carcinoma cell line,,,81037,BAO_0000219,F,,15694,,1,1,CHEMBL620437
6555,N,,625.0,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Expert,,A9,,,80024,BAO_0000219,F,,13038,,1,1,CHEMBL620438
6556,N,,625.0,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Expert,,A9,,,80024,BAO_0000219,F,,13038,,1,1,CHEMBL620439
6557,N,,625.0,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Expert,,A9,,,80024,BAO_0000219,F,,10923,,1,1,CHEMBL619657
6558,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,1,1,CHEMBL619658
6559,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,1,1,CHEMBL619659
6560,H,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",Expert,,,,,10649,BAO_0000019,F,,10923,,8,1,CHEMBL619660
6561,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,1,1,CHEMBL619661
6562,N,,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Intermediate,,A9,,,80024,BAO_0000219,F,,10923,,1,1,CHEMBL619662
6563,N,,975.0,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Intermediate,,AA6,,,80663,BAO_0000219,F,,8158,,1,1,CHEMBL619663
6564,U,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Autocuration,,,,,22226,BAO_0000219,F,,15494,,0,1,CHEMBL619664
6565,U,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Autocuration,,,,,22226,BAO_0000219,F,,15494,,0,1,CHEMBL619665
6566,N,,974.0,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Intermediate,,AA5,,,80662,BAO_0000219,F,,12348,,1,1,CHEMBL883244
6567,N,,974.0,,Cytotoxicity was measured against AA5/HIV-1(IIIB),Intermediate,,AA5,,,80662,BAO_0000219,F,,12348,,1,1,CHEMBL884011
6568,N,,974.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Intermediate,,AA5,,,80662,BAO_0000219,F,,2726,,1,1,CHEMBL619666
6569,N,,379.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Intermediate,,U-937,,,80566,BAO_0000219,F,,2726,,1,1,CHEMBL619667
6570,N,,274.0,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Intermediate,,UV4,,,80578,BAO_0000219,F,,10747,,1,1,CHEMBL619668
6571,N,,185.0,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11005,,1,1,CHEMBL619669
6572,N,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL876608
6573,N,,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL619670
6574,N,,185.0,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL619671
6575,N,,185.0,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL619672
6576,N,,185.0,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL619673
6577,N,,185.0,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,1,1,CHEMBL619674
6578,N,,185.0,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13435,,1,1,CHEMBL619675
6579,N,,185.0,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13302,,1,1,CHEMBL619676
6580,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL619677
6581,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,1,1,CHEMBL619678
6582,N,,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,1,1,CHEMBL619679
6583,N,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Expert,,CHO-AA8,,,80089,BAO_0000219,A,,12878,,1,1,CHEMBL619680
6584,N,,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12878,,1,1,CHEMBL621457
6585,N,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,1,1,CHEMBL876609
6586,N,,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,1,1,CHEMBL621458
6587,N,,185.0,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,12398,,1,1,CHEMBL621459
6588,N,,185.0,,Aerobic growth inhibition in Chinese hamster cell line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,12878,,1,1,CHEMBL621460
6589,N,,185.0,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,13820,,1,1,CHEMBL621461
6590,N,,185.0,,Inhibition of growth under aerobic conditions in AA8 cells,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,1,1,CHEMBL621462
6591,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL621463
6592,N,,,,Oral bioavailability in dog at 10 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,5711,,1,1,CHEMBL621464
6593,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL621465
6594,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL621466
6595,N,,,,Oral bioavailability in dog (mongrel),Intermediate,,,,,50588,BAO_0000218,A,,17800,,1,1,CHEMBL621467
6596,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,3994,,1,1,CHEMBL621468
6597,N,,,,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,,,50588,BAO_0000218,F,,3994,,1,1,CHEMBL876734
6598,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,,1,1,CHEMBL618476
6599,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL618477
6600,N,,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL618478
6601,N,,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL618479
6602,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4273,,1,1,CHEMBL618480
6603,N,,,,Bioavailability in dog (dose 3-10 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,12500,,1,1,CHEMBL618481
6604,N,,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL618482
6605,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL618483
6606,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,3880,,1,1,CHEMBL618484
6607,N,,,,Bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4838,,1,1,CHEMBL618485
6608,N,,,,oral bioavailability was measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,15600,,1,1,CHEMBL618486
6609,N,,,,Compound was tested for plasma protein binding in dog; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17248,,1,1,CHEMBL618487
6610,N,,,,Compound was tested for plasma protein binding of dog,Intermediate,,,,,50588,BAO_0000218,A,,17248,,1,1,CHEMBL618488
6611,N,,,,Compound was tested for plasma protein binding of dog; Not determined,Intermediate,,,,,50588,BAO_0000218,A,,17248,,1,1,CHEMBL876735
6612,N,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Intermediate,,,,,50588,BAO_0000218,A,,17443,,1,1,CHEMBL618489
6613,N,,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,,,50588,BAO_0000218,A,,4186,,1,1,CHEMBL618490
6614,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3749,,1,1,CHEMBL618491
6615,N,,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3249,,1,1,CHEMBL618492
6616,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,3022,,1,1,CHEMBL873354
6617,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3749,,1,1,CHEMBL618493
6618,N,,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,,50588,BAO_0000218,A,,2517,,1,1,CHEMBL618494
6619,N,,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,948.0,50588,BAO_0000218,A,,2517,Heart,1,1,CHEMBL618495
6620,N,,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2113.0,50588,BAO_0000218,A,,2517,Kidney,1,1,CHEMBL618496
6621,N,,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2107.0,50588,BAO_0000218,A,,2517,Liver,1,1,CHEMBL618497
6622,N,,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2048.0,50588,BAO_0000218,A,,2517,Lung,1,1,CHEMBL618498
6623,N,,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,,2106.0,50588,BAO_0000218,A,,2517,Spleen,1,1,CHEMBL618499
6624,N,,,,LogP in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL876736
6625,N,,,,Partition coefficient (logP),Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL618500
6626,N,,,,Partition coefficient in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL857831
6627,N,,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL618501
6628,N,,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL618502
6629,N,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL618503
6630,N,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Intermediate,,,,,50588,BAO_0000218,A,,14294,,1,1,CHEMBL618504
6631,N,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50588,BAO_0000218,A,,14294,,1,1,CHEMBL618505
6632,N,,,,Metabolism of compound in dog S9 microsomes; Trace,Intermediate,,,,,50588,BAO_0000218,A,,14294,,1,1,CHEMBL618506
6633,N,,,,In vitro metabolic potential in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,6251,Liver,1,1,CHEMBL618507
6634,N,,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3748,,1,1,CHEMBL876737
6635,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,2713,,1,1,CHEMBL618508
6636,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6512,,1,1,CHEMBL618509
6637,N,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,,1,1,CHEMBL618510
6638,N,,,,The compound was tested for bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3749,,1,1,CHEMBL618511
6639,N,,,,The compound was tested for oral bioavailability in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3749,,1,1,CHEMBL618512
6640,N,,,,Oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,6742,,1,1,CHEMBL618513
6641,N,,,,Compound was tested for percent protein binding (PB) in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL618514
6642,N,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Intermediate,,,,,50588,BAO_0000218,A,,6874,,1,1,CHEMBL620052
6643,N,,,,Compound was evaluated for plasma clearance.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,2877,Plasma,1,1,CHEMBL620053
6644,N,,,,The compound was tested for plasma clearance in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL620054
6645,N,,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL620055
6646,N,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL620056
6647,N,,,,In vitro relative rate of metabolism was determined in dog liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,5542,Liver,1,1,CHEMBL620057
6648,N,,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,,1,1,CHEMBL618939
6649,N,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL618940
6650,N,,,,Half life after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL618941
6651,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL624473
6652,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL624474
6653,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,2048.0,50594,BAO_0000218,A,,6599,Lung,1,1,CHEMBL624475
6654,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL624476
6655,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL623478
6656,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL623479
6657,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL623480
6658,N,,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Intermediate,,CCRF S-180,,,50594,BAO_0000218,A,,6599,,1,1,CHEMBL623481
6659,N,,,,C2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,Brain,1,1,CHEMBL623482
6660,N,,,,C2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,Kidney,1,1,CHEMBL623483
6661,N,,,,C2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,Liver,1,1,CHEMBL623484
6662,N,,,,C2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,Lung,1,1,CHEMBL623485
6663,N,,,,C2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,Spleen,1,1,CHEMBL623486
6664,N,,,,Plasma clearance in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,,1,1,CHEMBL623487
6665,N,,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL623488
6666,N,,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,1,1,CHEMBL623489
6667,N,,,,Clearance was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL875157
6668,N,,,,Clearance was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL623490
6669,N,,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,,1,1,CHEMBL623491
6670,N,,,,Plasma clearance of compound was determined at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL623492
6671,N,,,,Plasma clearance of at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL623493
6672,N,,,,Plasma clearance at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL623494
6673,N,,,,Plasma clearance at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL623495
6674,N,,,,Plasma clearance in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,,1,1,CHEMBL623496
6675,N,,,,Plasma clearance value upon iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL623497
6676,N,,,,Total plasma clearance in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,5980,Plasma,1,1,CHEMBL623498
6677,N,,,,Clearance in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,,1,1,CHEMBL623499
6678,N,,,,Clearance value was determined,Intermediate,,,,,50594,BAO_0000218,A,,17718,,1,1,CHEMBL623500
6679,N,,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL623501
6680,U,,,,Calculated partition coefficient (clogP),Intermediate,,,,,22229,BAO_0000100,P,,17384,,0,1,CHEMBL875158
6681,N,,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,1,1,CHEMBL623502
6682,N,,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL623503
6683,N,,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,,1,1,CHEMBL623504
6684,N,,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL623505
6685,N,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL623506
6686,N,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL623507
6687,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL623508
6688,N,,,,Cmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,,,50594,BAO_0000218,A,,5781,,1,1,CHEMBL623509
6689,N,,,,Cmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,,,50594,BAO_0000218,A,,17764,,1,1,CHEMBL875159
6690,N,,,,Cmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,,955.0,50594,BAO_0000218,A,,17641,Brain,1,1,CHEMBL623510
6691,N,,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,,2113.0,50594,BAO_0000218,A,,17641,Kidney,1,1,CHEMBL623511
6692,N,,,,Cmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,,2107.0,50594,BAO_0000218,A,,17641,Liver,1,1,CHEMBL623512
6693,N,,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,,2048.0,50594,BAO_0000218,A,,17641,Lung,1,1,CHEMBL623513
6694,N,,,,Cmax in mice at 18 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL623514
6695,N,,,,Cmax in mice at 23 uM/kg i.v. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622609
6696,N,,,,Cmax in mice at 24 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL622610
6697,N,,,,Cmax in mice at 25 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL621823
6698,N,,,,Cmax in mice at 26 uM/kg i.p. administration,Intermediate,,,,,50594,BAO_0000218,F,,17764,,1,1,CHEMBL621824
6699,N,,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,,2106.0,50594,BAO_0000218,A,,17641,Spleen,1,1,CHEMBL621825
6700,N,,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL621826
6701,N,,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL621827
6702,N,,,,Cmax value was determined,Intermediate,,,,,50594,BAO_0000218,A,,5727,,1,1,CHEMBL621828
6703,N,,,,Cmax value in IRC mice,Intermediate,,,,,50594,BAO_0000218,A,,5951,,1,1,CHEMBL621829
6704,N,,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL621830
6705,N,,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL621831
6706,N,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14239,Plasma,1,1,CHEMBL621832
6707,N,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Intermediate,,,,1969.0,50594,BAO_0000218,A,,4890,Plasma,1,1,CHEMBL624579
6708,N,,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,429,,1,1,CHEMBL624580
6709,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL624581
6710,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL624582
6711,N,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Intermediate,,,,,50535,BAO_0000218,F,,10986,,1,1,CHEMBL624583
6712,N,,455.0,,Inhibitory activity against human tumor cell line A0375 melanoma.,Intermediate,,A-375,,,80018,BAO_0000219,F,,13227,,1,1,CHEMBL624584
6713,D,,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Expert,,,,,12512,BAO_0000249,B,Brain membranes,4481,,9,1,CHEMBL624585
6714,D,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,Expert,,,,,114,BAO_0000019,F,,16931,,9,1,CHEMBL875165
6715,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619490
6716,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619491
6717,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619492
6718,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619493
6719,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619494
6720,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619495
6721,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619496
6722,D,,449.0,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,9,1,CHEMBL619497
6723,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619498
6724,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619499
6725,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619500
6726,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619501
6727,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619502
6728,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619503
6729,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL619504
6730,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL621298
6731,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL621299
6732,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL621300
6733,H,,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL621301
6734,H,,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Expert,,CHO,,,114,BAO_0000219,F,,3850,,8,1,CHEMBL621302
6735,N,,164.0,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Intermediate,,A10,,,80013,BAO_0000219,F,,12680,,1,1,CHEMBL621303
6736,U,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Autocuration,,A10,,,22226,BAO_0000219,F,,1313,,0,1,CHEMBL621304
6737,U,,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Autocuration,,A10,,,22226,BAO_0000219,F,,1313,,0,1,CHEMBL621305
6738,N,,164.0,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Intermediate,,A10,,,80013,BAO_0000219,F,,17567,,1,1,CHEMBL621306
6739,N,,164.0,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Intermediate,,A10,,,80013,BAO_0000219,F,,17567,,1,1,CHEMBL618444
6740,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Intermediate,,A10,,,80013,BAO_0000219,F,,11819,,1,1,CHEMBL618445
6741,N,,185.0,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,1,1,CHEMBL618446
6742,N,,185.0,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL618447
6743,N,,185.0,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12651,,1,1,CHEMBL618448
6744,N,,185.0,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13300,,1,1,CHEMBL618449
6745,N,,185.0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,15296,,1,1,CHEMBL618637
6746,N,,185.0,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,15328,,1,1,CHEMBL618638
6747,N,,185.0,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13302,,1,1,CHEMBL618639
6748,N,,185.0,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Expert,,CHO-AA8,,,80089,BAO_0000219,F,,14367,,1,1,CHEMBL618640
6749,N,,185.0,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,17002,,1,1,CHEMBL618641
6750,N,,185.0,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13436,,1,1,CHEMBL618642
6751,N,,185.0,,Inhibitory activity against aerobic growth of AA8 cells.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,13435,,1,1,CHEMBL618643
6752,N,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,10503,,1,1,CHEMBL884013
6753,N,,185.0,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,10503,,1,1,CHEMBL622723
6754,N,,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10503,,1,1,CHEMBL622724
6755,N,,185.0,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,15090,,1,1,CHEMBL622725
6756,N,,185.0,,Cytotoxicity against AA8 cell line,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,10368,,1,1,CHEMBL622726
6757,N,,185.0,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12651,,1,1,CHEMBL622727
6758,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,1,1,CHEMBL622728
6759,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,12687,,1,1,CHEMBL622729
6760,N,,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,CHO-AA8,,,80089,BAO_0000219,A,,12687,,1,1,CHEMBL622730
6761,N,,185.0,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,1890,,1,1,CHEMBL622731
6762,N,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10747,,1,1,CHEMBL622732
6763,N,,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,CHO-AA8,,,80089,BAO_0000219,F,,10747,,1,1,CHEMBL622733
6764,U,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Autocuration,,,,,22224,BAO_0000218,F,,11616,,0,1,CHEMBL622734
6765,N,,185.0,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,1,1,CHEMBL622735
6766,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL618746
6767,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL618747
6768,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL620540
6769,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL620541
6770,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL620542
6771,U,,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL620543
6772,U,,185.0,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,3471,,0,1,CHEMBL618832
6773,N,,185.0,,Concentration required to reduce AA8 cell survival by 10%,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,1,1,CHEMBL618833
6774,U,,185.0,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2656,,0,1,CHEMBL618834
6775,U,,185.0,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL618835
6776,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL618836
6777,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL618837
6778,U,,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL618838
6779,U,,185.0,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,16156,,0,1,CHEMBL618839
6780,U,,185.0,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2656,,0,1,CHEMBL618840
6781,U,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Autocuration,,,,,22224,BAO_0000019,F,,11005,,0,1,CHEMBL618841
6782,U,,185.0,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11942,,0,1,CHEMBL618842
6783,U,,185.0,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,2128,,0,1,CHEMBL618843
6784,N,,,,Half life period after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL618844
6785,N,,,,Half life period after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL618845
6786,N,,,,Half life was measured after oral 2b administration (tested in 6 dogs),Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL618846
6787,N,,,,Half life was measured in dog after oral 17b administration,Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL618847
6788,N,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL618848
6789,N,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Intermediate,,,,,50588,BAO_0000218,A,,9579,,1,1,CHEMBL618849
6790,N,,,,Tmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL618850
6791,N,,,,Tmax value after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL618851
6792,N,,,,Compound was evaluated for its half life when administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,,1,1,CHEMBL873815
6793,N,,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,5017,Plasma,1,1,CHEMBL618852
6794,N,,,,Elimination Half-life of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,,1,1,CHEMBL618853
6795,N,,,,Half life of compound in dog following oral administration,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL618854
6796,N,,,,Half life of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,17267,,1,1,CHEMBL618855
6797,N,,,,Half life of compound was determined in dog blood,Intermediate,,,,178.0,50588,BAO_0000218,A,,4727,Blood,1,1,CHEMBL618856
6798,N,,,,Half life after oral and iv dosing in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5238,,1,1,CHEMBL875827
6799,N,,,,Half life in dogs in hours,Intermediate,,,,,50588,BAO_0000218,A,,4942,,1,1,CHEMBL618857
6800,N,,,,Half life on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,,1,1,CHEMBL618858
6801,N,,,,t1/2 in dog after oral dose (1 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5130,,1,1,CHEMBL618859
6802,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1475,,1,1,CHEMBL618860
6803,N,,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17804,,1,1,CHEMBL618861
6804,N,,,,Half life period of compound was determined after peroral administration at 2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17804,,1,1,CHEMBL622539
6805,N,,,,Half life period (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL622540
6806,N,,,,Half life period (10 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL873803
6807,N,,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL873804
6808,N,,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL624311
6809,N,,,,Half life period in dog,Intermediate,,,,,50588,BAO_0000218,A,,6084,,1,1,CHEMBL624312
6810,N,,,,Half life period in dogs after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6241,,1,1,CHEMBL624313
6811,N,,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,1,1,CHEMBL624314
6812,N,,,,Half-life of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6621,,1,1,CHEMBL624315
6813,N,,,,Half-life in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1696,Plasma,1,1,CHEMBL624316
6814,N,,,,Half-life in mongrel dogs was determined,Intermediate,,,,,50588,BAO_0000218,A,,17800,,1,1,CHEMBL624317
6815,N,,,,Half-life in dog upon oral administration,Intermediate,,,,,50588,BAO_0000218,A,,17657,,1,1,CHEMBL624318
6816,N,,,,Half-life in dog upon oral administration; Unable to calculate,Intermediate,,,,,50588,BAO_0000218,A,,17657,,1,1,CHEMBL624319
6817,N,,,,Half-life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,,1,1,CHEMBL624496
6818,N,,,,Half-life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,5985,,1,1,CHEMBL624497
6819,N,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Intermediate,,,,,50588,BAO_0000218,A,,9932,,1,1,CHEMBL624498
6820,N,,,,Oral half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5199,,1,1,CHEMBL624499
6821,N,,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL624500
6822,N,,,,Plasma half life was evaluated,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,Plasma,1,1,CHEMBL624501
6823,N,,,,Plasma half life was evaluated in Dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,Plasma,1,1,CHEMBL623666
6824,N,,,,Plasma half life was evaluated in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,1475,Plasma,1,1,CHEMBL623667
6825,N,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,,1,1,CHEMBL623668
6826,N,,,,Tested for the half life value in dog,Intermediate,,,,,50588,BAO_0000218,A,,4883,,1,1,CHEMBL623669
6827,N,,,,Maximum time at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,,1,1,CHEMBL623670
6828,N,,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,,,50588,BAO_0000218,A,,1916,,1,1,CHEMBL623671
6829,N,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,Blood,1,1,CHEMBL875945
6830,N,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,Blood,1,1,CHEMBL623672
6831,N,,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,,1,1,CHEMBL623673
6832,N,,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL623674
6833,N,,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,,,50588,BAO_0000218,A,,5983,,1,1,CHEMBL623675
6834,N,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL872526
6835,N,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Intermediate,,,,,50588,BAO_0000218,A,,5313,,1,1,CHEMBL623676
6836,N,,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17650,Plasma,1,1,CHEMBL623677
6837,N,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL623678
6838,N,,,,Time taken for maximum plasma concentration in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,933,Plasma,1,1,CHEMBL623679
6839,N,,,,Time to reach Cmax after oral administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL623680
6840,N,,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6348,Plasma,1,1,CHEMBL623681
6841,N,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6316,,1,1,CHEMBL623682
6842,N,,,,Tmax after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,,1,1,CHEMBL623683
6843,N,,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,1,1,CHEMBL623684
6844,N,,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL622745
6845,N,,,,Tmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL622746
6846,N,,,,In vivo Cmax in mice at dose of 100 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL622747
6847,N,,,,In vivo Cmax in mice at dose of 50 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,5969,,1,1,CHEMBL622748
6848,N,,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,,1,1,CHEMBL622749
6849,N,,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,1969.0,50594,BAO_0000218,A,,3277,Plasma,1,1,CHEMBL622750
6850,N,,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17734,Plasma,1,1,CHEMBL623411
6851,N,,,,Maximum concentration obtained in mouse plasma was determined,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL875946
6852,N,,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL623412
6853,N,,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,6348,Plasma,1,1,CHEMBL623413
6854,N,,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,Plasma,1,1,CHEMBL623414
6855,N,,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,Plasma,1,1,CHEMBL623415
6856,N,,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17729,Plasma,1,1,CHEMBL623416
6857,N,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,Plasma,1,1,CHEMBL623417
6858,N,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,Plasma,1,1,CHEMBL623418
6859,N,,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17728,Plasma,1,1,CHEMBL623419
6860,N,,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,4066,,1,1,CHEMBL622816
6861,N,,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,1,1,CHEMBL623313
6862,N,,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,6178,,1,1,CHEMBL623314
6863,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL876788
6864,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL623315
6865,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL623316
6866,N,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL623317
6868,N,,,,Cmax in male mice after 2 mg/kg oral dose,Intermediate,,,,,50594,BAO_0000218,A,,5961,,1,1,CHEMBL623319
6869,N,,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Intermediate,,,,,50594,BAO_0000218,A,,6137,,1,1,CHEMBL623320
6870,N,,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3802,,1,1,CHEMBL623321
6871,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623322
6872,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623323
6873,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623324
6874,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623325
6875,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623326
6876,N,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Intermediate,,,,,50594,BAO_0000218,A,,3535,,1,1,CHEMBL623327
6877,N,,,,Maximum concentration in plasma upon oral administration in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2862,Plasma,1,1,CHEMBL623328
6878,N,,,,Maximum plasma concentration was evaluated in mice after oral administration,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2675,Plasma,1,1,CHEMBL623329
6879,N,,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Intermediate,,,,1969.0,50594,BAO_0000218,A,,2675,Plasma,1,1,CHEMBL623330
6880,N,,,,Dose at which the compound induced fecal excretion in mice,Intermediate,,,,,50594,BAO_0000218,A,,5399,,1,1,CHEMBL876789
6893,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,1,1,CHEMBL623333
6894,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,1,1,CHEMBL623334
6895,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,1,1,CHEMBL627536
6896,N,,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Expert,,A10,,,80013,BAO_0000219,F,,11819,,1,1,CHEMBL627537
6897,N,,164.0,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Intermediate,,A10,,,80013,BAO_0000219,F,,16361,,1,1,CHEMBL627538
6898,N,,393.0,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Intermediate,,A121,,,80655,BAO_0000219,F,,2288,,1,1,CHEMBL884106
6899,N,,393.0,,Anticancer activity against human ovarian carcinoma A121 cells,Intermediate,,A121,,,80655,BAO_0000219,F,,10404,,1,1,CHEMBL625294
6900,N,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,1,1,CHEMBL625295
6901,N,,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,1,1,CHEMBL625296
6902,N,,393.0,,Growth inhibition of human ovarian carcinoma (A121) cell line,Expert,,A121,,,80655,BAO_0000219,F,,14253,,1,1,CHEMBL625297
6903,N,,393.0,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Expert,,A121,,,80655,BAO_0000219,F,,13617,,1,1,CHEMBL625298
6904,N,,393.0,,Cytotoxicity against human A121 ovarian cells,Intermediate,,A121,,,80655,BAO_0000219,F,,1003,,1,1,CHEMBL625960
6905,N,,393.0,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Intermediate,,A121,,,80655,BAO_0000219,F,,830,,1,1,CHEMBL625961
6906,N,,393.0,,In vitro cytotoxicity against human ovarian carcinoma A21,Intermediate,,A121,,,80655,BAO_0000219,F,,12307,,1,1,CHEMBL625962
6907,N,,393.0,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Intermediate,,A121,,,80655,BAO_0000219,F,,14254,,1,1,CHEMBL624717
6908,N,,393.0,,Inhibitory activity of compound against human A121 ovarian cell line.,Intermediate,,A121,,,80655,BAO_0000219,F,,13370,,1,1,CHEMBL624718
6909,N,,393.0,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Intermediate,,A121,,,80655,BAO_0000219,F,,14790,,1,1,CHEMBL624719
6910,N,,393.0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Intermediate,,A121,,,80655,BAO_0000219,F,,3614,,1,1,CHEMBL624720
6911,N,,622.0,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2664,,1,1,CHEMBL624721
6912,N,,622.0,,In vitro cytotoxicity against A172 human tumor cell lines.,Expert,,A 172,,,80012,BAO_0000219,F,,2037,,1,1,CHEMBL624722
6913,N,,622.0,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Intermediate,,A 172,,,80012,BAO_0000219,F,,14539,,1,1,CHEMBL877597
6914,N,,622.0,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Intermediate,,A 172,,,80012,BAO_0000219,F,,2836,,1,1,CHEMBL624723
6915,N,,622.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Intermediate,,A 172,,,80012,BAO_0000219,F,,10708,,1,1,CHEMBL624724
6916,H,,,,Association constant against A2 adenosine receptor,Autocuration,,,,,104729,BAO_0000224,B,,8975,,4,1,CHEMBL624725
6917,N,,1085.0,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,Intermediate,,A2,,,80656,BAO_0000219,F,,7645,,1,1,CHEMBL624726
6918,D,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,Autocuration,,,,,104713,BAO_0000224,B,,11377,,5,1,CHEMBL857535
6919,N,,623.0,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Expert,,A204,,,80014,BAO_0000219,F,,13528,,1,1,CHEMBL624727
6920,N,,623.0,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Expert,,A204,,,80014,BAO_0000219,F,,10160,,1,1,CHEMBL624728
6921,N,,404.0,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Intermediate,,A2058,,,80015,BAO_0000219,F,,15144,,1,1,CHEMBL624729
6922,N,,973.0,,Growth inhibition against Human squamous cell line(A 253),Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,13160,,1,1,CHEMBL624730
6923,N,,973.0,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,12898,,1,1,CHEMBL624731
6924,N,,973.0,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,13069,,1,1,CHEMBL624732
6925,N,,973.0,,Growth inhibition of A253 cell lines.,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15984,,1,1,CHEMBL883245
6926,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,1,1,CHEMBL624733
6927,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,1,1,CHEMBL624734
6928,N,,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,A253 cell line,,,80657,BAO_0000219,F,,15564,,1,1,CHEMBL624735
6929,N,,478.0,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4720,,1,1,CHEMBL621780
6930,N,,478.0,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,16112,,1,1,CHEMBL877598
6931,N,,478.0,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,1,1,CHEMBL621781
6932,N,,478.0,,Cytotoxicity against human cancer cell lines A2780 (ovarian),Intermediate,,A2780,,,81034,BAO_0000219,F,,16378,,1,1,CHEMBL621782
6933,N,,478.0,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,16085,,1,1,CHEMBL621783
6934,N,,478.0,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,1,1,CHEMBL621784
6935,N,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,1,1,CHEMBL621785
6936,N,,478.0,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,1,1,CHEMBL621968
6937,N,,478.0,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,1,1,CHEMBL621969
6938,N,,478.0,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,16597,,1,1,CHEMBL621970
6939,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL621971
6940,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL621972
6941,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL884108
6942,U,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Autocuration,,,,,22224,BAO_0000019,F,,15296,,0,1,CHEMBL623826
6943,U,,185.0,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,A,,10251,,0,1,CHEMBL623827
6944,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,0,1,CHEMBL623828
6945,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,0,1,CHEMBL623829
6946,U,,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10251,,0,1,CHEMBL623830
6947,U,,,,Growth inhibition against CHO-derived cell line AA8,Autocuration,,,,,22224,BAO_0000019,F,,11858,,0,1,CHEMBL623831
6948,U,,185.0,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11858,,0,1,CHEMBL623832
6949,N,,185.0,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,1,1,CHEMBL623833
6950,N,,185.0,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,1,1,CHEMBL623834
6951,U,,185.0,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL623835
6952,U,,185.0,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,11396,,0,1,CHEMBL623836
6953,U,,185.0,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Autocuration,,CHO-AA8,,,22224,BAO_0000219,F,,10518,,0,1,CHEMBL623837
6954,N,,185.0,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Expert,,CHO-AA8,,,80089,BAO_0000219,F,,11616,,1,1,CHEMBL623838
6955,H,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,Autocuration,,,,,12675,BAO_0000019,F,,14837,,8,1,CHEMBL623839
6956,H,,,,Number of binding sites (n) of isolated serum protein AAG,Autocuration,,,,,12675,BAO_0000019,F,,14837,,8,1,CHEMBL623840
6957,M,,,,Association constant for binding to AATT duplex,Intermediate,,,,,22222,BAO_0000225,B,,16037,,3,1,CHEMBL623841
6958,N,,416.0,,Inhibition of ABAE human fibroblast cell proliferation,Expert,,ABAE,,,100090,BAO_0000219,F,,16597,,1,1,CHEMBL623842
6959,N,,1064.0,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Intermediate,,AC755,,,80668,BAO_0000218,F,,8831,,1,1,CHEMBL623843
6960,D,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Expert,,,,,102444,BAO_0000218,F,,13419,,9,1,CHEMBL618669
6961,D,,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Expert,,,,,102444,BAO_0000218,F,,13419,,9,1,CHEMBL618670
6962,H,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,Autocuration,,,,,69,BAO_0000357,B,,15778,,8,1,CHEMBL618671
6963,H,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,Autocuration,,,,,69,BAO_0000357,B,,15778,,8,1,CHEMBL618672
6964,N,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Intermediate,,ACH-2 cell line,,,80669,BAO_0000219,F,,12988,,1,1,CHEMBL618673
6965,N,,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Intermediate,,ACH-2 cell line,,,80669,BAO_0000219,F,,12988,,1,1,CHEMBL618674
6966,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,0,1,CHEMBL618675
6967,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,0,1,CHEMBL618676
6968,U,,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,T cell line,,,22224,BAO_0000219,F,,12988,,0,1,CHEMBL618677
6969,N,,626.0,,Inhibition of growth of renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,11843,,1,1,CHEMBL618678
6970,N,,626.0,,Inhibition of growth of ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16939,,1,1,CHEMBL618679
6971,N,,626.0,,Inhibitory concentration required against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4782,,1,1,CHEMBL618680
6972,N,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line,Expert,,ACHN,,,80025,BAO_0000219,F,,6310,,1,1,CHEMBL618681
6973,N,,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6310,,1,1,CHEMBL618682
6974,N,,626.0,,Cytotoxic activity against ACHN Renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12858,,1,1,CHEMBL618683
6975,N,,626.0,,Cytotoxicity evaluation against ACHN renal cancer cells,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17380,,1,1,CHEMBL618684
6976,N,,626.0,,In vitro antitumor activity against human renal ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,5858,,1,1,CHEMBL618685
6977,N,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3838,,1,1,CHEMBL876499
6978,N,,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3838,,1,1,CHEMBL618686
6979,N,,626.0,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Intermediate,,ACHN,,,80025,BAO_0000219,F,,5406,,1,1,CHEMBL618687
6980,N,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4071,,1,1,CHEMBL618688
6981,N,,626.0,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Expert,,ACHN,,,80025,BAO_0000219,F,,4071,,1,1,CHEMBL618689
6982,N,,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,4071,,1,1,CHEMBL618690
6983,N,,626.0,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15002,,1,1,CHEMBL618691
6984,N,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,ACHN,,,80025,BAO_0000219,F,,14769,,1,1,CHEMBL619373
6985,N,,626.0,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Intermediate,,ACHN,,,80025,BAO_0000219,F,,13958,,1,1,CHEMBL884008
6986,N,,626.0,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Intermediate,,ACHN,,,80025,BAO_0000219,F,,1665,,1,1,CHEMBL619374
6987,N,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15354,,1,1,CHEMBL619375
6988,N,,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15354,,1,1,CHEMBL619376
6989,N,,626.0,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,13978,,1,1,CHEMBL619377
6990,N,,626.0,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6798,,1,1,CHEMBL619378
6991,N,,,,Tmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,,1,1,CHEMBL872527
6992,N,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9932,,1,1,CHEMBL876500
6993,N,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,,1,1,CHEMBL619379
6994,N,,,,Volume distribution after 15 mg/kg iv dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL619538
6995,N,,,,Volume distribution after 30 mg/kg po dose in Dogs,Intermediate,,,,,50588,BAO_0000218,A,,16907,,1,1,CHEMBL619539
6996,N,,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,,1,1,CHEMBL619540
6997,N,,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,4305,,1,1,CHEMBL619541
6998,N,,,,Volume of distribution was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL619542
6999,N,,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,1,1,CHEMBL619543
7000,N,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,,,50588,BAO_0000218,A,,3598,,1,1,CHEMBL619544
7001,N,,,,The compound was tested for volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,12500,,1,1,CHEMBL619545
7002,N,,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Intermediate,,,,,50588,BAO_0000218,A,,12500,,1,1,CHEMBL619546
7003,N,,,,Vd (1 mg/kg) was determined in dog (in vivo),Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL619547
7004,N,,,,Vd in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL619548
7005,N,,,,Volume distribution was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,,1,1,CHEMBL619549
7006,N,,,,Volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,1696,,1,1,CHEMBL619550
7007,N,,,,Volume of distribution by as 4 fold increase by iv administration in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5542,,1,1,CHEMBL876501
7008,N,,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50588,BAO_0000218,A,,5199,,1,1,CHEMBL619551
7009,N,,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,,1,1,CHEMBL619552
7010,N,,,,Volume distribution at the dose of 2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4727,,1,1,CHEMBL619553
7011,N,,,,Steady state volume of distribution was determined,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL618722
7012,N,,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL618723
7013,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL618724
7014,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL618725
7015,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL618726
7016,N,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,,1,1,CHEMBL618727
7017,N,,,,Pharmacokinetic property (vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,4239,,1,1,CHEMBL624233
7018,N,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL624234
7019,N,,,,Vdss was determined after iv 0.1 mg/kg administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL624235
7020,N,,,,Volume displacement was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL624236
7021,N,,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,,1,1,CHEMBL624237
7022,N,,,,Volume distribution constant was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,,1,1,CHEMBL624238
7023,N,,,,Volume distribution at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL624239
7024,N,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL875829
7025,N,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL624240
7026,N,,,,Volume distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL624241
7027,N,,,,Volume distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL624242
7028,N,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,,1,1,CHEMBL624243
7029,N,,,,Volume of distribution in steady state was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,,1,1,CHEMBL624244
7030,N,,,,Volume of distribution of compound was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6821,,1,1,CHEMBL624245
7031,N,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,,1,1,CHEMBL624246
7032,N,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,,,50588,BAO_0000218,A,,5334,,1,1,CHEMBL624247
7033,N,,,,Volume of distribution (Vdss) was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL624248
7034,N,,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL624249
7035,N,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,,1,1,CHEMBL624250
7036,N,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL624251
7037,N,,,,Maximum rate of depolarization of the upstroke of the action potential,Intermediate,,,,,50588,BAO_0000218,A,,11659,,1,1,CHEMBL624252
7038,N,,,,Steady state volume distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL624253
7039,N,,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL624950
7040,N,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,1466,,1,1,CHEMBL624951
7041,N,,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL875830
7042,N,,,,Volume distribution in dog after administration of 1 mg/kg iv,Intermediate,,,,,50588,BAO_0000218,A,,6535,,1,1,CHEMBL624952
7043,N,,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17764,,1,1,CHEMBL624953
7044,N,,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,,1,1,CHEMBL624954
7045,N,,,,Vss on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,6505,,1,1,CHEMBL624955
7046,N,,,,Vss was determined,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL624956
7047,N,,,,Vss in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL625129
7048,N,,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,1,1,CHEMBL625130
7049,N,,,,Volume distribution in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4942,,1,1,CHEMBL625131
7050,N,,,,Volume of distribution in dog,Intermediate,,,,,50588,BAO_0000218,A,,17796,,1,1,CHEMBL625132
7051,N,,,,Tested for the oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,4883,,1,1,CHEMBL872263
7060,N,,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,17837,,1,1,CHEMBL624336
7061,N,,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL624337
7062,N,,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL624338
7063,N,,,,Bioavailability was measured in mouse,Intermediate,,,,,50594,BAO_0000218,A,,4239,,1,1,CHEMBL624339
7064,N,,,,Bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,,1,1,CHEMBL624340
7065,N,,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,,1,1,CHEMBL624341
7066,N,,,,Bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2801,,1,1,CHEMBL624342
7067,N,,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,2801,,1,1,CHEMBL624343
7068,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17718,,1,1,CHEMBL624344
7069,N,,,,Oral availability at 50 mg/kg po in male mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,,1,1,CHEMBL624345
7070,N,,,,Oral bioavailability in mouse (dose 10 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,5302,,1,1,CHEMBL624346
7071,N,,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Expert,,,,,50594,BAO_0000218,A,,3598,,1,1,CHEMBL624347
7072,N,,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Intermediate,,,,,50594,BAO_0000218,A,,5961,,1,1,CHEMBL624348
7074,N,,,,Oral bioavailability in mouse,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL622754
7075,N,,,,Oral bioavailability in vivo in mice;ND=Not determined,Intermediate,,,,,50594,BAO_0000218,A,,6091,,1,1,CHEMBL622755
7076,N,,,,Oral bioavailability in mouse at 10 mg/kg of the compound,Intermediate,,,,,50594,BAO_0000218,A,,5711,,1,1,CHEMBL622756
7077,N,,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL622757
7078,N,,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL622758
7079,N,,,,Tested for bioavailability of the compound,Intermediate,,,,,50594,BAO_0000218,A,,3802,,1,1,CHEMBL622759
7080,N,,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,Intermediate,,,,,50594,BAO_0000218,A,,3802,,1,1,CHEMBL622760
7081,N,,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,Plasma,1,1,CHEMBL622761
7082,N,,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,Plasma,1,1,CHEMBL622762
7083,N,,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,Plasma,1,1,CHEMBL622763
7084,N,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,Plasma,1,1,CHEMBL622764
7085,N,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14029,Plasma,1,1,CHEMBL622765
7086,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Intermediate,,,,,50594,BAO_0000218,F,,17753,,1,1,CHEMBL622766
7087,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL622767
7088,N,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Intermediate,,,,,50594,BAO_0000218,A,,17753,,1,1,CHEMBL622768
7089,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL875948
7090,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622769
7091,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622770
7092,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622771
7093,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622772
7094,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622773
7095,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,178.0,50594,BAO_0000218,A,,10107,Blood,1,1,CHEMBL622774
7096,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL621725
7097,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL621726
7098,N,,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Intermediate,,A2780,,,81034,BAO_0000219,F,,15608,,1,1,CHEMBL621727
7099,N,,478.0,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Expert,,A2780,,,81034,BAO_0000219,F,,3290,,1,1,CHEMBL622413
7100,N,,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2859,,1,1,CHEMBL622414
7101,N,,478.0,,Inhibition of A2780 cell clonogenic assay,Expert,,A2780,,,81034,BAO_0000219,F,,15688,,1,1,CHEMBL622415
7102,N,,478.0,,Cytotoxic effect on ovarian cancer cell line (A2780),Expert,,A2780,,,81034,BAO_0000219,F,,5642,,1,1,CHEMBL884001
7103,N,,478.0,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,1,1,CHEMBL622416
7104,N,,478.0,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Intermediate,,A2780,,,81034,BAO_0000219,F,,3906,,1,1,CHEMBL622417
7105,N,,478.0,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Expert,,A2780,,,81034,BAO_0000219,F,,6788,,1,1,CHEMBL622590
7106,N,,478.0,,Antiproliferative activity against human A2780 cells,Expert,,A2780,,,81034,BAO_0000219,F,,17582,,1,1,CHEMBL622591
7107,N,,478.0,,Inhibition of human A2780 cell proliferation,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,1,1,CHEMBL622592
7108,N,,478.0,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,1,1,CHEMBL622593
7109,N,,478.0,,Inhibition of human A2780 cell proliferation (No data),Expert,,A2780,,,81034,BAO_0000219,F,,17764,,1,1,CHEMBL622594
7110,N,,478.0,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,2815,,1,1,CHEMBL622595
7111,N,,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,16930,,1,1,CHEMBL622596
7112,N,,478.0,,Growth inhibition against A2780 wild-type ovarian cell lines,Expert,,A2780,,,81034,BAO_0000219,F,,17777,,1,1,CHEMBL622597
7113,N,,478.0,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Intermediate,,A2780,,,81034,BAO_0000219,F,,17777,,1,1,CHEMBL622598
7114,D,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Autocuration,,,,,104766,BAO_0000019,F,,16936,,5,1,CHEMBL622599
7115,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,1,1,CHEMBL622600
7116,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,1,1,CHEMBL622601
7117,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,1,1,CHEMBL622602
7118,N,,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,A2780,,,81034,BAO_0000219,F,,13759,,1,1,CHEMBL622603
7119,N,,478.0,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,A2780,,,81034,BAO_0000219,F,,15292,,1,1,CHEMBL622604
7120,N,,478.0,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,A2780,,,81034,BAO_0000219,F,,15292,,1,1,CHEMBL622605
7121,N,,478.0,,In vitro inhibition of human ovarian cell line A2780,Expert,,A2780,,,81034,BAO_0000219,F,,15069,,1,1,CHEMBL622606
7122,N,,478.0,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Expert,,A2780,,,81034,BAO_0000219,F,,15069,,1,1,CHEMBL619463
7123,N,,478.0,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Intermediate,,A2780,,,81034,BAO_0000219,F,,14073,,1,1,CHEMBL619464
7124,N,,478.0,,Concentration required to inhibit A2780-cell growth by 50%,Expert,,A2780,,,81034,BAO_0000219,F,,14553,,1,1,CHEMBL619465
7125,N,,478.0,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Expert,,A2780,,,81034,BAO_0000219,F,,13040,,1,1,CHEMBL619466
7126,N,,478.0,,Cytotoxic effect on human ovarian (A2780) cancer cell line,Expert,,A2780,,,81034,BAO_0000219,F,,6891,,1,1,CHEMBL619467
7127,N,,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Intermediate,,A2780,,,81034,BAO_0000219,F,,15569,,1,1,CHEMBL619468
7128,N,,478.0,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Expert,,A2780,,,81034,BAO_0000219,F,,14190,,1,1,CHEMBL619469
7129,N,,478.0,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Expert,,A2780,,,81034,BAO_0000219,F,,15014,,1,1,CHEMBL619470
7130,N,,478.0,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,15014,,1,1,CHEMBL619471
7131,N,,478.0,,Cytotoxicity against human ovarian carcinoma A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17496,,1,1,CHEMBL619472
7132,N,,478.0,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,1,1,CHEMBL619473
7133,N,,478.0,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,1,1,CHEMBL874368
7134,N,,478.0,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,1,1,CHEMBL884003
7135,N,,478.0,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Intermediate,,A2780,,,81034,BAO_0000219,F,,13617,,1,1,CHEMBL622690
7136,N,,478.0,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Intermediate,,A2780,,,81034,BAO_0000219,F,,17672,,1,1,CHEMBL622691
7137,N,,478.0,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,4544,,1,1,CHEMBL622692
7138,N,,478.0,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,A2780,,,81034,BAO_0000219,F,,4544,,1,1,CHEMBL623406
7139,N,,478.0,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,1,1,CHEMBL884004
7140,N,,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,15099,,1,1,CHEMBL623407
7141,N,,478.0,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,13978,,1,1,CHEMBL623408
7142,N,,478.0,,In vitro antitumor activity against A2780 cell line.,Expert,,A2780,,,81034,BAO_0000219,F,,12989,,1,1,CHEMBL623409
7143,N,,478.0,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Intermediate,,A2780,,,81034,BAO_0000219,F,,5574,,1,1,CHEMBL623410
7144,N,,478.0,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Expert,,A2780,,,81034,BAO_0000219,F,,13528,,1,1,CHEMBL623576
7145,N,,626.0,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12782,,1,1,CHEMBL623577
7146,N,,626.0,,The IC50 value was measured on ACHN cell line in renal tumor type.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14255,,1,1,CHEMBL623578
7147,N,,626.0,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16364,,1,1,CHEMBL623579
7148,N,,626.0,,In vitro lethal concentration against most sensitive ACHN cell line,Expert,,ACHN,,,80025,BAO_0000219,F,,17376,,1,1,CHEMBL623580
7149,N,,626.0,,Tested for cytotoxic activity against renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12016,,1,1,CHEMBL623581
7150,N,,626.0,,Compound tested for growth inhibition of renal cancer cell line ACHN,Intermediate,,ACHN,,,80025,BAO_0000219,F,,6058,,1,1,CHEMBL857456
7151,N,,626.0,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17708,,1,1,CHEMBL623582
7152,N,,626.0,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15176,,1,1,CHEMBL623583
7153,N,,626.0,,In vitro anticancer activity against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,2806,,1,1,CHEMBL623584
7154,N,,626.0,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15300,,1,1,CHEMBL623585
7155,N,,626.0,,Percent selectivity was evaluated in renal ACHN cell lines,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16364,,1,1,CHEMBL623586
7156,N,,626.0,,In vitro inhibitory activity against renal ACHN cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,13859,,1,1,CHEMBL623587
7157,N,,626.0,,Tested for cytotoxicity against ACHN cell lines in renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,11970,,1,1,CHEMBL875279
7158,N,,626.0,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,2450,,1,1,CHEMBL623588
7159,N,,626.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12696,,1,1,CHEMBL623589
7160,N,,626.0,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12400,,1,1,CHEMBL623590
7161,N,,626.0,,Cytotoxic effect on renal cancer line ACHN,Expert,,ACHN,,,80025,BAO_0000219,F,,12888,,1,1,CHEMBL623591
7162,N,,626.0,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3156,,1,1,CHEMBL623592
7163,N,,626.0,,In vitro inhibition of Renal Cancer ACHN cell lines,Intermediate,,ACHN,,,80025,BAO_0000219,F,,3381,,1,1,CHEMBL623593
7164,N,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells,Intermediate,,ACHN,,,80025,BAO_0000219,F,,16747,,1,1,CHEMBL623594
7165,N,,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells.,Expert,,ACHN,,,80025,BAO_0000219,F,,16748,,1,1,CHEMBL621833
7166,N,,626.0,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Intermediate,,ACHN,,,80025,BAO_0000219,F,,12062,,1,1,CHEMBL621834
7167,N,,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,ACHN,,,80025,BAO_0000219,F,,14769,,1,1,CHEMBL621835
7168,N,,626.0,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Intermediate,,ACHN,,,80025,BAO_0000219,F,,15895,,1,1,CHEMBL621836
7169,N,,626.0,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Intermediate,,ACHN,,,80025,BAO_0000219,F,,17376,,1,1,CHEMBL621837
7170,N,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14882,,1,1,CHEMBL875280
7171,N,,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Intermediate,,ACHN,,,80025,BAO_0000219,F,,14882,,1,1,CHEMBL621838
7172,N,,626.0,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Intermediate,,ACHN,,,80025,BAO_0000219,F,,15661,,1,1,CHEMBL621839
7173,U,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL621840
7174,H,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,Autocuration,,,,,10647,BAO_0000019,F,,14579,,8,1,CHEMBL621841
7175,N,,468.0,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Expert,,HEL,,,50529,BAO_0000218,F,,17290,,1,1,CHEMBL622979
7176,N,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Intermediate,,,,,50529,BAO_0000218,F,,17290,,1,1,CHEMBL876595
7177,H,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,12159,BAO_0000357,B,,15891,,8,1,CHEMBL620221
7178,H,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,12159,BAO_0000357,B,,15890,,8,1,CHEMBL620222
7179,N,,979.0,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Intermediate,,ADDP cell line,,,80670,BAO_0000219,F,,3801,,1,1,CHEMBL620506
7180,N,,980.0,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,9222,,1,1,CHEMBL620507
7181,N,,980.0,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,9222,,1,1,CHEMBL620508
7182,N,,980.0,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,7257,,1,1,CHEMBL620509
7183,N,,980.0,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,7257,,1,1,CHEMBL620510
7184,N,,980.0,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,A,,7257,,1,1,CHEMBL620511
7185,N,,980.0,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Intermediate,,ADJ/PC6,,,80671,BAO_0000219,F,,8084,,1,1,CHEMBL620512
7186,U,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Autocuration,,,,,22224,BAO_0000019,F,,14943,,0,1,CHEMBL620513
7187,U,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Autocuration,,,,,22224,BAO_0000019,F,,14943,,0,1,CHEMBL620514
7188,U,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Autocuration,,,,,22224,BAO_0000019,F,,14943,,0,1,CHEMBL620515
7189,U,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,10524,,0,1,CHEMBL620516
7190,N,,,,AUC value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3546,Plasma,1,1,CHEMBL620517
7191,N,,,,AUC value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3546,Plasma,1,1,CHEMBL620518
7192,N,,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,1,1,CHEMBL620519
7193,N,,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,1,1,CHEMBL621386
7194,N,,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,1,1,CHEMBL621387
7195,N,,,,Compound was evaluated for its clearance when administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,3184,,1,1,CHEMBL621388
7196,N,,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,,1,1,CHEMBL621389
7197,N,,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL621390
7198,U,,,,Calculated partition coefficient (clogP),Intermediate,,,,,22229,BAO_0000100,P,,4219,,0,1,CHEMBL621391
7199,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,3748,,1,1,CHEMBL621392
7200,N,,,,Time taken for EC90 was determined when tested in dog,Intermediate,,,,,50588,BAO_0000218,A,,3132,,1,1,CHEMBL621393
7201,N,,,,Half life (iv) was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,,1,1,CHEMBL621394
7202,N,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Intermediate,,,,2107.0,50588,BAO_0000218,A,,16907,Liver,1,1,CHEMBL621395
7203,N,,,,Area under the curve was calculated in dog after iv administration,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL621396
7204,N,,,,Area under the curve was calculated in dog after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL621397
7205,N,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,,1,1,CHEMBL621398
7206,N,,,,pKa was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,3639,,1,1,CHEMBL618818
7207,N,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14541,,1,1,CHEMBL618819
7208,N,,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,,1,1,CHEMBL618820
7209,N,,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,16456,,1,1,CHEMBL873810
7210,N,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,,,50588,BAO_0000218,A,,2652,,1,1,CHEMBL876606
7211,N,,,,Compound was evaluated for the half-life (t 1/2) in hours,Intermediate,,,,,50588,BAO_0000218,A,,3624,,1,1,CHEMBL618821
7212,N,,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,Blood,1,1,CHEMBL618822
7213,N,,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,,178.0,50588,BAO_0000218,A,,1337,Blood,1,1,CHEMBL618823
7214,N,,,,Half life after intravenous administration of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4709,,1,1,CHEMBL618824
7215,N,,,,Half life was measured in dog,Intermediate,,,,,50588,BAO_0000218,A,,15660,,1,1,CHEMBL618825
7216,N,,,,Half life period in dog after 5 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,5302,,1,1,CHEMBL618826
7217,N,,,,Half life period was evaluated in dog; 4-4.8,Intermediate,,,,,50588,BAO_0000218,A,,17791,,1,1,CHEMBL618827
7218,N,,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,,,50588,BAO_0000218,A,,6348,,1,1,CHEMBL618828
7219,N,,,,Half-life was determined in dog after a3 mg/kg of iv dose,Intermediate,,,,,50588,BAO_0000218,A,,4257,,1,1,CHEMBL618829
7220,N,,,,Half-life was determined,Intermediate,,,,,50588,BAO_0000218,A,,3771,,1,1,CHEMBL618830
7221,N,,,,Half life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,6305,,1,1,CHEMBL618831
7222,N,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13501,Plasma,1,1,CHEMBL619489
7223,N,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,,1,1,CHEMBL619649
7224,N,,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,3045,,1,1,CHEMBL876607
7225,N,,,,Compound was evaluated for the half life period after oral administration in conscious dog.,Intermediate,,,,,50588,BAO_0000218,A,,3043,,1,1,CHEMBL619650
7226,N,,,,Compound was tested for half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,,1,1,CHEMBL619651
7227,N,,,,Compound was tested for its half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4839,,1,1,CHEMBL619652
7228,N,,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,,,50588,BAO_0000218,A,,5802,,1,1,CHEMBL619653
7229,N,,,,Half life of compound in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL619654
7230,N,,,,Half life (iv) was determined,Intermediate,,,,,50588,BAO_0000218,A,,4219,,1,1,CHEMBL619655
7231,N,,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Intermediate,,,,178.0,50588,BAO_0000218,A,,13966,Blood,1,1,CHEMBL619656
7232,N,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3994,Plasma,1,1,CHEMBL873812
7233,N,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,,1969.0,50588,BAO_0000218,F,,3994,Plasma,1,1,CHEMBL621365
7234,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,4453,,1,1,CHEMBL621366
7235,N,,,,Half life in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,Plasma,1,1,CHEMBL621367
7236,N,,,,Half life in dog plasma after administration of 0.25 mg/kg iv,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,Plasma,1,1,CHEMBL621368
7237,N,,,,Half life in dog plasma after administration of 1 mg/kg iv,Intermediate,,,,1969.0,50588,BAO_0000218,A,,6535,Plasma,1,1,CHEMBL621369
7238,N,,,,Half life in dog plasma was determined at dose 10 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL621370
7239,N,,,,Half life in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,5374,,1,1,CHEMBL621371
7240,N,,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,5007,,1,1,CHEMBL621372
7241,N,,,,Half life upon exposure to human plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,16907,Plasma,1,1,CHEMBL621373
7242,N,,,,Half life was calculated in dog,Intermediate,,,,,50588,BAO_0000218,A,,6057,,1,1,CHEMBL621374
7243,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL621375
7244,N,,,,Half life was determined,Intermediate,,,,,50588,BAO_0000218,A,,5473,,1,1,CHEMBL621376
7245,N,,,,Half life by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,4368,,1,1,CHEMBL619624
7246,N,,,,Half life in dog,Intermediate,,,,,50588,BAO_0000218,A,,6448,,1,1,CHEMBL875840
7247,N,,,,Half life in dog after intra venous administration of the compound,Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL619625
7248,N,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL619626
7249,N,,,,Half life in dog after po administration of the compound,Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL619627
7250,N,,,,Half life in dog after po administration of the compound; ND means Not determined,Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL873817
7251,N,,,,Half life in dog at the single oral dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6265,,1,1,CHEMBL619628
7252,N,,,,Half life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5006,,1,1,CHEMBL619629
7253,N,,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Intermediate,,,,,50588,BAO_0000218,A,,5356,,1,1,CHEMBL619630
7254,N,,,,Half life in rat,Intermediate,,,,,50588,BAO_0000218,A,,405,,1,1,CHEMBL619631
7255,N,,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL619632
7256,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL619633
7257,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL875841
7258,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL619634
7259,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL619635
7260,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,10107,Bone,1,1,CHEMBL619636
7261,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619637
7262,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619638
7263,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619639
7264,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619640
7265,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619641
7266,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619642
7267,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,10000004.0,50594,BAO_0000218,A,,10107,Gut,1,1,CHEMBL619643
7268,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL619644
7269,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621112
7270,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621113
7271,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621114
7272,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621115
7273,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621116
7274,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,948.0,50594,BAO_0000218,A,,10107,Heart,1,1,CHEMBL621117
7275,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621118
7276,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621119
7277,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621120
7278,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621757
7279,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621758
7280,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621759
7281,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2113.0,50594,BAO_0000218,A,,10107,Kidney,1,1,CHEMBL621760
7282,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL621761
7283,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL621762
7284,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL621763
7285,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL624502
7286,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL624503
7287,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL624504
7288,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2107.0,50594,BAO_0000218,A,,10107,Liver,1,1,CHEMBL624505
7289,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL624506
7290,N,,478.0,,In vitro cytotoxicity against A2780 (human ovarian cancer),Intermediate,,A2780,,,81034,BAO_0000219,F,,5895,,1,1,CHEMBL624507
7291,N,,478.0,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Intermediate,,A2780,,,81034,BAO_0000219,F,,6338,,1,1,CHEMBL624508
7292,N,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Intermediate,,A2780,,,81034,BAO_0000219,F,,15163,,1,1,CHEMBL624509
7293,N,,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Intermediate,,A2780,,,81034,BAO_0000219,F,,15163,,1,1,CHEMBL624510
7294,N,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,1,1,CHEMBL875956
7295,N,,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,1,1,CHEMBL839885
7296,N,,478.0,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Expert,,A2780,,,81034,BAO_0000219,F,,14729,,1,1,CHEMBL624511
7297,N,,478.0,,In vitro cytotoxicity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17270,,1,1,CHEMBL624512
7298,N,,478.0,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Intermediate,,A2780,,,81034,BAO_0000219,F,,5685,,1,1,CHEMBL624513
7299,N,,478.0,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,3563,,1,1,CHEMBL624514
7300,N,,478.0,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,,1,1,CHEMBL618547
7301,N,,478.0,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,A2780,,,81034,BAO_0000219,F,,16317,,1,1,CHEMBL618548
7302,N,,478.0,,Inhibition of tubulin polymerization in analogy of ca.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL618549
7303,N,,478.0,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Intermediate,,A2780,,,81034,BAO_0000219,F,,3801,,1,1,CHEMBL618550
7304,N,,478.0,,Cytotoxic effect in ovarian cancer cell line (A2780),Expert,,A2780,,,81034,BAO_0000219,F,,6181,,1,1,CHEMBL618551
7305,N,,478.0,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Intermediate,,A2780,,,81034,BAO_0000219,F,,5318,,1,1,CHEMBL618552
7306,N,,478.0,,Tested for the cytotoxicity in A2780 ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,4840,,1,1,CHEMBL618553
7307,N,,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,1,1,CHEMBL618554
7308,N,,478.0,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Intermediate,,A2780,,,81034,BAO_0000219,F,,15748,,1,1,CHEMBL618555
7309,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,1,1,CHEMBL618556
7310,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,1,1,CHEMBL618557
7311,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,1,1,CHEMBL618558
7312,N,,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),Intermediate,,A2780cisR,,,80017,BAO_0000219,F,,15748,,1,1,CHEMBL618559
7313,N,,478.0,,In vivo log of cells killed after administration of compound in A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,,1,1,CHEMBL618560
7314,N,,478.0,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000218,F,,17753,,1,1,CHEMBL618561
7315,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL618562
7316,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL618563
7317,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL618564
7318,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL618565
7319,N,,478.0,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Intermediate,,A2780,,,81034,BAO_0000218,F,,17528,,1,1,CHEMBL618566
7320,N,,478.0,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,6633,,1,1,CHEMBL618567
7321,N,,478.0,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Expert,,A2780,,,81034,BAO_0000219,F,,15000,,1,1,CHEMBL618568
7322,N,,478.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,A2780,,,81034,BAO_0000219,F,,17528,,1,1,CHEMBL618569
7323,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621857
7324,N,,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621858
7325,N,,478.0,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621859
7326,N,,478.0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621860
7327,N,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621861
7328,N,,478.0,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Expert,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621862
7329,N,,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621863
7330,N,,478.0,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621864
7331,N,,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,A2780,,,81034,BAO_0000219,F,,16936,,1,1,CHEMBL621865
7332,N,,478.0,,In vitro antiproliferative activity against A2780 cell line,Intermediate,,A2780,,,81034,BAO_0000219,F,,17737,,1,1,CHEMBL621866
7333,N,,478.0,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Expert,,A2780,,,81034,BAO_0000219,F,,17764,,1,1,CHEMBL621867
7334,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3830,,1,1,CHEMBL621868
7335,N,,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Intermediate,,A2780,,,81034,BAO_0000219,F,,3829,,1,1,CHEMBL875282
7336,N,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,1,1,CHEMBL621869
7337,N,,,,Half life period in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,3546,,1,1,CHEMBL621870
7338,U,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000019,A,,5668,,0,1,CHEMBL621871
7339,U,,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3443,Plasma,0,1,CHEMBL621243
7340,U,,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3443,Plasma,0,1,CHEMBL621244
7341,U,,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL621245
7342,U,,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL621246
7343,U,,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL621247
7344,U,,,,Oral Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL618386
7345,U,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,,,22224,BAO_0000218,A,,1916,,0,1,CHEMBL618387
7346,U,,,,Area under curve value in monkey at a dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5302,,0,1,CHEMBL618388
7347,U,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Autocuration,,,,,22224,BAO_0000218,A,,4257,,0,1,CHEMBL618389
7348,U,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000019,A,,5355,,0,1,CHEMBL618574
7349,U,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000019,A,,5355,,0,1,CHEMBL618575
7350,U,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Autocuration,,,,,22224,BAO_0000019,A,,5355,,0,1,CHEMBL618576
7351,U,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,0,1,CHEMBL618577
7352,U,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,6078,,0,1,CHEMBL876487
7353,U,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6062,,0,1,CHEMBL618578
7354,U,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL618579
7355,U,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000019,A,,2661,,0,1,CHEMBL618580
7356,U,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,,0,1,CHEMBL618581
7357,U,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Autocuration,,,,,22224,BAO_0000218,A,,4397,,0,1,CHEMBL618582
7358,U,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,0,1,CHEMBL618583
7359,U,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,,,22224,BAO_0000218,A,,17509,,0,1,CHEMBL618584
7360,U,,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Autocuration,,,,,22224,BAO_0000218,A,,6641,,0,1,CHEMBL618585
7361,U,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL618586
7362,U,,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL618587
7363,U,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,,,22224,BAO_0000218,A,,3443,,0,1,CHEMBL618588
7364,U,,,,Binding towards monkey plasma protein at 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,0,1,CHEMBL618589
7365,U,,,,Binding towards monkey plasma protein at 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,17409,,0,1,CHEMBL618590
7366,U,,,,Apparent bioavailability in squirrel monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,1052,,0,1,CHEMBL872262
7367,U,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,13501,,0,1,CHEMBL618591
7368,U,,,,Bioavailability in monkey (dose 2 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,17509,,0,1,CHEMBL618592
7369,U,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5394,,0,1,CHEMBL876488
7370,U,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL618593
7371,U,,,,Bioavailability in monkey (i.d. dosing),Autocuration,,,,,22224,BAO_0000218,A,,11219,,0,1,CHEMBL618594
7372,U,,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,3045,,0,1,CHEMBL618595
7373,U,,,,Clearance of the drug was measured in cynomolgus,Autocuration,,,,,22224,BAO_0000019,A,,17796,,0,1,CHEMBL621469
7374,U,,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,1399,,0,1,CHEMBL621470
7375,U,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,2661,,0,1,CHEMBL621471
7376,U,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL621472
7377,U,,,,Plasma clearance in rhesus monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,17267,,0,1,CHEMBL621473
7378,U,,,,Plasma clearance in monkey after administration of 1 mg/kg iv,Autocuration,,,,,22224,BAO_0000218,A,,6535,,0,1,CHEMBL621474
7379,U,,,,Plasma clearance in cynomolgus monkey,Autocuration,,,,,22224,BAO_0000218,A,,5922,,0,1,CHEMBL621475
7380,U,,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,,,22224,BAO_0000218,A,,6221,,0,1,CHEMBL621476
7381,U,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,Autocuration,,,,,22224,BAO_0000218,A,,5668,,0,1,CHEMBL624290
7382,U,,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL624291
7383,U,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL624292
7384,U,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,,,22224,BAO_0000218,A,,5355,,0,1,CHEMBL624293
7385,U,,,,Tested for Clearance upon iv administration to african green monkey,Autocuration,,,,,22224,BAO_0000218,A,,4578,,0,1,CHEMBL624294
7386,U,,,,Clearance in monkey,Autocuration,,,,,22224,BAO_0000218,A,,17592,,0,1,CHEMBL624295
7387,N,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6641,,1,1,CHEMBL624296
7388,N,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,,,50588,BAO_0000218,A,,6642,,1,1,CHEMBL624297
7389,N,,,,Half life was evaluated after intravenous administration to dogs,Intermediate,,,,,50588,BAO_0000218,A,,16367,,1,1,CHEMBL624298
7390,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5472,,1,1,CHEMBL624299
7391,N,,,,Half life was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,5474,,1,1,CHEMBL624300
7392,N,,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5654,,1,1,CHEMBL624301
7393,N,,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL624302
7394,N,,,,Half life period after intravenous administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL876026
7395,N,,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6221,,1,1,CHEMBL624303
7396,N,,,,Half life period at a dose of 1 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL624304
7397,N,,,,Half life period was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL624305
7398,N,,,,Half life period was determine after peroral administration at 5 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5668,,1,1,CHEMBL624306
7399,N,,,,Half life period was determined,Intermediate,,,,,50588,BAO_0000218,A,,3854,,1,1,CHEMBL624307
7400,N,,,,Half life period was determined,Intermediate,,,,,50588,BAO_0000218,A,,5505,,1,1,CHEMBL624308
7401,N,,,,Half life period by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6251,,1,1,CHEMBL624309
7402,N,,,,Half life period was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,1918,,1,1,CHEMBL624310
7403,N,,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50588,BAO_0000218,A,,5546,,1,1,CHEMBL625003
7404,N,,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4809,,1,1,CHEMBL625004
7405,N,,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,,,50588,BAO_0000218,A,,6215,,1,1,CHEMBL625005
7406,N,,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,4527,,1,1,CHEMBL873813
7407,N,,,,Half-life after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,17594,,1,1,CHEMBL625006
7408,N,,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL625007
7409,N,,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL876027
7410,N,,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL625008
7411,N,,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,17839,,1,1,CHEMBL625009
7412,N,,,,Half-life of compound in plasma of dog was determined,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5210,Plasma,1,1,CHEMBL625010
7413,N,,,,Half-life of compound was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,5210,,1,1,CHEMBL625011
7414,N,,,,Half-life after administration of 4 mg/Kg oral dose in dog,Intermediate,,,,,50588,BAO_0000218,A,,2959,,1,1,CHEMBL621553
7415,N,,,,Half-life after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,,,50588,BAO_0000218,A,,4137,,1,1,CHEMBL621554
7416,N,,,,Half-life in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5064,,1,1,CHEMBL621555
7417,N,,,,Half-life in Dog,Intermediate,,,,,50588,BAO_0000218,A,,5147,,1,1,CHEMBL621556
7418,N,,,,Half-life in dog,Intermediate,,,,,50588,BAO_0000218,A,,5145,,1,1,CHEMBL621557
7419,N,,,,Half-life in dog after oral administration at 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6123,,1,1,CHEMBL621558
7420,N,,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Intermediate,,,,,50588,BAO_0000218,A,,6123,,1,1,CHEMBL621559
7421,N,,,,Half-life in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4333,,1,1,CHEMBL621560
7422,N,,,,Half-life in dogs; ND indicates not determined,Intermediate,,,,,50588,BAO_0000218,A,,4333,,1,1,CHEMBL876028
7423,N,,,,Half-life in plasma of dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL621561
7424,N,,,,Half-life in plasma of dog at dose of 3-10 mgkg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL621562
7425,N,,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6005,,1,1,CHEMBL621563
7426,N,,,,Half-life was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6062,,1,1,CHEMBL621564
7427,N,,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,,,50588,BAO_0000218,A,,17650,,1,1,CHEMBL621565
7428,N,,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621566
7429,N,,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,5530,,1,1,CHEMBL621567
7430,N,,,,Half-life of the compound after 0.3 mg/kg po administration in dog,Intermediate,,,,,50588,BAO_0000218,A,,5600,,1,1,CHEMBL622978
7431,N,,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL873814
7432,N,,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL623219
7433,N,,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,,,50588,BAO_0000218,A,,6039,,1,1,CHEMBL624477
7434,N,,,,t1/2 in dog,Intermediate,,,,,50588,BAO_0000218,A,,6227,,1,1,CHEMBL624478
7435,N,,,,Half-life period measured in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14541,,1,1,CHEMBL624479
7436,N,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL624480
7437,N,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,,,50588,BAO_0000218,A,,4521,,1,1,CHEMBL623595
7438,N,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50588,BAO_0000218,A,,6679,,1,1,CHEMBL623596
7439,N,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,1116,Plasma,1,1,CHEMBL623597
7440,N,,,,In vivo half life period was calculated at 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL623598
7441,N,,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Intermediate,,,,,50588,BAO_0000218,A,,5444,,1,1,CHEMBL623599
7442,N,,,,Longer half-life in dog (i.v.) at 0.5 mpk,Intermediate,,,,,50588,BAO_0000218,A,,17853,,1,1,CHEMBL623600
7443,N,,,,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,,,50588,BAO_0000218,A,,4353,,1,1,CHEMBL623601
7444,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL623602
7445,N,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL623603
7446,N,,,,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL623604
7447,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623605
7448,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623606
7449,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623607
7450,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623608
7451,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623609
7452,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2048.0,50594,BAO_0000218,A,,10107,Lung,1,1,CHEMBL623610
7453,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623611
7454,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623612
7455,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623613
7456,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623614
7457,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623615
7458,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623616
7459,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2385.0,50594,BAO_0000218,A,,10107,Muscle tissue,1,1,CHEMBL623617
7460,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL875944
7461,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623618
7462,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623619
7463,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623620
7464,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623621
7465,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623622
7466,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,14.0,50594,BAO_0000218,A,,10107,Zone of skin,1,1,CHEMBL623623
7467,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL623624
7468,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL618521
7469,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL618522
7470,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL618523
7471,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL618524
7472,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL618525
7473,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,2106.0,50594,BAO_0000218,A,,10107,Spleen,1,1,CHEMBL624586
7474,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624587
7475,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624588
7476,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624589
7477,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624590
7478,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624591
7479,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624592
7480,N,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,,945.0,50594,BAO_0000218,A,,10107,Stomach,1,1,CHEMBL624593
7481,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL624594
7482,N,,,,Tested for the bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4950,,1,1,CHEMBL624595
7483,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5328,,1,1,CHEMBL624596
7484,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,406,,1,1,CHEMBL624597
7485,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12500,,1,1,CHEMBL624598
7486,N,,,,Bioavailability in rat (dose 3-10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,12500,,1,1,CHEMBL624599
7487,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5247,,1,1,CHEMBL875166
7488,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL624600
7489,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL624601
7490,N,,,,Half life after oral administration was determined in rats at 6 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL624602
7491,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,6484,,1,1,CHEMBL624603
7492,N,,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3249,,1,1,CHEMBL624604
7493,N,,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6281,Plasma,1,1,CHEMBL624605
7494,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3307,,1,1,CHEMBL624606
7495,N,,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,12058,Blood,1,1,CHEMBL624607
7496,N,,,,Hill coefficient of the compound,Intermediate,,,,,50597,BAO_0000218,A,,8833,,1,1,CHEMBL624608
7497,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624609
7498,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624610
7499,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624611
7500,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624612
7501,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL875167
7502,N,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624613
7503,N,,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Intermediate,,,,178.0,50597,BAO_0000218,A,,3193,Blood,1,1,CHEMBL624614
7504,N,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL624392
7505,N,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL624393
7506,N,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL624394
7507,N,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL624395
7508,N,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL624396
7509,N,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL624397
7510,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,Thyroid gland,1,1,CHEMBL624398
7511,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,Thyroid gland,1,1,CHEMBL624399
7512,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,Thyroid gland,1,1,CHEMBL624400
7513,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,Thyroid gland,1,1,CHEMBL624401
7514,N,,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13950,Thyroid gland,1,1,CHEMBL624402
7515,N,,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL624403
7516,N,,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL624404
7517,N,,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL624405
7518,N,,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL624406
7519,N,,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL624407
7520,N,,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL624408
7521,N,,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL618644
7522,N,,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL618645
7523,N,,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL618646
7524,N,,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL618647
7525,N,,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL618648
7526,N,,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL618649
7527,N,,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL618650
7528,N,,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL618651
7529,N,,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL876497
7530,N,,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,Lung,1,1,CHEMBL618652
7531,N,,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,Lung,1,1,CHEMBL618653
7532,N,,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9866,Lung,1,1,CHEMBL618654
7533,N,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,6351,,1,1,CHEMBL618655
7534,N,,,,Compound was tested for solubility in water,Intermediate,,,,,50597,BAO_0000218,A,,1465,,1,1,CHEMBL618656
7535,U,,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),Intermediate,,,,,22229,BAO_0000100,P,,5182,,0,1,CHEMBL618657
7536,N,,,,Solubility was determined,Intermediate,,,,,50597,BAO_0000218,A,,17847,,1,1,CHEMBL618658
7537,N,,,,solubility in water (ug/mL) at 37 degree C.,Intermediate,,,,,50597,BAO_0000218,A,,15339,,1,1,CHEMBL618659
7538,N,,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,Intermediate,,,,,50597,BAO_0000218,A,,5202,,1,1,CHEMBL618660
7539,N,,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,Intermediate,,,,,50597,BAO_0000218,A,,1088,,1,1,CHEMBL618661
7540,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL873807
7541,N,,,,Half life in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,,1,1,CHEMBL618662
7542,N,,,,Half life period after 3 mg/kg iv administration,Intermediate,,,,,50597,BAO_0000218,A,,2864,,1,1,CHEMBL618663
7543,N,,,,Half life period after 3 mg/kg iv administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,,1,1,CHEMBL618664
7544,N,,,,Half life period after 3 mg/kg iv administration in the rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,,1,1,CHEMBL618665
7545,N,,,,Half life period in female Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6362,,1,1,CHEMBL876498
7546,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,,1,1,CHEMBL618666
7547,N,,,,Half-life in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL620440
7548,N,,,,Half-life in rats with metabolic oxidation,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL620441
7549,N,,,,Half-life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL620442
7550,N,,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL620443
7551,N,,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL620444
7552,N,,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL620445
7553,N,,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL620446
7554,N,,,,Biological half-life measured in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,Plasma,1,1,CHEMBL620447
7555,N,,,,Biological half-life measured in plasma of rat; 22-25,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,Plasma,1,1,CHEMBL621129
7556,N,,,,Biological half-life measured in plasma of rat; 9-16,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,Plasma,1,1,CHEMBL621130
7557,N,,,,Compound was evaluated for its half life when administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,,1,1,CHEMBL873808
7558,N,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,Intermediate,,,,,50597,BAO_0000218,A,,4891,,1,1,CHEMBL876598
7559,N,,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL621131
7560,N,,,,Half life (T1/2) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL621132
7561,N,,,,Half life of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,,1,1,CHEMBL621133
7562,N,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL621312
7563,N,,,,Half life of compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17267,,1,1,CHEMBL621313
7564,N,,,,Half life of compound was determined in rat blood,Intermediate,,,,178.0,50597,BAO_0000218,A,,4727,Blood,1,1,CHEMBL621314
7565,N,,,,Half life at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL621315
7566,N,,,,Half life at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL621316
7567,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,401,,1,1,CHEMBL621317
7568,N,,,,Half life in rats in hours,Intermediate,,,,,50597,BAO_0000218,A,,4942,,1,1,CHEMBL621318
7569,N,,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,,1,1,CHEMBL621319
7570,N,,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,,1,1,CHEMBL621377
7571,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,5213,,1,1,CHEMBL621378
7572,N,,,,Half life after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,,1,1,CHEMBL876599
7573,N,,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,,1,1,CHEMBL621379
7574,N,,,,Half life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5819,Plasma,1,1,CHEMBL621380
7575,N,,,,Half life in rat plasma; Not detected,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5819,Plasma,1,1,CHEMBL621381
7576,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,,1,1,CHEMBL618515
7577,N,,,,Half life period of compound was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL618516
7578,N,,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL618517
7579,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,,1,1,CHEMBL618518
7580,N,,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL618519
7581,N,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL618698
7582,N,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL618862
7583,N,,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL618863
7584,N,,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL618864
7585,N,,,,Half life time in rat the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL618865
7586,N,,,,Half-life 24 hr after 10 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL618866
7587,N,,,,Half-life 24 hr after 2 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL618867
7588,N,,,,Half-life consistent with the observed metabolic steady state in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL875828
7589,N,,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,,1,1,CHEMBL618868
7590,N,,,,Half-life for oxidative metabolic stability was determined using male human,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL618869
7591,N,,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,,1,1,CHEMBL618870
7592,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1696,Plasma,1,1,CHEMBL618871
7593,N,,,,Half-life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,Plasma,1,1,CHEMBL618872
7594,N,,,,Half-life in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17800,,1,1,CHEMBL873816
7595,U,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,Autocuration,,,,,22224,BAO_0000218,A,,12923,,0,1,CHEMBL618873
7596,U,,,,Area under curve after oral dose of 0.1 mg//kg,Autocuration,,,,,22224,BAO_0000019,A,,11954,,0,1,CHEMBL621602
7597,U,,,,Area under curve after oral dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621603
7598,U,,,,Area under curve after oral dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621604
7599,U,,,,Area under curve after oral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621605
7600,U,,,,Area under curve after oral dose of 23.4 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621606
7601,U,,,,Area under curve after oral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621607
7602,U,,,,Area under curve after oral dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL621608
7603,U,,,,Area under curve was determined,Autocuration,,,,,22224,BAO_0000019,A,,5237,,0,1,CHEMBL621609
7604,U,,,,Area under curve at a dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,4026,,0,1,CHEMBL621610
7605,N,,,,Area under curve was determined; ND=No data,Intermediate,,,,,50597,BAO_0000218,A,,5237,,1,1,CHEMBL621611
7606,N,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL621612
7607,N,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622308
7608,N,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622309
7609,N,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622310
7610,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622311
7611,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622312
7612,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622931
7613,N,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL622932
7614,N,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622736
7615,N,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622737
7616,N,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622738
7617,N,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622739
7618,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622740
7619,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622741
7620,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622742
7621,N,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL622743
7622,N,,,,AUC in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,11637,Plasma,1,1,CHEMBL622744
7623,U,,,,Area under curve was measured from the graph obtained from concentration Vs time,Autocuration,,,,,22224,BAO_0000019,A,,11149,,0,1,CHEMBL624134
7624,U,,,,Area under curve value of compound per hour after oral administration,Autocuration,,,,,22224,BAO_0000019,A,,10016,,0,1,CHEMBL624135
7625,N,,,,Area under curve was determined after oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL624136
7626,N,,,,Area under curve was determined after oral administration in rats; No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL624137
7627,N,,,,Area under curve was determined after oral administration in rats;No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL624320
7628,N,,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,1,1,CHEMBL624321
7629,N,,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624322
7630,N,,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624323
7631,N,,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624324
7632,N,,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624325
7633,N,,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624326
7634,N,,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624327
7635,N,,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL624328
7636,N,,,,Area under curve was determined in Dogs after peroral administration,Intermediate,,,,,50588,BAO_0000218,A,,14169,,1,1,CHEMBL627848
7637,N,,,,Area under curve was determined in Rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,14169,,1,1,CHEMBL627849
7638,N,,,,Area under curve was determined in carotid blood of rat when administered intradermally,Intermediate,,,,,50597,BAO_0000218,A,,14258,,1,1,CHEMBL627850
7639,N,,,,Area under curve was determined in portal blood of rat when administered intradermally,Intermediate,,,,,50597,BAO_0000218,A,,14258,,1,1,CHEMBL627851
7640,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627852
7641,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627853
7642,N,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627854
7643,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627855
7644,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627856
7645,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL875339
7646,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627857
7647,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,Spleen,1,1,CHEMBL627858
7648,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,Blood,1,1,CHEMBL627859
7649,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,Brain,1,1,CHEMBL627860
7650,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,Heart,1,1,CHEMBL627019
7651,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,Liver,1,1,CHEMBL627020
7652,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,Lung,1,1,CHEMBL627021
7653,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,Muscle tissue,1,1,CHEMBL627022
7654,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL627023
7655,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,Spleen,1,1,CHEMBL627024
7656,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,Thyroid gland,1,1,CHEMBL627025
7657,N,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,Kidney,1,1,CHEMBL627026
7658,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,Blood,1,1,CHEMBL627027
7659,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,Brain,1,1,CHEMBL627028
7660,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,Heart,1,1,CHEMBL627029
7661,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,Kidney,1,1,CHEMBL627030
7662,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,Liver,1,1,CHEMBL627031
7663,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,Lung,1,1,CHEMBL627032
7664,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,Muscle tissue,1,1,CHEMBL627033
7665,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL627034
7666,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,Spleen,1,1,CHEMBL627035
7667,N,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,Thyroid gland,1,1,CHEMBL627036
7668,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,10130,Blood,1,1,CHEMBL875340
7669,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,10130,Heart,1,1,CHEMBL627037
7670,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10130,Kidney,1,1,CHEMBL627038
7671,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10130,Liver,1,1,CHEMBL627039
7672,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10130,Muscle tissue,1,1,CHEMBL627040
7673,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10130,Spleen,1,1,CHEMBL624663
7674,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10130,Thyroid gland,1,1,CHEMBL625963
7675,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,10130,Brain,1,1,CHEMBL876799
7676,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10130,Lung,1,1,CHEMBL626133
7677,N,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL626134
7678,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,1,1,CHEMBL626135
7679,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,1,1,CHEMBL626136
7680,N,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,Intermediate,,,,,50597,BAO_0000218,A,,6296,,1,1,CHEMBL626137
7681,N,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,1,1,CHEMBL626138
7682,N,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,1,1,CHEMBL626139
7683,N,,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL626140
7684,N,,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL626141
7685,N,,,,C24h in rat p.o. at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL626142
7686,N,,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL627930
7687,N,,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL627931
7688,N,,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL627932
7689,N,,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL627933
7690,N,,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL627934
7691,N,,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL627935
7692,N,,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627936
7693,N,,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627937
7694,N,,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627938
7695,N,,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627939
7696,N,,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627940
7697,N,,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627941
7698,N,,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL876800
7699,N,,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627942
7700,N,,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627943
7701,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627944
7702,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627945
7703,N,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628584
7704,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628585
7705,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628586
7706,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628587
7707,N,,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628588
7708,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL628589
7709,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL625304
7710,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL625305
7711,N,,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL625306
7712,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL625307
7713,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL625308
7714,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627740
7715,N,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627741
7716,N,,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627742
7717,N,,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627743
7718,N,,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Intermediate,,,,178.0,50597,BAO_0000218,A,,9866,Blood,1,1,CHEMBL627744
7719,N,,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627745
7720,N,,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627746
7721,N,,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627747
7722,N,,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL876810
7723,N,,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627748
7724,N,,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627749
7725,N,,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL627750
7726,N,,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618728
7727,N,,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618729
7728,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618730
7729,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618731
7730,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618732
7731,N,,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618733
7732,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618734
7733,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618735
7734,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL876602
7735,N,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618736
7736,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618737
7737,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618738
7738,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618739
7739,N,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618740
7740,N,,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618741
7741,N,,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618742
7742,N,,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,9866,Bone,1,1,CHEMBL618743
7743,N,,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,Plasma,1,1,CHEMBL618744
7744,N,,,,Half-life in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,1,1,CHEMBL618745
7745,N,,,,Half-life in rat after peroral administration at 10 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL620479
7746,N,,,,Half-life in rat after peroral administration at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL620480
7747,N,,,,Half-life in rat at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17771,,1,1,CHEMBL620481
7748,N,,,,Half-life was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1974,,1,1,CHEMBL620482
7749,N,,,,Half-life was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,,1,1,CHEMBL876603
7750,N,,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6681,,1,1,CHEMBL620483
7751,N,,,,Half-life period in rats after intravenous administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17752,,1,1,CHEMBL620484
7752,N,,,,Half-life period in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,,1,1,CHEMBL620485
7753,N,,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL620486
7754,N,,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL620487
7755,N,,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL620488
7756,N,,,,Half-life time in rat the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL620489
7757,N,,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,Intermediate,,,,,50597,BAO_0000218,A,,1088,,1,1,CHEMBL620490
7758,N,,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5610,,1,1,CHEMBL620491
7759,N,,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3032,Plasma,1,1,CHEMBL876604
7760,N,,,,Oral half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,5199,,1,1,CHEMBL620492
7761,N,,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL620493
7762,N,,,,Pharmacokinetic property (t1/2) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,,1,1,CHEMBL620494
7763,N,,,,Plasma elimination half-life was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2552,Plasma,1,1,CHEMBL620495
7764,N,,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL620496
7765,N,,,,Plasma half life was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL620497
7766,N,,,,Plasma half-life was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1465,Plasma,1,1,CHEMBL620498
7767,N,,,,Plasma half-life following oral administration in Fisher rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1446,Plasma,1,1,CHEMBL620499
7768,N,,,,Plasma half-life in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,Plasma,1,1,CHEMBL620500
7769,N,,,,Plasmatic Half-life after intravenous administration to rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17533,Plasma,1,1,CHEMBL873809
7770,N,,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,,1,1,CHEMBL620501
7771,N,,,,Terminal half life after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL620502
7772,N,,,,Terminal half life in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL620503
7773,N,,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,,,,50597,BAO_0000218,A,,2463,,1,1,CHEMBL620504
7774,N,,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL876605
7775,N,,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL620505
7776,N,,,,plasma half life was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL873811
7777,N,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL624016
7778,N,,,,Half life of compound determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL624017
7779,N,,,,Mean residence time determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL624018
7780,N,,,,Plasma half life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL624019
7781,N,,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,Brain,1,1,CHEMBL624020
7782,N,,,,Compound was evaluated for pharmacokinetic parameter maximum time period,Intermediate,,,,,50597,BAO_0000218,A,,4891,,1,1,CHEMBL624201
7783,N,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL872528
7784,N,,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624202
7785,N,,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624203
7786,N,,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624350
7787,N,,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL621320
7788,N,,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL621321
7789,N,,,,Maximum time (Tmax) required to reach Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL621322
7790,N,,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL621323
7791,N,,,,Maximum time of clearance of compound in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL621324
7792,N,,,,Maximum time at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL621325
7793,N,,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17651,Plasma,1,1,CHEMBL875837
7794,N,,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17651,Plasma,1,1,CHEMBL621326
7795,N,,,,Tmax in Guinea pig (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,14465,,1,1,CHEMBL621327
7796,N,,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL621328
7797,N,,,,Pharmacokinetic parameter (Tmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL621329
7798,N,,,,Pharmacokinetic parameter (Tmax) was estimated,Intermediate,,,,,50597,BAO_0000218,A,,5022,,1,1,CHEMBL621330
7799,N,,,,Pharmacokinetic property (Tmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,,1,1,CHEMBL621331
7800,N,,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL621332
7801,N,,,,T max in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL621333
7802,N,,,,T max was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL621334
7803,N,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL621335
7804,N,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14180,,1,1,CHEMBL621336
7805,N,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,14180,,1,1,CHEMBL621337
7806,N,,,,Area under curve was measured after i.v. administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL621338
7807,N,,,,Area under curve was measured after iv administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL875838
7808,N,,,,Area under curve was measured after po administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL621339
7809,N,,,,Area under curve was measured after po administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL621340
7810,U,,,,Area under curve was measured at peroral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15675,,0,1,CHEMBL621341
7811,U,,,,Area under curve was measured by using concentration Vs time,Autocuration,,,,,22224,BAO_0000019,A,,12706,,0,1,CHEMBL621342
7812,U,,,,Area under curve was measured by using concentration Vs time; not tested,Autocuration,,,,,22224,BAO_0000019,A,,12706,,0,1,CHEMBL621343
7813,N,,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,9750,,1,1,CHEMBL621344
7814,N,,,,Area under curve(AUC) was measured in mice after oral administration.,Intermediate,,,,,50594,BAO_0000218,A,,9750,,1,1,CHEMBL621345
7815,U,,,,Area under curve(AUC) value of the compound,Autocuration,,,,,22224,BAO_0000019,A,,14691,,0,1,CHEMBL621346
7816,U,,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,Autocuration,,,,,22224,BAO_0000218,A,,14691,,0,1,CHEMBL621347
7817,N,,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,Intermediate,,,,,50588,BAO_0000218,A,,14691,,1,1,CHEMBL621348
7818,U,,,,Area under curve(carotid artery) was determined by the availability in blood,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL621349
7819,U,,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL621350
7820,U,,,,Area under curve(carotid artery) was determined by the availability in blood; No data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL875839
7821,U,,,,Area under curve(portal vein) was determined by the availability in blood,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL620211
7822,U,,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL620212
7823,U,,,,Area under curve(portal vein) was determined by the availability in blood; No data,Autocuration,,,,178.0,22224,BAO_0000019,A,,2939,Blood,0,1,CHEMBL620213
7824,N,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,Plasma,1,1,CHEMBL620214
7825,N,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,Plasma,1,1,CHEMBL620215
7826,N,,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Intermediate,,,,1969.0,50797,BAO_0000218,A,,9552,Plasma,1,1,CHEMBL620216
7827,N,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Intermediate,,,,1969.0,50588,BAO_0000218,A,,9552,Plasma,1,1,CHEMBL620888
7828,N,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Intermediate,,,,1969.0,50588,BAO_0000218,A,,9552,Plasma,1,1,CHEMBL620889
7829,U,,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,Autocuration,,,,1969.0,22224,BAO_0000019,A,,9552,Plasma,0,1,CHEMBL620890
7830,N,,,,Area under plasma time curve determined in male rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,11911,Plasma,1,1,CHEMBL620891
7831,U,,,,Area under the MAP curve measured over 5 min.,Autocuration,,,,,22224,BAO_0000019,A,,16618,,0,1,CHEMBL620892
7832,N,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,,1,1,CHEMBL621079
7833,N,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,,1,1,CHEMBL621080
7834,N,,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,12836,,1,1,CHEMBL621081
7835,N,,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,Intermediate,,,,,100712,BAO_0000218,A,,12836,,1,1,CHEMBL621082
7836,N,,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,12836,,1,1,CHEMBL621083
7837,N,,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,1,1,CHEMBL621084
7838,N,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,1,1,CHEMBL621085
7839,N,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,1,1,CHEMBL621086
7840,N,,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,10524,,1,1,CHEMBL621087
7841,N,,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,9994,,1,1,CHEMBL622607
7842,N,,,,Serum AUC in marmosets (IV dose),Intermediate,,,,,50588,BAO_0000218,A,,11325,,1,1,CHEMBL622608
7843,U,,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,0,1,CHEMBL624481
7844,U,,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,0,1,CHEMBL624482
7845,U,,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,0,1,CHEMBL624483
7846,U,,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,0,1,CHEMBL624484
7847,U,,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,12536,,0,1,CHEMBL624485
7848,N,,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,Intermediate,,,,,50597,BAO_0000218,A,,15556,,1,1,CHEMBL624486
7849,U,,,,Area under the curve for the compound was calculated.,Autocuration,,,,,22224,BAO_0000019,A,,2809,,0,1,CHEMBL624487
7850,U,,,,Area under the curve in concentration/ time,Autocuration,,,,,22224,BAO_0000019,A,,9511,,0,1,CHEMBL624488
7851,N,,,,Area under the curve administered intraintestinal in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,,1,1,CHEMBL624489
7852,N,,,,Area under the curve administered intravenously in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,,1,1,CHEMBL625184
7853,U,,,,Area under the curve during intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,15118,,0,1,CHEMBL625185
7854,U,,,,Area under the curve during intravenous administration; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,15118,,0,1,CHEMBL875954
7855,U,,,,Area under the curve during systemic administration,Autocuration,,,,,22224,BAO_0000019,A,,15118,,0,1,CHEMBL625186
7856,U,,,,Area under the curve during systemic administration; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,15118,,0,1,CHEMBL625187
7857,U,,,,Area under the curve was calculated for the compound.,Autocuration,,,,,22224,BAO_0000019,A,,2632,,0,1,CHEMBL625188
7858,N,,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,1,1,CHEMBL625189
7859,N,,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,1,1,CHEMBL625190
7860,N,,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL621733
7861,N,,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL621734
7862,N,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,,1,1,CHEMBL621735
7863,N,,,,Clearance of the drug was measured in the plasma of rat; No data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17796,Plasma,1,1,CHEMBL621736
7864,N,,,,The pharmacokinetic parameter plasma clearance in vivo in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5247,Plasma,1,1,CHEMBL621737
7865,N,,,,Plasma clearance at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL621738
7866,N,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL622806
7867,N,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL623519
7868,N,,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL623520
7869,N,,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,,1,1,CHEMBL623521
7870,N,,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL623522
7871,N,,,,Clearance rate in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,,1,1,CHEMBL623523
7872,N,,,,Clearance rate in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,,1,1,CHEMBL623690
7873,N,,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL623691
7874,N,,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL623692
7875,N,,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL623693
7876,N,,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL623694
7877,N,,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,,1,1,CHEMBL623695
7878,N,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL623696
7879,N,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL623697
7880,U,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL623698
7881,U,,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL623699
7882,N,,,,Mean (%CV) PK parameters for CL(mL/min/kg).,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL623700
7883,N,,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3747,,1,1,CHEMBL623701
7884,N,,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16366,Plasma,1,1,CHEMBL623702
7885,N,,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL623703
7886,N,,,,Plasma clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,17267,,1,1,CHEMBL623704
7887,N,,,,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL623705
7888,N,,,,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL623706
7889,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL623707
7890,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL623708
7891,N,,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,,1,1,CHEMBL623709
7892,N,,,,Plasma clearance in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,,1,1,CHEMBL623710
7893,N,,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL623711
7894,N,,,,Plasma clearance in rat p.o.,Intermediate,,,,,50597,BAO_0000218,A,,6504,,1,1,CHEMBL623712
7895,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,,1,1,CHEMBL623713
7896,N,,,,Plasma clearance was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL623714
7897,N,,,,Plasma clearance was determined; ND denotes not determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL623715
7898,N,,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL623716
7899,N,,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50597,BAO_0000218,A,,5199,,1,1,CHEMBL622980
7900,N,,,,Plasma administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL622981
7901,N,,,,Plasma clearance of the compound in female Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6362,,1,1,CHEMBL622982
7902,N,,,,Plasma clearance was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL622983
7903,N,,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,,1,1,CHEMBL622984
7904,N,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL622985
7905,N,,,,plasma clearance was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL623631
7906,N,,,,In vivo CL/F determined,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL623632
7907,N,,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2792,Plasma,1,1,CHEMBL623633
7908,N,,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2792,Plasma,1,1,CHEMBL623634
7909,N,,,,Compound was tested for the lower blood clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5213,,1,1,CHEMBL623635
7910,N,,,,Evaluated for the low clearance in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,,1,1,CHEMBL621195
7911,N,,,,Pharmacokinetic property (CLb)of the compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,1,1,CHEMBL621196
7912,N,,,,Rapid clearance after intravenous administration in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4690,,1,1,CHEMBL875287
7913,N,,,,Clearance measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,5702,,1,1,CHEMBL621197
7914,N,,,,Compound was evaluated for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,740,Plasma,1,1,CHEMBL621198
7915,N,,,,Low plasma clearance was calculated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4853,Plasma,1,1,CHEMBL621199
7916,N,,,,Pharmacokinetic property (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,,1,1,CHEMBL621200
7917,N,,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL621201
7918,N,,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL621202
7919,N,,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL621203
7920,N,,,,Plasma clearance after IV dosing at 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL621204
7921,N,,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621205
7922,N,,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621206
7923,N,,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621207
7924,N,,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621208
7925,N,,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621209
7926,N,,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL876484
7927,N,,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621210
7928,N,,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621211
7929,N,,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621212
7930,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621213
7931,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621214
7932,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621215
7933,N,,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621216
7934,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621217
7935,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621218
7936,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621219
7937,N,,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621220
7938,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621221
7939,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621222
7940,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621223
7941,N,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL876485
7942,N,,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621224
7943,N,,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621225
7944,N,,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Intermediate,,,,948.0,50597,BAO_0000218,A,,9866,Heart,1,1,CHEMBL621226
7945,N,,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621227
7946,N,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621228
7947,N,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621229
7948,N,,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621230
7949,N,,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621231
7950,N,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621232
7951,N,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621233
7952,N,,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621234
7953,N,,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621235
7954,N,,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621236
7955,N,,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL621237
7956,N,,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9866,Kidney,1,1,CHEMBL876486
7957,N,,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL622436
7958,N,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL622437
7959,N,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL622438
7960,N,,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622439
7961,N,,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622440
7962,N,,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622441
7963,N,,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622442
7964,N,,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622443
7965,N,,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622444
7966,N,,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622445
7967,N,,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622446
7968,N,,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622447
7969,N,,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622448
7970,N,,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622449
7971,N,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622450
7972,N,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622451
7973,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622452
7974,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622453
7975,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622454
7976,N,,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL622455
7977,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL876024
7978,N,,,,T max was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL622456
7979,N,,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622457
7980,N,,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622458
7981,N,,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL622459
7982,N,,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL873343
7983,N,,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL622460
7984,N,,,,Time for maximum plasma concentration determined in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4576,Plasma,1,1,CHEMBL622461
7985,N,,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6681,Plasma,1,1,CHEMBL622462
7986,N,,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622463
7987,N,,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622464
7988,N,,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622465
7989,N,,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622466
7990,N,,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622467
7991,N,,,,Time of maximum plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,Plasma,1,1,CHEMBL622468
7992,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL876025
7993,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL622469
7994,N,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL622470
7995,N,,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL622471
7996,N,,,,Time required to reach maximum concentration in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,Plasma,1,1,CHEMBL622472
7997,N,,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2774,Plasma,1,1,CHEMBL622473
7998,N,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL624282
7999,N,,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL624283
8000,N,,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL624284
8001,N,,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1916,Plasma,1,1,CHEMBL624285
8002,N,,,,Time to reach Cmax after oral administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL624286
8003,N,,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL624287
8004,N,,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,Intermediate,,,,,50597,BAO_0000218,A,,216,,1,1,CHEMBL624288
8005,N,,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,Plasma,1,1,CHEMBL624289
8006,N,,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,Plasma,1,1,CHEMBL873344
8007,N,,,,Tmax after peroral administration (10 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,,1,1,CHEMBL619623
8008,N,,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL621399
8009,N,,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL621400
8010,N,,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,,1,1,CHEMBL621401
8011,N,,,,Tmax was determined,Intermediate,,,,,50597,BAO_0000218,A,,1465,,1,1,CHEMBL621402
8012,N,,,,Tmax was determined,Intermediate,,,,,50597,BAO_0000218,A,,2552,,1,1,CHEMBL621403
8013,N,,,,Tmax after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL621121
8014,N,,,,Tmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL872525
8015,N,,,,Tmax in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,1,1,CHEMBL621122
8016,N,,,,Tmax in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,,1,1,CHEMBL621123
8017,N,,,,Tmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL621124
8018,N,,,,Tmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL621125
8019,N,,,,Tmax was measured in rats after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL621126
8020,N,,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,,1,1,CHEMBL621127
8021,N,,,,Tmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,,1,1,CHEMBL621128
8022,N,,,,Tmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL618263
8023,N,,,,Tmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL618264
8024,N,,,,Tmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL618265
8025,N,,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL618266
8026,N,,,,time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL618267
8027,N,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Intermediate,,,,1088.0,50597,BAO_0000218,A,,429,Urine,1,1,CHEMBL618450
8028,N,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Intermediate,,,,1088.0,50597,BAO_0000218,A,,429,Urine,1,1,CHEMBL618451
8029,N,,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,,1,1,CHEMBL618452
8030,N,,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,Urine,1,1,CHEMBL618453
8031,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,Urine,1,1,CHEMBL618454
8032,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3173,Urine,1,1,CHEMBL618455
8033,N,,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,,1,1,CHEMBL618456
8034,N,,,,Compound distribution in rat tissues was determined,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL618457
8035,N,,,,Volume of distribution was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL618458
8036,N,,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618459
8037,N,,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL876733
8038,N,,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,1,1,CHEMBL618460
8039,N,,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618461
8040,U,,,,Area under the curve was determined after oral administration (300 uM/Kg),Autocuration,,,,,22224,BAO_0000019,A,,15469,,0,1,CHEMBL618462
8041,N,,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618463
8042,N,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618464
8043,N,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618465
8044,N,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618466
8045,N,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL618467
8046,N,,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL618468
8047,N,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12935,Plasma,1,1,CHEMBL618469
8048,N,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12935,Plasma,1,1,CHEMBL618470
8049,U,,,,Plasma drug AUC in rat (PO dose),Autocuration,,,,,22224,BAO_0000218,A,,14813,,0,1,CHEMBL618471
8050,N,,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,Intermediate,,,,,50594,BAO_0000218,A,,15792,,1,1,CHEMBL618472
8051,U,,,,Area under was determined at a dose of 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3579,,0,1,CHEMBL618473
8052,N,,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,Intermediate,,,,,50506,BAO_0000218,A,,12487,,1,1,CHEMBL621699
8053,N,,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,12487,,1,1,CHEMBL621700
8054,N,,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,12487,,1,1,CHEMBL621701
8055,N,,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,Intermediate,,,,,50506,BAO_0000218,A,,12487,,1,1,CHEMBL621702
8056,N,,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,1,1,CHEMBL621703
8057,N,,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,1,1,CHEMBL621704
8058,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624259
8059,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624260
8060,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624430
8061,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624431
8062,N,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624432
8063,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624433
8064,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624434
8065,N,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL624435
8066,N,,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL618570
8067,N,,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL618571
8068,N,,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL618572
8069,N,,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL618573
8070,N,,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL619267
8071,N,,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL619431
8072,N,,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL619432
8073,N,,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL619433
8074,U,,,,AUC in mice after oral dose (50 mg/kg),Autocuration,,,,1969.0,22224,BAO_0000218,A,,13298,Plasma,0,1,CHEMBL619434
8075,N,,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Intermediate,,,,1977.0,50594,BAO_0000218,A,,12226,Serum,1,1,CHEMBL619435
8076,U,,,,AUC (0-4 hr) ug/ml/h,Autocuration,,,,1969.0,22224,BAO_0000019,A,,12634,Plasma,0,1,CHEMBL619436
8077,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,Intermediate,,,,,50597,BAO_0000218,A,,14810,,1,1,CHEMBL619437
8078,U,,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,Autocuration,,,,,22224,BAO_0000218,A,,13889,,0,1,CHEMBL619438
8079,N,,,,Compound was evaluated for Area under curve in mice,Intermediate,,,,,50594,BAO_0000218,A,,10018,,1,1,CHEMBL619439
8080,N,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,1,1,CHEMBL619440
8081,U,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Autocuration,,,,,22224,BAO_0000218,F,,8758,,0,1,CHEMBL619441
8082,N,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,1,1,CHEMBL619442
8083,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,Autocuration,,,,,22224,BAO_0000019,A,,2249,,0,1,CHEMBL875156
8084,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,Autocuration,,,,,22224,BAO_0000019,A,,2249,,0,1,CHEMBL619443
8085,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,Autocuration,,,,,22224,BAO_0000019,A,,2249,,0,1,CHEMBL619444
8086,U,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,Autocuration,,,,,22224,BAO_0000019,A,,2249,,0,1,CHEMBL623464
8087,N,,,,Compound was evaluated for area under curve when administered through oral route in mouse,Intermediate,,,,,50594,BAO_0000218,A,,15115,,1,1,CHEMBL623465
8088,N,,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623466
8089,N,,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623467
8090,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,,1,1,CHEMBL623468
8091,N,,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,,,,50597,BAO_0000218,A,,2463,,1,1,CHEMBL622660
8092,N,,,,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4969,,1,1,CHEMBL622661
8093,N,,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,F,,17720,,1,1,CHEMBL622662
8094,N,,,,Pharmacokinetic property (total body clearance) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3457,,1,1,CHEMBL622663
8095,N,,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL622664
8096,N,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,1,1,CHEMBL622665
8097,N,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,1,1,CHEMBL622666
8098,N,,,,Cl in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL621615
8099,N,,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL621616
8100,N,,,,Clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,,1,1,CHEMBL621617
8101,N,,,,Clearance by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,1,1,CHEMBL621618
8102,N,,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,,1,1,CHEMBL621619
8103,N,,,,Clearance rate after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,1,1,CHEMBL621620
8104,N,,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL621786
8105,N,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL621787
8106,N,,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,,1,1,CHEMBL621788
8107,N,,,,Clearance (Cl) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL621789
8108,N,,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL621790
8109,N,,,,Compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4839,Plasma,1,1,CHEMBL621791
8110,N,,,,In vitro microsome metabolism clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,Microsomes,5041,,1,1,CHEMBL621792
8111,N,,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,Microsomes,5041,,1,1,CHEMBL621793
8112,N,,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL621794
8113,N,,,,In vivo plasma clearance was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5496,Plasma,1,1,CHEMBL621795
8114,N,,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,,1,1,CHEMBL621796
8115,N,,401.0,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,5676,Liver,1,1,CHEMBL621797
8116,N,,,,Pharmacokinetic property (Plasma clearance) was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,,1,1,CHEMBL621798
8117,N,,,,Pharmacokinetic property (clearance) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,,1,1,CHEMBL621799
8118,N,,,,"Plasma Clearance was evaluated in rats, iv",Intermediate,,,,,50597,BAO_0000218,A,,1918,,1,1,CHEMBL621800
8119,N,,,,Plasma clearance (in vivo) in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17800,,1,1,CHEMBL621801
8120,N,,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,,1,1,CHEMBL621802
8121,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5496,,1,1,CHEMBL618596
8122,N,,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL618597
8123,N,,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL618598
8124,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,17752,,1,1,CHEMBL618599
8125,N,,,,Plasma clearance rate determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL618600
8126,N,,,,Plasma clearance was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL618601
8127,N,,,,Plasma clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL618602
8128,N,,,,Plasma clearance value in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,,1,1,CHEMBL618603
8129,N,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6125,Liver,1,1,CHEMBL618604
8130,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,,1,1,CHEMBL618605
8131,N,,,,Total body clearance in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL618606
8132,N,,,,Clearance of compound in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL618607
8133,N,,,,Clearance after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,,1,1,CHEMBL618608
8134,N,,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618609
8135,N,,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618610
8136,N,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618611
8137,N,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618612
8138,N,,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618613
8139,N,,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL621076
8140,N,,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL621077
8141,N,,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,,1,1,CHEMBL621078
8142,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5970,,1,1,CHEMBL621251
8143,N,,,,Clearance in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL621252
8144,N,,,,Clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,4590,,1,1,CHEMBL621253
8145,N,,,,Clearance rate following an oral dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,6193,,1,1,CHEMBL621254
8146,N,,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,2832,,1,1,CHEMBL621255
8147,N,,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1052,Plasma,1,1,CHEMBL621256
8148,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621257
8149,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621258
8150,N,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621259
8151,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621260
8152,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL876494
8153,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621261
8154,N,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621262
8155,N,,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621263
8156,N,,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9866,Liver,1,1,CHEMBL621264
8157,N,,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621265
8158,N,,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621266
8159,N,,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621267
8160,N,,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621268
8161,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621269
8162,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621270
8163,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621271
8164,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621272
8165,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621273
8166,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621274
8167,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL876495
8168,N,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621275
8169,N,,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621276
8170,N,,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9866,Muscle tissue,1,1,CHEMBL621277
8171,N,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL621278
8172,N,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL621279
8173,N,,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intermediate,,,,160.0,50597,BAO_0000218,A,,9866,Intestine,1,1,CHEMBL621280
8174,N,,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621281
8175,N,,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621282
8176,N,,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621283
8177,N,,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621284
8178,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621285
8179,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL621286
8180,N,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL623220
8181,N,,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL623221
8182,N,,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Intermediate,,,,2106.0,50597,BAO_0000218,A,,9866,Spleen,1,1,CHEMBL876029
8183,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,Stomach,1,1,CHEMBL623222
8184,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,Stomach,1,1,CHEMBL623223
8185,N,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Intermediate,,,,945.0,50597,BAO_0000218,A,,9866,Stomach,1,1,CHEMBL621445
8186,N,,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,Blood,1,1,CHEMBL621446
8187,N,,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,Blood,1,1,CHEMBL621447
8188,N,,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,Blood,1,1,CHEMBL619681
8189,N,,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,Blood,1,1,CHEMBL619682
8190,N,,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,13950,Blood,1,1,CHEMBL619683
8191,N,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL619684
8192,N,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL619685
8193,N,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL619686
8194,N,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL619687
8195,N,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,955.0,50597,BAO_0000218,A,,13950,Brain,1,1,CHEMBL619688
8196,N,,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,Heart,1,1,CHEMBL619689
8197,N,,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,Heart,1,1,CHEMBL619690
8198,N,,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,Heart,1,1,CHEMBL619691
8199,N,,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,1,1,CHEMBL619692
8200,N,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL619693
8201,N,,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,,1,1,CHEMBL619694
8202,N,,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL619695
8203,N,,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,Intermediate,,,,,50597,BAO_0000218,A,,4891,,1,1,CHEMBL619696
8204,N,,,,Compound was evaluated for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,740,,1,1,CHEMBL619697
8205,N,,,,Steady state volume distribution was determined; steady state(ss),Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL619698
8206,N,,,,Steady state volume of distribution after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,,1,1,CHEMBL619699
8207,N,,,,Steady state volume of distribution dosing at 3 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,2552,,1,1,CHEMBL619700
8208,N,,,,The compound was evaluated for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,406,,1,1,CHEMBL619701
8209,N,,,,The compound was tested for volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,12500,,1,1,CHEMBL619702
8210,N,,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,Intermediate,,,,,50597,BAO_0000218,A,,12500,,1,1,CHEMBL620335
8211,N,,,,Volume distribution (VD) after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL620336
8212,N,,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL620337
8213,N,,,,Volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,1094,,1,1,CHEMBL620520
8214,N,,,,Volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,,1,1,CHEMBL620521
8215,N,,,,Volume distribution in rat after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL875825
8216,N,,,,Volume distribution in rat after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL620522
8217,N,,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,,1,1,CHEMBL620523
8218,N,,,,Volume of distribution in rat.,Intermediate,,,,,50597,BAO_0000218,A,,1696,,1,1,CHEMBL620524
8219,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,,1,1,CHEMBL620525
8220,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,,1,1,CHEMBL620526
8221,N,,,,Volume of distribution in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,,1,1,CHEMBL620527
8222,N,,,,Volume of distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,6803,,1,1,CHEMBL620528
8223,N,,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,,,50597,BAO_0000218,A,,5199,,1,1,CHEMBL620529
8224,N,,,,Volume distribution at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL620530
8225,N,,,,Steady state volume of distribution was determined,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL620531
8226,U,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL620532
8227,U,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL620533
8228,U,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL620534
8229,N,,,,Mean (%CV) PK parameters for Vdss(mL/kg).,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL620535
8230,N,,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL875826
8231,N,,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL620536
8232,N,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL620537
8233,N,,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL618526
8234,N,,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,,1,1,CHEMBL618527
8235,N,,,,Pharmacokinetic property (Vdss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,,1,1,CHEMBL618528
8236,N,,,,Pharmacokinetic property (vdss) was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,,1,1,CHEMBL618529
8237,N,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL618530
8238,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,,1,1,CHEMBL618531
8239,N,,,,The pharmacokinetic parameter volume of distribution in vivo in rats,Intermediate,,,,,50597,BAO_0000218,A,,5247,,1,1,CHEMBL618532
8240,N,,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,F,,17720,,1,1,CHEMBL618533
8241,N,,,,Vdss in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL618534
8242,N,,,,Volume distribution after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL618535
8243,N,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL618536
8244,N,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL618537
8245,N,,,,Volume distribution at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL618538
8246,N,,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,,1,1,CHEMBL618539
8247,N,,,,Volume distribution was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL618540
8248,N,,,,Volume distribution was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL618541
8249,N,,,,Volume of distribution after intravenous administration was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,2938,,1,1,CHEMBL618542
8250,N,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,,1,1,CHEMBL622544
8251,N,,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622545
8252,N,,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622546
8253,N,,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622547
8254,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,,1,1,CHEMBL622548
8255,N,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL622549
8256,N,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL622550
8257,N,,,,Compound was evaluated for area under curve when administered through oral route to mouse,Intermediate,,,,,50594,BAO_0000218,A,,15115,,1,1,CHEMBL622551
8258,N,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,1,1,CHEMBL622552
8259,N,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,8758,,1,1,CHEMBL622553
8260,U,,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,Autocuration,,,,,22224,BAO_0000218,F,,8267,,0,1,CHEMBL622554
8261,N,,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,8267,,1,1,CHEMBL622555
8262,N,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,1,1,CHEMBL622556
8263,N,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,1,1,CHEMBL622557
8264,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL622558
8265,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL622559
8266,N,,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,Intermediate,,,,,50588,BAO_0000218,A,,10754,,1,1,CHEMBL622560
8267,N,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,,1,1,CHEMBL622561
8268,N,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,Intermediate,,,,,50597,BAO_0000218,A,,14681,,1,1,CHEMBL622562
8269,N,,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,,1,1,CHEMBL622563
8270,U,,,,Concentration of compound in Central nervous system,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622564
8271,U,,,,Concentration of compound in Central nervous system; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622565
8272,N,,,,"Concentration of diester in the blood, following oral administration in mice",Intermediate,,,,,50594,BAO_0000218,A,,13318,,1,1,CHEMBL622566
8273,N,,,,"Concentration of monoester in the blood, following oral administration in mice",Intermediate,,,,,50594,BAO_0000218,A,,13318,,1,1,CHEMBL624515
8274,N,,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,Intermediate,,,,,50594,BAO_0000218,A,,13318,,1,1,CHEMBL624516
8275,U,,,,Evaluated for Pharmacokinetic property: Area under the curve,Autocuration,,,,,22224,BAO_0000019,A,,15692,,0,1,CHEMBL624517
8276,N,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL624518
8277,N,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624519
8278,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624520
8279,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624521
8280,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624522
8281,N,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624523
8282,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624409
8283,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624410
8284,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL624411
8285,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL623531
8286,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL623532
8287,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL623533
8288,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL623534
8289,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623535
8290,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623536
8291,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623537
8292,N,,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623538
8293,N,,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623539
8294,N,,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623540
8295,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623541
8296,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623542
8297,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623543
8298,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623544
8299,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623545
8300,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623546
8301,N,,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,Plasma,1,1,CHEMBL623547
8302,N,,,,High i.v. clearance in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,,1,1,CHEMBL623548
8303,N,,,,In vitro clearance in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,17538,Liver,1,1,CHEMBL623549
8304,N,,,,Intrinsic clearance in rat liver microsomes was determined,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,6331,Liver,1,1,CHEMBL623550
8305,N,,401.0,,Intrinsic clearance in rat hepatocytes was determined,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,5948,Liver,1,1,CHEMBL875276
8306,N,,,,Plasma Clearance was determined,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL621872
8307,N,,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL621873
8308,N,,,,Plasma clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,1696,,1,1,CHEMBL621874
8309,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL621875
8310,N,,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,347,,1,1,CHEMBL621876
8311,N,,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL621877
8312,N,,,,Plasma clearance was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,2879,,1,1,CHEMBL621878
8313,N,,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL621879
8314,N,,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Intermediate,,,,1969.0,50597,BAO_0000218,A,,5328,Plasma,1,1,CHEMBL621880
8315,N,,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5160,,1,1,CHEMBL621881
8316,N,,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL621882
8317,N,,,,Total clearance at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL875283
8318,N,,,,Total clearance at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL621883
8319,N,,,,Clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,,1,1,CHEMBL621884
8320,N,,,,Plasma clearance rate determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,1,1,CHEMBL621885
8321,N,,,,Clearance of compound in rat was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6850,,1,1,CHEMBL621886
8322,N,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL621887
8323,N,,,,Pharmacokinetic property (blood clearance) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,1,1,CHEMBL621888
8324,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,,1,1,CHEMBL621889
8325,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,4942,,1,1,CHEMBL621890
8326,N,,,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,6838,Liver,1,1,CHEMBL621891
8327,N,,,,Clearance in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,,1,1,CHEMBL621892
8328,N,,,,Clearance rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL621893
8329,N,,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL621894
8330,N,,,,Clearance rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL621895
8331,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL875284
8332,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL618699
8333,N,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL618700
8334,N,,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,1,1,CHEMBL618701
8335,N,,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL876600
8336,N,,,,Clearance of compound in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL618702
8337,N,,,,Compound was evaluated for Hepatic clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,,1,1,CHEMBL618703
8338,N,,,,In vivo clearance after 5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,4891,,1,1,CHEMBL618704
8339,N,,,,Compound was tested for plasma clearance in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1094,Plasma,1,1,CHEMBL618705
8340,N,,,,Hepatic clearance after intravenous administration was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,2938,,1,1,CHEMBL618706
8341,N,,,,Lower clearance in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL618707
8342,N,,,,Pharmacokinetic parameter expressed as plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6049,Plasma,1,1,CHEMBL618708
8343,N,,,,Pharmacokinetic property (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5789,,1,1,CHEMBL618709
8344,N,,,,Plasma clearance in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4514,,1,1,CHEMBL618710
8345,N,,,,Plasma clearance (Clp) in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL618711
8346,N,,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,1,1,CHEMBL618712
8347,N,,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL618713
8348,N,,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL618714
8349,N,,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,,1,1,CHEMBL618715
8350,N,,,,Plasma clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,1742,,1,1,CHEMBL618716
8351,N,,,,Plasma clearance measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL876601
8352,N,,,,Plasma clearance was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL618717
8353,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,,1,1,CHEMBL618718
8354,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,,1,1,CHEMBL618719
8355,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,,1,1,CHEMBL618720
8356,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL618721
8357,N,,,,Plasma clearance in rats,Intermediate,,,,,50597,BAO_0000218,A,,6305,,1,1,CHEMBL621477
8358,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,,1,1,CHEMBL621478
8359,N,,,,Plasma clearance was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL621479
8360,N,,,,Plasma clearance was evaluated in rat; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL621480
8361,N,,,,Plasma clearance rate was determined for the compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,5144,,1,1,CHEMBL621481
8362,N,,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL621482
8363,N,,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL621483
8364,N,,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL621484
8365,N,,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,Heart,1,1,CHEMBL621485
8366,N,,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,13950,Heart,1,1,CHEMBL621486
8367,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,Intestine,1,1,CHEMBL621487
8368,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,Intestine,1,1,CHEMBL621488
8369,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,Intestine,1,1,CHEMBL621489
8370,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,Intestine,1,1,CHEMBL621490
8371,N,,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,160.0,50597,BAO_0000218,A,,13950,Intestine,1,1,CHEMBL621491
8372,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,Kidney,1,1,CHEMBL621492
8373,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,Kidney,1,1,CHEMBL621493
8374,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,Kidney,1,1,CHEMBL621494
8375,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,Kidney,1,1,CHEMBL621495
8376,N,,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13950,Kidney,1,1,CHEMBL621496
8377,N,,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,Liver,1,1,CHEMBL621497
8378,N,,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,Liver,1,1,CHEMBL621498
8379,N,,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,Liver,1,1,CHEMBL621499
8380,N,,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,Liver,1,1,CHEMBL618634
8381,N,,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13950,Liver,1,1,CHEMBL618635
8382,N,,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,Lung,1,1,CHEMBL618636
8383,N,,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,Lung,1,1,CHEMBL619737
8384,N,,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,Lung,1,1,CHEMBL619738
8385,N,,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,Lung,1,1,CHEMBL624329
8386,N,,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13950,Lung,1,1,CHEMBL624330
8387,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,Muscle tissue,1,1,CHEMBL624331
8388,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,Muscle tissue,1,1,CHEMBL624332
8389,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,Muscle tissue,1,1,CHEMBL624333
8390,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,Muscle tissue,1,1,CHEMBL624334
8391,N,,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13950,Muscle tissue,1,1,CHEMBL624335
8392,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,Spleen,1,1,CHEMBL620016
8393,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,Spleen,1,1,CHEMBL620169
8394,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,Spleen,1,1,CHEMBL620170
8395,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,Spleen,1,1,CHEMBL620171
8396,N,,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13950,Spleen,1,1,CHEMBL620172
8397,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,Stomach,1,1,CHEMBL620173
8398,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,Stomach,1,1,CHEMBL620174
8399,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,Stomach,1,1,CHEMBL620175
8400,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,Stomach,1,1,CHEMBL620176
8401,N,,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,,,945.0,50597,BAO_0000218,A,,13950,Stomach,1,1,CHEMBL620177
8402,N,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13950,Cerebellum,1,1,CHEMBL620178
8403,N,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13950,Cerebellum,1,1,CHEMBL620179
8404,N,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620180
8405,N,,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL620181
8406,N,,,,Volume of distribution of compound in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL620182
8407,N,,,,Volume of distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,,1,1,CHEMBL620183
8408,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL620184
8409,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL620185
8410,N,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL620186
8411,N,,,,Volume of distribution was determined in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5353,,1,1,CHEMBL620187
8412,N,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL620188
8413,N,,,,Volume of distribution was reported in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL620189
8414,N,,,,Volumes of distribution in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL620190
8415,N,,,,Volumes of distribution in rat after po administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL620191
8416,N,,,,Volumes of distribution in rat after po administration; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL620192
8417,N,,,,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,,1,1,CHEMBL620193
8418,N,,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL620194
8419,N,,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17670,,1,1,CHEMBL876730
8420,N,,,,Volume distribution in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL620195
8421,N,,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,5408,,1,1,CHEMBL620196
8422,N,,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL620197
8423,N,,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL620198
8424,N,,,,Volume of distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL620199
8425,N,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL620200
8426,N,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL620201
8427,N,,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL620202
8428,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL620203
8429,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL620204
8430,N,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL620205
8431,N,,,,Pharmacokinetic parameter (Vss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL624664
8432,N,,,,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5676,,1,1,CHEMBL624665
8433,N,,,,Pharmacokinetic property (Vss) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5948,,1,1,CHEMBL624666
8434,N,,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,,,,50597,BAO_0000218,A,,5979,,1,1,CHEMBL624667
8435,N,,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL624668
8436,N,,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL624669
8437,N,,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL624670
8438,N,,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL624671
8439,N,,,,Steady state volume distribution in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL624672
8440,N,,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL624673
8441,N,,,,Steady state volume of distribution determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL624674
8442,N,,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL624675
8443,N,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL621728
8444,N,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL621729
8445,N,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL621730
8446,N,,,,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL621731
8447,N,,,,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL621732
8448,N,,,,Volume in steady state distribution value was determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL621908
8449,N,,,,Volume in steady state distribution value was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL875347
8450,N,,,,Volume in steady state distribution value was determined; ND denotes not determined,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL621909
8451,N,,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,,1,1,CHEMBL621910
8452,N,,,,Volume of distribution at steady state was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL621911
8453,N,,,,Volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL621912
8454,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6485,,1,1,CHEMBL621913
8455,N,,,,Volume of distribution in steady state was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,1,1,CHEMBL621914
8456,N,,,,Volume of distribution after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,,1,1,CHEMBL621915
8457,N,,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL621916
8458,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL621917
8459,N,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL621918
8460,N,,,,Biodistribution of compound (oxidized form) in spleen tissue,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL621919
8461,N,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL621920
8462,N,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL621921
8463,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL622401
8464,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL875348
8465,N,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL622402
8466,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622403
8467,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,178.0,50594,BAO_0000218,A,,16438,Blood,1,1,CHEMBL622404
8468,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622405
8469,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622406
8470,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,955.0,50594,BAO_0000218,A,,16438,Brain,1,1,CHEMBL622407
8471,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622408
8472,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622409
8473,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,948.0,50594,BAO_0000218,A,,16438,Heart,1,1,CHEMBL622410
8474,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL622411
8475,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL627864
8476,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2113.0,50594,BAO_0000218,A,,16438,Kidney,1,1,CHEMBL627865
8477,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL627866
8478,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2107.0,50594,BAO_0000218,A,,16438,Liver,1,1,CHEMBL627751
8479,N,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL627752
8480,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL627753
8481,N,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,,2106.0,50594,BAO_0000218,A,,16438,Spleen,1,1,CHEMBL627754
8482,N,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,Intermediate,,,,,50594,BAO_0000218,A,,12467,,1,1,CHEMBL627755
8483,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627756
8484,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627757
8485,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627758
8486,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627759
8487,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627760
8488,N,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,955.0,50594,BAO_0000218,A,,17208,Brain,1,1,CHEMBL627761
8489,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL876811
8490,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL627762
8491,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL627763
8492,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL627764
8493,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL627765
8494,N,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,948.0,50594,BAO_0000218,A,,17208,Heart,1,1,CHEMBL627766
8495,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL627767
8496,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL627768
8497,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL628422
8498,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL628423
8499,N,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,,1,1,CHEMBL628424
8500,N,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,,1,1,CHEMBL628425
8501,N,,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,,1,1,CHEMBL628426
8502,N,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,,1,1,CHEMBL628427
8503,N,,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,,1,1,CHEMBL626938
8504,N,,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6141,,1,1,CHEMBL626939
8505,N,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL626940
8506,N,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL626941
8507,N,,,,Plasma clearance was reported in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL626942
8508,N,,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL876812
8509,N,,,,Plasma clearance of compound in rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6848,,1,1,CHEMBL626943
8510,N,,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,Intermediate,,,,,50597,BAO_0000218,A,,6848,,1,1,CHEMBL626944
8511,N,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL626945
8512,N,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL626946
8513,N,,,,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4956,,1,1,CHEMBL626856
8514,N,,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,,1,1,CHEMBL626857
8515,N,,,,The compound was evaluated for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,406,Plasma,1,1,CHEMBL626858
8516,N,,,,Total plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,Plasma,1,1,CHEMBL627018
8517,N,,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Intermediate,,,,178.0,50597,BAO_0000218,A,,3293,Blood,1,1,CHEMBL625331
8518,N,,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Intermediate,,,,178.0,50597,BAO_0000218,A,,4075,Blood,1,1,CHEMBL625332
8519,N,,,,C max was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL877590
8520,N,,,,C max was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL625333
8521,N,,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,,1,1,CHEMBL625334
8522,N,,,,Cmax after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,,1,1,CHEMBL625335
8523,N,,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,,1,1,CHEMBL625336
8524,N,,,,Cmax 24 hr after 10 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL625337
8525,N,,,,Cmax 24 hr after 2 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL625338
8526,N,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1466,Plasma,1,1,CHEMBL625339
8527,N,,,,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL625340
8528,N,,,,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL625341
8529,N,,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL622687
8530,N,,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6515,Plasma,1,1,CHEMBL622688
8531,N,,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,Blood,1,1,CHEMBL622689
8532,N,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,Blood,1,1,CHEMBL620295
8533,N,,,,Cmax after 10 mg/kg oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17858,,1,1,CHEMBL620296
8534,N,,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL620297
8535,N,,,,Cmax after IV dosing at 1 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL620298
8536,N,,,,Cmax after oral administration at 20 mpk in rats,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL620299
8537,N,,,,Cmax after oral administration at 20 mpk in rats; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL620300
8538,N,,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL620301
8539,N,,,,Cmax after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL620302
8540,N,,,,Cmax after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL620303
8541,N,,,,Cmax after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL620304
8542,N,,,,Cmax in rats after 20 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,6113,,1,1,CHEMBL620305
8543,N,,,,Cmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL620306
8544,N,,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL620307
8545,N,,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL620308
8546,N,,,,Cmax by administering at 20 mg/kg p.o. in rats,Intermediate,,,,,50597,BAO_0000218,A,,6402,,1,1,CHEMBL620309
8547,N,,,,Cmax in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,1,1,CHEMBL620310
8548,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,,1,1,CHEMBL620311
8549,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL620312
8550,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,6504,,1,1,CHEMBL620313
8551,N,,,,Cmax in rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6046,,1,1,CHEMBL620314
8552,N,,,,Cmax in rat at the dose of 1 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6504,,1,1,CHEMBL620315
8553,N,,,,Cmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL620316
8554,N,,,,Cmax in rat p.o. at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL620317
8555,N,,,,Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,5836,,1,1,CHEMBL620318
8556,N,,,,Cmax in rats,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL620319
8557,N,,,,Cmax was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL620320
8558,N,,,,Cmax was measured in rats after peroral administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL620321
8559,N,,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,,1,1,CHEMBL620322
8560,N,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620323
8561,N,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1870.0,50597,BAO_0000218,A,,13950,Frontal cortex,1,1,CHEMBL620324
8562,N,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1870.0,50597,BAO_0000218,A,,13950,Frontal cortex,1,1,CHEMBL620325
8563,N,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13950,Hippocampus,1,1,CHEMBL620326
8564,N,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13950,Hippocampus,1,1,CHEMBL620327
8565,N,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620328
8566,N,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620329
8567,N,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1891.0,50597,BAO_0000218,A,,13950,Midbrain,1,1,CHEMBL620330
8568,N,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,1891.0,50597,BAO_0000218,A,,13950,Midbrain,1,1,CHEMBL875286
8569,N,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620331
8570,N,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,,50597,BAO_0000218,A,,13950,,1,1,CHEMBL620332
8571,N,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13950,Striatum,1,1,CHEMBL620333
8572,N,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13950,Striatum,1,1,CHEMBL620334
8573,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621015
8574,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621016
8575,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621191
8576,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621192
8577,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621193
8578,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL621194
8579,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL624204
8580,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL624205
8581,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624206
8582,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624207
8583,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624208
8584,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624209
8585,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624210
8586,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624211
8587,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624212
8588,N,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624213
8589,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL876611
8590,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL624214
8591,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16434,Blood,1,1,CHEMBL624215
8592,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624216
8593,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624217
8594,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624218
8595,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624219
8596,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624220
8597,N,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,16435,Blood,1,1,CHEMBL624221
8598,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL624222
8599,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL624223
8600,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL624224
8601,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL624225
8602,N,,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL622420
8603,N,,,,Volume of steady state distribution after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,1,1,CHEMBL622421
8604,N,,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,,1,1,CHEMBL622422
8605,N,,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL622423
8606,N,,,,Vss was determined,Intermediate,,,,,50597,BAO_0000218,A,,17752,,1,1,CHEMBL622424
8607,N,,,,Vss in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,,1,1,CHEMBL622425
8608,N,,,,Vss was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL876612
8609,N,,,,volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL622426
8610,N,,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,1,1,CHEMBL622427
8611,N,,,,Pharmacokinetic (PK) parameter Vz in rat,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL622428
8612,N,,,,Volume distribution in rats,Intermediate,,,,,50597,BAO_0000218,A,,4942,,1,1,CHEMBL622429
8613,N,,,,Volume of distribution in rat; No data,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL622430
8614,N,,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL622431
8615,N,,,,% absorption predicted from in vitro rat ileum transport studies,Intermediate,,,,2116.0,50597,BAO_0000218,A,,15765,Ileum,1,1,CHEMBL622432
8616,N,,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL622433
8617,N,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL622434
8618,N,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL622435
8619,N,,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618748
8620,N,,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618749
8621,N,,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618750
8622,N,,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618751
8623,N,,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,13569,,1,1,CHEMBL618752
8624,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL618753
8625,N,,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Intermediate,,,,1969.0,50597,BAO_0000218,A,,750,Plasma,1,1,CHEMBL618754
8626,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,750,,1,1,CHEMBL618755
8627,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4590,,1,1,CHEMBL618756
8628,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1716,,1,1,CHEMBL618757
8629,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1974,,1,1,CHEMBL618758
8630,N,,,,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4502,,1,1,CHEMBL621088
8631,N,,,,Pharmacokinetic property (cLogP) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,1,1,CHEMBL621089
8632,N,,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Intermediate,,,,178.0,50597,BAO_0000218,F,,9099,Blood,1,1,CHEMBL621090
8633,N,,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Intermediate,,,,178.0,50597,BAO_0000218,F,,9099,Blood,1,1,CHEMBL621091
8634,N,,,,Clearance in rat.,Intermediate,,,,,50597,BAO_0000218,A,,4590,,1,1,CHEMBL876731
8635,N,,,,Compound was evaluated for its clearance when administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,,1,1,CHEMBL621092
8636,N,,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,,1,1,CHEMBL621093
8637,N,,,,Blood: Brain distribution ratio is determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL621094
8638,N,,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL621095
8639,N,,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL621096
8640,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,Kidney,1,1,CHEMBL621097
8641,N,,,,Percent dose excreted in 0-48 hours administered ip to male rat,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL621098
8642,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,Cerebellum,1,1,CHEMBL621099
8643,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,Cerebellum,1,1,CHEMBL621100
8644,N,,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,Cerebellum,1,1,CHEMBL621101
8645,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,Cerebellum,1,1,CHEMBL621102
8646,N,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2037.0,50597,BAO_0000218,A,,11977,Cerebellum,1,1,CHEMBL876732
8647,N,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621103
8648,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621104
8649,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621105
8650,N,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621106
8651,N,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621107
8652,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621108
8653,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL621109
8654,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL621110
8655,N,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2113.0,50594,BAO_0000218,A,,17208,Kidney,1,1,CHEMBL621111
8656,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL622541
8657,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL622542
8658,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL622543
8659,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL624412
8660,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL624413
8661,N,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2107.0,50594,BAO_0000218,A,,17208,Liver,1,1,CHEMBL624414
8662,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624415
8663,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624416
8664,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624417
8665,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624418
8666,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624419
8667,N,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2048.0,50594,BAO_0000218,A,,17208,Lung,1,1,CHEMBL624420
8668,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL624421
8669,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL624422
8670,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL624423
8671,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL625123
8672,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL625124
8673,N,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2385.0,50594,BAO_0000218,A,,17208,Muscle tissue,1,1,CHEMBL625125
8674,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL625126
8675,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL626947
8676,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL626948
8677,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL626949
8678,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL626950
8679,N,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,14.0,50594,BAO_0000218,A,,17208,Zone of skin,1,1,CHEMBL626951
8680,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626952
8681,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626953
8682,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626954
8683,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626955
8684,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626956
8685,N,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,2106.0,50594,BAO_0000218,A,,17208,Spleen,1,1,CHEMBL626957
8686,N,,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL626958
8687,N,,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL626959
8688,N,,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL626960
8689,N,,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL626961
8690,N,,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL627589
8691,N,,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,,,178.0,50594,BAO_0000218,A,,17208,Blood,1,1,CHEMBL627590
8692,N,,,,Time taken for EC90 was determined when tested in mouse,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL627591
8693,N,,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,3132,,1,1,CHEMBL627592
8694,N,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,,,,50594,BAO_0000218,A,,16597,,1,1,CHEMBL627593
8695,N,,,,Half life in mice,Intermediate,,,,,50594,BAO_0000218,A,,5727,,1,1,CHEMBL627594
8696,N,,,,Half life period in mouse after 10 mg/Kg dose,Intermediate,,,,,50594,BAO_0000218,A,,5302,,1,1,CHEMBL876813
8697,N,,,,Half life period in mouse after 10 mg/kg dose,Intermediate,,,,,50594,BAO_0000218,A,,5302,,1,1,CHEMBL627595
8698,N,,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,,,50594,BAO_0000218,A,,6348,,1,1,CHEMBL627596
8699,N,,,,Cmax value at 5 mg/kg po was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL627597
8700,N,,,,Cmax value evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL627598
8701,N,,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Intermediate,,,,955.0,50597,BAO_0000218,A,,5206,Brain,1,1,CHEMBL627599
8702,N,,,,Cmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,,1,1,CHEMBL627600
8703,N,,,,Cmax value at 1 mg/kg po in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL627601
8704,N,,,,Cmax value at 5 mg/kg po in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL627776
8705,N,,,,Cmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627777
8706,N,,,,Cmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627778
8707,N,,,,Cmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627779
8708,N,,,,Cmax value in rats at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17617,,1,1,CHEMBL876814
8709,N,,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,1445,,1,1,CHEMBL627780
8710,N,,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6082,,1,1,CHEMBL627781
8711,N,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,,,,50597,BAO_0000218,A,,1446,,1,1,CHEMBL627782
8712,N,,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5407,Plasma,1,1,CHEMBL627783
8713,N,,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2690,Plasma,1,1,CHEMBL627784
8714,N,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627785
8715,N,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627786
8716,N,,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4891,Plasma,1,1,CHEMBL627787
8717,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,Plasma,1,1,CHEMBL627788
8718,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,Plasma,1,1,CHEMBL626579
8719,N,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2807,Plasma,1,1,CHEMBL626580
8720,N,,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,3634,,1,1,CHEMBL876815
8721,N,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1881,Plasma,1,1,CHEMBL626581
8722,N,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1881,Plasma,1,1,CHEMBL626582
8723,N,,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL626583
8724,N,,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL626205
8725,N,,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL626206
8726,N,,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL626207
8727,N,,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL623882
8728,N,,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL623883
8729,N,,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL623884
8730,N,,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3032,Plasma,1,1,CHEMBL623885
8731,N,,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6295,Plasma,1,1,CHEMBL623886
8732,N,,,,Maximal concentration in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,6619,,1,1,CHEMBL623887
8733,N,,,,Maximal concentration after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,,1,1,CHEMBL623888
8734,N,,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3249,Plasma,1,1,CHEMBL623889
8735,N,,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17791,Plasma,1,1,CHEMBL623890
8736,N,,,,Cmax in rat plasma after oral dose (50 mg/Kg),Intermediate,,,,1969.0,50597,BAO_0000218,A,,17791,Plasma,1,1,CHEMBL623891
8737,N,,,,Maximal plasma concentration was determined.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1360,Plasma,1,1,CHEMBL623892
8738,N,,,,Maximal plasma drug concentration was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2552,Plasma,1,1,CHEMBL623893
8739,N,,,,Maximal concentration in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL877616
8740,N,,,,Maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL623894
8741,N,,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6567,Plasma,1,1,CHEMBL623895
8742,N,,,,Maximum concentration of compound in rat was evaluated.,Intermediate,,,,,50597,BAO_0000218,A,,3031,,1,1,CHEMBL623896
8743,N,,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,,1,1,CHEMBL623897
8744,N,,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,,1,1,CHEMBL623898
8745,N,,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,,1,1,CHEMBL623899
8746,N,,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,3436,,1,1,CHEMBL623900
8747,N,,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL623901
8748,N,,,,Maximum concentration was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1974,,1,1,CHEMBL623902
8749,N,,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,1359.0,50597,BAO_0000218,A,,3307,Cerebrospinal fluid,1,1,CHEMBL623903
8750,N,,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3307,Plasma,1,1,CHEMBL623904
8751,N,,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1916,Plasma,1,1,CHEMBL877617
8752,N,,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,1,1,CHEMBL623905
8753,N,,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,1,1,CHEMBL623906
8754,N,,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL623907
8755,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623908
8756,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623909
8757,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623910
8758,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623911
8759,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623912
8760,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624616
8761,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624617
8762,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624618
8763,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624619
8764,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624794
8765,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL624795
8766,N,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623921
8767,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623922
8768,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623923
8769,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623924
8770,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623925
8771,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623926
8772,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623927
8773,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623928
8774,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623929
8775,N,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623930
8776,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL623931
8777,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL622165
8778,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621249
8779,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621250
8780,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621448
8781,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621449
8782,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621450
8783,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL621451
8784,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL621452
8785,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL621453
8786,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL621454
8787,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL621455
8788,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL621456
8789,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625145
8790,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL875847
8791,N,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625146
8792,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL625147
8793,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL625148
8794,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16434,Brain,1,1,CHEMBL625149
8795,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625150
8796,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625151
8797,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625152
8798,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625153
8799,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625154
8800,N,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,16435,Brain,1,1,CHEMBL625155
8801,N,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL625156
8802,N,,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL624354
8803,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,Hippocampus,1,1,CHEMBL624355
8804,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,Hippocampus,1,1,CHEMBL624356
8805,N,,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,Hippocampus,1,1,CHEMBL624357
8806,N,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,10000000.0,50597,BAO_0000218,A,,11977,Hippocampus,1,1,CHEMBL624358
8807,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,Striatum,1,1,CHEMBL624359
8808,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,Striatum,1,1,CHEMBL624360
8809,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,Striatum,1,1,CHEMBL624361
8810,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,Striatum,1,1,CHEMBL624362
8811,N,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2435.0,50597,BAO_0000218,A,,11977,Striatum,1,1,CHEMBL624363
8812,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,Blood,1,1,CHEMBL624364
8813,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,Blood,1,1,CHEMBL624365
8814,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,Blood,1,1,CHEMBL624366
8815,N,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,178.0,50597,BAO_0000218,A,,11977,Blood,1,1,CHEMBL624367
8816,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,Brain,1,1,CHEMBL624368
8817,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,Brain,1,1,CHEMBL624369
8818,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,Brain,1,1,CHEMBL624370
8819,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,Brain,1,1,CHEMBL625069
8820,N,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,955.0,50597,BAO_0000218,A,,11977,Brain,1,1,CHEMBL625070
8821,N,,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,Heart,1,1,CHEMBL626051
8822,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,Heart,1,1,CHEMBL626052
8823,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,Heart,1,1,CHEMBL626053
8824,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,Heart,1,1,CHEMBL626054
8825,N,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,948.0,50597,BAO_0000218,A,,11977,Heart,1,1,CHEMBL626055
8826,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,Kidney,1,1,CHEMBL626056
8827,N,,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,Kidney,1,1,CHEMBL626057
8828,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,Kidney,1,1,CHEMBL625193
8829,N,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2113.0,50597,BAO_0000218,A,,11977,Kidney,1,1,CHEMBL625194
8830,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL625195
8831,N,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL625196
8832,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL625197
8833,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL625198
8834,N,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL627929
8835,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,Lung,1,1,CHEMBL627074
8836,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,Lung,1,1,CHEMBL627075
8837,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,Lung,1,1,CHEMBL627076
8838,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,Lung,1,1,CHEMBL627077
8839,N,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2048.0,50597,BAO_0000218,A,,11977,Lung,1,1,CHEMBL627078
8840,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL627079
8841,N,,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,,,50594,BAO_0000218,A,,4573,,1,1,CHEMBL873824
8842,N,,,,Half life in mouse plasma was determined at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL627080
8843,N,,,,Half life was determined,Intermediate,,,,,50594,BAO_0000218,A,,17718,,1,1,CHEMBL627081
8844,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL627082
8845,N,,,,Half-life in male mice after 1 mg/kg intravenous dose,Intermediate,,,,,50594,BAO_0000218,A,,5961,,1,1,CHEMBL627083
8847,N,,,,Half life in mice plasma,Intermediate,,,,1969.0,50594,BAO_0000218,A,,17731,Plasma,1,1,CHEMBL627085
8848,N,,,,Half life in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17592,,1,1,CHEMBL627086
8849,N,,,,Half life in mouse plasma at dose 25 mg/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,3132,Plasma,1,1,CHEMBL627087
8850,N,,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL627088
8851,N,,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL627089
8852,N,,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,Intermediate,,,,,50594,BAO_0000218,A,,17729,,1,1,CHEMBL627090
8853,N,,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,,,50594,BAO_0000218,A,,3277,,1,1,CHEMBL627091
8854,N,,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL627092
8855,N,,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,,,,50594,BAO_0000218,A,,3760,,1,1,CHEMBL876785
8856,N,,,,Half-life by iv administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL627093
8857,N,,,,Half-life by oral administration in mouse,Intermediate,,,,,50594,BAO_0000218,A,,2862,,1,1,CHEMBL627094
8858,N,,,,Half-life in mice,Intermediate,,,,,50594,BAO_0000218,A,,5980,,1,1,CHEMBL627095
8859,N,,,,Half-life using mouse brain homogenate,Intermediate,,,,955.0,50594,BAO_0000218,A,,6159,Brain,1,1,CHEMBL627096
8860,N,,,,Half-life was measured in mice,Intermediate,,,,,50594,BAO_0000218,A,,6254,,1,1,CHEMBL627097
8861,N,,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,6062,,1,1,CHEMBL627098
8862,N,,,,Half-life period was determined in mouse blood,Intermediate,,,,178.0,50594,BAO_0000218,A,,1574,Blood,1,1,CHEMBL627099
8863,N,,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Intermediate,,,,955.0,50594,BAO_0000218,A,,56,Brain,1,1,CHEMBL627100
8864,N,,,,Plasma half life in mouse,Intermediate,,,,1969.0,50594,BAO_0000218,A,,993,Plasma,1,1,CHEMBL627101
8865,N,,,,Stability of the peptide in the presence of mouse serum,Intermediate,,,,,50594,BAO_0000218,A,,6652,,1,1,CHEMBL627102
8866,N,,,,Terminal half life of compound was determined in mouse,Intermediate,,,,,50594,BAO_0000218,A,,17852,,1,1,CHEMBL627103
8867,N,,,,Terminal half life was evaluated in mice after intravenous administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL627104
8868,N,,,,Terminal half life was evaluated in mice after oral administration,Intermediate,,,,,50594,BAO_0000218,A,,2675,,1,1,CHEMBL627105
8869,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,Intermediate,,,,,50594,BAO_0000218,A,,499,,1,1,CHEMBL876786
8870,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,Intermediate,,,,,50594,BAO_0000218,A,,499,,1,1,CHEMBL873825
8871,N,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,Intermediate,,,,,50594,BAO_0000218,A,,499,,1,1,CHEMBL627106
8872,N,,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,14239,,1,1,CHEMBL626336
8873,N,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL877462
8874,N,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",Intermediate,,,,,50594,BAO_0000218,A,,5506,,1,1,CHEMBL626337
8875,N,,,,Half life after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,,,50594,BAO_0000218,A,,17734,,1,1,CHEMBL626338
8876,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL626339
8877,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL626340
8878,N,,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL625377
8879,N,,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL625378
8880,N,,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,Intermediate,,,,,50594,BAO_0000218,A,,17728,,1,1,CHEMBL625379
8881,U,,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL625380
8882,U,,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL625381
8883,U,,,,Stability to porcine renal DHP-I,Autocuration,,,,,22224,BAO_0000019,A,,6056,,0,1,CHEMBL625382
8884,U,,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,Autocuration,,,,,22224,BAO_0000218,A,,1317,,0,1,CHEMBL873828
8885,U,,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,Autocuration,,,,,22224,BAO_0000218,A,,1317,,0,1,CHEMBL625383
8886,U,,,,Half-life of the parent prodrug in porcine esterase solution,Autocuration,,,,,22224,BAO_0000019,A,,5229,,0,1,CHEMBL625384
8887,U,,,,"First order rate constant, k was determined in in pig liver Esterase",Autocuration,,,,,22224,BAO_0000019,A,,4231,,0,1,CHEMBL625385
8888,U,,,,Half life of the in pig liver Esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,4231,Liver,0,1,CHEMBL625386
8889,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,Liver,0,1,CHEMBL623571
8890,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,Liver,0,1,CHEMBL623572
8891,U,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,5318,Liver,0,1,CHEMBL623573
8892,U,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3305,Liver,0,1,CHEMBL623574
8893,U,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3305,Liver,0,1,CHEMBL623575
8894,U,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Autocuration,,,,2107.0,22224,BAO_0000221,A,,2842,Liver,0,1,CHEMBL623749
8895,U,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Autocuration,,,,2107.0,22224,BAO_0000221,A,,2842,Liver,0,1,CHEMBL623750
8896,U,,,,Half-life in vitro in pig liver,Autocuration,,,,2107.0,22224,BAO_0000221,A,,889,Liver,0,1,CHEMBL623751
8897,U,,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Autocuration,,,,2107.0,22224,BAO_0000221,A,,1904,Liver,0,1,CHEMBL623752
8898,N,,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL623753
8899,N,,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2774,Plasma,1,1,CHEMBL623754
8900,N,,,,Maximum concentration in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1742,Plasma,1,1,CHEMBL623755
8901,N,,,,Maximum concentration in rats,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL623756
8902,N,,,,Maximum concentration in rats at 1-2 hours,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL623757
8903,N,,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,Intermediate,,,,,50597,BAO_0000218,A,,2081,,1,1,CHEMBL623758
8904,N,,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,3307,Brain,1,1,CHEMBL623759
8905,N,,,,Maximum concentration at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL623760
8906,N,,,,Maximum concentration was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL623761
8907,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,Plasma,1,1,CHEMBL623762
8908,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,Plasma,1,1,CHEMBL877594
8909,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,Plasma,1,1,CHEMBL623763
8910,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,Plasma,1,1,CHEMBL623764
8911,N,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16365,Plasma,1,1,CHEMBL623765
8912,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,Blood,1,1,CHEMBL623766
8913,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,Blood,1,1,CHEMBL623767
8914,N,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,2591,Blood,1,1,CHEMBL623768
8915,N,,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623769
8916,N,,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623770
8917,N,,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623771
8918,N,,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623772
8919,N,,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623773
8920,N,,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623774
8921,N,,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5978,Plasma,1,1,CHEMBL623775
8922,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,14465,,1,1,CHEMBL623776
8923,N,,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4723,Plasma,1,1,CHEMBL622191
8924,N,,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4723,Plasma,1,1,CHEMBL622192
8925,N,,,,Maximum plasma concentration determined in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4576,Plasma,1,1,CHEMBL622193
8926,N,,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL622194
8927,N,,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL622195
8928,N,,,,Maximum plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6824,Plasma,1,1,CHEMBL622196
8929,N,,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17065,Plasma,1,1,CHEMBL622197
8930,N,,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,Plasma,1,1,CHEMBL622198
8931,N,,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,Plasma,1,1,CHEMBL622199
8932,N,,,,Maximum plasma concentration of compound was measured in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2879,Plasma,1,1,CHEMBL622200
8933,N,,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2864,Plasma,1,1,CHEMBL622201
8934,N,,,,Maximum plasma concentration after oral administration to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16367,Plasma,1,1,CHEMBL623990
8935,N,,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,Plasma,1,1,CHEMBL623991
8936,N,,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,Plasma,1,1,CHEMBL623992
8937,N,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,Plasma,1,1,CHEMBL623993
8938,N,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17717,Plasma,1,1,CHEMBL623994
8939,N,,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,Plasma,1,1,CHEMBL623995
8940,N,,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,Plasma,1,1,CHEMBL623996
8941,N,,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,F,,17720,Plasma,1,1,CHEMBL623997
8942,N,,,,Maximum plasma concentration dosed orally in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,Plasma,1,1,CHEMBL623998
8943,N,,,,Maximum plasma concentration dosed orally in rats after 6 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,Plasma,1,1,CHEMBL623999
8944,N,,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4516,Plasma,1,1,CHEMBL624000
8945,N,,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5199,Plasma,1,1,CHEMBL624001
8946,N,,,,Maximum plasma concentration in rat after po administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17538,Plasma,1,1,CHEMBL624002
8947,N,,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL624003
8948,N,,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL624004
8949,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624005
8950,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624006
8951,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624007
8952,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624008
8953,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624009
8954,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL874387
8955,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624010
8956,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624011
8957,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624012
8958,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624013
8959,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624736
8960,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624737
8961,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624738
8962,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624739
8963,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16434,Heart,1,1,CHEMBL624740
8964,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624896
8965,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624897
8966,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624108
8967,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624109
8968,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624110
8969,N,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624111
8970,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624112
8971,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL624113
8972,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL619709
8973,N,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,948.0,50597,BAO_0000218,A,,16435,Heart,1,1,CHEMBL619710
8974,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619711
8975,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619712
8976,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619713
8977,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619714
8978,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619715
8979,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619716
8980,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619717
8981,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619718
8982,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619719
8983,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL875329
8984,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619720
8985,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619721
8986,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619722
8987,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619723
8988,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619724
8989,N,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619725
8990,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619726
8991,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619727
8992,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16434,Kidney,1,1,CHEMBL619728
8993,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL619729
8994,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL619730
8995,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL619731
8996,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL619732
8997,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL619733
8998,N,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2385.0,50597,BAO_0000218,A,,11977,Muscle tissue,1,1,CHEMBL619734
8999,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,Zone of skin,1,1,CHEMBL619735
9000,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,Zone of skin,1,1,CHEMBL875330
9001,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,Zone of skin,1,1,CHEMBL628465
9002,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,Zone of skin,1,1,CHEMBL628466
9003,N,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,14.0,50597,BAO_0000218,A,,11977,Zone of skin,1,1,CHEMBL628467
9004,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,Spleen,1,1,CHEMBL628468
9005,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,Spleen,1,1,CHEMBL628469
9006,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,Spleen,1,1,CHEMBL628470
9007,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,Spleen,1,1,CHEMBL628471
9008,N,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2106.0,50597,BAO_0000218,A,,11977,Spleen,1,1,CHEMBL628472
9009,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,Thyroid gland,1,1,CHEMBL625191
9010,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,Thyroid gland,1,1,CHEMBL625192
9011,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,Thyroid gland,1,1,CHEMBL875337
9012,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,Thyroid gland,1,1,CHEMBL626341
9013,N,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2046.0,50597,BAO_0000218,A,,11977,Thyroid gland,1,1,CHEMBL626342
9014,N,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,,,2107.0,50597,BAO_0000218,A,,11977,Liver,1,1,CHEMBL621943
9015,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,3748,,1,1,CHEMBL621944
9016,N,,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL621945
9017,N,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),Intermediate,,,,,50597,BAO_0000218,A,,4871,,1,1,CHEMBL621946
9018,N,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4871,,1,1,CHEMBL621947
9019,N,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),Intermediate,,,,,50597,BAO_0000218,A,,4872,,1,1,CHEMBL621948
9020,N,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4872,,1,1,CHEMBL621949
9021,N,,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),Intermediate,,,,,50597,BAO_0000218,A,,5413,,1,1,CHEMBL621950
9022,N,,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,Intermediate,,,,,50597,BAO_0000218,A,,5413,,1,1,CHEMBL621951
9023,N,,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,15272,Blood,1,1,CHEMBL621952
9024,N,,,,Stability (%) in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4689,Liver,1,1,CHEMBL621953
9025,N,,,,Area under curve was calculated after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL621954
9026,N,,,,Area under the curve was calculated after iv administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL621955
9027,N,,,,Area under the curve was calculated in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL621956
9028,N,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,1,1,CHEMBL621957
9029,N,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL621958
9030,N,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL621959
9031,N,,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL621960
9032,N,,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL621961
9033,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL621962
9034,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,F,,15765,,1,1,CHEMBL876787
9035,N,,,,p value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL621963
9036,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL622637
9037,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL622638
9038,N,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL626561
9039,U,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Autocuration,,,,,22224,BAO_0000019,F,,7991,,0,1,CHEMBL626562
9040,U,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),Autocuration,,,,,22224,BAO_0000218,A,,429,,0,1,CHEMBL626563
9041,U,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),Autocuration,,,,,22224,BAO_0000218,A,,429,,0,1,CHEMBL626564
9042,U,,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,,,,22224,BAO_0000218,A,,6253,,0,1,CHEMBL626565
9043,U,,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,,,,22224,BAO_0000218,A,,6253,,0,1,CHEMBL626566
9044,U,,,,Clearance rate in rabbits,Autocuration,,,,,22224,BAO_0000218,A,,3615,,0,1,CHEMBL626567
9045,U,,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,,22224,BAO_0000218,A,,4059,,0,1,CHEMBL626568
9046,U,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL626569
9047,U,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL626570
9048,U,,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL626571
9049,U,,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,,0,1,CHEMBL626572
9050,U,,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4059,Plasma,0,1,CHEMBL626573
9051,U,,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,9659,Liver,0,1,CHEMBL626574
9052,U,,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Autocuration,,,,2107.0,22224,BAO_0000251,A,Microsomes,9659,Liver,0,1,CHEMBL626575
9053,U,,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,Autocuration,,,,,22224,BAO_0000218,A,,3639,,0,1,CHEMBL626576
9054,U,,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,Autocuration,,,,,22224,BAO_0000218,A,,3639,,0,1,CHEMBL626577
9055,U,,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,Autocuration,,,,,22224,BAO_0000218,A,,3639,,0,1,CHEMBL626578
9056,U,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL625263
9057,U,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL625264
9058,U,,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5124,,0,1,CHEMBL625265
9059,U,,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL625266
9060,U,,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14294,,0,1,CHEMBL876796
9061,U,,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,,0,1,CHEMBL625267
9062,U,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,Plasma,0,1,CHEMBL625268
9063,U,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,Plasma,0,1,CHEMBL625269
9064,U,,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,5124,Plasma,0,1,CHEMBL624689
9065,U,,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,429,,0,1,CHEMBL624690
9066,U,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Autocuration,,,,1088.0,22224,BAO_0000218,A,,429,Urine,0,1,CHEMBL624691
9067,U,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Autocuration,,,,1088.0,22224,BAO_0000218,A,,429,Urine,0,1,CHEMBL624692
9068,U,,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,,,,22224,BAO_0000218,A,,4059,,0,1,CHEMBL624693
9069,U,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Autocuration,,,,,22224,BAO_0000218,A,,4137,,0,1,CHEMBL624694
9070,U,,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,Autocuration,,,,,22224,BAO_0000221,A,,11672,,0,1,CHEMBL877596
9071,U,,,,Time within which only 10% of the drug was degraded,Autocuration,,,,,22224,BAO_0000019,A,,12886,,0,1,CHEMBL624695
9072,U,,,,Half life period in rabbit liver homogenate,Autocuration,,,,2107.0,22224,BAO_0000221,A,,3853,Liver,0,1,CHEMBL624696
9073,U,,,,Half life value in rabbits,Autocuration,,,,,22224,BAO_0000019,A,,3615,,0,1,CHEMBL624697
9074,U,,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,,,178.0,22224,BAO_0000218,A,,6253,Blood,0,1,CHEMBL624698
9075,U,,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,,,178.0,22224,BAO_0000218,A,,6253,Blood,0,1,CHEMBL624699
9076,U,,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,6077,,0,1,CHEMBL624700
9077,N,,,,AUC 0-8 hr value in rats at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17617,Plasma,1,1,CHEMBL622903
9078,N,,,,AUC after administration at 2000 mg/kg/day in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,Plasma,1,1,CHEMBL622904
9079,N,,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6149,Plasma,1,1,CHEMBL622905
9080,N,,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17260,Plasma,1,1,CHEMBL622906
9081,N,,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17260,Plasma,1,1,CHEMBL622907
9082,N,,,,AUC in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,Plasma,1,1,CHEMBL622908
9083,N,,,,AUC in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,Plasma,1,1,CHEMBL622909
9084,N,,,,AUC in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6644,Plasma,1,1,CHEMBL622910
9085,N,,,,AUC in rat brain after oral administration at 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,6495,Brain,1,1,CHEMBL622911
9086,N,,,,AUC in rat p.o.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6504,Plasma,1,1,CHEMBL622912
9087,N,,,,AUC in rat p.o. at 20 mg/kg concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17686,Plasma,1,1,CHEMBL622913
9088,N,,,,AUC in rat plasma after oral administration at 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6495,Plasma,1,1,CHEMBL622914
9089,N,,,,AUC in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,216,Plasma,1,1,CHEMBL622915
9090,N,,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1908,Plasma,1,1,CHEMBL622916
9091,N,,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1908,Plasma,1,1,CHEMBL622917
9092,N,,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,1969.0,50597,BAO_0000218,A,,6685,Plasma,1,1,CHEMBL622918
9093,N,,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Intermediate,,,,1969.0,50597,BAO_0000218,A,,216,Plasma,1,1,CHEMBL622919
9094,N,,,,Maximum plasma concentration was evaluated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6049,Plasma,1,1,CHEMBL622920
9095,N,,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2463,Plasma,1,1,CHEMBL622921
9096,N,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6679,Plasma,1,1,CHEMBL622922
9097,N,,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6681,Plasma,1,1,CHEMBL622923
9098,N,,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4890,Plasma,1,1,CHEMBL877604
9099,N,,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,Plasma,1,1,CHEMBL622924
9100,N,,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6410,Plasma,1,1,CHEMBL622925
9101,N,,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16366,Plasma,1,1,CHEMBL622926
9102,N,,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6227,Plasma,1,1,CHEMBL623625
9103,N,,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,1969.0,50597,BAO_0000218,A,,3598,Plasma,1,1,CHEMBL623626
9104,N,,,,Maximum plasma drug concentration was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1465,Plasma,1,1,CHEMBL623627
9105,N,,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,1,1,CHEMBL623628
9106,N,,,,Mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL623629
9107,N,,,,Mean peak plasma concentration was observed after oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL623630
9108,N,,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL623804
9109,N,,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL623805
9110,N,,,,Peak oral plasma concentration was determined in rats by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1567,Plasma,1,1,CHEMBL623806
9111,N,,,,Peak plasma concentration (Cmax) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4026,Plasma,1,1,CHEMBL623807
9112,N,,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6193,Plasma,1,1,CHEMBL623808
9113,N,,,,Peak plasma concentration (Cmax) in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4026,Plasma,1,1,CHEMBL623809
9114,N,,,,Peak plasma concentration at 1 mg/kg peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6485,Plasma,1,1,CHEMBL623810
9115,N,,,,Peak plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,Plasma,1,1,CHEMBL623811
9116,N,,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,Plasma,1,1,CHEMBL623812
9117,N,,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,,1,1,CHEMBL877605
9118,N,,,,Pharmacokinetic property (Cmax) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,,1,1,CHEMBL623813
9119,N,,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL623814
9120,N,,,,Cmax in rat after 3mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4878,,1,1,CHEMBL623815
9121,N,,,Sprague-Dawley,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,5862,,1,1,CHEMBL623816
9122,N,,,,Cmax in rats after 20 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4517,,1,1,CHEMBL623145
9123,N,,,,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL623146
9124,N,,,,Plasma concentration after oral administration of 100 mg/kg to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5436,Plasma,1,1,CHEMBL623147
9125,N,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,Brain,1,1,CHEMBL623042
9126,N,,,,Tested for the Cmax in rat at 10 mg/kg per orally,Intermediate,,,,,50597,BAO_0000218,A,,4950,,1,1,CHEMBL623043
9127,N,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL623044
9128,N,,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL623045
9129,N,,,,Bioavailability as oral Cmax in rats at 30 mins,Intermediate,,,,,50597,BAO_0000218,A,,3360,,1,1,CHEMBL623046
9130,N,,,,Bioavailability as oral Cmax in rats at 6hr,Intermediate,,,,,50597,BAO_0000218,A,,3360,,1,1,CHEMBL623226
9131,N,,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL623227
9132,N,,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL623228
9133,N,,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL623229
9134,N,,,,The maximum plasma levels for the compounds were determined by LC-MS.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5160,Plasma,1,1,CHEMBL623230
9135,N,,,,mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL623231
9136,N,,,,mean peak plasma concentration was observed after oral administration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15662,Plasma,1,1,CHEMBL623232
9137,N,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL623233
9138,N,,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623234
9139,N,,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623235
9140,N,,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623236
9141,N,,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623237
9142,N,,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623238
9143,N,,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,3535,,1,1,CHEMBL623239
9144,U,,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL623240
9145,N,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Intermediate,,,,1898.0,50597,BAO_0000218,A,,6326,Hypothalamus,1,1,CHEMBL623241
9146,N,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Intermediate,,,,1898.0,50597,BAO_0000218,A,,6326,Hypothalamus,1,1,CHEMBL623242
9147,N,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",Intermediate,,,,,50597,BAO_0000218,A,,6326,,1,1,CHEMBL874394
9148,N,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",Intermediate,,,,,50597,BAO_0000218,A,,6326,,1,1,CHEMBL623243
9149,N,,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL623244
9150,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL623245
9151,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL623246
9152,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL623247
9153,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL623248
9154,N,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,16435,Kidney,1,1,CHEMBL623249
9155,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625072
9156,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625073
9157,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625074
9158,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625075
9159,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625076
9160,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625077
9161,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625078
9162,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL874395
9163,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625079
9164,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625080
9165,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625081
9166,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625082
9167,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625083
9168,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625084
9169,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625085
9170,N,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL625086
9171,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625087
9172,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL625088
9173,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16434,Liver,1,1,CHEMBL622205
9174,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL622206
9175,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL622207
9176,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL622366
9177,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL622367
9178,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL875331
9179,N,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,16435,Liver,1,1,CHEMBL622368
9180,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622369
9181,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622370
9182,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622371
9183,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622372
9184,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622373
9185,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622374
9186,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622375
9187,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622376
9188,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622377
9189,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622378
9190,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622379
9191,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622380
9192,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622381
9193,N,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622382
9194,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL622383
9195,N,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL875332
9196,N,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL622384
9197,N,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL622385
9198,N,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,,,945.0,50597,BAO_0000218,A,,6175,Stomach,1,1,CHEMBL622386
9199,N,,,,The compound was tested for the plasma binding in rat,Intermediate,,,,,50597,BAO_0000218,A,,10839,,1,1,CHEMBL622387
9200,N,,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622388
9201,N,,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622389
9202,N,,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622390
9203,N,,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622391
9204,N,,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622392
9205,N,,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,16459,,1,1,CHEMBL622393
9206,N,,,,Plasma level at 2 hr after administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3278,,1,1,CHEMBL622394
9207,N,,,,plasma level at 2 hr after administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3278,,1,1,CHEMBL622395
9208,N,,,,Stability in rat serum measured as % recovery at 1 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL622396
9209,N,,,,Stability in rat serum measured as % recovery at 10 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624894
9210,N,,,,Stability in rat serum measured as % recovery at 10 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624895
9211,N,,,,Stability in rat serum measured as % recovery at 2 hr,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624058
9212,N,,,,Stability in rat serum measured as % recovery at 3 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624059
9213,N,,,,Stability in rat serum measured as % recovery at 3 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624060
9214,N,,,,Stability in rat serum measured as % recovery at 5 min,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624061
9215,N,,,,Stability in rat serum measured as % recovery at 5 mins,Intermediate,,,,1977.0,50597,BAO_0000218,A,,4684,Serum,1,1,CHEMBL624062
9216,N,,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,,1,1,CHEMBL624063
9217,N,,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,,1,1,CHEMBL624064
9218,N,,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,723,Plasma,1,1,CHEMBL624065
9219,N,,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,723,Plasma,1,1,CHEMBL624066
9220,N,,,,Half life tested in mature male rat at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5160,,1,1,CHEMBL877490
9221,N,,,,Half life after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL874442
9222,N,,,,Half life period after administration (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5633,,1,1,CHEMBL626890
9223,N,,,,Half life period in rat after 5 mg/Kg dose,Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL626891
9224,N,,,,Half life period in rat after 5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL626892
9225,N,,,,Half life period was determined,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL626893
9226,N,,,,Half life period was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL626894
9227,N,,,,Half life period was evaluated in rat; 0.5-1.0,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL626895
9228,N,,,,Half life period was evaluated in rat; 5.9-7.5,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL626896
9229,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14512,Plasma,1,1,CHEMBL626897
9230,N,,,,Half-life time in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,6230,,1,1,CHEMBL626898
9231,N,,,,Terminal half-life after iv administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,3364,,1,1,CHEMBL626899
9232,N,,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,6874,,1,1,CHEMBL626900
9233,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,857,,1,1,CHEMBL626901
9234,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),Intermediate,,,,,50597,BAO_0000218,A,,858,,1,1,CHEMBL626902
9235,N,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),Intermediate,,,,,50597,BAO_0000218,A,,858,,1,1,CHEMBL626903
9236,N,,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL874443
9237,N,,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL626904
9238,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6305,,1,1,CHEMBL626905
9239,N,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13501,Plasma,1,1,CHEMBL873830
9240,N,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,,1,1,CHEMBL626906
9241,N,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4186,Plasma,1,1,CHEMBL631076
9242,N,,,,Biological half-life was measured in plasma of rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2932,Plasma,1,1,CHEMBL631077
9243,N,,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,,1,1,CHEMBL631078
9244,N,,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL631079
9245,N,,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,1,1,CHEMBL631080
9246,N,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL631081
9247,N,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL631239
9248,N,,,,Compound was evaluated for plasma half life in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,740,Plasma,1,1,CHEMBL631240
9249,N,,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6597,Plasma,1,1,CHEMBL631241
9250,N,,,,AUC value after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2959,Plasma,1,1,CHEMBL631242
9251,N,,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,Plasma,1,1,CHEMBL631243
9252,N,,,,AUC0-96 after administration at 50 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17596,Plasma,1,1,CHEMBL874444
9253,N,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17594,Plasma,1,1,CHEMBL631244
9254,N,,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",Intermediate,,,,,50597,BAO_0000218,A,,3293,,1,1,CHEMBL631245
9255,N,,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627162
9256,N,,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627163
9257,N,,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,Intermediate,,,,,50597,BAO_0000218,A,,6757,,1,1,CHEMBL627164
9258,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Intermediate,,,,2113.0,50597,BAO_0000218,A,,5979,Kidney,1,1,CHEMBL627165
9259,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,Intermediate,,,,,50597,BAO_0000218,A,,5979,,1,1,CHEMBL627166
9260,N,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,Intermediate,,,,,50597,BAO_0000218,A,,5979,,1,1,CHEMBL627167
9261,N,,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL627822
9262,N,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL627823
9263,N,,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL627824
9264,N,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,5355,,1,1,CHEMBL627825
9265,N,,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,5633,,1,1,CHEMBL627826
9266,N,,,,Area under curve (Pharmacokinetic property) was determined,Intermediate,,,,,50597,BAO_0000218,A,,1716,,1,1,CHEMBL627827
9267,N,,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,1716,,1,1,CHEMBL627828
9268,N,,,,Area under curve after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL627829
9269,N,,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL627830
9270,N,,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL627831
9271,N,,,,Area under curve in male SD rats was observed after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL627832
9272,N,,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,4413,,1,1,CHEMBL627833
9273,N,,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL627834
9274,N,,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL628004
9275,N,,,,Area under curve at 5 mg/kg po was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL628005
9276,N,,,,Area under curve in Rat at a oral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL628006
9277,N,,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,,,50597,BAO_0000218,A,,4186,,1,1,CHEMBL628007
9278,N,,,,Area under curve was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL625676
9279,N,,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,Intermediate,,,,,50597,BAO_0000218,A,,17858,,1,1,CHEMBL631309
9280,N,,,,Area under curve after intravenous administration at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL631310
9281,N,,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,Intermediate,,,,,50597,BAO_0000218,A,,6106,,1,1,CHEMBL631311
9282,N,,,,Area under curve at 4 hr in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL631312
9283,N,,,,Area under curve at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL631313
9284,N,,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL631314
9285,N,,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL631315
9286,N,,,,Area under curve for a 2-mpk po dose in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,1,1,CHEMBL631316
9287,N,,,,Area under curve in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,1,1,CHEMBL631317
9288,N,,,,Area under curve in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL874471
9289,N,,,,Area under curve in rat by po administration at 0-24 hr,Intermediate,,,,,50597,BAO_0000218,A,,5871,,1,1,CHEMBL631318
9290,N,,,,Area under curve in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5919,Plasma,1,1,CHEMBL631319
9291,N,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL631320
9292,N,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL631321
9293,N,,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,10,,1,1,CHEMBL631322
9294,N,,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,,1,1,CHEMBL631323
9295,N,,,,Area under curve value in rat at a dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL631324
9296,N,,,,Area under curve was determined after oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL631325
9297,N,,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL631326
9298,N,,,,Area under curve was determined after peroral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL631327
9299,N,,,,Area under curve was determined at a dose 30 mpk administered orally.,Intermediate,,,,,50597,BAO_0000218,A,,5375,,1,1,CHEMBL631328
9300,N,,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL631329
9301,N,,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,1,1,CHEMBL627217
9302,N,,,,Area under curve was determined in male rat,Intermediate,,,,,50597,BAO_0000218,A,,5610,,1,1,CHEMBL626352
9303,N,,,,Area under curve was determined in rat after PO administration,Intermediate,,,,,50597,BAO_0000218,A,,5833,,1,1,CHEMBL626353
9304,N,,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,Intermediate,,,,,50597,BAO_0000218,A,,4257,,1,1,CHEMBL626354
9305,N,,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,,1,1,CHEMBL626355
9306,N,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5932,,1,1,CHEMBL626356
9307,N,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,Intermediate,,,,,50597,BAO_0000218,A,,5932,,1,1,CHEMBL626357
9308,N,,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL626358
9309,N,,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL626359
9310,N,,,,Peak plasma concentration in rat at a dose of 3 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17771,Plasma,1,1,CHEMBL626360
9311,N,,,,Plasma concentration at 2 hr in rats was evaluated.,Intermediate,,,,,50597,BAO_0000218,A,,1628,,1,1,CHEMBL626361
9312,N,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,Intermediate,,,,,50597,BAO_0000218,A,,1628,,1,1,CHEMBL626362
9313,N,,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL626363
9314,N,,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL626970
9315,N,,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL626971
9316,N,,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL626972
9317,N,,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL626973
9318,N,,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL626974
9319,N,,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL874592
9320,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626975
9321,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626976
9322,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626977
9323,N,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626978
9324,N,,,,PK study was carried to determine the relative absorption ranking in rat.,Intermediate,,,,,50597,BAO_0000218,A,,16427,,1,1,CHEMBL626979
9325,N,,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4689,Plasma,1,1,CHEMBL626980
9326,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL626981
9327,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL626982
9328,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL626983
9329,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL622522
9330,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL622523
9331,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,11450,Blood,1,1,CHEMBL622524
9332,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL622525
9333,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL622526
9334,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL619849
9335,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL619850
9336,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL623864
9337,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,11450,Brain,1,1,CHEMBL623865
9338,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL623866
9339,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL623867
9340,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL877615
9341,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL623868
9342,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL623869
9343,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,11450,Heart,1,1,CHEMBL623870
9344,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL623871
9345,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16434,Lung,1,1,CHEMBL623872
9346,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622129
9347,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622130
9348,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622131
9349,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622132
9350,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622133
9351,N,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622134
9352,N,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622135
9353,N,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,16435,Lung,1,1,CHEMBL622136
9354,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL622137
9355,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL622138
9356,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623017
9357,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623018
9358,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623019
9359,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623020
9360,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623021
9361,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL623022
9362,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL623023
9363,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL623024
9364,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL623025
9365,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620545
9366,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620546
9367,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620547
9368,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620548
9369,N,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620549
9370,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL620550
9371,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL620551
9372,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16434,Muscle tissue,1,1,CHEMBL620552
9373,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620553
9374,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620554
9375,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL875845
9376,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620555
9377,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620556
9378,N,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,16435,Muscle tissue,1,1,CHEMBL620557
9379,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL620558
9380,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL620559
9381,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622939
9382,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622940
9383,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622941
9384,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622942
9385,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622943
9386,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622944
9387,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622945
9388,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622946
9389,N,,,,Compound was evaluated for terminal half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,,1,1,CHEMBL622947
9390,N,,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3634,Plasma,1,1,CHEMBL622948
9391,N,,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3634,Plasma,1,1,CHEMBL622949
9392,N,,,,Compound was tested for its half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,,1,1,CHEMBL622950
9393,U,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Intermediate,,,,1969.0,22224,BAO_0000218,A,,5005,Plasma,0,1,CHEMBL622951
9394,U,,,,Compound was tested for its plasma half life in Sprague Dawley rats,Intermediate,,,,1969.0,22224,BAO_0000366,A,,5005,Plasma,0,1,CHEMBL622952
9395,U,,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Intermediate,,,,1969.0,22224,BAO_0000366,A,,5005,Plasma,0,1,CHEMBL622953
9396,N,,,,Compound was tested for plasma half-life period in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1094,Plasma,1,1,CHEMBL873818
9397,N,,,,Elimination half life after i.v. administration of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,1,1,CHEMBL622954
9398,N,,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL622955
9399,N,,,,Elimination half-life after IV dosing at 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL875229
9400,N,,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL622956
9401,N,,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL622957
9402,N,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,,,955.0,50597,BAO_0000218,A,,5408,Brain,1,1,CHEMBL622958
9403,N,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,Plasma,1,1,CHEMBL622959
9404,N,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,,,955.0,50597,BAO_0000218,A,,5408,Brain,1,1,CHEMBL622960
9405,N,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5408,Plasma,1,1,CHEMBL622961
9406,N,,,,Evaluated for the half life in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,,1,1,CHEMBL622962
9407,N,,,,Hafl life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL622963
9408,N,,,,Hafl life rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL622964
9409,N,,,,Hafl life rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL622965
9410,N,,,,Hafl life rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL622966
9411,N,,,,Hafl life rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL622967
9412,N,,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17411,Kidney,1,1,CHEMBL622968
9413,N,,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17411,Liver,1,1,CHEMBL622969
9414,N,,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17411,Lung,1,1,CHEMBL875327
9415,N,,,,Half life in rat after 1 mg/kg i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL628638
9416,N,,,,Half life in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL628639
9417,N,,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL625840
9418,N,,,,Half life of 10 mg/kg oral dose determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4722,,1,1,CHEMBL625841
9419,N,,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL625842
9420,N,,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL625843
9421,N,,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL625844
9422,N,,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL873822
9423,N,,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL625845
9424,N,,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL627059
9425,N,,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL627060
9426,N,,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL627061
9427,N,,,,Half life of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,,1,1,CHEMBL627709
9428,N,,,,Half life of compound determined after intravenous administration to rat,Intermediate,,,,,50597,BAO_0000218,A,,5327,,1,1,CHEMBL627710
9429,N,,,,Half life of compound was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4847,,1,1,CHEMBL627711
9430,N,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,Plasma,1,1,CHEMBL627712
9431,N,,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL627713
9432,N,,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL627714
9433,U,,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Intermediate,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL627889
9434,U,,,,Half life determined in rat by intravenous administration,Intermediate,,,,,22224,BAO_0000218,A,,4256,,0,1,CHEMBL627890
9435,N,,,,Half life determined in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,4722,,1,1,CHEMBL627891
9436,N,,,,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6535,Plasma,1,1,CHEMBL627892
9437,N,,,,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6535,Plasma,1,1,CHEMBL627893
9438,N,,,,Half life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1435,Plasma,1,1,CHEMBL627894
9439,N,,,,Half life in rat plasma was determined; NA means not applicable,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1435,Plasma,1,1,CHEMBL627895
9440,N,,,,Half life in rat was tested,Intermediate,,,,,50597,BAO_0000218,A,,5206,,1,1,CHEMBL627896
9441,N,,,,Half life measured in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6080,Plasma,1,1,CHEMBL627897
9442,N,,,,Half life recorded in rats,Intermediate,,,,,50597,BAO_0000218,A,,4449,,1,1,CHEMBL627898
9443,N,,,,Half life was calculated,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL627899
9444,N,,,,Half life was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL873823
9445,N,,,,Half life was determined,Intermediate,,,,,50597,BAO_0000218,A,,3747,,1,1,CHEMBL627900
9446,N,,,,Half life after 10 mg/kg oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17858,,1,1,CHEMBL627901
9447,N,,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL627902
9448,N,,,,Half life after administering orally a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL627903
9449,N,,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,1,1,CHEMBL627904
9450,N,,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,Intermediate,,,,,50597,BAO_0000218,A,,4722,,1,1,CHEMBL627905
9451,N,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL627906
9452,N,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL627907
9453,N,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL876783
9454,N,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL627908
9455,N,,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,,,,50597,BAO_0000218,A,,17065,,1,1,CHEMBL627909
9456,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,Intermediate,,,,,50597,BAO_0000218,A,,1353,,1,1,CHEMBL627910
9457,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),Intermediate,,,,,50597,BAO_0000218,A,,1353,,1,1,CHEMBL627911
9458,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),Intermediate,,,,,50597,BAO_0000218,A,,1353,,1,1,CHEMBL627912
9459,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),Intermediate,,,,,50597,BAO_0000218,A,,1353,,1,1,CHEMBL627913
9460,N,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),Intermediate,,,,,50597,BAO_0000218,A,,1353,,1,1,CHEMBL627914
9461,N,,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL627915
9462,N,,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL627916
9463,N,,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,1,1,CHEMBL627917
9464,N,,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6056,,1,1,CHEMBL627918
9465,N,,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL627919
9466,N,,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL627920
9467,N,,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL627921
9468,N,,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL627922
9469,N,,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL876784
9470,N,,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL627923
9471,N,,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL626208
9472,N,,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL626209
9473,N,,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL626210
9474,N,,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2463,Plasma,1,1,CHEMBL627994
9475,N,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL627995
9476,N,,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,Intermediate,,,,,50597,BAO_0000218,A,,4075,,1,1,CHEMBL627996
9477,N,,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,Intermediate,,,,,50597,BAO_0000218,A,,5394,,1,1,CHEMBL627997
9478,N,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627998
9479,N,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL628640
9480,N,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL628641
9481,N,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL628642
9482,N,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL628643
9483,N,,,,Compound was tested for area under curve in rat,Intermediate,,,,,50597,BAO_0000218,A,,2591,,1,1,CHEMBL628644
9484,N,,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,Intermediate,,,,,50597,BAO_0000218,A,,6567,,1,1,CHEMBL628645
9485,N,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,1,1,CHEMBL628646
9486,N,,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,,1,1,CHEMBL628647
9487,N,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,,,,50597,BAO_0000218,A,,5408,,1,1,CHEMBL628648
9488,N,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,5408,,1,1,CHEMBL625358
9489,N,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,,,,50597,BAO_0000218,A,,5408,,1,1,CHEMBL625359
9490,N,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,5408,,1,1,CHEMBL625360
9491,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL625361
9492,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL625362
9493,N,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL625363
9494,N,,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,1,1,CHEMBL625364
9495,N,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625365
9496,N,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625366
9497,N,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625367
9498,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625368
9499,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625369
9500,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625370
9501,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625371
9502,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625372
9503,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,11450,Kidney,1,1,CHEMBL625373
9504,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL625374
9505,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL877593
9506,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL625375
9507,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL625376
9508,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL621973
9509,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,11450,Liver,1,1,CHEMBL621974
9510,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL621975
9511,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL622166
9512,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL622167
9513,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL622168
9514,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL622169
9515,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,11450,Lung,1,1,CHEMBL622170
9516,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622171
9517,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622172
9518,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622173
9519,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622174
9520,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622175
9521,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622176
9522,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622177
9523,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622178
9524,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622179
9525,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622180
9526,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622181
9527,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622182
9528,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622183
9529,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622184
9530,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622185
9531,N,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622186
9532,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622187
9533,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL625002
9534,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622090
9535,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622091
9536,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622092
9537,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622093
9538,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622094
9539,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622095
9540,N,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622264
9541,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL622265
9542,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL622266
9543,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL622267
9544,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL622268
9545,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL622269
9546,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL625071
9547,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL621621
9548,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL621622
9549,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621623
9550,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621624
9551,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621625
9552,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621626
9553,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621627
9554,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621628
9555,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL875328
9556,N,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621629
9557,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL621630
9558,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL621631
9559,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16434,Spleen,1,1,CHEMBL621632
9560,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621633
9561,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621634
9562,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621635
9563,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621636
9564,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621637
9565,N,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,16435,Spleen,1,1,CHEMBL621638
9566,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL618883
9567,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL618884
9568,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL628627
9569,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL628628
9570,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL628629
9571,N,,,,Half life after administering orally a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL628630
9572,N,,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL628631
9573,N,,,,Half life after administering intravenously a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL628632
9574,N,,,,Half life after oral dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,526,,1,1,CHEMBL628633
9575,N,,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL628634
9576,N,,,,Half life by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,1,1,CHEMBL627789
9577,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3371,,1,1,CHEMBL627790
9578,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL627791
9579,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,,1,1,CHEMBL627792
9580,N,,,,Half life in rat after intravenous administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,4353,,1,1,CHEMBL627793
9581,N,,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,Plasma,1,1,CHEMBL627794
9582,N,,,,Half life in rat after po administration of the compound,Intermediate,,,,,50597,BAO_0000218,A,,4353,,1,1,CHEMBL627795
9583,N,,,,Half life in rat after po administration of the compound; ND means Not determined,Intermediate,,,,,50597,BAO_0000218,A,,4353,,1,1,CHEMBL627796
9584,N,,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,Plasma,1,1,CHEMBL875335
9585,N,,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4353,Plasma,1,1,CHEMBL627797
9586,N,,,,Half life in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5789,,1,1,CHEMBL627798
9587,N,,,,Half life in rat i.v. at 2 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL627799
9588,N,,,,Half life in rats,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL627800
9589,N,,,,Half life in rats after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,484,,1,1,CHEMBL627801
9590,N,,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL627802
9591,N,,,,Half life in rat,Expert,,,,,50597,BAO_0000218,A,,6642,,1,1,CHEMBL627803
9592,N,,,,Half life was evaluated after intravenous administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL873820
9593,N,,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),Intermediate,,,,,50597,BAO_0000218,A,,1369,,1,1,CHEMBL627804
9594,N,,,,Half life was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL627805
9595,N,,,,Half life was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6049,,1,1,CHEMBL627806
9596,N,,,,Half life was evaluated in rat; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL627107
9597,N,,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL627108
9598,N,,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,Intermediate,,,,,50597,BAO_0000218,A,,11149,,1,1,CHEMBL627109
9599,N,,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,11149,Blood,1,1,CHEMBL627110
9600,U,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL627111
9601,U,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL627112
9602,U,,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL627113
9603,U,,,,Half life was measured in rat at dose of 30 mg/kg by po administration,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL627114
9604,N,,,,Half life (t1/2) was determined,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL627115
9605,N,,,,Half life period at a dose of 10 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL627116
9606,N,,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL627117
9607,N,,,,Half life period was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,,1,1,CHEMBL627118
9608,N,,,,Half life period after intravenous administration at 20 mpk in rats,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL627119
9609,N,,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL627120
9610,N,,,,Half life period after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6109,,1,1,CHEMBL626922
9611,N,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL626923
9612,N,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL626924
9613,N,,,,Half life period in 80% rat plasma at 37 degree Centigrade,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4755,Plasma,1,1,CHEMBL626925
9614,N,,,,Half life period in SD rats,Intermediate,,,,,50597,BAO_0000218,A,,5862,,1,1,CHEMBL626926
9615,N,,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626927
9616,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626928
9617,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626929
9618,N,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626930
9619,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL626931
9620,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6103,,1,1,CHEMBL626932
9621,N,,,,Half life period in rat,Intermediate,,,,,50597,BAO_0000218,A,,6317,,1,1,CHEMBL626933
9622,N,,,,Half life period in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL873826
9623,N,,,,Half life period in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL626934
9624,N,,,,Half life period in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL626935
9625,N,,,,Half life period in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL626936
9626,N,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL626937
9627,N,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6295,,1,1,CHEMBL625906
9628,N,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6296,,1,1,CHEMBL625907
9629,N,,,,PK study was carried to determine AUC (area under curve) value in rat,Intermediate,,,,,50597,BAO_0000218,A,,16427,,1,1,CHEMBL625908
9630,N,,,,Pharmacokinetic parameter AUC after intravenous administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL625909
9631,N,,,,Pharmacokinetic parameter AUC after oral administration to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL625910
9632,N,,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL625911
9633,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL625912
9634,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL626538
9635,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL876794
9636,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL626539
9637,N,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL626540
9638,N,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,,1,1,CHEMBL626541
9639,N,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5394,,1,1,CHEMBL626542
9640,N,,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL626543
9641,N,,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL626544
9642,N,,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL626545
9643,N,,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL626546
9644,N,,,,Pharmacokinetic parameter area under curve was reported,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL626547
9645,N,,,,Pharmacokinetic property (AUC) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4408,,1,1,CHEMBL626548
9646,N,,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL626549
9647,N,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,Intermediate,,,,,50597,BAO_0000218,A,,4397,,1,1,CHEMBL626550
9648,N,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,4397,,1,1,CHEMBL626551
9649,N,,,,Pharmacokinetic property was determined,Intermediate,,,,,50597,BAO_0000218,A,,5491,,1,1,CHEMBL623777
9650,N,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5491,,1,1,CHEMBL623778
9651,N,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5491,,1,1,CHEMBL623779
9652,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,Plasma,1,1,CHEMBL623780
9653,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,Plasma,1,1,CHEMBL622015
9654,N,,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4199,Plasma,1,1,CHEMBL622016
9655,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,1,1,CHEMBL622017
9656,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,1,1,CHEMBL622018
9657,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,1,1,CHEMBL622019
9658,N,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",Intermediate,,,,,50597,BAO_0000218,A,,5173,,1,1,CHEMBL622020
9659,N,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL622021
9660,N,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL622022
9661,N,,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5327,,1,1,CHEMBL622023
9662,N,,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6681,,1,1,CHEMBL622024
9663,N,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),Intermediate,,,,,50597,BAO_0000218,A,,12873,,1,1,CHEMBL622693
9664,N,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),Intermediate,,,,,50597,BAO_0000218,A,,12873,,1,1,CHEMBL622694
9665,N,,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622695
9666,N,,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622696
9667,N,,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL622697
9668,N,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50597,BAO_0000218,A,,6619,,1,1,CHEMBL622874
9669,N,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",Intermediate,,,,,50597,BAO_0000218,A,,6619,,1,1,CHEMBL622875
9670,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,,,,,50597,BAO_0000218,A,,10363,,1,1,CHEMBL622876
9671,N,,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,1,1,CHEMBL622877
9672,N,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL622878
9673,N,,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL622879
9674,N,,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,Intermediate,,,,,50597,BAO_0000218,A,,4839,,1,1,CHEMBL877602
9675,N,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622880
9676,N,,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622881
9677,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622882
9678,N,,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL622883
9679,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622884
9680,N,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Intermediate,,,,2046.0,50597,BAO_0000218,A,,11450,Thyroid gland,1,1,CHEMBL622885
9681,N,,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL622886
9682,N,,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL622887
9683,N,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8151,Urine,1,1,CHEMBL622888
9684,N,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,Blood,1,1,CHEMBL622889
9685,N,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,Blood,1,1,CHEMBL622890
9686,N,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,Blood,1,1,CHEMBL622891
9687,N,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,178.0,50597,BAO_0000218,A,,8677,Blood,1,1,CHEMBL877603
9688,N,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,Brain,1,1,CHEMBL622892
9689,N,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,Brain,1,1,CHEMBL622893
9690,N,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,Brain,1,1,CHEMBL622894
9691,N,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,Brain,1,1,CHEMBL622895
9692,N,,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,8677,Brain,1,1,CHEMBL622896
9693,N,,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,Heart,1,1,CHEMBL622897
9694,N,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,Heart,1,1,CHEMBL622898
9695,N,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,Heart,1,1,CHEMBL622899
9696,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,Kidney,1,1,CHEMBL622900
9697,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,Kidney,1,1,CHEMBL624114
9698,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,Kidney,1,1,CHEMBL624115
9699,N,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2113.0,50597,BAO_0000218,A,,8677,Kidney,1,1,CHEMBL624116
9700,N,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,Liver,1,1,CHEMBL624117
9701,N,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,Liver,1,1,CHEMBL624118
9702,N,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,Liver,1,1,CHEMBL624119
9703,N,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8677,Liver,1,1,CHEMBL624120
9704,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,Lung,1,1,CHEMBL624121
9705,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,Lung,1,1,CHEMBL624122
9706,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,Lung,1,1,CHEMBL624123
9707,N,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8677,Lung,1,1,CHEMBL624124
9708,N,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,Muscle tissue,1,1,CHEMBL624125
9709,N,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,Muscle tissue,1,1,CHEMBL624126
9710,N,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,Muscle tissue,1,1,CHEMBL624127
9711,N,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,Muscle tissue,1,1,CHEMBL624128
9712,N,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,Zone of skin,1,1,CHEMBL624129
9713,N,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,Zone of skin,1,1,CHEMBL624130
9714,N,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,Zone of skin,1,1,CHEMBL622340
9715,N,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,14.0,50597,BAO_0000218,A,,8677,Zone of skin,1,1,CHEMBL622341
9716,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,Intestine,1,1,CHEMBL622342
9717,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,Intestine,1,1,CHEMBL622343
9718,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,Intestine,1,1,CHEMBL622344
9719,N,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,160.0,50597,BAO_0000218,A,,8677,Intestine,1,1,CHEMBL622345
9720,N,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,Spleen,1,1,CHEMBL622346
9721,N,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,Spleen,1,1,CHEMBL622347
9722,N,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,Spleen,1,1,CHEMBL622348
9723,N,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8677,Spleen,1,1,CHEMBL622349
9724,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622350
9725,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622351
9726,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622352
9727,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622353
9728,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622354
9729,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622355
9730,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622356
9731,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622357
9732,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622358
9733,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL622359
9734,N,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL874393
9735,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622872
9736,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL622873
9737,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL623047
9738,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623048
9739,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623049
9740,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623050
9741,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623051
9742,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL623052
9743,N,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL626343
9744,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626344
9745,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626345
9746,N,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626346
9747,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626347
9748,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626348
9749,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16434,,1,1,CHEMBL626349
9750,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,F,,16435,,1,1,CHEMBL626350
9751,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL626351
9752,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL627650
9753,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,,,,50597,BAO_0000218,F,,16435,,1,1,CHEMBL627651
9754,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL627652
9755,N,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,16435,,1,1,CHEMBL627653
9756,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627654
9757,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627835
9758,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627836
9759,N,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627837
9760,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627838
9761,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL875338
9762,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627839
9763,N,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627840
9764,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627841
9765,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627842
9766,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627843
9767,N,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627844
9768,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL627845
9769,N,,,,Half life period in rat by iv administration at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL627846
9770,N,,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL627847
9771,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL873821
9772,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626079
9773,N,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1515,Plasma,1,1,CHEMBL626080
9774,N,,,,Half life period was evaluated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5491,Plasma,1,1,CHEMBL626081
9775,N,,,,Half life period was evaluated in rat plasma; Not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5491,Plasma,1,1,CHEMBL875344
9776,N,,,,Half life period was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,1918,,1,1,CHEMBL626082
9777,N,,,,"Half life period was evaluated in rats, iv",Intermediate,,,,,50597,BAO_0000218,A,,1918,,1,1,CHEMBL626250
9778,N,,,,Half life period after intravenous administration at 5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6113,,1,1,CHEMBL626251
9779,N,,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,,1,1,CHEMBL626252
9780,N,,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5553,,1,1,CHEMBL626253
9781,N,,,,Half life stability of compound was evaluated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4188,Plasma,1,1,CHEMBL626254
9782,N,,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,,1,1,CHEMBL626255
9783,N,,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6141,,1,1,CHEMBL626256
9784,N,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL626257
9785,N,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL626258
9786,N,,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL626259
9787,N,,,,Half in rat i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5789,,1,1,CHEMBL626260
9788,N,,,,Half period in rat after intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL875345
9789,N,,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17594,,1,1,CHEMBL626261
9790,N,,,,Half-life measured in in vitro Cathepsin B assay in rat liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12357,Liver,1,1,CHEMBL626262
9791,N,,,,Half-life of compound was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5210,,1,1,CHEMBL626263
9792,N,,,,Half-life at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL625270
9793,N,,,,Half-life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,,1,1,CHEMBL625271
9794,N,,,,Half-life determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,,1,1,CHEMBL625272
9795,N,,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,955.0,50597,BAO_0000218,A,,4910,Brain,1,1,CHEMBL625273
9796,N,,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Intermediate,,,,1969.0,50597,BAO_0000218,A,,3741,Plasma,1,1,CHEMBL625274
9797,N,,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL625275
9798,N,,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4910,Plasma,1,1,CHEMBL625276
9799,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17537,Plasma,1,1,CHEMBL625277
9800,N,,,,Half-life in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4965,Plasma,1,1,CHEMBL625278
9801,N,,,,Half-life in rat plasma; Not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17537,Plasma,1,1,CHEMBL625279
9802,N,,,,Half-life in rat serum,Intermediate,,,,1977.0,50597,BAO_0000218,A,,6124,Serum,1,1,CHEMBL625280
9803,N,,,,Half-life in rat serum; na is not available,Intermediate,,,,1977.0,50597,BAO_0000218,A,,6124,Serum,1,1,CHEMBL876797
9804,N,,,,Half-life was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL625281
9805,N,,,,Half-life was calculated in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17668,Plasma,1,1,CHEMBL873827
9806,N,,,,Half-life was determined,Intermediate,,,,,50597,BAO_0000218,A,,3185,,1,1,CHEMBL625282
9807,N,,,,Half-life was determined,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL625283
9808,N,,,,Half-life after administration of 20 mg/Kg oral dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,2959,,1,1,CHEMBL625284
9809,N,,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,,1,1,CHEMBL625285
9810,N,,,,Half-life after intravenous administration in female rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,,1,1,CHEMBL625286
9811,N,,,,Half-life after intravenous administration in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,,1,1,CHEMBL625287
9812,N,,,,Half-life after intravenous dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,6180,,1,1,CHEMBL625288
9813,N,,,,Half-life in a rat liver homogenate preparation,Intermediate,,,,2107.0,50597,BAO_0000218,A,,1557,Liver,1,1,CHEMBL625289
9814,N,,,,Half-life in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL625290
9815,N,,,,Half-life in plasma of rat at dose of 3-10 mgkg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL876798
9816,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5064,,1,1,CHEMBL625291
9817,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,,1,1,CHEMBL625292
9818,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5147,,1,1,CHEMBL625293
9819,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,,1,1,CHEMBL622832
9820,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,,1,1,CHEMBL622833
9821,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,1,1,CHEMBL622834
9822,N,,,,Half-life in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL622835
9823,N,,,,Half-life in rat after po administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17538,,1,1,CHEMBL622836
9824,N,,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50597,BAO_0000218,A,,17538,,1,1,CHEMBL622837
9825,N,,,,Half-life in rat at 3 mg/kg dose administered intravenously,Intermediate,,,,,50597,BAO_0000218,A,,10,,1,1,CHEMBL622838
9826,N,,,,Half-life in rat brain homogenate,Intermediate,,,,955.0,50597,BAO_0000218,A,,17669,Brain,1,1,CHEMBL622839
9827,N,,,,Half-life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17065,Plasma,1,1,CHEMBL622840
9828,N,,,,Half-life in rats,Intermediate,,,,,50597,BAO_0000218,A,,4333,,1,1,CHEMBL622841
9829,N,,,,Half-life in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,,1,1,CHEMBL622842
9830,N,,,,Half-life in vitro in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,889,Plasma,1,1,CHEMBL622843
9831,N,,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,889,Plasma,1,1,CHEMBL622844
9832,N,,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",Intermediate,,,,,50597,BAO_0000218,A,,3747,,1,1,CHEMBL622845
9833,N,,,,The area under the curve of compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL622846
9834,N,,,,The area under the curve of compound was measured at the dose of 300 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL622847
9835,N,,,,The area under the curve of compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL622848
9836,N,,,,Bioavailability as oral AUC in rats,Intermediate,,,,,50597,BAO_0000218,A,,3360,,1,1,CHEMBL622849
9837,N,,,,The plasma concentration versus time curve (AUC) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL622850
9838,N,,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL876807
9839,N,,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL622851
9840,N,,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL622852
9841,N,,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL622853
9842,N,,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL622854
9843,N,,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17411,,1,1,CHEMBL622855
9844,N,,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,Plasma,1,1,CHEMBL622856
9845,N,,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14941,Plasma,1,1,CHEMBL622857
9846,N,,,,AUC in rat after po administration at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17538,Plasma,1,1,CHEMBL622858
9847,N,,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,Plasma,1,1,CHEMBL622859
9848,N,,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL622860
9849,N,,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL622861
9850,N,,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL622862
9851,N,,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL622863
9852,N,,,,Area under curve value 6 hr after po administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL623817
9853,N,,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL623818
9854,N,,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL623819
9855,N,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL623820
9856,N,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL623821
9857,N,,,,AUC normalized for dose (AUCN) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6642,Plasma,1,1,CHEMBL623822
9858,N,,,,Area under curve in rat after p.o. administration,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL623823
9859,N,,,,Area under curve in rat after p.o. administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL623824
9860,N,,,,Area under curve in rat after p.o. administration; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL623825
9861,N,,,,Area under curve in rat after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL622070
9862,N,,,,Area under curve (carotid artery) value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3603,,1,1,CHEMBL622071
9863,N,,,,Bioavailability expressed as the area under curve of rat carotid artery,Intermediate,,,,,50597,BAO_0000218,A,,3550,,1,1,CHEMBL622072
9864,N,,,,Area under curve in male SD rats was observed after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL622073
9865,N,,,,Area under curve of the compound was determined,Intermediate,,,,,50597,BAO_0000218,A,,17720,,1,1,CHEMBL622074
9866,N,,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,Intermediate,,,,,50597,BAO_0000218,A,,5407,,1,1,CHEMBL622075
9867,N,,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,Plasma,1,1,CHEMBL622076
9868,N,,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,Plasma,1,1,CHEMBL622077
9869,N,,,,Area under curve (portal vein) value of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3603,,1,1,CHEMBL622078
9870,N,,,,Bioavailability expressed as the area under curve of rat portal vein,Intermediate,,,,,50597,BAO_0000218,A,,3550,,1,1,CHEMBL622079
9871,N,,,,Area Under plasma concentration time curve in rat upon peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17655,Plasma,1,1,CHEMBL622080
9872,N,,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL877612
9873,N,,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL622081
9874,N,,,,Compound was evaluated for oral bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622082
9875,N,,,,Compound was evaluated for oral bioavailability in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622083
9876,N,,,,Compound was evaluated for oral bioavailability in rats; 30-80,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622084
9877,N,,,,Compound was evaluated for oral bioavailability in rats; 50-60,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622085
9878,N,,,,Compound was evaluated for oral bioavailability in rats; no data,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622086
9879,N,,,,Compound was evaluated for oral bioavailability in rats; peptide,Intermediate,,,,,50597,BAO_0000218,A,,17791,,1,1,CHEMBL622087
9880,N,,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL622088
9881,N,,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL622089
9882,N,,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL623685
9883,N,,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL623686
9884,N,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,Stomach,1,1,CHEMBL623687
9885,N,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,Stomach,1,1,CHEMBL623688
9886,N,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,Stomach,1,1,CHEMBL623689
9887,N,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,945.0,50597,BAO_0000218,A,,8677,Stomach,1,1,CHEMBL622485
9888,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,Thyroid gland,1,1,CHEMBL622486
9889,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,Thyroid gland,1,1,CHEMBL877613
9890,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,Thyroid gland,1,1,CHEMBL622487
9891,N,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8677,Thyroid gland,1,1,CHEMBL622488
9892,N,,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,,,948.0,50597,BAO_0000218,A,,8677,Heart,1,1,CHEMBL622489
9893,N,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,Urine,1,1,CHEMBL622490
9894,N,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,Urine,1,1,CHEMBL622491
9895,N,,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6899,Liver,1,1,CHEMBL622492
9896,N,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,Urine,1,1,CHEMBL622493
9897,N,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,Urine,1,1,CHEMBL622494
9898,N,,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8677,Muscle tissue,1,1,CHEMBL622495
9899,N,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,Intermediate,,,,,50597,BAO_0000218,A,,6899,,1,1,CHEMBL622496
9900,N,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,6899,Urine,1,1,CHEMBL622497
9901,N,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,Intermediate,,,,,50597,BAO_0000218,A,,2189,,1,1,CHEMBL622498
9902,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Intermediate,,,,1088.0,50597,BAO_0000218,A,,2189,Urine,1,1,CHEMBL624918
9903,N,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,,1088.0,50597,BAO_0000218,A,,2189,Urine,1,1,CHEMBL624919
9904,N,,,,Biodistribution of compound in rat blood after 5 min of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,10839,Blood,1,1,CHEMBL624920
9905,N,,,,Biodistribution of compound in rat blood after 5 min of administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,10839,Blood,1,1,CHEMBL624921
9906,N,,,,Biodistribution of compound in rat brain after 5 min of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,10839,Brain,1,1,CHEMBL624922
9907,N,,,,Biodistribution of compound in rat heart after 5 min of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,10839,Heart,1,1,CHEMBL624923
9908,N,,,,Biodistribution of compound in rat heart after 5 min of administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,10839,Heart,1,1,CHEMBL624924
9909,N,,,,Biodistribution of compound in rat kidney after 5 min of administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10839,Kidney,1,1,CHEMBL624925
9910,N,,,,Biodistribution of compound in rat kidney after 5 min of administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10839,Kidney,1,1,CHEMBL624926
9911,N,,,,Biodistribution of compound in rat liver after 5 min of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10839,Liver,1,1,CHEMBL624927
9912,N,,,,Biodistribution of compound in rat liver after 5 min of administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10839,Liver,1,1,CHEMBL874402
9913,N,,,,Biodistribution of compound in rat lung after 5 min of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10839,Lung,1,1,CHEMBL624928
9914,N,,,,Biodistribution of compound in rat lung after 5 min of administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10839,Lung,1,1,CHEMBL624929
9915,N,,,,Biodistribution of compound in rat muscle after 5 min of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10839,Muscle tissue,1,1,CHEMBL624930
9916,N,,,,Biodistribution of compound in rat muscle after 5 min of administration.,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10839,Muscle tissue,1,1,CHEMBL624931
9917,N,,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,948.0,50597,BAO_0000218,A,,4043,Heart,1,1,CHEMBL624932
9918,N,,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,948.0,50597,BAO_0000218,A,,4043,Heart,1,1,CHEMBL624933
9919,N,,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4043,Liver,1,1,CHEMBL624934
9920,N,,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2107.0,50597,BAO_0000218,A,,4043,Liver,1,1,CHEMBL624935
9921,N,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,1,1,CHEMBL624936
9922,N,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,1,1,CHEMBL624937
9923,N,,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2106.0,50597,BAO_0000218,A,,4043,Spleen,1,1,CHEMBL624938
9924,N,,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,2106.0,50597,BAO_0000218,A,,4043,Spleen,1,1,CHEMBL624939
9925,N,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,1,1,CHEMBL624940
9926,N,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,,,,50597,BAO_0000218,A,,4043,,1,1,CHEMBL874403
9927,N,,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,Intermediate,,,,,50597,BAO_0000218,A,,1446,,1,1,CHEMBL624941
9928,N,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Intermediate,,,,1088.0,50597,BAO_0000218,A,,9971,Urine,1,1,CHEMBL624942
9929,N,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Intermediate,,,,1088.0,50597,BAO_0000218,A,,9971,Urine,1,1,CHEMBL624943
9930,N,,,,% Bioavailability after 1 day of the drug administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5765,,1,1,CHEMBL624944
9931,N,,,,% Bioavailability after 4 day of the drug administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5765,,1,1,CHEMBL624945
9932,N,,,,Absolute bioavailability was evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,4257,,1,1,CHEMBL624946
9933,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624947
9934,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624948
9935,N,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624949
9936,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,Kidney,1,1,CHEMBL622025
9937,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,Kidney,1,1,CHEMBL622026
9938,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,Kidney,1,1,CHEMBL622027
9939,N,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13091,Kidney,1,1,CHEMBL622028
9940,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,Liver,1,1,CHEMBL622029
9941,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,Liver,1,1,CHEMBL622208
9942,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,Liver,1,1,CHEMBL622209
9943,N,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13091,Liver,1,1,CHEMBL622210
9944,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL622211
9945,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL622212
9946,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL622213
9947,N,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL874404
9948,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL620452
9949,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL620453
9950,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL620454
9951,N,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL624067
9952,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624068
9953,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,Female gonad,1,1,CHEMBL624069
9954,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,Female gonad,1,1,CHEMBL624070
9955,N,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Intermediate,,,,992.0,50597,BAO_0000218,A,,13091,Female gonad,1,1,CHEMBL624071
9956,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,Uterus,1,1,CHEMBL624072
9957,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,Uterus,1,1,CHEMBL624073
9958,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,Uterus,1,1,CHEMBL624788
9959,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Intermediate,,,,995.0,50597,BAO_0000218,A,,13091,Uterus,1,1,CHEMBL624789
9960,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624790
9961,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624791
9962,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624792
9963,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,Intermediate,,,,,50597,BAO_0000218,A,,13091,,1,1,CHEMBL624793
9964,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL877491
9965,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL624957
9966,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL624958
9967,N,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13091,Muscle tissue,1,1,CHEMBL624959
9968,N,,,,Dissociation constant was determined,Intermediate,,,,,50597,BAO_0000218,A,,11977,,1,1,CHEMBL624960
9969,N,,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL624961
9970,N,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL624962
9971,N,,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL624963
9972,N,,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,Intermediate,,,,,50597,BAO_0000218,A,,4755,,1,1,CHEMBL624964
9973,N,,,,LogP value was evaluated in the in situ rat gut perfusion assay,Intermediate,,,,,50597,BAO_0000218,A,,589,,1,1,CHEMBL624965
9974,N,,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL624966
9975,N,,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,5031,,1,1,CHEMBL624967
9976,N,,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL624968
9977,N,,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,17720,,1,1,CHEMBL624969
9978,N,,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,1,1,CHEMBL624970
9979,N,,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL624971
9980,N,,,,Half-life was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL624972
9981,N,,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,,1,1,CHEMBL624973
9982,N,,,,Half-life was evaluated in plasma of rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2938,Plasma,1,1,CHEMBL624974
9983,N,,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL624975
9984,N,,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL877492
9985,N,,,,Half-life was measured in rat after an iv dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6062,,1,1,CHEMBL624976
9986,N,,,,Half-life period of compound in rats after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL624977
9987,N,,,,Half-life period of compound was measured in rat plasma.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,Plasma,1,1,CHEMBL626848
9988,N,,,,Half-life period of compound was measured in rat plasma; ND is not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,Plasma,1,1,CHEMBL626849
9989,N,,,,Half-life period of compound was measured in rat plasma; not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3136,Plasma,1,1,CHEMBL626850
9990,N,,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,,1,1,CHEMBL626851
9991,N,,,,Half-life period in rat by iv administration,Intermediate,,,,,50597,BAO_0000218,A,,5871,,1,1,CHEMBL626852
9992,N,,,,Half-life period in rats following intravenous administration at 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6077,,1,1,CHEMBL626853
9993,N,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,,1,1,CHEMBL626854
9994,N,,,,Half-life period was determined for the compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,5144,,1,1,CHEMBL627486
9995,N,,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,,,,50597,BAO_0000218,A,,4498,,1,1,CHEMBL627487
9996,N,,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,,,,50597,BAO_0000218,A,,4498,,1,1,CHEMBL627488
9997,N,,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,,,,50597,BAO_0000218,A,,1908,,1,1,CHEMBL627489
9998,N,,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6211,,1,1,CHEMBL627490
9999,N,,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,,1,1,CHEMBL873829
10000,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL627655
10001,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL625994
10002,N,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,,,,50597,BAO_0000218,A,,6444,,1,1,CHEMBL625995
10003,N,,,,Half-life in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,,1,1,CHEMBL625996
10004,N,,,,In vitro half life in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,530,Plasma,1,1,CHEMBL625850
10005,N,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Intermediate,,,,1969.0,50597,BAO_0000218,A,,1116,Plasma,1,1,CHEMBL625851
10006,N,,,,In vitro half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,3219,,1,1,CHEMBL625852
10007,N,,,,In vivo half life period after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,6109,,1,1,CHEMBL625853
10008,N,,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL625854
10009,N,,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL874450
10010,N,,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625855
10011,N,,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625856
10012,N,,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL625857
10013,N,,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL873831
10014,N,,,,Longer half-life in rat (i.v.) at 0.5 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL625858
10015,N,,,,Longer half-life in rat (p.o.) at 2.0 mpk,Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL625859
10016,N,,,,Pharmacokinetic property (half life) in rat,Intermediate,,,,,50597,BAO_0000218,A,,3457,,1,1,CHEMBL625860
10017,N,,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL625861
10018,N,,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL625862
10019,N,,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL625863
10020,N,,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL625864
10021,N,,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5739,,1,1,CHEMBL625865
10022,N,,,,Pharmacokinetic half time was determined intravenously in rats.,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL625866
10023,N,,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6567,Plasma,1,1,CHEMBL625867
10024,N,,,,Plasma half life of hydrolysis of the compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2448,Plasma,1,1,CHEMBL625868
10025,N,,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5423,Plasma,1,1,CHEMBL625869
10026,N,,,,Plasma half life period was calculated in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4853,Plasma,1,1,CHEMBL874451
10027,N,,,,Plasma half-life in Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4514,Plasma,1,1,CHEMBL625870
10028,N,,,,Plasma half-life in Sprague-Dawley rats; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4514,Plasma,1,1,CHEMBL625871
10029,N,,,,Plasma half-life in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1500,Plasma,1,1,CHEMBL625872
10030,N,,,,Plasma half-life in rats; <MQL,Intermediate,,,,1969.0,50597,BAO_0000218,A,,1500,Plasma,1,1,CHEMBL625873
10031,N,,,,Plasma half-life period (0-8 h) was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL625874
10032,N,,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL625875
10033,N,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL625876
10034,N,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5334,Plasma,1,1,CHEMBL631258
10035,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4956,Plasma,1,1,CHEMBL631259
10036,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4956,Plasma,1,1,CHEMBL631260
10037,N,,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL631261
10038,N,,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL631262
10039,N,,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Intermediate,,,,178.0,50597,BAO_0000218,A,,7768,Blood,1,1,CHEMBL631263
10040,N,,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631264
10041,N,,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631265
10042,N,,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631266
10043,N,,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631267
10044,N,,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631268
10045,N,,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631269
10046,N,,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",Intermediate,,,,,50597,BAO_0000218,A,,7768,,1,1,CHEMBL631270
10047,N,,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL631271
10048,N,,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL631272
10049,N,,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL631273
10050,N,,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL631274
10051,N,,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL631275
10052,N,,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL626984
10053,N,,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Intermediate,,,,948.0,50597,BAO_0000218,A,,7768,Heart,1,1,CHEMBL626985
10054,N,,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626986
10055,N,,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626987
10056,N,,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626988
10057,N,,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626989
10058,N,,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626990
10059,N,,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626991
10060,N,,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Intermediate,,,,2107.0,50597,BAO_0000218,A,,7768,Liver,1,1,CHEMBL626992
10061,N,,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626993
10062,N,,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL874593
10063,N,,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626994
10064,N,,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626995
10065,N,,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626190
10066,N,,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626191
10067,N,,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Intermediate,,,,2048.0,50597,BAO_0000218,A,,7768,Lung,1,1,CHEMBL626364
10068,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626365
10069,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626366
10070,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626367
10071,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626368
10072,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626369
10073,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626370
10074,N,,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,,,,50597,BAO_0000218,A,,4498,,1,1,CHEMBL626371
10075,N,,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,,,,50597,BAO_0000218,A,,4498,,1,1,CHEMBL626372
10076,N,,,,Bioavailability after a dose of 10 mg/kg p.o.,Intermediate,,,,,50597,BAO_0000218,A,,3603,,1,1,CHEMBL626373
10077,N,,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,6215,,1,1,CHEMBL626374
10078,N,,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL626375
10079,N,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5710,,1,1,CHEMBL626376
10080,N,,,,Bioavailability in rat po was determined,Intermediate,,,,,50597,BAO_0000218,A,,5676,,1,1,CHEMBL626377
10081,N,,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,Intermediate,,,,,50597,BAO_0000218,A,,17667,,1,1,CHEMBL626378
10082,N,,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,17667,,1,1,CHEMBL626379
10083,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6848,,1,1,CHEMBL626380
10084,N,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6848,,1,1,CHEMBL626381
10085,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17267,,1,1,CHEMBL626382
10086,N,,,,Bioavailability in rat (Sprague-Dawley) (female),Intermediate,,,,,50597,BAO_0000218,A,,6362,,1,1,CHEMBL626383
10087,N,,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL874652
10088,N,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,17671,,1,1,CHEMBL626384
10089,N,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,4333,,1,1,CHEMBL626385
10090,N,,,,Bioavailability in rat at an oral dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6077,,1,1,CHEMBL626386
10091,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3278,,1,1,CHEMBL626387
10092,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5964,,1,1,CHEMBL626388
10093,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4884,,1,1,CHEMBL626389
10094,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4905,,1,1,CHEMBL626390
10095,N,,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,Intermediate,,,,,50597,BAO_0000218,A,,4884,,1,1,CHEMBL626391
10096,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6850,,1,1,CHEMBL626392
10097,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2864,,1,1,CHEMBL626393
10098,N,,,,Bioavailability was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,5780,,1,1,CHEMBL623026
10099,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,1465,,1,1,CHEMBL623027
10100,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5199,,1,1,CHEMBL623028
10101,N,,,,Bioavailability in rat after 1 day dosing,Intermediate,,,,,50597,BAO_0000218,A,,5765,,1,1,CHEMBL623029
10102,N,,,,Bioavailability in rat after 4 day dosing,Intermediate,,,,,50597,BAO_0000218,A,,5765,,1,1,CHEMBL623030
10103,N,,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623031
10104,N,,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623032
10105,N,,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623033
10106,N,,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,6518,,1,1,CHEMBL623034
10107,N,,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,,,,50597,BAO_0000218,A,,2083,,1,1,CHEMBL623035
10108,N,,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,17260,,1,1,CHEMBL623036
10109,N,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4956,,1,1,CHEMBL623037
10110,N,,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4368,,1,1,CHEMBL623038
10111,N,,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17752,Plasma,1,1,CHEMBL874385
10112,N,,,,Bioavailability in rat (Fisher) (fasted),Intermediate,,,,,50597,BAO_0000218,A,,1446,,1,1,CHEMBL623039
10113,U,,,,Bioavailability in monkey after po administration of 10 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL623040
10114,U,,,,Oral bioavailability in monkey (dose 10 mg/kg),Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL623041
10115,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6672,,1,1,CHEMBL623741
10116,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6673,,1,1,CHEMBL623742
10117,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,1,1,CHEMBL623743
10118,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL623744
10119,N,,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17853,,1,1,CHEMBL623745
10120,N,,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4521,,1,1,CHEMBL623746
10121,N,,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4940,,1,1,CHEMBL623747
10122,U,,,,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL623748
10123,U,,,,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,,,,22224,BAO_0000218,A,,2891,,0,1,CHEMBL623916
10124,N,,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,4521,,1,1,CHEMBL623917
10125,N,,,,Bioavailability in rat (dose 2 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17686,,1,1,CHEMBL623918
10126,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL874386
10127,N,,,,Bioavailability in rat; Only traces detected in rat plasma,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17796,Plasma,1,1,CHEMBL623919
10128,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5064,,1,1,CHEMBL623920
10129,N,,,,Bioavailability upon oral administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,5147,,1,1,CHEMBL623148
10130,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,1916,,1,1,CHEMBL623149
10131,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6049,,1,1,CHEMBL623150
10132,N,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",Intermediate,,,,,50597,BAO_0000218,A,,1445,,1,1,CHEMBL623151
10133,N,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",Intermediate,,,,,50597,BAO_0000218,A,,1445,,1,1,CHEMBL623152
10134,N,,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,1,1,CHEMBL623153
10135,N,,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,Expert,,,,,50597,BAO_0000218,F,,2862,,1,1,CHEMBL623154
10136,N,,,,In vitro and metabolic stability was determined,Intermediate,,,,,50597,BAO_0000218,A,,4194,,1,1,CHEMBL623155
10137,N,,,,In vitro metabolic stability in rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,4194,,1,1,CHEMBL623156
10138,N,,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,Intermediate,,,,,50597,BAO_0000218,A,,5486,,1,1,CHEMBL623157
10139,N,,401.0,,Metabolic rate for compound was observed in rat hepatocytes,Intermediate,,Hepatocyte,,2107.0,50597,BAO_0000218,A,,17582,Liver,1,1,CHEMBL623158
10140,N,,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,Intermediate,,,,,50597,BAO_0000218,A,,5600,,1,1,CHEMBL623159
10141,N,,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,,,,50597,BAO_0000218,A,,14294,,1,1,CHEMBL874390
10142,N,,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,,,50597,BAO_0000218,A,,14294,,1,1,CHEMBL623160
10143,N,,,,Metabolism of compound in rat S9 microsomes; Trace,Intermediate,,,,,50597,BAO_0000218,A,,14294,,1,1,CHEMBL623161
10144,N,,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,17847,,1,1,CHEMBL623162
10145,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623163
10146,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623164
10147,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623165
10148,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623166
10149,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624983
10150,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624984
10151,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624985
10152,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622970
10153,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622971
10154,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622972
10155,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622973
10156,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622974
10157,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622975
10158,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622976
10159,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622977
10160,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624351
10161,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624352
10162,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL624353
10163,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622397
10164,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622398
10165,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622399
10166,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL622400
10167,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628428
10168,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628590
10169,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628591
10170,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628592
10171,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628593
10172,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL875333
10173,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628594
10174,N,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4969,Plasma,1,1,CHEMBL628595
10175,N,,,,Stability in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6737,Plasma,1,1,CHEMBL628596
10176,N,,,,Stability in rat plasma was determined; ND= no data,Intermediate,,,,1969.0,50597,BAO_0000218,A,,6737,Plasma,1,1,CHEMBL628597
10177,N,,,,Tested for plasma half life period in rat (0-8 hr),Intermediate,,,,1969.0,50597,BAO_0000218,A,,5089,Plasma,1,1,CHEMBL628598
10178,N,,,,Tested for plasma half life period in rat (0-8 hr); Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5089,Plasma,1,1,CHEMBL628599
10179,N,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL628600
10180,N,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL628601
10181,N,,,,Tested for the half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,4950,,1,1,CHEMBL628602
10182,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,Intermediate,,,,,50597,BAO_0000218,A,,2412,,1,1,CHEMBL628603
10183,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,2412,,1,1,CHEMBL628604
10184,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,Intermediate,,,,,50597,BAO_0000218,A,,2412,,1,1,CHEMBL628605
10185,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,Intermediate,,,,,50597,BAO_0000218,A,,2412,,1,1,CHEMBL628606
10186,N,,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,Intermediate,,,,,50597,BAO_0000218,A,,2412,,1,1,CHEMBL628607
10187,N,,,,The biological half life the compound was measured at the dose of 100 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL628608
10188,N,,,,The biological half life the compound was measured at the dose of 30 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,15022,,1,1,CHEMBL628609
10189,N,,,,The compound was evaluated for plasma half life period in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,406,Plasma,1,1,CHEMBL628610
10190,N,,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL873819
10191,N,,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL628611
10192,N,,,,The pharmacokinetic parameter half-life period in vivo in rats,Intermediate,,,,,50597,BAO_0000218,A,,5247,,1,1,CHEMBL628612
10193,N,,,,"The pharmacokinetic property, Half-life was determined",Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL628613
10194,N,,,,"The pharmacokinetic property, Half-life in rat in vivo",Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL628614
10195,N,,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL628615
10196,N,,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL628616
10197,N,,,,The plasma half life period in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,3918,Plasma,1,1,CHEMBL627924
10198,N,,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,2906,Liver,1,1,CHEMBL627925
10199,N,,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,,,,50597,BAO_0000218,A,,6467,,1,1,CHEMBL627926
10200,N,,,,t1/2 (apparent elimination)of the compound was determined,Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL627927
10201,N,,,,t1/2 value in rat,Intermediate,,,,,50597,BAO_0000218,A,,3788,,1,1,CHEMBL627928
10202,N,,,,Half life in rat,Intermediate,,,,,50597,BAO_0000218,A,,17796,,1,1,CHEMBL627539
10203,N,,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,,,1969.0,50597,BAO_0000218,A,,12873,Plasma,1,1,CHEMBL876790
10204,N,,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL858186
10205,N,,,,Half-life period in fasted rats,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL627540
10206,N,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627541
10207,N,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627715
10208,N,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,429,,1,1,CHEMBL627716
10209,N,,,,Maximum time required to achieve Cmax was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17655,,1,1,CHEMBL627717
10210,N,,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL627718
10211,N,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL627719
10212,N,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL627720
10213,N,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL627721
10214,N,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL627722
10215,N,,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL627723
10216,N,,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL626058
10217,N,,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL626059
10218,N,,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL626060
10219,N,,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,Plasma,1,1,CHEMBL626061
10220,N,,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL876791
10221,N,,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,,,,50597,BAO_0000218,A,,4723,,1,1,CHEMBL626062
10222,N,,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL626063
10223,N,,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL626064
10224,N,,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,Plasma,1,1,CHEMBL626065
10225,N,,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17720,Plasma,1,1,CHEMBL626066
10226,N,,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL626067
10227,N,,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626068
10228,N,,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626069
10229,N,,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626070
10230,N,,,,Percent total excretion of N-methoxyacetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626071
10231,N,,,,Percent total excretion of N-methoxyacetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626072
10232,N,,,,Percent total excretion of acetaminophen,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626073
10233,N,,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Intermediate,,,,2046.0,50597,BAO_0000218,A,,7768,Thyroid gland,1,1,CHEMBL626741
10234,N,,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",Intermediate,,,,,50597,BAO_0000218,A,,17655,,1,1,CHEMBL626742
10235,N,,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,Intermediate,,,,,50597,BAO_0000218,A,,17735,,1,1,CHEMBL626743
10236,N,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL876792
10237,N,,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,,,,50597,BAO_0000218,A,,17735,,1,1,CHEMBL626744
10238,N,,,,Compound was tested for antidiuretic activity in rats,Intermediate,,,,,50597,BAO_0000218,A,,7116,,1,1,CHEMBL626745
10239,N,,,,AUC in rat after 3mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,4878,Plasma,1,1,CHEMBL626746
10240,N,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL626747
10241,N,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL626748
10242,N,,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,Intermediate,,,,,50597,BAO_0000218,A,,16367,,1,1,CHEMBL626749
10243,N,,,,Oral Bioavailability was determined,Intermediate,,,,,50597,BAO_0000218,A,,16366,,1,1,CHEMBL626750
10244,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL626751
10245,N,,,,Oral bioavailability in rat; Not performed.,Intermediate,,,,,50597,BAO_0000218,A,,4426,,1,1,CHEMBL626913
10246,N,,,,Bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL626914
10247,N,,,,Bioavailability was determined; ND denotes no data,Intermediate,,,,,50597,BAO_0000218,A,,5041,,1,1,CHEMBL626915
10248,N,,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,1,1,CHEMBL626916
10249,N,,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,1500,,1,1,CHEMBL626917
10250,N,,,,Binding towards rat plasma protein at 10 uM,Intermediate,,,,,50597,BAO_0000218,A,,17409,,1,1,CHEMBL626918
10251,N,,,,Binding towards rat plasma protein at 100 uM,Intermediate,,,,,50597,BAO_0000218,A,,17409,,1,1,CHEMBL626919
10252,N,,,,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,2959,,1,1,CHEMBL626920
10253,N,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13501,,1,1,CHEMBL621976
10254,N,,,,Bioavailability in rat after 5 mg/kg oral gavage,Intermediate,,,,,50597,BAO_0000218,A,,6567,,1,1,CHEMBL877599
10255,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6571,,1,1,CHEMBL621977
10256,N,,,,Bioavailability in rat (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,6715,,1,1,CHEMBL621978
10257,N,,,,Bioavailability in rat (dose 3 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6715,,1,1,CHEMBL621979
10258,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2932,,1,1,CHEMBL621980
10259,N,,,,Bioavailability of the compound in rats after administration of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4171,,1,1,CHEMBL621981
10260,N,,,,Bioavailability after administration of 10 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL621982
10261,N,,,,Bioavailability after administration of 2 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,17509,,1,1,CHEMBL882953
10262,N,,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,4527,,1,1,CHEMBL621983
10263,N,,,,Bioavailability in dogs was determined; high,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL621984
10264,N,,,,Bioavailability in monkey after intravenous administration at 1 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,,1,1,CHEMBL621985
10265,N,,,,Bioavailability in monkey after peroral administration at 10 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,,1,1,CHEMBL621986
10266,N,,,,Bioavailability in rat after intravenous administration at 1 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,,1,1,CHEMBL621987
10267,N,,,,Bioavailability in rat after intravenous administration at 2 mpk,Intermediate,,,,,50597,BAO_0000218,F,,6659,,1,1,CHEMBL877600
10268,N,,,,Bioavailability in rat after peroral administration at 30 mpk,Intermediate,,,,,50597,BAO_0000218,A,,6659,,1,1,CHEMBL621988
10269,N,,,,Bioavailability in rat after peroral administration at at 100 mpk,Intermediate,,,,,50597,BAO_0000218,F,,6659,,1,1,CHEMBL621989
10270,N,,,,Bioavailability in rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,6597,,1,1,CHEMBL621990
10271,N,,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,,1,1,CHEMBL621991
10272,N,,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,,1,1,CHEMBL621992
10273,N,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,,1,1,CHEMBL621993
10274,N,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,1202,,1,1,CHEMBL621994
10275,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5207,,1,1,CHEMBL621995
10276,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5970,,1,1,CHEMBL621996
10277,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,17538,,1,1,CHEMBL621997
10278,N,,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,,,50597,BAO_0000218,A,,17538,,1,1,CHEMBL621998
10279,N,,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,1466,,1,1,CHEMBL621999
10280,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,2879,,1,1,CHEMBL622000
10281,N,,,,Bioavailability was measured in rat after oral administration; 2-4,Intermediate,,,,,50597,BAO_0000218,A,,2879,,1,1,CHEMBL622001
10282,N,,,,Bioavailability was measured in rat after oral administration; 3-7,Intermediate,,,,,50597,BAO_0000218,A,,2879,,1,1,CHEMBL622002
10283,N,,,,Bioavailability in rat (intraduodenal administration),Intermediate,,,,,50597,BAO_0000218,A,,3777,,1,1,CHEMBL622003
10284,N,,,,Bioavailability in rat (intraduodenal administration),Intermediate,,,,,50597,BAO_0000218,A,,3777,,1,1,CHEMBL877601
10285,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3777,,1,1,CHEMBL624871
10286,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3777,,1,1,CHEMBL622004
10287,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5423,,1,1,CHEMBL882954
10288,N,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622005
10289,N,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,Intermediate,,,,,50597,BAO_0000218,A,,16365,,1,1,CHEMBL622006
10290,N,,,,Bioavailability was measured in rat,Intermediate,,,,,50597,BAO_0000218,A,,4239,,1,1,CHEMBL622007
10291,N,,,,Bioavailability was reported,Intermediate,,,,,50597,BAO_0000218,A,,5438,,1,1,CHEMBL622008
10292,N,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL622009
10293,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL622010
10294,N,,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL622011
10295,N,,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL622012
10296,N,,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),Intermediate,,,,,50597,BAO_0000218,A,,4199,,1,1,CHEMBL622013
10297,N,,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4890,,1,1,CHEMBL622014
10298,N,,,,Bioavailability was determined at 3 mg/kg po dose in rats,Intermediate,,,,,50597,BAO_0000218,A,,2792,,1,1,CHEMBL624749
10299,N,,,,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5529,,1,1,CHEMBL624750
10300,N,,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL624751
10301,N,,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL624752
10302,N,,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,,,,50597,BAO_0000218,A,,6685,,1,1,CHEMBL624753
10303,N,,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6005,,1,1,CHEMBL624754
10304,N,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL624755
10305,N,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL624756
10306,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6103,,1,1,CHEMBL624757
10307,N,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL624758
10308,N,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6410,,1,1,CHEMBL622270
10309,N,,,,Bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,5353,,1,1,CHEMBL622271
10310,N,,,,Bioavailability in rat at the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL622272
10311,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL622273
10312,N,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5809,,1,1,CHEMBL622274
10313,N,,,,Bioavailability value of compound in rats was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL622275
10314,N,,,,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,3634,,1,1,CHEMBL622276
10315,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3341,,1,1,CHEMBL622277
10316,N,,,,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,2690,,1,1,CHEMBL622278
10317,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3184,,1,1,CHEMBL622279
10318,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,740,,1,1,CHEMBL622280
10319,N,,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,Intermediate,,,,,50597,BAO_0000218,A,,1806,,1,1,CHEMBL624083
10320,N,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,Intermediate,,,,,50597,BAO_0000218,A,,4891,,1,1,CHEMBL624084
10321,N,,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),Intermediate,,,,,50597,BAO_0000218,A,,3634,,1,1,CHEMBL624085
10322,N,,,,Compound was tested for bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,64,,1,1,CHEMBL624086
10323,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4839,,1,1,CHEMBL624087
10324,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1094,,1,1,CHEMBL624088
10325,U,,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL624089
10326,U,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,,,22224,BAO_0000218,A,,5005,,0,1,CHEMBL624090
10327,N,,,,Evaluated for the bioavailability in rat (in vivo),Intermediate,,,,,50597,BAO_0000218,A,,4687,,1,1,CHEMBL624091
10328,N,,,,F value of compound in rats was determined after peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,17804,,1,1,CHEMBL624092
10329,N,,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624093
10330,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624094
10331,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624095
10332,N,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5974,,1,1,CHEMBL624096
10333,N,,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",Intermediate,,,,,50597,BAO_0000218,A,,1088,,1,1,CHEMBL624097
10334,N,,,,Maximum fall in carotid flow in rat,Intermediate,,,,,50597,BAO_0000218,A,,1742,,1,1,CHEMBL624098
10335,N,,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,4689,,1,1,CHEMBL874392
10336,N,,,,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,2463,,1,1,CHEMBL624099
10337,N,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL624100
10338,N,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,5654,,1,1,CHEMBL624101
10339,N,,,,Oral bioavailability in rat (male Wistar),Intermediate,,,,,50597,BAO_0000218,A,,6874,,1,1,CHEMBL624102
10340,N,,,,Oral bioavailability after administration (30 mg/kg) in rat; good,Intermediate,,,,,50597,BAO_0000218,A,,5633,,1,1,CHEMBL624103
10341,N,,,,Oral bioavailability at the dose of 2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,5496,,1,1,CHEMBL624104
10342,N,,,,Oral bioavailability determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,2358,,1,1,CHEMBL624105
10343,N,,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,16456,,1,1,CHEMBL624106
10344,N,,,,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL624107
10345,N,,,,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL623943
10346,N,,,,Oral bioavailability in rat (dose 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5302,,1,1,CHEMBL623944
10347,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623945
10348,N,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623946
10349,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623947
10350,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623948
10351,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623949
10352,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623950
10353,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL874398
10354,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623951
10355,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623952
10356,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623953
10357,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623954
10358,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623955
10359,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL623956
10360,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627807
10361,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627808
10362,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627809
10363,N,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627810
10364,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627811
10365,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627812
10366,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627813
10367,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627814
10368,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL875336
10369,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627815
10370,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627816
10371,N,,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627817
10372,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627818
10373,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627819
10374,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627820
10375,N,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL627821
10376,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL628464
10377,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626239
10378,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626240
10379,N,,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626241
10380,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626242
10381,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626243
10382,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626244
10383,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626907
10384,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626908
10385,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626909
10386,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL626910
10387,N,,,,Percent total excretion of acetaminophen cysteine conjugate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL875342
10388,N,,,,Percent total excretion of acetaminophen glucuronide,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626911
10389,N,,,,Percent total excretion of acetaminophen sulfate,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL626912
10390,N,,,,Percent total excretion of acetaminophen-mercapturic acid,Intermediate,,,,,50597,BAO_0000218,F,,7449,,1,1,CHEMBL627065
10391,N,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,3172,Urine,1,1,CHEMBL627066
10392,N,,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,16456,,1,1,CHEMBL627067
10393,U,,,,Biodistribution of compound in rat muscle after 5 min of administration,Autocuration,,,,2385.0,22224,BAO_0000218,A,,10839,Muscle tissue,0,1,CHEMBL627068
10394,U,,,,Biodistribution of compound in rat muscle after 5 min of administration.,Autocuration,,,,2385.0,22224,BAO_0000218,A,,10839,Muscle tissue,0,1,CHEMBL627069
10395,U,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL627070
10396,U,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL627071
10397,U,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL627072
10398,U,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL627073
10399,U,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL625387
10400,U,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,,22224,BAO_0000218,A,,5334,,0,1,CHEMBL625388
10401,U,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,Plasma,0,1,CHEMBL625389
10402,U,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,,,1969.0,22224,BAO_0000218,A,,5334,Plasma,0,1,CHEMBL875343
10403,N,,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),Intermediate,,,,,50497,BAO_0000218,A,,1735,,1,1,CHEMBL876795
10404,N,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,Intermediate,,,,,50497,BAO_0000218,A,,1469,,1,1,CHEMBL626552
10405,N,,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,Intermediate,,,,,50497,BAO_0000218,A,,1336,,1,1,CHEMBL626553
10406,U,,,,The human biological plasma half life of the compound,Autocuration,,,,1969.0,22224,BAO_0000366,A,,12403,Plasma,0,1,CHEMBL626554
10407,N,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8151,Urine,1,1,CHEMBL626555
10408,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL626556
10409,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL626557
10410,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL626558
10411,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL626559
10412,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL626560
10413,N,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL876803
10414,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627964
10415,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627965
10416,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627966
10417,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627967
10418,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627968
10419,N,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627969
10420,N,,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,,,,50597,BAO_0000218,A,,8004,,1,1,CHEMBL627970
10421,N,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8004,Blood,1,1,CHEMBL627971
10422,N,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8004,Blood,1,1,CHEMBL627972
10423,D,,,,Dissociation constant against binding to human cyclophilin A,Expert,,,,,180,BAO_0000357,B,,15917,,9,1,CHEMBL856029
10424,H,,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,Expert,,,,,11591,BAO_0000019,B,,12396,,8,1,CHEMBL627973
10425,U,,,,-Log C was determined by performing the electroshock minimum test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,0,1,CHEMBL627974
10426,U,,,,-Log C was determined by performing the foot shock test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,0,1,CHEMBL627975
10427,U,,,,-Log C was determined by performing the incl screen test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,0,1,CHEMBL627976
10428,U,,,,-Log C was determined by performing the maximum electroshock test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,0,1,CHEMBL627977
10429,U,,,,-Log C was determined by performing the pentylenetetrazole test,Autocuration,,,,,22224,BAO_0000019,A,,7065,,0,1,CHEMBL627978
10430,U,,,,Tested for experimental arotinoid inhibitory dose,Autocuration,,,,,22224,BAO_0000019,A,,12415,,0,1,CHEMBL627979
10431,U,,,,Negative log transformed activity,Autocuration,,,,,22224,BAO_0000019,A,,10256,,0,1,CHEMBL876804
10432,U,,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",Autocuration,,,,,22224,BAO_0000019,A,,7991,,0,1,CHEMBL627980
10433,N,,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,1,1,CHEMBL627981
10434,N,,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,1,1,CHEMBL627982
10435,N,,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,Intermediate,,,,,50512,BAO_0000218,A,,14342,,1,1,CHEMBL627983
10436,N,,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Intermediate,,,,2116.0,50512,BAO_0000218,A,,14342,Ileum,1,1,CHEMBL627984
10437,U,,,,Solubility in water was determined; values expressed as -log,Autocuration,,,,,22229,BAO_0000100,P,,6047,,0,1,CHEMBL627985
10438,U,,,,Ratio of Kcat to that of Km was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,0,1,CHEMBL627986
10439,U,,,,Observed first order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,0,1,CHEMBL627987
10440,U,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,Autocuration,,,,,22224,BAO_0000019,A,,14583,,0,1,CHEMBL627988
10441,N,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627989
10442,N,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,2661,,1,1,CHEMBL627990
10443,N,,,,Oral Bioavailability after administration of 10 mg/kg in male rat,Intermediate,,,,,50597,BAO_0000218,A,,4029,,1,1,CHEMBL876805
10444,N,,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17735,,1,1,CHEMBL627991
10445,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4576,,1,1,CHEMBL627992
10446,N,,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,,,,50597,BAO_0000218,A,,17582,,1,1,CHEMBL627993
10447,N,,,,Oral bioavailability at 1 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL622817
10448,N,,,,Oral bioavailability at 10 mg/kg was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,17651,,1,1,CHEMBL622818
10449,N,,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",Intermediate,,,,,50597,BAO_0000218,A,,17670,,1,1,CHEMBL622819
10450,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5045,,1,1,CHEMBL872267
10451,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1696,,1,1,CHEMBL622820
10452,N,,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,Intermediate,,,,,50597,BAO_0000218,A,,17764,,1,1,CHEMBL622821
10453,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL622822
10454,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6596,,1,1,CHEMBL622823
10455,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17547,,1,1,CHEMBL622824
10456,N,,,,Oral bioavailability in rat at a dose of 3 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17771,,1,1,CHEMBL622825
10457,N,,,,Oral bioavailability in rat after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL622901
10458,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4558,,1,1,CHEMBL622902
10459,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL621844
10460,N,,,,Oral bioavailability in Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,6827,,1,1,CHEMBL621845
10461,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,4026,,1,1,CHEMBL621846
10462,N,,,,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,10,,1,1,CHEMBL621847
10463,N,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL877609
10464,N,,,,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL621848
10465,N,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL621849
10466,N,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL622030
10467,N,,,,Percent oral bioavailability determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,4796,,1,1,CHEMBL622031
10468,N,,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL622032
10469,N,,,,The compound was evaluated for bioavailability in rats; 32-51,Intermediate,,,,,50597,BAO_0000218,A,,2137,,1,1,CHEMBL622033
10470,N,,,,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,2959,,1,1,CHEMBL622034
10471,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,1361,,1,1,CHEMBL622035
10472,N,,,,Bioavailability percent in rat at the dose of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4727,,1,1,CHEMBL882966
10473,N,,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,Intermediate,,,,,50597,BAO_0000218,A,,16423,,1,1,CHEMBL622036
10474,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5206,,1,1,CHEMBL622037
10475,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL622038
10476,N,,,,Bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,17723,,1,1,CHEMBL622039
10477,N,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,Blood,1,1,CHEMBL622040
10478,N,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,Blood,1,1,CHEMBL622041
10479,N,,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,Blood,1,1,CHEMBL622042
10480,N,,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,Blood,1,1,CHEMBL622043
10481,N,,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,17738,Blood,1,1,CHEMBL622044
10482,N,,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,Bone,1,1,CHEMBL622045
10483,N,,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,Bone,1,1,CHEMBL622046
10484,N,,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,Bone,1,1,CHEMBL622047
10485,N,,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,17738,Bone,1,1,CHEMBL877610
10486,N,,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,Brain,1,1,CHEMBL622048
10487,N,,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,Brain,1,1,CHEMBL622049
10488,N,,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,Brain,1,1,CHEMBL622050
10489,N,,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,17738,Brain,1,1,CHEMBL622051
10490,N,,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,,1,1,CHEMBL622052
10491,N,,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,,1,1,CHEMBL622053
10492,N,,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,,1,1,CHEMBL622054
10493,N,,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,Intermediate,,,,,50597,BAO_0000218,A,,17738,,1,1,CHEMBL622055
10494,N,,,,Oral bioavailability in rats was determined; High,Intermediate,,,,,50597,BAO_0000218,A,,5237,,1,1,CHEMBL622056
10495,N,,,,Oral bioavailability in the rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5503,,1,1,CHEMBL622057
10496,N,,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,Intermediate,,,,,50597,BAO_0000218,A,,15765,,1,1,CHEMBL628008
10497,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,15660,,1,1,CHEMBL622058
10498,N,,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL622059
10499,N,,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL622060
10500,N,,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL622061
10501,N,,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,,,,50597,BAO_0000218,A,,5978,,1,1,CHEMBL622062
10502,N,,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL622063
10503,N,,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,,,,50597,BAO_0000218,A,,3598,,1,1,CHEMBL877611
10504,N,,,,Oral bioavailability of compound in Sprague Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4216,,1,1,CHEMBL622064
10505,N,,,,Oral bioavailability of compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,17839,,1,1,CHEMBL622065
10506,N,,,,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6570,,1,1,CHEMBL622066
10507,N,,,,Oral bioavailability of compound in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,5334,,1,1,CHEMBL622067
10508,N,,,,Oral bioavailability of compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,6886,,1,1,CHEMBL622068
10509,N,,,,Oral bioavailability of compound was determined in rats,Intermediate,,,,,50597,BAO_0000218,A,,5210,,1,1,CHEMBL622069
10510,N,,,,Oral bioavailability at a dose of 30 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,4170,,1,1,CHEMBL624796
10511,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6028,,1,1,CHEMBL624797
10512,N,,,,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6028,,1,1,CHEMBL623053
10513,N,,,,Oral bioavailability evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL623054
10514,N,,,,Oral bioavailability in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,,1,1,CHEMBL623055
10515,N,,,,Oral bioavailability in fed rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,,1,1,CHEMBL623056
10516,N,,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,5160,,1,1,CHEMBL623057
10517,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL623058
10518,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL623059
10519,N,,,,Oral bioavailability in rat after administration of 10 mg/kg po,Intermediate,,,,,50597,BAO_0000218,A,,6535,,1,1,CHEMBL623060
10520,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4194,,1,1,CHEMBL623061
10521,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6230,,1,1,CHEMBL623062
10522,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6619,,1,1,CHEMBL623063
10523,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17607,,1,1,CHEMBL623064
10524,N,,,,Oral bioavailability in ratrs,Intermediate,,,,,50597,BAO_0000218,A,,4942,,1,1,CHEMBL623065
10525,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4942,,1,1,CHEMBL623066
10526,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6646,,1,1,CHEMBL623067
10527,N,,,,Oral bioavailability in rats was determined; High,Intermediate,,,,,50597,BAO_0000218,A,,5237,,1,1,CHEMBL623068
10528,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6646,,1,1,CHEMBL623069
10529,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4449,,1,1,CHEMBL623070
10530,N,,,,Oral bioavailability was calculated in rat,Intermediate,,,,,50597,BAO_0000218,A,,6057,,1,1,CHEMBL623071
10531,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,2552,,1,1,CHEMBL623072
10532,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5496,,1,1,CHEMBL623073
10533,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,6484,,1,1,CHEMBL623074
10534,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,6485,,1,1,CHEMBL623075
10535,N,,,,Oral bioavailability after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,6616,,1,1,CHEMBL623076
10536,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4969,,1,1,CHEMBL623077
10537,N,,,,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,5862,,1,1,CHEMBL623078
10538,N,,,,Oral bioavailability in Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,4514,,1,1,CHEMBL623079
10539,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4514,,1,1,CHEMBL623080
10540,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4514,,1,1,CHEMBL623081
10541,N,,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,Intermediate,,,,,50597,BAO_0000218,A,,5546,,1,1,CHEMBL623082
10542,N,,,,Oral bioavailability in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,,1,1,CHEMBL874400
10543,N,,,,Oral bioavailability in fed rat,Intermediate,,,,,50597,BAO_0000218,A,,6168,,1,1,CHEMBL623083
10544,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3624,,1,1,CHEMBL623084
10545,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5213,,1,1,CHEMBL623085
10546,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5496,,1,1,CHEMBL623086
10547,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5553,,1,1,CHEMBL623087
10548,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5833,,1,1,CHEMBL623088
10549,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5836,,1,1,CHEMBL623089
10550,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5865,,1,1,CHEMBL623090
10551,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5960,,1,1,CHEMBL623091
10552,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6249,,1,1,CHEMBL623092
10553,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6448,,1,1,CHEMBL623093
10554,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6453,,1,1,CHEMBL874401
10555,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL623094
10556,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17607,,1,1,CHEMBL623095
10557,N,,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL623096
10558,N,,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5939,,1,1,CHEMBL624913
10559,N,,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6281,,1,1,CHEMBL624914
10560,N,,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5874,,1,1,CHEMBL624915
10561,N,,,,Oral bioavailability in rat; Not measured,Intermediate,,,,,50597,BAO_0000218,A,,5213,,1,1,CHEMBL624916
10562,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4964,,1,1,CHEMBL624917
10563,N,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,,,,50597,BAO_0000218,A,,11020,,1,1,CHEMBL625157
10564,N,,,,In vitro metabolic potential in rat liver microsomes,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6251,Liver,1,1,CHEMBL625158
10565,N,,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",Intermediate,,,,,50597,BAO_0000218,A,,1568,,1,1,CHEMBL625159
10566,N,,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",Intermediate,,,,,50597,BAO_0000218,A,,3032,,1,1,CHEMBL625160
10567,N,,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,Intermediate,,,,,50597,BAO_0000218,A,,3748,,1,1,CHEMBL625161
10568,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,401,,1,1,CHEMBL625162
10569,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6512,,1,1,CHEMBL625163
10570,N,,,,Oral bioavailability in rats at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17617,,1,1,CHEMBL625164
10571,N,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,,,50597,BAO_0000218,A,,6679,,1,1,CHEMBL625165
10572,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6742,,1,1,CHEMBL625166
10573,N,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,Intermediate,,,,,50597,BAO_0000218,A,,589,,1,1,CHEMBL625167
10574,N,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,Intermediate,,,,,50597,BAO_0000218,A,,589,,1,1,CHEMBL625168
10575,N,,,,Plasma clearance of the compound,Intermediate,,,,,50597,BAO_0000218,A,,3185,,1,1,CHEMBL625169
10576,N,,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,Intermediate,,,,,50597,BAO_0000218,A,,17596,,1,1,CHEMBL626264
10577,N,,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,1,1,CHEMBL626265
10578,N,,,,The compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL626266
10579,N,,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12500,Plasma,1,1,CHEMBL626267
10580,N,,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,1,1,CHEMBL626268
10581,N,,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,Intermediate,,,,,50597,BAO_0000218,A,,1446,,1,1,CHEMBL626269
10582,N,,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,Intermediate,,,,,50597,BAO_0000218,A,,6227,,1,1,CHEMBL626270
10583,N,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,4709,,1,1,CHEMBL626271
10584,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626272
10585,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626273
10586,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL875346
10587,N,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",Intermediate,,,,,50597,BAO_0000218,A,,5510,,1,1,CHEMBL626274
10588,N,,,,Compound was tested for protein binding in rat plasma,Intermediate,,,,,50597,BAO_0000218,A,,4514,,1,1,CHEMBL626275
10589,N,,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,Intermediate,,,,,50597,BAO_0000218,A,,2713,,1,1,CHEMBL624646
10590,N,,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,2713,,1,1,CHEMBL624647
10591,N,,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Intermediate,,,,2107.0,50597,BAO_0000218,A,,5340,Liver,1,1,CHEMBL624648
10592,N,,,,Area under curve ratio was determined (po/iv) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12058,,1,1,CHEMBL624649
10593,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,1,1,CHEMBL624650
10594,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,1,1,CHEMBL624651
10595,N,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,Intermediate,,,,,50597,BAO_0000218,A,,11195,,1,1,CHEMBL624652
10596,N,,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6495,,1,1,CHEMBL624653
10597,N,,,,Ratio of AUCbrain to AUCplasma,Intermediate,,,,,50597,BAO_0000218,A,,6078,,1,1,CHEMBL624654
10598,N,,,,Ratio of brain to plasma,Intermediate,,,,,50597,BAO_0000218,A,,5656,,1,1,CHEMBL624655
10599,N,,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL624656
10600,N,,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL624657
10601,N,,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL624658
10602,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL624659
10603,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL624660
10604,N,,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,Intermediate,,,,,50597,BAO_0000218,A,,10130,,1,1,CHEMBL624661
10605,N,,,,Steady state brain :blood ratio was determined,Intermediate,,,,,50597,BAO_0000218,A,,5213,,1,1,CHEMBL624662
10606,N,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL625199
10607,N,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL625200
10608,N,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL625201
10609,N,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,,,,50597,BAO_0000218,A,,4910,,1,1,CHEMBL625202
10610,N,,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,Intermediate,,,,,50597,BAO_0000218,A,,2083,,1,1,CHEMBL625203
10611,N,,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,,,,50597,BAO_0000218,A,,2082,,1,1,CHEMBL625204
10612,N,,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,,,,50597,BAO_0000218,A,,2082,,1,1,CHEMBL625205
10613,N,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,6351,,1,1,CHEMBL625206
10614,U,,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",Autocuration,,,,,22224,BAO_0000019,A,,14583,,0,1,CHEMBL625207
10615,U,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,Autocuration,,,,,22224,BAO_0000019,A,,14583,,0,1,CHEMBL625208
10616,N,,495.0,,In vivo absorption in Caco-2 cell line monolayers was determined,Intermediate,,Caco-2,,,50587,BAO_0000218,A,,4608,,1,1,CHEMBL625209
10617,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,0,1,CHEMBL625210
10618,N,,,,Area under curve was determine after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL625211
10619,N,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,,1,1,CHEMBL625212
10620,N,,,,Area under curve was determine after peroral administration at 160 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL625213
10621,N,,,,Area under curve was determine after peroral administration at 20 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL625214
10622,N,,,,Area under curve was determine after peroral administration at 50 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL874542
10623,U,,,,Calculated partition coefficient (clogP) (AlogP),Autocuration,,,,,22229,BAO_0000100,P,,6472,,0,1,CHEMBL625215
10624,U,,,,Activated partial thromboplastin time measured,Autocuration,,,,,22224,BAO_0000019,A,,15106,,0,1,CHEMBL625216
10625,U,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),Autocuration,,,,,22224,BAO_0000100,P,,15207,,0,1,CHEMBL625217
10626,U,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),Autocuration,,,,,22224,BAO_0000100,P,,15207,,0,1,CHEMBL625218
10627,N,,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL622864
10628,N,,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL622865
10629,N,,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL622866
10630,N,,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL622867
10631,N,,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,1969.0,50512,BAO_0000218,A,,15240,Plasma,1,1,CHEMBL876808
10632,U,,,,AUC in brain,Autocuration,,,,955.0,22224,BAO_0000019,A,,10655,Brain,0,1,CHEMBL627725
10633,U,,,,AUC in serum,Autocuration,,,,1977.0,22224,BAO_0000019,A,,10655,Serum,0,1,CHEMBL627726
10634,U,,,,AUC was determined,Autocuration,,,,1969.0,22224,BAO_0000019,A,,6504,Plasma,0,1,CHEMBL627727
10635,U,,,,AUC of the compound.,Autocuration,,,,1969.0,22224,BAO_0000019,A,,10615,Plasma,0,1,CHEMBL627728
10636,U,,,,AUC value (0-4 hr),Autocuration,,,,1969.0,22224,BAO_0000019,A,,10353,Plasma,0,1,CHEMBL627729
10637,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,Plasma,0,1,CHEMBL627730
10638,U,,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,Plasma,0,1,CHEMBL627731
10639,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,Plasma,0,1,CHEMBL627732
10640,U,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Autocuration,,,,1969.0,22224,BAO_0000019,A,,14907,Plasma,0,1,CHEMBL627733
10641,N,,,,AUC(area under curve) was determined after intravenous administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16359,Plasma,1,1,CHEMBL627734
10642,N,,,,AUC(area under curve) was determined after oral administration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16359,Plasma,1,1,CHEMBL627735
10643,N,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,1969.0,50512,BAO_0000218,A,,15240,Plasma,1,1,CHEMBL627736
10644,N,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15240,Plasma,1,1,CHEMBL876809
10645,U,,,,Area Under Curve after oral dosing of 100 uM/Kg,Autocuration,,,,,22224,BAO_0000019,A,,15469,,0,1,CHEMBL627737
10646,U,,,,Area Under Curve after oral dosing of 30 uM/Kg,Autocuration,,,,,22224,BAO_0000019,A,,15469,,0,1,CHEMBL627738
10647,U,,,,Area Under Curve was measured by ploting the graph between concentration verses time,Autocuration,,,,,22224,BAO_0000019,A,,13520,,0,1,CHEMBL627739
10648,N,,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,Intermediate,,,,,50588,BAO_0000218,A,,17025,,1,1,CHEMBL626143
10649,U,,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,17025,,0,1,CHEMBL626144
10650,N,,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL626145
10651,N,,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,Intermediate,,,,,50597,BAO_0000218,A,,17025,,1,1,CHEMBL626146
10652,N,,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Intermediate,,,,178.0,50597,BAO_0000218,A,,12032,Blood,1,1,CHEMBL626147
10653,U,,,,Area under curve (AUC) was determined,Autocuration,,,,,22224,BAO_0000019,A,,10291,,0,1,CHEMBL626148
10654,U,,,,Area under curve (AUC) following ip administration at 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5767,,0,1,CHEMBL626149
10655,U,,,,Area under curve (AUC) was determined; ND is Not determined,Autocuration,,,,,22224,BAO_0000019,A,,1434,,0,1,CHEMBL626150
10656,N,,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,1,1,CHEMBL626151
10657,N,,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,1,1,CHEMBL626152
10658,N,,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,Intermediate,,,,,50588,BAO_0000218,A,,14925,,1,1,CHEMBL626153
10659,U,,,,Area under curve (AUR) was determined,Autocuration,,,,,22224,BAO_0000019,A,,1434,,0,1,CHEMBL626154
10660,U,,,,Area under curve at 1 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000019,A,,11883,,0,1,CHEMBL626155
10661,U,,,,Area under curve at 10 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000019,A,,11883,,0,1,CHEMBL626156
10662,U,,,,Area under curve at 2 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000019,A,,11883,,0,1,CHEMBL626157
10663,U,,,,Area under curve at 20 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000019,A,,11883,,0,1,CHEMBL626158
10664,N,,,,Area under curve at a peroral dose of 3 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,15233,,1,1,CHEMBL626159
10665,N,,,,Area under curve at a peroral dose of 3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,15233,,1,1,CHEMBL626160
10666,N,,,,Area under curve at an iv dose of 1 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,15233,,1,1,CHEMBL626161
10667,N,,,,Area under curve at an iv dose of 1 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,15233,,1,1,CHEMBL626162
10668,U,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,12978,,0,1,CHEMBL626163
10669,U,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,Autocuration,,,,,22224,BAO_0000019,A,,12978,,0,1,CHEMBL626164
10670,N,,,,Area under curve measured as conc vs time after intravenous administration to mice.,Intermediate,,,,,50594,BAO_0000218,A,,11355,,1,1,CHEMBL626165
10671,N,,,,Area under curve measured as conc vs time after peroral administration to mice.,Intermediate,,,,,50594,BAO_0000218,A,,11355,,1,1,CHEMBL626166
10672,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,1,1,CHEMBL626167
10673,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,1,1,CHEMBL626168
10674,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,1,1,CHEMBL877463
10675,N,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,Intermediate,,,,,50588,BAO_0000218,A,,12923,,1,1,CHEMBL626169
10676,N,,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,Heart,1,1,CHEMBL626170
10677,N,,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,Heart,1,1,CHEMBL626171
10678,N,,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,Heart,1,1,CHEMBL626172
10679,N,,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,17738,Heart,1,1,CHEMBL626173
10680,N,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,Kidney,1,1,CHEMBL626174
10681,N,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,Kidney,1,1,CHEMBL626175
10682,N,,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,Kidney,1,1,CHEMBL626176
10683,N,,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,Kidney,1,1,CHEMBL626177
10684,N,,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,17738,Kidney,1,1,CHEMBL622499
10685,N,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,Liver,1,1,CHEMBL622500
10686,N,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,Liver,1,1,CHEMBL622501
10687,N,,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,Liver,1,1,CHEMBL622502
10688,N,,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,Liver,1,1,CHEMBL622503
10689,N,,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,17738,Liver,1,1,CHEMBL877614
10690,N,,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,Lung,1,1,CHEMBL624839
10691,N,,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,Lung,1,1,CHEMBL624840
10692,N,,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,Lung,1,1,CHEMBL624841
10693,N,,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,17738,Lung,1,1,CHEMBL624842
10694,N,,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,Muscle tissue,1,1,CHEMBL624843
10695,N,,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,Muscle tissue,1,1,CHEMBL624844
10696,N,,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,Muscle tissue,1,1,CHEMBL624845
10697,N,,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,17738,Muscle tissue,1,1,CHEMBL621904
10698,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,Blood,1,1,CHEMBL621905
10699,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,Blood,1,1,CHEMBL874382
10700,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,11195,Blood,1,1,CHEMBL621906
10701,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,Brain,1,1,CHEMBL621907
10702,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,Brain,1,1,CHEMBL622096
10703,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,11195,Brain,1,1,CHEMBL622097
10704,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,Heart,1,1,CHEMBL622098
10705,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,Heart,1,1,CHEMBL622099
10706,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,11195,Heart,1,1,CHEMBL622100
10707,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,Kidney,1,1,CHEMBL622101
10708,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,Kidney,1,1,CHEMBL622102
10709,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,11195,Kidney,1,1,CHEMBL622103
10710,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,Liver,1,1,CHEMBL622104
10711,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,Liver,1,1,CHEMBL622105
10712,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,11195,Liver,1,1,CHEMBL622106
10713,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,Lung,1,1,CHEMBL622107
10714,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,Lung,1,1,CHEMBL622108
10715,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,11195,Lung,1,1,CHEMBL622109
10716,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,Muscle tissue,1,1,CHEMBL622110
10717,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,Muscle tissue,1,1,CHEMBL622111
10718,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11195,Muscle tissue,1,1,CHEMBL874383
10719,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,Zone of skin,1,1,CHEMBL622112
10720,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,Zone of skin,1,1,CHEMBL622113
10721,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Intermediate,,,,14.0,50597,BAO_0000218,A,,11195,Zone of skin,1,1,CHEMBL622114
10722,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,Spleen,1,1,CHEMBL622115
10723,N,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Intermediate,,,,2106.0,50597,BAO_0000218,A,,11195,Spleen,1,1,CHEMBL622116
10724,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6193,,1,1,CHEMBL622117
10725,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6803,,1,1,CHEMBL622118
10726,N,,,,Oral bioavailability in rats at 6 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL622119
10727,N,,,,Oral bioavailability in rat (dose 6 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL622120
10728,N,,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,6647,,1,1,CHEMBL622121
10729,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6640,,1,1,CHEMBL622122
10730,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL622123
10731,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6641,,1,1,CHEMBL622124
10732,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6642,,1,1,CHEMBL622125
10733,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL622126
10734,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6141,,1,1,CHEMBL620455
10735,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,4390,,1,1,CHEMBL620456
10736,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL620457
10737,N,,,,Oral bioavailability was evaluated; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,5472,,1,1,CHEMBL620458
10738,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,5438,,1,1,CHEMBL620459
10739,N,,,,Oral bioavailability in rat by oral dosing,Intermediate,,,,,50597,BAO_0000218,A,,4883,,1,1,CHEMBL620460
10740,N,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,1908,,1,1,CHEMBL620461
10741,N,,,,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620462
10742,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620463
10743,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620464
10744,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620465
10745,N,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620466
10746,N,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620467
10747,N,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4853,,1,1,CHEMBL620468
10748,N,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,Intermediate,,,,,50597,BAO_0000218,A,,12873,,1,1,CHEMBL620469
10749,N,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,Intermediate,,,,,50597,BAO_0000218,A,,12873,,1,1,CHEMBL620470
10750,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3169,,1,1,CHEMBL620471
10751,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6305,,1,1,CHEMBL620472
10752,N,,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,,,,50597,BAO_0000218,A,,4762,,1,1,CHEMBL620473
10753,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17847,,1,1,CHEMBL620474
10754,N,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,6211,,1,1,CHEMBL620475
10755,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6011,,1,1,CHEMBL620476
10756,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,6317,,1,1,CHEMBL620477
10757,N,,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL620478
10758,N,,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL618768
10759,N,,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL618769
10760,N,,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,6644,,1,1,CHEMBL618770
10761,N,,,,Oral bioavailability (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,6113,,1,1,CHEMBL618771
10762,N,,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5937,,1,1,CHEMBL618772
10763,N,,,,Oral bioavailability in rat at 10 mg/kg of the compound,Intermediate,,,,,50597,BAO_0000218,A,,5711,,1,1,CHEMBL618773
10764,N,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL875842
10765,N,,,,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL618774
10766,N,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL618775
10767,N,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,17717,,1,1,CHEMBL618776
10768,N,,,,Percent bioavailability (F) in rats after iv administration,Intermediate,,,,,50597,BAO_0000218,A,,4722,,1,1,CHEMBL618777
10769,N,,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,4722,,1,1,CHEMBL618778
10770,N,,,,Bioavailability in rat (dose 5 uM/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4353,,1,1,CHEMBL618779
10771,N,,,,Oral bioavailability,Intermediate,,,,,50597,BAO_0000218,A,,15662,,1,1,CHEMBL618780
10772,N,,,,Bioavailability in rat (dose 2 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL618781
10773,N,,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,4756,,1,1,CHEMBL618782
10774,N,,,,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,,,,50597,BAO_0000218,A,,3436,,1,1,CHEMBL618783
10775,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,17800,,1,1,CHEMBL618784
10776,N,,,,Percent oral bioavailability evaluated in rat,Intermediate,,,,,50597,BAO_0000218,A,,15762,,1,1,CHEMBL618785
10777,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5089,,1,1,CHEMBL618786
10778,N,,,,Percent oral bioavailability in rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,5089,,1,1,CHEMBL618787
10779,N,,,,Oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,3185,,1,1,CHEMBL618788
10780,N,,,,Bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,5145,,1,1,CHEMBL618789
10781,N,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),Intermediate,,,,,50597,BAO_0000218,A,,3457,,1,1,CHEMBL618790
10782,N,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),Intermediate,,,,,50597,BAO_0000218,A,,3457,,1,1,CHEMBL618791
10783,N,,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,5983,,1,1,CHEMBL875843
10784,N,,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,,,,50597,BAO_0000218,A,,5739,,1,1,CHEMBL618792
10785,N,,,,Cmax at a dose of 30 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,3579,,1,1,CHEMBL623395
10786,U,,,,Cmax in monkeys at a dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,17788,,0,1,CHEMBL623396
10787,N,,,,Cmax in rat,Intermediate,,,,,50597,BAO_0000218,A,,14956,,1,1,CHEMBL623397
10788,N,,,,Cmax in rats at a dose of 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,17788,,1,1,CHEMBL623398
10789,N,,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,Intermediate,,,,,50594,BAO_0000218,A,,9750,,1,1,CHEMBL623399
10790,U,,,,"Cmax value at a dose of 12.7 uM/kg, po",Autocuration,,,,,22224,BAO_0000218,A,,12767,,0,1,CHEMBL623400
10791,U,,,,"Cmax value at a dose of 6.3 uM/kg, iv",Autocuration,,,,,22224,BAO_0000218,A,,12767,,0,1,CHEMBL623401
10792,U,,,,"Cmax value at a dose of 7.1 uM/kg, iv",Autocuration,,,,,22224,BAO_0000218,A,,12767,,0,1,CHEMBL623402
10793,U,,,,Cmax value of compound was determined after 1 hr,Autocuration,,,,,22224,BAO_0000218,A,,12703,,0,1,CHEMBL623403
10794,U,,,,Cmax value of the compound,Autocuration,,,,,22224,BAO_0000218,A,,15778,,0,1,CHEMBL623404
10795,N,,,,Cmax value administered intraintestinal in rats.,Intermediate,,,,,50597,BAO_0000218,A,,12818,,1,1,CHEMBL625997
10796,N,,,,Cmax value administered perorally was determined in rat; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,14964,,1,1,CHEMBL625998
10797,U,,,,Cmax value at the dose of 2.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15808,,0,1,CHEMBL625999
10798,U,,,,Cmax value at the dose of 5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15808,,0,1,CHEMBL626000
10799,U,,,,Cmax value in the period of 8 hr after dosing. ,Autocuration,,,,,22224,BAO_0000218,A,,15778,,0,1,CHEMBL626001
10800,U,,,,Cmax value at a oral dose of 20 mg/kg; Not tested,Autocuration,,,,,22224,BAO_0000218,A,,3715,,0,1,CHEMBL626002
10801,U,,,,Cmax value at a oral dose of 20 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,3715,,0,1,CHEMBL626003
10802,N,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,,,,50597,BAO_0000218,A,,1446,,1,1,CHEMBL626004
10803,N,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,,50512,BAO_0000218,A,,15240,,1,1,CHEMBL626005
10804,N,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,,,,50597,BAO_0000218,A,,15240,,1,1,CHEMBL626006
10805,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14810,Plasma,1,1,CHEMBL626007
10806,N,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14239,Plasma,1,1,CHEMBL626008
10807,N,,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Intermediate,,,,2107.0,50588,BAO_0000218,A,,12555,Liver,1,1,CHEMBL626009
10808,N,,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,Intermediate,,,,,50588,BAO_0000218,A,,10754,,1,1,CHEMBL626010
10809,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL626011
10810,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL626012
10811,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL626013
10812,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL626014
10813,N,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Intermediate,,,,178.0,50594,BAO_0000218,A,,10754,Blood,1,1,CHEMBL877496
10814,N,,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,,1,1,CHEMBL626015
10815,N,,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,,1,1,CHEMBL626016
10816,N,,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,,,,50588,BAO_0000218,F,,14600,,1,1,CHEMBL626017
10817,N,,,,Bioavailability as maximal plasma concentration in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13543,Plasma,1,1,CHEMBL626018
10818,N,,,,Bioavailability as maximal plasma concentration in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13543,Plasma,1,1,CHEMBL626692
10819,N,,,,Bioavailability as maximal plasma concentration in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13543,Plasma,1,1,CHEMBL626693
10820,U,,,,Bioavailability as maximal plasma concentration in rats,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13543,Plasma,0,1,CHEMBL626694
10821,N,,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626695
10822,N,,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626696
10823,N,,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626697
10824,N,,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626859
10825,N,,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626860
10826,N,,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,,,178.0,50588,BAO_0000218,A,,14600,Blood,1,1,CHEMBL626861
10827,N,,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,,,,50597,BAO_0000218,A,,14681,,1,1,CHEMBL626296
10828,U,,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15905,,0,1,CHEMBL626297
10829,U,,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15905,Plasma,0,1,CHEMBL626298
10830,N,,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Intermediate,,,,1969.0,50597,BAO_0000218,A,,13304,Plasma,1,1,CHEMBL626299
10831,N,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL626300
10832,N,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL626301
10833,N,,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL626962
10834,N,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL626963
10835,N,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL626964
10836,N,,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL626965
10837,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL626966
10838,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL626967
10839,N,,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL626968
10840,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL626969
10841,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL627126
10842,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631276
10843,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631277
10844,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631278
10845,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL874457
10846,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631279
10847,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631280
10848,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631281
10849,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631968
10850,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631969
10851,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631970
10852,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631971
10853,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL631972
10854,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL630435
10855,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL630436
10856,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL630437
10857,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL630438
10858,N,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Intermediate,,,,948.0,50597,BAO_0000218,A,,8418,Heart,1,1,CHEMBL630439
10859,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL630440
10860,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL630441
10861,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL630442
10862,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL625234
10863,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL625235
10864,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL625236
10865,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL625237
10866,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626125
10867,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626126
10868,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626127
10869,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626128
10870,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626129
10871,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626130
10872,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626131
10873,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626132
10874,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626752
10875,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626753
10876,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626754
10877,N,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8418,Kidney,1,1,CHEMBL626755
10878,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL626756
10879,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL626757
10880,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL626758
10881,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL626759
10882,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL626760
10883,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626394
10884,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626395
10885,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626396
10886,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626397
10887,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626398
10888,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL626399
10889,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL874653
10890,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626400
10891,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626401
10892,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626402
10893,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626403
10894,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626404
10895,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL626405
10896,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625529
10897,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625530
10898,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625531
10899,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625532
10900,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625533
10901,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL875474
10902,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625534
10903,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625535
10904,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625536
10905,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625537
10906,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625538
10907,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625539
10908,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625540
10909,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625541
10910,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625542
10911,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625543
10912,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625544
10913,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625545
10914,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625546
10915,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625547
10916,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625548
10917,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625549
10918,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625550
10919,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625551
10920,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL875475
10921,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625552
10922,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625553
10923,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625554
10924,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625555
10925,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL625556
10926,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624986
10927,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624987
10928,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624988
10929,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624989
10930,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624990
10931,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL874391
10932,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624991
10933,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624992
10934,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624993
10935,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624994
10936,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624995
10937,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624996
10938,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624997
10939,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624998
10940,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624999
10941,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL882955
10942,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625000
10943,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625001
10944,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625089
10945,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625090
10946,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625091
10947,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625092
10948,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625093
10949,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625094
10950,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL625095
10951,N,,,,Compound was evaluated for its bioavailability in the dogs,Intermediate,,,,,50588,BAO_0000218,A,,2249,,1,1,CHEMBL625096
10952,N,,,,Compound was evaluated for its bioavailability in the rats,Intermediate,,,,,50597,BAO_0000218,A,,2249,,1,1,CHEMBL625097
10953,U,,,,Compound was evaluated for oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,17515,,0,1,CHEMBL882956
10954,N,,,,Compound was evaluated for percentage of Oral bioavailability in rats,Intermediate,,,,,50597,BAO_0000218,A,,14541,,1,1,CHEMBL625098
10955,U,,,,Bioavailability in guinea pig,Autocuration,,,,,22224,BAO_0000218,A,,12797,,0,1,CHEMBL625099
10956,N,,,,Compound was evaluated for the oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,,1,1,CHEMBL625100
10957,N,,,,Compound was evaluated for the oral bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,12797,,1,1,CHEMBL625101
10958,N,,,,Compound was evaluated for the oral bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,,1,1,CHEMBL874396
10959,U,,,,Bioavailability in dog (dosed i.v.),Autocuration,,,,,22224,BAO_0000218,F,,11727,,0,1,CHEMBL625102
10960,N,,,,Compound was tested for in vivo bioavailability in dog,Intermediate,,,,,50588,BAO_0000218,A,,13249,,1,1,CHEMBL625103
10961,N,,,,Compound was tested for in vivo bioavailability in hamsters,Intermediate,,,,,100712,BAO_0000218,A,,13249,,1,1,CHEMBL625104
10962,U,,,,Compound was tested for in vivo bioavailability in monkey,Autocuration,,,,,22224,BAO_0000218,A,,13249,,0,1,CHEMBL625105
10963,N,,,,Compound was tested for in vivo bioavailability in rat,Intermediate,,,,,50597,BAO_0000218,A,,13249,,1,1,CHEMBL625106
10964,U,,,,Oral bioavailability in mouse,Autocuration,,,,,22224,BAO_0000218,A,,9552,,0,1,CHEMBL625107
10965,N,,,,Compound was tested for percent of oral bioavailability in mice; 56-74,Intermediate,,,,,50594,BAO_0000218,A,,9552,,1,1,CHEMBL625108
10966,U,,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,14839,,0,1,CHEMBL625109
10967,U,,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,14839,,0,1,CHEMBL625110
10968,U,,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,14839,,0,1,CHEMBL625111
10969,N,,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL625112
10970,N,,,,Oral bioavailability in nude mice,Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL875334
10971,U,,,,Bioavailability in monkey (i.d. dosing),Autocuration,,,,,22224,BAO_0000218,A,,11219,,0,1,CHEMBL628617
10972,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,9552,,0,1,CHEMBL628618
10973,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL628619
10974,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL628620
10975,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL628621
10976,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL628622
10977,N,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,,,,100710,BAO_0000218,A,,14839,,1,1,CHEMBL628623
10978,N,,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL628624
10979,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL628625
10980,N,,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Intermediate,,,,1969.0,100710,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL628626
10981,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL627041
10982,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL627042
10983,N,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14839,Plasma,1,1,CHEMBL627043
10984,U,,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13932,Plasma,0,1,CHEMBL627044
10985,N,,,,Cmax in mouse plasma,Intermediate,,,,1969.0,50594,BAO_0000218,A,,11637,Plasma,1,1,CHEMBL627045
10986,U,,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Autocuration,,,,1969.0,22224,BAO_0000218,A,,11637,Plasma,0,1,CHEMBL627046
10987,N,,,,Maximal plasma concentration in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13960,Plasma,1,1,CHEMBL627047
10988,N,,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15905,Plasma,1,1,CHEMBL627048
10989,N,,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627049
10990,N,,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627050
10991,N,,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627051
10992,N,,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627052
10993,N,,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627053
10994,N,,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL627054
10995,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627055
10996,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627056
10997,N,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627057
10998,N,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL627058
10999,N,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL626211
11000,U,,,,Maximum Concentration of the compound.,Autocuration,,,,,22224,BAO_0000218,A,,10291,,0,1,CHEMBL626212
11001,N,,,,Maximum Concentration was measured after iv administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL626213
11002,N,,,,Maximum Concentration was measured after iv administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL626214
11003,N,,,,Maximum Concentration was measured after po administration into Beagle dog,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL626215
11004,N,,,,Maximum Concentration was measured after po administration into Beagle dog.,Intermediate,,,,,50588,BAO_0000218,A,,14599,,1,1,CHEMBL626216
11005,U,,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626217
11006,U,,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626218
11007,U,,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626219
11008,U,,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626220
11009,U,,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626221
11010,U,,,,Maximum blood level reached at dose of 10.6 uM/kg orally,Autocuration,,,,178.0,22224,BAO_0000218,A,,12767,Blood,0,1,CHEMBL626222
11011,N,,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,,1,1,CHEMBL626223
11012,N,,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,,1,1,CHEMBL626224
11013,N,,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,Brain,1,1,CHEMBL626225
11014,N,,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,Brain,1,1,CHEMBL626226
11015,N,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,Brain,1,1,CHEMBL626227
11016,N,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Intermediate,,,,955.0,50597,BAO_0000218,A,,14793,Brain,1,1,CHEMBL626228
11017,N,,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL626229
11018,N,,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL626921
11019,N,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL876793
11020,N,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14793,,1,1,CHEMBL625309
11021,N,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,,,,50278,BAO_0000218,A,,10524,,1,1,CHEMBL625310
11022,U,,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11871,,0,1,CHEMBL625311
11023,N,,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,11871,,1,1,CHEMBL625312
11024,U,,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,Autocuration,,,,,22224,BAO_0000218,A,,3437,,0,1,CHEMBL625313
11025,N,,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,Intermediate,,,,,50594,BAO_0000218,A,,12038,,1,1,CHEMBL625314
11026,N,,,,Maximum concentration in male rats after iv administration of 20 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12038,,1,1,CHEMBL625315
11027,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625316
11028,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625317
11029,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625318
11030,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625319
11031,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625320
11032,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625321
11033,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625322
11034,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL876801
11035,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625323
11036,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625324
11037,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625325
11038,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625326
11039,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625327
11040,N,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8418,Liver,1,1,CHEMBL625328
11041,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL625329
11042,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL625330
11043,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627774
11044,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627775
11045,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627949
11046,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627950
11047,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627951
11048,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627952
11049,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627953
11050,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627954
11051,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627955
11052,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627956
11053,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL876802
11054,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627957
11055,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627958
11056,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627959
11057,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627960
11058,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627961
11059,N,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8418,Lung,1,1,CHEMBL627962
11060,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,1,1,CHEMBL627963
11061,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,1,1,CHEMBL624759
11062,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,1,1,CHEMBL624760
11063,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,1,1,CHEMBL624761
11064,N,,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,,50597,BAO_0000218,A,,9796,,1,1,CHEMBL877607
11065,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,Liver,1,1,CHEMBL624762
11066,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,Liver,1,1,CHEMBL624763
11067,N,,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,Liver,1,1,CHEMBL624764
11068,N,,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,Liver,1,1,CHEMBL624765
11069,N,,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9796,Liver,1,1,CHEMBL624766
11070,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624767
11071,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624768
11072,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624769
11073,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624770
11074,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624771
11075,N,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624772
11076,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624773
11077,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624774
11078,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624775
11079,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624776
11080,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624777
11081,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624778
11082,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624779
11083,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624780
11084,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624781
11085,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL877608
11086,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624782
11087,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624783
11088,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624784
11089,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624785
11090,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624786
11091,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL624787
11092,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL628676
11093,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL621842
11094,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL621843
11095,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL623873
11096,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL623874
11097,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL623875
11098,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL623876
11099,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623877
11100,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623878
11101,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623879
11102,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623880
11103,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623881
11104,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623957
11105,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623958
11106,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623959
11107,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623960
11108,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623961
11109,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL623962
11110,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624676
11111,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624677
11112,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624678
11113,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624679
11114,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624680
11115,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL624849
11116,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL624850
11117,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL874399
11118,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL624851
11119,U,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,Autocuration,,,,,22224,BAO_0000218,A,,11732,,0,1,CHEMBL624852
11120,U,,,,Oral bioavailability in rat (dose 10 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,13359,,0,1,CHEMBL624853
11121,U,,,,Oral bioavailability in rat (Sprague-Dawley),Autocuration,,,,,22224,BAO_0000218,A,,16618,,0,1,CHEMBL624854
11122,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,13960,,0,1,CHEMBL624855
11123,U,,,,Oral bioavailability in rats was determined in vivo,Autocuration,,,,,22224,BAO_0000218,A,,13917,,0,1,CHEMBL624856
11124,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,14266,,0,1,CHEMBL882957
11125,U,,,,Oral bioavailability of compound in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12359,,0,1,CHEMBL624857
11126,N,,,,Oral bioavailability of compound in rat,Intermediate,,,,,50597,BAO_0000218,A,,12359,,1,1,CHEMBL622202
11127,U,,,,Bioavailability in rat of PMEA prodrug,Autocuration,,,,,22224,BAO_0000218,A,,12359,,0,1,CHEMBL622203
11128,N,,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,Intermediate,,,,,50597,BAO_0000218,A,,12359,,1,1,CHEMBL625522
11129,U,,,,Serum conc at 3 hours following 25 mg/kg dose,Autocuration,,,,,22224,BAO_0000218,A,,10791,,0,1,CHEMBL622868
11130,U,,,,Urine conc 0-5 hours following 25 mg/kg dose,Autocuration,,,,1088.0,22224,BAO_0000218,A,,10791,Urine,0,1,CHEMBL622869
11131,U,,,,Urine conc 0-24 hours following 25 mg/kg dose,Autocuration,,,,1088.0,22224,BAO_0000218,A,,10791,Urine,0,1,CHEMBL622870
11132,U,,,,Oral bioavailability in African green monkeys; 20-25,Autocuration,,,,,22224,BAO_0000218,A,,138,,0,1,CHEMBL622871
11133,N,,,,Oral bioavailability in cynomolgus monkey.,Intermediate,,,,,100710,BAO_0000218,A,,14521,,1,1,CHEMBL620560
11134,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,13953,,0,1,CHEMBL620561
11135,N,,,,Oral bioavailability in dog at 10 mg/kg oral dose,Intermediate,,,,,50588,BAO_0000218,A,,12836,,1,1,CHEMBL620562
11136,N,,,,Oral bioavailability in hamster at 10 mg/kg oral dose,Intermediate,,,,,100712,BAO_0000218,A,,12836,,1,1,CHEMBL620563
11137,N,,,,Oral bioavailability in rat at 10 mg/kg oral dose,Intermediate,,,,,50597,BAO_0000218,A,,12836,,1,1,CHEMBL620564
11138,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,14521,,0,1,CHEMBL872265
11139,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,13953,,0,1,CHEMBL620565
11140,U,,,,Oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,6799,,0,1,CHEMBL620566
11141,U,,,,Oral bioavailability was determined; range 49-102%,Autocuration,,,,,22224,BAO_0000218,A,,11311,,0,1,CHEMBL620567
11142,N,,,,Oral bioavailability was determined in dogs,Intermediate,,,,,50588,BAO_0000218,A,,4013,,1,1,CHEMBL620568
11143,U,,,,Oral bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,4013,,0,1,CHEMBL620569
11144,U,,,,Oral bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,17591,,0,1,CHEMBL620570
11145,U,,,,Oral bioavailability was determined; Not orally available,Autocuration,,,,,22224,BAO_0000218,A,,17591,,0,1,CHEMBL620571
11146,N,,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,,,,50594,BAO_0000218,A,,15011,,1,1,CHEMBL620572
11147,U,,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,15011,,0,1,CHEMBL620573
11148,U,,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15011,,0,1,CHEMBL620574
11149,U,,,,Oral bioavailability in Rhesus monkey,Autocuration,,,,,22224,BAO_0000218,A,,9552,,0,1,CHEMBL620575
11150,U,,,,Oral bioavailability in dog (female mongrel),Autocuration,,,,,22224,BAO_0000218,A,,9552,,0,1,CHEMBL620576
11151,U,,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,Autocuration,,,,,22224,BAO_0000218,A,,3639,,0,1,CHEMBL875846
11152,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,13397,,0,1,CHEMBL620577
11153,U,,,,Percentage Bioavailability was evaluated.,Autocuration,,,,,22224,BAO_0000218,A,,3031,,0,1,CHEMBL620578
11154,U,,,,Bioavailability in rat administered i.d.,Autocuration,,,,,22224,BAO_0000218,A,,12818,,0,1,CHEMBL620579
11155,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,4847,,0,1,CHEMBL621248
11156,U,,,,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,12421,,0,1,CHEMBL625390
11157,U,,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",Autocuration,,,,,22224,BAO_0000218,A,,11966,,0,1,CHEMBL625391
11158,U,,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,11218,,0,1,CHEMBL872266
11159,U,,,,Oral bioavailability in rat (Sprague-Dawley) (male),Autocuration,,,,,22224,BAO_0000218,A,,13129,,0,1,CHEMBL625392
11160,N,,,,The oral bioavailability was measured on rats after oral administration,Intermediate,,,,,50597,BAO_0000218,A,,12350,,1,1,CHEMBL625393
11161,N,,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,2231,,1,1,CHEMBL625394
11162,N,,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,,,,50797,BAO_0000218,A,,2231,,1,1,CHEMBL625395
11163,U,,,,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625396
11164,U,,,,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,,,,22224,BAO_0000218,A,,12421,,0,1,CHEMBL625397
11165,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL625398
11166,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,Blood,1,1,CHEMBL625399
11167,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,Cerebellum,1,1,CHEMBL626074
11168,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL626075
11169,N,,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2231,Plasma,1,1,CHEMBL626076
11170,N,,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,,,1969.0,50797,BAO_0000218,A,,2231,Plasma,1,1,CHEMBL626077
11171,N,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Intermediate,,,,178.0,50597,BAO_0000218,A,,12178,Blood,1,1,CHEMBL626078
11172,U,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Autocuration,,,,178.0,22224,BAO_0000218,A,,12178,Blood,0,1,CHEMBL625846
11173,U,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Autocuration,,,,178.0,22224,BAO_0000218,A,,12178,Blood,0,1,CHEMBL625847
11174,N,,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,Expert,,,,,50597,BAO_0000218,A,,15633,,1,1,CHEMBL625848
11175,N,,,,Maximum concentration of compound in plasma administered orally to rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14258,Plasma,1,1,CHEMBL625849
11176,N,,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL626023
11177,N,,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL626024
11178,N,,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL626025
11179,U,,,,Maximum concentration after 10 mg/kg by oral administration,Autocuration,,,,,22224,BAO_0000218,A,,5566,,0,1,CHEMBL626026
11180,U,,,,Maximum concentration at a dose of 1.5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,,0,1,CHEMBL626027
11181,U,,,,Maximum concentration at a dose of 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,,0,1,CHEMBL626028
11182,N,,,,Maximum concentration in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL626029
11183,U,,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,Plasma,0,1,CHEMBL626030
11184,U,,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,Plasma,0,1,CHEMBL626031
11185,U,,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,Plasma,0,1,CHEMBL626032
11186,U,,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,Plasma,0,1,CHEMBL626033
11187,U,,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Autocuration,,,,1969.0,22224,BAO_0000218,A,,12536,Plasma,0,1,CHEMBL626034
11188,N,,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,9994,Plasma,1,1,CHEMBL626035
11189,U,,,,Maximum concentration in plasma at Tmax,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1434,Plasma,0,1,CHEMBL626036
11190,N,,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Expert,,,,1969.0,50588,BAO_0000218,A,,12836,Plasma,1,1,CHEMBL626037
11191,N,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12836,Plasma,1,1,CHEMBL626038
11192,N,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12836,Plasma,1,1,CHEMBL626039
11193,N,,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12545,Plasma,1,1,CHEMBL626040
11194,N,,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Intermediate,,,,1969.0,50592,BAO_0000218,A,,13856,Plasma,1,1,CHEMBL626041
11195,U,,,,Maximum concentration was calculated,Autocuration,,,,,22224,BAO_0000218,A,,3550,,0,1,CHEMBL626042
11196,U,,,,Maximum concentration was calculated.,Autocuration,,,,,22224,BAO_0000218,A,,2632,,0,1,CHEMBL626043
11197,U,,,,Maximum concentration at a peroral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5566,,0,1,CHEMBL626044
11198,U,,,,Maximum concentration of the drug at 10 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,11883,,0,1,CHEMBL626045
11199,U,,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,11883,,0,1,CHEMBL626046
11200,N,,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14122,Plasma,1,1,CHEMBL626047
11201,N,,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,100712,BAO_0000218,A,,14122,Plasma,1,1,CHEMBL626048
11202,N,,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,14122,Plasma,1,1,CHEMBL626049
11203,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12542,Plasma,1,1,CHEMBL626050
11204,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,12542,Plasma,1,1,CHEMBL874541
11205,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12542,Plasma,1,1,CHEMBL622826
11206,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Intermediate,,,,1969.0,100712,BAO_0000218,A,,12542,Plasma,1,1,CHEMBL622827
11207,N,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12542,Plasma,1,1,CHEMBL622828
11208,N,,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14080,Plasma,1,1,CHEMBL622829
11209,N,,,,Maximum concentration reached following intravenous administration in male rat,Intermediate,,,,,50597,BAO_0000218,A,,11911,,1,1,CHEMBL876806
11210,N,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,Intermediate,,,,,50588,BAO_0000218,A,,13204,,1,1,CHEMBL622830
11211,N,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,Intermediate,,,,,50597,BAO_0000218,A,,13204,,1,1,CHEMBL622831
11212,N,,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,14346,,1,1,CHEMBL626794
11213,N,,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL626795
11214,N,,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL626796
11215,N,,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,14346,,1,1,CHEMBL626797
11216,N,,,,Maximum drug concentration is determined after oral dosing in rats.,Intermediate,,,,,50597,BAO_0000218,A,,14127,,1,1,CHEMBL626798
11217,N,,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,1,1,CHEMBL626799
11218,N,,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,Intermediate,,,,,50588,BAO_0000218,A,,14339,,1,1,CHEMBL626800
11219,U,,,,Maximum plasma concentration,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13494,Plasma,0,1,CHEMBL626801
11220,N,,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14925,Plasma,1,1,CHEMBL876816
11221,N,,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14474,Plasma,1,1,CHEMBL626802
11222,N,,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14474,Plasma,1,1,CHEMBL626803
11223,U,,,,Maximum plasma concentration following oral administration of 30 umol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13917,Plasma,0,1,CHEMBL626804
11224,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,Plasma,1,1,CHEMBL626805
11225,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,Plasma,1,1,CHEMBL626309
11226,N,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,Plasma,1,1,CHEMBL626310
11227,N,,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,Plasma,1,1,CHEMBL626311
11228,N,,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,9796,Plasma,1,1,CHEMBL626312
11229,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,Uterus,1,1,CHEMBL626313
11230,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,Uterus,1,1,CHEMBL626314
11231,N,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,Uterus,1,1,CHEMBL626315
11232,N,,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,Uterus,1,1,CHEMBL626316
11233,N,,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,,,995.0,50597,BAO_0000218,A,,9796,Uterus,1,1,CHEMBL626317
11234,N,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626318
11235,N,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626319
11236,N,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626320
11237,N,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL875053
11238,N,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626321
11239,N,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626322
11240,N,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626323
11241,N,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626324
11242,N,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626325
11243,N,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626326
11244,N,,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626327
11245,N,,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,,,,50597,BAO_0000218,A,,8363,,1,1,CHEMBL626328
11246,N,,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626329
11247,N,,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626330
11248,N,,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626331
11249,N,,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626332
11250,N,,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626333
11251,N,,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626334
11252,N,,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL626335
11253,N,,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,178.0,50597,BAO_0000218,A,,8684,Blood,1,1,CHEMBL624798
11254,N,,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624799
11255,N,,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624800
11256,N,,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624801
11257,N,,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624802
11258,N,,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624803
11259,N,,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624804
11260,N,,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624805
11261,N,,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Intermediate,,,,955.0,50597,BAO_0000218,A,,8684,Brain,1,1,CHEMBL624806
11262,N,,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624807
11263,N,,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624808
11264,N,,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624809
11265,N,,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624810
11266,N,,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL877618
11267,N,,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624811
11268,N,,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624812
11269,N,,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624813
11270,N,,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624814
11271,N,,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624815
11272,N,,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624816
11273,N,,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624817
11274,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624818
11275,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624819
11276,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624820
11277,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624821
11278,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624822
11279,N,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624823
11280,N,,,,Observed diffusion coefficient in organic solvent for Escherichia coli,Intermediate,,,,,50212,BAO_0000218,A,,15599,,1,1,CHEMBL624824
11281,N,,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,178.0,50597,BAO_0000218,A,,9614,Blood,1,1,CHEMBL624825
11282,N,,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,9614,Blood,1,1,CHEMBL624826
11283,N,,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,Cardiac atrium,1,1,CHEMBL876817
11284,N,,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,Cardiac atrium,1,1,CHEMBL624827
11285,N,,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,,50597,BAO_0000218,A,,9614,,1,1,CHEMBL624828
11286,N,,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,,50597,BAO_0000218,A,,9614,,1,1,CHEMBL624829
11287,N,,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2107.0,50597,BAO_0000218,A,,9614,Liver,1,1,CHEMBL624830
11288,N,,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,9614,Liver,1,1,CHEMBL624831
11289,N,,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,Cardiac atrium,1,1,CHEMBL624832
11290,N,,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2081.0,50597,BAO_0000218,A,,9614,Cardiac atrium,1,1,CHEMBL624833
11291,N,,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,,50597,BAO_0000218,A,,9614,,1,1,CHEMBL624834
11292,N,,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,,50597,BAO_0000218,A,,9614,,1,1,CHEMBL624835
11293,N,,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,,,,2106.0,50597,BAO_0000218,A,,9614,Spleen,1,1,CHEMBL624836
11294,N,,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,,,,2106.0,50597,BAO_0000218,A,,9614,Spleen,1,1,CHEMBL624837
11295,N,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9071,Blood,1,1,CHEMBL624838
11296,N,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9071,Blood,1,1,CHEMBL622188
11297,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,Heart,1,1,CHEMBL622189
11298,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,Heart,1,1,CHEMBL622190
11299,N,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9071,Heart,1,1,CHEMBL625170
11300,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,Kidney,1,1,CHEMBL625171
11301,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,Kidney,1,1,CHEMBL625172
11302,N,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Intermediate,,,,2113.0,50597,BAO_0000218,A,,9071,Kidney,1,1,CHEMBL625173
11303,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,Liver,1,1,CHEMBL625174
11304,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,Liver,1,1,CHEMBL625175
11305,N,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9071,Liver,1,1,CHEMBL625176
11306,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,Lung,1,1,CHEMBL625177
11307,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,Lung,1,1,CHEMBL625178
11308,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,Lung,1,1,CHEMBL625179
11309,N,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9071,Lung,1,1,CHEMBL625180
11310,U,,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",Autocuration,,,,,22224,BAO_0000218,A,,10677,,0,1,CHEMBL625181
11311,N,,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,9750,Urine,1,1,CHEMBL625182
11312,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL625183
11313,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL875848
11314,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL622260
11315,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL622261
11316,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL622262
11317,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL622263
11318,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL622418
11319,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,Liver,1,1,CHEMBL622419
11320,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL623388
11321,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,Liver,1,1,CHEMBL623389
11322,N,,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL623390
11323,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL623391
11324,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,Blood,1,1,CHEMBL623392
11325,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,Cerebellum,1,1,CHEMBL623393
11326,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL623394
11327,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL618885
11328,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,Liver,1,1,CHEMBL618886
11329,N,,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL618887
11330,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL619535
11331,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,Blood,1,1,CHEMBL619536
11332,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,Cerebellum,1,1,CHEMBL619537
11333,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL619705
11334,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL619706
11335,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,Liver,1,1,CHEMBL619707
11336,N,,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL619708
11337,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL625219
11338,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,178.0,50594,BAO_0000218,A,,13256,Blood,1,1,CHEMBL625220
11339,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2037.0,50594,BAO_0000218,A,,13256,Cerebellum,1,1,CHEMBL625221
11340,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL625222
11341,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL625223
11342,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,2107.0,50594,BAO_0000218,A,,13256,Liver,1,1,CHEMBL625224
11343,N,,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,,,,50594,BAO_0000218,A,,13256,,1,1,CHEMBL625225
11344,N,,,,Biodistribution in Rat blood after 24 hours of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL625226
11345,N,,,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL625227
11346,N,,,,Biodistribution in Rat blood after 30 minutes of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL625228
11347,N,,,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL875354
11348,N,,,,Biodistribution in Rat blood after 5 minutes of iv administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL625229
11349,N,,,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Intermediate,,,,178.0,50597,BAO_0000218,A,,8829,Blood,1,1,CHEMBL625230
11350,N,,,,Biodistribution in Rat heart after 24 hours of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625231
11351,N,,,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625900
11352,N,,,,Biodistribution in Rat heart after 30 minutes of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625901
11353,N,,,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625902
11354,N,,,,Biodistribution in Rat heart after 5 minutes of iv administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625903
11355,N,,,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Intermediate,,,,948.0,50597,BAO_0000218,A,,8829,Heart,1,1,CHEMBL625904
11356,N,,,,Biodistribution in Rat liver after 24 hours of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL625905
11357,N,,,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL627861
11358,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL627862
11359,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL627863
11360,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL627769
11361,N,,,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13249,Plasma,1,1,CHEMBL627770
11362,N,,,,Cmax in cynomolgus monkey (PO dose),Intermediate,,,,,100710,BAO_0000218,A,,13622,,1,1,CHEMBL627771
11363,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,13622,,1,1,CHEMBL627772
11364,N,,,,Cmax in rat (PO dose),Intermediate,,,,,50597,BAO_0000218,A,,13622,,1,1,CHEMBL627773
11365,N,,,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13494,Plasma,1,1,CHEMBL621922
11366,N,,,,Cmax in rat plasma after oral dose (10 mg/kg),Intermediate,,,,1969.0,50597,BAO_0000218,A,,12170,Plasma,1,1,CHEMBL621923
11367,U,,,,Cmax in plasma after oral dose (10 mg/kg),Autocuration,,,,1969.0,22224,BAO_0000218,A,,12170,Plasma,0,1,CHEMBL621924
11368,N,,,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17025,Plasma,1,1,CHEMBL621925
11369,U,,,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17025,Plasma,0,1,CHEMBL621926
11370,N,,,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Intermediate,,,,1969.0,50592,BAO_0000218,A,,17025,Plasma,1,1,CHEMBL621927
11371,N,,,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17025,Plasma,1,1,CHEMBL621928
11372,N,,,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14187,Plasma,1,1,CHEMBL621929
11373,N,,,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14816,Plasma,1,1,CHEMBL621930
11374,N,,,,Maximum plasma concentration after oral dosing in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17820,Plasma,1,1,CHEMBL621931
11375,U,,,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621932
11376,U,,,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621933
11377,N,,,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14691,Plasma,1,1,CHEMBL621934
11378,N,,,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14691,Plasma,1,1,CHEMBL621935
11379,N,,,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13375,Plasma,1,1,CHEMBL621936
11380,U,,,,Maximum plasma concentration was determined,Autocuration,,,,1969.0,22224,BAO_0000218,A,,6236,Plasma,0,1,CHEMBL621937
11381,U,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621938
11382,U,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621939
11383,U,,,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621940
11384,U,,,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621941
11385,U,,,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL621942
11386,U,,,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL626178
11387,U,,,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL626179
11388,U,,,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14380,Plasma,0,1,CHEMBL626180
11389,N,,,,Plasma Cmax in rat (PO dose),Intermediate,,,,1969.0,50597,BAO_0000218,A,,13622,Plasma,1,1,CHEMBL626181
11390,N,,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL626182
11391,N,,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL626183
11392,N,,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL626184
11393,N,,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,,,,,50597,BAO_0000218,A,,15372,,1,1,CHEMBL626185
11394,N,,,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14925,Plasma,1,1,CHEMBL626186
11395,N,,,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14925,Plasma,1,1,CHEMBL877589
11396,U,,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,11883,,0,1,CHEMBL626187
11397,U,,,,Maximum concentration of the drug at 20 uM/dg administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,11883,,0,1,CHEMBL626188
11398,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,13391,,0,1,CHEMBL626189
11399,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL626855
11400,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL623781
11401,U,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL623782
11402,N,,,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16360,Plasma,1,1,CHEMBL623783
11403,N,,,,Cmax in dog plasma after 1mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,3673,Plasma,1,1,CHEMBL623784
11404,N,,,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14431,Plasma,1,1,CHEMBL623785
11405,N,,,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14431,Plasma,1,1,CHEMBL623786
11406,N,,,,Oral maximum concentration in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,,1,1,CHEMBL623787
11407,N,,,,Oral maximum concentration in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,,1,1,CHEMBL623788
11408,N,,,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,14209,Plasma,1,1,CHEMBL623789
11409,N,,,,Peak concentration in blood after intravenous administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,11355,Blood,1,1,CHEMBL623790
11410,N,,,,Peak concentration in blood after peroral administration to mice,Intermediate,,,,178.0,50594,BAO_0000218,A,,11355,Blood,1,1,CHEMBL623791
11411,N,,,,Peak concentration in rat plasma was determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,11966,Plasma,1,1,CHEMBL623792
11412,U,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,8918,Plasma,0,1,CHEMBL623793
11413,N,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,8918,Plasma,1,1,CHEMBL623794
11414,N,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,8918,Plasma,1,1,CHEMBL623795
11415,N,,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623796
11416,N,,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623797
11417,N,,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623798
11418,N,,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623799
11419,N,,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624490
11420,N,,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624491
11421,N,,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624492
11422,N,,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624493
11423,N,,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL877595
11424,N,,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624494
11425,N,,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624495
11426,N,,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,160.0,50597,BAO_0000218,A,,8684,Intestine,1,1,CHEMBL624681
11427,N,,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624682
11428,N,,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624683
11429,N,,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624684
11430,N,,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624685
11431,N,,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624686
11432,N,,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624687
11433,N,,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624688
11434,N,,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL627161
11435,N,,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL622127
11436,N,,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL622128
11437,N,,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL874384
11438,N,,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624898
11439,N,,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624899
11440,N,,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624900
11441,N,,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624901
11442,N,,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624902
11443,N,,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624903
11444,N,,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624904
11445,N,,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624905
11446,N,,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624906
11447,N,,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624907
11448,N,,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624908
11449,N,,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624909
11450,N,,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL624910
11451,N,,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL624911
11452,N,,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL874388
11453,N,,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL624912
11454,N,,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL622930
11455,N,,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL623121
11456,N,,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL623122
11457,N,,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL623123
11458,N,,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,2385.0,50597,BAO_0000218,A,,8684,Muscle tissue,1,1,CHEMBL623124
11459,N,,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623125
11460,N,,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623126
11461,N,,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623127
11462,N,,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623128
11463,N,,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623129
11464,N,,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623130
11465,N,,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623131
11466,N,,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL623132
11467,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,Liver,1,1,CHEMBL623133
11468,N,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623134
11469,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL874389
11470,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623135
11471,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623136
11472,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623137
11473,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623138
11474,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL623139
11475,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL623140
11476,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,Liver,1,1,CHEMBL623141
11477,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8319,Liver,1,1,CHEMBL623142
11478,N,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL623143
11479,N,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,14571,Urine,1,1,CHEMBL623144
11480,N,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Intermediate,,,,1088.0,50597,BAO_0000218,A,,14571,Urine,1,1,CHEMBL623405
11481,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624074
11482,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624075
11483,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624076
11484,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624077
11485,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624078
11486,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL624079
11487,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL624261
11488,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624262
11489,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624263
11490,N,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624264
11491,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624265
11492,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624266
11493,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624267
11494,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624268
11495,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL875227
11496,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL624269
11497,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8319,Kidney,1,1,CHEMBL624270
11498,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624271
11499,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624272
11500,N,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,,,,,50597,BAO_0000218,A,,8319,,1,1,CHEMBL624273
11501,N,,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,Urine,1,1,CHEMBL624274
11502,N,,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,Urine,1,1,CHEMBL624275
11503,N,,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12064,Urine,1,1,CHEMBL624276
11504,N,,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12038,Urine,1,1,CHEMBL624277
11505,U,,,,% dose converted to 2-amino-5-chlorophenyl sulfate,Autocuration,,,,,22224,BAO_0000019,A,,14314,,0,1,CHEMBL624278
11506,U,,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),Autocuration,,,,,22224,BAO_0000019,A,,14314,,0,1,CHEMBL624279
11507,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,Feces,1,1,CHEMBL624280
11508,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,Feces,1,1,CHEMBL624281
11509,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,Feces,1,1,CHEMBL622933
11510,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,Feces,1,1,CHEMBL622934
11511,N,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL622935
11512,N,,,,Biodistribution in Rat liver after 5 minutes of iv administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL622936
11513,N,,,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8829,Liver,1,1,CHEMBL875228
11514,N,,,,Biodistribution in Rat lung after 24 hours of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL622937
11515,N,,,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL622938
11516,N,,,,Biodistribution in Rat lung after 30 minutes of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL619736
11517,N,,,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL625117
11518,N,,,,Biodistribution in Rat lung after 5 minutes of iv administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL625118
11519,N,,,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8829,Lung,1,1,CHEMBL625119
11520,N,,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Intermediate,,,,2037.0,50597,BAO_0000218,A,,14972,Cerebellum,1,1,CHEMBL625120
11521,N,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Intermediate,,,,,50597,BAO_0000218,A,,14972,,1,1,CHEMBL625121
11522,N,,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Intermediate,,,,10000006.0,50597,BAO_0000218,A,,14972,Thalamus,1,1,CHEMBL625122
11523,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,Blood,1,1,CHEMBL622204
11524,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,Blood,1,1,CHEMBL877503
11525,N,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,14608,Blood,1,1,CHEMBL627127
11526,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,Hippocampus,0,1,CHEMBL627128
11527,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,Hippocampus,0,1,CHEMBL627129
11528,U,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Autocuration,,,,10000000.0,22224,BAO_0000218,A,,14608,Hippocampus,0,1,CHEMBL627130
11529,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,Brain,1,1,CHEMBL627131
11530,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,Brain,1,1,CHEMBL627132
11531,N,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,955.0,50597,BAO_0000218,A,,14608,Brain,1,1,CHEMBL627133
11532,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,Cerebellum,1,1,CHEMBL627134
11533,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,Cerebellum,1,1,CHEMBL627135
11534,N,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14608,Cerebellum,1,1,CHEMBL627136
11535,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,,1,1,CHEMBL628435
11536,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,,1,1,CHEMBL628436
11537,N,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,,50597,BAO_0000218,A,,14608,,1,1,CHEMBL628437
11538,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,Heart,1,1,CHEMBL628438
11539,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,Heart,1,1,CHEMBL628439
11540,N,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,948.0,50597,BAO_0000218,A,,14608,Heart,1,1,CHEMBL628440
11541,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,Hippocampus,1,1,CHEMBL628441
11542,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,Hippocampus,1,1,CHEMBL628442
11543,N,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,14608,Hippocampus,1,1,CHEMBL628443
11544,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,Kidney,1,1,CHEMBL628444
11545,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,Kidney,1,1,CHEMBL628445
11546,N,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14608,Kidney,1,1,CHEMBL877504
11547,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,Liver,1,1,CHEMBL628446
11548,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,Liver,1,1,CHEMBL626874
11549,N,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14608,Liver,1,1,CHEMBL626875
11550,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,Lung,1,1,CHEMBL626876
11551,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,Lung,1,1,CHEMBL626877
11552,N,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14608,Lung,1,1,CHEMBL626878
11553,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,Muscle tissue,1,1,CHEMBL626879
11554,U,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,8918,Plasma,0,1,CHEMBL626880
11555,N,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50594,BAO_0000218,A,,8918,Plasma,1,1,CHEMBL626881
11556,N,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,8918,Plasma,1,1,CHEMBL626882
11557,N,,,,Peak plasma concentration was measured in dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14470,Plasma,1,1,CHEMBL626883
11558,N,,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL626884
11559,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL626885
11560,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL626886
11561,N,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL626887
11562,N,,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL626888
11563,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL626889
11564,U,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,Autocuration,,,,,22224,BAO_0000218,A,,13465,,0,1,CHEMBL626761
11565,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL626762
11566,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL626763
11567,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,,1,1,CHEMBL626764
11568,N,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,,1,1,CHEMBL626765
11569,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL626766
11570,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,,1,1,CHEMBL626767
11571,N,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,Intermediate,,,,,50597,BAO_0000218,A,,13465,,1,1,CHEMBL626768
11572,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL626769
11573,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,Intermediate,,,,,50588,BAO_0000218,A,,13465,,1,1,CHEMBL874463
11574,U,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,Autocuration,,,,,22224,BAO_0000218,A,,13465,,0,1,CHEMBL626770
11575,U,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,Autocuration,,,,,22224,BAO_0000218,A,,13465,,0,1,CHEMBL626771
11576,N,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,Intermediate,,,,,50597,BAO_0000218,A,,13465,,1,1,CHEMBL626772
11577,N,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,,,,,100710,BAO_0000218,A,,14731,,1,1,CHEMBL626773
11578,N,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,Intermediate,,,,,50594,BAO_0000218,A,,14731,,1,1,CHEMBL626774
11579,N,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,1,1,CHEMBL626775
11580,N,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,1,1,CHEMBL626776
11581,N,,,,Maximum concentration (Cmax) in rat when administered orally,Intermediate,,,,,50597,BAO_0000218,A,,14443,,1,1,CHEMBL626777
11582,U,,,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13465,Plasma,0,1,CHEMBL626778
11583,U,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",Autocuration,,,,,22224,BAO_0000218,A,,16359,,0,1,CHEMBL626779
11584,U,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",Autocuration,,,,,22224,BAO_0000218,A,,16359,,0,1,CHEMBL626780
11585,U,,,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15618,Plasma,0,1,CHEMBL626781
11586,N,,,,Pharmacokinetic profile Cmax was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,14554,,1,1,CHEMBL632164
11587,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,11537,,1,1,CHEMBL632165
11588,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,11537,,1,1,CHEMBL632166
11589,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),Intermediate,,,,,50588,BAO_0000218,A,,11537,,1,1,CHEMBL632167
11590,N,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),Intermediate,,,,,50594,BAO_0000218,A,,11537,,1,1,CHEMBL632168
11591,U,,,,Cmax in rat plasma,Autocuration,,,,1969.0,22224,BAO_0000218,A,,2021,Plasma,0,1,CHEMBL632169
11592,N,,,,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL632170
11593,N,,,,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL632171
11594,N,,,,Plasma level in rats at 30 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17320,Plasma,1,1,CHEMBL632172
11595,N,,,,Tested for maximum plasma concentration in mice,Intermediate,,,,1969.0,50594,BAO_0000218,A,,15831,Plasma,1,1,CHEMBL632173
11596,N,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL632174
11597,N,,,,The Cmax values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL632175
11598,N,,,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15343,Plasma,1,1,CHEMBL632176
11599,N,,,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15343,Plasma,1,1,CHEMBL632177
11600,N,,,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14856,Plasma,1,1,CHEMBL632178
11601,N,,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,,,,,50597,BAO_0000218,A,,13129,,1,1,CHEMBL632179
11602,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,Blood,1,1,CHEMBL632180
11603,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,Blood,1,1,CHEMBL632181
11604,N,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13098,Blood,1,1,CHEMBL632182
11605,U,,,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Autocuration,,,,178.0,22224,BAO_0000218,A,,15478,Blood,0,1,CHEMBL632183
11606,N,,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,Intermediate,,,,,50588,BAO_0000218,A,,15341,,1,1,CHEMBL632184
11607,N,,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL874470
11608,N,,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631302
11609,N,,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631303
11610,N,,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631304
11611,N,,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631305
11612,N,,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631306
11613,N,,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631307
11614,N,,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL631308
11615,N,,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,,50597,BAO_0000218,A,,8684,,1,1,CHEMBL625557
11616,N,,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625558
11617,N,,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625559
11618,N,,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625560
11619,N,,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625561
11620,N,,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625562
11621,N,,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL875320
11622,N,,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625563
11623,N,,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,2106.0,50597,BAO_0000218,A,,8684,Spleen,1,1,CHEMBL625564
11624,N,,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL625565
11625,N,,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL625566
11626,N,,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL625567
11627,N,,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL625568
11628,N,,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL628217
11629,N,,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL628218
11630,N,,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL628219
11631,N,,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Intermediate,,,,995.0,50597,BAO_0000218,A,,8684,Uterus,1,1,CHEMBL628220
11632,U,,,,Distribution in the blood after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628221
11633,U,,,,Distribution in the blood after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628222
11634,U,,,,Distribution in the blood after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628223
11635,U,,,,Distribution in the blood after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628224
11636,U,,,,Distribution in the blood after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628225
11637,U,,,,Distribution in the blood after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628226
11638,U,,,,Distribution in the bone after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628227
11639,U,,,,Distribution in the bone after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL875481
11640,U,,,,Distribution in the bone after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628228
11641,U,,,,Distribution in the bone after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628229
11642,U,,,,Distribution in the bone after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628230
11643,U,,,,Distribution in the bone after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628231
11644,U,,,,Distribution in the heart after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628232
11645,U,,,,Distribution in the heart after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628233
11646,U,,,,Distribution in the heart after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628234
11647,U,,,,Distribution in the heart after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628235
11648,U,,,,Distribution in the heart after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628236
11649,U,,,,Distribution in the heart after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628237
11650,U,,,,Distribution in the kidneys after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628238
11651,U,,,,Distribution in the kidneys after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628239
11652,U,,,,Distribution in the kidneys after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628240
11653,U,,,,Distribution in the kidneys after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628241
11654,U,,,,Distribution in the kidneys after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628242
11655,U,,,,Distribution in the kidneys after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL875482
11656,U,,,,Distribution in the liver after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628243
11657,U,,,,Distribution in the liver after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628244
11658,U,,,,Distribution in the liver after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628245
11659,U,,,,Distribution in the liver after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628246
11660,U,,,,Distribution in the liver after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628247
11661,U,,,,Distribution in the liver after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628248
11662,U,,,,Distribution in the lung after 120 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628249
11663,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL625452
11664,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL625453
11665,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL625454
11666,N,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,,,,50594,BAO_0000218,A,,14839,,1,1,CHEMBL623844
11667,N,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12178,,1,1,CHEMBL623845
11668,N,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,,,,,50597,BAO_0000218,A,,12178,,1,1,CHEMBL623846
11669,U,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,Autocuration,,,,,22224,BAO_0000218,A,,12178,,0,1,CHEMBL623847
11670,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL623848
11671,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL623849
11672,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL623850
11673,N,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL623851
11674,U,,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL623852
11675,N,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,,,,,50506,BAO_0000218,A,,12187,,1,1,CHEMBL624551
11676,N,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,,,,,50506,BAO_0000218,A,,12187,,1,1,CHEMBL624552
11677,U,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL624553
11678,U,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL624554
11679,N,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12187,,1,1,CHEMBL624555
11680,N,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,,1,1,CHEMBL624741
11681,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,,,,,50588,BAO_0000218,A,,14122,,1,1,CHEMBL624742
11682,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,1,1,CHEMBL624743
11683,N,,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,,,,,50597,BAO_0000218,A,,14122,,1,1,CHEMBL877606
11684,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,13391,,0,1,CHEMBL624744
11685,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL624745
11686,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL624746
11687,U,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,,178.0,22224,BAO_0000218,A,,13391,Blood,0,1,CHEMBL624747
11688,U,,,,Oral absorption expressed as Area under curve was determined,Autocuration,,,,,22224,BAO_0000019,A,,16360,,0,1,CHEMBL624748
11689,N,,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,Intermediate,,,,,50588,BAO_0000218,A,,3673,,1,1,CHEMBL622504
11690,N,,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,,,,,50588,BAO_0000218,A,,14122,,1,1,CHEMBL622505
11691,N,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,1,1,CHEMBL622506
11692,N,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,,,,,100712,BAO_0000218,A,,14122,,1,1,CHEMBL622507
11693,N,,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,,,,,50597,BAO_0000218,A,,14122,,1,1,CHEMBL622508
11694,U,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,Autocuration,,,,,22224,BAO_0000019,A,,13889,,0,1,CHEMBL622509
11695,N,,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL622510
11696,N,,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),Intermediate,,,,,50597,BAO_0000218,A,,17279,,1,1,CHEMBL622511
11697,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,1,1,CHEMBL622512
11698,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,1,1,CHEMBL622513
11699,N,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,1,1,CHEMBL622514
11700,N,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,,1,1,CHEMBL622515
11701,N,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,,1,1,CHEMBL622516
11702,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,1,1,CHEMBL622517
11703,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,1,1,CHEMBL622518
11704,N,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,1,1,CHEMBL622519
11705,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,Muscle tissue,1,1,CHEMBL622520
11706,N,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14608,Muscle tissue,1,1,CHEMBL622521
11707,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,14.0,50594,BAO_0000218,A,,14608,Zone of skin,1,1,CHEMBL625113
11708,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,14.0,50597,BAO_0000218,A,,14608,Zone of skin,1,1,CHEMBL625114
11709,N,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,14.0,50597,BAO_0000218,A,,14608,Zone of skin,1,1,CHEMBL874397
11710,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,Spleen,1,1,CHEMBL625115
11711,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,Spleen,1,1,CHEMBL625116
11712,N,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14608,Spleen,1,1,CHEMBL623932
11713,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,Striatum,1,1,CHEMBL623933
11714,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,Striatum,1,1,CHEMBL623934
11715,N,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2435.0,50597,BAO_0000218,A,,14608,Striatum,1,1,CHEMBL623935
11716,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,Thyroid gland,1,1,CHEMBL623936
11717,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,Thyroid gland,1,1,CHEMBL623937
11718,N,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14608,Thyroid gland,1,1,CHEMBL623938
11719,N,,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL623939
11720,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL623940
11721,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL623941
11722,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL627216
11723,N,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL623942
11724,N,,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,Brain,1,1,CHEMBL618793
11725,N,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,Brain,1,1,CHEMBL618794
11726,N,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,955.0,50594,BAO_0000218,A,,15383,Brain,1,1,CHEMBL618795
11727,N,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618796
11728,N,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618797
11729,N,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618798
11730,N,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618799
11731,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618800
11732,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618801
11733,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618802
11734,N,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15383,Kidney,1,1,CHEMBL618803
11735,N,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618804
11736,N,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618805
11737,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618806
11738,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618807
11739,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618808
11740,N,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15383,Liver,1,1,CHEMBL618809
11741,N,,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,Muscle tissue,1,1,CHEMBL618810
11742,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,Muscle tissue,1,1,CHEMBL618811
11743,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,Muscle tissue,1,1,CHEMBL875844
11744,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,Muscle tissue,1,1,CHEMBL618812
11745,N,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2385.0,50594,BAO_0000218,A,,15383,Muscle tissue,1,1,CHEMBL618813
11746,N,,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618814
11747,N,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618815
11748,N,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618816
11749,N,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL618817
11750,N,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL620544
11751,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL626230
11752,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL626231
11753,N,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL626232
11754,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14906,Plasma,1,1,CHEMBL626233
11755,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14906,Plasma,1,1,CHEMBL626234
11756,N,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14906,Plasma,1,1,CHEMBL875341
11757,N,,,,The maximum plasma concentration (100 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL626235
11758,U,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,Plasma,0,1,CHEMBL626236
11759,U,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,Plasma,0,1,CHEMBL626237
11760,N,,,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL626238
11761,N,,,,The maximum plasma concentration (200 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL622412
11762,N,,,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL623114
11763,U,,,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,Plasma,0,1,CHEMBL623115
11764,U,,,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,Plasma,0,1,CHEMBL623116
11765,U,,,,The maximum plasma concentration (30 mg/kg) administered orally in dog,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14215,Plasma,0,1,CHEMBL623117
11766,N,,,,The maximum plasma concentration (400 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL623118
11767,N,,,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL623119
11768,N,,,,The maximum plasma concentration (50 mg/kg) administered orally in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL623120
11769,N,,,,The maximum plasma concentration (800 mg/kg) administered orally in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14215,Plasma,1,1,CHEMBL623286
11770,N,,,,The maximum plasma concentration was measured on rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14067,Plasma,1,1,CHEMBL623287
11771,N,,,,The maximum plasma concentration was measured on rats after oral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12350,Plasma,1,1,CHEMBL623288
11772,N,,,,Plasma drug Cmax in rat (PO dose),Intermediate,,,,1969.0,50597,BAO_0000218,A,,14813,Plasma,1,1,CHEMBL623289
11773,U,,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,Autocuration,,,,,22224,BAO_0000218,A,,12536,,0,1,CHEMBL623290
11774,N,,,,maximum Plasma concentration in Dog was determined after Peroral administration,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14169,Plasma,1,1,CHEMBL623291
11775,N,,,,maximum Plasma concentration in Rats was determined after Peroral administration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14169,Plasma,1,1,CHEMBL623292
11776,N,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15604,Plasma,1,1,CHEMBL623293
11777,U,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15604,Plasma,0,1,CHEMBL623294
11778,N,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15604,Plasma,1,1,CHEMBL623295
11779,N,,,,maximum concentration was measured when administered through oral route in mice,Intermediate,,,,,50594,BAO_0000218,A,,14387,,1,1,CHEMBL623296
11780,N,,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,Intermediate,,,,,50594,BAO_0000218,A,,15115,,1,1,CHEMBL875349
11781,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,Autocuration,,,,,22224,BAO_0000019,A,,15115,,0,1,CHEMBL623297
11782,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,Autocuration,,,,,22224,BAO_0000019,A,,15115,,0,1,CHEMBL623298
11783,U,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,Autocuration,,,,,22224,BAO_0000019,A,,15115,,0,1,CHEMBL623299
11784,N,,,,Pharmacokinetic parameter was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,16359,,1,1,CHEMBL623300
11785,N,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,1,1,CHEMBL623301
11786,N,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,1,1,CHEMBL623302
11787,N,,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,1,1,CHEMBL623303
11788,N,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,1,1,CHEMBL623304
11789,N,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,Intermediate,,,,,50594,BAO_0000218,A,,12829,,1,1,CHEMBL623305
11790,N,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL623306
11791,N,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL623307
11792,N,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL623308
11793,N,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Intermediate,,,,1969.0,50594,BAO_0000218,A,,15137,Plasma,1,1,CHEMBL623309
11794,N,,,,Plasma Concentration after 120 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,1,1,CHEMBL623310
11795,N,,,,Plasma Concentration after 30 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,1,1,CHEMBL623311
11796,N,,,,Plasma Concentration after 60 min of oral administration to mice,Intermediate,,,,,100710,BAO_0000218,A,,13509,,1,1,CHEMBL623312
11797,N,,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,Intermediate,,,,,50594,BAO_0000218,A,,13509,,1,1,CHEMBL875350
11798,N,,,,Plasma Concentration after 90 min of oral administration to mice,Intermediate,,,,,50594,BAO_0000218,A,,13509,,1,1,CHEMBL628635
11799,N,,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,1,1,CHEMBL628636
11800,N,,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,1,1,CHEMBL628637
11801,N,,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,12064,,1,1,CHEMBL628058
11802,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL628059
11803,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL628060
11804,U,,,,Distribution in the lung after 15 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628061
11805,U,,,,Distribution in the lung after 30 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628062
11806,U,,,,Distribution in the lung after 5 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628063
11807,U,,,,Distribution in the lung after 60 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628064
11808,U,,,,Distribution in the lung after 90 min of intravenous administration,Autocuration,,,,,22224,BAO_0000019,A,,8926,,0,1,CHEMBL628065
11809,U,,,,Distribution in the muscle after 120 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,Muscle tissue,0,1,CHEMBL628066
11810,U,,,,Distribution in the muscle after 15 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,Muscle tissue,0,1,CHEMBL628067
11811,N,,,,Distribution in the muscle after 30 min of intravenous administration,Intermediate,,,,2385.0,50594,BAO_0000218,A,,8926,Muscle tissue,1,1,CHEMBL874646
11812,U,,,,Distribution in the muscle after 5 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,Muscle tissue,0,1,CHEMBL628068
11813,U,,,,Distribution in the muscle after 60 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,Muscle tissue,0,1,CHEMBL628069
11814,U,,,,Distribution in the muscle after 90 min of intravenous administration,Autocuration,,,,2385.0,22224,BAO_0000019,A,,8926,Muscle tissue,0,1,CHEMBL628070
11815,U,,,,Distribution in the spleen after 120 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628071
11816,U,,,,Distribution in the spleen after 15 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628072
11817,U,,,,Distribution in the spleen after 30 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628073
11818,U,,,,Distribution in the spleen after 5 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628074
11819,U,,,,Distribution in the spleen after 60 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628075
11820,U,,,,Distribution in the spleen after 90 min of intravenous administration,Autocuration,,,,2106.0,22224,BAO_0000019,A,,8926,Spleen,0,1,CHEMBL628076
11821,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,,,,1235.0,50597,BAO_0000218,A,,7570,Adrenal cortex,1,1,CHEMBL628077
11822,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,7570,Blood,1,1,CHEMBL628078
11823,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7570,Liver,1,1,CHEMBL628079
11824,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,,,,992.0,50597,BAO_0000218,A,,7570,Female gonad,1,1,CHEMBL628080
11825,N,,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,,,,2046.0,50597,BAO_0000218,A,,7570,Thyroid gland,1,1,CHEMBL628081
11826,N,,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,,,,1235.0,50597,BAO_0000218,A,,7570,Adrenal cortex,1,1,CHEMBL628082
11827,N,,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Intermediate,,,,178.0,50597,BAO_0000218,A,,7570,Blood,1,1,CHEMBL874647
11828,N,,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7570,Liver,1,1,CHEMBL626406
11829,N,,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,,,,992.0,50597,BAO_0000218,A,,7570,Female gonad,1,1,CHEMBL626407
11830,N,,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,,,,2046.0,50597,BAO_0000218,A,,7570,Thyroid gland,1,1,CHEMBL626408
11831,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626409
11832,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626410
11833,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626411
11834,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626412
11835,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626413
11836,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626414
11837,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626415
11838,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL626416
11839,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627062
11840,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627063
11841,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627064
11842,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627227
11843,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627228
11844,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL627229
11845,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL625792
11846,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL625793
11847,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL625794
11848,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Intermediate,,,,178.0,50597,BAO_0000218,A,,8608,Blood,1,1,CHEMBL625795
11849,N,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,Intermediate,,,,,50594,BAO_0000218,A,,13792,,1,1,CHEMBL625796
11850,N,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,1,1,CHEMBL625797
11851,N,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,1,1,CHEMBL625798
11852,U,,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL875613
11853,U,,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL625799
11854,U,,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL625800
11855,U,,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL625801
11856,U,,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL625802
11857,U,,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL625803
11858,U,,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,Autocuration,,,,,22224,BAO_0000019,A,,14380,,0,1,CHEMBL625804
11859,U,,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,14380,,0,1,CHEMBL622530
11860,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL622531
11861,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL622532
11862,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623176
11863,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623177
11864,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623178
11865,N,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623179
11866,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623180
11867,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL623181
11868,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624131
11869,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624132
11870,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624133
11871,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624846
11872,N,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624847
11873,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL624848
11874,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625012
11875,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625013
11876,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625014
11877,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625015
11878,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625016
11879,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625017
11880,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625018
11881,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625019
11882,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625020
11883,N,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL625021
11884,N,,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL625022
11885,N,,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,Intermediate,,,,,50594,BAO_0000218,A,,14731,,1,1,CHEMBL625023
11886,N,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,Intermediate,,,,,100710,BAO_0000218,A,,14731,,1,1,CHEMBL625024
11887,N,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,,,,,100710,BAO_0000218,A,,14731,,1,1,CHEMBL627626
11888,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,Brain,0,1,CHEMBL627627
11889,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Autocuration,,,,1977.0,22224,BAO_0000218,A,,13758,Serum,0,1,CHEMBL627628
11890,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,Brain,0,1,CHEMBL627629
11891,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Autocuration,,,,1977.0,22224,BAO_0000218,A,,13758,Serum,0,1,CHEMBL627630
11892,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),Autocuration,,,,,22224,BAO_0000019,A,,16359,,0,1,CHEMBL627631
11893,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),Autocuration,,,,,22224,BAO_0000218,A,,16359,,0,1,CHEMBL629515
11894,N,,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,Spleen,1,1,CHEMBL629516
11895,N,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,Spleen,1,1,CHEMBL629517
11896,N,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15383,Spleen,1,1,CHEMBL629518
11897,N,,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL877499
11898,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL629519
11899,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL629520
11900,N,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,,,,,50594,BAO_0000218,A,,15383,,1,1,CHEMBL629521
11901,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629522
11902,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629523
11903,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629524
11904,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629525
11905,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629526
11906,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629527
11907,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629528
11908,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629529
11909,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629530
11910,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL629531
11911,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628656
11912,N,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628657
11913,N,,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628658
11914,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628659
11915,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL877500
11916,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628660
11917,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628661
11918,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628662
11919,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628663
11920,N,,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL628664
11921,N,,,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628665
11922,N,,,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628666
11923,N,,,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628667
11924,N,,,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628668
11925,N,,,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628669
11926,N,,,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628670
11927,N,,,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,178.0,50597,BAO_0000218,A,,13751,Blood,1,1,CHEMBL628671
11928,N,,,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,Bone,1,1,CHEMBL628672
11929,N,,,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,Bone,1,1,CHEMBL630300
11930,N,,,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,Bone,1,1,CHEMBL629787
11931,N,,,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,10000001.0,50597,BAO_0000218,A,,13751,Bone,1,1,CHEMBL629788
11932,N,,,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629789
11933,N,,,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629790
11934,N,,,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629791
11935,N,,,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629792
11936,N,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629793
11937,N,,,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629794
11938,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL874459
11939,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL629795
11940,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL629796
11941,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL629797
11942,N,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,Intermediate,,,,,50597,BAO_0000218,A,,10677,,1,1,CHEMBL629798
11943,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,Adrenal gland,1,1,CHEMBL629799
11944,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,Adrenal gland,1,1,CHEMBL629800
11945,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,Adrenal gland,1,1,CHEMBL629801
11946,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,Adrenal gland,1,1,CHEMBL629802
11947,N,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2369.0,50597,BAO_0000218,A,,10911,Adrenal gland,1,1,CHEMBL629803
11948,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,Blood,1,1,CHEMBL629804
11949,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,Blood,1,1,CHEMBL629805
11950,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,Blood,1,1,CHEMBL629806
11951,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,Blood,1,1,CHEMBL629807
11952,N,,,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,178.0,50597,BAO_0000218,A,,10911,Blood,1,1,CHEMBL629808
11953,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL629809
11954,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL629810
11955,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL629811
11956,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL629812
11957,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL629813
11958,N,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,955.0,50597,BAO_0000218,A,,10911,Brain,1,1,CHEMBL874460
11959,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,,1,1,CHEMBL629814
11960,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,,1,1,CHEMBL629815
11961,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,,1,1,CHEMBL629816
11962,N,,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,,50597,BAO_0000218,A,,10911,,1,1,CHEMBL629817
11963,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,Kidney,1,1,CHEMBL626643
11964,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,Kidney,1,1,CHEMBL626644
11965,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,Kidney,1,1,CHEMBL626806
11966,N,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2113.0,50597,BAO_0000218,A,,10911,Kidney,1,1,CHEMBL626807
11967,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,Liver,1,1,CHEMBL627261
11968,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,Liver,1,1,CHEMBL627262
11969,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,Liver,1,1,CHEMBL627263
11970,N,,,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2107.0,50597,BAO_0000218,A,,10911,Liver,1,1,CHEMBL627264
11971,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,Lung,1,1,CHEMBL627265
11972,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,Lung,1,1,CHEMBL627266
11973,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,Lung,1,1,CHEMBL627267
11974,N,,,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2048.0,50597,BAO_0000218,A,,10911,Lung,1,1,CHEMBL627268
11975,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,Muscle tissue,1,1,CHEMBL627269
11976,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,Muscle tissue,1,1,CHEMBL627270
11977,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627271
11978,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627946
11979,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL875472
11980,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627947
11981,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627948
11982,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628113
11983,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628114
11984,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628115
11985,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628116
11986,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628117
11987,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628118
11988,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628119
11989,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628120
11990,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628121
11991,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL628122
11992,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627297
11993,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627298
11994,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627299
11995,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627300
11996,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627301
11997,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627302
11998,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627303
11999,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627304
12000,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627305
12001,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL627306
12002,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623982
12003,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623983
12004,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623984
12005,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623985
12006,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623986
12007,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623987
12008,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623988
12009,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL623989
12010,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL622215
12011,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL622216
12012,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",Intermediate,,,,,50597,BAO_0000218,A,,8608,,1,1,CHEMBL877481
12013,U,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),Autocuration,,,,,22224,BAO_0000218,A,,16359,,0,1,CHEMBL622217
12014,N,,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,,,,,50594,BAO_0000218,A,,13701,,1,1,CHEMBL622218
12015,N,,,,Pharmacokinetic profile AUC was evaluated in rats,Intermediate,,,,,50597,BAO_0000218,A,,14554,,1,1,CHEMBL622219
12016,U,,,,Pharmacokinetic property (Area under curve),Autocuration,,,,,22224,BAO_0000019,A,,6241,,0,1,CHEMBL622220
12017,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",Intermediate,,,,,50588,BAO_0000218,A,,11537,,1,1,CHEMBL622221
12018,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",Intermediate,,,,,50594,BAO_0000218,A,,11537,,1,1,CHEMBL622222
12019,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",Intermediate,,,,,50588,BAO_0000218,A,,11537,,1,1,CHEMBL622223
12020,N,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",Intermediate,,,,,50594,BAO_0000218,A,,11537,,1,1,CHEMBL622224
12021,U,,,,Plasma concentration (AUC) was determined,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622225
12022,U,,,,Plasma concentration (AUC) was determined; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622226
12023,N,,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),Intermediate,,,,,50512,BAO_0000218,A,,9562,,1,1,CHEMBL624154
12024,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,1,1,CHEMBL624155
12025,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,,,,,50597,BAO_0000218,A,,10363,,1,1,CHEMBL624156
12026,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,1,1,CHEMBL624157
12027,N,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,10363,,1,1,CHEMBL624158
12028,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL624159
12029,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL624160
12030,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL624161
12031,N,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL624162
12032,N,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,Intermediate,,,,,50588,BAO_0000218,A,,13317,,1,1,CHEMBL624163
12033,N,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL624164
12034,N,,,,The AUC(0-infinity) values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL624165
12035,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL624166
12036,N,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL624167
12037,N,,,,The AUC(0-t)values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL624168
12038,N,,,,The Area under the concentration time curve of compound was measured on rats,Intermediate,,,,,50597,BAO_0000218,A,,14067,,1,1,CHEMBL624169
12039,N,,,,The area under curve (100 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,1,1,CHEMBL624170
12040,U,,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,14215,,0,1,CHEMBL624171
12041,U,,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,Autocuration,,,,,22224,BAO_0000218,A,,14215,,0,1,CHEMBL624172
12042,N,,,,The area under curve (15 mg/kg) administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,14215,,1,1,CHEMBL624173
12043,N,,,,The area under curve (200 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,1,1,CHEMBL877488
12044,N,,,,The area under curve (25 mg/kg) administered intravenously in rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,1,1,CHEMBL624174
12045,U,,,,The area under curve (25 mg/kg) administered orally in marmoset,Autocuration,,,,,22224,BAO_0000218,A,,14215,,0,1,CHEMBL624175
12046,U,,,,The area under curve (25 mg/kg) administered orally in monkey,Autocuration,,,,,22224,BAO_0000218,A,,14215,,0,1,CHEMBL624176
12047,N,,,,The area under curve (30 mg/kg) administered orally in dog,Intermediate,,,,,50588,BAO_0000218,A,,14215,,1,1,CHEMBL624177
12048,N,,,,The area under curve (400 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,1,1,CHEMBL624178
12049,N,,,,The area under curve (50 mg/kg) administered orally in fasted rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,1,1,CHEMBL624179
12050,N,,,,The area under curve (50 mg/kg) administered orally in rat,Intermediate,,,,,50597,BAO_0000218,A,,14215,,1,1,CHEMBL627689
12051,N,,,,The area under curve (800 mg/kg) administered orally in humans,Intermediate,,,,,50587,BAO_0000218,A,,14215,,1,1,CHEMBL627690
12052,U,,,,The compound was evaluated for area under the curve,Autocuration,,,,,22224,BAO_0000019,A,,11324,,0,1,CHEMBL627691
12053,U,,,,The compound was evaluated for area under the curve in marmosets,Autocuration,,,,,22224,BAO_0000019,A,,11324,,0,1,CHEMBL627692
12054,U,,,,The compound was evaluated for area under the curve in marmosets,Autocuration,,,,,22224,BAO_0000019,A,,11324,,0,1,CHEMBL627693
12055,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,1,1,CHEMBL627694
12056,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,1,1,CHEMBL627695
12057,U,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),Autocuration,,,,,22224,BAO_0000218,A,,13875,,0,1,CHEMBL627696
12058,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,1,1,CHEMBL627697
12059,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,1,1,CHEMBL627698
12060,N,,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,,,,,50597,BAO_0000218,A,,13875,,1,1,CHEMBL627699
12061,N,,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,Intermediate,,,,,50597,BAO_0000218,A,,13807,,1,1,CHEMBL627700
12062,N,,,,Total drug exposure is determined after oral dosing in rats.,Intermediate,,,,,50597,BAO_0000218,A,,14127,,1,1,CHEMBL627701
12063,U,,,,Total drug exposure (5 mg/kg) when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,15116,,0,1,CHEMBL627702
12064,U,,,,Total drug exposure (5 mg/kg) when administered orally,Autocuration,,,,,22224,BAO_0000218,A,,15116,,0,1,CHEMBL627703
12065,U,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,,,,,22224,BAO_0000218,A,,15604,,0,1,CHEMBL626873
12066,N,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,15604,,1,1,CHEMBL629583
12067,N,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,,,,,50588,BAO_0000218,A,,15604,,1,1,CHEMBL629584
12068,N,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,,,,,50588,BAO_0000218,A,,15604,,1,1,CHEMBL629585
12069,N,,,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629586
12070,N,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,955.0,50597,BAO_0000218,A,,13751,Brain,1,1,CHEMBL629587
12071,N,,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629588
12072,N,,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629589
12073,N,,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629590
12074,N,,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629591
12075,N,,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629592
12076,N,,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629593
12077,N,,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL629594
12078,N,,,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL629595
12079,N,,,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL630290
12080,N,,,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL627137
12081,N,,,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL627138
12082,N,,,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL627139
12083,N,,,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL627140
12084,N,,,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,948.0,50597,BAO_0000218,A,,13751,Heart,1,1,CHEMBL627141
12085,N,,,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627142
12086,N,,,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627143
12087,N,,,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL874449
12088,N,,,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627144
12089,N,,,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627145
12090,N,,,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627146
12091,N,,,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2113.0,50597,BAO_0000218,A,,13751,Kidney,1,1,CHEMBL627147
12092,N,,,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL627148
12093,N,,,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL627149
12094,N,,,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL632160
12095,N,,,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL632161
12096,N,,,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL632162
12097,N,,,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL632163
12098,N,,,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL874469
12099,N,,,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2048.0,50597,BAO_0000218,A,,13751,Lung,1,1,CHEMBL627182
12100,N,,,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627183
12101,N,,,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627184
12102,N,,,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627185
12103,N,,,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627186
12104,N,,,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627187
12105,N,,,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627188
12106,N,,,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2385.0,50597,BAO_0000218,A,,13751,Muscle tissue,1,1,CHEMBL627189
12107,N,,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,,50597,BAO_0000218,A,,13751,,1,1,CHEMBL627190
12108,N,,,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL627191
12109,N,,,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL627192
12110,N,,,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL627193
12111,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,Muscle tissue,1,1,CHEMBL874590
12112,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,Muscle tissue,1,1,CHEMBL627194
12113,N,,,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10911,Muscle tissue,1,1,CHEMBL627195
12114,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,Female gonad,1,1,CHEMBL627196
12115,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,Female gonad,1,1,CHEMBL627197
12116,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,Female gonad,1,1,CHEMBL627198
12117,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,Female gonad,1,1,CHEMBL627199
12118,N,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,992.0,50597,BAO_0000218,A,,10911,Female gonad,1,1,CHEMBL627200
12119,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,Plasma,1,1,CHEMBL627201
12120,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,Plasma,1,1,CHEMBL627202
12121,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,Plasma,1,1,CHEMBL627203
12122,N,,,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,1969.0,50597,BAO_0000218,A,,10911,Plasma,1,1,CHEMBL627204
12123,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,Spleen,1,1,CHEMBL627205
12124,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,Spleen,1,1,CHEMBL627206
12125,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,Spleen,1,1,CHEMBL627207
12126,N,,,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2106.0,50597,BAO_0000218,A,,10911,Spleen,1,1,CHEMBL627208
12127,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,Thyroid gland,1,1,CHEMBL627209
12128,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,Thyroid gland,1,1,CHEMBL627210
12129,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,Thyroid gland,1,1,CHEMBL627211
12130,N,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,2046.0,50597,BAO_0000218,A,,10911,Thyroid gland,1,1,CHEMBL627212
12131,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,Uterus,1,1,CHEMBL627213
12132,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,Uterus,1,1,CHEMBL626599
12133,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,Uterus,1,1,CHEMBL626600
12134,N,,,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,,,,995.0,50597,BAO_0000218,A,,10911,Uterus,1,1,CHEMBL626601
12135,U,,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,Autocuration,,,,,22224,BAO_0000019,A,,8081,,0,1,CHEMBL627484
12136,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL627485
12137,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628147
12138,N,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Intermediate,,,,1969.0,100710,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628148
12139,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628149
12140,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628150
12141,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628318
12142,N,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17248,Plasma,1,1,CHEMBL628319
12143,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,,,,,50588,BAO_0000218,A,,15592,,1,1,CHEMBL875609
12144,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628320
12145,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628321
12146,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628322
12147,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628323
12148,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628324
12149,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628325
12150,U,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,Autocuration,,,,,22224,BAO_0000019,A,,7040,,0,1,CHEMBL628326
12151,N,,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Intermediate,,,,1236.0,50588,BAO_0000218,A,,9614,Adrenal medulla,1,1,CHEMBL628327
12152,N,,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Intermediate,,,,1236.0,50588,BAO_0000218,A,,9614,Adrenal medulla,1,1,CHEMBL628328
12153,N,,,,"Concentration of compound in blood of dog 1, after administering intravenously",Intermediate,,,,178.0,50588,BAO_0000218,A,,9614,Blood,1,1,CHEMBL628329
12154,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628330
12155,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628331
12156,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628332
12157,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628333
12158,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628334
12159,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628335
12160,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628336
12161,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628337
12162,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628338
12163,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL875610
12164,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628339
12165,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628340
12166,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL628341
12167,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL622214
12168,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL623167
12169,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL623168
12170,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL623169
12171,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Intermediate,,,,2107.0,50597,BAO_0000218,A,,8608,Liver,1,1,CHEMBL623170
12172,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL627224
12173,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL875634
12174,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL627225
12175,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL627226
12176,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626083
12177,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626084
12178,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626085
12179,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626086
12180,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626087
12181,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626088
12182,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626089
12183,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626090
12184,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626091
12185,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626092
12186,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626093
12187,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626094
12188,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626095
12189,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Intermediate,,,,2048.0,50597,BAO_0000218,A,,8608,Lung,1,1,CHEMBL626096
12190,U,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,,,,,22224,BAO_0000218,A,,15604,,0,1,CHEMBL626097
12191,N,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,15604,,1,1,CHEMBL626098
12192,U,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1806,Plasma,0,1,CHEMBL626099
12193,U,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Autocuration,,,,1969.0,22224,BAO_0000218,A,,1806,Plasma,0,1,CHEMBL626100
12194,N,,,,AUC 0-inf in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17237,Plasma,1,1,CHEMBL626101
12195,N,,,,AUC 0-inf in guinea pig,Intermediate,,,,1969.0,50512,BAO_0000218,A,,17237,Plasma,1,1,CHEMBL626102
12196,N,,,,AUC 0-t in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,17237,Plasma,1,1,CHEMBL626103
12197,N,,,,AUC 0-t in guinea pig,Intermediate,,,,1969.0,50512,BAO_0000218,A,,17237,Plasma,1,1,CHEMBL628391
12198,N,,,,The compound was tested for brain to plasma partition in rat,Intermediate,,,,,50597,BAO_0000218,A,,15194,,1,1,CHEMBL628392
12199,N,,,,The compound was tested for brain to plasma partition in rat.,Intermediate,,,,,50597,BAO_0000218,A,,15194,,1,1,CHEMBL628393
12200,U,,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Autocuration,,,,178.0,22224,BAO_0000019,A,,8787,Blood,0,1,CHEMBL628394
12201,N,,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,,1,1,CHEMBL628395
12202,U,,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,,0,1,CHEMBL628396
12203,N,,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL628397
12204,N,,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,,1,1,CHEMBL628398
12205,N,,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,,,,,50797,BAO_0000218,A,,4236,,1,1,CHEMBL628399
12206,N,,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,15343,,1,1,CHEMBL628400
12207,N,,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,15343,,1,1,CHEMBL874907
12208,U,,,,Area under curve of the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,17720,,0,1,CHEMBL628401
12209,U,,,,AUC in monkeys at a dose of 1 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,17788,Plasma,0,1,CHEMBL628402
12210,N,,,,AUC in rats at a dose of 1 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,17788,Plasma,1,1,CHEMBL628403
12211,U,,,,Compound was evaluated for the overall absorbance loss at pH of 2,Autocuration,,,,,22224,BAO_0000019,A,,8778,,0,1,CHEMBL628404
12212,U,,,,Compound was evaluated for the overall absorbance loss at pH of 4,Autocuration,,,,,22224,BAO_0000019,A,,8778,,0,1,CHEMBL628405
12213,U,,,,Compound was evaluated for the overall absorbance loss at pH of 7,Autocuration,,,,,22224,BAO_0000019,A,,8778,,0,1,CHEMBL628406
12214,N,,,,Compound was evaluated for its absorption in the rats,Intermediate,,,,,50597,BAO_0000218,A,,2249,,1,1,CHEMBL628407
12215,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,Urine,1,1,CHEMBL628408
12216,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,Urine,1,1,CHEMBL629171
12217,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,Urine,1,1,CHEMBL629172
12218,N,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Intermediate,,,,1088.0,50597,BAO_0000218,A,,8881,Urine,1,1,CHEMBL629173
12219,N,,,,In vitro percent permeability into rat ileum,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL629174
12220,N,,,,In vitro percent permeability into rat ileum; Range is 10-17,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL629175
12221,N,,,,In vitro percent permeability into rat ileum; Range is 10-18,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL629176
12222,N,,,,In vitro percent permeability into rat ileum; Range is 10-19,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL629177
12223,N,,,,In vitro percent permeability into rat ileum; Range is 12-15,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL629178
12224,N,,,,In vitro percent permeability into rat ileum; Range is 13-19,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631869
12225,N,,,,In vitro percent permeability into rat ileum; Range is 14-17,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631870
12226,N,,,,In vitro percent permeability into rat ileum; Range is 15-18,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631871
12227,N,,,,In vitro percent permeability into rat ileum; Range is 2-5,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631872
12228,U,,,,In vitro percent permeability into rat ileum; Range is 23-42,Autocuration,,,,2116.0,22224,BAO_0000221,A,,15286,Ileum,0,1,CHEMBL875775
12229,N,,,,In vitro percent permeability into rat ileum; Range is 28-36,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631873
12230,N,,,,In vitro percent permeability into rat ileum; Range is 29-35,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631874
12231,N,,,,In vitro percent permeability into rat ileum; Range is 46-66,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631875
12232,N,,,,In vitro percent permeability into rat ileum; Range is 50-68,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631876
12233,N,,,,In vitro percent permeability into rat ileum; Range is 78-81,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631877
12234,N,,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631878
12235,N,,,,In vitro percent permeability into rat ileum; nd indicates not detected,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631879
12236,N,,,,In vitro percent permeability into rat ileum; nt indicates not detected,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631880
12237,N,,,,In vitro percent permeability into rat ileum; nt indicates not tested,Intermediate,,,,,50597,BAO_0000218,A,,15286,,1,1,CHEMBL631881
12238,N,,,,Compound was tested for oral absorption in bile-duct cannulated rats,Intermediate,,,,,50597,BAO_0000218,A,,13770,,1,1,CHEMBL631882
12239,N,,,,Compound was tested for oral absorption in bile-duct cannulated rats.,Intermediate,,,,,50597,BAO_0000218,A,,13770,,1,1,CHEMBL630749
12240,N,,,,Oral absorption using Caco-2 cell monolayers.,Intermediate,,,,,50587,BAO_0000218,A,,5202,,1,1,CHEMBL630750
12241,N,,,,Percent of the drug absorbed after administration to humans was determined,Intermediate,,,,,50587,BAO_0000218,A,,14920,,1,1,CHEMBL630253
12242,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL630254
12243,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL630255
12244,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL630256
12245,N,,,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL875781
12246,N,,,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL630257
12247,N,,,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,,,,2107.0,50597,BAO_0000218,A,,13751,Liver,1,1,CHEMBL630258
12248,N,,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,,50597,BAO_0000218,A,,15807,,1,1,CHEMBL630259
12249,N,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,2435.0,50597,BAO_0000218,A,,15807,Striatum,1,1,CHEMBL630260
12250,N,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,,,,2435.0,50597,BAO_0000218,A,,15807,Striatum,1,1,CHEMBL630261
12251,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630262
12252,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630263
12253,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630264
12254,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630265
12255,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630266
12256,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14950,Kidney,1,1,CHEMBL630267
12257,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14950,Kidney,1,1,CHEMBL630268
12258,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630269
12259,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630270
12260,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14950,Lung,1,1,CHEMBL630141
12261,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14950,Lung,1,1,CHEMBL630142
12262,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,Muscle tissue,1,1,CHEMBL630143
12263,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,Muscle tissue,1,1,CHEMBL630144
12264,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Intermediate,,,,2367.0,50597,BAO_0000218,A,,14950,Prostate gland,1,1,CHEMBL630145
12265,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Intermediate,,,,2367.0,50597,BAO_0000218,A,,14950,Prostate gland,1,1,CHEMBL630146
12266,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630147
12267,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630148
12268,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL630149
12269,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14950,Spleen,1,1,CHEMBL630150
12270,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14950,Spleen,1,1,CHEMBL630151
12271,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,Thyroid gland,1,1,CHEMBL632031
12272,N,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,Thyroid gland,1,1,CHEMBL632032
12273,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL632033
12274,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL632034
12275,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14950,Muscle tissue,1,1,CHEMBL632035
12276,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,Intermediate,,,,,50597,BAO_0000218,A,,14950,,1,1,CHEMBL632036
12277,N,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Intermediate,,,,2046.0,50597,BAO_0000218,A,,14950,Thyroid gland,1,1,CHEMBL632037
12278,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL632038
12279,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL632039
12280,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL632040
12281,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL632041
12282,N,,,,"Concentration of compound in blood of dog 2, after administering intravenously",Intermediate,,,,178.0,50588,BAO_0000218,A,,9614,Blood,1,1,CHEMBL632042
12283,N,,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9614,,1,1,CHEMBL632043
12284,N,,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",Intermediate,,,,,50588,BAO_0000218,A,,9614,,1,1,CHEMBL632044
12285,N,,,,"Concentration of compound in liver of dog 1, after administering intravenously",Intermediate,,,,2107.0,50588,BAO_0000218,A,,9614,Liver,1,1,CHEMBL632045
12286,N,,,,"Concentration of compound in liver of dog 2, after administering intravenously",Intermediate,,,,2107.0,50588,BAO_0000218,A,,9614,Liver,1,1,CHEMBL632046
12287,N,,,,"Concentration of compound in lung of dog 1, after administering intravenously",Intermediate,,,,2048.0,50588,BAO_0000218,A,,9614,Lung,1,1,CHEMBL632047
12288,N,,,,"Concentration of compound in lung of dog 2, after administering intravenously",Intermediate,,,,2048.0,50588,BAO_0000218,A,,9614,Lung,1,1,CHEMBL632048
12289,N,,,,"Concentration of compound in muscle of dog 1, after administering intravenously",Intermediate,,,,2385.0,50588,BAO_0000218,A,,9614,Muscle tissue,1,1,CHEMBL632049
12290,N,,,,"Concentration of compound in muscle of dog 2, after administering intravenously",Intermediate,,,,2385.0,50588,BAO_0000218,A,,9614,Muscle tissue,1,1,CHEMBL876418
12291,N,,,,"Concentration of compound in spleen of dog 1,after administering intravenously",Intermediate,,,,2106.0,50588,BAO_0000218,A,,9614,Spleen,1,1,CHEMBL632050
12292,N,,,,"Concentration of compound in spleen of dog 2, after administering intravenously",Intermediate,,,,2106.0,50588,BAO_0000218,A,,9614,Spleen,1,1,CHEMBL632051
12293,U,,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,0,1,CHEMBL632052
12294,U,,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,0,1,CHEMBL632053
12295,U,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,A,,10353,,0,1,CHEMBL632054
12296,U,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,0,1,CHEMBL632055
12297,U,,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,Autocuration,,,,,22224,BAO_0000218,F,,10353,,0,1,CHEMBL631181
12298,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL631182
12299,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL631183
12300,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL631184
12301,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL629774
12302,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL629775
12303,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL876549
12304,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628172
12305,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628173
12306,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628174
12307,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628175
12308,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628176
12309,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628177
12310,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628178
12311,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628179
12312,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628180
12313,U,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628181
12314,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628182
12315,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628183
12316,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628184
12317,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628185
12318,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL875617
12319,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628186
12320,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628187
12321,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628188
12322,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628189
12323,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628190
12324,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628191
12325,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626513
12326,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626514
12327,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626515
12328,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626516
12329,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626517
12330,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626518
12331,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626519
12332,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626520
12333,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626521
12334,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626522
12335,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626523
12336,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626524
12337,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626688
12338,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626689
12339,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626690
12340,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL626691
12341,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL627319
12342,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL624052
12343,N,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Intermediate,,,,2046.0,50597,BAO_0000218,A,,8608,Thyroid gland,1,1,CHEMBL624053
12344,N,,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,1,1,CHEMBL624054
12345,N,,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,1,1,CHEMBL624055
12346,N,,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,8085,,1,1,CHEMBL624056
12347,N,,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL624057
12348,N,,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622281
12349,N,,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622282
12350,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622283
12351,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622284
12352,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622285
12353,N,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,,,,995.0,50597,BAO_0000218,A,,8085,Uterus,1,1,CHEMBL622286
12354,U,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,Autocuration,,,,,22224,BAO_0000100,P,,7657,,0,1,CHEMBL622287
12355,N,,,,Partition coefficient (logD7.4),Intermediate,,,,,50594,BAO_0000218,A,,8935,,1,1,CHEMBL622288
12356,N,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,,,,,50594,BAO_0000218,A,,13792,,1,1,CHEMBL622289
12357,N,,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL622290
12358,N,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,,,,,50594,BAO_0000218,A,,13792,,1,1,CHEMBL622291
12359,N,,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL622292
12360,N,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,,,,,50594,BAO_0000218,A,,13792,,1,1,CHEMBL622293
12361,N,,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL622294
12362,N,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,,,,,50594,BAO_0000218,A,,13792,,1,1,CHEMBL622295
12363,N,,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,,,,955.0,50597,BAO_0000218,A,,13792,Brain,1,1,CHEMBL622296
12364,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL874409
12365,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622297
12366,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622298
12367,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622299
12368,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622300
12369,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622301
12370,N,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622302
12371,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622303
12372,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622304
12373,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622305
12374,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL622306
12375,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626864
12376,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626865
12377,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626866
12378,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626867
12379,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626868
12380,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626869
12381,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626870
12382,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626871
12383,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL626872
12384,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL632185
12385,N,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14103,Plasma,1,1,CHEMBL632186
12386,U,,,,Amount of acetic acid produced by the compound,Autocuration,,,,,22224,BAO_0000019,A,,12904,,0,1,CHEMBL629310
12387,U,,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,0,1,CHEMBL629311
12388,N,,,,Log of (Cbrain/Cblood) in rats,Intermediate,,,,,50597,BAO_0000218,A,,9663,,1,1,CHEMBL629312
12389,U,,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,0,1,CHEMBL629313
12390,U,,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,0,1,CHEMBL629314
12391,U,,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,0,1,CHEMBL629315
12392,U,,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000219,B,,7652,,0,1,CHEMBL629316
12393,U,,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000221,A,,7652,,0,1,CHEMBL629317
12394,U,,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629318
12395,U,,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL877497
12396,U,,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629319
12397,U,,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629320
12398,U,,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629496
12399,U,,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629497
12400,U,,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629498
12401,U,,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629499
12402,U,,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629500
12403,U,,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629501
12404,U,,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),Autocuration,,,,,22224,BAO_0000019,A,,7652,,0,1,CHEMBL629502
12405,U,,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,Autocuration,,,,,22224,BAO_0000218,F,,8267,,0,1,CHEMBL629503
12406,N,,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,8267,,1,1,CHEMBL629504
12407,U,,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,Autocuration,,,,,22224,BAO_0000019,A,,14479,,0,1,CHEMBL629505
12408,U,,,,Compound was evaluated for total body clearance,Autocuration,,,,,22224,BAO_0000019,A,,17515,,0,1,CHEMBL629506
12409,U,,,,Compound was evaluated for volume of distribution at steady state,Autocuration,,,,,22224,BAO_0000019,A,,17515,,0,1,CHEMBL629507
12410,U,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,Autocuration,,,,,22224,BAO_0000019,A,,8142,,0,1,CHEMBL877498
12411,U,,,,Percentage of the diamine which is monoprotonated at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,14849,,0,1,CHEMBL629508
12412,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,Autocuration,,,,,22224,BAO_0000019,A,,7653,,0,1,CHEMBL629509
12413,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL629510
12414,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL629511
12415,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL629512
12416,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL629513
12417,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL629514
12418,N,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL628447
12419,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL628448
12420,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL628449
12421,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631119
12422,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631120
12423,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631121
12424,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL874458
12425,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631122
12426,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631123
12427,N,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631124
12428,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631125
12429,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631290
12430,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631291
12431,N,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631292
12432,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631293
12433,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631294
12434,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631295
12435,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631296
12436,N,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,,,,178.0,50597,BAO_0000218,A,,8631,Blood,1,1,CHEMBL631297
12437,U,,,,Maximum biodistribution (Bmax) was determined.,Autocuration,,,,,22224,BAO_0000218,A,,10263,,0,1,CHEMBL631298
12438,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,1,1,CHEMBL631299
12439,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,1,1,CHEMBL631300
12440,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,1,1,CHEMBL631301
12441,N,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,Intermediate,,,,,50594,BAO_0000218,A,,12364,,1,1,CHEMBL630291
12442,U,,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL630292
12443,U,,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL630293
12444,U,,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL630294
12445,U,,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL630295
12446,U,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL630296
12447,U,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626782
12448,U,,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626783
12449,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626784
12450,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626785
12451,U,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626786
12452,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626787
12453,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626788
12454,U,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625927
12455,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625928
12456,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625929
12457,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625930
12458,N,,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625931
12459,N,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627230
12460,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627231
12461,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627232
12462,N,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627233
12463,N,,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL875470
12464,N,,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627234
12465,N,,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627235
12466,N,,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627236
12467,N,,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627237
12468,N,,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627238
12469,N,,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627239
12470,N,,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627240
12471,N,,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627241
12472,N,,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627242
12473,N,,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627243
12474,N,,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627244
12475,N,,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627245
12476,N,,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627246
12477,N,,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627247
12478,N,,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627248
12479,N,,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627249
12480,N,,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625569
12481,N,,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625570
12482,N,,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625571
12483,N,,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625572
12484,N,,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625573
12485,N,,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL625574
12486,N,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL626245
12487,N,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL626246
12488,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626247
12489,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626248
12490,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626249
12491,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626420
12492,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626421
12493,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626422
12494,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626423
12495,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626424
12496,N,,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,Intermediate,,,,,50588,BAO_0000218,A,,12023,,1,1,CHEMBL626425
12497,N,,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,Intermediate,,,,,50597,BAO_0000218,A,,12023,,1,1,CHEMBL875476
12498,N,,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,Intermediate,,,,,100710,BAO_0000218,A,,12023,,1,1,CHEMBL626426
12499,U,,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,,,22224,BAO_0000100,P,,10580,,0,1,CHEMBL626427
12500,U,,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,,,22224,BAO_0000100,P,,10580,,0,1,CHEMBL626428
12501,U,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,Autocuration,,,,,22224,BAO_0000019,A,,16032,,0,1,CHEMBL626429
12502,U,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,16032,Urine,0,1,CHEMBL625025
12503,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625026
12504,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625027
12505,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL874410
12506,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625028
12507,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625029
12508,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625030
12509,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625031
12510,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625032
12511,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625033
12512,N,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL625034
12513,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624872
12514,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624873
12515,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624874
12516,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624875
12517,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624876
12518,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624877
12519,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624878
12520,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624879
12521,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624880
12522,N,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624881
12523,N,,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL624882
12524,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624883
12525,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624884
12526,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624885
12527,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624886
12528,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624887
12529,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624888
12530,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624889
12531,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL624890
12532,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL621964
12533,N,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL621965
12534,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL621966
12535,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL621967
12536,N,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL622164
12537,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),Autocuration,,,,,22224,BAO_0000019,A,,7653,,0,1,CHEMBL623097
12538,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),Autocuration,,,,,22224,BAO_0000019,A,,7653,,0,1,CHEMBL623098
12539,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,Autocuration,,,,,22224,BAO_0000019,A,,7653,,0,1,CHEMBL623099
12540,U,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,Autocuration,,,,,22224,BAO_0000019,A,,7653,,0,1,CHEMBL623100
12541,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL628673
12542,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL628674
12543,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL628675
12544,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL627644
12545,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL627645
12546,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL627646
12547,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL627647
12548,N,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",Intermediate,,,,,50597,BAO_0000218,A,,9104,,1,1,CHEMBL627648
12549,N,,,,Free level in rat plasma,Intermediate,,,,,50597,BAO_0000218,A,,12902,,1,1,CHEMBL627649
12550,U,,,,Level reaching in blood plasma of rat or human was determined,Autocuration,,,,,22224,BAO_0000019,A,,6614,,0,1,CHEMBL628313
12551,N,,,,Log (Cbrain/Cblood) in rats,Intermediate,,,,,50597,BAO_0000218,A,,9663,,1,1,CHEMBL628314
12552,U,,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,Autocuration,,,,,22224,BAO_0000019,A,,17658,,0,1,CHEMBL628315
12553,U,,,,Mean percentage of compound transport through membrane; expressed as membrane transport,Autocuration,,,,,22224,BAO_0000019,A,,17658,,0,1,CHEMBL628316
12554,U,,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,Autocuration,,,,,22224,BAO_0000218,A,,14314,,0,1,CHEMBL628317
12555,U,,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,Autocuration,,,,,22224,BAO_0000019,A,,7385,,0,1,CHEMBL628473
12556,U,,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",Autocuration,,,,,22224,BAO_0000019,A,,7385,,0,1,CHEMBL628474
12557,U,,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,Autocuration,,,,,22224,BAO_0000019,A,,7385,,0,1,CHEMBL628475
12558,U,,,,Net water uptake by a carrier mediated transport (%cm) mechanism,Autocuration,,,,,22224,BAO_0000019,A,,1329,,0,1,CHEMBL628476
12559,U,,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL628477
12560,N,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,,,,,50506,BAO_0000218,A,,12187,,1,1,CHEMBL628478
12561,N,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,,,,,50506,BAO_0000218,A,,12187,,1,1,CHEMBL628479
12562,U,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL628480
12563,U,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL628481
12564,N,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12187,,1,1,CHEMBL628482
12565,N,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,,1,1,CHEMBL628483
12566,N,,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628484
12567,N,,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628485
12568,N,,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Intermediate,,,,1969.0,100710,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628486
12569,N,,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Intermediate,,,,1969.0,50587,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628487
12570,N,,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628488
12571,N,,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628489
12572,N,,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,,,,1969.0,50597,BAO_0000218,A,,9278,Plasma,1,1,CHEMBL628490
12573,N,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL628491
12574,N,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL877507
12575,U,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Autocuration,,,,,22224,BAO_0000218,A,,12186,,0,1,CHEMBL628492
12576,U,,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),Autocuration,,,,,22224,BAO_0000019,A,,12041,,0,1,CHEMBL628493
12577,U,,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,12041,,0,1,CHEMBL628494
12578,U,,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),Autocuration,,,,,22224,BAO_0000019,A,,12041,,0,1,CHEMBL628495
12579,N,,,,Permeability in Caco-2 assay at 10E-6,Intermediate,,,,,50587,BAO_0000218,A,,6737,,1,1,CHEMBL628496
12580,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,Brain,0,1,CHEMBL628497
12581,U,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,,955.0,22224,BAO_0000218,A,,13758,Brain,0,1,CHEMBL628498
12582,U,,,,Plasma protein binding was determined,Autocuration,,,,,22224,BAO_0000019,A,,5676,,0,1,CHEMBL628499
12583,U,,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL627656
12584,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL627657
12585,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626808
12586,U,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626809
12587,U,,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626810
12588,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626811
12589,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL874465
12590,U,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626812
12591,U,,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626813
12592,U,,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL626814
12593,U,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,Autocuration,,,,,22224,BAO_0000019,A,,14000,,0,1,CHEMBL626815
12594,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,5948,,0,1,CHEMBL628566
12595,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,0,1,CHEMBL628567
12596,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,10778,,0,1,CHEMBL628568
12597,N,,,,C max in dog,Intermediate,,,,,50588,BAO_0000218,A,,17237,,1,1,CHEMBL628569
12598,N,,,,C max in guinea pig,Intermediate,,,,,50512,BAO_0000218,A,,17237,,1,1,CHEMBL628570
12599,U,,,,C max value was evaluated,Autocuration,,,,,22224,BAO_0000218,A,,2809,,0,1,CHEMBL628571
12600,U,,,,Cmax value after oral dose of 0.1 mg//kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628572
12601,U,,,,Cmax value after oral dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628573
12602,U,,,,Cmax value after oral dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628574
12603,U,,,,Cmax value after oral dose of 10 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628575
12604,U,,,,Cmax value after oral dose of 23.4 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628576
12605,U,,,,Cmax value after oral dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628577
12606,U,,,,Cmax value after oral dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL628578
12607,N,,,,Cmax value in female Beagle dogs,Intermediate,,,,,50588,BAO_0000218,A,,12768,,1,1,CHEMBL874466
12608,N,,,,Cmax value in male rats,Intermediate,,,,,50597,BAO_0000218,A,,12768,,1,1,CHEMBL628579
12609,N,,,,Cmax value in rat plasma when administered 20 mg/kg perorally,Intermediate,,,,1969.0,50597,BAO_0000218,A,,12780,Plasma,1,1,CHEMBL628580
12610,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,Plasma,1,1,CHEMBL628581
12611,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,Plasma,1,1,CHEMBL628582
12612,N,,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,,1,1,CHEMBL628583
12613,U,,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,,0,1,CHEMBL625782
12614,N,,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL625783
12615,N,,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,,1,1,CHEMBL625784
12616,N,,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,,,,1969.0,50797,BAO_0000218,A,,4236,Plasma,1,1,CHEMBL625785
12617,N,,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,15791,,1,1,CHEMBL625786
12618,U,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,Autocuration,,,,,22224,BAO_0000019,A,,11149,,0,1,CHEMBL874467
12619,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,,,,,50588,BAO_0000218,A,,15592,,1,1,CHEMBL625787
12620,N,,,,cytotoxicity against HIV protease enzyme.,Intermediate,,,,,50677,BAO_0000218,A,,15778,,1,1,CHEMBL625964
12621,N,,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL625965
12622,N,,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,Intermediate,,,,,50594,BAO_0000218,A,,12745,,1,1,CHEMBL625966
12623,N,,,,The plasma clearance in dog.,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL625967
12624,N,,,,The plasma clearance in rat.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13941,Plasma,1,1,CHEMBL625968
12625,N,,,,Clearance from plasma in male Sprague-Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,16449,Plasma,1,1,CHEMBL625969
12626,N,,,,Clearance from plasma in male cynomolgus monkeys,Intermediate,,,,1969.0,100710,BAO_0000218,A,,16449,Plasma,1,1,CHEMBL625970
12627,N,,,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL625971
12628,N,,,,Clearance of compound in dog plasma,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL625972
12629,N,,,,Clearance of compound in human plasma,Intermediate,,,,1969.0,50587,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL625973
12630,N,,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,Intermediate,,,,,50588,BAO_0000218,A,,14317,,1,1,CHEMBL625974
12631,N,,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,Intermediate,,,,,50588,BAO_0000218,A,,14317,,1,1,CHEMBL625975
12632,N,,,,"Clearance (10 mg/kg, intravenously) in dog plasma",Intermediate,,,,1969.0,50588,BAO_0000218,A,,14224,Plasma,1,1,CHEMBL625976
12633,N,,,,Clearance value in dog,Intermediate,,,,,50588,BAO_0000218,A,,17237,,1,1,CHEMBL625977
12634,N,,,,Clearance value in guinea pig,Intermediate,,,,,50512,BAO_0000218,A,,17237,,1,1,CHEMBL625978
12635,N,,,,Clearance values in rats after iv administration.,Intermediate,,,,,50597,BAO_0000218,A,,14187,,1,1,CHEMBL874468
12636,U,,,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Autocuration,,,,1969.0,22224,BAO_0000218,A,,4806,Plasma,0,1,CHEMBL625421
12637,N,,,,In vivo clearance (5 mg/kg) was determined in rabbits,Intermediate,,,,,50592,BAO_0000218,A,,15025,,1,1,CHEMBL625422
12638,N,,,,Plasma Clearance rate was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13197,,1,1,CHEMBL625423
12639,U,,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,Autocuration,,,,,22224,BAO_0000218,A,,13197,,0,1,CHEMBL625424
12640,N,,,,Plasma clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,13960,,1,1,CHEMBL625425
12641,U,,,,Plasma clearance of the compound,Autocuration,,,,,22224,BAO_0000218,A,,17820,,0,1,CHEMBL625426
12642,N,,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,,1,1,CHEMBL625427
12643,N,,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,Intermediate,,,,,50512,BAO_0000218,A,,14706,,1,1,CHEMBL625428
12644,U,,,,Plasma clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,6504,,0,1,CHEMBL625429
12645,N,,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,Intermediate,,,,,50588,BAO_0000218,A,,14925,,1,1,CHEMBL625430
12646,N,,,,Plasma clearance rate was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13197,,1,1,CHEMBL625431
12647,U,,,,Plasma clearance rate was determined for the compound in squirrel monkeys,Autocuration,,,,,22224,BAO_0000218,A,,13197,,0,1,CHEMBL627307
12648,U,,,,Slow clearance (CL) was determined,Autocuration,,,,,22224,BAO_0000218,A,,3437,,0,1,CHEMBL627308
12649,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627309
12650,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627310
12651,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627311
12652,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627312
12653,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627313
12654,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627314
12655,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627315
12656,U,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627316
12657,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627317
12658,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627318
12659,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL627999
12660,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628000
12661,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628001
12662,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL628002
12663,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625610
12664,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625611
12665,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625612
12666,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625613
12667,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL875479
12668,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625614
12669,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL625615
12670,U,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,9196,,0,1,CHEMBL626302
12671,N,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL626303
12672,N,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,,,,178.0,50597,BAO_0000218,A,,8374,Blood,1,1,CHEMBL627420
12673,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL627421
12674,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL625695
12675,N,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL625696
12676,N,,,,Distribution of compound in mice brain was measured after 1 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,Brain,1,1,CHEMBL875606
12677,N,,,,Distribution of compound in mice brain was measured after 24 hr r,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,Brain,1,1,CHEMBL625697
12678,N,,,,Distribution of compound in mice brain was measured after 2 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,Brain,1,1,CHEMBL625698
12679,N,,,,Distribution of compound in mice brain was measured after 3 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,Brain,1,1,CHEMBL625699
12680,N,,,,Distribution of compound in mice brain was measured after 6 hr,Intermediate,,,,955.0,50594,BAO_0000218,A,,10009,Brain,1,1,CHEMBL625700
12681,N,,,,Distribution of compound in mice liver was measured after 1 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625701
12682,N,,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625702
12683,N,,,,Distribution of compound in mice liver was measured after 2 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625703
12684,N,,,,Distribution of compound in mice liver was measured after 3 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625704
12685,N,,,,Distribution of compound in mice liver was measured after 6 hr,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625705
12686,N,,,,Distribution in dog adrenal medulla 30 min after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,Adrenal medulla,1,1,CHEMBL625706
12687,N,,,,Distribution in dog adrenal medulla 72 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,Adrenal medulla,1,1,CHEMBL625707
12688,N,,,,Distribution in female dog Ovary 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL625708
12689,N,,,,Distribution in female dog Ovary 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL625709
12690,N,,,,Distribution in female dog adipose 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624180
12691,N,,,,Distribution in female dog adipose 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624181
12692,N,,,,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,,,,1235.0,50588,BAO_0000218,A,,8170,Adrenal cortex,1,1,CHEMBL624182
12693,N,,,,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,,,,1235.0,50588,BAO_0000218,A,,8170,Adrenal cortex,1,1,CHEMBL624183
12694,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL624184
12695,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL877489
12696,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL624185
12697,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL624186
12698,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL624187
12699,N,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL624188
12700,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624189
12701,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624190
12702,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624191
12703,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624192
12704,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624193
12705,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624194
12706,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624891
12707,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624892
12708,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL624893
12709,N,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL627632
12710,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627633
12711,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627634
12712,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627635
12713,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627636
12714,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626816
12715,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626817
12716,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626818
12717,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626819
12718,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626820
12719,N,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL626821
12720,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626822
12721,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626823
12722,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626824
12723,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626825
12724,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626826
12725,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626827
12726,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626828
12727,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626829
12728,N,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL626830
12729,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627150
12730,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627151
12731,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627152
12732,N,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL627153
12733,U,,,,Rate of acetate production by the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,0,1,CHEMBL627154
12734,U,,,,Rate of acetate production by the compound was determined; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,12904,,0,1,CHEMBL627155
12735,U,,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,Autocuration,,,,,22224,BAO_0000019,A,,3730,,0,1,CHEMBL627156
12736,U,,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,Autocuration,,,,,22224,BAO_0000019,A,,3627,,0,1,CHEMBL627157
12737,N,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,,,,,50592,BAO_0000218,A,,13799,,1,1,CHEMBL627158
12738,N,,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,,,,1969.0,50592,BAO_0000218,A,,13799,Plasma,1,1,CHEMBL627159
12739,N,,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,,50594,BAO_0000218,A,,13799,,1,1,CHEMBL627160
12740,N,,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,,50597,BAO_0000218,A,,13799,,1,1,CHEMBL628540
12741,N,,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,Plasma,1,1,CHEMBL628541
12742,N,,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,Plasma,1,1,CHEMBL628542
12743,U,,,,Solubility after at a pH 1.2,Autocuration,,,,,22229,BAO_0000100,P,,6629,,0,1,CHEMBL628543
12744,U,,,,Solubility after at pH 1.2,Autocuration,,,,,22229,BAO_0000100,P,,6629,,0,1,CHEMBL628544
12745,U,,,,Solubility after injection of water,Autocuration,,,,,22229,BAO_0000100,P,,6629,,0,1,CHEMBL628545
12746,U,,,,Statistical significance of IC 50 values; Expressed as R value,Autocuration,,,,,22224,BAO_0000019,A,,14000,,0,1,CHEMBL628546
12747,U,,,,Systemic availability with respect to methyldopa was determined,Autocuration,,,,,22224,BAO_0000019,A,,8267,,0,1,CHEMBL874455
12748,N,,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,,,,,50597,BAO_0000218,A,,13799,,1,1,CHEMBL628547
12749,N,,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,,,,1969.0,50597,BAO_0000218,A,,13799,Plasma,1,1,CHEMBL628548
12750,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628549
12751,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628550
12752,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628551
12753,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628552
12754,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628553
12755,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628554
12756,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628555
12757,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628556
12758,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Intermediate,,,,2113.0,50592,BAO_0000218,A,,7132,Kidney,1,1,CHEMBL628557
12759,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628558
12760,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628559
12761,N,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628560
12762,N,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL874456
12763,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628561
12764,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL628562
12765,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628563
12766,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628564
12767,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL628565
12768,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL631248
12769,N,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL631249
12770,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Intermediate,,,,2113.0,50592,BAO_0000218,A,,7132,Kidney,1,1,CHEMBL627214
12771,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL874591
12772,N,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL627215
12773,N,,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL625471
12774,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,Intermediate,,,,,50592,BAO_0000218,A,,7132,,1,1,CHEMBL625472
12775,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,Intermediate,,,,,50592,BAO_0000218,A,,7132,,1,1,CHEMBL625473
12776,N,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,Intermediate,,,,,50588,BAO_0000218,A,,13317,,1,1,CHEMBL625474
12777,N,,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,Intermediate,,,,,50588,BAO_0000218,A,,15341,,1,1,CHEMBL625475
12778,N,,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL625476
12779,N,,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL625477
12780,N,,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,,,,,50597,BAO_0000218,A,,15341,,1,1,CHEMBL625478
12781,N,,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,Intermediate,,,,,50597,BAO_0000218,A,,12801,esophageal tunica muscularis mucosae,1,1,CHEMBL625479
12782,N,,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,Intermediate,,,,,50597,BAO_0000218,A,,12801,esophageal tunica muscularis mucosae,1,1,CHEMBL625480
12783,N,,,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14856,Plasma,1,1,CHEMBL625481
12784,N,,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL625482
12785,N,,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL625483
12786,N,,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL625484
12787,N,,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,14062,,1,1,CHEMBL625485
12788,N,,,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625486
12789,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625487
12790,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625488
12791,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625489
12792,N,,,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625490
12793,N,,,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625491
12794,N,,,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14346,Plasma,1,1,CHEMBL625492
12795,N,,,,plasma clearance in human,Intermediate,,,,1969.0,50587,BAO_0000218,A,,15711,Plasma,1,1,CHEMBL625493
12796,N,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL625494
12797,N,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL625495
12798,N,,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,14886,,1,1,CHEMBL625496
12799,U,,,,1-Octanol/water partition coefficient measured at 7.4,Autocuration,,,,,22229,BAO_0000100,P,,4115,,0,1,CHEMBL625497
12800,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13733,,0,1,CHEMBL625498
12801,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,12102,,0,1,CHEMBL625499
12802,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12676,,0,1,CHEMBL625500
12803,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13733,,0,1,CHEMBL625501
12804,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13740,,0,1,CHEMBL625502
12805,U,,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),Autocuration,,,,,22229,BAO_0000100,P,,12766,,0,1,CHEMBL625503
12806,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2764,,0,1,CHEMBL625504
12807,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12355,,0,1,CHEMBL625505
12808,U,,,,Calculated partition coefficient of the compound,Autocuration,,,,,22229,BAO_0000100,P,,11314,,0,1,CHEMBL625506
12809,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,12706,,0,1,CHEMBL625507
12810,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12645,,0,1,CHEMBL625508
12811,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,0,1,CHEMBL625509
12812,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12819,,0,1,CHEMBL625510
12813,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13668,,0,1,CHEMBL883125
12814,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13017,,0,1,CHEMBL625511
12815,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,2448,,0,1,CHEMBL874650
12816,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,11526,,0,1,CHEMBL625512
12817,U,,,,Partition coefficient of compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,12426,,0,1,CHEMBL625513
12818,U,,,,Partition coefficient was determined,Autocuration,,,,,22224,BAO_0000019,A,,2448,,0,1,CHEMBL625514
12819,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12001,,0,1,CHEMBL625515
12820,U,,,,partition coefficient of compound was determined,Autocuration,,,,,22229,BAO_0000100,P,,12426,,0,1,CHEMBL625516
12821,N,,,,The total body administered intravenously in dog,Intermediate,,,,,50588,BAO_0000218,A,,13204,,1,1,CHEMBL625517
12822,N,,,,The total body administered intravenously in rats,Intermediate,,,,,50597,BAO_0000218,A,,13204,,1,1,CHEMBL625518
12823,N,,,,Time taken for the administration to female NIH mice weighing 25-30 g.,Intermediate,,,,,50594,BAO_0000218,A,,13889,,1,1,CHEMBL625519
12824,U,,,,Time taken for the administration,Autocuration,,,,,22224,BAO_0000019,A,,13889,,0,1,CHEMBL625520
12825,N,,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,,,,,50588,BAO_0000218,A,,17025,,1,1,CHEMBL874651
12826,U,,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,,,,,22224,BAO_0000218,A,,17025,,0,1,CHEMBL625521
12827,N,,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL623171
12828,N,,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,,,,,50597,BAO_0000218,A,,17025,,1,1,CHEMBL623853
12829,U,,,,Plasma clearance for the compound was determined.,Autocuration,,,,,22224,BAO_0000019,A,,15067,,0,1,CHEMBL623854
12830,U,,,,CLog P value of the compound,Autocuration,,,,,22224,BAO_0000100,P,,3091,,0,1,CHEMBL874405
12831,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,15592,,0,1,CHEMBL623855
12832,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14738,,0,1,CHEMBL623856
12833,U,,,,ClogP value of the compound; nd ='no data',Autocuration,,,,,22224,BAO_0000100,P,,14738,,0,1,CHEMBL623857
12834,U,,,,ClogP value of the compound; nd ='not determined',Autocuration,,,,,22224,BAO_0000100,P,,14738,,0,1,CHEMBL623858
12835,U,,,,CLog P was determined,Autocuration,,,,,22224,BAO_0000100,P,,6076,,0,1,CHEMBL623859
12836,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17840,,0,1,CHEMBL839829
12837,U,,,,CLogP was calculated,Autocuration,,,,,22224,BAO_0000019,A,,13589,,0,1,CHEMBL623860
12838,U,,,,CLogP value was determined,Autocuration,,,,,22224,BAO_0000019,A,,17655,,0,1,CHEMBL623861
12839,U,,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,Autocuration,,,,,22224,BAO_0000019,A,,5867,,0,1,CHEMBL623862
12840,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,5867,,0,1,CHEMBL874406
12841,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,10783,,0,1,CHEMBL623863
12842,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14849,,0,1,CHEMBL624021
12843,N,,,,Distribution in female dog adrenal medulla 24 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,Adrenal medulla,1,1,CHEMBL624022
12844,N,,,,Distribution in female dog adrenal medulla 72 hours after administration.,Intermediate,,,,1236.0,50588,BAO_0000218,A,,8170,Adrenal medulla,1,1,CHEMBL624023
12845,N,,,,Distribution in female dog bile 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624024
12846,N,,,,Distribution in female dog bile 72 hr after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624025
12847,N,,,,Distribution in female dog blood 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624026
12848,N,,,,Distribution in female dog blood 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624027
12849,N,,,,Distribution in female dog heart 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624028
12850,N,,,,Distribution in female dog heart 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624029
12851,N,,,,Distribution in female dog kidney 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624030
12852,N,,,,Distribution in female dog kidney 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624031
12853,N,,,,Distribution in female dog large intestine 24 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,Intestine,1,1,CHEMBL624032
12854,N,,,,Distribution in female dog large intestine 72 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,Intestine,1,1,CHEMBL874407
12855,N,,,,Distribution in female dog liver 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624033
12856,N,,,,Distribution in female dog liver 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624034
12857,N,,,,Distribution in female dog lung 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624035
12858,N,,,,Distribution in female dog lung 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624036
12859,N,,,,Distribution in female dog muscle 24 hours after administration.,Intermediate,,,,2385.0,50588,BAO_0000218,A,,8170,Muscle tissue,1,1,CHEMBL624037
12860,N,,,,Distribution in female dog muscle 72 hours after administration.,Intermediate,,,,2385.0,50588,BAO_0000218,A,,8170,Muscle tissue,1,1,CHEMBL624038
12861,N,,,,Distribution in female dog pancreas 24 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624039
12862,N,,,,Distribution in female dog pancreas 72 hours after administration.,Intermediate,,,,,50588,BAO_0000218,A,,8170,,1,1,CHEMBL624040
12863,N,,,,Distribution in female dog small intestine 24 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,Intestine,1,1,CHEMBL624041
12864,N,,,,Distribution in female dog small intestine 72 hours after administration.,Intermediate,,,,160.0,50588,BAO_0000218,A,,8170,Intestine,1,1,CHEMBL624042
12865,N,,,,Distribution in female dog spleen 24 hours after administration.,Intermediate,,,,2106.0,50588,BAO_0000218,A,,8170,Spleen,1,1,CHEMBL624043
12866,N,,,,Distribution in female dog spleen 72 hours after administration.,Intermediate,,,,2106.0,50588,BAO_0000218,A,,8170,Spleen,1,1,CHEMBL624044
12867,N,,,,Distribution in female dog stomach 24 hours after administration.,Intermediate,,,,945.0,50588,BAO_0000218,A,,8170,Stomach,1,1,CHEMBL624045
12868,N,,,,Distribution in female dog stomach 72 hours after administration.,Intermediate,,,,945.0,50588,BAO_0000218,A,,8170,Stomach,1,1,CHEMBL624046
12869,N,,,,Distribution in female dog thyroid 24 hours after administration.,Intermediate,,,,2046.0,50588,BAO_0000218,A,,8170,Thyroid gland,1,1,CHEMBL624047
12870,N,,,,Distribution in female dog thyroid 72 hours after administration.,Intermediate,,,,2046.0,50588,BAO_0000218,A,,8170,Thyroid gland,1,1,CHEMBL624048
12871,N,,,,Distribution in female dog urine 24 hours after administration.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,8170,Urine,1,1,CHEMBL874408
12872,N,,,,Distribution in female dog urine 72 hr after administration.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,8170,Urine,1,1,CHEMBL624049
12873,U,,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Autocuration,,,,1969.0,22224,BAO_0000218,A,,14283,Plasma,0,1,CHEMBL624050
12874,U,,,,Plasma concentration at 7 hr after intravenous dosing,Autocuration,,,,,22224,BAO_0000019,A,,5623,,0,1,CHEMBL624051
12875,N,,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623278
12876,N,,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623279
12877,N,,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623280
12878,N,,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623963
12879,N,,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623964
12880,N,,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623965
12881,N,,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623966
12882,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL874415
12883,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623967
12884,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623968
12885,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL623969
12886,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL628409
12887,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL628410
12888,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL628411
12889,N,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL628412
12890,U,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,Autocuration,,,,,22224,BAO_0000019,A,,12553,,0,1,CHEMBL628413
12891,U,,,,The concentration in plasmat; Not determined,Autocuration,,,,1969.0,22224,BAO_0000019,A,,14548,Plasma,0,1,CHEMBL628414
12892,N,,,,Tissue level at 10 mg/kg/po in wistar rats in blood,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL628415
12893,N,,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL628416
12894,N,,,,Tissue level at 10 mg/kg/po in wistar rats in heart,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL628417
12895,N,,,,Tissue level at 10 mg/kg/po in wistar rats in liver,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14393,Liver,1,1,CHEMBL874908
12896,N,,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL628418
12897,N,,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14393,Muscle tissue,1,1,CHEMBL628419
12898,N,,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL628420
12899,U,,,,Water solubility at 37 degree C.,Autocuration,,,,,22224,BAO_0000019,A,,1629,,0,1,CHEMBL628421
12900,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626726
12901,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626727
12902,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL626728
12903,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL626729
12904,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL626730
12905,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL626731
12906,N,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,178.0,50597,BAO_0000218,A,,8594,Blood,1,1,CHEMBL626732
12907,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL626733
12908,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL626734
12909,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL626735
12910,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL874909
12911,N,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,948.0,50597,BAO_0000218,A,,8594,Heart,1,1,CHEMBL626736
12912,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL626737
12913,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL630999
12914,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL631000
12915,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL631001
12916,N,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2113.0,50597,BAO_0000218,A,,8594,Kidney,1,1,CHEMBL631002
12917,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL631003
12918,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL631004
12919,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL631005
12920,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL631006
12921,N,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2107.0,50597,BAO_0000218,A,,8594,Liver,1,1,CHEMBL631007
12922,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL631008
12923,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL631009
12924,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL631010
12925,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL631011
12926,N,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2048.0,50597,BAO_0000218,A,,8594,Lung,1,1,CHEMBL631012
12927,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL630271
12928,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL630272
12929,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL630273
12930,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL630274
12931,N,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,2046.0,50597,BAO_0000218,A,,8594,Thyroid gland,1,1,CHEMBL630275
12932,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL875782
12933,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL630276
12934,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL630277
12935,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL630278
12936,N,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,Intermediate,,,,,50597,BAO_0000218,A,,8594,,1,1,CHEMBL630279
12937,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,0,1,CHEMBL630280
12938,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,0,1,CHEMBL630281
12939,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,Intermediate,,,,,50592,BAO_0000218,A,,7132,,1,1,CHEMBL630282
12940,N,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,Intermediate,,,,,50592,BAO_0000218,A,,7132,,1,1,CHEMBL630283
12941,U,,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),Autocuration,,,,,22224,BAO_0000019,A,,5797,,0,1,CHEMBL630284
12942,U,,,,Alkylating activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,7849,,0,1,CHEMBL630285
12943,U,,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),Autocuration,,,,,22224,BAO_0000251,A,Microsomes,14220,,0,1,CHEMBL630286
12944,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",Intermediate,,,,,50592,BAO_0000218,A,,8650,,1,1,CHEMBL630069
12945,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,1,1,CHEMBL630070
12946,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,1,1,CHEMBL630071
12947,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",Intermediate,,,,,50592,BAO_0000218,A,,8650,,1,1,CHEMBL630072
12948,N,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",Intermediate,,,,,50592,BAO_0000218,A,,8650,,1,1,CHEMBL875110
12949,N,,,,Compound was tested for antidiuretic activity in rats,Intermediate,,,,,50597,BAO_0000218,A,,7116,,1,1,CHEMBL630073
12950,U,,,,Compound was tested for inactivation kinetic values,Autocuration,,,,,22224,BAO_0000019,A,,14131,,0,1,CHEMBL630074
12951,U,,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,Autocuration,,,,,22224,BAO_0000218,A,,7415,,0,1,CHEMBL630075
12952,U,,,,Dissociation rate calculated from the first-order equation using the t1/2 value,Autocuration,,,,,22224,BAO_0000019,A,,13178,,0,1,CHEMBL630076
12953,U,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,Autocuration,,,,,22229,BAO_0000100,P,,8815,,0,1,CHEMBL630077
12954,U,,,,Aqueous solubility was measured,Autocuration,,,,,22229,BAO_0000100,P,,1450,,0,1,CHEMBL630078
12955,U,,,,Aqueous solubility was measured at a pH 4,Autocuration,,,,,22229,BAO_0000100,P,,1450,,0,1,CHEMBL630079
12956,U,,,,Aqueous solubility (pH 7),Autocuration,,,,,22229,BAO_0000100,P,,1450,,0,1,CHEMBL630080
12957,U,,,,Aqueous solubility was measured at a pH 9,Autocuration,,,,,22229,BAO_0000100,P,,1450,,0,1,CHEMBL630081
12958,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",Autocuration,,,,,22224,BAO_0000019,A,,12711,,0,1,CHEMBL630082
12959,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,,,22224,BAO_0000019,A,,12711,,0,1,CHEMBL630083
12960,U,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,,,22224,BAO_0000019,A,,12711,,0,1,CHEMBL630084
12961,U,,,,Aqueous solubility of the compound,Autocuration,,,,,22229,BAO_0000100,P,,15032,,0,1,CHEMBL629198
12962,U,,,,Aqueous solubility at 37 degree Celsius at pH 7.38,Autocuration,,,,,22229,BAO_0000100,P,,9964,,0,1,CHEMBL629199
12963,U,,,,Aqueous solubility in pH 7.4 phosphate buffer,Autocuration,,,,,22229,BAO_0000100,P,,14962,,0,1,CHEMBL629200
12964,N,,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,1,1,CHEMBL629201
12965,N,,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,Intermediate,,,,,50588,BAO_0000218,A,,12487,,1,1,CHEMBL629202
12966,N,,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,1,1,CHEMBL875111
12967,N,,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,1,1,CHEMBL629203
12968,N,,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,1,1,CHEMBL629204
12969,N,,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,1,1,CHEMBL629205
12970,N,,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,,,,,50587,BAO_0000218,A,,10026,,1,1,CHEMBL629206
12971,U,,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,Autocuration,,,,,22224,BAO_0000019,A,,10026,,0,1,CHEMBL631185
12972,N,,,,Compound was evaluated for the average bile flow rat in rats,Intermediate,,,,,50597,BAO_0000218,A,,7415,,1,1,CHEMBL631186
12973,N,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL631187
12974,N,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,,,,,50592,BAO_0000218,A,,17025,,1,1,CHEMBL631188
12975,U,,,,Average half life period was determined,Autocuration,,,,,22224,BAO_0000019,A,,10184,,0,1,CHEMBL876419
12976,U,,,,Average half life period was determined,Autocuration,,,,,22224,BAO_0000019,A,,10184,,0,1,CHEMBL631189
12977,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL631190
12978,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL631191
12979,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL631192
12980,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632400
12981,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL630564
12982,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL630565
12983,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL630566
12984,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL631229
12985,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL631230
12986,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6030,,0,1,CHEMBL876428
12987,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6147,,0,1,CHEMBL631231
12988,U,,,,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,,,22229,BAO_0000100,P,,14556,,0,1,CHEMBL631232
12989,U,,,,Hydrophilicity was determined,Autocuration,,,,,22224,BAO_0000019,A,,768,,0,1,CHEMBL631233
12990,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14452,,0,1,CHEMBL631234
12991,U,,,,Increased absorption was determined,Autocuration,,,,,22224,BAO_0000019,A,,5237,,0,1,CHEMBL883126
12992,U,,,,Lipophilicity value was evaluated,Autocuration,,,,,22224,BAO_0000100,P,,14378,,0,1,CHEMBL631235
12993,U,,,,Log P value of the compound.,Autocuration,,,,,22224,BAO_0000100,P,,14418,,0,1,CHEMBL631236
12994,U,,,,Partition coefficient of compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,5249,,0,1,CHEMBL631237
12995,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14621,,0,1,CHEMBL631238
12996,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12542,,0,1,CHEMBL876429
12997,U,,,,Partition coefficient was measured by medchem software; Not calculated,Autocuration,,,,,22224,BAO_0000019,A,,12542,,0,1,CHEMBL631414
12998,U,,,,Partition coefficient was measured by octanol-water using standard shake-flask method,Autocuration,,,,,22224,BAO_0000100,P,,12542,,0,1,CHEMBL631415
12999,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,15462,,0,1,CHEMBL631416
13000,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,14884,,0,1,CHEMBL631417
13001,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,16526,,0,1,CHEMBL631418
13002,U,,,,The Octanol/Water partition coefficient CLogP,Autocuration,,,,,22229,BAO_0000100,P,,13693,,0,1,CHEMBL631419
13003,U,,,,The pharmacokinetic parameter C Log p was reported,Autocuration,,,,,22224,BAO_0000019,A,,13693,,0,1,CHEMBL631420
13004,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13779,,0,1,CHEMBL631421
13005,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14772,,0,1,CHEMBL631422
13006,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,14393,,0,1,CHEMBL631423
13007,N,,,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL876430
13008,N,,,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL631424
13009,N,,,,Compound was administered intravenously in dog to evaluate plasma clearance values,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13744,Plasma,1,1,CHEMBL631425
13010,U,,,,Compound was administered intravenously in monkey to evaluate plasma clearance values,Autocuration,,,,1969.0,22224,BAO_0000218,A,,13744,Plasma,0,1,CHEMBL631426
13011,N,,,,Compound was administered intravenously in mouse to evaluate plasma clearance values,Intermediate,,,,1969.0,50594,BAO_0000218,A,,13744,Plasma,1,1,CHEMBL631427
13012,N,,,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Intermediate,,,,1969.0,50588,BAO_0000218,A,,13207,Plasma,1,1,CHEMBL631428
13013,N,,,,Intrinsic clearance in Rhesus liver microsome,Intermediate,,,,2107.0,50797,BAO_0000218,A,Microsomes,5669,Liver,1,1,CHEMBL631429
13014,N,,,,Intrinsic clearance in dog liver microsome,Intermediate,,,,2107.0,50588,BAO_0000218,A,Microsomes,5669,Liver,1,1,CHEMBL631430
13015,N,,,,Intrinsic clearance in rat liver microsome,Intermediate,,,,2107.0,50597,BAO_0000218,A,Microsomes,5669,Liver,1,1,CHEMBL631431
13016,N,,,,Low plasma clearance was calculated in rhesus monkey,Intermediate,,,,1969.0,50797,BAO_0000218,A,,4853,Plasma,1,1,CHEMBL631432
13017,N,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,,,50588,BAO_0000218,A,,16452,,1,1,CHEMBL631433
13018,U,,,,Plasma clearance after intravenous dose of 0.3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL631434
13019,U,,,,Plasma clearance after intravenous dose of 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL631435
13020,U,,,,Plasma clearance after intravenous dose of 3 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL631436
13021,U,,,,Plasma clearance after intravenous dose of 3.87 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,11954,,0,1,CHEMBL631437
13022,N,,,,Plasma clearance after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL631438
13023,N,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,,1,1,CHEMBL876431
13024,N,,,,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5669,,1,1,CHEMBL631439
13025,N,,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,Intermediate,,,,,50597,BAO_0000218,A,,13662,,1,1,CHEMBL631440
13026,U,,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),Autocuration,,,,,22224,BAO_0000019,A,,8272,,0,1,CHEMBL631441
13027,U,,,,Critical Micellar concentration was determined,Autocuration,,,,,22224,BAO_0000019,A,,13410,,0,1,CHEMBL631442
13028,U,,,,Critical Micellar concentration of the compound. was determined,Autocuration,,,,,22224,BAO_0000019,A,,13410,,0,1,CHEMBL626525
13029,U,,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,Autocuration,,,,,22224,BAO_0000019,A,,12628,,0,1,CHEMBL627168
13030,U,,,,Critical micellar concentration was measured in water by the dye solubilization method,Autocuration,,,,,22224,BAO_0000019,A,,9675,,0,1,CHEMBL875618
13031,U,,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,Autocuration,,,,,22224,BAO_0000019,B,,12628,,0,1,CHEMBL626612
13032,U,,,,CMR value (relative to BAY K 8644),Autocuration,,,,,22224,BAO_0000019,A,,12766,,0,1,CHEMBL626613
13033,U,,,,Carbamoylating activity was determined,Autocuration,,,,,22224,BAO_0000019,A,,7849,,0,1,CHEMBL626614
13034,U,,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL626615
13035,U,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,2040,,0,1,CHEMBL626616
13036,U,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,2040,,0,1,CHEMBL626617
13037,N,,,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Intermediate,,,,1969.0,50588,BAO_0000218,A,,14180,Plasma,1,1,CHEMBL626618
13038,N,,,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14180,Plasma,1,1,CHEMBL626619
13039,N,,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",Intermediate,,,,,50588,BAO_0000218,A,,14474,,1,1,CHEMBL626620
13040,N,,,,"Clearance rate at 5.5 mg/kg, iv, in rat",Intermediate,,,,,50597,BAO_0000218,A,,14474,,1,1,CHEMBL626621
13041,N,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,1,1,CHEMBL626622
13042,N,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,,,,,100710,BAO_0000218,A,,14548,,1,1,CHEMBL626623
13043,N,,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,,,,,50588,BAO_0000218,A,,14548,,1,1,CHEMBL626624
13044,N,,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,14548,,1,1,CHEMBL626625
13045,N,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6125,Liver,1,1,CHEMBL626626
13046,U,,,,Tested for the total clearance of the compound,Autocuration,,,,,22224,BAO_0000218,A,,6874,,0,1,CHEMBL626627
13047,N,,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,Intermediate,,,,,50588,BAO_0000218,A,,15343,,1,1,CHEMBL626628
13048,U,,,,Total body clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,6236,,0,1,CHEMBL626629
13049,N,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626630
13050,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626631
13051,U,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626632
13052,U,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626633
13053,U,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626634
13054,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626635
13055,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626636
13056,U,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,,,22229,BAO_0000100,P,,8194,,0,1,CHEMBL626637
13057,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL626638
13058,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL626639
13059,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL626640
13060,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL626641
13061,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL627272
13062,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL627273
13063,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL627441
13064,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL628355
13065,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL628356
13066,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL628357
13067,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL628358
13068,N,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),Intermediate,,,,,50339,BAO_0000218,A,,13273,,1,1,CHEMBL622307
13069,U,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622527
13070,U,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622528
13071,U,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622529
13072,U,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622992
13073,U,,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622993
13074,U,,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,Autocuration,,,,,22224,BAO_0000019,A,,13118,,0,1,CHEMBL622994
13075,N,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,1,1,CHEMBL622995
13076,N,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",Intermediate,,,,,50597,BAO_0000218,A,,10633,,1,1,CHEMBL622996
13077,N,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,1,1,CHEMBL622997
13078,N,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",Intermediate,,,,,50597,BAO_0000218,A,,10633,,1,1,CHEMBL622998
13079,U,,,,Cp max following ip administration at 1 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,5767,,0,1,CHEMBL622999
13080,U,,,,Maximum concentration in plasma was reported at 0.5 hour,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3302,Plasma,0,1,CHEMBL623000
13081,U,,,,Maximum concentration in plasma was reported at 2 hour,Autocuration,,,,1969.0,22224,BAO_0000218,A,,3302,Plasma,0,1,CHEMBL623001
13082,N,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,Intermediate,,,,,50594,BAO_0000218,A,,12467,,1,1,CHEMBL623002
13083,U,,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),Autocuration,,,,,22229,BAO_0000100,P,,11778,,0,1,CHEMBL623003
13084,U,,,,Steady state concentration was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,4321,,0,1,CHEMBL623004
13085,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,14884,,0,1,CHEMBL623005
13086,U,,,,Partition coefficient (logD7.4),Autocuration,,,,,22224,BAO_0000019,A,,15234,,0,1,CHEMBL623006
13087,N,,,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,Liver,1,1,CHEMBL623007
13088,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,Bone,1,1,CHEMBL623008
13089,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,Cerebellum,1,1,CHEMBL876654
13090,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL623009
13091,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL623010
13092,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,Heart,1,1,CHEMBL623011
13093,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,Intestine,1,1,CHEMBL623012
13094,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,0,1,CHEMBL623013
13095,U,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,,,22224,BAO_0000019,A,,8151,,0,1,CHEMBL623014
13096,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,Urine,0,1,CHEMBL623015
13097,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,Urine,0,1,CHEMBL623016
13098,U,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Autocuration,,,,1088.0,22224,BAO_0000019,A,,8151,Urine,0,1,CHEMBL624858
13099,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL624859
13100,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL624860
13101,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL624861
13102,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL624862
13103,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL624863
13104,N,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,,,,50597,BAO_0000218,A,,8151,,1,1,CHEMBL876655
13105,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624864
13106,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624865
13107,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624866
13108,N,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,Expert,,,,,50588,BAO_0000218,F,,6996,,1,1,CHEMBL624867
13109,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL624868
13110,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628450
13111,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628451
13112,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628452
13113,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628453
13114,N,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628454
13115,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628455
13116,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628456
13117,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628457
13118,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL877505
13119,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628458
13120,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628459
13121,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628460
13122,N,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628461
13123,U,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",Autocuration,,,,,22224,BAO_0000218,B,,6996,,0,1,CHEMBL628462
13124,N,,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL628463
13125,N,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",Expert,,,,,50597,BAO_0000218,F,,6996,,1,1,CHEMBL625666
13126,U,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Autocuration,,,,,22224,BAO_0000218,B,,6996,,0,1,CHEMBL625667
13127,N,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Expert,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625668
13128,N,,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL625669
13129,U,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,Autocuration,,,,,22224,BAO_0000019,A,,7114,,0,1,CHEMBL625670
13130,N,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,Intermediate,,,,,50597,BAO_0000218,A,,7114,,1,1,CHEMBL625671
13131,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL625672
13132,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL625673
13133,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL625674
13134,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL625675
13135,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627637
13136,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627638
13137,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627639
13138,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627640
13139,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627641
13140,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL627642
13141,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL877506
13142,N,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,,,,,50594,BAO_0000218,A,,8613,,1,1,CHEMBL627275
13143,N,,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL627643
13144,N,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL631246
13145,N,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL631247
13146,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL629532
13147,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL629533
13148,N,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL629534
13149,N,,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,Intermediate,,,,,50506,BAO_0000218,A,,11219,,1,1,CHEMBL629535
13150,U,,,,Pharmacokinetic parameter :drug bound to plasma was reported,Autocuration,,,,,22224,BAO_0000019,A,,14837,,0,1,CHEMBL625932
13151,U,,,,compound was evaluated for drug bound in plasma,Autocuration,,,,,22224,BAO_0000019,A,,14837,,0,1,CHEMBL625933
13152,N,,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,Intermediate,,,,,50597,BAO_0000218,A,,15343,,1,1,CHEMBL625934
13153,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,13761,,0,1,CHEMBL625935
13154,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,Intermediate,,,,,50597,BAO_0000218,A,,14810,,1,1,CHEMBL625936
13155,N,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,Intermediate,,,,,50597,BAO_0000218,A,,14810,,1,1,CHEMBL625937
13156,N,,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,,,,,50588,BAO_0000218,A,,13249,,1,1,CHEMBL625938
13157,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL625939
13158,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL625940
13159,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL874464
13160,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL625941
13161,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL625942
13162,N,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Intermediate,,,,1970.0,50597,BAO_0000218,A,,9267,Bile,1,1,CHEMBL625943
13163,N,,,,In vitro protein binding in human serum at 5 ug/ml,Intermediate,,,,1977.0,50587,BAO_0000218,A,,15549,Serum,1,1,CHEMBL625944
13164,U,,,,Serum protein binding ability was measured,Autocuration,,,,,22224,BAO_0000019,A,,10929,,0,1,CHEMBL625945
13165,U,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,,,22224,BAO_0000019,A,,15444,,0,1,CHEMBL625946
13166,U,,,,Oral bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,12860,,0,1,CHEMBL625947
13167,N,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Intermediate,,,,,50597,BAO_0000218,A,,12170,,1,1,CHEMBL625948
13168,U,,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625949
13169,U,,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625950
13170,U,,,,Oral bioavailability (dose 15 mg/kg i.v.),Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625951
13171,U,,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625952
13172,U,,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625953
13173,U,,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL625954
13174,U,,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL882959
13175,N,,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,Intermediate,,,,,50588,BAO_0000218,A,,11767,,1,1,CHEMBL625955
13176,U,,,,Bioavailability in ferret,Autocuration,,,,,22224,BAO_0000218,A,,11219,,0,1,CHEMBL625956
13177,N,,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,Intermediate,,,,,100710,BAO_0000218,A,,12186,,1,1,CHEMBL625957
13178,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL625958
13179,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL625959
13180,N,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626642
13181,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL631330
13182,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL631331
13183,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL631332
13184,N,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL631333
13185,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632018
13186,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632019
13187,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632020
13188,N,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632021
13189,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632022
13190,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632023
13191,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632024
13192,N,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL874472
13193,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632025
13194,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632026
13195,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632027
13196,N,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL632028
13197,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626430
13198,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626431
13199,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626432
13200,N,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626433
13201,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626434
13202,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627280
13203,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627281
13204,N,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627282
13205,U,,,,Total body clearance was measured at given dose,Autocuration,,,,,22224,BAO_0000019,A,,7199,,0,1,CHEMBL627283
13206,U,,,,Total body clearance was measured at given dose.,Autocuration,,,,,22224,BAO_0000218,A,,7199,,0,1,CHEMBL627284
13207,N,,,,Metabolic clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,,1,1,CHEMBL627285
13208,U,,,,Renal clearance from the body,Autocuration,,,,,22224,BAO_0000218,A,,7095,,0,1,CHEMBL627286
13209,N,,,,Renal clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,,1,1,CHEMBL875477
13210,N,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,12528,,1,1,CHEMBL627287
13211,N,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,Intermediate,,,,,50588,BAO_0000218,A,,12528,,1,1,CHEMBL627288
13212,N,,,,Total clearance from the body in rat,Intermediate,,,,,50597,BAO_0000218,A,,7095,,1,1,CHEMBL627289
13213,N,,,,Clearance into cortex from rat plasma or PBS,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14223,Plasma,1,1,CHEMBL627290
13214,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,,0,1,CHEMBL627291
13215,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,,0,1,CHEMBL627292
13216,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,,0,1,CHEMBL627293
13217,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,,0,1,CHEMBL627294
13218,U,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,Autocuration,,,,,22224,BAO_0000218,A,,13569,,0,1,CHEMBL875478
13219,U,,,,Clearance was determined,Autocuration,,,,,22224,BAO_0000218,A,,13979,,0,1,CHEMBL627295
13220,N,,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50594,BAO_0000218,A,,14315,,1,1,CHEMBL627296
13221,N,,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50592,BAO_0000218,A,,14315,,1,1,CHEMBL626119
13222,N,,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,Intermediate,,,,,50597,BAO_0000218,A,,14315,,1,1,CHEMBL626120
13223,N,,,,Clearance in rat after iv dose (100 ug/kg),Intermediate,,,,,50597,BAO_0000218,A,,12174,,1,1,CHEMBL626121
13224,U,,,,Clearance in guinea pig,Autocuration,,,,,22224,BAO_0000218,A,,12797,,0,1,CHEMBL626122
13225,N,,,,Compound was evaluated for clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,,1,1,CHEMBL626123
13226,N,,,,Compound was evaluated for the clearance in dog,Intermediate,,,,,50588,BAO_0000218,A,,12797,,1,1,CHEMBL623456
13227,N,,,,Compound was evaluated for the clearance in rat,Intermediate,,,,,50597,BAO_0000218,A,,12797,,1,1,CHEMBL623457
13228,N,,,,Compound was tested in vivo for clearance after iv administration in the rat,Intermediate,,,,,50597,BAO_0000218,A,,11500,,1,1,CHEMBL623458
13229,U,,,,IV clearance determined at an iv dose of 14 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL623459
13230,U,,,,IV clearance determined at an iv dose of 15.2 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL875484
13231,U,,,,IV clearance determined at an iv dose of 15 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL623460
13232,U,,,,IV clearance determined at an peroral dose of 30 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL623461
13233,U,,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL623462
13234,U,,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL627386
13235,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,Kidney,1,1,CHEMBL627387
13236,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,Liver,1,1,CHEMBL627388
13237,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,Lung,1,1,CHEMBL627389
13238,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,Muscle tissue,1,1,CHEMBL627390
13239,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,Plasma,1,1,CHEMBL627391
13240,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL627392
13241,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,Spleen,1,1,CHEMBL627393
13242,N,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,Trachea,1,1,CHEMBL627394
13243,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,Bone,1,1,CHEMBL627395
13244,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,Cerebellum,1,1,CHEMBL875485
13245,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL627396
13246,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL627397
13247,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,Heart,1,1,CHEMBL627398
13248,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,Bone,1,1,CHEMBL627399
13249,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,Kidney,1,1,CHEMBL627400
13250,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,Liver,1,1,CHEMBL627401
13251,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,Lung,1,1,CHEMBL627402
13252,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,Muscle tissue,1,1,CHEMBL627403
13253,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,Plasma,1,1,CHEMBL627404
13254,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL623101
13255,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,Spleen,1,1,CHEMBL877480
13256,N,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,Trachea,1,1,CHEMBL623102
13257,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,Bone,1,1,CHEMBL623103
13258,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,Cerebellum,1,1,CHEMBL623104
13259,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL623105
13260,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL623106
13261,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,Heart,1,1,CHEMBL623107
13262,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,Intestine,1,1,CHEMBL623108
13263,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,Kidney,1,1,CHEMBL623109
13264,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,,,,2107.0,50597,BAO_0000218,A,,14198,Liver,1,1,CHEMBL623110
13265,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,Lung,1,1,CHEMBL623111
13266,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,Muscle tissue,1,1,CHEMBL625060
13267,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,Plasma,1,1,CHEMBL625061
13268,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL625062
13269,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,Spleen,1,1,CHEMBL625063
13270,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,Trachea,1,1,CHEMBL625064
13271,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,,,,10000001.0,50597,BAO_0000218,A,,14198,Bone,1,1,CHEMBL625065
13272,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,,,,2037.0,50597,BAO_0000218,A,,14198,Cerebellum,1,1,CHEMBL625066
13273,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL625067
13274,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL625068
13275,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,,,,948.0,50597,BAO_0000218,A,,14198,Heart,1,1,CHEMBL622159
13276,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intermediate,,,,160.0,50597,BAO_0000218,A,,14198,Intestine,1,1,CHEMBL622160
13277,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,,,,2113.0,50597,BAO_0000218,A,,14198,Kidney,1,1,CHEMBL622161
13278,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,,,,2048.0,50597,BAO_0000218,A,,14198,Lung,1,1,CHEMBL622162
13279,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,,,,2385.0,50597,BAO_0000218,A,,14198,Muscle tissue,1,1,CHEMBL622163
13280,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14198,Plasma,1,1,CHEMBL622313
13281,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14198,,1,1,CHEMBL622314
13282,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,,,,2106.0,50597,BAO_0000218,A,,14198,Spleen,1,1,CHEMBL622315
13283,N,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,,,,3126.0,50597,BAO_0000218,A,,14198,Trachea,1,1,CHEMBL622316
13284,N,,,,Normal diffusion coefficient in water for Escherichia coli,Intermediate,,,,,50212,BAO_0000218,A,,15599,,1,1,CHEMBL877486
13285,U,,,,Average max percent decrease in RVR (renal vascular resistance) was determined,Autocuration,,,,,22224,BAO_0000019,A,,8204,,0,1,CHEMBL622317
13286,U,,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,Autocuration,,,,,22224,BAO_0000019,A,,8204,,0,1,CHEMBL622318
13287,U,,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL622319
13288,U,,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL622320
13289,U,,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL622321
13290,U,,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL622322
13291,U,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,Autocuration,,,,,22224,BAO_0000019,A,,7114,,0,1,CHEMBL622323
13292,N,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,Intermediate,,,,,50597,BAO_0000218,A,,7114,,1,1,CHEMBL622324
13293,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622325
13294,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622326
13295,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL877487
13296,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622327
13297,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622328
13298,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622329
13299,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622330
13300,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622331
13301,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622332
13302,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL622333
13303,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL627658
13304,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL630428
13305,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL630429
13306,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL630430
13307,U,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL630431
13308,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL630432
13309,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL630433
13310,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL630434
13311,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629372
13312,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629553
13313,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629554
13314,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL874447
13315,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629555
13316,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629556
13317,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629557
13318,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629558
13319,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629559
13320,N,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629560
13321,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629561
13322,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629562
13323,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629563
13324,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629564
13325,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629565
13326,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629566
13327,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629567
13328,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629568
13329,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629569
13330,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629570
13331,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL629571
13332,U,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,,,,,22224,BAO_0000218,A,,12170,,0,1,CHEMBL629572
13333,U,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,,,,,22224,BAO_0000218,A,,12170,,0,1,CHEMBL629573
13334,U,,,,Bioavailability (dose 20 mg/kg),Autocuration,,,,,22224,BAO_0000218,A,,4985,,0,1,CHEMBL629574
13335,U,,,,Bioavailability in dog,Autocuration,,,,,22224,BAO_0000218,A,,15145,,0,1,CHEMBL629575
13336,U,,,,Bioavailability in rat (Sprague-Dawley) (male),Autocuration,,,,,22224,BAO_0000218,A,,14080,,0,1,CHEMBL874448
13337,U,,,,Bioavailability in monkey (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,11219,,0,1,CHEMBL629576
13338,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,15145,,0,1,CHEMBL629577
13339,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,15145,,0,1,CHEMBL629578
13340,U,,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,1202,,0,1,CHEMBL629579
13341,U,,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,Autocuration,,,,,22224,BAO_0000218,A,,1202,,0,1,CHEMBL882958
13342,N,,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,Intermediate,,,,,50505,BAO_0000218,A,,1202,,1,1,CHEMBL629580
13343,U,,,,Bioavailability,Autocuration,,,,,22224,BAO_0000218,A,,4026,,0,1,CHEMBL629581
13344,U,,,,Bioavailability in squirrel monkey,Autocuration,,,,,22224,BAO_0000218,A,,1492,,0,1,CHEMBL629582
13345,N,,,,Bioavailability was evaluated in dog,Intermediate,,,,,50588,BAO_0000218,A,,12793,,1,1,CHEMBL628522
13346,N,,,,Bioavailability was evaluated in hamster,Intermediate,,,,,100712,BAO_0000218,A,,12793,,1,1,CHEMBL625432
13347,U,,,,Bioavailability in rat,Autocuration,,,,,22224,BAO_0000218,A,,12793,,0,1,CHEMBL625433
13348,N,,,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL625434
13349,N,,,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Intermediate,,,,1969.0,50597,BAO_0000218,A,,14793,Plasma,1,1,CHEMBL625435
13350,U,,,,Bioavailability in rat (dose 10 mg/kg p.o.),Autocuration,,,,,22224,BAO_0000218,A,,14793,,0,1,CHEMBL625436
13351,N,,,,Bioavailability was measured in cynomolgus monkeys.,Intermediate,,,,,100710,BAO_0000218,A,,14731,,1,1,CHEMBL874588
13352,N,,,,Bioavailability was measured in nude mice.,Intermediate,,,,,50594,BAO_0000218,A,,14731,,1,1,CHEMBL625437
13353,U,,,,Bioavailability in ferret (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625438
13354,U,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625439
13355,U,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625440
13356,U,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625441
13357,U,,,,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,,,,,22224,BAO_0000218,A,,12187,,0,1,CHEMBL625442
13358,N,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,,,,,50597,BAO_0000218,A,,12187,,1,1,CHEMBL625443
13359,U,,,,Bioavailability was determined; extremely poor,Autocuration,,,,,22224,BAO_0000218,A,,17431,,0,1,CHEMBL625444
13360,N,,,,% bioavailability in mice after oral administration of prodrug,Intermediate,,,,,50594,BAO_0000218,A,,13318,,1,1,CHEMBL625445
13361,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625446
13362,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL882960
13363,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625447
13364,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625448
13365,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625449
13366,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL874589
13367,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625450
13368,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625451
13369,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626584
13370,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626585
13371,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626586
13372,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626587
13373,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626588
13374,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626589
13375,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626590
13376,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL626591
13377,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL627181
13378,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628083
13379,U,,,,IV clearance determined at an peroral dose of 15 mg/kg.,Autocuration,,,,,22224,BAO_0000218,A,,15173,,0,1,CHEMBL628084
13380,N,,,,Mouse oral clearance was measured against Hymenolepiasis nana.,Expert,,,,,50064,BAO_0000218,F,,7732,,1,1,CHEMBL628085
13381,N,,,,Mouse oral clearance was measured against Nematospiroides dubius,Expert,,,,,50545,BAO_0000218,F,,7732,,1,1,CHEMBL628086
13382,U,,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,Autocuration,,,,,22224,BAO_0000218,F,,7732,,0,1,CHEMBL628087
13383,N,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,Intermediate,,,,,50594,BAO_0000218,A,,7732,,1,1,CHEMBL628088
13384,U,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,Autocuration,,,,,22224,BAO_0000218,B,,7732,,0,1,CHEMBL628089
13385,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL628090
13386,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL628091
13387,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL628092
13388,U,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL628093
13389,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL875607
13390,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL625710
13391,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL625711
13392,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL625712
13393,U,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,,,22224,BAO_0000218,A,,8328,,0,1,CHEMBL625713
13394,N,,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,Intermediate,,,,,50588,BAO_0000218,A,,13376,,1,1,CHEMBL625714
13395,N,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,Intermediate,,,,,50797,BAO_0000218,A,,13477,,1,1,CHEMBL625715
13396,N,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL625716
13397,N,,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,Intermediate,,,,,50597,BAO_0000218,A,,13477,,1,1,CHEMBL625717
13398,N,,,,Plasma clearance was determined for the compound in rats,Intermediate,,,,,50597,BAO_0000218,A,,13313,,1,1,CHEMBL625718
13399,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL625719
13400,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL625720
13401,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL625721
13402,N,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,,,,,50597,BAO_0000218,A,,12504,,1,1,CHEMBL625722
13403,N,,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,,,,,50597,BAO_0000218,A,,13129,,1,1,CHEMBL625723
13404,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,,1,1,CHEMBL625724
13405,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,,1,1,CHEMBL625725
13406,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,,1,1,CHEMBL625726
13407,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,,1,1,CHEMBL875608
13408,N,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,Intermediate,,,,,50545,BAO_0000218,A,,7732,,1,1,CHEMBL625727
13409,U,,,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,Urine,0,1,CHEMBL625728
13410,U,,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,,,,,22224,BAO_0000218,A,,9278,,0,1,CHEMBL625729
13411,U,,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,Autocuration,,,,,22224,BAO_0000218,A,,9278,,0,1,CHEMBL625730
13412,U,,,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,Urine,0,1,CHEMBL625731
13413,U,,,,Urinary clearance was determined in rat at 25 mg/kg os dosage,Autocuration,,,,1088.0,22224,BAO_0000218,A,,9278,Urine,0,1,CHEMBL626417
13414,N,,,,Urinary clearance was determined at 100 mg/kg oral dosage in human,Intermediate,,,,1088.0,50587,BAO_0000218,A,,9278,Urine,1,1,CHEMBL626418
13415,N,,,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Intermediate,,,,1088.0,50588,BAO_0000218,A,,9278,Urine,1,1,CHEMBL626419
13416,N,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50588,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL626592
13417,N,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,,,,1969.0,50597,BAO_0000218,A,,5932,Plasma,1,1,CHEMBL626593
13418,N,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,,,,50597,BAO_0000218,A,,5182,,1,1,CHEMBL626594
13419,N,,,,Clearance rate in dogs,Intermediate,,,,,50588,BAO_0000218,A,,10499,,1,1,CHEMBL625035
13420,U,,,,Compound was measured for intrinsic clearance,Autocuration,,,,,22224,BAO_0000019,A,,6051,,0,1,CHEMBL625036
13421,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17508,,0,1,CHEMBL625037
13422,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6228,,0,1,CHEMBL625038
13423,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6231,,0,1,CHEMBL625039
13424,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17740,,0,1,CHEMBL625040
13425,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6495,,0,1,CHEMBL625041
13426,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2171,,0,1,CHEMBL625042
13427,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,3255,,0,1,CHEMBL874411
13428,U,,,,Permeability,Autocuration,,,,,22224,BAO_0000019,A,,6821,,0,1,CHEMBL625043
13429,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,2685,,0,1,CHEMBL625044
13430,U,,,,Partition coefficient (logD),Autocuration,,,,,22224,BAO_0000019,A,,17584,,0,1,CHEMBL625045
13431,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,0,1,CHEMBL625046
13432,U,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,,,22229,BAO_0000100,P,,13824,,0,1,CHEMBL625047
13433,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,16479,,0,1,CHEMBL625048
13434,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,11997,,0,1,CHEMBL625049
13435,U,,,,Calculated logarithm of partition coefficient (P) was determined,Autocuration,,,,,22229,BAO_0000100,P,,2988,,0,1,CHEMBL625050
13436,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,931,,0,1,CHEMBL625051
13437,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4381,,0,1,CHEMBL874412
13438,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4397,,0,1,CHEMBL625052
13439,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,5889,,0,1,CHEMBL625053
13440,U,,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623250
13441,U,,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623251
13442,U,,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623252
13443,U,,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623253
13444,U,,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623254
13445,U,,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,,,22224,BAO_0000019,A,,6154,,0,1,CHEMBL623255
13446,U,,,,Percent degradation of compound at a pH of 1 over a 18 hr period,Autocuration,,,,,22224,BAO_0000019,A,,6887,,0,1,CHEMBL626831
13447,U,,,,Percent degradation of compound at pH of 1 over an 18 hr period,Autocuration,,,,,22224,BAO_0000019,A,,6887,,0,1,CHEMBL877494
13448,U,,,,Delta Logarithm of Partition Coefficient value was determined.,Autocuration,,,,,22224,BAO_0000019,A,,14116,,0,1,CHEMBL626832
13449,U,,,,Delta logPoct-cyc,Autocuration,,,,,22224,BAO_0000019,A,,11137,,0,1,CHEMBL626833
13450,U,,,,Lipophilicity estimated on reversed phase TLC,Autocuration,,,,,22224,BAO_0000100,P,,7230,,0,1,CHEMBL626834
13451,U,,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,Autocuration,,,,,22224,BAO_0000019,A,,15741,,0,1,CHEMBL626835
13452,U,,,,Delta logPoct-cyc,Autocuration,,,,,22224,BAO_0000019,A,,9663,,0,1,CHEMBL626836
13453,U,,,,Change in logarithm of partition coefficient of the compound,Autocuration,,,,,22229,BAO_0000100,P,,9663,,0,1,CHEMBL626837
13454,U,,,,Delta logD (pH 6.5),Autocuration,,,,,22224,BAO_0000019,A,,13807,,0,1,CHEMBL626838
13455,U,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",Autocuration,,,,,22224,BAO_0000100,P,,13807,,0,1,CHEMBL626839
13456,U,,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,Autocuration,,,,,22224,BAO_0000019,A,,17425,,0,1,CHEMBL626840
13457,U,,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),Autocuration,,,,,22224,BAO_0000019,A,,12143,,0,1,CHEMBL626841
13458,U,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,Autocuration,,,,,22224,BAO_0000219,A,,12608,,0,1,CHEMBL626842
13459,U,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,Autocuration,,,,,22224,BAO_0000219,A,,12608,,0,1,CHEMBL626843
13460,N,,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL626844
13461,N,,,,Amount of deuterium retained was reported after normal workup in rats,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL877495
13462,N,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL626845
13463,N,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL626846
13464,N,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL626847
13465,N,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL628677
13466,N,,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,Intermediate,,,,,50597,BAO_0000218,A,,8649,,1,1,CHEMBL628678
13467,U,,,,Compound was subjected to electrochemical oxidation,Autocuration,,,,,22224,BAO_0000019,A,,9659,,0,1,CHEMBL628679
13468,U,,,,Compound was subjected to photochemical oxidation,Autocuration,,,,,22224,BAO_0000019,A,,9659,,0,1,CHEMBL628680
13469,U,,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,0,1,CHEMBL628681
13470,U,,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,0,1,CHEMBL628682
13471,U,,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,Autocuration,,,,,22224,BAO_0000019,A,,9659,,0,1,CHEMBL628683
13472,N,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,Intermediate,,,,,50597,BAO_0000218,A,,9607,,1,1,CHEMBL628684
13473,U,,,,Dissociation constant (pKa),Autocuration,,,,,22229,BAO_0000100,P,,7057,,0,1,CHEMBL877501
13474,U,,,,Dissociation constant value of the compound; ND means not determined.,Autocuration,,,,,22224,BAO_0000100,P,,7057,,0,1,CHEMBL628685
13475,N,,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Intermediate,,,,178.0,50597,BAO_0000218,A,,7911,Blood,1,1,CHEMBL628686
13476,N,,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,178.0,50597,BAO_0000218,A,,7911,Blood,1,1,CHEMBL628687
13477,N,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,1,1,CHEMBL628688
13478,N,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,1,1,CHEMBL628689
13479,N,,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7911,Liver,1,1,CHEMBL628690
13480,N,,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,,,,2107.0,50597,BAO_0000218,A,,7911,Liver,1,1,CHEMBL629363
13481,N,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Intermediate,,,,2106.0,50597,BAO_0000218,A,,7911,Spleen,1,1,CHEMBL629364
13482,N,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,2106.0,50597,BAO_0000218,A,,7911,Spleen,1,1,CHEMBL629365
13483,N,,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,Intermediate,,,,,50597,BAO_0000218,A,,7911,,1,1,CHEMBL629366
13484,N,,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7911,Urine,1,1,CHEMBL629367
13485,N,,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,,,,1988.0,50597,BAO_0000218,A,,7911,Feces,1,1,CHEMBL629368
13486,N,,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7911,Urine,1,1,CHEMBL877502
13487,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Intermediate,,,,2037.0,50594,BAO_0000218,A,,13792,Cerebellum,1,1,CHEMBL629369
13488,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL629370
13489,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL629371
13490,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL626276
13491,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL626277
13492,U,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL631250
13493,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631251
13494,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631252
13495,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631253
13496,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631254
13497,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631255
13498,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631256
13499,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL631257
13500,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628009
13501,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628010
13502,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628011
13503,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628012
13504,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628013
13505,N,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628014
13506,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628015
13507,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628016
13508,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL874461
13509,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628017
13510,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628018
13511,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628019
13512,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628020
13513,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628021
13514,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628022
13515,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,,,,1088.0,50588,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628023
13516,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL628024
13517,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL628025
13518,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL628026
13519,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL628027
13520,U,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,,,,1088.0,22224,BAO_0000218,A,,8133,Urine,0,1,CHEMBL628028
13521,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628029
13522,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628030
13523,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628031
13524,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628032
13525,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628033
13526,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628034
13527,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628035
13528,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL628036
13529,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL874462
13530,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628037
13531,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628123
13532,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628124
13533,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628125
13534,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628126
13535,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628127
13536,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628128
13537,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628129
13538,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628130
13539,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628131
13540,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628132
13541,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628133
13542,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628134
13543,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628135
13544,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628136
13545,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628137
13546,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628138
13547,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628139
13548,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628140
13549,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628141
13550,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628142
13551,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628143
13552,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628144
13553,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628145
13554,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL628146
13555,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625355
13556,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625356
13557,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625357
13558,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625527
13559,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL875473
13560,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,Intermediate,,,,,50588,BAO_0000218,A,,9025,,1,1,CHEMBL625528
13561,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,Intermediate,,,,,50597,BAO_0000218,A,,9025,,1,1,CHEMBL626304
13562,N,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Intermediate,,,,1637.0,50588,BAO_0000218,A,,9025,Artery,1,1,CHEMBL624138
13563,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6448,,0,1,CHEMBL624139
13564,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17221,,0,1,CHEMBL624140
13565,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6545,,0,1,CHEMBL624141
13566,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,577,,0,1,CHEMBL624142
13567,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6285,,0,1,CHEMBL624143
13568,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6500,,0,1,CHEMBL624144
13569,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6716,,0,1,CHEMBL624145
13570,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,13658,,0,1,CHEMBL624146
13571,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6549,,0,1,CHEMBL624147
13572,U,,,,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,,,22229,BAO_0000100,P,,14685,,0,1,CHEMBL883123
13573,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,6893,,0,1,CHEMBL624148
13574,U,,,,Kinetic parameter was determined,Autocuration,,,,,22224,BAO_0000019,A,,3687,,0,1,CHEMBL874416
13575,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4207,,0,1,CHEMBL624149
13576,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,4626,,0,1,CHEMBL624150
13577,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,1021,,0,1,CHEMBL624151
13578,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,3777,,0,1,CHEMBL624152
13579,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,17533,,0,1,CHEMBL622139
13580,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,6524,,0,1,CHEMBL622140
13581,U,,,,Lipophilicity was determined,Autocuration,,,,,22224,BAO_0000100,P,,17533,,0,1,CHEMBL622141
13582,U,,,,Lipophilicity in octanol-water,Autocuration,,,,,22224,BAO_0000100,P,,6480,,0,1,CHEMBL622142
13583,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,17606,,0,1,CHEMBL622143
13584,U,,,,Octanol-water partition coefficient was determined,Autocuration,,,,,22229,BAO_0000100,P,,6863,,0,1,CHEMBL622144
13585,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,1356,,0,1,CHEMBL877473
13586,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,3326,,0,1,CHEMBL622145
13587,U,,,,Partition coefficient was determined; ND means not determined,Autocuration,,,,,22224,BAO_0000019,A,,1356,,0,1,CHEMBL622146
13588,U,,,,Calculated partition coefficient (clogP),Autocuration,,,,,22229,BAO_0000100,P,,12984,,0,1,CHEMBL622147
13589,U,,,,Partition coefficient of the compound,Autocuration,,,,,22224,BAO_0000019,A,,17363,,0,1,CHEMBL622148
13590,U,,,,Permeability was determined,Autocuration,,,,,22224,BAO_0000019,A,,6827,,0,1,CHEMBL883124
13591,U,,,,The compound was evaluated for the partition coefficient,Autocuration,,,,,22229,BAO_0000100,P,,261,,0,1,CHEMBL622149
13592,U,,,,Partition coefficient (logP),Autocuration,,,,,22224,BAO_0000019,A,,2685,,0,1,CHEMBL622150
13593,U,,,,The lipophilicity was reported,Autocuration,,,,,22224,BAO_0000100,P,,414,,0,1,CHEMBL622151
13594,U,,,,logarithm of the octanol-water partition coefficient for the compound,Autocuration,,,,,22229,BAO_0000100,P,,15769,,0,1,CHEMBL622152
13595,U,,,,Clogp value was determined,Autocuration,,,,,22224,BAO_0000019,A,,17248,,0,1,CHEMBL622153
13596,U,,,,Clp at a dose of 1.5 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,,0,1,CHEMBL877474
13597,U,,,,Clp at a dose of 2.0 mg/kg,Autocuration,,,,,22224,BAO_0000218,A,,16935,,0,1,CHEMBL622154
13598,U,,,,"Clp, plasma clearance at a dose of 10 mg/kg",Autocuration,,,,1969.0,22224,BAO_0000218,A,,14832,Plasma,0,1,CHEMBL622155
13599,U,,,,"Clp, plasma clearance at a dose of 50 mg/kg",Autocuration,,,,1969.0,22224,BAO_0000218,A,,14832,Plasma,0,1,CHEMBL622156
13600,N,,,,Compound was tested for plasma clearance in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2399,Plasma,1,1,CHEMBL622157
13601,N,,,,Compound was tested for plasma clearance in rat; Not determined,Intermediate,,,,1969.0,50597,BAO_0000218,A,,2399,Plasma,1,1,CHEMBL622158
13602,N,,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,6227,,1,1,CHEMBL622807
13603,N,,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,Intermediate,,,,,50797,BAO_0000218,A,,6227,,1,1,CHEMBL622808
13604,U,,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,Autocuration,,,,,22224,BAO_0000218,A,,5623,,0,1,CHEMBL622809
13605,U,,,,Plasma clearance determined,Autocuration,,,,,22224,BAO_0000218,A,,4854,,0,1,CHEMBL622810
13606,N,,,,Plasma clearance after iv administration at 3 mg/kg in hamster,Intermediate,,,,,100712,BAO_0000218,A,,4493,,1,1,CHEMBL876653
13607,N,,,,Plasma clearance after iv administration at 4 mg/kg in hamster,Intermediate,,,,,100712,BAO_0000218,A,,4493,,1,1,CHEMBL622811
13608,N,,,,Rate of clearance in rat was determined,Intermediate,,,,,50597,BAO_0000218,A,,14956,,1,1,CHEMBL622986
13609,N,,,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,Plasma,1,1,CHEMBL622987
13610,N,,,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,Plasma,1,1,CHEMBL622988
13611,N,,,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,Plasma,1,1,CHEMBL622989
13612,N,,,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15372,Plasma,1,1,CHEMBL622990
13613,U,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,,,,1969.0,22224,BAO_0000218,A,,15604,Plasma,0,1,CHEMBL622991
13614,N,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15604,Plasma,1,1,CHEMBL622227
13615,N,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15604,Plasma,1,1,CHEMBL622228
13616,N,,,,Clpl value in rat,Intermediate,,,,,50597,BAO_0000218,A,,14964,,1,1,CHEMBL622229
13617,N,,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,,,,,50512,BAO_0000218,A,,15240,,1,1,CHEMBL622230
13618,N,,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,Intermediate,,,,,50597,BAO_0000218,A,,16449,,1,1,CHEMBL622231
13619,N,,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,Intermediate,,,,,100710,BAO_0000218,A,,16449,,1,1,CHEMBL622232
13620,U,,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622233
13621,U,,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622234
13622,U,,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622235
13623,U,,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622236
13624,U,,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622237
13625,U,,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL877482
13626,U,,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622238
13627,U,,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,Autocuration,,,,,22224,BAO_0000218,A,,12902,,0,1,CHEMBL622239
13628,U,,,,Cmax was calculated as maximum concentration reached in the blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,11149,Blood,0,1,CHEMBL622240
13629,U,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Autocuration,,,,178.0,22224,BAO_0000218,A,,11149,Blood,0,1,CHEMBL622241
13630,N,,,,Cmax was determine after peroral administration at 10 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL631013
13631,N,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,Intermediate,,,,,50797,BAO_0000218,A,,5669,,1,1,CHEMBL631014
13632,N,,,,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,,,,50588,BAO_0000218,A,,5669,,1,1,CHEMBL631015
13633,N,,,,Cmax was determine after peroral administration at 160 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL631016
13634,N,,,,Cmax was determine after peroral administration at 20 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL631017
13635,N,,,,Cmax was determine after peroral administration at 50 mpk in Rat,Intermediate,,,,,50597,BAO_0000218,A,,5669,,1,1,CHEMBL631018
13636,U,,,,Cmax was determined,Autocuration,,,,,22224,BAO_0000218,A,,4236,,0,1,CHEMBL631019
13637,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL875761
13638,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL631020
13639,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL631669
13640,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Intermediate,,,,955.0,50594,BAO_0000218,A,,13792,Brain,1,1,CHEMBL631670
13641,N,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Intermediate,,,,2435.0,50594,BAO_0000218,A,,13792,Striatum,1,1,CHEMBL631671
13642,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631672
13643,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631673
13644,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631856
13645,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631857
13646,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631858
13647,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631859
13648,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631860
13649,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631861
13650,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631862
13651,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631863
13652,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631864
13653,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631865
13654,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL631866
13655,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL629360
13656,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL629361
13657,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL629362
13658,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL630740
13659,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL630741
13660,N,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Intermediate,,,,178.0,50597,BAO_0000218,A,,8418,Blood,1,1,CHEMBL630742
13661,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630743
13662,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630744
13663,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630745
13664,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630746
13665,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630747
13666,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL630748
13667,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632056
13668,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632057
13669,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632058
13670,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632059
13671,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632060
13672,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL632061
13673,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629207
13674,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629208
13675,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629209
13676,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629210
13677,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629211
13678,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629212
13679,N,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,Intermediate,,,,,50597,BAO_0000218,A,,8418,,1,1,CHEMBL629213
13680,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629214
13681,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL629215
13682,N,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Intermediate,,,,1088.0,50597,BAO_0000218,A,,8133,Urine,1,1,CHEMBL635154
13683,N,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629216
13684,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629217
13685,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629218
13686,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629219
13687,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629220
13688,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL629221
13689,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631127
13690,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631128
13691,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631129
13692,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631130
13693,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631131
13694,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631132
13695,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631133
13696,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631134
13697,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL875120
13698,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631135
13699,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631136
13700,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631137
13701,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631138
13702,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631139
13703,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631140
13704,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631141
13705,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631142
13706,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631143
13707,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,,,,50597,BAO_0000218,A,,6996,,1,1,CHEMBL631144
13708,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631145
13709,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631146
13710,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631147
13711,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631148
13712,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631149
13713,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631150
13714,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631151
13715,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631152
13716,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631443
13717,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631444
13718,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631445
13719,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631446
13720,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631447
13721,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631448
13722,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631449
13723,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL631450
13724,N,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,,,,50588,BAO_0000218,A,,6996,,1,1,CHEMBL629724
13725,N,,,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,14.0,50594,BAO_0000218,A,,9716,Zone of skin,1,1,CHEMBL629725
13726,N,,,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,14.0,50594,BAO_0000218,A,,9716,Zone of skin,1,1,CHEMBL629726
13727,N,,,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,Spleen,1,1,CHEMBL629727
13728,N,,,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,Spleen,1,1,CHEMBL630404
13729,N,,,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,Spleen,1,1,CHEMBL630405
13730,N,,,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,2106.0,50594,BAO_0000218,A,,9716,Spleen,1,1,CHEMBL630406
13731,N,,,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,Stomach,1,1,CHEMBL630407
13732,N,,,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,Stomach,1,1,CHEMBL630573
13733,N,,,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,Stomach,1,1,CHEMBL630574
13734,N,,,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,945.0,50594,BAO_0000218,A,,9716,Stomach,1,1,CHEMBL630575
13735,N,,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,,1,1,CHEMBL630576
13736,N,,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,,1,1,CHEMBL630577
13737,N,,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,,1,1,CHEMBL630578
13738,N,,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,,,,,50594,BAO_0000218,A,,9716,,1,1,CHEMBL630579
13739,N,,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,Kidney,1,1,CHEMBL630580
13740,N,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,Kidney,1,1,CHEMBL630581
13741,N,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Intermediate,,,,2113.0,50594,BAO_0000218,A,,12192,Kidney,1,1,CHEMBL630582
13742,N,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630583
13743,N,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630584
13744,N,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630585
13745,N,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630586
13746,N,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630587
13747,N,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630588
13748,N,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630589
13749,N,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),Intermediate,,,,,50594,BAO_0000218,A,,12192,,1,1,CHEMBL630590
13750,U,,,,Removal of 238-Plutonium(IV) in feces at 24 h,Autocuration,,,,1988.0,22224,BAO_0000019,A,,12192,Feces,0,1,CHEMBL630591
13751,U,,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Autocuration,,,,1988.0,22224,BAO_0000019,A,,12192,Feces,0,1,CHEMBL630592
13752,U,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,Autocuration,,,,,22224,BAO_0000019,A,,12192,,0,1,CHEMBL630593
13753,U,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),Autocuration,,,,,22224,BAO_0000019,A,,12192,,0,1,CHEMBL630594
13754,U,,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630595
13755,U,,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630596
13756,U,,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630597
13757,U,,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630598
13758,U,,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630599
13759,U,,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630600
13760,U,,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630601
13761,U,,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630602
13762,U,,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630603
13763,U,,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Autocuration,,,,1088.0,22224,BAO_0000019,A,,12192,Urine,0,1,CHEMBL630604
13764,N,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL624869
13765,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL624870
13766,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL623189
13767,N,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL623190
13768,N,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL623191
13769,N,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL623192
13770,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL623193
13771,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL623194
13772,N,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL623195
13773,N,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL623196
13774,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,Intermediate,,,,,50597,BAO_0000218,A,,11836,,1,1,CHEMBL623197
13775,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,,50597,BAO_0000218,A,,11836,,1,1,CHEMBL623198
13776,N,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,,,,,50597,BAO_0000218,A,,11836,,1,1,CHEMBL623199
13777,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623200
13778,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623201
13779,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623202
13780,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623203
13781,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623204
13782,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623205
13783,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623206
13784,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623207
13785,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623208
13786,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623209
13787,N,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,11836,Muscle tissue,1,1,CHEMBL623210
13788,N,,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,,,,,50597,BAO_0000218,A,,11836,,1,1,CHEMBL623211
13789,N,,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,,,,995.0,50597,BAO_0000218,A,,11836,Uterus,1,1,CHEMBL623212
13790,U,,,,Tested in vitro for intrinsic activity relative to quinpirole,Autocuration,,,,,22224,BAO_0000019,A,,12640,,0,1,CHEMBL623213
13791,U,,,,"Relative ion enhancement, determined in pulsed ultrafiltration",Autocuration,,,,,22224,BAO_0000019,A,,14218,,0,1,CHEMBL623214
13792,U,,,,% ionization at the pH 7.4 at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,11296,,0,1,CHEMBL623215
13793,U,,,,Percentage ionization was measured,Autocuration,,,,,22224,BAO_0000019,A,,10929,,0,1,CHEMBL623216
13794,N,,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,Intermediate,,,,,50591,BAO_0000218,A,,13841,,1,1,CHEMBL623217
13795,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL623218
13796,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL623913
13797,U,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL623914
13798,U,,,,Compound was evaluated for the partition coefficient in octanol/water,Autocuration,,,,,22229,BAO_0000100,P,,8826,,0,1,CHEMBL623915
13799,U,,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),Autocuration,,,,,22229,BAO_0000100,P,,8826,,0,1,CHEMBL624080
13800,U,,,,Equilibrium constant measured by the pulse radiolysis at pH 7,Autocuration,,,,,22224,BAO_0000019,A,,9884,,0,1,CHEMBL624081
13801,N,,,,In vitro hydrolytic rate constant determined in human blood,Intermediate,,,,,50587,BAO_0000218,A,,9827,,1,1,CHEMBL624082
13802,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,Intermediate,,,,,50587,BAO_0000218,A,,10009,,1,1,CHEMBL625054
13803,U,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,Autocuration,,,,,22224,BAO_0000019,A,,10009,,0,1,CHEMBL877485
13804,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625055
13805,N,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625056
13806,N,,,,In vitro oxidation of compound in presence of human plasma,Intermediate,,,,,50587,BAO_0000218,A,,10009,,1,1,CHEMBL625057
13807,U,,,,In vitro oxidation of compound in presence of hydrogen peroxide,Autocuration,,,,,22224,BAO_0000019,A,,10009,,0,1,CHEMBL625058
13808,N,,,,In vitro oxidation of compound in presence of mouse brain homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL625059
13809,N,,,,In vitro oxidation of compound in presence of mouse liver homogenate,Intermediate,,,,,50594,BAO_0000218,A,,10009,,1,1,CHEMBL629536
13810,N,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629537
13811,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629538
13812,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629539
13813,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL874445
13814,N,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629540
13815,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629541
13816,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629542
13817,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630243
13818,N,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630244
13819,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630245
13820,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630246
13821,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630247
13822,N,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630248
13823,N,,,,Biodistribution in rat blood at 240 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,Blood,1,1,CHEMBL630249
13824,N,,,,Biodistribution in rat blood at 30 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,Blood,1,1,CHEMBL630250
13825,N,,,,Biodistribution in rat blood at 360 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,Blood,1,1,CHEMBL630251
13826,N,,,,Biodistribution in rat blood at 3 hr after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,Blood,1,1,CHEMBL630252
13827,N,,,,Biodistribution in rat blood at 60 minutes after dose administration.,Intermediate,,,,178.0,50597,BAO_0000218,A,,13100,Blood,1,1,CHEMBL630408
13828,N,,,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630409
13829,N,,,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL874446
13830,N,,,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630410
13831,N,,,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630411
13832,N,,,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630412
13833,N,,,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630413
13834,N,,,,Biodistribution in rat cerebellum at 3 hr after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630414
13835,N,,,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,13100,Cerebellum,1,1,CHEMBL630415
13836,N,,,,Biodistribution in rat cortex at 120 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630416
13837,N,,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630417
13838,N,,,,Biodistribution in rat cortex at 15 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630418
13839,N,,,,Biodistribution in rat cortex at 240 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630419
13840,N,,,,Biodistribution in rat cortex at 30 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630420
13841,N,,,,Biodistribution in rat cortex at 360 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630421
13842,N,,,,Biodistribution in rat cortex at 3 hr after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630422
13843,N,,,,Biodistribution in rat cortex at 60 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL630423
13844,N,,,,Biodistribution in rat heart at 120 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL630424
13845,N,,,,Biodistribution in rat heart at 15 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL630425
13846,N,,,,Biodistribution in rat heart at 240 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL629462
13847,N,,,,Biodistribution in rat heart at 30 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL630426
13848,N,,,,Biodistribution in rat heart at 360 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL630427
13849,N,,,,Biodistribution in rat heart at 3 hr after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL625877
13850,N,,,,Biodistribution in rat heart at 60 minutes after dose administration.,Intermediate,,,,948.0,50597,BAO_0000218,A,,13100,Heart,1,1,CHEMBL625878
13851,N,,,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,Hippocampus,1,1,CHEMBL625879
13852,N,,,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,Hippocampus,1,1,CHEMBL625880
13853,N,,,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,Hippocampus,1,1,CHEMBL625881
13854,N,,,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,Hippocampus,1,1,CHEMBL625882
13855,N,,,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,13100,Hippocampus,1,1,CHEMBL625883
13856,N,,,,Biodistribution in rat kidney at 120 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL625884
13857,N,,,,Biodistribution in rat kidney at 1440 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL625885
13858,N,,,,Biodistribution in rat kidney at 15 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL628649
13859,N,,,,Biodistribution in rat kidney at 240 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL628650
13860,N,,,,Biodistribution in rat kidney at 30 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL628651
13861,N,,,,Biodistribution in rat kidney at 360 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL628652
13862,N,,,,Biodistribution in rat kidney at 60 minutes after dose administration.,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13100,Kidney,1,1,CHEMBL628653
13863,N,,,,Biodistribution in rat liver at 120 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL628654
13864,N,,,,Biodistribution in rat liver at 1440 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL628655
13865,N,,,,Biodistribution in rat liver at 15 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL625238
13866,N,,,,Biodistribution in rat liver at 240 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL625239
13867,N,,,,Biodistribution in rat liver at 30 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL625240
13868,N,,,,Biodistribution in rat liver at 360 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL625241
13869,N,,,,Biodistribution in rat liver at 60 minutes after dose administration.,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13100,Liver,1,1,CHEMBL625242
13870,N,,,,Biodistribution in rat lung at 120 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL874587
13871,N,,,,Biodistribution in rat lung at 1440 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL625405
13872,N,,,,Biodistribution in rat lung at 15 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL625406
13873,N,,,,Biodistribution in rat lung at 240 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL625407
13874,N,,,,Biodistribution in rat lung at 30 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL625408
13875,N,,,,Biodistribution in rat lung at 360 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL625409
13876,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625410
13877,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625411
13878,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625412
13879,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625413
13880,N,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625414
13881,N,,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625415
13882,N,,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,,,,1515.0,50597,BAO_0000218,A,,12361,Thoracic aorta,1,1,CHEMBL625416
13883,N,,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12712,Urine,1,1,CHEMBL625417
13884,N,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Intermediate,,,,1988.0,50597,BAO_0000218,A,,7415,Feces,1,1,CHEMBL625418
13885,N,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Intermediate,,,,1088.0,50597,BAO_0000218,A,,7415,Urine,1,1,CHEMBL625419
13886,N,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,7415,,1,1,CHEMBL625420
13887,N,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,Intermediate,,,,,50597,BAO_0000218,A,,7415,,1,1,CHEMBL626996
13888,N,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Intermediate,,,,1988.0,50597,BAO_0000218,A,,7415,Feces,1,1,CHEMBL626997
13889,N,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Intermediate,,,,1088.0,50597,BAO_0000218,A,,7415,Urine,1,1,CHEMBL626998
13890,N,,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",Intermediate,,,,,50597,BAO_0000218,A,,7415,,1,1,CHEMBL626999
13891,N,,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,1,1,CHEMBL627000
13892,N,,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,1,1,CHEMBL627001
13893,N,,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,1,1,CHEMBL627002
13894,N,,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,Intermediate,,,,,50594,BAO_0000218,A,,8050,,1,1,CHEMBL627003
13895,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627004
13896,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627005
13897,N,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL874594
13898,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627006
13899,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627007
13900,N,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627884
13901,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627885
13902,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627886
13903,N,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627887
13904,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627888
13905,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL628057
13906,N,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Intermediate,,,,1088.0,50594,BAO_0000218,A,,8050,Urine,1,1,CHEMBL627405
13907,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627406
13908,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627407
13909,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627408
13910,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627409
13911,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875486
13912,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627410
13913,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627411
13914,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627412
13915,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627413
13916,N,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627414
13917,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627415
13918,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627416
13919,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627417
13920,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627418
13921,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627419
13922,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627320
13923,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627321
13924,N,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL627322
13925,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL627323
13926,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL627491
13927,N,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL627492
13928,N,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL627493
13929,N,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL627494
13930,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL627495
13931,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL627496
13932,N,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL627497
13933,N,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL627498
13934,N,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL627499
13935,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL627500
13936,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL627501
13937,N,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL625616
13938,N,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL625617
13939,N,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL625618
13940,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL625619
13941,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL625620
13942,N,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL625621
13943,N,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL625622
13944,N,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL625788
13945,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL625789
13946,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL625790
13947,N,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL625791
13948,N,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL622334
13949,N,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL622335
13950,N,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL622336
13951,N,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL622337
13952,N,,,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL622338
13953,N,,,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL622339
13954,N,,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL624153
13955,N,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL628430
13956,N,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL628431
13957,N,,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL628432
13958,N,,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL628433
13959,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL628434
13960,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL626789
13961,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL626790
13962,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL626791
13963,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL626792
13964,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL626793
13965,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627436
13966,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627437
13967,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627438
13968,N,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627439
13969,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627440
13970,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627602
13971,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627603
13972,N,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627604
13973,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627605
13974,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627606
13975,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627607
13976,N,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627608
13977,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627609
13978,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627610
13979,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627611
13980,N,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL627612
13981,U,,,,Octanol:water partition coefficient is evaluated,Autocuration,,,,,22229,BAO_0000100,P,,8362,,0,1,CHEMBL627613
13982,U,,,,Partition coefficient in 1-octanol/water system,Autocuration,,,,,22224,BAO_0000100,P,,8257,,0,1,CHEMBL627614
13983,U,,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,Autocuration,,,,,22224,BAO_0000100,P,,8257,,0,1,CHEMBL627615
13984,U,,,,Partition coefficient in octanol/water system was determined,Autocuration,,,,,22224,BAO_0000100,P,,9468,,0,1,CHEMBL627616
13985,U,,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,Autocuration,,,,,22224,BAO_0000100,P,,9468,,0,1,CHEMBL627617
13986,U,,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,10568,,0,1,CHEMBL627618
13987,U,,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,10568,,0,1,CHEMBL627619
13988,U,,,,Pseudo-first-order rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,15359,,0,1,CHEMBL627620
13989,U,,,,Pseudo-first-order rate constant with 1-min time point,Autocuration,,,,,22224,BAO_0000019,A,,15359,,0,1,CHEMBL627621
13990,U,,,,Pseudo-first-order rate constant without 1-min time point,Autocuration,,,,,22224,BAO_0000019,A,,15359,,0,1,CHEMBL627622
13991,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL627623
13992,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL627624
13993,U,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,Autocuration,,,,,22224,BAO_0000019,A,,10431,,0,1,CHEMBL627625
13994,U,,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,15704,,0,1,CHEMBL628523
13995,U,,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,Autocuration,,,,,22224,BAO_0000019,A,,15287,,0,1,CHEMBL628524
13996,U,,,,The efflux rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,7516,,0,1,CHEMBL628525
13997,U,,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,A,,12973,,0,1,CHEMBL625732
13998,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,A,,12973,,0,1,CHEMBL625733
13999,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,,,22224,BAO_0000019,F,,12973,,0,1,CHEMBL625734
14000,U,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,Autocuration,,,,,22224,BAO_0000019,A,,12973,,0,1,CHEMBL625913
14001,U,,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,Autocuration,,,,,22224,BAO_0000019,A,,8696,,0,1,CHEMBL625914
14002,U,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,Autocuration,,,,,22224,BAO_0000019,A,,15052,,0,1,CHEMBL625915
14003,U,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,Autocuration,,,,,22224,BAO_0000019,A,,15052,,0,1,CHEMBL625916
14004,U,,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),Autocuration,,,,,22224,BAO_0000019,A,,10503,,0,1,CHEMBL625917
14005,U,,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625918
14006,U,,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625919
14007,U,,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625920
14008,U,,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL874453
14009,U,,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625921
14010,U,,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,Autocuration,,,,,22224,BAO_0000019,A,,10503,,0,1,CHEMBL625922
14011,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625923
14012,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625924
14013,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625925
14014,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL625926
14015,N,,,,Biodistribution in rat lung at 60 minutes after dose administration.,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13100,Lung,1,1,CHEMBL627704
14016,N,,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL627705
14017,N,,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL627706
14018,N,,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL627707
14019,N,,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL627708
14020,N,,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL628361
14021,N,,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,Intermediate,,,,,50597,BAO_0000218,A,,13100,,1,1,CHEMBL628362
14022,N,,,,Biodistribution in rat striatum at 120 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628363
14023,N,,,,Biodistribution in rat striatum at 1440 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628364
14024,N,,,,Biodistribution in rat striatum at 15 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628365
14025,N,,,,Biodistribution in rat striatum at 240 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL874454
14026,N,,,,Biodistribution in rat striatum at 30 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628531
14027,N,,,,Biodistribution in rat striatum at 360 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628532
14028,N,,,,Biodistribution in rat striatum at 3 hr after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628533
14029,N,,,,Biodistribution in rat striatum at 60 minutes after dose administration.,Intermediate,,,,2435.0,50597,BAO_0000218,A,,13100,Striatum,1,1,CHEMBL628534
14030,N,,,,Biodistribution in rat thyroid at 120 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL628535
14031,N,,,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL628536
14032,N,,,,Biodistribution in rat thyroid at 15 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL628537
14033,N,,,,Biodistribution in rat thyroid at 240 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL628538
14034,N,,,,Biodistribution in rat thyroid at 30 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL628539
14035,N,,,,Biodistribution in rat thyroid at 360 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL630297
14036,N,,,,Biodistribution in rat thyroid at 60 minutes after dose administration.,Intermediate,,,,2046.0,50597,BAO_0000218,A,,13100,Thyroid gland,1,1,CHEMBL630298
14037,N,,,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL630299
14038,N,,,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL628094
14039,N,,,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL628095
14040,N,,,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL874648
14041,N,,,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL628096
14042,N,,,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL628097
14043,N,,,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Intermediate,,,,955.0,50597,BAO_0000218,A,,13100,Brain,1,1,CHEMBL628098
14044,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628099
14045,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628100
14046,U,,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628101
14047,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628102
14048,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628103
14049,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628104
14050,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628105
14051,U,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",Autocuration,,,,,22224,BAO_0000019,A,,13331,,0,1,CHEMBL628106
14052,N,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL628107
14053,U,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Autocuration,,,,1088.0,22224,BAO_0000218,F,,10086,Urine,0,1,CHEMBL628108
14054,N,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL628109
14055,U,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Autocuration,,,,1088.0,22224,BAO_0000218,F,,10086,Urine,0,1,CHEMBL625299
14056,N,,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL625300
14057,N,,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL625301
14058,N,,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL625302
14059,N,,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Intermediate,,,,1088.0,50597,BAO_0000218,A,,10086,Urine,1,1,CHEMBL874649
14060,N,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,Intermediate,,,,,50597,BAO_0000218,A,,13248,,1,1,CHEMBL625303
14061,N,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,Intermediate,,,,,50597,BAO_0000218,A,,13248,,1,1,CHEMBL625463
14062,N,,,,In vitro metabolism in human liver microsomes,Intermediate,,,,2107.0,50587,BAO_0000218,A,,14527,Liver,1,1,CHEMBL625464
14063,N,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,Intermediate,,,,,50587,BAO_0000218,A,,3008,,1,1,CHEMBL625465
14064,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625466
14065,N,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625467
14066,N,,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625468
14067,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625469
14068,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625470
14069,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL632418
14070,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627250
14071,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627251
14072,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627252
14073,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627253
14074,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627254
14075,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875471
14076,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627255
14077,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627256
14078,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627257
14079,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627258
14080,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627259
14081,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627260
14082,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623256
14083,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL874413
14084,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623257
14085,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623258
14086,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623259
14087,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623260
14088,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623261
14089,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623262
14090,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623263
14091,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623264
14092,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623265
14093,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623266
14094,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623267
14095,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623268
14096,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623269
14097,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623270
14098,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623271
14099,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623272
14100,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623273
14101,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623274
14102,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL874414
14103,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623275
14104,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL629150
14105,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623276
14106,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623277
14107,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623112
14108,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623113
14109,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623800
14110,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623801
14111,N,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL623802
14112,N,,,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,Uterus,1,1,CHEMBL623803
14113,N,,,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,Uterus,1,1,CHEMBL623970
14114,N,,,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,995.0,50597,BAO_0000218,A,,12017,Uterus,1,1,CHEMBL623971
14115,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,Blood,1,1,CHEMBL623972
14116,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,Blood,1,1,CHEMBL623973
14117,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,Blood,1,1,CHEMBL623974
14118,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Intermediate,,,,178.0,50597,BAO_0000218,A,,14045,Blood,1,1,CHEMBL623975
14119,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,Brain,1,1,CHEMBL623976
14120,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,Brain,1,1,CHEMBL623977
14121,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,Brain,1,1,CHEMBL623978
14122,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Intermediate,,,,955.0,50597,BAO_0000218,A,,14045,Brain,1,1,CHEMBL623979
14123,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,,1,1,CHEMBL623980
14124,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,,1,1,CHEMBL623981
14125,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,,1,1,CHEMBL626278
14126,N,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),Intermediate,,,,,50597,BAO_0000218,A,,14045,,1,1,CHEMBL626279
14127,N,,,,Biodistribution in mice bladder plus excreted urine was determined,Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626280
14128,N,,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626281
14129,N,,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626282
14130,N,,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626283
14131,N,,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626284
14132,N,,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,Brain,1,1,CHEMBL626285
14133,N,,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,Brain,1,1,CHEMBL626286
14134,N,,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,Brain,1,1,CHEMBL626287
14135,N,,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",Intermediate,,,,955.0,50594,BAO_0000218,A,,14045,Brain,1,1,CHEMBL626288
14136,N,,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626289
14137,N,,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626290
14138,N,,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL626291
14139,N,,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL839888
14140,N,,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,Intestine,1,1,CHEMBL626292
14141,N,,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,Intestine,1,1,CHEMBL626293
14142,N,,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,Intestine,1,1,CHEMBL626294
14143,N,,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intermediate,,,,160.0,50594,BAO_0000218,A,,14045,Intestine,1,1,CHEMBL626295
14144,N,,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,Liver,1,1,CHEMBL627659
14145,N,,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,Liver,1,1,CHEMBL627660
14146,N,,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,Liver,1,1,CHEMBL627661
14147,N,,,,Biodistribution in mice liver at 60 minutes of post injection,Intermediate,,,,2107.0,50594,BAO_0000218,A,,14045,Liver,1,1,CHEMBL627662
14148,N,,,,Biodistribution in mice lungs at 10 min of post injection,Intermediate,,,,2048.0,50594,BAO_0000218,A,,14045,Lung,1,1,CHEMBL627663
14149,N,,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL627664
14150,N,,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",Intermediate,,,,,50594,BAO_0000218,A,,14045,,1,1,CHEMBL627665
14151,N,,,,Biodistribution in mice lungs at 60 min of post injection,Intermediate,,,,2048.0,50594,BAO_0000218,A,,14045,Lung,1,1,CHEMBL627666
14152,N,,,,Percentage biodistribution in mouse spleen,Intermediate,,,,2106.0,50594,BAO_0000218,A,,14045,Spleen,1,1,CHEMBL627667
14153,N,,,,Percentage biodistribution in mouse stomach,Intermediate,,,,945.0,50594,BAO_0000218,A,,14045,Stomach,1,1,CHEMBL627668
14154,N,,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Intermediate,,,,1088.0,50594,BAO_0000218,A,,11745,Urine,1,1,CHEMBL627669
14155,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,Urinary bladder,0,1,CHEMBL627670
14156,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,Blood,0,1,CHEMBL627671
14157,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,Bone element,0,1,CHEMBL627672
14158,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL627673
14159,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,Kidney,0,1,CHEMBL627674
14160,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,Liver,0,1,CHEMBL627675
14161,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,Lung,0,1,CHEMBL627676
14162,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627677
14163,U,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL627678
14164,N,,,,Affinity for protein binding expressed as association constant in fresh rat serum,Intermediate,,,,1977.0,50597,BAO_0000218,A,,7095,Serum,1,1,CHEMBL627679
14165,U,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,,,22224,BAO_0000019,A,,12185,,0,1,CHEMBL627680
14166,U,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,,,22224,BAO_0000019,A,,12185,,0,1,CHEMBL627681
14167,U,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,,,22224,BAO_0000019,A,,12185,,0,1,CHEMBL627682
14168,U,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,,,22224,BAO_0000019,A,,12185,,0,1,CHEMBL627683
14169,U,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,Autocuration,,,,,22224,BAO_0000019,A,,12686,,0,1,CHEMBL627684
14170,U,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,,,22224,BAO_0000019,A,,12686,,0,1,CHEMBL874441
14171,U,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,Autocuration,,,,,22224,BAO_0000019,A,,12686,,0,1,CHEMBL627685
14172,U,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,,,22224,BAO_0000019,A,,12686,,0,1,CHEMBL627686
14173,U,,,,Apparent rate constant Koff for inactivation of dTMP synthase.,Autocuration,,,,,22224,BAO_0000019,A,,8057,,0,1,CHEMBL627687
14174,U,,,,The irreversible inhibitor activity by second order rate equation.,Autocuration,,,,,22224,BAO_0000019,A,,15778,,0,1,CHEMBL627688
14175,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,1,1,CHEMBL628038
14176,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,1,1,CHEMBL628039
14177,N,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,Intermediate,,,,,50597,BAO_0000218,A,,12375,,1,1,CHEMBL628040
14178,U,,,,Dissociation rate calculated from the first-order equation using t1/2 value,Autocuration,,,,,22224,BAO_0000019,A,,13588,,0,1,CHEMBL628041
14179,U,,,,The compound was tested for Binding constant against DNA,Autocuration,,,,,22224,BAO_0000019,A,,15039,,0,1,CHEMBL630226
14180,U,,,,First order rate constant for cyclization of the compound,Autocuration,,,,,22224,BAO_0000019,A,,9500,,0,1,CHEMBL628042
14181,U,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,0,1,CHEMBL625232
14182,U,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,0,1,CHEMBL625233
14183,U,,,,Hydrolysis rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL625979
14184,U,,,,Observed first order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,0,1,CHEMBL625980
14185,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,0,1,CHEMBL625981
14186,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,0,1,CHEMBL625982
14187,U,,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL625983
14188,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625984
14189,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625985
14190,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625986
14191,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625987
14192,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625988
14193,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625989
14194,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625990
14195,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625991
14196,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625992
14197,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL625993
14198,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL631973
14199,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632143
14200,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632144
14201,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632145
14202,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632146
14203,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632147
14204,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632148
14205,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632149
14206,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632150
14207,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL632151
14208,N,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,Intermediate,,,,,50587,BAO_0000218,A,,3008,,1,1,CHEMBL632152
14209,N,,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,,,,,50587,BAO_0000218,A,,4509,,1,1,CHEMBL632153
14210,N,,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,,,,,50587,BAO_0000218,A,,4509,,1,1,CHEMBL632154
14211,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632155
14212,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632156
14213,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632157
14214,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632158
14215,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL632159
14216,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626305
14217,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626306
14218,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626307
14219,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626308
14220,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626479
14221,N,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,Intermediate,,,,,50602,BAO_0000218,A,,8613,,1,1,CHEMBL626480
14222,U,,,,Calculated partition coefficient (clogP) (MlogP),Autocuration,,,,,22229,BAO_0000100,P,,6021,,0,1,CHEMBL626481
14223,U,,,,Equipotent potent ratio relative to carbachol (nicotinic activity),Autocuration,,,,,22224,BAO_0000019,A,,9348,,0,1,CHEMBL626482
14224,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",Intermediate,,,,,50588,BAO_0000218,A,,15592,,1,1,CHEMBL626483
14225,N,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",Intermediate,,,,,50588,BAO_0000218,A,,15592,,1,1,CHEMBL626484
14226,U,,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,0,1,CHEMBL626485
14227,U,,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,0,1,CHEMBL626486
14228,U,,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,Autocuration,,,,,22229,BAO_0000100,P,,15592,,0,1,CHEMBL626487
14229,N,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,,,,1969.0,50588,BAO_0000218,A,,15592,Plasma,1,1,CHEMBL626488
14230,N,,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Intermediate,,,,1977.0,50597,BAO_0000218,A,,7095,Serum,1,1,CHEMBL626489
14231,U,,,,Area under the MAP curve measured over 5 min; ND means Not determined,Autocuration,,,,,22224,BAO_0000019,A,,16618,,0,1,CHEMBL626490
14232,U,,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,Autocuration,,,,,22224,BAO_0000100,P,,16835,,0,1,CHEMBL626491
14233,U,,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,Autocuration,,,,,22229,BAO_0000100,P,,15284,,0,1,CHEMBL626492
14234,U,,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,Autocuration,,,,,22224,BAO_0000019,A,,15750,,0,1,CHEMBL626493
14235,N,,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,,,,,50597,BAO_0000218,A,,16618,,1,1,CHEMBL626494
14236,U,,,,Half life after oral tested,Autocuration,,,,,22224,BAO_0000218,A,,16618,,0,1,CHEMBL626495
14237,N,,,,Half life was determined in plasma of rat; NT indicates not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,Plasma,1,1,CHEMBL626496
14238,N,,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,,,,,50597,BAO_0000218,A,,16618,,1,1,CHEMBL626497
14239,U,,,,Oral bioavailability after oral tested,Autocuration,,,,,22224,BAO_0000218,A,,16618,,0,1,CHEMBL626498
14240,N,,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),Intermediate,,,,,50597,BAO_0000218,A,,13098,,1,1,CHEMBL626499
14241,N,,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),Intermediate,,,,,50597,BAO_0000218,A,,13098,,1,1,CHEMBL626500
14242,N,,,,half life was determined in plasma of rat; NT indicates not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,Plasma,1,1,CHEMBL626501
14243,N,,,,half life was determined in plasma of rat; NT means not tested,Intermediate,,,,1969.0,50597,BAO_0000218,A,,15812,Plasma,1,1,CHEMBL626502
14244,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626503
14245,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626504
14246,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626505
14247,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626506
14248,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626507
14249,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626508
14250,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626509
14251,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL875480
14252,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626510
14253,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626511
14254,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL626512
14255,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628208
14256,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628209
14257,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628210
14258,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628211
14259,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628212
14260,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL628213
14261,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628214
14262,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628215
14263,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628216
14264,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626595
14265,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626596
14266,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626597
14267,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626598
14268,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622242
14269,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622243
14270,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622244
14271,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622245
14272,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622246
14273,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622247
14274,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622248
14275,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL877483
14276,N,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622249
14277,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622250
14278,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622251
14279,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622252
14280,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622253
14281,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622254
14282,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622255
14283,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622256
14284,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622257
14285,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622258
14286,N,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622259
14287,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622927
14288,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622928
14289,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL622929
14290,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623182
14291,N,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623183
14292,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623184
14293,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623185
14294,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL877484
14295,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627274
14296,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623186
14297,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623187
14298,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL623188
14299,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628055
14300,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628056
14301,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628200
14302,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628201
14303,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628202
14304,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628203
14305,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628204
14306,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628205
14307,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628206
14308,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL628207
14309,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627220
14310,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627221
14311,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627222
14312,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL627223
14313,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL632062
14314,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,Spleen,0,1,CHEMBL632063
14315,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,Urinary bladder,0,1,CHEMBL632064
14316,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,Blood,0,1,CHEMBL632065
14317,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,Bone element,0,1,CHEMBL632066
14318,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL632067
14319,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,Kidney,0,1,CHEMBL629188
14320,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,Liver,0,1,CHEMBL629189
14321,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,Lung,0,1,CHEMBL629190
14322,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629191
14323,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629192
14324,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629193
14325,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629194
14326,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL629195
14327,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629373
14328,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,Spleen,0,1,CHEMBL629374
14329,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629375
14330,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,Urinary bladder,0,1,CHEMBL629376
14331,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,Blood,0,1,CHEMBL629377
14332,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,Bone element,0,1,CHEMBL629378
14333,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL629379
14334,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,Kidney,0,1,CHEMBL629151
14335,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,Liver,0,1,CHEMBL629152
14336,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,Lung,0,1,CHEMBL629153
14337,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629154
14338,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629155
14339,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629156
14340,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629157
14341,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL629158
14342,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL629159
14343,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629160
14344,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,Spleen,0,1,CHEMBL629161
14345,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,Urinary bladder,0,1,CHEMBL629162
14346,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,Blood,0,1,CHEMBL629163
14347,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,Bone element,0,1,CHEMBL629164
14348,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL629165
14349,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,Liver,0,1,CHEMBL629166
14350,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,Lung,0,1,CHEMBL629167
14351,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL629168
14352,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL629169
14353,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL629170
14354,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL631153
14355,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL875121
14356,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL631154
14357,U,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,Autocuration,,,,,22224,BAO_0000019,A,,2193,,0,1,CHEMBL631155
14358,U,,,,Hydrolysis rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL631156
14359,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631157
14360,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631158
14361,U,,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631159
14362,U,,,,Observed second order rate constant,Autocuration,,,,,22224,BAO_0000019,A,,10026,,0,1,CHEMBL631160
14363,U,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,10281,,0,1,CHEMBL631161
14364,U,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,0,1,CHEMBL631162
14365,U,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,,,22224,BAO_0000019,A,,10014,,0,1,CHEMBL630313
14366,U,,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL630314
14367,U,,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL630315
14368,U,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630316
14369,U,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630986
14370,U,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630987
14371,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630988
14372,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630989
14373,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630990
14374,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630991
14375,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630992
14376,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630993
14377,U,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,,,22224,BAO_0000019,A,,13028,,0,1,CHEMBL630994
14378,N,,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,Intermediate,,,,,50597,BAO_0000218,A,,10014,,1,1,CHEMBL630995
14379,U,,,,Association constant for compound at 31 degree C was determined,Autocuration,,,,,22224,BAO_0000019,A,,9962,,0,1,CHEMBL629252
14380,U,,,,Calculated antagonist equilibrium dissociation constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,12029,,0,1,CHEMBL629253
14381,U,,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,Autocuration,,,,,22224,BAO_0000019,A,,12029,,0,1,CHEMBL629944
14382,N,,,,Dissociation constants vs LTE4 on guinea pig trachea,Intermediate,,,,3126.0,50512,BAO_0000218,A,,10583,Trachea,1,1,CHEMBL629945
14383,U,,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL629946
14384,U,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL629947
14385,U,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL629948
14386,U,,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL856024
14387,U,,,,Affinity constant KD value was derived from TMP,Autocuration,,,,,22224,BAO_0000019,A,,7493,,0,1,CHEMBL629949
14388,U,,,,Apparent dissociation (binding) rate constant was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8371,,0,1,CHEMBL629950
14389,U,,,,Dissociation constant (KD) of the compound,Autocuration,,,,,22224,BAO_0000100,P,,13114,,0,1,CHEMBL630127
14390,U,,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,Autocuration,,,,,22224,BAO_0000100,P,,15515,,0,1,CHEMBL630128
14391,U,,,,Dissociation constant from ESR titration experiments,Autocuration,,,,,22224,BAO_0000100,P,,522,,0,1,CHEMBL630129
14392,U,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),Autocuration,,,,,22224,BAO_0000019,,,13888,,0,1,CHEMBL630130
14393,U,,,,Dissociation constant was evaluated.,Autocuration,,,,,22224,BAO_0000100,P,,2616,,0,1,CHEMBL875234
14394,U,,,,Dissociation constant was reported,Autocuration,,,,,22224,BAO_0000100,P,,3798,,0,1,CHEMBL630131
14395,N,,,,Dissociation constant was determined in rat pituitary cells.,Intermediate,,,,,50597,BAO_0000218,A,,8731,,1,1,CHEMBL630132
14396,U,,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,Autocuration,,,,,22224,BAO_0000019,A,,11892,,0,1,CHEMBL630133
14397,U,,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,Autocuration,,,,,22224,BAO_0000019,A,,11892,,0,1,CHEMBL630134
14398,U,,,,Equilibrium dissociation constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,2582,,0,1,CHEMBL630135
14399,U,,,,Equilibrium dissociation constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,11892,,0,1,CHEMBL630136
14400,U,,,,Kinetic constant KD was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,13396,,0,1,CHEMBL630137
14401,U,,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,Autocuration,,,,,22224,BAO_0000019,A,,603,,0,1,CHEMBL630138
14402,U,,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,Autocuration,,,,,22224,BAO_0000019,A,,15673,,0,1,CHEMBL630139
14403,U,,,,Rate constant for hydrolysis in aqueous acetone.,Autocuration,,,,,22224,BAO_0000019,A,,10368,,0,1,CHEMBL630140
14404,U,,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,Autocuration,,,,,22224,BAO_0000019,A,,14228,,0,1,CHEMBL875235
14405,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL876439
14406,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630605
14407,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630606
14408,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630607
14409,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630608
14410,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630609
14411,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630610
14412,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL630611
14413,N,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629552
14414,N,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629733
14415,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629734
14416,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629735
14417,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629736
14418,N,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629737
14419,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629738
14420,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629739
14421,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629740
14422,N,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629741
14423,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629742
14424,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629743
14425,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629744
14426,N,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629745
14427,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629746
14428,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629747
14429,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629748
14430,N,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629749
14431,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629750
14432,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629751
14433,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629752
14434,N,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629753
14435,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629754
14436,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629755
14437,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629756
14438,N,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629757
14439,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629758
14440,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629759
14441,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL629760
14442,N,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,,,,,50597,BAO_0000218,A,,11510,,1,1,CHEMBL876443
14443,N,,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,1,1,CHEMBL629761
14444,N,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,1,1,CHEMBL629762
14445,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629763
14446,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629764
14447,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629765
14448,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629766
14449,N,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629767
14450,N,,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,1,1,CHEMBL629768
14451,N,,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629769
14452,N,,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,,,,,50588,BAO_0000218,A,,8310,,1,1,CHEMBL629770
14453,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,Intermediate,,,,,50588,BAO_0000218,A,,8310,,1,1,CHEMBL629771
14454,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629772
14455,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL629773
14456,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL625455
14457,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL625456
14458,N,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,Intermediate,,,,,50594,BAO_0000218,A,,8310,,1,1,CHEMBL625457
14459,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625458
14460,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625459
14461,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875483
14462,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL634779
14463,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625460
14464,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626117
14465,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626118
14466,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628342
14467,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628343
14468,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628344
14469,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628345
14470,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628346
14471,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628347
14472,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628348
14473,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628349
14474,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875611
14475,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628350
14476,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628351
14477,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628352
14478,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628353
14479,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628354
14480,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626667
14481,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626668
14482,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626669
14483,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626670
14484,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626671
14485,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626672
14486,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626673
14487,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626674
14488,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626675
14489,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626676
14490,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626677
14491,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626678
14492,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626679
14493,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875612
14494,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626680
14495,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626681
14496,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626682
14497,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626683
14498,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626684
14499,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626685
14500,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626686
14501,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626687
14502,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL624978
14503,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL624979
14504,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL624980
14505,N,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL624981
14506,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL624982
14507,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627564
14508,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627565
14509,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL627566
14510,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627567
14511,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,Spleen,0,1,CHEMBL627568
14512,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,Kidney,0,1,CHEMBL627569
14513,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Autocuration,,,,1255.0,22224,BAO_0000218,A,,13257,Urinary bladder,0,1,CHEMBL627570
14514,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Autocuration,,,,178.0,22224,BAO_0000218,A,,13257,Blood,0,1,CHEMBL627571
14515,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Autocuration,,,,1474.0,22224,BAO_0000218,A,,13257,Bone element,0,1,CHEMBL627572
14516,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL627573
14517,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Autocuration,,,,2113.0,22224,BAO_0000218,A,,13257,Kidney,0,1,CHEMBL627574
14518,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Autocuration,,,,2107.0,22224,BAO_0000218,A,,13257,Liver,0,1,CHEMBL627575
14519,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Autocuration,,,,2048.0,22224,BAO_0000218,A,,13257,Lung,0,1,CHEMBL627576
14520,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627577
14521,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627578
14522,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627579
14523,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627580
14524,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627581
14525,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,Autocuration,,,,,22224,BAO_0000218,A,,13257,,0,1,CHEMBL627582
14526,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627583
14527,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Autocuration,,,,2106.0,22224,BAO_0000218,A,,13257,Spleen,0,1,CHEMBL627584
14528,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Autocuration,,,,2367.0,22224,BAO_0000218,A,,13257,Prostate gland,0,1,CHEMBL627585
14529,U,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Autocuration,,,,2385.0,22224,BAO_0000218,A,,13257,Muscle tissue,0,1,CHEMBL627586
14530,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL627587
14531,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL627588
14532,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628250
14533,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628251
14534,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL628252
14535,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL628253
14536,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL628254
14537,N,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL877493
14538,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628255
14539,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628256
14540,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL628257
14541,N,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL628258
14542,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628259
14543,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL628429
14544,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL626862
14545,N,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL626863
14546,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,Cerebellum,1,1,CHEMBL625886
14547,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,Cerebellum,1,1,CHEMBL625887
14548,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL625888
14549,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL625889
14550,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL625890
14551,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL625891
14552,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL625892
14553,N,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL625893
14554,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Intermediate,,,,2037.0,50597,BAO_0000218,A,,15413,Cerebellum,1,1,CHEMBL625894
14555,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,Intermediate,,,,,50597,BAO_0000218,A,,15413,,1,1,CHEMBL625895
14556,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,0,1,CHEMBL625896
14557,U,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL625897
14558,U,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL625898
14559,U,,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,,,22224,BAO_0000019,A,,568,,0,1,CHEMBL625899
14560,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,0,1,CHEMBL626124
14561,N,,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,Intermediate,,,,,50212,BAO_0000218,A,,7624,,1,1,CHEMBL628500
14562,N,,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",Intermediate,,,,,50597,BAO_0000218,A,,7624,,1,1,CHEMBL857856
14563,N,,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",Intermediate,,,,,50597,BAO_0000218,A,,7624,,1,1,CHEMBL628501
14564,U,,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",Autocuration,,,,,22224,BAO_0000019,A,,4643,,0,1,CHEMBL628502
14565,U,,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,Autocuration,,,,,22224,BAO_0000019,A,,11532,,0,1,CHEMBL628503
14566,U,,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,11018,,0,1,CHEMBL628504
14567,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL628505
14568,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL874452
14569,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL628506
14570,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL628507
14571,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL628508
14572,U,,,,Michaelis constant (KM) was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8949,,0,1,CHEMBL628509
14573,U,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,,,22224,BAO_0000019,A,,12404,,0,1,CHEMBL628510
14574,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,Autocuration,,,,,22224,BAO_0000019,B,,7625,,0,1,CHEMBL628511
14575,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,Autocuration,,,,,22224,BAO_0000019,B,,7625,,0,1,CHEMBL628512
14576,U,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,Autocuration,,,,,22224,BAO_0000019,B,,7625,,0,1,CHEMBL628513
14577,U,,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,Autocuration,,,,,22224,BAO_0000019,B,,7625,,0,1,CHEMBL628514
14578,U,,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,Autocuration,,,,,22224,BAO_0000019,A,,12908,,0,1,CHEMBL628515
14579,U,,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,Autocuration,,,,,22224,BAO_0000019,A,,10368,,0,1,CHEMBL628516
14580,U,,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,,,22224,BAO_0000019,A,,13108,,0,1,CHEMBL628517
14581,U,,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,,,22224,BAO_0000019,A,,13108,,0,1,CHEMBL628518
14582,U,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,Autocuration,,,,,22224,BAO_0000019,A,,15217,,0,1,CHEMBL628519
14583,U,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,Autocuration,,,,,22224,BAO_0000019,A,,15217,,0,1,CHEMBL628520
14584,U,,,,Binding constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,10933,,0,1,CHEMBL628521
14585,U,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL630443
14586,U,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL630444
14587,U,,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL857732
14588,U,,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,Autocuration,,,,,22224,BAO_0000100,P,,14915,,0,1,CHEMBL630445
14589,U,,,,Catalytic rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,8847,,0,1,CHEMBL630446
14590,U,,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,Autocuration,,,,,22224,BAO_0000019,B,,15357,,0,1,CHEMBL630447
14591,U,,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),Autocuration,,,,,22224,BAO_0000019,A,,2869,,0,1,CHEMBL630448
14592,U,,,,Catalytic rate constant against phospholipase A2 was determined,Autocuration,,,,,22224,BAO_0000019,A,,3484,,0,1,CHEMBL630449
14593,U,,,,"Compound was evaluated for catalytic constant, Kcat",Autocuration,,,,,22224,BAO_0000019,A,,1373,,0,1,CHEMBL630450
14594,U,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,8142,,0,1,CHEMBL630451
14595,U,,,,Kcat calculated from 0.693/T1/2,Autocuration,,,,,22224,BAO_0000019,A,,14131,,0,1,CHEMBL630452
14596,U,,,,Kcat was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,0,1,CHEMBL630453
14597,U,,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,0,1,CHEMBL630454
14598,U,,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,0,1,CHEMBL630455
14599,U,,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,,,22224,BAO_0000019,A,,3485,,0,1,CHEMBL631487
14600,U,,,,Kcat value was determined,Autocuration,,,,,22224,BAO_0000019,A,,5962,,0,1,CHEMBL631488
14601,U,,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,0,1,CHEMBL876440
14602,U,,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,0,1,CHEMBL631489
14603,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL857742
14604,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL631490
14605,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL631491
14606,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL631492
14607,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL631493
14608,U,,,,Kinetic parameter for rate of conversion to PABA was determined,Autocuration,,,,,22224,BAO_0000019,A,,4892,,0,1,CHEMBL631494
14609,U,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,0,1,CHEMBL631495
14610,N,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,,,,1988.0,50597,BAO_0000218,A,,11488,Feces,1,1,CHEMBL631496
14611,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,Urine,1,1,CHEMBL631497
14612,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,Urine,1,1,CHEMBL631498
14613,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,Urine,1,1,CHEMBL629776
14614,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,Urine,1,1,CHEMBL629777
14615,N,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,,,,1088.0,50597,BAO_0000218,A,,11488,Urine,1,1,CHEMBL629778
14616,N,,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630456
14617,N,,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630457
14618,N,,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630458
14619,N,,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630459
14620,N,,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630460
14621,N,,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL876550
14622,N,,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630461
14623,N,,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630462
14624,N,,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630463
14625,N,,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630464
14626,N,,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630465
14627,N,,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630466
14628,N,,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630467
14629,N,,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630633
14630,N,,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630634
14631,N,,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630635
14632,N,,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630636
14633,N,,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,Intermediate,,,,,50597,BAO_0000218,A,,11488,,1,1,CHEMBL630637
14634,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL630638
14635,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL630639
14636,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL630640
14637,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL876551
14638,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL630641
14639,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL630642
14640,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL630643
14641,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL630644
14642,N,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL630645
14643,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL625599
14644,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL625600
14645,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL625601
14646,N,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,,,,1988.0,50592,BAO_0000218,A,,7132,Feces,1,1,CHEMBL625602
14647,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL627470
14648,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL627471
14649,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL627472
14650,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL627473
14651,N,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,,,,1088.0,50592,BAO_0000218,A,,7132,Urine,1,1,CHEMBL627474
14652,N,,,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,13925,Blood,1,1,CHEMBL627475
14653,N,,,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,178.0,50597,BAO_0000218,A,,13925,Blood,1,1,CHEMBL627476
14654,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627477
14655,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627478
14656,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627479
14657,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627480
14658,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627481
14659,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627482
14660,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL627483
14661,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875636
14662,N,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625764
14663,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625765
14664,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625766
14665,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625767
14666,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625768
14667,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625769
14668,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625770
14669,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625771
14670,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625772
14671,N,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,,,,1088.0,50588,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625773
14672,N,,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625774
14673,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625775
14674,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625776
14675,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625777
14676,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625778
14677,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625779
14678,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625780
14679,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL625781
14680,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875637
14681,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626473
14682,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626474
14683,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626475
14684,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626476
14685,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL634397
14686,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL626477
14687,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631069
14688,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631070
14689,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631071
14690,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631072
14691,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631073
14692,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631074
14693,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631075
14694,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631725
14695,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631726
14696,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631727
14697,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631728
14698,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631729
14699,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631730
14700,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631731
14701,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631910
14702,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Intermediate,,,,10000000.0,50597,BAO_0000218,A,,15413,Hippocampus,1,1,CHEMBL631911
14703,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL631912
14704,N,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Intermediate,,,,1898.0,50597,BAO_0000218,A,,15413,Hypothalamus,1,1,CHEMBL631913
14705,N,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631914
14706,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631915
14707,N,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL875778
14708,N,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631916
14709,N,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631917
14710,N,,,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631918
14711,N,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631919
14712,N,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631920
14713,N,,,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631921
14714,N,,,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631922
14715,N,,,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,178.0,50597,BAO_0000218,A,,12017,Blood,1,1,CHEMBL631923
14716,N,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL631924
14717,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630234
14718,N,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630235
14719,N,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630236
14720,N,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630237
14721,N,,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630238
14722,N,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630239
14723,N,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630303
14724,N,,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630304
14725,N,,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,,50597,BAO_0000218,A,,12017,,1,1,CHEMBL630305
14726,N,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL630306
14727,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL630307
14728,N,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL630308
14729,N,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL630309
14730,N,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL629309
14731,N,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL629993
14732,N,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL629994
14733,N,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL629995
14734,N,,,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL631993
14735,N,,,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL631994
14736,N,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2113.0,50597,BAO_0000218,A,,12017,Kidney,1,1,CHEMBL631995
14737,N,,,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL631996
14738,N,,,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL631997
14739,N,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL631998
14740,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL631999
14741,N,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL632000
14742,N,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL632001
14743,N,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL874424
14744,N,,,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL632002
14745,N,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL632003
14746,U,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,3133,,0,1,CHEMBL632004
14747,U,,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632005
14748,U,,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632006
14749,U,,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632007
14750,U,,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632008
14751,U,,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632009
14752,U,,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632010
14753,U,,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL857750
14754,U,,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,Autocuration,,,,,22224,BAO_0000019,A,,2742,,0,1,CHEMBL632011
14755,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL632012
14756,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL632013
14757,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL632014
14758,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL629622
14759,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL629623
14760,U,,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL629624
14761,U,,,,Ratio of Kcat to that of Km was determined,Autocuration,,,,,22224,BAO_0000019,A,,17269,,0,1,CHEMBL629625
14762,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL629626
14763,U,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,,,22224,BAO_0000019,A,,2276,,0,1,CHEMBL629627
14764,U,,,,"Compound was evaluated for constant, Kd",Autocuration,,,,,22224,BAO_0000019,A,,15917,,0,1,CHEMBL629628
14765,U,,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,10933,,0,1,CHEMBL629629
14766,U,,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,10933,,0,1,CHEMBL629630
14767,U,,,,Dissociation Constant of compound determined,Autocuration,,,,,22224,BAO_0000019,A,,14293,,0,1,CHEMBL856030
14768,U,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,Autocuration,,,,,22224,BAO_0000019,B,,6698,,0,1,CHEMBL629631
14769,U,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,Autocuration,,,,,22224,BAO_0000019,B,,6698,,0,1,CHEMBL629632
14770,U,,,,Dissociation constant of compound with Fructose was determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,0,1,CHEMBL629633
14771,U,,,,Dissociation constant of compound with Fructose was determined; Not determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,0,1,CHEMBL629634
14772,U,,,,Dissociation constant of compound with Lactulose was determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,0,1,CHEMBL629635
14773,U,,,,Dissociation constant of compound with Lactulose was determined; Not determined,Autocuration,,,,,22224,BAO_0000100,P,,4318,,0,1,CHEMBL629636
14774,U,,,,Dissociation constant of the Compound,Autocuration,,,,,22224,BAO_0000100,P,,14959,,0,1,CHEMBL629637
14775,U,,,,Dissociation constant by non-linear regression analysis,Autocuration,,,,,22224,BAO_0000100,P,,5913,,0,1,CHEMBL629638
14776,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,14218,,0,1,CHEMBL629639
14777,U,,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,Autocuration,,,,,22224,BAO_0000100,P,,10689,,0,1,CHEMBL629640
14778,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,13925,,0,1,CHEMBL629641
14779,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,16359,,0,1,CHEMBL631344
14780,N,,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10944,Muscle tissue,1,1,CHEMBL631345
14781,U,,,,The dissociation constant determined by fluorescence displacement assay,Autocuration,,,,,22224,BAO_0000019,A,,11080,,0,1,CHEMBL631346
14782,U,,,,kd value surface plasmon resonance (SPR) method,Autocuration,,,,,22224,BAO_0000019,A,,17805,,0,1,CHEMBL631524
14783,N,,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Intermediate,,,,2385.0,50597,BAO_0000218,A,,10944,Muscle tissue,1,1,CHEMBL631525
14784,U,,,,First dissociation constant of the binding of compound to V30M TTR,Autocuration,,,,,22224,BAO_0000019,F,,16645,,0,1,CHEMBL631526
14785,U,,,,Second dissociation constant of the binding of compound to V30M TTR,Autocuration,,,,,22224,BAO_0000019,F,,16645,,0,1,CHEMBL631527
14786,U,,,,"Compound was evaluated for equilibrium constant, Ke",Autocuration,,,,,22224,BAO_0000019,A,,7793,,0,1,CHEMBL631528
14787,U,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Autocuration,,,,1898.0,22224,BAO_0000019,A,,12199,Hypothalamus,0,1,CHEMBL631529
14788,U,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Autocuration,,,,1898.0,22224,BAO_0000019,A,,12199,Hypothalamus,0,1,CHEMBL631530
14789,U,,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631531
14790,U,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631532
14791,U,,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,9680,,0,1,CHEMBL631533
14792,N,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL876552
14793,N,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631534
14794,N,,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631535
14795,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631536
14796,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631537
14797,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631538
14798,N,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631539
14799,N,,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,,,,,50594,BAO_0000218,A,,13758,,1,1,CHEMBL631540
14800,N,,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL625637
14801,N,,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,,,,,50597,BAO_0000218,A,,14393,,1,1,CHEMBL625638
14802,N,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,,,,50597,BAO_0000218,A,,15078,,1,1,CHEMBL625639
14803,N,,,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13925,Brain,1,1,CHEMBL625640
14804,N,,,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,955.0,50597,BAO_0000218,A,,13925,Brain,1,1,CHEMBL625641
14805,N,,,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,13925,Heart,1,1,CHEMBL625642
14806,N,,,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,948.0,50597,BAO_0000218,A,,13925,Heart,1,1,CHEMBL625643
14807,N,,,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13925,Kidney,1,1,CHEMBL625644
14808,N,,,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2113.0,50597,BAO_0000218,A,,13925,Kidney,1,1,CHEMBL625645
14809,N,,,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13925,Liver,1,1,CHEMBL625646
14810,N,,,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2107.0,50597,BAO_0000218,A,,13925,Liver,1,1,CHEMBL625647
14811,N,,,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13925,Lung,1,1,CHEMBL625648
14812,N,,,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2048.0,50597,BAO_0000218,A,,13925,Lung,1,1,CHEMBL625649
14813,N,,,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13925,Muscle tissue,1,1,CHEMBL625650
14814,N,,,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2385.0,50597,BAO_0000218,A,,13925,Muscle tissue,1,1,CHEMBL625651
14815,N,,,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,14.0,50597,BAO_0000218,A,,13925,Zone of skin,1,1,CHEMBL625652
14816,N,,,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,14.0,50597,BAO_0000218,A,,13925,Zone of skin,1,1,CHEMBL625653
14817,N,,,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13925,Spleen,1,1,CHEMBL625654
14818,N,,,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,,,,2106.0,50597,BAO_0000218,A,,13925,Spleen,1,1,CHEMBL625655
14819,N,,,,Biodistribution of Compound in rat blood after 15 minutes of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9712,Blood,1,1,CHEMBL625656
14820,N,,,,Biodistribution of Compound in rat blood after 2 minutes of administration,Intermediate,,,,178.0,50597,BAO_0000218,A,,9712,Blood,1,1,CHEMBL625657
14821,N,,,,Biodistribution of Compound in rat brain after 15 minutes of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,9712,Brain,1,1,CHEMBL625658
14822,N,,,,Biodistribution of Compound in rat brain after 2 minutes of administration,Intermediate,,,,955.0,50597,BAO_0000218,A,,9712,Brain,1,1,CHEMBL625659
14823,N,,,,Biodistribution of Compound in rat heart after 15 minutes of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9712,Heart,1,1,CHEMBL625660
14824,N,,,,Biodistribution of Compound in rat heart after 2 minutes of administration,Intermediate,,,,948.0,50597,BAO_0000218,A,,9712,Heart,1,1,CHEMBL625661
14825,N,,,,Biodistribution of Compound in rat liver after 15 minutes of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9712,Liver,1,1,CHEMBL625662
14826,N,,,,Biodistribution of Compound in rat liver after 2 minutes of administration,Intermediate,,,,2107.0,50597,BAO_0000218,A,,9712,Liver,1,1,CHEMBL625663
14827,N,,,,Biodistribution of Compound in rat lung after 15 minutes of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9712,Lung,1,1,CHEMBL875621
14828,N,,,,Biodistribution of Compound in rat lung after 2 minutes of administration,Intermediate,,,,2048.0,50597,BAO_0000218,A,,9712,Lung,1,1,CHEMBL628382
14829,N,,,,Biodistribution of Compound in rat muscle after 15 minutes of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9712,Muscle tissue,1,1,CHEMBL628383
14830,N,,,,Biodistribution of Compound in rat muscle after 2 minutes of administration,Intermediate,,,,2385.0,50597,BAO_0000218,A,,9712,Muscle tissue,1,1,CHEMBL628384
14831,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,1,1,CHEMBL628385
14832,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,1,1,CHEMBL875753
14833,N,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,Intermediate,,,,,50597,BAO_0000218,A,,13925,,1,1,CHEMBL628386
14834,N,,,,Organ distribution in rat blood 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL628387
14835,N,,,,Organ distribution in rat blood 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL628388
14836,N,,,,Organ distribution in rat blood 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL628389
14837,N,,,,Organ distribution in rat blood 30 min after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL632756
14838,N,,,,Organ distribution in rat brain 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL628390
14839,N,,,,Organ distribution in rat brain 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631811
14840,N,,,,Organ distribution in rat brain 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631812
14841,N,,,,Organ distribution in rat heart 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631813
14842,N,,,,Organ distribution in rat heart 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631814
14843,N,,,,Organ distribution in rat heart 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631815
14844,N,,,,Organ distribution in rat kidney 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631816
14845,N,,,,Organ distribution in rat kidney 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL875758
14846,N,,,,Organ distribution in rat kidney 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631817
14847,N,,,,Organ distribution in rat liver 2 minutes after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,Liver,1,1,CHEMBL631818
14848,N,,,,Organ distribution in rat liver 2 hr after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,Liver,1,1,CHEMBL631819
14849,N,,,,Organ distribution in rat liver 30 minutes after intravenous injection,Intermediate,,,,2107.0,50597,BAO_0000218,A,,6941,Liver,1,1,CHEMBL631820
14850,N,,,,Organ distribution in rat lung 2 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631821
14851,N,,,,Organ distribution in rat lung 2 hr after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631822
14852,N,,,,Organ distribution in rat lung 30 minutes after intravenous injection,Intermediate,,,,,50597,BAO_0000218,A,,6941,,1,1,CHEMBL631823
14853,N,,,,Organ distribution in rat muscle 2 minutes after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,Muscle tissue,1,1,CHEMBL631824
14854,N,,,,Organ distribution in rat muscle 2 hr after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,Muscle tissue,1,1,CHEMBL631825
14855,N,,,,Organ distribution in rat muscle 30 minutes after intravenous injection,Intermediate,,,,2385.0,50597,BAO_0000218,A,,6941,Muscle tissue,1,1,CHEMBL631826
14856,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL631827
14857,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL631828
14858,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL631829
14859,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875759
14860,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631830
14861,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631831
14862,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631832
14863,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631833
14864,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631834
14865,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631835
14866,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631836
14867,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631837
14868,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631838
14869,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631839
14870,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631840
14871,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631841
14872,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631842
14873,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631843
14874,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631844
14875,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631845
14876,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631846
14877,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL875760
14878,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL632199
14879,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631847
14880,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL631848
14881,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628707
14882,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628708
14883,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628709
14884,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628710
14885,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628711
14886,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628712
14887,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628713
14888,N,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,,,,1088.0,50597,BAO_0000218,A,,12582,Urine,1,1,CHEMBL628714
14889,N,,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",Intermediate,,,,,50597,BAO_0000218,A,,7415,,1,1,CHEMBL628715
14890,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,0,1,CHEMBL629179
14891,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,0,1,CHEMBL629180
14892,U,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,Autocuration,,,,,22224,BAO_0000019,A,,7313,,0,1,CHEMBL875108
14893,U,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629181
14894,U,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629182
14895,U,,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629183
14896,U,,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629184
14897,U,,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629185
14898,U,,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629186
14899,U,,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629187
14900,U,,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629887
14901,U,,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629888
14902,U,,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629889
14903,U,,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629890
14904,U,,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629891
14905,U,,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629892
14906,U,,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,,1235.0,22224,BAO_0000019,A,,7570,Adrenal cortex,0,1,CHEMBL629893
14907,U,,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629894
14908,U,,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,,,22224,BAO_0000019,A,,7570,,0,1,CHEMBL629895
14909,U,,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",Autocuration,,,,,22224,BAO_0000218,A,,14122,,0,1,CHEMBL875109
14910,U,,,,Absolute bioavailability in male cynomolgus monkeys,Autocuration,,,,,22224,BAO_0000218,A,,16449,,0,1,CHEMBL629896
14911,U,,,,Absolute bioavailability in maleSprague-Dawley rats,Autocuration,,,,,22224,BAO_0000218,A,,16449,,0,1,CHEMBL629897
14912,N,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL629898
14913,N,,,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL630057
14914,N,,,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2107.0,50597,BAO_0000218,A,,12017,Liver,1,1,CHEMBL630058
14915,N,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630059
14916,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630060
14917,N,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630061
14918,N,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630062
14919,N,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630063
14920,N,,,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630064
14921,N,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630065
14922,N,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630066
14923,N,,,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630067
14924,N,,,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2048.0,50597,BAO_0000218,A,,12017,Lung,1,1,CHEMBL630068
14925,N,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL631113
14926,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL631114
14927,N,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL631115
14928,N,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL631116
14929,N,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630528
14930,N,,,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630529
14931,N,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630530
14932,N,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630531
14933,N,,,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630532
14934,N,,,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2385.0,50597,BAO_0000218,A,,12017,Muscle tissue,1,1,CHEMBL630533
14935,N,,,,Biodistribution in normal mice blood after 120 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,Blood,1,1,CHEMBL630534
14936,N,,,,Biodistribution in normal mice blood after 24 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,Blood,1,1,CHEMBL630535
14937,N,,,,Biodistribution in normal mice blood after 4 hr,Intermediate,,,,178.0,50594,BAO_0000218,A,,15045,Blood,1,1,CHEMBL630536
14938,N,,,,Biodistribution in normal mice bone after 120 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,Bone,1,1,CHEMBL630537
14939,N,,,,Biodistribution in normal mice bone after 24 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,Bone,1,1,CHEMBL630538
14940,N,,,,Biodistribution in normal mice bone after 4 hr,Intermediate,,,,10000001.0,50594,BAO_0000218,A,,15045,Bone,1,1,CHEMBL630539
14941,N,,,,Biodistribution in normal mice heart after 120 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,Heart,1,1,CHEMBL630540
14942,N,,,,Biodistribution in normal mice heart after 24 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,Heart,1,1,CHEMBL630541
14943,N,,,,Biodistribution in normal mice heart after 4 hr,Intermediate,,,,948.0,50594,BAO_0000218,A,,15045,Heart,1,1,CHEMBL630542
14944,N,,,,Biodistribution in normal mice kidney after 120 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,Kidney,1,1,CHEMBL630543
14945,N,,,,Biodistribution in normal mice kidney after 24 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,Kidney,1,1,CHEMBL630544
14946,N,,,,Biodistribution in normal mice kidney after 4 hr,Intermediate,,,,2113.0,50594,BAO_0000218,A,,15045,Kidney,1,1,CHEMBL630545
14947,N,,,,Biodistribution in normal mice liver after 120 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,Liver,1,1,CHEMBL630546
14948,N,,,,Biodistribution in normal mice liver after 24 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,Liver,1,1,CHEMBL630547
14949,N,,,,Biodistribution in normal mice liver after 4 hr,Intermediate,,,,2107.0,50594,BAO_0000218,A,,15045,Liver,1,1,CHEMBL630548
14950,N,,,,Biodistribution in normal mice spleen after 120 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,Spleen,1,1,CHEMBL630549
14951,N,,,,Biodistribution in normal mice spleen after 24 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,Spleen,1,1,CHEMBL630550
14952,N,,,,Biodistribution in normal mice spleen after 4 hr,Intermediate,,,,2106.0,50594,BAO_0000218,A,,15045,Spleen,1,1,CHEMBL876426
14953,N,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630551
14954,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630552
14955,N,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630553
14956,N,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630554
14957,N,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630555
14958,N,,,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630556
14959,N,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630557
14960,N,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630558
14961,N,,,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630559
14962,N,,,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2106.0,50597,BAO_0000218,A,,12017,Spleen,1,1,CHEMBL630560
14963,N,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,,,,2046.0,50597,BAO_0000218,A,,12017,Thyroid gland,1,1,CHEMBL876427
14964,N,,,,The Kel values in female wistar rats.,Intermediate,,,,,50597,BAO_0000218,A,,14941,,1,1,CHEMBL630561
14965,U,,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,4646,,0,1,CHEMBL630562
14966,U,,,,Hydrolysis rate constant of the compound,Autocuration,,,,,22224,BAO_0000019,A,,8847,,0,1,CHEMBL630563
14967,U,,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,Autocuration,,,,,22229,BAO_0000100,P,,11778,,0,1,CHEMBL629673
14968,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL629674
14969,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL629675
14970,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL629676
14971,U,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",Autocuration,,,,,22224,BAO_0000019,A,,2363,,0,1,CHEMBL629677
14972,U,,,,Apparent inactivation rate constant was evaluated,Autocuration,,,,,22224,BAO_0000019,A,,8371,,0,1,CHEMBL629678
14973,U,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,Autocuration,,,,,22224,BAO_0000019,A,,14883,,0,1,CHEMBL629679
14974,U,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,Autocuration,,,,,22224,BAO_0000019,A,,14883,,0,1,CHEMBL629680
14975,U,,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,Autocuration,,,,,22224,BAO_0000019,A,,4643,,0,1,CHEMBL629681
14976,U,,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,Autocuration,,,,,22224,BAO_0000019,A,,3519,,0,1,CHEMBL629682
14977,U,,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,Autocuration,,,,,22224,BAO_0000019,A,,10600,,0,1,CHEMBL629683
14978,U,,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,Autocuration,,,,,22224,BAO_0000019,F,,8501,,0,1,CHEMBL629684
14979,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,8505,,0,1,CHEMBL629685
14980,U,,,,Dissociation constant was determined,Autocuration,,,,,22224,BAO_0000100,P,,9778,,0,1,CHEMBL629686
14981,U,,,,Dissociation constant at pH 7.4,Autocuration,,,,,22224,BAO_0000100,P,,9778,,0,1,CHEMBL872932
14982,U,,,,Dissociation constant in presence of 1 mM dithiothreitol,Autocuration,,,,,22224,BAO_0000100,P,,9778,,0,1,CHEMBL629687
14983,U,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,0,1,CHEMBL872931
14984,U,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,0,1,CHEMBL628151
14985,U,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,0,1,CHEMBL628152
14986,U,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,,,22224,BAO_0000019,A,,13007,,0,1,CHEMBL628153
14987,U,,,,Kinetic constant for aromatization of androstenedione,Autocuration,,,,,22224,BAO_0000019,A,,11482,,0,1,CHEMBL628154
14988,U,,,,Kinetic constant for aromatization of testosterone,Autocuration,,,,,22224,BAO_0000019,A,,11482,,0,1,CHEMBL628155
14989,U,,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,Autocuration,,,,,22224,BAO_0000019,A,,2303,,0,1,CHEMBL628156
14990,U,,,,Local inhibition constant was determined,Autocuration,,,,,22224,BAO_0000019,A,,11964,,0,1,CHEMBL628157
14991,N,,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,Intermediate,,,,,50347,BAO_0000218,A,,3140,,1,1,CHEMBL857533
14992,U,,,,Dissociation constant value of the compound,Autocuration,,,,,22224,BAO_0000100,P,,10650,,0,1,CHEMBL628158
14993,U,,,,In vitro permeability through cornea without epithelium,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,Cornea,0,1,CHEMBL628159
14994,U,,,,In vitro permeability through intact cornea,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,Cornea,0,1,CHEMBL875616
14995,N,,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Intermediate,,,,964.0,50592,BAO_0000218,A,,9199,Cornea,1,1,CHEMBL628160
14996,U,,,,Rate of enzyme inactivation for the compound was determined,Autocuration,,,,,22224,BAO_0000019,A,,11966,,0,1,CHEMBL628161
14997,U,,,,In vitro permeability through cornea without epithelium,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,Cornea,0,1,CHEMBL628162
14998,U,,,,In vitro permeability through intact cornea,Autocuration,,,,964.0,22224,BAO_0000019,A,,4667,Cornea,0,1,CHEMBL628163
14999,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628164
15000,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628165
15001,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628166
15002,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628167
15003,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628168
15004,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628169
15005,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628170
15006,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628171
15007,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL627434
15008,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL627435
15009,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628110
15010,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628111
15011,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628112
15012,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628260
15013,U,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,,,22224,BAO_0000019,A,,8354,,0,1,CHEMBL628261
15014,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628262
15015,N,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,,,,,50587,BAO_0000218,A,,14439,,1,1,CHEMBL628263
15016,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628264
15017,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628265
15018,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628266
15019,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628267
15020,N,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628268
15021,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628269
15022,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628270
15023,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628271
15024,N,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),Intermediate,,,,,50594,BAO_0000218,A,,14439,,1,1,CHEMBL628272
